SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

       (Mark One)

       [X]    Quarterly report pursuant to Section 13 or 15(d) of the Securities
              Exchange Act of 1934

       For the Quarterly Period Ended September 30, 1999

                                       OR

       [ ]    Transition report pursuant to Section 13 or 15(d) of the
              Securities Exchange Act of 1934

                         Commission File Number: 0-19756

                            PROTEIN DESIGN LABS, INC.
             (Exact name of registrant as specified in its charter)

                   Delaware                               94-3023969
        (State or other jurisdiction of                (I.R.S. Employer
        incorporation or organization)              Identification Number)


                               34801 Campus Drive
                               Fremont, Ca. 94555
                    (Address of principal executive offices)
                         Telephone Number (510) 574-1400

       Indicate by check mark whether the registrant (1) has filed all reports
       required to be filed by Section 13 or 15(d) of the Securities Exchange
       Act of 1934 during the preceding 12 months (or for such shorter period
       that the registrant was required to file such reports) and, (2) has been
       subject to such filing requirements for the past 90 days:

                          Yes [X]              No [ ]


     As of September 30, 1999, there were 18,723,114 shares of the Registrant's
     Common Stock outstanding.



PROTEIN DESIGN LABS, INC. INDEX PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS Condensed Consolidated Statements of Operations Three months ended September 30, 1999 and 1998 and Nine months ended September 30, 1999 and 1998 Condensed Consolidated Balance Sheets September 30, 1999 and December 31, 1998 Condensed Consolidated Statements of Cash Flows Nine months ended September 30, 1999 and 1998 Notes to Unaudited Financial Statements ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK PART II. OTHER INFORMATION ITEM 5. OTHER INFORMATION - RISK FACTORS ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K Signatures

PART I. FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS PROTEIN DESIGN LABS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except net income (loss) per share data) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, --------------------- --------------------- 1999 1998 1999 1998 ---------- ---------- ---------- ---------- Revenues: Revenue under agreements with third parties $8,401 $9,610 $20,902 $17,274 Interest and other income 2,172 2,268 6,795 7,198 ---------- ---------- ---------- ---------- Total revenues 10,573 11,878 27,697 24,472 ---------- ---------- ---------- ---------- Costs and expenses: Research and development 7,944 8,949 24,738 22,683 General and administrative 2,448 2,240 7,343 6,040 ---------- ---------- ---------- ---------- Total costs and expenses 10,392 11,189 32,081 28,723 ---------- ---------- ---------- ---------- Net income (loss) $181 $689 ($4,384) ($4,251) ========== ========== ========== ========== Net income (loss) per share: Basic $0.01 $0.04 ($0.24) ($0.23) Diluted $0.01 $0.04 ($0.24) ($0.23) ========== ========== ========== ========== Weighted average number of shares: Basic 18,668 18,545 18,637 18,506 Diluted 19,355 18,845 18,637 18,506 ========== ========== ========== ========== See accompanying notes

PROTEIN DESIGN LABS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value per share) September 30, December 31, 1999 1998 ------------ ----------- (unaudited) ASSETS Current assets: Cash and cash equivalents $14,341 $27,907 Short-term investments 6,538 59,233 Other current assets 3,000 4,608 ------------ ----------- Total current assets 23,879 91,748 Property and equipment, net 37,727 23,016 Long-term investments 113,789 56,299 Other assets 550 787 ------------ ----------- $175,945 $171,850 ============ =========== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $822 $1,310 Accrued compensation 1,156 925 Accrued clinical trials 203 1,293 Other accrued liabilities 1,700 3,591 Deferred revenue 3,169 2,235 Current portion of long-term debt 343 -- ------------ ----------- Total current liabilities 7,393 9,354 Long-term debt 9,807 -- ------------ ----------- Total liabilities 17,200 9,354 Stockholders' equity: Preferred stock, par value $0.01 per share, 10,000 shares authorized; no shares issued and outstanding -- -- Common stock, par value $0.01 per share, 40,000 shares authorized; 18,723 and 18,595 issued and outstanding at September 30, 1999 and December 31, 1998, respectively 187 186 Additional paid-in capital 233,405 231,035 Accumulated deficit (73,269) (68,884) Accumulated other comprehensive income (loss) (1,578) 159 ------------ ----------- Total stockholders' equity 158,745 162,496 ------------ ----------- $175,945 $171,850 ============ =========== See accompanying notes

PROTEIN DESIGN LABS, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (unaudited) (In thousands) Nine Months Ended September 30, ---------------------- 1999 1998 ---------- ---------- Cash flows from operating activities: Net loss ($4,384) ($4,251) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 2,667 2,595 Other (175) 735 Changes in assets and liabilities: Other current assets 1,608 (9,028) Accounts payable (488) 700 Accrued liabilities (2,751) 2,508 Deferred revenue 934 1,125 ---------- ---------- Total adjustments 1,795 (1,365) ---------- ---------- Net cash used in operating activities (2,589) (5,616) Cash flows from investing activities: Purchases of short- and long-term investments (81,336) (92,320) Maturities of short- and long-term investments 74,900 145,000 Capital expenditures (17,624) (14,810) Proceeds from sale of equipment 325 - (Increase) decrease in other assets 237 (114) ---------- ---------- Net cash provided by (used in) investing activities (23,498) 37,756 Cash flows from financing activities: Proceeds from issuance of capital stock 2,371 3,334 Proceeds from long-term debt 10,150 - ---------- ---------- Net cash provided by financing activities 12,521 3,334 ---------- ---------- Net increase (decrease) in cash and cash equivalents (13,566) 35,474 Cash and cash equivalents at beginning of period 27,907 9,266 ---------- ---------- Cash and cash equivalents at end of period $14,341 $44,740 ========== ========== See accompanying notes

PROTEIN DESIGN LABS, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS September 30, 1999 (unaudited) Summary of Significant Accounting Policies Organization and Business Since the Company's founding in 1986, a primary focus of its operations has been research and development. Achievement of successful research and development and commercialization of products derived from such efforts is subject to high levels of risk and significant resource commitments. The Company has a history of operating losses and expects to incur substantial additional expenses over at least the next few years as it continues to develop its proprietary products, devote significant resources to preclinical studies, clinical trials, and manufacturing and to defend its patents and other proprietary rights. The Company's revenues to date have consisted principally of research and development funding, licensing and signing fees, milestone payments and royalties from pharmaceutical and biotechnology companies under collaborative research and development, humanization, patent licensing and clinical supply agreements. These revenues may vary considerably from quarter to quarter and from year to year, and revenues in any period may not be predictive of revenues in any subsequent period, and variations may be significant depending on the terms of the particular agreements. The Company receives royalties on sales of Synagisr, Herceptinr and Zenapaxr. Royalty revenues from third party sales of these licensed humanized antibodies are subject to the specific terms of each agreement and, under the Company's policy, are recognized by the Company during the quarter such royalties are reported to PDL. This method of revenue recognition may increase fluctuations reported in any particular quarter since the agreements generally provide for royalty reports to the Company following completion of each calendar quarter or semi-annual period. Further, royalty revenues are unpredictable as they are dependent upon numerous factors including the seasonality of sales of licensed products, the existence of competing products, the marketing efforts of the Company's licensees and the rights certain licensees have to partially offset certain previously paid milestones and third party royalties against royalties payable to the Company. In addition, expenses may fluctuate from quarter to quarter due to the timing of certain expenses, including milestone payments that may be payable by the Company under certain licensing arrangements. Although the Company anticipates entering into new collaborations from time to time, the Company presently does not know whether or not it will realize non-royalty revenue from its new and proposed collaborations at levels commensurate with the revenue historically recognized under its older collaborations. Moreover, the Company anticipates that it will incur significant operating expenses as the Company significantly increases its research and development, manufacturing, preclinical, clinical, marketing and administrative and patent activities. In particular, the commitment of resources to the development of Zenapax and the humanized anti-IL-4 antibody, two humanized antibodies with respect to which PDL recently obtained development rights, taken together with the continued development of the Company's existing products will require significant additional funds for development. Accordingly, in the absence of substantial revenues from new corporate collaborations or patent licensing or humanization agreements, significant royalties on sales of products licensed under the Company's intellectual property rights, or other sources, the Company expects to incur substantial operating losses in the foreseeable future as the Company undertakes development of Zenapax in autoimmune indications and the humanized anti-IL-4 antibody, as certain of its earlier stage potential products move into later stage clinical development, as additional potential products are selected as clinical candidates for further development, as the Company invests in additional manufacturing capacity, as the Company defends or prosecutes its patents and patent applications and as the Company invests in research or acquires additional technologies, product candidates or businesses. Basis of Presentation and Responsibility for Quarterly Financial Statements The consolidated balance sheet as of September 30, 1999, and the consolidated statements of operations for the three and nine month periods and cash flows for the nine month periods ended September 30, 1999 and 1998 are unaudited but include all adjustments (consisting only of normal recurring adjustments) which the Company considers necessary for a fair presentation of the financial position at such dates and the operating results and cash flows for those periods. During the third quarter of 1999, the Company formed two wholly owned subsidiaries to facilitate the purchase of the Company's Fremont, California facilities. Financial statements are presented on a consolidated basis to include these subsidiaries. Although the Company believes that the disclosures in these financial statements are adequate to make the information presented not misleading, certain information and footnote information normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission. The accompanying financial statements should be read in conjunction with the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission, for the year ended December 31, 1998. The balance sheet as of December 31, 1998 is derived from audited financial statements. Results for any quarterly period are not necessarily indicative of results for any other quarterly period or for the entire year. Cash Equivalents, Investments and Concentration of Credit Risk The Company considers all highly liquid investments purchased with a maturity of three months or less at the date of acquisition to be cash equivalents. Included in the "Other" adjustments line item in the Statements of Cash Flows is the accretion of the book value of certain debt securities. The Company places its cash and short-term and long-term investments with high-credit-quality financial institutions and in securities of the U.S. government and U.S. government agencies and, by policy, limits the amount of credit exposure in any one financial instrument. To date, the Company has not experienced credit losses on investments in these instruments. Cash and cash equivalents for the period ended September 30, 1999 decreased primarily as a result of the purchases of short-term investments and long- term investments. Long-term investments increased during the period as a result of the Company purchasing investments with maturities longer than twelve months. Revenue Recognition Contract revenues from research and development arrangements are recorded as earned based on the performance requirements of the contracts. Revenues from achievement of milestone events are recognized when the funding party agrees that the scientific or clinical results stipulated in the agreement have been met. Deferred revenue arises principally due to timing of cash payments received under research and development contracts. The Company's collaborative, humanization and patent licensing agreements with third parties provide for the payment of royalties to the Company based on net sales of the licensed product under the agreement. The agreements generally provide for royalty payments to the Company following completion of each calendar quarter or semi-annual period and royalty revenue is recognized when royalty reports are received from the third party. Non- refundable signing and licensing fees under these arrangements are recognized as revenue when there are no future performance obligations remaining with respect to such fees. Net Income (Loss) Per Share In accordance with Financial Accounting Standards Board Statement No. 128, "Earnings Per Share" ("FAS 128"), basic and diluted net income (loss) per share amounts have been computed using the weighted average number of shares of common stock outstanding during the periods presented. Calculation of diluted net income per share includes the dilutive effect of stock options. If the Company had a net loss position for the applicable period, as is the case for the nine month periods ended September 30, 1999 and 1998, FAS 128 specifies that the Company shall not include the effect of stock options outstanding for the applicable period as the effect would be antidilutive. The following is a reconciliation of the numerators and denominators of the basic and diluted net income (loss) per share computations for the periods presented below: Three Months Ended Nine Months Ended September 30, September 30, --------------------- --------------------- 1999 1998 1999 1998 ---------- ---------- ---------- ---------- Numerator: Net income (loss) $181 $689 $(4,384) $(4,251) ========== ========== ========== ========== Denominator: Basic net income (loss) per share - weighted-average shares 18,668 18,545 18,637 18,506 Dilutive potential common shares: Stock Options 687 300 -- -- ---------- ---------- ---------- ---------- Denominator for diluted net loss per share 19,355 18,845 18,667 18,506 ========== ========== ========== ========== Basic net income (loss) per share $0.01 $0.04 $(0.24) $(0.23) ========== ========== ========== ========== Diluted net income (loss) per share $0.01 $0.04 $(0.24) $(0.23) ========== ========== ========== ========== Comprehensive Income (Loss) In accordance with Financial Accounting Standards Statement No. 130, "Reporting Comprehensive Income," ("FAS 130"), the Company is required to display comprehensive income (loss) and its components as part of the Company's complete set of financial statements. The measurement and presentation of net loss did not change. Comprehensive income (loss) is comprised of net loss and other comprehensive income (loss). Other comprehensive income (loss) includes certain changes in equity of the Company that are excluded from net loss. Specifically, FAS 130 requires unrealized gains and losses on the Company's holdings of available-for-sale securities, which were reported separately in stockholders' equity, to be included in accumulated other comprehensive income (loss). FAS 130 permits the disclosure of this information in notes to interim financial statements and the Company has elected this approach. For the three month periods ended September 30, 1999 and 1998, total comprehensive income (loss) amounted to ($0.1) million and $0.9 million respectively. For the nine month periods ended September 30, 1999 and 1998, total comprehensive income (loss) amounted to ($6.1) million and ($4.2) million, respectively. Derivative Instruments and Hedging Activities In June 1998, the Financial Accounting Standards Board issued Statement No. 133 "Accounting for Derivative Instruments and Hedging Activities" ("FAS 133"). FAS 133 is not required to be adopted until 2001. However, the Company has reviewed FAS 133 and because it does not use derivatives, the adoption of FAS 133 is not expected to effect the results of operations or the financial position of the Company. Management Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires the use of management's estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. For example, the Company has a policy of recording expenses for clinical trials based upon pro rating estimated total costs of a clinical trial over the estimated length of the clinical trial and the number of patients anticipated to be enrolled in the trial. Expenses related to each patient are recognized ratably beginning upon entry into the trial and over the course of the trial. In the event of early termination of a clinical trial, management accrues an amount based on its estimate of the remaining non-cancellable obligations associated with the winding down of the clinical trial. These estimates and assumptions could differ significantly from the amounts which may actually be realized. Property, Plant and Equipment Property, plant and equipment increased at September 30, 1999 compared to December 31, 1998 primarily as a result of the purchase of the Company's Fremont, California facilities which has an estimated useful life of thirty years. Accrued Clinical Trials Accrued clinical trials reflected a $1.1 million reduction associated with the favorable resolution of a contract-related dispute with Boehringer Mannheim GmbH (which was acquired by affiliates of F. Hoffmann-La Roche Ltd). Long-Term Debt In September 1999, Fremont Holding L.L.C. (a wholly owned subsidiary of Protein Design Labs, Inc.) obtained a $10.2 million term loan to purchase its Fremont, California facilities. The loan bears interest at the rate of 7.64% per year amortized over 15 years with principal and interest payable monthly beginning in October 1999. The loan is secured by the Company's Fremont, California facilities and is subject to the terms and covenants of the loan agreement. ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS This Quarterly Report contains forward-looking statements which involve risks and uncertainties. The Company's actual results may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include, but are not limited to those discussed in "Risk Factors" as well as those discussed elsewhere in this document and the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission for the year ended December 31, 1998. OVERVIEW Since the Company's founding in 1986, a primary focus of its operations has been research and development. Achievement of successful research and development and commercialization of products derived from such efforts is subject to high levels of risk and significant resource commitments. The Company has a history of operating losses and expects to incur substantial additional expenses over at least the next few years as it continues to develop its proprietary products, devote significant resources to preclinical studies, clinical trials, and manufacturing and to defend its patents and other proprietary rights. The Company's revenues to date have consisted principally of research and development funding, licensing and signing fees, milestone payments and royalties from pharmaceutical and biotechnology companies under collaborative research and development, humanization, patent licensing and clinical supply agreements. These revenues may vary considerably from quarter to quarter and from year to year, and revenues in any period may not be predictive of revenues in any subsequent period, and variations may be significant depending on the terms of the particular agreements. The Company receives royalties on sales of Synagis[R], Herceptin[R] and Zenapax[R]. Royalty revenues from third party sales of these licensed humanized antibodies are subject to the specific terms of each agreement and, under the Company's policy, are recognized by the Company during the quarter such royalties are reported to PDL. This method of revenue recognition may increase fluctuations reported in any particular quarter since the agreements generally provide for royalty reports to the Company following completion of each calendar quarter or semi-annual period. Further, royalty revenues are unpredictable as they are dependent upon numerous factors including the seasonality of sales of licensed products, the existence of competing products, the marketing efforts of the Company's licensees and the rights certain licensees have to partially offset certain previously paid milestones and third party royalties against royalties payable to the Company. In addition, expenses may fluctuate from quarter to quarter due to the timing of certain expenses, including milestone payments that may be payable by the Company under certain licensing arrangements. Although the Company anticipates entering into new collaborations from time to time, the Company presently does not know whether or not it will realize non-royalty revenue from its new and proposed collaborations at levels commensurate with the revenue historically recognized under its older collaborations. Moreover, the Company anticipates that it will incur significant operating expenses as the Company significantly increases its research and development, manufacturing, preclinical, clinical, marketing and administrative and patent activities. In particular, the commitment of resources to the development of Zenapax and the humanized anti-IL-4 antibody, two humanized antibodies with respect to which PDL recently obtained development rights, taken together with the continued development of the Company's existing products will require significant additional funds for development. Accordingly, in the absence of substantial revenues from new corporate collaborations or patent licensing or humanization agreements, significant royalties on sales of products licensed under the Company's intellectual property rights, or other sources, the Company expects to incur substantial operating losses in the foreseeable future as the Company undertakes development of Zenapax in autoimmune indications and the humanized anti-IL-4 antibody, as certain of its earlier stage potential products move into later stage clinical development, as additional potential products are selected as clinical candidates for further development, as the Company invests in additional manufacturing capacity, as the Company defends or prosecutes its patents and patent applications and as the Company invests in research or acquires additional technologies, product candidates or businesses. Contract revenues from research and development are recorded as earned based on the performance requirements of the contracts. Revenues from achievement of milestone events are recognized when the funding party agrees that the scientific or clinical results stipulated in the agreement have been met. Deferred revenue arises principally due to timing of cash payments received under research and development contracts. RESULTS OF OPERATIONS Three Months Ended September 30, 1999 and 1998 The Company's total revenues for the three months ended September 30, 1999 were $10.6 million compared to $11.9 million in the third quarter of 1998. Total revenues recognized under agreements with third parties were $8.4 million in the third quarter of 1999 compared to $9.6 million in the comparable period in 1998. Interest and other income was $2.2 million in the third quarter of 1999 compared to $2.3 million in the comparable period in 1998. Revenues under agreements with third parties of $8.4 million for the three months ended September 30, 1999 consisted principally of milestone payments earned under licensing agreements, royalties, signing and licensing fees and research and development reimbursement funding. In the third quarter of 1998, revenues of $9.6 million under agreements with third parties consisted principally of a $6.0 million licensing and signing fee from Genentech, Inc. ("Genentech"), milestone payments earned under licensing agreements, manufacturing services revenues under clinical supply agreements, research and development reimbursement funding and royalties. Total costs and expenses for the three months ended September 30, 1999 were $10.4 million compared with $11.2 million in the comparable period in 1998. Total cost and expenses in the 1999 third quarter reflected a $1.1 million reduction associated with the favorable resolution of a contract dispute with a third party. In 1998, total cost and expenses in the third quarter included a $1.0 million licensing and signing fee paid to Genentech. Excluding these non-recurring items in the third quarters of 1999 and 1998, total costs and expenses increased by $1.3 million, primarily due to the addition of staff in the Company's pharmaceutical research and development programs, administrative functions and associated expenses to manage and support the Company's expanding operations. Research and development expenses for the three month period ended September 30, 1999 were $7.9 million compared with $8.9 million in the year- earlier quarter. Excluding the two non-recurring items discussed above, research and development costs increased by $1.1 million, primarily due to the addition of staff, the continuation of clinical trials and expansion of research and pharmaceutical development capabilities, including support for both clinical development and manufacturing process development. General and administrative expenses for the three months ended September 30, 1999 increased to $2.4 million from $2.2 million in the comparable period in 1998. These increases were primarily the result of increased staffing and associated expenses to manage and support the Company's expanding operations. Nine Months Ended September 30, 1999 and 1998 The Company's total revenues for the nine months ended September 30, 1999 were $27.7 million compared with $24.5 million for the nine months ended September 30, 1998. Total revenues recognized under agreements with third parties were $20.9 million in the nine month period of 1999 compared with $17.3 million in the comparable period in 1998. Interest and other income was $6.8 million in the nine month period of 1999 compared with $7.2 million in the comparable period in 1998. Revenues under agreements with third parties of $20.9 million for the nine months ended September 30, 1999 consisted principally of royalties, signing and licensing fees, maintenance fees and research and development reimbursement funding. In the comparable period of 1998, revenues of $17.3 million under agreements with third parties consisted principally of signing and licensing fees, milestone payments earned under licensing agreements, manufacturing services revenues under clinical supply agreements, research and development reimbursement funding and royalties. Total costs and expenses for the nine months ended September 30, 1999 increased to $32.1 million from $28.7 million in the comparable period in 1998. Excluding non-recurring expense adjustments due to one-time events, the increase in costs and expenses was primarily due to the addition of staff in the Company's pharmaceutical research and development programs, administrative functions and associated expenses to manage and support the Company's expanding operations. Research and development expenses for the nine month period ended September 30, 1999 increased to $24.7 million from $22.7 million in the comparable period in 1998. Excluding the two non-recurring items discussed above, the increase in costs was primarily due to the addition of staff, the continuation of clinical trials and expansion of research and pharmaceutical development capabilities, including support for both clinical development and manufacturing process development. General and administrative expenses for the nine months ended September 30, 1999 increased to $7.3 million from $6.0 million in the comparable period in 1998. These increases were primarily the result of increased staffing and associated expenses to manage and support the Company's expanding operations. LIQUIDITY AND CAPITAL RESOURCES To date, the Company has financed its operations primarily through public and private placements of equity securities, research and development revenues and interest income on invested capital. At September 30, 1999, the Company had cash, cash equivalents and investments in the aggregate of $134.7 million, compared to $143.4 million at December 31, 1998. As set forth in the Statements of Cash Flows, net cash used in operating activities was $2.6 million for the nine months ended September 30, 1999 compared to $5.6 million in the same period in 1998. This change was primarily the result of changes in other current assets and accrued liabilities. As set forth in the Statements of Cash Flows, net cash used in investing activities for the nine months ended September 30, 1999 was $23.5 million resulting primarily from the reinvestment of maturing investments and the purchase of the Company's Fremont, California facilities. Net cash provided by investing activities for the comparable period in 1998 was $37.8 million resulting primarily from the maturities of short- and long-term investments. As set forth in the Statements of Cash Flows, net cash provided by financing activities for the nine months ended September 30, 1999 was $12.5 million resulting primarily from the proceeds associated with the long-term financing of the Company's purchase of its Fremont, California facilities. Net cash provided by financing activities in the comparable period in 1998 was $3.3 million resulting primarily from the exercise of outstanding stock options. The Company's future capital requirements will depend on numerous factors, including, among others, royalties from sales of products of third party licensees, including Synagis, Herceptin and Zenapax; the ability of the Company to enter into additional collaborative, humanization and patent licensing arrangements; the progress of the Company's product candidates in clinical trials; the ability of the Company's licensees to obtain regulatory approval and successfully manufacture and market products licensed under the Company's patents; the continued or additional support by collaborative partners or other third parties of research and development efforts and clinical trials; enhancement of existing and investment in new research and development programs; the time required to gain regulatory approvals; the resources the Company devotes to self-funded products, manufacturing facilities and methods and advanced technologies; the ability of the Company to obtain and retain funding from third parties under collaborative arrangements; the continued development of internal marketing and sales capabilities; the demand for the Company's potential products, if and when approved; potential acquisitions of technology, product candidates or businesses by the Company; and the costs of defending or prosecuting any patent opposition or litigation necessary to protect the Company's proprietary technology. In order to develop and commercialize its potential products the Company may need to raise substantial additional funds through equity or debt financings, collaborative arrangements, the use of sponsored research efforts or other means. No assurance can be given that such additional financing will be available on acceptable terms, if at all, and such financing may only be available on terms dilutive to existing stockholders. The Company believes that existing capital resources will be adequate to satisfy its capital needs through at least 2001. YEAR 2000 COMPLIANCE As is true for most companies, the ability of the Company's systems and equipment as well as those of its key suppliers to address the Year 2000 ("Y2K") issue presents a potential risk for the Company. If systems software and/or equipment containing embedded software or controllers do not correctly recognize date information when the year changes to 2000, there could be an adverse impact on the Company's operations. The risk for the Company exists in two areas: systems used by the Company to run its business and systems used by the Company's suppliers. The Company is currently evaluating its exposure in these two areas and has completed a review of at least 90% of potentially affected systems. The Company has also reviewed, but views as a much less significant risk, claims related to potential warranty or other claims from its collaborative research customers. Based on a comprehensive assessment recently completed by an outside consultant retained by the Company, the Company believes that its most important information systems, equipment and facilities are Y2K-compliant. To date, the Company has either received software or system upgrades or assurances that Y2K-compliant software will be made available in a manner designed for the Company to timely address the Y2K issue with respect to its key systems. The outside consultant retained by the Company performed a comprehensive inventory and review of all significant systems and equipment of the Company and is in the process of preparing a contingency plan for any mission critical systems that may present potential Y2K problems. The Company has established a Y2K committee with responsibility for coordinating awareness and identifying potential Y2K risk areas within the Company. As part of its comprehensive review of potentially affected systems, equipment and facilities, the Company is also reviewing controllers used to perform key functions in its manufacturing facility in Plymouth, Minnesota. At this time, the Company has been advised that the need for remediation or replacement plans for systems and equipment is minimal. For Y2K non-compliance issues identified to date, the cost of upgrade or remediation has not been and is not expected to be material to the Company's operating results. The Company has completed a work and project plan for Company awareness and a detailed assessment and inventory review process corresponding to the five-step General Accounting Office recommended process guidelines. For Y2K compliance, the total out-of-pocket costs expended to date and currently planned budget expenditures are expected to be less than the originally estimated $100,000 amount budgeted. However, if implementation of scheduled replacement systems is significantly delayed, or if any significant new non-compliance issues are identified, the Company's results of operations or financial condition could be materially adversely affected. The Company has identified and inquired of most of its critical suppliers and has ongoing inquiries of other suppliers in order to determine whether the operations and the products or services provided by these identified vendors are Y2K-compliant. Where practicable, the Company will attempt to mitigate its risks with respect to the failure of vendors to be Y2K-compliant. In the event that vendors are not compliant, the Company may adjust its purchasing decisions or seek alternative sources of supplies or services. However, many of the Company's vendors have been qualified for regulatory purposes such that qualifying new vendors could involve significant time and resource commitments by the Company. Failure of vendors to be Y2K-compliant remains a possibility and could limit the ability of the Company to manufacture material for clinical studies or timely conduct regulatory compliance programs that would result in a delay in the initiation or continuation of certain planned clinical studies. Significant delays or expenditures due to vendors' failures to become Y2K-compliant could have an adverse impact on the Company's results of operations or financial condition. With respect to research conducted by the Company in support of its collaborative research customers, many of the systems and software used to support such efforts are new. Where appropriate, the Company has, as a condition to accepting such systems and software, required that the systems be Y2K-compliant. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK The Company maintains a non-trading investment portfolio of investment grade, highly liquid, debt securities which limits the amount of credit exposure to any one issue, issuer, or type of instrument. The Company does not use derivative financial instruments for speculative or trading purposes. The securities in the Company's investment portfolio are not leveraged and are classified as available for sale and therefore are subject to interest rate risk. The Company does not currently hedge interest rate exposure. As of September 30, 1999, there has been no material change in the Company's interest rate exposure from that described in the Company's Annual Report on Form 10-K for the year ended December 31, 1998. PART II. OTHER INFORMATION ITEM 5. OTHER INFORMATION - RISK FACTORS This Quarterly Report contains, in addition to historical information, forward-looking statements which involve risks and uncertainties. The Company's actual results may differ significantly from the results discussed in forward-looking statements. Factors that may cause such a difference include those discussed in the material set forth in this document and in the discussion captioned "Risk Factors" in the Company's Annual Report on Form 10-K for the year ending December 31, 1998. History Of Losses; Future Profitability Uncertain. The Company has a history of operating losses and expects to incur substantial additional expenses over at least the next several years as it continues to develop its potential products, to invest in new research areas and to devote significant resources to preclinical studies, clinical trials and manufacturing. As of September 30, 1999, the Company had an accumulated deficit of approximately $73.3 million. The time and resource commitment required to achieve market success for any individual product is extensive and uncertain. No assurance can be given that the Company, its collaborative partners or licensees will successfully develop products, obtain required regulatory approvals, manufacture products at an acceptable cost and with appropriate quality, or successfully market such products. The Company's revenues to date have consisted principally of research and development funding, licensing and signing fees, milestone payments and royalties from pharmaceutical and biotechnology companies under collaborative research and development, humanization, patent licensing and clinical supply agreements. These revenues may vary considerably from quarter to quarter and from year to year, and revenues in any period may not be predictive of revenues in any subsequent period, and variations may be significant depending on the terms of the particular agreements. Further, royalty revenues are unpredictable as they are dependent upon numerous factors, including the seasonality of sales of licensed products, the existence of competing products, the marketing efforts of the Company's licensees and rights certain licensees may have to partially offset certain previously paid milestones and third party royalties against royalties payable to the Company. In addition, expenses may fluctuate from quarter to quarter due to the timing of certain expenses, including milestone payments that may be payable by the Company under licensing arrangements. Although the Company anticipates entering into new collaborations from time to time, the Company presently does not know whether or not it will realize non-royalty revenue from its new and proposed collaborations at levels commensurate with the revenue historically recognized under its older collaborations. Moreover, the Company anticipates that it will incur significant operating expenses as the Company significantly increases its research and development, manufacturing, preclinical, clinical, marketing and administrative and patent activities. In particular, the commitment of resources to the development of Zenapax and the humanized anti-IL-4 antibody, two humanized antibodies with respect to which PDL recently obtained development rights, taken together with the continued development of the Company's existing products, will require significant additional funds for development. Accordingly, in the absence of substantial revenues from new corporate collaborations or patent licensing or humanization agreements, significant royalties on sales of products licensed under the Company's intellectual property rights, or other sources, which may or may not occur, the Company expects to incur substantial operating losses in the foreseeable future as the Company undertakes development of Zenapax in autoimmune indications and the humanized anti-IL-4 antibody, as certain of its earlier stage potential products move into later stage clinical development, as additional potential products are selected as clinical candidates for further development, as the Company invests in additional manufacturing capacity, as the Company defends or prosecutes its patents and patent applications and as the Company invests in research or acquires additional technologies, product candidates or businesses. For example, revenues in the third quarter of 1999 included significant amounts from certain milestones and non-refundable, non-creditable licensing and signing fees. Moreover, expenses in the third quarter were also reduced by $1.1 million due to a favorable resolution of a contract dispute with a third party. Revenues in the fourth quarter of 1999 are not expected to include arrangements involving payments to the Company of a similar magnitude and certain of the milestone payments in the third quarter which are expected to be credited against royalties which otherwise would be due to the Company in the fourth quarter of 1999. In the absence of substantial non-recurring revenues or significant royalty revenues in any future period, there can be no assurance that the Company's level of revenue in any particular reporting period will be similar to or higher than that reported for the prior corresponding period. Hoffmann-La Roche Inc. and its affiliates ("Roche") have received regulatory approval to distribute Zenapax in the U.S. and certain other countries. Zenapax, a product created by the Company, is licensed exclusively to Roche. The Company has also entered into nonexclusive patent license agreements covering Synagis[R], a product developed by MedImmune, Inc., and Herceptin[R], a product developed by Genentech, Inc. The Company recognizes royalty revenues when royalty reports are received from its collaborative partners, including Roche. With respect to royalties based on revenue from sales of Zenapax by Roche, royalties based on U.S. sales are reported to the Company on a quarterly basis and royalties based on sales outside of the U.S. are currently reported on a semi-annual basis. With respect to royalties on sales of Synagis and Herceptin, royalty reports are due in the quarter following the quarter in which sales occur or are reported by sublicensees, as the case may be. Each of these licensees has certain rights to partially offset certain payments previously made to the Company or paid to third parties. For example, Roche has a right to partially offset certain third party royalties, patent reimbursement expenses and previously paid milestones against royalties payable to the Company with respect to Zenapax. The Company records revenue when reports are received from its licensees. This method of accounting for royalty revenues from the Company's licensees, taken together with the unpredictable timing of payments of non-recurring licensing and signing fees, payments for manufacturing services and milestones under new and existing collaborative, humanization, patent licensing and clinical supply agreements, is likely to result in significant quarterly fluctuations in revenues in quarterly and annual periods. Thus, revenues in any period may not be predictive of revenues in any subsequent period, and variations may be significant depending on the terms of the particular agreements. The amount of net losses and the time required to reach sustained profitability are highly uncertain. To achieve sustained profitable operations, the Company, alone or with its collaborative partners, must successfully discover, develop, manufacture, obtain regulatory approvals for and market potential products. No assurances can be given that the Company will be able to achieve or sustain profitability, and results are expected to fluctuate from quarter to quarter and year to year. Dependence On Licensees With Respect to Royalties. The Company is dependent upon the development and marketing efforts of its licensees with respect to products for which the Company may receive royalties. For example, in 1998, the Company began receiving royalties from sales of Zenapax, a product exclusively licensed to Roche. The Company's royalties on Zenapax sales in transplantation depend upon the efforts of Roche and there can be no assurance that Roche's development, regulatory and marketing efforts will be successful, including without limitation, whether or how quickly Zenapax might receive regulatory approvals in various countries throughout the world and how rapidly it might be adopted by the medical community. Moreover, Simulect[R], a product competitive with Zenapax, is marketed in the U.S. and other countries and there can be no assurance that Roche will successfully market and sell Zenapax against this and other available competitive products. In addition, there can be no assurance that other independently developed products of Roche, including CellCept[R], or others will not compete with or prevent Zenapax from achieving meaningful sales. Roche's development and marketing efforts for CellCept may result in delays or a relatively smaller resource commitment to marketing and sales support efforts than might otherwise be obtained for Zenapax if this potentially competitive product were not under development or being marketed. In addition, the Company recently obtained exclusive rights to develop Zenapax in autoimmune indications. There can be no assurance that the Company's development efforts in autoimmune indications will show that Zenapax is safe and efficacious in this setting, or that the clinical trials will result in approval to market Zenapax in these indications. Any adverse event or announcement related to Zenapax would have a material adverse effect on the business and financial condition of the Company. The Company has also entered into non-exclusive patent licensing arrangements for Synagis and Herceptin. The Company is dependent upon the further development, regulatory and marketing efforts of its licensees with respect to these products and there can be no assurance that the development, regulatory and marketing efforts of these licensees will be successful, including, without limitation, if and when regulatory approvals in various countries may be obtained and whether or how quickly these products might be adopted by the medical community. Uncertainty Of Patents And Proprietary Technology; Opposition Proceedings. The Company's success is significantly dependent on its ability to obtain and maintain patent protection for its products and technologies and to preserve its trade secrets and operate without infringing on the proprietary rights of third parties. The Company files and prosecutes patent applications to protect its inventions. No assurance can be given that the Company's pending patent applications will result in the issuance of patents or that any patents will provide competitive advantages or will not be invalidated or circumvented by its competitors. Moreover, no assurance can be given that patents are not issued to, or patent applications have not been filed by, other companies which would have an adverse effect on the Company's ability to use, import, manufacture, market or sell its products or maintain its competitive position with respect to its products. Other companies obtaining patents claiming products or processes useful to the Company may bring infringement actions against the Company. As a result, the Company may be required to obtain licenses from others or not be able to use, import, manufacture, market or sell its products. Such licenses may not be available on commercially reasonable terms, if at all. Patents in the U.S. are issued to the party that is first to invent the claimed invention. Since patent applications in the U.S. are maintained in secrecy until patents issue, the Company cannot be certain that it was the first inventor of the inventions covered by its pending patent applications or patents or that it was the first to file patent applications for such inventions. The patent positions of biotechnology firms generally are highly uncertain and involve complex legal and factual questions. No consistent policy has emerged regarding the breadth of claims in biotechnology patents, and patents of biotechnology products are uncertain, so that even issued patents may later be modified or revoked by the U.S. Patent and Trademark Office ("PTO") or the courts. Moreover, the issuance of a patent in one country does not assure the issuance of a patent with similar claims in another country, and claim interpretation and infringement laws vary among countries, so the extent of any patent protection may vary in different countries. The Company has a number of patents and has exclusively licensed certain patents from third parties. In June 1996, the Company was issued a U.S. patent covering Zenapax and certain related antibodies against the IL-2 receptor. The Company has been issued patents by the PTO, the Japanese Patent Office ("JPO"), European Patent Office ("EPO") and other patent offices around the world that relate to humanized antibodies and the methods of making those antibodies. With respect to its issued antibody humanization patents, the Company believes the patent claims cover Zenapax, Herceptin and Synagis and, based on its review of the scientific literature, most other humanized antibodies. In addition, the Company is currently prosecuting other patent applications with the PTO and in other countries, including members of the European Patent Convention, Canada, Japan and Australia. The patent applications are directed to various aspects of the Company's SMART and human antibodies, antibody technology and other programs, and include claims relating to compositions of matter, methods of preparation and use of a number of the Company's compounds. However, the Company does not know whether any pending applications will result in the issuance of patents or whether such patents will provide protection of commercial significance. Further, there can be no assurance that the Company's patents will prevent others from developing competitive products using related technology. The Company's two humanization patents issued by the EPO apply in the United Kingdom, Germany, France, Italy and eight other European countries. The EPO (but not PTO) procedures provide for an opposition period in which other parties submit arguments as to why the patent was incorrectly granted and should be withdrawn or limited. Eighteen notices of opposition to the Company's first European patent were filed during the opposition period for such patent, including oppositions by major pharmaceutical and biotechnology companies, which cited references and made arguments not considered by the EPO and PTO before grant of the respective patents. The Company submitted its response to the briefs filed by these parties and a preliminary view from the EPO was received in May 1999. The preliminary view represents the initial non-binding statement from the EPO with respect to the issued European patent and does not represent the final determination concerning the patent. Complex preliminary views are common in EPO proceedings, and are intended to set an agenda for discussion at the oral hearing. The final determination from the EPO is expected to occur at an oral hearing currently scheduled to take place in March 2000. At or following the oral hearing, the Company expects that the European patent will either be maintained in full, maintained in an amended version or revoked. Any of the parties to the opposition may appeal a decision to a board of appeals within the EPO. Such an appeal can take two or more years to be resolved. The preliminary view from the EPO raises significant questions regarding the validity of the first European patent, which, if not satisfactorily responded to by the Company in the oral hearing, could result in revocation of certain claims or the entire European patent. If the key claims in the European patent are revoked following the oral hearing and the Company's other humanization patents do not provide sufficient coverage of certain products licensed under the Company's patents, then the Company's ability to collect royalties on European sales of existing licensed products and to license its patents relating to humanized antibodies may be materially adversely affected, which would have a material adverse affect on the business and financial condition of the Company. The Company is currently reviewing the preliminary view with counsel in preparation for the scheduled oral hearing. Although the entire opposition process, including appeals, may take several years to complete, and although the European patent remains issued and any revocation of the European patent is suspended during the appeals process, the validity of the European patent will be at issue, which may limit the Company's ability to collect royalties or to negotiate future licensing or collaborative research and development arrangements based on this patent. In addition, the Company may need to initiate formal legal actions, if permissible, in order to enforce its rights under its various humanization patents, including the European patent, and there can be no assurance that the Company will successfully enforce its rights under the European or similar U.S. and Japanese patents of the Company. The nine month opposition period for the Company's second European antibody humanization patent has recently begun and the Company expects that, depending upon the outcome of the opposition proceedings for the first European patent, a significant number of notices of opposition may be filed with respect to the second European patent. A similar opposition period in Japan has recently expired with respect to the Company's humanization patent issued in Japan in late 1998. Similar to the process in Europe, third parties had the opportunity to file their opposition to the issuance of the JPO patent. The Company has been advised that three opposition statements have been filed. The Company intends to vigorously defend the European patent and the Japanese patent and, if necessary, the U.S. patents; however, there can be no assurance that the Company will prevail in the opposition proceedings or any litigation contesting the validity or scope of these patents. If the outcome of the European or Japanese opposition proceeding or any litigation involving the Company's antibody humanization patents were to be unfavorable, the Company's ability to collect royalties on existing licensed products and to license its patents relating to humanized antibodies may be materially adversely affected, which could have a material adverse affect on the business and financial condition of the Company. In addition, such proceedings or litigation, or any other proceedings or litigation to protect the Company's intellectual property rights or defend against infringement claims by others, could result in substantial costs and diversion of management's time and attention, which could have a material adverse effect on the business and financial condition of the Company. A number of companies, universities and research institutions have filed patent applications or received patents in the areas of antibodies and other fields relating to the Company's programs. Some of these applications or patents may be competitive with the Company's applications or contain claims that conflict with those made under the Company's patent applications or patents. Such conflicts could prevent issuance of patents to the Company, provoke an interference with the Company's patents or result in a significant reduction in the scope or invalidation of the Company's patents, if issued. An interference is an administrative proceeding conducted by the PTO to determine the priority of invention and may determine questions of patentability. Moreover, if patents are held by or issued to other parties that contain claims relating to the Company's products or processes, and such claims are ultimately determined to be valid, no assurance can be given that the Company would be able to obtain licenses to these patents at a reasonable cost, if at all, or to develop or obtain alternative technology. The Company is aware that Celltech Limited ("Celltech") has been granted a patent by the EPO covering certain humanized antibodies ("European Adair Patent"), which the Company has opposed, and that Celltech has also been issued a corresponding U.S. patent (the "U.S. Adair Patent") that contains claims that may be considered broader in scope than the European Adair Patent. If it were determined that the Company's SMART antibodies were covered by the European or U.S. Adair Patents, the Company might be required to obtain a license under such patents or to significantly alter its processes or products, if necessary to make, use or sell its products in Europe and the U.S. There can be no assurance that the Company would be able to successfully alter its processes or products to avoid infringing such patents or to obtain such a license from Celltech on commercially reasonable terms, if at all, and the failure to do so could have a material adverse effect on the business and financial condition of the Company. In addition, if the claims of the U.S. Adair Patent or any related patent applications conflict with claims in the Company's U.S. patents or patent applications, there can be no assurance that an interference would not be declared by the PTO, which could take several years to resolve and could involve significant expense to the Company. Also, such conflict could prevent issuance of additional patents to the Company relating to humanization of antibodies or result in a significant reduction in the scope or invalidation of the Company's patents, if issued. Moreover, uncertainty as to the validity or scope of patents issued to the Company relating generally to humanization of antibodies may limit the Company's ability to negotiate or collect royalties or to negotiate future collaborative research and development agreements based on these patents. The Company is aware that Lonza Biologics, Inc. has a patent issued in Europe to which the Company does not have a license (although Roche has advised the Company that it has a license covering Zenapax), which may cover a process the Company uses to produce its potential products. If it were determined that the Company's processes were covered by such patent, the Company might be required to obtain a license under such patent or to significantly alter its processes or products, if necessary to manufacture or import its products in Europe. There can be no assurance that the Company would be able to successfully alter its processes or products to avoid infringing such patent or to obtain such a license on commercially reasonable terms, if at all, and the failure to do so could have a material adverse effect on the business and financial condition of the Company. The Company is also aware of an issued U.S. patent assigned to Stanford University and Columbia University to which the Company does not have a license, which may cover a process the Company uses to produce its potential products. The Company has been advised that an exclusive license has been previously granted to a third party under this patent. If it were determined that the Company's processes were covered by such patent, the Company might be required to obtain a license under such patent or to significantly alter its processes or products, if necessary to manufacture or import its products in the U.S. There can be no assurance that the Company would be able to successfully alter its processes or products to avoid infringing such patent or to obtain such a license on commercially reasonable terms, if at all, and the failure to do so could have a material adverse effect on the business and financial condition of the Company. Moreover, any alteration of processes or products to avoid infringing the patent could result in a significant delay in achieving regulatory approval with respect to the products affected by such alterations. In addition to seeking the protection of patents and licenses, the Company also relies upon trade secrets, know-how and continuing technological innovation which it seeks to protect, in part, by confidentiality agreements with employees, consultants, suppliers and licensees. There can be no assurance that these agreements will not be breached, that the Company would have adequate remedies for any breach or that the Company's trade secrets will not otherwise become known, independently developed or patented by competitors. Uncertainty Of Clinical Trial Results. Before obtaining regulatory approval for the commercial sale of any of its potential products, the Company must demonstrate through preclinical studies and clinical trials that the product is safe and efficacious for use in the clinical indication for which approval is sought. There can be no assurance that the Company will be permitted to undertake or continue clinical trials for any of its potential products or, if permitted, that such products will be demonstrated to be safe and efficacious. Moreover, the results from preclinical studies and early-stage clinical trials may not be predictive of results that will be obtained in late-stage clinical trials. Thus, there can be no assurance that the Company's present or future clinical trials will demonstrate the safety and efficacy of any potential products or will result in approval to market products. In advanced clinical development, numerous factors may be involved that may lead to different results in larger, late-stage clinical trials from those obtained in early-stage trials. For example, early-stage clinical trials usually involve a small number of patients, often at a single center, and thus may not accurately predict the actual results regarding safety and efficacy that may be demonstrated with a large number of patients in a late- stage multi-center clinical trial. Also, differences in the clinical trial design between early-stage and late-stage clinical trials may cause different results regarding the safety and efficacy of a product to be obtained. In addition, many early-stage trials are unblinded and based on qualitative evaluations by clinicians involved in the performance of the trial, whereas late-stage trials are generally required to be blinded in order to provide more objective data for assessing the safety and efficacy of the product. Moreover, preliminary results from clinical trials may not be representative of results that may be obtained as the trial proceeds to completion. The Company may at times elect to aggressively enter potential products into Phase I/II trials to determine preliminary safety and efficacy in specific indications. In addition, in certain cases the Company has commenced clinical trials without conducting preclinical animal testing where an appropriate animal model does not exist. Similarly, the Company or its partners at times will conduct potentially pivotal Phase II/III or Phase III trials based on limited Phase I or Phase I/II data. As a result of these and other factors, the Company anticipates that only some of its potential products will show safety and efficacy in clinical trials and that the number of products that fail to show safety and efficacy may be significant. For example, the Company has entered the SMART M195 Antibody into a Phase III clinical trial in acute myelogenous leukemia with a clinical regimen that has not been tested previously with this antibody. Results from the Company's prior Phase II and Phase II/III studies showed a limited number of complete and partial remissions. In addition, the Phase III study was initiated by the Company without a meeting with the FDA or European regulatory authorities to discuss the protocol and its adequacy to support registration of the SMART M195 Antibody. The Company believes that its Phase III program is reasonable in view of the nature and severity of the disease. However, there can be no assurance that the study will be successful or that the FDA or European regulatory authorities will agree that the study will be adequate to obtain regulatory approval, even if the study is successful. Limited Experience With Clinical Trials; Risk Of Delay. The Company has conducted only a limited number of clinical trials to date. There can be no assurance that the Company will be able to successfully commence and complete all of its planned clinical trials without significant additional resources and expertise. In addition, there can be no assurance that the Company will meet its contemplated development schedule for any of its potential products. The inability of the Company or its collaborative partners to commence or continue clinical trials as currently planned, to complete the clinical trials on a timely basis or to demonstrate the safety and efficacy of its potential products, would have a material adverse effect on the business and financial condition of the Company. The rate of completion of the Company's or its collaborators' clinical trials is significantly dependent upon, among other factors, the rate of patient enrollment. Patient enrollment is a function of many factors, including, among others, the size of the patient population, perceived risks and benefits of the drug under study, availability of competing therapies, access to reimbursement from insurance companies or government sources, design of the protocol, proximity of and access by patients to clinical sites, patient referral practices, eligibility criteria for the study in question and efforts of the sponsor of and clinical sites involved in the trial to facilitate timely enrollment in the trial. Delays in the planned rate of patient enrollment may result in increased costs and expenses in completion of the trial or may require the Company to undertake additional studies in order to obtain regulatory approval if the applicable standard of care changes in the therapeutic indication under study. These considerations may lead the Company to consider the termination of ongoing clinical trials or halting further development of a product for a particular indication. Dependence On Collaborative Partners. The Company has collaborative agreements with several pharmaceutical or other companies to develop, manufacture and market certain potential products. The Company granted its collaborative partners certain exclusive rights to commercialize the products covered by these collaborative agreements. In some cases, the Company is relying on its collaborative partners to conduct clinical trials, to compile and analyze the data received from such trials, to obtain regulatory approvals and, if approved, to manufacture and market these licensed products. As a result, the Company often has little or no control over the development and marketing of these potential products and little or no opportunity to review clinical data prior to or following public announcement. The Company's collaborative research agreements are generally terminable by its partners on short notice. Suspension or termination of certain of the Company's current collaborative research agreements could have a material adverse effect on the Company's operations and could significantly delay the development of the affected products. Continued funding and participation by collaborative partners will depend on the timely achievement of research and development objectives by the Company, the retention of key personnel performing work under those agreements and the successful achievement of research or clinical trial goals, none of which can be assured, as well as on each collaborative partner's own financial, competitive, marketing and strategic considerations. Such considerations include, among other things, the commitment of management of the collaborative partners to the continued development of the licensed products, the relationships among the individuals responsible for the implementation and maintenance of the collaborative efforts, the relative advantages of alternative products being marketed or developed by the collaborators or by others, including their relative patent and proprietary technology positions, and their ability to manufacture potential products successfully. The Company's ability to enter into new collaborations and the willingness of the Company's existing collaborators to continue development of the Company's potential products depends upon, among other things, the Company's patent position with respect to such products. In this regard, the Company has been issued patents by PTO, EPO and JPO with claims that the Company believes, based on its survey of the scientific literature, cover most humanized antibodies. The Company has also been allowed patents with similar claims in other countries and has applied for similar patents in certain other countries. See "Risk Factors -- Uncertainty of Patents and Proprietary Technology; Opposition Proceedings." The EPO and JPO patents are currently in the opposition proceeding stages in those patent offices. In addition, all of the Company's antibody humanization patents may be further challenged through administrative or judicial proceedings. The Company has entered into several collaborations related to both the humanization and patent licensing of certain antibodies whereby it granted licenses to its patent rights relating to such antibodies, and the Company anticipates entering into additional collaborations and patent licensing agreements partially as a result of the Company's patent and patent applications with respect to humanized antibodies. As a result, the inability of the Company to successfully defend the opposition proceedings before the EPO or JPO or, if necessary, to defend patents granted by the PTO, EPO or JPO or to successfully prosecute the corresponding patent applications in other countries could adversely affect the ability of the Company to collect royalties on existing licensed products, and enter into additional collaborations, humanization or patent licensing agreements and could therefore have a material adverse effect on the Company's business or financial condition. No Sales And Marketing Experience; Further Development of Zenapax. The Company intends to market and sell certain of its products, if successfully developed and approved, either directly or through sales and marketing partnership arrangements with collaborative partners. Although the Company does not expect to establish a direct sales capability at this time, the Company has no history or experience in sales, marketing or distribution. To market products directly, the Company must either establish a more extensive marketing group and direct sales force or obtain the assistance of another company. There can be no assurance that the Company will be able to establish marketing, sales and distribution capabilities or succeed in gaining market acceptance for its products. If the Company enters into co- promotion or other marketing or patent licensing arrangements with pharmaceutical or biotechnology companies, the Company's revenues will be subject to the payment provisions of such arrangements and dependent on the efforts of third parties. The Company has recently obtained rights from Roche to conduct development activities for Zenapax in autoimmune indications. The Company has no experience in conducting development activities for products that are currently approved and marketed for use in other indications such as Zenapax. U.S. Food and Drug Administration ("FDA") regulations prohibit promotion of the use of Zenapax for unapproved indications until appropriate clinical studies are conducted and the data from those studies is presented for the FDA to review and approve. There can be no assurance that the Company will be able to successfully develop Zenapax in autoimmune indications and substantial investment by the Company in such development may be required with no assurance that such efforts will be successful. Even if such development efforts succeed, there can be no assurance that the Company, by itself or with a collaborative partner, will successfully market, promote and detail Zenapax in those countries where PDL has or obtains such rights. The inability of the Company, Roche or its other collaborators to develop, market and sell Zenapax could have a material adverse effect on the business and financial condition of the Company. Absence Of Manufacturing Experience. Of the products which are currently in clinical development by the Company, Roche is responsible for manufacturing Zenapax, Smithkline Beecham is responsible for manufacturing the humanized anti-IL-4 antibody and BioNet is responsible for manufacturing the SMART Anti-L-Selectin Antibody. The Company is responsible for manufacturing the Company's other products for its own development. The Company currently leases approximately 47,000 square feet housing its manufacturing facilities in Plymouth, Minnesota. The Company intends to continue to manufacture potential products for use in preclinical and clinical trials using this manufacturing facility in accordance with standard procedures that comply with current Good Manufacturing Practices ("cGMP") and appropriate regulatory standards. The manufacture of sufficient quantities of antibody products in accordance with such standards is an expensive, time-consuming and complex process and is subject to a number of risks that could result in delays. For example, the Company has experienced some difficulties in the past in manufacturing certain potential products on a consistent basis. Production interruptions, if they occur, could significantly delay clinical development of potential products, reduce third party or clinical researcher interest and support of proposed clinical trials, and possibly delay commercialization of such products and impair their competitive position, which would have a material adverse effect on the business and financial condition of the Company. The Company has no experience in manufacturing commercial quantities of its potential products and currently does not have sufficient capacity to manufacture all of its potential products on a commercial scale. In order to obtain regulatory approvals and to create capacity to produce its products for commercial sale at an acceptable cost, the Company will need to improve and expand its existing manufacturing capabilities, including demonstration to the FDA and corresponding foreign authorities of its ability to manufacture its products using controlled, reproducible processes. The Company has approved plans to improve and expand the capacity of its current manufacturing facility. Such plans, if fully implemented, will result in substantial costs to the Company. There can be no assurance that construction delays will not occur, and any such delays could impair the Company's ability to produce adequate supplies of its potential products for clinical use or commercial sale on a timely basis. Further, there can be no assurance that the Company will successfully improve and expand its manufacturing capability sufficiently to obtain necessary regulatory approvals and to produce adequate commercial supplies of its potential products on a timely basis. Failure to do so could delay commercialization of such products and impair their competitive position, which could have a material adverse effect on the business or financial condition of the Company. Uncertainties Resulting From Manufacturing Changes. Manufacturing of antibodies for use as therapeutics in compliance with regulatory requirements is complex, time-consuming and expensive. When certain changes are made in the manufacturing process, it is necessary to demonstrate to the FDA and corresponding foreign authorities that the changes have not caused the resulting drug material to differ significantly from the drug material previously produced, if results of prior preclinical studies and clinical trials performed using the previously produced drug material are to be relied upon in regulatory filings. Such changes could include, for example, changing the cell line used to produce the antibody, changing the fermentation or purification process or moving the production process to a new manufacturing plant. Depending upon the type and degree of differences between the newer and older drug material, various studies could be required to demonstrate that the newly produced drug material is sufficiently similar to the previously produced drug material, possibly requiring additional animal studies or human clinical trials. Manufacturing changes have been made or are likely to be made for the production of the Company's products currently in clinical development, in particular the SMART M195 and SMART Anti-CD3 Antibodies. There can be no assurance that such changes will not result in delays in development or regulatory approvals or, if occurring after regulatory approval, in reduction or interruption of commercial sales. In addition, manufacturing changes to its manufacturing facility may require the Company to shut down production for a period of time. There can be no assurance that the Company will be able to reinitiate production in a timely manner, if at all, following such shutdown. Delays as a result of manufacturing changes or shutdown of the manufacturing facility could have an adverse effect on the competitive position of those products and could have a material adverse effect on the business and financial condition of the Company. Dependence On Suppliers. The Company is dependent on outside vendors for the supply of raw materials used to produce its product candidates. The Company currently qualifies only one or a few vendors for its source of certain raw materials. Therefore, once a supplier's materials have been selected for use in the Company's manufacturing process, the supplier in effect becomes a sole or limited source of such raw materials to the Company due to the extensive regulatory compliance procedures governing changes in manufacturing processes. Although the Company believes it could qualify alternative suppliers, there can be no assurance that the Company would not experience a disruption in manufacturing if it experienced a disruption in supply from any of these sources. Any significant interruption in the supply of any of the raw materials currently obtained from such sources, or the time and expense necessary to transition a replacement supplier's product into the Company's manufacturing process, could disrupt the Company's operations and have a material adverse effect on the business and financial condition of the Company. A problem or suspected problem with the quality of raw materials supplied could result in a suspension of clinical trials, notification of patients treated with products or product candidates produced using such materials, potential product liability claims, a recall of products or product candidates produced using such materials, and an interruption of supplies, any of which could have a material adverse effect on the business or financial condition of the Company. Competition; Rapid Technological Change. The Company's potential products are intended to address a wide variety of disease conditions, including autoimmune diseases, inflammatory conditions and cancers. Competition with respect to these disease conditions is intense and is expected to increase. This competition involves, among other things, successful research and development efforts, obtaining appropriate regulatory approvals, establishing and defending intellectual property rights, successful product manufacturing, marketing, distribution, market and physician acceptance, patient compliance, price and potentially securing eligibility for reimbursement or payment for the use of the Company's products. The Company believes its most significant competitors may be fully integrated pharmaceutical companies with substantial expertise in research and development, manufacturing, testing, obtaining regulatory approvals, marketing and securing eligibility for reimbursement or payment, and substantially greater financial and other resources than the Company. Smaller companies also may prove to be significant competitors, particularly through collaborative arrangements with large pharmaceutical companies. Furthermore, academic institutions, governmental agencies and other public and private research organizations conduct research, seek patent protection, and establish collaborative arrangements for product development, clinical development and marketing. These companies and institutions also compete with the Company in recruiting and retaining highly qualified personnel. The biotechnology and pharmaceutical industries are subject to rapid and substantial technological change. The Company's competitors may develop and introduce other technologies or approaches to accomplishing the intended purposes of the Company's products which may render the Company's technologies and products noncompetitive and obsolete. In addition to currently marketed competitive drugs, the Company is aware of potential products in research or development by its competitors that address all of the diseases being targeted by the Company. These and other products may compete directly with the potential products being developed by the Company. In this regard, the Company is aware that potential competitors are developing antibodies or other compounds for treating autoimmune diseases, inflammatory conditions and cancers. In particular, a number of other companies have developed and will continue to develop human and humanized antibodies. In addition, protein design is being actively pursued at a number of academic and commercial organizations, and several companies have developed or may develop technologies that can compete with the Company's SMART and human antibody technologies. In particular, the Company believes that certain companies that use alternative technologies to produce human-like antibodies have recently entered into collaborative arrangements that are competitive with and may negatively impact the Company's efforts to enter into humanization and development arrangements for early stage antibody research and development. There can be no assurance that competitors will not succeed in more rapidly developing and marketing technologies and products that are more effective than the products being developed by the Company or that would render the Company's products or technology obsolete or noncompetitive. Further, there can be no assurance that the Company's collaborative partners will not independently develop products competitive with those licensed to such partners by the Company, thereby reducing the likelihood that the Company will receive revenues under its agreements with such partners. Any potential product that the Company or its collaborative partners succeed in developing and for which regulatory approval is obtained must then compete for market acceptance and market share. For certain of the Company's potential products, an important factor will be the timing of market introduction of competitive products. Accordingly, the relative speed with which the Company and its collaborative partners can develop products, complete the clinical testing and approval processes, and supply commercial quantities of the products to the market compared to competitive companies is expected to be an important determinant of market success. For example, Novartis has received approval to market Simulect, a product competitive with Zenapax, in the U.S. and Europe. In addition to an earlier launch in Europe, Novartis has a significant marketing and sales force directed to the transplantation market and there can be no assurance that Roche will successfully market and sell Zenapax against this and other available products. Other competitive factors include the capabilities of the Company's collaborative partners, product efficacy and safety, timing and scope of regulatory approval, product availability, marketing and sales capabilities, reimbursement coverage, the amount of clinical benefit of the Company's products relative to their cost, method of administration, price and patent protection. There can be no assurance that the Company's competitors will not develop more efficacious or more affordable products, or achieve earlier product development completion, patent protection, regulatory approval or product commercialization than the Company. The occurrence of any of these events by the Company's competitors could have a material adverse effect on the business and financial condition of the Company. Dependence on Key Personnel. The Company's success is dependent to a significant degree on its key management personnel. To be successful, the Company will have to retain its qualified clinical, manufacturing, scientific and management personnel. The Company faces competition for personnel from other companies, academic institutions, government entities and other organizations. There can be no assurance that the Company will be successful in hiring or retaining qualified personnel, and its failure to do so could have a material adverse effect on the business and financial condition of the Company. Potential Volatility Of Stock Price. The market for the Company's securities is volatile and investment in these securities involves substantial risk. The market prices for securities of biotechnology companies (including the Company) have been highly volatile, and the stock market from time to time has experienced significant price and volume fluctuations that may be unrelated to the operating performance of particular companies. Factors such as disappointing sales of approved products, approval or introduction of competing products and technologies, results of clinical trials, delays in manufacturing or clinical trial plans, fluctuations in the Company's operating results, disputes or disagreements with collaborative partners, unfavorable news or information resulting in the reduction in value of significant intellectual property assets, market reaction to announcements by other biotechnology or pharmaceutical companies, announcements of technological innovations or new commercial therapeutic products by the Company or its competitors, initiation, termination or modification of agreements with collaborative partners, failures or unexpected delays in manufacturing or in obtaining regulatory approvals or FDA advisory panel recommendations, developments or disputes as to patent or other proprietary rights, loss of key personnel, litigation, public concern as to the safety of drugs developed by the Company, regulatory developments in either the U.S. or foreign countries (such as opinions, recommendations or statements by the FDA or FDA advisory panels, health care reform measures or proposals), market acceptance of products developed and marketed by the Company's collaborators, sales of the Company's common stock held by collaborative partners or insiders and general market conditions could result in the Company's failure to meet the expectations of securities analysts or investors. In such event, or in the event that adverse conditions prevail or are perceived to prevail with respect to the Company's business, the price of the Company's common stock would likely drop significantly. With respect to the possible sale of the Company's common stock held by collaborative partners, Roche acquired 1,682,877 shares of the Company's common stock held by Corange Limited which are no longer subject to the contractual limitations on disposition other than certain restrictions on transfers of significant blocks of stock. In the past, following significant drops in the price of a company's common stock, securities class action litigation has often been instituted against such a company. Such litigation against the Company could result in substantial costs and a diversion of management's attention and resources, which would have a material adverse effect on the Company's business and financial condition. ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K (a) Exhibits Exhibit 10.46 Agreement of Purchase and Sale between Fremont Holding L.L.C., a Delaware limited liability company, as assignee effective September 13, 1999, and Ardenstone LLC, a Delaware limited liability company, effective June 21, 1999. Exhibit 10.47 Promissory Note between Fremont Holding L.L.C., a Delaware limited liability company and Wells Fargo Bank, National Association, dated September 9, 1999. Exhibit 10.48 Deed of Trust and Absolute Assignment of Rents and Security Agreement (Fixture Filings) between Fremont Holding L.L.C., a Delaware limited liability company and Wells Fargo Bank, National Association, dated September 9, 1999. Exhibit 10.49 Patent Rights Agreement between the Company and Smithkline Beecham Corporation, effective as of September 28, 1999 (with certain confidential portions deleted and marked by notation indicating such deletion). Exhibit 10.50 IL-5 Patent License Agreement between the Company and Smithkline Beecham Corporation, effective as of September 28, 1999 (with certain confidential portions deleted and marked by notation indicating such deletion). Exhibit 10.51 Development and License Agreement between the Company and Smithkline Beecham Corporation, effective as of September 28, 1999 (with certain confidential portions deleted and marked by notation indicating such deletion). Exhibit 10.52 Amended and Restated Agreement between the Company and Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd, dated as of October 20, 1999 (with certain confidential portions deleted and marked by notation indicating such deletion). Exhibit 10.53 Amended and Restated Agreement between the Company and F. Hoffmann-La Roche Ltd, dated as of October 20, 1999 (with certain confidential portions deleted and marked by notation indicating such deletion). Exhibit 21.1 Fremont Holding L.L.C., a Delaware limited liability company. Fremont Management, Inc., a Delaware corporation, doing business in California as Delaware Fremont Management. (b) No Reports on Form 8-K were filed during the quarter ended June 30, 1999. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its be half by the undersigned thereunto duly authorized. Dated: November 15, 1999 PROTEIN DESIGN LABS, INC. (Registrant) /s/Laurence Jay Korn Chief Executive Officer, Chairperson of the Board of Directors (Principal Executive Officer) /s/Robert Kirkman Vice President Corporate Communications and Business Development (Principal Accounting Officer)


AGREEMENT OF PURCHASE AND SALE
SUMMARY OF CERTAIN TERMS
EFFECTIVE DATE:
June ___,1999
SELLER:
ARDENSTONE LLC, a Delaware limited liability company
SELLER'S ADDRESSES:
c/o Freestone Properties, Inc.
4400 Bohannon Drive, Suite 260
Menlo Park, CA  94025
Attn:  Mr. Michael E. Tamas
Telephone:      (650) 329-9030
Facsimile:      (650) 329-0129
        With a copy to:
Brobeck, Phleger & Harrison LLP
One Market
Spear Street Tower, Floor 25
San Francisco, CA  94105
Attn:  Michael F. Potter, Esq.
Telephone:      (415) 442-1163
Facsimile:      (415) 979-2580
BUYER:
PROTEIN DESIGN LABS, INC., a Delaware corporation
BUYER'S ADDRESS:
34801 Campus Drive
Fremont, CA  94555
Attn:  Chief Executive Officer
Telephone:      (510) 574-1400
Facsimile:      (510) 574-1500
        With a copy to:
Protein Design Labs, Inc.
34801 Campus Drive
Fremont, CA  94555
Attn:  General Counsel
Telephone:      (510) 574-1400
Facsimile:      (510) 574-1500
REAL PROPERTY:
That certain improved real property commonly known as
34801 Campus Drive/7450 Paseo Padre Parkway and
34781 Campus Drive/7400 Paseo Padre Parkway, located
in Ardenwood Corporate Commons, Fremont, California.
The land portion is more particularly described in
Exhibit A, attached hereto.

PURCHASE PRICE:
Thirteen Million Five Hundred Thirty Thousand Dollars
($13,530,000.00).
DUE DILIGENCE
PERIOD:

The period commencing on the Effective Date and
ending at 5:00 p.m. Pacific Daylight Savings Time on
the thirtieth (30th) day after the Effective Date.
FINANCING CONTINGENCY
EXPIRATION DATE:


The sixtieth (60th) day after the Effective Date.
SELLER'S
REPRESENTATIVE:

Mr. Michael E. Tamas
BUYER'S
REPRESENTATIVES:

Mr. Glen Y. Sato and Mr. Douglas O. Ebersole
ESCROW HOLDER:
First American Title Company
1850 Mt. Diablo Blvd., Suite #300
Walnut Creek, CA  94596
Attn:  Ms. Kitty Schlesinger
Telephone:      (925) 927-2100
Facsimile:      (925) 927-2180

SCHEDULED
CLOSING DATE:

The fifteenth (15th) day after the satisfaction or
waiver of the conditions precedent set forth in
Sections 9.2.1, 9.2.2, 9.2.3 and 9.2.4.
SELLER'S BROKER:
None
BUYER'S BROKER:
Cornish and Carey Commercial
CLOSING COST
ALLOCATIONS:


- - BUYER:
TITLE INSURANCE
100%

ESCROW FEES
100%

RECORDING FEES (DEED)
100%

ALTA SURVEY
100%

PHASE I ENVIRONMENTAL REPORT
100%
- - SELLER:
COUNTY TRANSFER TAXES
100%

RECORDING FEES (OTHER)
100%


TABLE OF CONTENTS
Page
1.      Purchase and Sale of Property
1.1.    Real Property
1.2.    Intangible Property
1.3.    Lease
2.      Purchase Price
3.      Escrow.
4.      Payment of Purchase Price
5.      Remedies; Liquidated Damages
5.1.    Tenant Improvement Allowance
5.2.    Remedies
5.3.    LIQUIDATED DAMAGES
6.      Due Diligence
6.1.    Seller's Studies
6.2.    Survey
6.3.    Buyer's Inspections
6.4.    Designation of Representatives
6.5.    Disapproval of Seller's Studies or Buyer's Inspections
6.6.    Title Review
6.7.    Modification of Title Report
6.8.    Assumption of Bonds
7.      Status
7.1.    As-Is Purchase
7.2.    Release
7.3.    Operation of Property Through Closing Date
8.      Grant Deed
9.      Conditions Precedent
9.1.    Seller
9.2.    Buyer
9.3.    Failure of Buyer's Conditions Precedent
9.4.    Waiver
10.     Closing Date
11.     Escrow
11.1.   Time
11.2.   Documents
11.3.   Procedure
11.4.   Possession
11.5.   Deliveries Outside Escrow
11.6.   Escrow Instructions
11.7.   Closing Costs and Prorations
12.     Brokerage Commission
13.     Condemnation/Casualty
13.1.   Right to Terminate
13.2.   Election to Terminate
13.3.   No Election to Terminate
13.4.   Definition of Materiality
13.5.   Damage Caused by Tenant
14.     Representations and Warranties
14.1.   Buyer
14.2.   Seller
14.3.   No Warranties
15.     Miscellaneous
15.1.   Indemnity
15.2.   Successors and Assigns
15.3.   Entire Agreement
15.4.   Attorneys' Fees
15.5.   Governing Law
15.6.   Further Assurances
15.7.   Severability
15.8.   Notices
15.9.   Counterparts
15.10.  Time
15.11.  Nonwaiver
15.12.  Survival
15.13.  Captions
15.14.  Exhibits
15.15.  Construction
15.16.  Confidentiality
15.17.  Tenant Improvement Allowance
16.     Deferred Exchange

EXHIBITS:       A       -       Land
                B       -       Lease
                C       -       Service Contracts
                D       -       Due Diligence Documents
                E       -       Grant Deed
                F       -       General Assignment
                G       -       Non-Foreign Certificate
                H       -       Seller's Date Down Certificate
                I       -       Buyer's Date Down Certificate

AGREEMENT OF PURCHASE AND SALE
        THIS AGREEMENT OF PURCHASE AND SALE (this "Agreement") is entered into
as of June ___, 1999 (the "Effective Date"), by and among ARDENSTONE LLC, a
Delaware limited liability company ("Seller"), and PROTEIN DESIGN LABS, INC.,
a Delaware corporation ("Buyer").
        THIS AGREEMENT IS ENTERED INTO on the basis of the following facts,
intentions and understandings of the parties:
A. Seller is the owner of the land (the "Land") and the
improvements located thereon (the "Improvements"), commonly known as 34801
Campus Drive/7450 Paseo Padre Parkway and 34781 Campus Drive/7400 Paseo Padre
Parkway, located in Ardenwood Corporate Commons, Fremont, California.  The
Land is more particularly described in Exhibit A, attached hereto.  The Land
and the Improvements are hereinafter collectively referred to as the "Real
Property."
B. The Real Property is subject to that certain lease (the
"Lease") listed on Exhibit B, attached hereto.
C. Seller desires to sell the Property (as hereinafter defined) to
Buyer, and Buyer desires to purchase the Property from Seller, in accordance
with the terms of this Agreement.
        NOW THEREFORE, for valuable consideration, the receipt and adequacy of
which are hereby acknowledged, Seller and Buyer hereby agree as follows:
Purchase and Sale of Property.  Seller shall sell and assign to Buyer,
and Buyer shall purchase and assume from Seller, on the terms, covenants and
conditions set forth in this Agreement, the following described property
(collectively, the "Property"):
Real Property.  All of Seller's interest in the Real Property, and
all rights and appurtenances pertaining thereto;
Intangible Property.  Seller's interest in any and all intangible
personal property (collectively, the "Intangible Property") arising out of or
in connection with the ownership or operation of the Real Property, including
the right to use the current names of the Real Property, all licenses,
permits, certificates of occupancy and franchises issued to Seller by federal,
state or local municipal authorities relating to the use, maintenance,
occupancy or operation of the Real Property, all warranties given by third
parties with respect to the Real Property (including all warranties given to
Seller under or in connection with construction contracts entered into by
Seller for the construction of Improvements) and all service, equipment,
maintenance and employment agreements (collectively, the "Service Contracts")
entered into by Seller with respect to the Real Property and listed on
Exhibit C, attached hereto; and
Lease.  The Lease, together with all security and damage deposits
held by Seller in accordance with the terms of the Lease.
Purchase Price.  Buyer shall pay to Seller the purchase price (the
"Purchase Price") in the amount of Thirteen Million Five Hundred
Thirty Thousand Dollars ($13,530,000.00) for the Property.  The Purchase Price
shall be paid in the manner described in Section 4.
Escrow.  Buyer and Seller shall open an escrow account (the "Escrow")
with First American Title Company ("Escrow Holder") within three (3) business
days after the expiration of the Due Diligence Period.
Payment of Purchase Price.  On or before Close of Escrow, Buyer shall
deposit with Escrow Holder by immediately available federal wire transfer or
cashier's check an amount equal to the Purchase Price, plus or minus the
closing adjustments and prorations described in Section 11.7.
Remedies; Liquidated Damages.
Tenant Improvement Allowance.  Pursuant to the terms of the Lease,
Seller, as landlord, is obligated to pay to Buyer, as tenant, a tenant
improvement allowance (the "Tenant Improvement Allowance") in the amount of
One Million Eight Hundred Forty-Five Thousand Dollars ($1,845,000.00) upon the
satisfaction of certain conditions set forth therein.  With respect thereto,
Buyer, as tenant, and Seller, as landlord, hereby agree that, notwithstanding
anything to the contrary contained in the Lease, (i) in the event that the
transfer of the Property from Seller to Buyer is not consummated due to a
default by Buyer under this Agreement, the amount of the Tenant Improvement
Allowance shall be reduced by Five Hundred Thousand Dollars ($500,000.00) (the
"Liquidated Damages Amount") and Seller shall be entitled to retain the
Liquidated Damages Amount as liquidated damages pursuant to Section 5.3 below
and (ii) Buyer's entitlement to receive the Tenant Improvement Allowance shall
be deferred until (A) the termination of this Agreement or thirty (30) days
after Close of Escrow (whichever is first to occur) and (B) Buyer's
satisfaction of all of the conditions precedent set forth in Section VI.B of
the Work Letter, attached as Exhibit C to the Lease, regarding Seller's
obligation to pay to Buyer the Tenant Improvement Allowance.  In the event
that the transfer of the Property from Seller to Buyer is not consummated due
to any reason other than a default by Buyer under this Agreement, the amount
of the Tenant Improvement Allowance shall be One Million Eight Hundred
Forty-Five Thousand Dollars (1,845,000.00).
Remedies.  If the transfer of the Property from Seller to Buyer
does not close as a result of a default by Seller under this Agreement,
Buyer's sole remedy shall be either (but not both) (i) reimbursement of all
third party costs incurred by Buyer as a result of entering into this
Agreement (e.g., attorneys' fees) and in performing any due diligence in
connection with the Property, not to exceed Fifty Thousand Dollars
($50,000.00) in the aggregate (with Buyer thereby waiving any other remedy,
including specific performance, which Buyer may have against Seller), or
(ii) an action for specific performance of this Agreement (with Buyer thereby
waiving any other remedy which Buyer may have against Seller at law or in
equity).  In addition, provided and on the condition that (i) Buyer is the
tenant under the Lease and (ii) Buyer has satisfied all of the conditions
precedent set forth in Section VI.B of the Work Letter attached as Exhibit C
to the Lease with respect to Seller's obligation to pay to Buyer the Tenant
Improvement Allowance, Seller shall immediately pay to Buyer the Tenant
Improvement Allowance owed to Buyer under the Lease.
LIQUIDATED DAMAGES.  IF THE TRANSFER OF THE PROPERTY FROM SELLER
TO BUYER IS NOT CONSUMMATED DUE TO A DEFAULT BY BUYER UNDER THIS AGREEMENT,
SELLER SHALL HAVE THE RIGHT TO TERMINATE THIS AGREEMENT IN WRITING IMMEDIATELY
AND WITHOUT FURTHER OBLIGATION TO BUYER, AND SELLER SHALL HAVE THE RIGHT TO
(1) REDUCE THE TENANT IMPROVEMENT ALLOWANCE DUE TO THE TENANT UNDER THE LEASE
BY AN AMOUNT EQUAL TO THE LIQUIDATED DAMAGES AMOUNT AND (2) RETAIN THE
LIQUIDATED DAMAGES AMOUNT AS LIQUIDATED DAMAGES AND AS SELLER'S SOLE REMEDY
(EXCEPT AS PROVIDED BELOW).  THE PARTIES AGREE THAT SELLER'S ACTUAL DAMAGES AS
A RESULT OF BUYER'S DEFAULT UNDER THIS AGREEMENT WOULD BE DIFFICULT OR
IMPOSSIBLE TO DETERMINE, AND THE LIQUIDATED DAMAGES AMOUNT IS THE BEST
ESTIMATE OF THE AMOUNT OF DAMAGES SELLER WOULD SUFFER AS A RESULT OF SUCH
DEFAULT; PROVIDED, HOWEVER, THAT THIS PROVISION SHALL NOT , AFFECT BUYER'S
RESTORATION OBLIGATIONS UNDER SECTION 6.3.6, OR WAIVE OR AFFECT BUYER'S
INDEMNITY OBLIGATIONS UNDER SECTIONS 6.3.7 AND 12 AND SELLER'S RIGHTS TO THOSE
INDEMNITY OBLIGATIONS UNDER THIS AGREEMENT.  THE PAYMENT OF THE LIQUIDATED
DAMAGES AMOUNT AS LIQUIDATED DAMAGES IS NOT INTENDED AS A FORFEITURE OR
PENALTY WITHIN THE MEANING OF CALIFORNIA CIVIL CODE SECTIONS 3275 OR 3369, BUT
IS INTENDED TO CONSTITUTE LIQUIDATED DAMAGES TO SELLER PURSUANT TO CALIFORNIA
CIVIL CODE SECTIONS 1671, 1676 AND 1677.  SELLER HEREBY WAIVES THE PROVISIONS
OF CALIFORNIA CIVIL CODE SECTION 3389.  THE PARTIES WITNESS THEIR AGREEMENT TO
THIS LIQUIDATED DAMAGES PROVISION BY INITIALING THIS SECTION:
Seller:  (_____)                Buyer: (_____)
Due Diligence.
Seller's Studies.  Seller has provided to Buyer copies of the
documents (the "Due Diligence Documents") listed in Exhibit D, attached
hereto.  In addition, within five (5) days after Buyer's written request,
Seller shall make available at Seller's office for Buyer's review all studies,
reports, maps, surveys and other documents and information relating to the
Property in Seller's possession (together with the Due Diligence Documents
hereinafter referred to as the "Due Diligence Materials"); provided, however,
that Seller shall not make available for Seller's review and the Due Diligence
Materials shall not include (i) any proprietary information related to
Seller's ownership of the Property or Seller's financing or proposed financing
of the Property or other documents relating to Seller's venture (including,
without limitation, balance sheets, internal financial reports, lease
proposals and the operating agreement or partnership agreement of Seller),
(ii) any appraisals of the Property, (iii) any offers or solicitations to
purchase, sell or lease the Property, and (iv) any loan documents of Seller or
any correspondence between Seller and Seller's lenders.  At Buyer's request,
Seller shall deliver to Buyer copies of specific Due Diligence Materials.  The
Due Diligence Materials are for Buyer's use in connection with Buyer's
investigation of the Property.  Buyer acknowledges that the Due Diligence
Materials were prepared by or at the direction of others and that, except as
otherwise provided in Section 14.2, Seller is not making any representation or
warranty of any kind with respect to the Due Diligence Materials, including
their accuracy, completeness or suitability for reliance thereon by Buyer.
Survey.  Buyer, at its sole cost and expense, shall have the right
to update that certain ALTA survey (the "Survey") of the Real Property
prepared by Kier & Wright, dated September 2, 1998.
Buyer's Inspections.  During the period (the "Contract Period")
commencing on the Effective Date and ending on the earlier of Close of Escrow
or termination of this Agreement, Buyer and Buyer's representatives, agents,
consultants and contractors shall have the right to inspect (including the
performance of tests, surveys and other studies, inspections and
investigations) the Property including, without limitation, structural
components of the Improvements, plumbing, sewer/septic system, wells, heating,
ventilation and air conditioning systems, electrical systems and components,
built-in appliances, roofs, soils, foundation, existing pipelines and power
lines (each, a "Buyer Inspection"), pursuant to the following terms and
conditions:
No Default.  Buyer shall not be in default of this
Agreement.
Buyer's Expense.  Each Buyer Inspection shall be at Buyer's
sole cost and expense.
Licensed and Qualified.  The persons or entities performing
the Buyer Inspections shall be properly licensed and qualified and shall have
obtained all appropriate permits for performing relevant tests on the Real
Property and shall have delivered to Seller, prior to performing any tests on
the Real Property or entering the Real Property, copies of insurance policies
or certificates of insurance evidencing that such consultants have obtained
and are maintaining a policy of general commercial liability insurance
(occurrence form) having a combined single limit of not less than One Million
Dollars ($1,000,000.00) per occurrence and workers' compensation insurance
with limits not less than those required by law.
Seller's Approval Rights.  Seller shall have the right to
approve of any proposed physical testing or drilling of the Real Property,
which approval may not be unreasonably withheld.
Seller's Representatives.  Buyer shall provide Seller with
twenty-four (24) hours' prior written or oral notice of the date and time on
which Buyer proposes to conduct any physical testing or drilling of the Real
Property and Seller shall have right to have one (1) or more representatives
of Seller present during the physical testing or drilling.
Restoration.  Buyer, at Buyer's sole cost and expense, shall
immediately restore the Real Property to its condition existing immediately
prior to Buyer's Inspections if, for any reason, the Property is not
transferred by Seller to Buyer.  Until restoration is complete, Buyer shall
take all steps necessary to ensure that any conditions on the Real Property
created by Buyer's Inspections do not interfere with the normal operation of
the Real Property, create any dangerous, unhealthy, unsightly or noisy
conditions on the Real Property or violate the terms of the Lease.  The
restoration obligation contained in this Section 6.3.6 shall survive the
termination of this Agreement.
Indemnity.  Buyer shall indemnify, protect and defend (with
counsel reasonably acceptable to Seller) and hold harmless Seller for, from
and against any and all claims, damages, costs, liabilities and losses
(including mechanics' liens) and expenses (including, without limitation,
attorneys' fees) arising out of any entry by Buyer or its agents,
representatives, consultants or contractors; provided that this indemnity
shall not apply to, and Buyer shall not be obligated to remedy, any pre-
existing conditions, including those discovered by Buyer in any inspection
conducted in connection with this Agreement.  Notwithstanding the foregoing,
nothing contained in this Section shall reduce or modify Buyer's remediation
or indemnification obligations contained in the Lease.  The indemnity
obligations contained in this Section 6.3.7 shall survive Close of Escrow or
any termination of this Agreement.
Confidentiality.  Each Buyer's Inspection, and the results
thereof, shall remain confidential pursuant to the terms of Section 15.16 of
this Agreement.
Designation of Representatives.  Seller and Buyer each shall
designate one (1) or more representatives to act for them in scheduling and
arranging visits to and inspections of the Real Property and in coordinating
the delivery of and/or access to the Due Diligence Materials pursuant to
Section 6.1 above.  Buyer's Representative and Seller's Representative are
identified in the Summary of Certain Terms.  Each party shall have the right
to change its respective representative by notice to the other party given in
accordance with Section 15.8.
Disapproval of Seller's Studies or Buyer's Inspections.
Termination Notice.  Buyer shall have the right, at any time
during the period (the "Due Diligence Period") commencing on the Effective
Date and ending at 5:00 p.m. Pacific Daylight Savings Time on the
thirtieth (30th) day after the Effective Date, to disapprove of the results of
Buyer's review of the Due Diligence Materials, Buyer's Inspections of the Real
Property or any aspect of this transaction, by notifying Seller in writing (a
"Termination Notice").  If Buyer fails to provide Seller with a Termination
Notice prior to the expiration of the Due Diligence Period, then Buyer shall
be deemed to have disapproved the results of Buyer's review of the Due
Diligence Materials and Buyer's Inspections.  Nothing contained herein shall
prevent Buyer from waiving the condition precedent described in Section 9.2.1
and proceeding with Close of Escrow pursuant to the terms of this Agreement.
Result of Termination Notice.  If Buyer delivers a
Termination Notice to Seller during the Due Diligence Period or is deemed to
have disapproved the results of Buyer's review of the Due Diligence Materials
or Buyer's Inspections, then (i) this Agreement, and all of the obligations,
rights and liabilities of Buyer and Seller to each other hereunder (except for
Buyer's restoration obligation under Section 6.3.6, Buyer's indemnity
obligations under this Agreement, and the parties' confidentiality obligations
under Section 15.16) shall terminate; (ii) Buyer shall immediately return to
Seller all originals and copies of the Due Diligence Materials which Buyer or
Buyer's consultants, agents, contractors or representatives received from
Seller or copied from Seller's files and (iii) Buyer shall deliver to Seller,
at no cost to Seller, the updated Survey and any environmental or geotechnical
reports, tests and studies (collectively, the "Buyer Reports") obtained or
conducted by Buyer in connection with Buyer's due diligence of the Real
Property to the extent requested by Seller within five (5) days after Seller's
receipt of the Termination Notice.  Buyer makes no representation or warranty
regarding the Buyer Reports, including their accuracy, completeness or
suitability for reliance thereon by Seller.
Title Review.  Buyer shall notify Seller in writing (the "Title
Objection Notice") prior to the expiration of the Due Diligence Period if
Buyer objects to the condition of title as shown on a title report (the "Title
Report") for the Real Property issued by First American Title Insurance
Company ("Title Company") or any items shown on the Survey.  Buyer shall be
deemed to have approved the condition of title as shown on the Title Report
and the Survey if Buyer fails to deliver to Seller the Title Objection Notice
by the expiration of the Due Diligence Period.  If Buyer timely delivers to
Seller the Title Objection Notice, Seller shall notify Buyer in writing within
five (5) business days after Seller's receipt of the Title Objection Notice of
Seller's election to either (i) attempt to cure or satisfy all or some of the
objection(s) (the "Objections") set forth in the Title Objection Notice and/or
(ii) not to cure or satisfy any of the Objections.  Seller shall have until
Close of Escrow to cure or satisfy any Objections that Seller elects to cure
or satisfy.  If Seller fails to notify Buyer in writing of its election within
the five (5) business day period referenced above, Seller shall be deemed to
have elected not to cure or satisfy all of the Objections.  If Seller notifies
Buyer in writing of its election not to cure or satisfy any of the Objections
(or is deemed to have elected not to cure or satisfy the Objections), then
Buyer shall either: (A) waive the Objections and proceed with Close of Escrow
pursuant to all of the terms of this Agreement without any reduction in the
Purchase Price, or (B) terminate this Agreement by written notice to Seller.
Buyer shall notify Seller in writing of its election either to terminate this
Agreement or waive the Objections pursuant to the foregoing sentence on or
before the earlier of the second business day after (i) Buyer's receipt of
Seller's response to the Title Objection Notice or (ii) the expiration of the
five (5) business day period referenced above.  If Buyer fails to notify
Seller in writing of its election to terminate this Agreement within the time
period provided above, Buyer shall be deemed to have waived the Objections and
elected to proceed with Close of Escrow.
Modification of Title Report.  In the event that Title Company
issues any modification or supplement to the Title Report between the end of
the Due Diligence Period and Close of Escrow that is not the result of
activities of Buyer or any of Buyer's agents, representatives, consultants or
contractors, Buyer shall promptly give Seller written notice of the change
and, if, in Buyer's reasonable judgment, the change materially and adversely
affects the Real Property or Buyer's projected use thereof, Buyer shall have
three (3) days after receipt of the modification or supplement to the Title
Report in which to object thereto by written notice to Seller.  If Buyer
objects to such a change, Seller shall have ten (10) days after the date
Seller receives Buyer's objection notice (and, if necessary, Close of Escrow
shall be extended by the number of days necessary to give Seller this full ten
(10) day period) in which to satisfy Buyer's objection or notify Buyer in
writing of its election not to satisfy Buyer's objection.  If Seller fails to
satisfy Buyer's objection within the ten (10) day period or notifies Buyer in
writing of its election not to satisfy the objection, then Buyer shall either:
(A) waive the objection and proceed with Close of Escrow pursuant to all of
the terms of this Agreement without any reduction in the Purchase Price, or
(B) terminate this Agreement.  Buyer shall notify Seller in writing of its
election either to terminate this Agreement or waive its objection within two
(2) business days after the earlier of expiration of such ten (10) day period
or Buyer's receipt of Seller's written notice election not to cure Buyer's
objection.  If Buyer terminates this Agreement pursuant to this Section,
(i) this Agreement, and all of the obligations, rights and liabilities of
Buyer and Seller to each other hereunder (except for Buyer's restoration
obligation under Section  6.3.6, Buyer's indemnity obligations under this
Agreement, and the parties' confidentiality obligations under Section 15.16)
shall terminate; (ii) Buyer shall immediately return to Seller all originals
and copies of the Due Diligence Materials which Buyer or Buyer's consultants,
agents, contractors or representatives received from Seller or copied from
Seller's files and (iii) Buyer shall deliver to Seller, at no cost to Seller,
the updated Survey and any Buyer Reports within three (3) days after Buyer
notifies Seller of its election to terminate this Agreement to the extent
requested by Seller.
Assumption of Bonds.  Notwithstanding anything to the contrary
contained in Section 6.6 of this Agreement, Buyer agrees to purchase the
Property subject to outstanding bonds attributable to and unpaid assessments,
appropriately pro-rated and only to the extent not delinquent, that are
assessed against the Property (with no adjustment to the Purchase Price).
Status.
As-Is Purchase.  Except as otherwise provided in Section 14.2,
Seller hereby specifically disclaims any warranty, guaranty or representation,
oral or written, past, present or future, of, as to or concerning (i) the
nature and condition of the Property, including, but not by way of limitation,
the water, soil, geology, environmental conditions (including the presence or
absence of any Hazardous Materials (defined below)), and the suitability
thereof for any and all activities and uses which Buyer may elect to conduct
thereon; (ii) the nature and extent of any right-of-way, lease, possessory
interest, lien, encumbrance, license, reservation, condition or otherwise; and
(iii) the compliance of the Property or its operation with any laws,
ordinances or regulations of any government or other body.  The sale of the
Property as provided for herein is made on an "AS IS" basis, and Buyer
expressly acknowledges that, in consideration of the agreements of Seller
herein, and except as otherwise expressly specified herein, SELLER MAKES NO
WARRANTY OR REPRESENTATION, EXPRESS OR IMPLIED, OR ARISING BY OPERATION OF
LAW, INCLUDING, BUT IN NO WAY LIMITED TO, ANY WARRANTY OF CONDITION,
HABITABILITY, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE
PROPERTY.  The term "Hazardous Materials" shall mean any substance:  (i) the
presence of which requires investigation or remediation under any federal,
state or local statute, regulation, ordinance, order, action, policy or common
law; (ii) which is or becomes defined as a "hazardous waste," "hazardous
substance," pollutant or contaminant under any federal, state or local
statute, regulation, ordinance, rule, directive or order or any amendments
thereto (hereinafter referred to as "Environmental Laws") including, without
limitation, the Comprehensive Environmental Response, Compensation and
Liability Act (42 U.S.C. Section 9601 et seq.) and/or the Resource
Conservation and Recovery Act (41 U.S.C. Section 6901 et seq.); (iii) which is
toxic, explosive, corrosive, flammable, infectious, radioactive, carcinogenic,
mutagenic or otherwise hazardous and is or becomes regulated by any
governmental authority, agency, department, commission, board, agency or
instrumentality of the United States, the State of California or any political
subdivision thereof; (iv) which contains gasoline, diesel fuel or other
petroleum hydrocarbons; (v) which contains polychlorinated biphenyls (PCBs),
asbestos or urea formaldehyde foam insulation; or (vi) radon gas.
Release.  Excluding any claim that Buyer may have against Seller
as a result of any breach by Seller of any of Seller's representations or
warranties set forth in Section 14.2, effective as of Close of Escrow, Buyer,
for itself and its agents, affiliates, successors and assigns, hereby releases
and forever discharges Seller and its officers, directors, shareholders,
members, partners, agents, affiliates, successors and assigns (collectively,
"Seller's Parties") from, and waives any right to proceed against Seller or
Seller's Parties for, any and all costs, expenses, claims, liabilities and
demands (including attorneys' fees and costs) at law or in equity, whether
known or unknown, arising out of the physical, environmental, economic, legal
or other condition of the Property (collectively, "Claims"), including any
claims for contribution pursuant to the Comprehensive Environmental Response,
Compensation and Liability Act of 1980, as amended, or any other Environmental
Laws which Buyer has or may have in the future.  Without limiting the
foregoing, Buyer hereby specifically waives the provisions of Section 1542 of
the California Civil Code which provide:
"A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE
CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS
FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF
KNOWN BY HIM MUST HAVE MATERIALLY AFFECTED HIS
SETTLEMENT WITH THE DEBTOR."
Notwithstanding anything to the contrary contained in this Section 7.2, Buyer
shall not release Seller from any Claims which Buyer, as tenant, may have
against Seller, as landlord, under the Lease that accrue prior to Close of
Escrow, and such claims as against Seller shall survive Seller's assignment to
Buyer of the Lease.  Buyer hereby specifically acknowledges that Buyer has
carefully reviewed this Section 7.2, and discussed its import with legal
counsel, is fully aware of its consequences, and that the provisions of this
Section 7.2 are a material part of this Agreement.
Buyer (_____)   (_____) agrees.
Operation of Property Through Closing Date.  Seller hereby
covenants with Buyer that during the Contract Period:
Leases, Contracts.  Seller shall not enter into or amend any
lease, service contract or any other agreement or contract affecting or
relating to the Real Property that will survive Close of Escrow (including the
Lease or any Service Contract) without the prior written consent of Buyer,
which consent shall not be unreasonably withheld or conditioned.  Buyer shall
be deemed to have given its consent if Buyer does not deliver a written
response to Seller within five (5) days after Seller's written request for
such consent;
Insurance.  All insurance coverage carried by Seller with
respect to the Real Property and in effect as of the Effective Date shall
remain continuously in full force and effect; and
Maintenance.  Seller shall continue to maintain the Real
Property in substantially the same manner in which Seller is maintaining the
Real Property as of the Effective Date.
Grant Deed.  Seller shall convey to Buyer all of its interest in the
Real Property by a grant deed (the "Deed") in the form of Exhibit E, attached
hereto.
Conditions Precedent.  In addition to the documents and funds which must
be placed into Escrow prior to Close of Escrow as stated in Section 11 of this
Agreement, the following are conditions precedent to Close of Escrow:
Seller.  The following are conditions precedent to Seller's
obligation to proceed with Close of Escrow:
No Proceedings.  No suit, action or other proceeding
(instituted by any party other than Seller) shall be pending which seeks, nor
shall there exist any judgment the effect of which is, to restrain the
purchase and sale of the Property;
Buyer's Representations True and Correct.  Buyer's
representations and warranties set forth herein shall be true and correct in
all material respects on Close of Escrow;
Performance of Covenants.  Buyer shall have performed all of
Buyer's covenants and agreements contained in this Agreement that are required
to be performed by Buyer prior to or on Close of Escrow; and
Corporate Resolutions.  Buyer shall have provided to Seller
and Title Company prior to Close of Escrow certified copies of corporate
resolutions approving the execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby, together with such other
certificates of incumbency and other evidences of corporate or regulatory
authority, including certificates of good standing, as Seller or Title Company
may reasonably require.
Buyer.  The following are conditions precedent to the Buyer's
obligation to proceed with Close of Escrow:
Satisfaction with Due Diligence.  Buyer's inspection and
approval during the Due Diligence Period of the Due Diligence Materials, the
Service Contracts, the updated Survey and all other physical, environmental,
legal and any other matters relating to the Property that Buyer may elect to
investigate.
Title.  Buyer's inspection and approval or deemed approval
of all title and survey matters relating to the Property within the time
periods provided in Sections 6.6 and 6.7 and Escrow Holder shall be ready,
willing and able to insure Buyer's fee title interest in the Property subject
only to the exceptions approved (or deemed approved) by Buyer pursuant to
Sections 6.6 and 6.7 or those caused by or attributable to the acts of Buyer
or its consultants.
Financing Contingency.
Loan Commitment.  Buyer's receipt prior to the
sixtieth (60th) day after the Effective Date of a commitment (the "Loan
Commitment") from a lender acceptable to Buyer pursuant to which the lender
commits to lend to Buyer (the "Loan") an amount equal to sixty-five percent
(65%) of the Purchase Price at a fixed interest rate not to exceed eight
percent (8%), compounded monthly.  The Loan shall have a term of not less than
five (5) years and be amortized over twenty (20) year period.  The Loan shall
be secured by a first priority deed of trust on the Real Property.  The
contingency described in this Section 9.2.3.a is hereinafter referred to as
the "Financing Contingency."
Conditional Commitment Letter.  Within thirty (30)
days after the Effective Date, Buyer shall either (i) provide to Seller
evidence reasonably acceptable to Seller that Buyer has obtained the Loan
Commitment, subject only to the lender's review and approval of certain third
party reports regarding the condition of the Property and the estimated value
of the Property (e.g., Phase I Report, property condition assessment,
appraisal) and other commercially reasonable conditions or (ii) waive the
Financing Contingency by written notice to Seller.  If Buyer fails to provide
to Seller the evidence described in subsection (i) above or waive the
Financing Contingency by written notice to Seller, then Seller shall have the
right to terminate this Agreement by written notice to Buyer within five (5)
business days after the expiration of the thirty (30) day period referenced
above.  Failure by Seller to terminate this Agreement within the time period
provided above shall be deemed a waiver by Seller of its right to terminate
this Agreement pursuant to this Section.
Conditions as of Closing.  As of Close of Escrow:
No Proceedings.  No suit, action or other proceeding
(instituted by any party other than Buyer) shall be pending which seeks, nor
shall there exist any judgment the effect of which is, to restrain the
purchase and sale of the Property;
Seller's Representations True and Correct.  Seller's
representations and warranties set forth in this Agreement shall be true and
correct in all material respects; and
Performance and Covenants.  Seller shall have
performed all of the covenants and agreements herein that Seller is required
to perform on or before Close of Escrow.
Resolutions.  To the extent requested by Buyer or Title
Company, Seller shall have provided to Buyer and Title Company at Close of
Escrow with evidence of authority to transfer the Property to Buyer.
Failure of Buyer's Conditions Precedent.  If any of Buyer's
conditions precedent described in Section 9.2 have not been satisfied, waived
or deemed waived by the time provided therein, then, except in the case of a
failure of the condition precedent in Section 9.2.4.c or a failure of the
condition precedent set forth in Section 9.2.4.b. due to any reason other than
a change in circumstances over which Seller has no reasonable control (either
of which failure shall constitute a default by Seller under this Agreement),
this Agreement shall terminate.  If Close of Escrow fails to occur due to a
default under this Agreement by either Seller or Buyer, the parties'
respective remedies shall be as described in Section 5 hereof.
Waiver.  Notwithstanding anything to the contrary contained in
this Agreement, the parties' participation in Close of Escrow shall be deemed
a waiver of (i) each party's ability to terminate this Agreement on the basis
of any failure of any conditions precedent and (ii) each party's right to seek
damages from the other party for the breach of any representations, warranty
or covenant of which the non-breaching party had actual knowledge prior to
Close of Escrow; provided, however, that such waivers shall not be deemed to
waive a party's right to such damages for any subsequently discovered breach
of any representation, warranty or covenant made by the other party to this
Agreement, subject to the express limitations provided in Section 15.12.  For
purposes of this Section 9.4, a party shall be deemed to have "knowledge" of a
misrepresentation or breach of warranty or covenant if either it, or any of
its consultants in connection with this Agreement (including, without
limitation, in Buyer's case, Buyer's Representative), has such knowledge.
Closing Date.  The close of Escrow (the "Close of Escrow") shall occur
on the fifteenth (15th) day after the satisfaction or waiver of the conditions
precedent set forth in Sections 9.2.1, 9.2.2 and 9.2.3 above (the "Scheduled
Closing Date"); provided, however, so long as it is acceptable to Buyer's
lender, Seller shall have the right to delay the Scheduled Closing Date for up
to sixty (60) days by written notice to Buyer to the extent necessary in order
to cure any Objections.  The day on which Escrow actually closes is
hereinafter referred to as the "Closing Date."
Escrow.
Time.  Close of Escrow shall occur when all documents and funds
specified in this Section 11 have been deposited into Escrow.  The failure of
Seller or Buyer to be in a position by the Scheduled Closing Date to fulfill
their respective obligations with respect to Close of Escrow and thus enable
Title Company to cause Close of Escrow to occur on the Scheduled Closing Date
shall constitute a default by the party so failing.
Documents.  On or before the business day immediately preceding
the Scheduled Closing Date, the parties shall deposit into Escrow the funds
and documents described below.
Seller.  Seller shall deposit the following:
Deed.  A duly executed and acknowledged Deed,
conveying to Buyer all of its interest in the Real Property;
Assignment.  Two (2) duly executed counterparts of a
General Assignment (the "Assignment") in the form of Exhibit F, attached
hereto, transferring to Buyer all of Seller's interest in the Lease and
Intangible Property;
Non-Foreign Person Certificate.  A duly executed non-
foreign person certificate (the "Non-Foreign Person Certificate") under
Section 1445 of the Internal Revenue Code in the form of Exhibit G, attached
hereto;
Form 590-RE.  A duly executed Withholding Exemption
Certificate for Real Estate Sales (Form 590-RE) (the "Form 590-RE");
Seller's Date Down Certificates.  A Seller's Date Down
Certificate ("Seller's Date Down Certificate") in the form of Exhibit H,
attached hereto; and
Additional Documents.  Such additional documents and
funds, including without limitation, escrow instructions consistent with the
terms and conditions of this Agreement, as may be reasonably required of
Seller to close the transaction in accordance with this Agreement.
Buyer.  Buyer shall deposit the following:
Purchase Price.  The Purchase Price, plus or minus the
closing adjustments and prorations due hereunder;
Assignment.  Two (2) duly executed original
counterparts of the Assignment;
Buyer's Date Down Certificate.  A duly executed
Buyer's Date Down Certificate in the form of Exhibit I, attached hereto; and
Additional Documents.  Such additional documents and
funds, including without limitation, escrow instructions consistent with the
terms and conditions of this Agreement, as may be reasonably required of Buyer
to close the transaction in accordance with this Agreement.
Procedure.  Escrow Holder shall close the Escrow as follows:
Record Deed.  Record the Deed in the Official Records of
Alameda County, California (instructing the County Recorder not to affix the
amount of any documentary transfer taxes to the Deed but to attach a separate
statement to the Deed after recording) and deliver conformed copies thereof to
Buyer and Seller;
Purchase Price.  Deliver to Seller by wire transfer to the
account designated by Seller in writing, the Purchase Price, minus prorations
and closing costs;
Additional Deliveries to Seller.  Deliver to Seller one
(1) fully executed original of the Assignment and Buyer's Date Down
Certificate; and
Additional Deliveries to Buyer.  Deliver to Buyer (i) one
(1) fully executed original of the Non-Foreign Certificate, Assignment, Form
590-RE, and Seller's Date Down Certificate, and (ii) the owner's title policy
purchased by Buyer.
Possession.  To the extent Buyer is not already in possession of
the Property at Close of Escrow as the tenant under the Lease, Seller shall
deliver possession of the Property to Buyer at Close of Escrow.
Deliveries Outside Escrow.  Upon Close of Escrow, Seller shall
deliver (or shall have previously delivered) to Buyer, without any
representation as to accuracy or completeness, the following items to the
extent in Seller's possession:
Keys; Security Systems.  Keys to all buildings located on
the Real Property and access codes to any security systems comprising part of
the Property;
Approvals.  Originals or, to the extent originals are not
available, copies of all governmental licenses, permits and approvals relating
to the occupancy or use of the Real Property;
Project Agreements and Project Documents.  Originals, or to
the extent originals are not available, copies of all construction drawings
and specifications (including, without limitation, structural, electrical,
HVAC, mechanical and plumbing plans and specifications) and any addenda
thereto, and all other blueprints, architectural documents, operating manuals
and similar documents, landscaping plans, development plans and shop drawings
relating to the Improvements; and
Warranties.  Originals or, to the extent originals are not
available, copies of all existing warranties given by third parties with
respect to the Real Property that are in Seller's possession.
Escrow Instructions.  This Agreement shall serve as escrow
instructions and an executed copy of this Agreement shall be deposited by
Seller and Buyer with Escrow Holder following the execution and delivery
hereof.  The parties agree to execute for the benefit of Escrow Holder such
additional escrow instructions as required, provided that the additional
escrow instructions do not change the terms of this Agreement but merely offer
protection to Escrow Holder.  Seller and Buyer hereby designate Escrow Holder
as the "Reporting Person" for the transaction pursuant to Section 6045(e) of
the Internal Revenue Code.
Closing Costs and Prorations.
11.7.1. Closing Costs
Buyer's Share of Closing Costs.  Buyer shall pay the
following portions of the closing costs (the "Closing Costs") in connection
with transfer of the Property:  (A) the title insurance premiums for the
owner's title policy and any endorsements requested by Buyer; (B)  the Escrow
fees; and (C) all recording fees incurred in connection with the Deed.
Seller's Share of Closing Costs.  Seller shall pay the
following portions of the Closing Costs:  (A)  all County documentary transfer
taxes; and (B) all recording fees not the responsibility of Buyer pursuant to
Section 11.7.1.a above.
No Close of Escrow.  If Close of Escrow does not occur
because of a failure of either Seller or Buyer to comply with its obligations
under this Agreement, the costs incurred in connection with the Escrow,
including the cost of the Title Report and any cancellation fees or other
costs of Title Company, shall be paid by the defaulting party.  If Close of
Escrow does not occur because of any other reason, including any termination
of this Agreement by Buyer pursuant to Sections 6.5, 6.6 (other than as a
result of Seller's failure to cure or satisfy any Objection which Seller has
agreed to cure or satisfy) or 6.7, such costs shall be paid equally by Buyer
and Seller.
11.7.2. Lease Rentals
Prorations.  All accrued rent (including all accrued
operating expenses and tax escalations and recoveries), charges and revenues
of any kind under the Lease shall be prorated as of 11:59 p.m. Pacific
Daylight Savings Time on the day immediately prior to Close of Escrow (the
"Proration Date") based on the actual number of days in the month in which
Close of Escrow occurs; provided, however,  Seller shall receive a credit at
Close of Escrow for any uncollected rent, charges or revenues.  If, after
Close of Escrow, either Buyer or Seller receives any revenue to which it is
not entitled under the terms of this Agreement, the party receiving the
revenue shall promptly forward such amount to the other party.
Order of Application.  The rents and other payments
collected after the Proration Date from any tenant shall be applied to rents
and/or payments in the order in which the rents and/or payments became due
(i.e., on a FIFO basis).
Re-Proration.  After the Closing Date, when periodic tenant
reconciliations are performed (which tenant reconciliations shall be performed
no later than sixty (60) days after the end of the calendar year), Buyer and
Seller shall promptly re-prorate the rent, charges and revenues under the
Lease if any additional rent is due to or owed by the tenant under the terms
of the Lease for the period prior to Close of Escrow.  Any amounts due from
one party to the other as a result of the re-proration shall be paid in cash
at the time of the re-proration.
Leasing Costs.  All brokerage commissions which are the
obligation of the landlord due in connection with the Lease (collectively,
"Leasing Costs") shall be paid in full by Seller.  Buyer shall be responsible
for all brokerage commissions which shall become due after Close of Escrow in
connection with any modifications or amendments to the Lease or any other
leases entered into by Buyer.
Security Deposits.  Buyer shall receive a credit against the
Purchase Price equal to all security deposits or any other deposits currently
held by Seller in connection with the Lease.
Real Estate Taxes.  All real and personal property taxes,
installments of bonds and special taxes and assessments (collectively,
"Taxes") attributable to the Real Property (to the extent they are not the
obligation of the tenant under the Lease) shall be prorated as of 11:59 p.m.
Pacific Daylight Savings Time on the Proration Date based on a 365-day year
and the assessed value of the Property in effect on the Proration Date.
Seller shall pay or credit Buyer for all such Taxes attributable to periods
through and including the Proration Date.  If at any time after the Proration
Date additional or supplemental Taxes (which are not the obligation of the
tenant under the Lease) are assessed against the Real Property by reason of
any event occurring prior to or on the Proration Date, or there is any rebate
of such Taxes (with Seller being responsible for the supplemental or
additional taxes attributable to the period prior to and including the
Proration Date and Buyer being responsible for the supplemental or additional
taxes attributable to the period after the Proration Date), Buyer and Seller
shall promptly re-prorate such Taxes, and any amounts due from one party to
the other shall be paid in cash at that time.  All Taxes which the tenant is
obligated to pay to Seller as landlord under the Lease shall be considered to
be rent for purposes of prorating such Taxes and shall be prorated among Buyer
and Seller pursuant to Section 11.7.2.
Utilities.  Buyer shall arrange with all utility services
and companies serving the Real Property to have accounts started in the name
of Buyer or its property manager beginning as of the Closing Date.  Seller
shall not assign to Buyer any deposits Seller has with any utility services or
companies.  Buyer and Seller shall cooperate to have the utility services and
companies make utility readings as of the Proration Date.  If readings cannot
be made, utility charges shall be prorated as of 11:59 p.m. Pacific Daylight
Savings Time on the Proration Date based on estimates from the latest bills
available; provided, in any event, Seller shall pay, through and including the
Proration Date, all utility charges attributable to the Real Property that are
not payable directly by the tenant under the Lease.  All utility charges
attributable to the Real Property that the tenant is obligated to pay to
Seller as landlord under the Lease shall be considered to be rent for purposes
of prorating such utility charges and shall be prorated among Buyer and Seller
pursuant to Section 11.7.2).
Insurance.  Seller shall not assign to Buyer any insurance
policies in connection with the Property.
Owner's Association Dues.  All owner's association dues with
respect to the Property shall be prorated as of 11:59 p.m. on the Proration
Date, with Seller being responsible for all owner's association dues
applicable to the period prior to the Closing Date and Buyer being responsible
for all owner's association dues applicable to the period after and including
the Closing Date.
Calculations for Closing.  Seller and Buyer shall provide
Escrow Holder with a preliminary calculation of prorations no later than three
(3) days prior to the Proration Date and a final calculation no later than one
(1) day prior to the Proration Date.  The final calculation shall be executed
by each party and may be relied upon by Escrow Holder in completing the
closing adjustments and prorations.  In the event incomplete information is
available, or estimates have been utilized to calculate prorations as of the
Proration Date, any prorations relating thereto shall be further adjusted and
completed outside of Escrow within sixty (60) days after the Proration Date or
as soon as possible after complete information becomes available to Buyer and
Seller.  Any adjustments to initial estimated prorations that are required
upon review of such complete information shall be made by Buyer and Seller,
with due diligence and cooperation, by prompt cash payment to the party
entitled to a credit as a result of such adjustments.  Any errors or
adjustments in calculations of the foregoing adjustments shall be corrected or
adjusted as soon as practicable after Close of Escrow; provided, however, the
provisions hereof shall survive Close of Escrow for not more than one (1)
year.
Additional Costs.  Buyer and Seller each shall pay their own
legal, lending and other fees and expenses incurred in connection with the
negotiation, documentation and closing of the contemplated transactions.
Brokerage Commission.  Upon Close of Escrow, a real estate sales
commission (the "Commission") shall be paid by Seller to Buyer's Broker
(defined in the Summary of Certain Terms) pursuant to a separate agreement
entered into between Seller and Buyer's Broker.  Except for Seller's payment
to Buyer's Broker of the Commission (from payment of which Seller shall
indemnify and hold harmless Buyer), each party to this Agreement warrants to
the other that no person or entity can properly claim a right to a real estate
commission, finder's fee or other real estate brokerage-type compensation
(collectively, "Real Estate Compensation") based upon the acts of that party
with respect to the transaction contemplated by this Agreement.  Each party
hereby agrees to indemnify, protect and defend the other (by counsel
reasonably acceptable to the party seeking indemnification) against and hold
the other harmless from and against any and all loss, damage, liability or
expense, including costs and reasonable attorneys' fees, resulting from any
claims for Real Estate Compensation by any person or entity based upon such
acts.
Condemnation/Casualty.
Right to Terminate  If, before Close of Escrow, all or any portion
of the Real Property is materially (as defined below) damaged or destroyed by
fire or other casualty, or is taken by a material (as defined below)
condemnation or action of eminent domain (or a material condemnation or
eminent domain action has been commenced against all or any portion of the
Real Property), then (i) upon obtaining actual knowledge thereof each party
shall notify the other of the casualty or the condemnation or eminent domain
action and (ii) except as provided in this Section 13, Buyer shall have the
option to terminate this Agreement upon written notice to Seller within five
(5) business days after Buyer's receipt of notice of any casualty or
condemnation or eminent domain action.
Election to Terminate.  Provided and on the condition that (i)
Buyer is the tenant under the Lease and (ii) Buyer has satisfied all of the
conditions precedent set forth in Section VI.B of the Work Letter attached as
Exhibit C to the Lease with respect to Seller's obligation to pay to Buyer the
Tenant Improvement Allowance, Seller shall immediately pay to Buyer the Tenant
Improvement Allowance owed to Buyer under the Lease upon Buyer's termination
of this Agreement pursuant to Section 13.  Upon termination of this Agreement,
neither Buyer nor Seller shall have any further rights or obligations under
this Agreement (except for Buyer's restoration obligation under 6.3.6, Buyer's
indemnity obligations under this Agreement and the parties' confidentiality
obligations under Section 15.16).
No Election to Terminate.  If Buyer does not exercise the option
to terminate this Agreement, or does not have the option pursuant to the
express provisions of this Section 13, neither Buyer nor Seller shall have the
right to terminate this Agreement; however, Buyer shall be entitled to receive
and keep at Close of Escrow all insurance proceeds, in the event of any
casualty that occurs during the Contract Period, and all rights to receive
awards, in the case of a taking by condemnation or eminent domain that occurs
during the Contract Period with respect to the Property, regardless of when
paid and regardless of whether paid to Buyer or Seller, and Close of Escrow
shall be consummated pursuant to the terms hereof.  There shall be no
reduction of the Purchase Price as a result of the casualty or condemnation.
Definition of Materiality.
Casualty.  For purposes of this Agreement, the Real Property
shall be deemed "materially" damaged by fire or other casualty if (i) in the
reasonable opinion of Seller, it would take more than ninety (90) days from
after the date of the damage to repair the damage, or (ii) the cost of
repairing the damage caused by the fire or other casualty which is not covered
by insurance is reasonably estimated by Seller to exceed Two Hundred
Fifty Thousand Dollars ($250,000.00).  In addition, a casualty shall be deemed
material if the damage or loss is uninsured and the cost to repair the
Property to its condition prior to the occurrence of the damage or destruction
is reasonably estimated by Seller to exceed the amount of Two Hundred
Fifty Thousand Dollars ($250,000.00).
Condemnation.  For purposes of this Agreement, a material
condemnation or action in eminent domain shall be deemed to have occurred only
if, (i) the taking would materially impair access or require any substantial
reconfiguration of the Improvements located on the Real Property, or (ii) the
amount of the award as reasonably estimated by Seller would exceed Two Hundred
Fifty Thousand Dollars ($250,000.00).
Damage Caused by Tenant.  Notwithstanding anything to the contrary
contained in this Section, if the Real Property is damaged due to the gross
negligence or willful misconduct of the tenant under the Lease, Buyer shall
not have the right to terminate this Agreement.
Representations and Warranties.
Buyer.  Buyer represents and warrants to Seller the following:
Buyer's Investigation.  Buyer has (or will have) examined,
inspected and conducted its own investigation of all matters with respect to
the physical and environmental condition of the Property, taxes, bonds,
permissible uses, zoning, covenants, conditions and restrictions and all other
matters which in Buyer's judgment bear upon the value and suitability of the
Property for Buyer's purposes.  Buyer acknowledges that, except as otherwise
provided herein, Seller has not made any representation of any kind in
connection with soils, environmental or physical conditions on, or bearing on,
the use of the Real Property or the financial condition or creditworthiness of
any tenant, and Buyer is relying solely on Buyer's own inspection and
examination of such items and not on any representation of Seller.
Formation and Standing.  Buyer is a corporation, duly
organized, validly existing and in good standing under the laws of the State
of Delaware.
Authority.  Buyer has the full power to execute and deliver
and fully perform its obligations under this Agreement; and this Agreement
constitutes a valid and legally binding obligation of Buyer, enforceable in
accordance with its terms.
No Violation.  Neither this Agreement nor anything provided
to be done hereunder violates or shall violate any contract, agreement or
instrument to which Buyer is a party, the effect of which shall be to prohibit
or to seek or purport to prohibit Buyer from fulfilling its obligations under
this Agreement.
No Assignment.  Buyer has not made (i) a general assignment
for the benefit of creditors; (ii) filed any voluntary petition in bankruptcy
or suffered the filing of an involuntary petition by Buyer's creditors;
(iii) suffered the appointment of a receiver to take possession of all or
substantially all of Buyer's assets; (iv) suffered the attachment or other
judicial seizure of all, or substantially all, of Buyer's assets; (v) admitted
in writing its inability to pay its debts as they become due; or (vi) made an
offer of settlement, extension or composition to its creditors generally.
Seller.  Seller represents and warrants to Buyer the following:
Authority.  Seller has the full power to execute and deliver
and fully perform its obligations under this Agreement; and this Agreement
constitutes a valid and legally binding obligation of Seller, enforceable in
accordance with its terms.
No Conflicts.  There is no agreement to which Seller is a
party or, to Seller's actual knowledge, which is binding on Seller which is in
conflict with this Agreement.
No Assignment.  Seller has not (i) made a general assignment
for the benefit of creditors; (ii) filed any voluntary petition in bankruptcy
or suffered the filing of an involuntary petition by its creditors;
(iii) suffered the appointment of a receiver to take possession of all or
substantially all of its assets; (iv) suffered the attachment or other
judicial seizure of all, or substantially all, of its assets; (v) admitted in
writing its inability to pay its debts as they come due; or (vi) made an offer
of settlement, extension or composition to its creditors generally.
No Additional Leases.  Seller has not entered into or
assumed any lease relating to the Property that is in effect as of the
Effective Date except for the Lease.
Good Standing.  Seller is a limited liability company, duly
organized, validly existing and in good standing under the laws of the State
of Delaware.
No Warranties.  Except for those representations and warranties
expressly set forth in Section 14.2, the parties understand and acknowledge
that no person acting on behalf of either Seller or Buyer is authorized to
make, and by execution hereof each party hereto acknowledges that no person
has made, any representation or warranty regarding the Property, or the
transaction contemplated herein, or regarding the Lease or the zoning,
construction, physical condition or other status of the Real Property.  No
representation, warranty, agreement, statement, guaranty or promise, if any,
made by any person acting on behalf of either Seller or Buyer which is not
contained in this Agreement shall be valid or binding on that party.
Miscellaneous.
Indemnity.  Seller shall indemnify, protect and defend (by counsel
reasonably acceptable to Buyer) and hold harmless Buyer from any Leasing Costs
payable in connection with the Lease.  Buyer shall indemnify, protect and
defend (by counsel reasonably acceptable to Seller) and hold harmless Seller
from any brokerage commissions relating to any modification or amendment to
the Lease or the Property after Close of Escrow (other than Leasing Costs
payable by Seller pursuant to Section 11.7.4).  The indemnification
obligations set forth in this Section 15.1 shall survive Close of Escrow.
Successors and Assigns.  This Agreement shall be binding upon the
heirs, executors, administrator, and successors and assigns of Seller and
Buyer.  Notwithstanding the forgoing, neither party may assign its rights and
obligations under this Agreement without the prior written consent of the
other party (which consent may be withheld in each party's sole discretion);
provided, however, (i) Seller may assign this Agreement without Buyer's
consent to any member of Seller in connection with a transfer of a portion of
the Property by Seller to a member in order to facilitate an Exchange (defined
in Section 16) by the member, (ii) Seller may assign this Agreement without
Buyer's consent to effectuate an Exchange, and (iii) Buyer may assign this
Agreement without Seller's consent to an Affiliate or to effect an Exchange.
For purposes of this Section 15.2, an "Affiliate" means (a) an entity that
directly or indirectly controls, is controlled by or is under common control
with Buyer or (b) an entity at least a majority of whose economic interest is
owned by Buyer; and "control" means the power to direct the management of such
entity through voting rights, ownership or contractual obligations.  Any
assignment by Buyer (to which Seller has consented or for which Seller's
consent is not required) shall not be effective against Seller until Buyer
delivers to Seller a fully executed copy of the assignment instrument pursuant
to which the assignee (i) assumes and agrees to perform for the benefit of the
Seller all of the obligations of Buyer under this Agreement and (ii) makes the
warranties and representations required of Buyer under this Agreement.  No
assignment by Buyer shall result in Buyer being released from any obligations
of Buyer to Seller under this Agreement.  Any assignment in violation of this
Section shall be void.
Entire Agreement.  This Agreement contains all of the covenants,
conditions and agreements between the parties and shall supersede all prior
correspondence, agreements and understandings, both oral and written.
Attorneys' Fees.  Should either party employ attorneys to enforce
any of the provisions of this Agreement or to protect its interest in any
manner arising under this Agreement, or to recover damages for breach of this
Agreement, or to enforce any judgment relating to this Agreement and the
transaction contemplated hereby, the prevailing party shall be entitled to
reasonable attorneys' fees and court costs; provided, however, if Buyer
defaults hereunder the Liquidated Damages Amount shall be deemed to include
all attorneys' fees, court costs and all other amounts to which Seller
otherwise may be entitled under this Section 15.4, and Seller shall not be
entitled to recover any additional attorneys' fees and court costs under this
Agreement.
Governing Law.  This Agreement shall be governed by and construed
in accordance with the laws of the State of California.
Further Assurances.  Seller and Buyer shall promptly perform,
execute and deliver or cause to be performed, executed and/or delivered at or
after Close of Escrow any and all acts, deeds and assurances, including the
delivery of any documents, as either party or Escrow Holder may reasonably
require in order to carry out the intent and purpose of this Agreement.
Severability.  In case any one (1) or more of the provisions
contained in this Agreement for any reason is held to be invalid, illegal or
unenforceable in any respect, such invalidity, illegality or unenforceability
shall not affect any other provision hereof, and this Agreement shall be
construed as if such invalid, illegal or unenforceable provision had never
been contained herein.
Notices.
Means/Receipt.  All notices or other communications required
or permitted hereunder shall be in writing, and shall be personally delivered
or sent by national overnight courier service (next business day delivery) or
facsimile, and shall be deemed received upon the earlier of (i) if personally
delivered, the date of delivery to the address of the person to receive such
notice, (ii)  if sent by national overnight courier service (next business day
delivery), one (1) business day after delivery to such courier service, or
(iii) if given by facsimile, upon electronic evidence of receipt.  Notices or
other communications may not be sent by U.S. Mail.
Addresses.  Any notice to Seller shall be sent to Seller at
Seller's Address, as stated on page (i) of this Agreement.  Any notice to
Buyer shall be sent to Buyer at Buyer's Address, as stated on page (i) of this
Agreement.
Counterparts.  This Agreement may be executed in one (1) or more
counterparts, and all the counterparts shall constitute but one (1) and the
same agreement, notwithstanding that all parties hereto are not signatory to
the same or original counterpart.
Time.  Time is of the essence of every provision contained in this
Agreement.
Nonwaiver.  Unless otherwise expressly provided in this Agreement,
no waiver by Seller or Buyer of any provision hereof shall be deemed to have
been made unless expressed in writing and signed by Seller or Buyer, as the
case may be.  No delay or omission in the exercise of any right or remedy
accruing to Seller or Buyer, as the case may be, upon any breach under this
Agreement shall impair such right or remedy or be construed as a waiver of any
such breach theretofore or thereafter occurring.  The waiver by Seller or
Buyer of any breach of any term, covenant or condition herein stated shall not
be deemed to be a waiver of any other term, covenant or condition.
Survival.  Each of the terms, covenants and conditions of this
Agreement contained in Sections 6.3.7, 7.1, 7.2, 11.7.2, 11.7.3, 11.7.4,
11.7.6, 11.7.7, 11.7.9, , 11.7.10, 14, and 15 shall survive the delivery of
the Deed to Buyer and shall not be deemed to have merged into the Deed;
provided, however, that unless Seller or Buyer, as the case may be, receives a
written notice regarding an alleged breach of any representation, warranty or
covenant of Seller or Buyer contained in the Sections referenced above on or
prior to the date that is one (1) year after Close of Escrow, then Seller's or
Buyer's obligations and liability with respect to such representation,
warranty or covenant, as applicable, shall terminate on the date that is one
(1) year after Close of Escrow.
Captions.  Section titles or captions contained in this Agreement
are inserted as a matter of convenience and for reference, and in no way
define, limit, extent or describe the scope of this Agreement.
Exhibits.  All exhibits attached hereto shall be incorporated
herein by reference as if set out herein in full.
Construction.  The parties acknowledge that each party and its
counsel have reviewed and revised this Agreement and that the normal rule of
construction to the effect that any ambiguities are to be resolved against the
drafting party shall not be employed in the interpretation of this Agreement
or any amendment or exhibits hereto.
Confidentiality.  Neither Buyer nor Seller shall make any public
announcement or disclosure of any information related to this Agreement to
outside brokers or third parties, before or after the Close of Escrow, without
the specific prior written consent of the other, except for such disclosures
to the parties' lenders, creditors, partners, members, officers, employees,
agents, consultants, attorneys, accountants, and exchange facilitators as may
be necessary to permit each party to perform its obligations hereunder and as
required to comply with applicable laws and/or rules of any exchange upon
which a party's shares may be traded; provided, however, Seller may disclose
the existence of this Agreement and the contents of any Due Diligence
Materials to other potential purchases of the Property.  Seller's obligations
under this Section 15.16 shall terminate upon the termination of this
Agreement (other than by the Close of Escrow).  Buyer's obligations under this
Section 15.16 shall survive the termination of this Agreement; provided,
however, Buyer's obligations under this Section 15.16 shall terminate upon
Close of Escrow.
Tenant Improvement Allowance.  Buyer acknowledges that Seller is
assigning to Buyer all of its obligations under the Lease, including, without
limitation, the obligation to pay to the tenant under the Lease the Tenant
Improvement Allowance in the amount of One Million Eight Hundred
Forty-Five Thousand Dollars ($1,845,000.00).  There shall be no adjustment to
the Purchase Price as the result of Buyer's assumption of Seller's obligation
to pay the outstanding Tenant Improvement Allowance to the tenant under the
Lease.
Deferred Exchange.  Either party may consummate the purchase or sale of
the Property as part of a so-called like kind exchange (the "Exchange")
pursuant to Section 1031 of the Internal Revenue Code of 1986, as amended,
provided that (i) Close of Escrow shall not be delayed or affected by reason
of the Exchange, nor shall the consummation or accomplishment of the Exchange
be a condition precedent or condition subsequent to either party's obligations
under this Agreement; (ii) the party electing to consummate this transaction
as part of an Exchange (the "Electing Party") shall effect the Exchange
through an assignment of this Agreement, or its rights under this Agreement,
to a qualified intermediary; (iii) the other party (the "Accommodator") shall
not be required to take an assignment of the purchase agreement for the
relinquished property or be required to acquire or hold title to any real
property for purposes of consummating the Exchange; and (iv) at Close of
Escrow the Electing Party shall pay any additional costs that would not
otherwise have been incurred by the Accommodator had the Electing Party not
consummated this transaction through the Exchange.  The Accommodator shall not
by this Agreement or acquiescence to the Exchange proposed by the Electing
Party have its rights under this Agreement affected or diminished in any
manner or be responsible for compliance with or be deemed to have warranted to
the Electing Party that the Exchange in fact complies with Section 1031 of the
Internal Revenue Code of 1986, as amended.

[No further text on this page.]

        IN WITNESS WHEREOF, the parties hereto have executed this Agreement in
one or more counterparts, on the date set forth above, effective as of the
date first above written.
"Seller"

ARDENSTONE LLC,
a Delaware limited liability company

By:
Name:
Its:

By:
Name:
Its:

"Buyer"

PROTEIN DESIGN LABS, INC.,
a Delaware corporation

By:
Name:
Its:

By:
Name:
Its:


EXHIBIT A

LAND

REAL PROPERTY in the City of Fremont, County of Alameda, State of California,
described as follows:
Parcel 16, Parcel Map 4483, filed March 28, 1985 in
Book 152, Pages 78 through 82 of Maps, Alameda County
Records.

A.P. Nos.       543-0439-108
                543-0439-109

EXHIBIT B

LEASE

That certain Industrial Lease dated as of July 1, 1997, entered
into between Ardenstone LLC, a Delaware limited liability company, and Protein
Design Labs, Inc., a Delaware corporation, as amended.


EXHIBIT C

SERVICE CONTRACTS

EXHIBIT D

DUE DILIGENCE DOCUMENTS

EXHIBIT E
RECORDING REQUESTED BY
AND WHEN RECORDED MAIL TO:

Attn:

THE AREA ABOVE IS RESERVED FOR RECORDER'S USE
GRANT DEED
        FOR VALUABLE CONSIDERATION, receipt of which is hereby acknowledged,
______________________, a __________________ grants, transfers and assigns to
______________________, a __________________, all of its interest in that
certain real property located in the City of _______________, County of
_______________, State of California, and which is more particularly described
in Schedule 1, attached hereto and incorporated herein by this reference,
subject to all matters of record in the Official Records of _________________
County, California.
        IN WITNESS WHEREOF, this Grant Deed has been executed this         day
of _______________, ____.

a

By:
Name:
Its:

Date:
MAIL ALL TAX STATEMENTS TO:

________________________________________
________________________________________
________________________________________
________________________________________


EXHIBIT F

GENERAL ASSIGNMENT
        THIS GENERAL ASSIGNMENT (this "Assignment") is executed as of
_______________, _____, by and among ________________________, a
_________________ ("Assignor"), and _____________________________, a
_______________ ("Assignee"), with reference to the following facts:
   1.      Concurrently herewith, Assignor is conveying to Assignee certain
real property, together with all improvements thereon, situated in City of
________________, County of _______________, State of California, as described
on Exhibit 1, attached hereto (collectively, the "Property"), in accordance
with the terms of that certain Agreement of Purchase and Sale (the
"Agreement") dated as of ________________, _____, by and between Assignor and
Assignee.  Capitalized terms used herein and not defined herein shall have the
meanings set forth in the Agreement.
        2.  Assignor desires to assign, transfer and convey to Assignee all of
Assignor's interests in:  (i) the Lease listed in Exhibit 2, attached hereto,
and refundable security deposits, if any, posted by the tenant under the
Lease; and (ii) all Intangible Property, including the Service Contracts
listed on Exhibit 3, attached hereto, but only to the extent assignable (all
of the foregoing being referred to herein collectively as "Assigned
Property").  All of the exhibits attached hereto are incorporated herein by
reference thereto.
        NOW, THEREFORE, in consideration of the foregoing and other good and
valuable consideration in hand paid by Assignee to Assignor, the receipt and
sufficiency of which are hereby acknowledged, Assignor does hereby ASSIGN,
TRANSFER and DELIVER and GRANT, SELL and CONVEY to Assignee all of the
Assigned Property, including, without limitation of the generality of the
foregoing, the following:
        (a)     The Intangible Property; and
        (b)     The Lease.
        Assignor agrees to indemnify and hold harmless Assignee from all
obligations and liabilities arising prior to the Effective Date (hereinafter
defined) out of Assignor's performance or failure to perform Assignor's
obligations as landlord under the Lease and as owner under the Service
Contracts.
Assignee hereby accepts and agrees to perform all of the terms,
covenants and conditions of the Lease and Service Contracts on the part of the
landlord and owner therein required to be performed, from and after the
Effective Date but not prior thereto, including (i) the obligation to repay to
the tenant under the Lease the security and other deposits, but only to the
extent such deposits have been delivered (or credited) to Assignee and
(ii) the obligation to pay to the tenant under the Lease the outstanding
Tenant Improvement Allowance in the amount of One Million Eight Hundred
Forty-Five Thousand Dollars ($1,845,000.00).
        Assignee agrees to indemnify and hold harmless Assignor from all
obligations and liabilities arising from and after the Effective Date out of
Assignee's performance or failure to perform Assignee's obligations as
landlord under the Lease and as owner under the Service Contracts.
        This Assignment shall be governed by the laws of the State of
California.
        This Assignment shall be effective as of the Closing Date, as such term
is defined under the Agreement (the "Effective Date").
     This Assignment may be executed in one (1) or more counterparts, each of
which shall be deemed an original, but all of which when taken together shall
constitute one (1) agreement.
        IN WITNESS WHEREOF, the undersigned have executed this Assignment, on
the date set forth above, as of the Effective Date.
Assignor:

By:
Name:

Its:

By:
Name:

Its:

Assignee:

By:
Name:

Its:

By:
Name:

Its:

EXHIBIT G

NON-FOREIGN CERTIFICATE
        Section 1445 of the Internal Revenue Code provides that a buyer of a
U.S. real property interest must withhold tax if the seller is a foreign
person.  To inform ________________________________, a __________________
("Buyer"), that withholding of tax is not required upon the disposition of a
U.S. real property interest by ______________________, a __________________
("Seller"), the undersigned hereby certifies the following on behalf of
Seller:
     1.  Seller is not a foreign corporation, foreign partnership, foreign
trust or foreign estate (as those terms are defined in the Internal Revenue
Code and Income Tax Regulations);
     2.      Seller's U.S. employer identification number is _________________;
and
    3.      Seller's office address is _____________________________________.
        The undersigned understands that this certification may be disclosed to
the Internal Revenue Service by Buyer and that any false statement the
undersigned has made here could be punished by fine, imprisonment, or both.
        Under penalty of perjury, the undersigned declares that they have
examined this certification and to the best of their knowledge and belief it
is true, correct and complete, and the undersigned further declares that they
have the authority to sign this document on behalf of Seller.

By:
Name:
Its:

Dated:

By:
Name:
Its:

Dated:

EXHIBIT H
SELLER'S DATE DOWN CERTIFICATE
        This Seller's Date Down Certificate is made and delivered by
_____________________________, a _______________  ("Seller") with reference to
that certain Agreement of Purchase and Sale ("Agreement") dated __________,
____, entered into between Seller and _____________________________.
        Seller hereby restates and reaffirms its representations and warranties
set forth in Section 14.2 of the Agreement with full force and effect as if
set forth fully herein and made and delivered on the date hereof without any
exception or qualification.
"Seller"

By:
Name:
Title:


Dated:

EXHIBIT I
BUYER'S DATE DOWN CERTIFICATE
        This Buyer's Date Down Certificate is made and delivered by
_________________________, a __________________ ("Buyer") with reference to
that certain Agreement of Purchase and Sale (the "Agreement") dated
October __, 1997, entered into between _____________________________, a
_______________ and Buyer.
        Buyer hereby restates and reaffirms its representations and warranties
set forth in Section 14.1 of the Agreement with full force and effect as if
set forth fully herein and made and delivered on the date hereof without any
exception or qualification.
"Buyer"
By:
Name:
Title:

Dated:

By:
Name:
Title:


Dated:

iv.

06/22/99

21.

06/22/99

        EXHIBIT A

06/22/99

        EXHIBIT B

06/22/99

        EXHIBIT C

06/22/99

        EXHIBIT D

06/22/99

EXHIBIT E

06/22/99

EXHIBIT F
2.

06/22/99

EXHIBIT G

06/22/99

EXHIBIT H

06/22/99



EXHIBIT I

06/22/99




        Loan No. 31-0900011A
$10,150,000.00  San Francisco, California
        September 9, 1999


1.PROMISE TO PAY.  For value received, the undersigned FREMONT HOLDING L.L.C., a
Delaware limited liability company ("Borrower"), promise(s) to pay to the order
of WELLS FARGO BANK, NATIONAL ASSOCIATION ("Lender"), 1320 Willow Pass Road,
Suite 205, Concord, California 94520, or at such other place as may be
designated in writing by Lender, the principal sum of TEN MILLION ONE HUNDRED
FIFTY THOUSAND AND NO/100THS DOLLARS ($10,150,000.00) ("Loan"), with interest
thereon as specified herein.  All sums owing hereunder are payable in lawful
money of the United States of America, in immediately available funds, without
offset, deduction or counterclaim of any kind.

2.SECURED BY DEED OF TRUST.  This Note is secured by, among other things, that
Deed of Trust and Absolute Assignment of Rents and Leases and Security
Agreement(and Fixture Filing) ("Deed of Trust") of even date herewith,
encumbering certain real property described therein ("Property").

3.DEFINITIONS.  For the purposes of this Note, the following terms shall have
the following meanings:

"Business Day" shall mean any day other than a Saturday, Sunday, legal holiday
or other day on which commercial banks in California are authorized or required
by law to close.  All references in this Note to a "day" or a "date" shall be
to a calendar day unless specifically referenced as a Business Day.

"Default" shall have the meaning set forth in the Deed of Trust.

"Disbursement Date" shall mean the date upon which the Loan proceeds are funded
into escrow in connection with the closing of the Loan.

"Effective Date" shall mean the date the Deed of Trust is recorded in the
Office of the County Recorder of the county where the Property is located and
Lender authorizes the Loan proceeds to be released to Borrower.

"Loan Documents" shall mean the documents listed in Exhibit B attached hereto
and incorporated herein by this reference.

"Maturity Date" shall mean October 1, 2014.

4.      INTEREST; PAYMENTS.

4.1     Definitions.  The following terms shall have the meanings indicated:

"Actual/360 Basis" shall mean on the basis of a 360-day year and charged
on the basis of actual days elapsed for any whole or partial month in
which interest is being calculated.

"30/360 Basis" shall mean on the basis of a 360-day year consisting of 12
months of 30 days each.

"Interest Rate" shall mean a fixed interest rate equal to 1.70 plus the
yield to maturity at the bid price of obligations of the United States
Treasury which will mature on the date that is 15 years after the
Disbursement Date or, if a bid price is not readily quoted in the public
securities market for such obligations as will mature on the earliest date
thereafter for which a bid price is readily quoted in the public securities
market. The Interest Rate shall be determined on the Disbursement Date.

4.2  Interest Accrual.  Interest on the outstanding principal balance of this
Note shall accrue from the Disbursement Date at an annual rate equal to
the Interest Rate calculated on an Actual/360 Basis.

4.3 Payments.  Monthly payments hereunder shall commence on the first day of
the calendar month following the Disbursement Date and continue on the
first day of each calendar month thereafter through the Maturity Date.  If
the Disbursement Date is a date other than the first day of a calendar
month, the first monthly payment shall be interest only.  Subsequent
monthly payments shall be calculated on the basis of an equal-payment 15
year amortization of principal and interest.  Notwithstanding that interest
on this Note accrues on an Actual/360 Basis, the total amount of each such
amortized monthly payment of principal and interest shall be determined
using a 30/360 Basis.  On the Maturity Date, all unpaid principal and
accrued but unpaid interest shall be due and owing in full.  All interest
shall be paid in arrears.

4.4     Acknowledgments.  Borrower acknowledges that interest calculated on an
Actual/360 Basis exceeds interest calculated on a 30/360 Basis and,
therefore:  (a) a greater portion of each monthly installment of principal
and interest will be applied to interest using the Actual/360 Basis than
would be the case if interest accrued on a 30/360 Basis; and (b) the
unpaid principal balance of this Note on the Maturity Date will be greater
using the Actual/360 Basis than would be the case if interest accrued on a
30/360 Basis.

4.5     Application of Payments.  In the absence of a specific determination by
Lender to the contrary, all payments paid by Borrower to Lender in
connection with the obligations of Borrower under this Note and under the
other Loan Documents shall be applied in the following order of priority:
(a) to amounts, other than principal and interest, due to Lender pursuant
to this Note or the other Loan Documents; (b) to accrued but unpaid
interest on this Note; and (c) to the unpaid principal balance of this
Note.  Borrower irrevocably waives the right to direct the application of
any and all payments at any time hereafter received by Lender from or on
behalf of Borrower, and Borrower irrevocably agrees that Lender shall have
the continuing exclusive right to apply any and all such payments against
the then due and owing obligations of Borrower in such order of priority as
Lender may deem advisable.

5.      LATE CHARGE; DEFAULT RATE.

5.1 Late Charge.  If any payment required hereunder is not paid on or before
the fifth calendar day of the month in which it is due, Borrower shall pay
a late or collection charge, as liquidated damages, equal to 4% of the
amount of such unpaid payment.  Borrower acknowledges that Lender will
incur additional expenses as a result of any late payments hereunder, which
expenses would be impracticable to quantify, and that Borrower's payments
under this paragraph are a reasonable estimate of such expenses.  The
foregoing to the contrary notwithstanding, no late or collection charge
shall be payable by Borrower as a result of any delay in the payment of any
sum due and payable on the Maturity Date.

5.2 Default Rate. Commencing upon a Default and continuing until such Default
shall have been cured by Borrower, all sums owing on this Note shall bear
interest until paid in full at a rate per annum equal to 5% plus the
Interest Rate ("Default Rate").

6.MAXIMUM RATE PERMITTED BY LAW. Neither this Note nor any of the other Loan
Documents shall require the payment or permit the collection of any interest or
any late payment charge in excess of the maximum rate permitted by law. If any
such excess interest or late payment charge is provided for under this Note or
any of the other Loan Documents or if this Note or any of the other Loan
Documents shall be adjudicated to provide for such excess, neither Borrower nor
Borrower's successors or assigns shall be obligated to pay such excess, and the
right to demand the payment of any such excess shall be and hereby is waived,
and this provision shall control any other provision of this Note or any of the
other Loan Documents.  If Lender shall collect amounts which are deemed to
constitute interest and which would increase the effective interest rate to a
rate in excess of the maximum rate permitted by law, all such amounts deemed to
constitute interest in excess of the maximum legal rate shall, upon such
determination, at the option of Lender, be returned to Borrower or credited
against the outstanding principal balance of this Note.

7.ACCELERATION.  If (a) Borrower shall fail to pay when due any sums payable
under this Note; (b) any other Default shall occur; or (c) any other event or
condition shall occur which, under the terms of the Deed of Trust or any other
Loan Document, gives rise to a right of acceleration of sums owing under this
Note, then Lender, at its sole option, shall have the right to declare all sums
owing under this Note immediately due and payable; provided, however, that if
the Deed of Trust or any other Loan Document provides for the automatic
acceleration of payment of sums owing under this Note, all sums owing under this
Note shall be automatically due and payable in accordance with the terms of the
Deed of Trust or such other Loan Document.

8.      BORROWER'S LIABILITY.

8.1     Limitation.  Except as otherwise provided in this Section 8, Lender's
recovery against Borrower under this Note and the other Loan Documents
shall be limited solely to the Property and the "Collateral" (as defined in
the Deed of Trust).

8.2     Exceptions.  Nothing contained in Section 8.1 or elsewhere in this Note
or the other Loan Documents, however, shall limit in any way the personal
liability of Borrower owed to Lender for any losses or damages incurred by
Lender (including, without limitation, any impairment of Lender's security
for the Loan) with respect to any of the following matters: (a) fraud or
willful misrepresentation; (b) material physical waste of the Property or
the Collateral; (c) failure to pay property or other taxes, assessments or
charges (other than amounts paid to Lender for taxes, assessments or
charges pursuant to Impounds as defined in Exhibit A and where Lender
elects not to apply such funds toward payment of the taxes, assessments or
charges owed) which may create liens senior to the lien of the Deed of
Trust on all or any portion of the Property; (d) failure to deliver any
insurance or condemnation proceeds or awards or any security deposits
received by Borrower to Lender or to otherwise apply such sums as required
under the terms of the Loan Documents or any other instrument now or
hereafter securing this Note; (e) failure to apply any rents, royalties,
accounts, revenues, income, issues, profits and other benefits from the
Property which are collected or received by Borrower during the period of
any Default or after acceleration of the indebtedness and other sums owing
under the Loan Documents to the payment of either (i) such indebtedness or
other sums or (ii) the normal and necessary operating expenses of the
Property; or (f) any breach by Borrower of any covenant in this Note or in
the Deed of Trust regarding Hazardous Materials (as defined in the Deed of
Trust) or any representation or warranty of Borrower regarding Hazardous
Materials proving to have been untrue when made.

8.3     No Release or Impairment.  Nothing contained in Section 8.1 shall be
deemed to release, affect or impair the indebtedness evidenced by this Note
or the obligations of Borrower under, or the liens and security interests
created by the Loan Documents, or Lender's rights to enforce its remedies
under this Note and the other Loan Documents, including, without
limitation, the right to pursue any remedy for injunctive or other
equitable relief, or any suit or action in connection with the
preservation, enforcement or foreclosure of the liens, mortgages,
assignments and security interests which are now or at any time hereafter
security for the payment and performance of all obligations under this Note
or the other Loan Documents.

8.4  Prevail and Control.  The provisions of this Section 8 shall prevail and
control over any contrary provisions elsewhere in this Note or the other
Loan Documents.

9.NON-TRUSTOR BORROWER.  If any Borrower is not also a "Trustor" under the Deed
of Trust, such Borrower hereby makes all representations and warranties in favor
of Lender contained in Article 5 of the Deed of Trust, all covenants contained
in Section 6.15 of the Deed of Trust, and all indemnities of Lender contained in
Section 6.19 of the Deed of Trust, jointly and severally with the "Trustor."

10.     MISCELLANEOUS.

10.1    Joint and Several Liability.  If this Note is executed by more than one
person or entity as Borrower, the obligations of each such person or entity
shall be joint and several.  No person or entity shall be a mere
accommodation maker, but each shall be primarily and directly liable
hereunder.

10.2    Waiver of Presentment.  Except as otherwise provided in any other Loan
Document, Borrower hereby waives presentment, demand, notice of dishonor,
notice of default or delinquency, notice of acceleration, notice of
nonpayment, notice of costs, expenses or losses and interest thereon, and
notice of interest on interest and late charges.

10.3    Delay In Enforcement.  No previous waiver or failure or delay by Lender
in acting with respect to the terms of this Note or the Deed of Trust shall
constitute a waiver of any breach, default or failure of condition under
this Note, the Deed of Trust or the obligations secured thereby.  A waiver
of any term of this Note, the Deed of Trust or of any of the obligations
secured thereby must be made in writing signed by Lender, shall be limited
to the express terms of such waiver, and shall not constitute a waiver of
any subsequent obligation of Borrower.  The acceptance at any time by
Lender of any past-due amount shall not be deemed to be a waiver of the
right to require prompt payment when due of any other amounts then or
thereafter due and payable.

10.4    Time of the Essence.  Time is of the essence with respect to every
provision hereof.

10.5    Governing Law.  This Note was accepted by Lender in the state of
California and the proceeds of this Note were disbursed from the state of
California, which state the parties agree has a substantial relationship to
the parties and to the underlying transaction embodied hereby.
Accordingly, in all respects, including, without limiting the generality of
the foregoing, matters of construction, validity, enforceability and
performance, this Note, the Deed of Trust and the other Loan Documents and
the obligations arising hereunder and thereunder shall be governed by, and
construed in accordance with, the laws of the state of California
applicable to contracts made and performed in such state and any applicable
law of the United States of America, except that at all times the
provisions for the enforcement of Lender's STATUTORY POWER OF SALE granted
under the Deed of Trust securing this Note and the creation, perfection and
enforcement of the security interests created pursuant thereto and pursuant
to the other Loan Documents shall be governed by and construed according to
the law of the state where the Property is located.  Except as provided in
the immediately preceding sentence, Borrower hereby unconditionally and
irrevocably waives, to the fullest extent permitted by law, any claim to
assert that the law of any jurisdiction other than California governs the
Deed of Trust, this Note and the other Loan Documents.

10.6    Consent to Jurisdiction.  Borrower irrevocably submits to the
jurisdiction of: (a) any state or federal court sitting in the state of
California over any suit, action, or proceeding, brought by Borrower
against Lender, arising out of or relating to this Note or the Loan
evidenced hereby; (b) any state or federal court sitting in the state where
the Property is located or the state in which Borrower's principal place of
business is located over any suit, action or proceeding, brought by Lender
against Borrower, arising out of or relating to this Note or the Loan
evidenced hereby; and (c) any state court sitting in the county of the
state where the Property is located over any suit, action, or proceeding,
brought by Lender to exercise its STATUTORY POWER OF SALE under the Deed of
Trust or any action brought by the Lender to enforce its rights with
respect to the Collateral.  Borrower irrevocably waives, to the fullest
extent permitted by law, any objection that Borrower may now or hereafter
have to the laying of venue of any such suit, action, or proceeding brought
in any such court and any claim that any such suit, action, or proceeding
brought in any such court has been brought in an inconvenient forum.

10.7    Counterparts.  This Note may be executed in any number of counterparts,
each of which when executed and delivered shall be deemed an original and
all of which taken together shall be deemed to be one and the same Note.

10.8    Heirs, Successors and Assigns.  All of the terms, covenants, conditions
and indemnities contained in this Note and the other Loan Documents shall
be binding upon the heirs, successors and assigns of Borrower and shall
inure to the benefit of the successors and assigns of Lender.  The
foregoing sentence shall not be construed to permit Borrower to assign the
Loan except as otherwise permitted in this Note or the other Loan
Documents.

10.9    Severability.  If any term of this Note, or the application thereof to
any person or circumstances, shall, to any extent, be invalid or
unenforceable, the remainder of this Note, or the application of such term
to persons or circumstances other than those as to which it is invalid or
unenforceable, shall not be affected thereby, and each term of this Note
shall be valid and enforceable to the fullest extent permitted by law.

10.10 Consents and Approvals.  Wherever Lender's consent, approval, acceptance
or satisfaction is required under any provision of this Note or any of the
other Loan Documents, such consent, approval, acceptance or satisfaction
shall not be unreasonably withheld, conditioned or delayed by Lender unless
such provision expressly so provides.

11.NOTICES.  All notices and other communications that are required or permitted
to be given to a party under this Note shall be in writing and shall be sent to
such party, either by personal delivery, by overnight delivery service, by
certified first class mail, return receipt requested, or by facsimile
transmission to the address or facsimile number below.  All such notices and
communications shall be effective upon receipt of such delivery or facsimile
transmission.  The addresses and facsimile numbers of the parties shall be:

        Borrower:       Lender:
FREMONT HOLDING L.L.C.
34801 Campus Drive
Fremont, CA  94555
FAX No.: (510) 574-1500
Wells Fargo Bank, N.A.
1320 Willow Pass Road, Suite 205
Concord, CA  94520
Loan No. 31-0900011A
FAX No.: (925) 691-5947


12. ADDITIONAL TERMS AND CONDITIONS.  The additional terms and conditions set
forth in Exhibit A attached hereto are incorporated herein by this reference.

13.PREPAYMENT. Borrower acknowledges that any prepayment of this Note will cause
Lender to lose its interest rate yield on this Note and will possibly require
that Lender reinvest any such prepayment amount in loans of a lesser interest
rate yield (including, without limitation, in debt obligations other than first
mortgage loans on commercial properties).  As a consequence, Borrower agrees as
follows, as an integral part of the consideration for Lender's making the Loan:

13.1    Restrictions.  Any voluntary prepayment of this Note: (a) is prohibited
except during the last 3 months of the term, (b) is permitted in full
only, and not in part; and (c) may only be made on the first day of a
month.

13.2    Prepayment Charge.  Except as provided below, if this Note is prepaid
prior to the last 3 months of the term, whether such prepayment is
involuntary or upon acceleration of the principal amount of this Note by
Lender following a Default, Borrower shall pay to Lender on the prepayment
date (in addition to all other sums then due and owing to Lender under the
Loan Documents) a prepayment charge equal to the greater of the following
two amounts: (a) an amount equal to 1% of the then outstanding principal
balance of the Loan; or (b) an amount equal to (i) the amount, if any, by
which the sum of the present values as of the prepayment date of all
unpaid principal and interest payments required under this Note,
calculated by discounting such payments from their respective scheduled
payment dates back to the prepayment date at a discount rate equal to the
Periodic Treasury Yield (defined below) exceeds the outstanding principal
balance of the Loan as of the prepayment date, multiplied by (ii) a
fraction whose numerator is the amount of the prepayment and whose
denominator is the outstanding principal balance of the Loan as of the
prepayment date.  Notwithstanding the foregoing, no prepayment charge
shall apply in respect to any insurance or condemnation proceeds received
by Lender and applied by Lender to the outstanding principal balance of
the Loan.  For purposes of the foregoing, "Periodic Treasury Yield" means
(c) the annual yield to maturity of the actively traded non-callable
United States Treasury fixed interest rate security (other than any such
security which can be surrendered at the option of the holder at face
value in payment of federal estate tax or which was issued at a
substantial discount) that has a maturity closest to (whether before, on
or after) the Maturity Date (or if two or more such securities have
maturity dates equally close to the Maturity Date, the average annual
yield to maturity of all such securities), as reported in The Wall Street
Journal or other authoritative publication or news retrieval service on
the fifth Business Day preceding the prepayment date, divided by (d) 12,
if scheduled payment dates are monthly, or 4, if scheduled payment dates
are quarterly.

13.3    Waiver.  Borrower waives any right to prepay this Note except under the
terms and conditions set forth in this Section and agrees that if this
Note is prepaid, Borrower will pay the prepayment charge set forth above.
Borrower hereby acknowledges that: (a) the inclusion of this waiver of
prepayment rights and agreement to pay the prepayment charge for the right
to prepay this Note was separately negotiated with Lender; (b) the
economic value of the various elements of this waiver and agreement was
discussed; (c) the consideration given by Borrower for the Loan was
adjusted to reflect the specific waiver and agreement negotiated between
Borrower and Lender and contained herein; and (d) this waiver is intended
to comply with California Civil Code Section 2954.10.

Borrower's Initials: ________

13.4    Insurance Proceeds; Condemnation Awards.  Notwithstanding anything
herein to the contrary, no prepayment charge shall be due and owing with
respect to any involuntary prepayment resulting from Lender's application
of any insurance proceeds or condemnation awards to the Loan.

14.DEFEASANCE.  At any time after the Lockout Expiration Date (defined below),
Borrower may elect to cause Lender to release the Property and the Collateral
from the lien of the Deed of Trust and the other Loan Documents and to accept
other collateral in substitution therefor, in accordance with the provisions of
this Section ("Defeasance"), at Borrower's sole cost and expense.  "Lockout
Expiration Date" means the earlier of (a) the second anniversary of the
"startup day" (as defined in Internal Revenue Code Section 860(G)(a)(9)) of any
"real estate mortgage investment conduit" (as defined in Internal Revenue Code
Section 860D) that holds this Note and (b) the 4th anniversary of the date of
this Note.

14.1  Conditions.  Borrower shall only have the right to cause a Defeasance if
no Default has occurred and is continuing and all of the following
conditions have been satisfied:

a.  Notice.  Borrower shall give at least 60 days but not more than 90 days'
notice to Lender specifying the date of Borrower's intended
Defeasance ("Release Date"), which date shall be a scheduled payment
date;

b.      Payments.  Borrower shall pay in full, on or before the Release Date,
all accrued and unpaid interest and all other sums due under this
Note and the other Loan Documents on or before the Release Date,
including without limitation, (i) all costs and expenses paid or
incurred by Lender or its agents in connection with the Defeasance,
the purchase of the Defeasance Collateral (defined below), the
release of the Property and the Collateral, the review of the
proposed Defeasance Collateral and the preparation of the Defeasance
Security Agreement (defined below) and related documentation, and
(ii) any revenue, documentary stamp, intangible or other taxes,
charges or fees due in connection with the transfer or assumption of
this Note or the Defeasance;

c.      Deliveries.  Borrower shall deliver the following items to Lender on or
before the Release Date:

(i)     immediately available funds ("Defeasance Deposit") in an
amount sufficient to enable Lender to purchase, through means
and sources customarily employed and available to Lender, for
the account of Borrower, direct, non-callable obligations of
the United States of America that provide for payments prior,
but as close as possible, to all successive scheduled payment
dates occurring after the Release Date, with each such payment
being equal to or greater than the amount of  the corresponding
installment of principal and interest required to be paid under
this Note (including, without limitation, all amounts due on
the Maturity Date) for the balance of the term hereof
("Defeasance Collateral"), each of which shall be duly endorsed
by the holder as directed by Lender or accompanied by a written
instrument of transfer in form and substance satisfactory to
Lender in its sole discretion (including, without limitation,
such instruments as may be required by the depository
institution holding such securities or the issuer of such
securities, as the case may be, to effectuate book-entry
transfers and pledges through the book-entry facilities of such
institution) in order to perfect upon the delivery of the
Defeasance Security Agreement (as defined below) the first
priority security interest in the Defeasance Collateral in
favor of Lender;

(ii)    a pledge and security agreement, in form and substance
satisfactory to Lender in its sole discretion, creating a first
priority security interest in favor of Lender in the Defeasance
Collateral ("Defeasance Security Agreement"), which shall
provide, among other things, that any payments generated by the
Defeasance Collateral shall be paid directly to Lender and
applied by Lender to amounts then due and payable under this
Note and that any excess received by Lender from the Defeasance
Collateral over the amounts payable by Borrower under this Note
shall be refunded to Borrower promptly after each scheduled
payment date;

(iii)   a certificate of Borrower certifying that all of the
requirements of this Section 14.1 have been satisfied;

(iv)    an opinion of counsel for Borrower in form and substance and
delivered by counsel satisfactory to Lender in its sole
discretion stating, among other things, that (aa) Lender has a
perfected first priority security interest in the Defeasance
Collateral, (bb) the Defeasance Security Agreement is
enforceable against Borrower in accordance with its terms and
(cc) any REMIC Trust formed pursuant to a securitization will
not fail to maintain its status as a "real estate mortgage
investment conduit" within the meaning of Internal Revenue Code
Section 860D, as amended from time to time, or any successor
statute, as a result of the Defeasance;

(v)     a certificate from a firm of independent certified public
accountants acceptable to Lender certifying that the Defeasance
Collateral satisfies the requirements of Section 14.1c(i);

(vi)    written evidence from the applicable rating agencies that
the Defeasance will not result in a downgrading, withdrawal or
qualification of the respective ratings in effect immediately
prior to the Defeasance for any securities issued in connection
with the securitization which are then outstanding;

(vii)   such other certificates, documents or instruments as Lender
may reasonably require, including, without limitation, such
amendments to this Note and the other Loan Documents as Lender
deems appropriate to reflect the Defeasance.

14.2    Release of Lien.  Upon satisfaction of all conditions specified above,
the Property and the Collateral shall be released from the lien of the
Deed of Trust and the other Loan Documents, and the Defeasance Collateral
and the proceeds thereof shall constitute the only collateral which shall
secure the obligations of Borrower under this Note and the other Loan
Documents.  Lender shall, at Borrower's expense, execute and deliver any
agreements reasonably requested by Borrower to release the lien of the
Deed of Trust from the Property.

14.3    Defeasance Deposit.  Borrower hereby authorizes and directs Lender,
using the means and sources customarily employed and available to Lender,
to use the Defeasance Deposit to purchase the Defeasance Collateral as
agent and for the account of Borrower.  Payments from the Defeasance
Collateral shall be made directly to Lender for application to the Loan.
Any part of the Defeasance Deposit exceeding the amount necessary to
purchase the Defeasance Collateral and to pay the other costs which
Borrower is obligated to pay under this Section 14 shall be refunded to
Borrower. Borrower agrees to pay all sums referred to in Section 14.1b
above on or before the Release Date.

14.4    Assignment and Assumption.  Upon the release of the Property and the
Collateral in accordance with this Section 14, Borrower shall, at the
request of Lender, assign all of its right, title and interest in and to
the pledged Defeasance Collateral and all its obligations and rights under
this Note, the Defeasance Security Agreement and the other Loan Documents,
to a successor entity designated by Borrower and approved by Lender in its
sole discretion.  Such successor entity shall execute an assumption
agreement in form and substance satisfactory to Lender in its sole
discretion pursuant to which it shall assume Borrower's obligations under
this Note, the Defeasance Security Agreement and the other Loan Documents.
 As conditions to such assignment and assumption, Borrower shall: (a)
deliver to Lender a new limited guaranty in form and substance
satisfactory to Lender in its sole discretion executed by the principals
of such successor entity; (b) deliver to Lender an opinion of counsel in
form and substance and delivered by counsel satisfactory to Lender in its
sole discretion stating, among other things, that such assumption
agreement is enforceable against Borrower and such successor entity in
accordance with its terms and that this Note, the Defeasance Security
Agreement and the other Loan Documents, as so assumed, are enforceable
against such successor entity in accordance with their respective terms;
and (c) pay all costs and expenses incurred by Lender or its agents in
connection with such assignment and assumption (including, without
limitation, the review of the proposed transferee and the preparation of
the assumption agreement and related documentation).  Upon such
assumption, Borrower shall be relieved of its obligations under this Note,
the Defeasance Security Agreement and the other Loan Documents other than
those obligations which are specifically intended to survive the payment
of the Loan or other termination, satisfaction or assignment of this Note,
the Defeasance Security Agreement or the other Loan Documents or Lender's
exercise of its rights and remedies under any of such documents and
instruments.

15.WAIVER OF JURY TRIAL.  LENDER AND BORROWER HEREBY KNOWINGLY, VOLUNTARILY AND
INTENTIONALLY WAIVE ANY RIGHTS THEY MAY HAVE TO A TRIAL BY JURY IN RESPECT OF
ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER, OR IN CONNECTION WITH,
THIS NOTE OR ANY OTHER LOAN DOCUMENT, OR ANY COURSE OF CONDUCT, COURSE OF
DEALING, STATEMENTS (WHETHER ORAL OR WRITTEN), OR ACTIONS OF LENDER OR
BORROWER.  THIS PROVISION IS A MATERIAL INDUCEMENT FOR LENDER TO MAKE THE LOAN
TO BORROWER.


        "BORROWER"


FREMONT HOLDING L.L.C.,
a Delaware limited liability company

By:  Fremont Management, Inc.,
     a Delaware corporation,
     Manager

     By:  _______________________________

     Its: _______________________________




        Loan No. 31-0900011A

EXHIBIT A TO PROMISSORY NOTE
Additional Terms And Conditions


This Exhibit A is attached to and forms a part of that Promissory Note ("Note")
executed by FREMONT HOLDING L.L.C., a Delaware limited liability company
("Borrower") in favor of WELLS FARGO BANK, NATIONAL ASSOCIATION ("Lender").

16.     DISBURSEMENT OF LOAN PROCEEDS; LIMITATION OF LIABILITY. Borrower hereby
authorizes Lender to disburse the proceeds of the Loan, after deducting any and
all fees owed by Borrower to Lender in connection with the Loan, to First
American Title Guaranty Company. With respect to such disbursement, Borrower
understands and agrees that Lender does not accept responsibility for errors,
acts or omissions of others, including, without limitation, the escrow company,
other banks, communications carriers or clearinghouses through which the
transfer of Loan proceeds may be made or through which Lender receives or
transmits information, and no such entity shall be deemed Lender's agent. As a
consequence, Lender shall not be liable to Borrower for any actual (whether
direct or indirect), consequential or punitive damages which may arise with
respect to the disbursement of Loan proceeds, whether or not (a) any claim for
such damages is based on tort or contract, or (b) either Lender or Borrower
knew or should have known of the likelihood of such damages in any situation.

17.     FINANCIAL STATEMENTS.

17.1    Statements Required.  During the term of the Loan and while any
liabilities of Borrower to Lender under any of the Loan Documents remain
outstanding and unless Lender otherwise consents in writing, Borrower
shall provide to Lender the following:

a.      Operating Statement.  Not later than 30 days after and as of the end of
each calendar quarter, an operating statement, signed and dated by
Borrower and in a form acceptable to Lender, showing all revenues and
expenses during such month or quarter and year-to-date, relating to
the Property, including, without limitation, all information
requested under any of the Loan Documents;

b.      Rent Roll.  Not later than 30 days after and as of the end of each
calendar quarter, a rent roll signed and dated by Borrower and in a
form acceptable to Lender, showing the following lease information
with regard to each tenant: the name of the tenant, monthly or other
periodic rental amount, dates of commencement and expiration of the
lease, and payment status;

c.  Balance Sheet.  If requested by Lender, not later than 90 days after and
as of the end of each fiscal year, a balance sheet, signed and dated
by Borrower and in a form acceptable to Lender (or audited financial
statements if Borrower obtains them), showing all assets and
liabilities of Borrower; and

d.      Other Information.  From time to time, upon Lender's delivery to
Borrower of at least 10 days' prior written notice, such other
information with regard to Borrower, principals of Borrower,
guarantors or the Property as Lender may reasonably request in
writing.

17.2    Form; Warranty.  Borrower agrees that all financial statements to be
delivered to Lender pursuant to Section 2.1 shall: (a) be complete and
correct; (b) present fairly the financial condition of the party;
(c) disclose all liabilities that are required to be reflected or reserved
against; and (d) be prepared in accordance with the same accounting
standard used by Borrower to prepare the financial statements delivered to
and approved by Lender in connection with the making of the Loan or other
accounting standards acceptable to Lender. Borrower shall be deemed to
warrant and represent that, as of the date of delivery of any such
financial statement, there has been no material adverse change in
financial condition, nor have any assets or properties been sold,
transferred, assigned, mortgaged, pledged or encumbered since the date of
such financial statement except as disclosed by Borrower in a writing
delivered to Lender. Borrower agrees that all rent rolls and other
information to be delivered to Lender pursuant to Section 2.1 shall not
contain any misrepresentation or omission of a material fact.



17.3 Late Charge.  If any financial statement, leasing schedule or other item
required to be delivered to Lender pursuant to Section 2.1 is not timely
delivered, Borrower shall promptly pay to Lender, as a late charge, the
sum of $500 per item.  In addition, Borrower shall promptly pay to Lender
an additional late charge of $500 per item for each full month during
which such item remains undelivered following written notice from Lender.
 Borrower acknowledges that Lender will incur additional expenses as a
result of any such late deliveries, which expenses would be impracticable
to quantify, and that Borrower's payments under this Section 2.3 are a
reasonable estimate of such expenses.

18.     IMPOUNDS.

18.1    Amounts.  Borrower shall deposit with Lender, the amounts ("Impounds")
stated below on the dates stated below, for the purpose of paying the
costs stated below:

a.      Taxes.  On the first payment date on which both principal and interest
under the Loan are payable and on each payment date thereafter, an
amount estimated from time to time by Lender in its sole discretion
to be sufficient to pay for taxes and other liabilities payable by
Borrower under Section 6.9 of the Deed of Trust.  The initial
estimated monthly amount to be deposited by Borrower on each payment
date is $11,130.00.

b.  Capital Expenditures.  $1,538.00 on the first payment date on which both
principal and interest under the Loan are payable and on each payment
date thereafter for payment or reimbursement of Capital Expenditures
(defined below).

18.2    Application.

a.      Taxes.  If no Default exists, Lender shall apply the Impounds to the
payment of the taxes and other liabilities stated above.

b.      Capital Expenditures.  If no Default exists, Lender shall release the
Impounds to Borrower once a month, to pay or reimburse Borrower for
the Capital Expenditures stated above; provided, however, that Lender
shall have received and approved each of the following:

(i)     Borrower's written request for such release, describing the
Capital Expenditures and certifying that all Capital
Expenditures have been paid or incurred by Borrower for work
completed lien-free and in a workmanlike manner;

(ii)    copies of invoices supporting the request for such release;
and

(iii)   if deemed necessary by Lender, an inspection report signed
by an inspector selected by Lender, whose fees and expenses
shall be paid by Borrower, and such other evidence as Lender
shall require, confirming borrower's certification.

18.3    General.  Any portion of the Impounds that exceeds the amount required
for payment of the foregoing costs shall be repaid to Borrower upon
Borrower's compliance with the foregoing. Reference is made to
Section 6.12(b) of the Deed of Trust for a description of the account into
which the Impounds shall be deposited and for a description of certain
rights and remedies of Lender with respect to amounts in such account.
Notwithstanding anything to the contrary in the Deed of Trust, all
accounts containing Impounds for taxes, insurance and capital expenditures
shall bear interest at a rate established by Lender or its servicing
agent, which may or may not be the highest rate then available.

18.4    Maintenance and Construction.

a.   Capital Expenditures.  Borrower shall complete the lien-free performance
or installation of the Capital Expenditures (as defined below) from
time to time as necessary, in a workmanlike manner and in accordance
with all applicable laws, ordinances, rules and regulations. "Capital
Expenditures" shall mean major repairs and replacements to maintain or
improve the Property, including, without limitation, structural
repairs, roof replacements, HVAC repairs and replacements, mechanical
and plumbing repairs and replacements and boiler repair and
replacements.

b.      Right of Inspection.  Lender shall have the right to enter upon the
Property at all reasonable times to inspect all work for the purpose
of verifying information disclosed or required pursuant to this Note.
Notwithstanding the foregoing, Lender shall not be obligated to
supervise or inspect any work or to inform Borrower or any third
party regarding any aspect of any work.

18.5    Release.  Lender shall release any Impounds to Borrower through a funds
transfer of such Impounds initiated by Lender to the following account or
such other account as Borrower specifies in a notice to Lender:

Bank Name:

ABA Routing
No.:

Account Name:

Reference:

Advise:


Lender will determine the funds transfer system and other means to be used
in making each such release. Borrower agrees that each such funds transfer
initiated by Lender will be deemed to be a funds transfer properly
authorized by Borrower, even if the transfer is not actually properly
authorized by Borrower. Borrower acknowledges that Lender will rely on the
account number and ABA routing number set forth above or specified in a
notice from Borrower to Lender, even if such account number identifies an
account with a name different from the name so specified, or the routing
number identifies a bank different from the bank so specified.  If
Borrower learns of any error in the transfer of any Impounds or of any
transfer which was not properly authorized, Borrower shall notify Lender
as soon as possible in writing but in no case more than 14 days after
Lender's first confirmation to Borrower of such transfer.

19. ONE-TIME RIGHT OF TRANSFER OF PROPERTY.  Notwithstanding anything to the
contrary contained in Section 6.15 of the Deed of Trust, Lender shall, one time
only, consent to the voluntary sale or exchange of all of the Property by
Trustor (as defined in the Deed of Trust) to a bona-fide third party purchaser,
without any modification of the terms of this Note or the other Loan Documents,
if no Default has occurred and is continuing and all of the following
conditions have been satisfied:

19.1    Lender's reasonable determination that the proposed purchaser, the
proposed guarantor, if any, and the Property all satisfy Lender's then
applicable credit review and underwriting standards, taking into
consideration, among other things, (a) any decrease in the Property's cash
flow which would result from any increase in real property taxes due to
any anticipated reassessment of the Property for tax purposes and (b) any
requirement of Lender that the proposed borrowing entity satisfy Lender's
then applicable criteria for a single asset or special purpose bankruptcy
remote entity;

19.2    Lender's reasonable determination that the proposed purchaser possesses
satisfactory recent experience in the ownership and operation of properties
comparable to the Property;

19.3  the execution and delivery to Lender of such documents and instruments as
Lender shall reasonably require, in form and content reasonably
satisfactory to Lender, including, without limitation, (i) an assumption
agreement under which the purchaser assumes all obligations and liabilities
of Borrower under this Note and the other Loan Documents and agrees to
periodically pay such new or additional Impounds to Lender as Lender may
reasonably require, and (ii) a consent to the transfer by any existing
guarantor and a reaffirmation of such guarantor's obligations and
liabilities under any guaranty made in connection with the Loan or a new
guaranty executed by a new guarantor reasonably satisfactory to Lender;

19.4    if required by Lender, delivery to Lender of evidence of title insurance
reasonably satisfactory to Lender insuring Lender that the lien of the Deed
of Trust and the priority thereof will not be impaired or affected by
reason of such transfer or exchange of the Property;

19.5    payment to Lender of an assumption fee equal to 1% of the then
outstanding principal balance of this Note;

19.6    if required by Lender, deposit with Lender of any new or additional
Impounds;

19.7    reimbursement to Lender of any and all costs and expenses paid or
incurred by Lender in connection with such transfer or exchange, including,
without limitation, all in-house or outside counsel attorneys' fees, title
insurance fees, appraisal fees, inspection fees, environmental consultant's
fees and any fees or charges of the applicable rating agencies; and

19.8    if required by Lender, delivery to Lender of written evidence from the
applicable rating agencies that such transfer or exchange will not result
in a downgrading, withdrawal or qualification of the respective ratings in
effect immediately prior to the transfer or exchange for any securities
issued in connection with the securitization of the Loan which are then
outstanding.

Lender shall fully release Borrower and any existing guarantor from any further
obligation or liability to Lender under this Note and the other Loan Documents
upon the assumption by the purchaser and any new guarantor of all such
obligations and liabilities and the satisfaction of all other conditions
precedent to a transfer or exchange in accordance with the provisions of this
Section.

        Loan No. 31-0900011A

EXHIBIT B TO PROMISSORY NOTE
Loan Documents and Other Related Documents

This Exhibit B is attached to and forms a part of that Promissory Note ("Note")
executed by FREMONT HOLDING L.L.C., a Delaware limited liability company
("Borrower") in favor of WELLS FARGO BANK, NATIONAL ASSOCIATION ("Lender").

20.LOAN DOCUMENTS.  The documents numbered 1.1 through 1.6 below of even date
herewith (unless otherwise specified) and any amendments, modifications and
supplements thereto which have received the prior written approval of Lender
and any documents executed in the future that are approved by Lender and that
recite that they are "Loan Documents" for purposes of this Note are
collectively referred to as the "Loan Documents".

20.1    This Note;

20.2    Deed of Trust;

20.3 State of California Uniform Commercial Code - Financing Statement - Form
UCC-1;

20.4    Limited Liability Company Borrowing Certificate;

20.5    Corporate Resolution Authorizing Limited Liability Company Activity and
Certificate of Incumbency;

20.6    Estoppel, Non-Disturbance and Attornment Agreement.

21.     OTHER RELATED DOCUMENTS WHICH ARE NOT LOAN DOCUMENTS.

21.1    Agreement for Disbursement Prior to Recording and Amendment to Note.

        PROMISSORY NOTE SECURED BY DEED OF TRUST


Recording Requested by
and when recorded return to:

WELLS FARGO BANK, N.A.
Commercial Mortgage Servicing
417 Montgomery Street, 5th Floor
San Francisco, California 94104

Attention:      Jean Hembree
Loan No. :      31-0900011A





                       D E E D  O F  T R U S T
                                and
            A B S O L U T E  A S S I G N M E N T  O F  R E N T S
                          A N D  L E A S E S
                                 and
                S E C U R I T Y  A G R E E M E N T
                    (A N D  F I X T U R E  F I L I N G)


The parties to this DEED OF TRUST AND ABSOLUTE ASSIGNMENT OF RENTS AND LEASES
AND SECURITY AGREEMENT (AND FIXTURE FILING) ("Deed of Trust"), dated as of
September 9, 1999 are FREMONT HOLDING L.L.C., a Delaware limited liability
company ("Trustor"), with a mailing address at 34801 Campus Drive, Fremont, CA
94555, AMERICAN SECURITIES COMPANY, a California corporation ("Trustee"), with
a mailing address at 1320 Willow Pass Road, Suite 205, Concord, California
94520, and WELLS FARGO BANK, NATIONAL ASSOCIATION ("Beneficiary"), with a
mailing address at 1320 Willow Pass Road, Suite 205, Concord, California 94520.


R E C I T A L S

A. FREMONT HOLDING L.L.C., a Delaware limited liability company ("Borrower")
proposes to borrow from Beneficiary, and Beneficiary proposes to lend to
Borrower the principal sum of TEN MILLION ONE HUNDRED FIFTY THOUSAND AND
NO/100THS DOLLARS ($10,150,000.00) ("Loan").  The Loan is evidenced by a
promissory note ("Note") executed by Borrower, dated the date of this Deed
of Trust, payable to the order of Beneficiary in the principal amount of
the Loan.

B. The loan documents include this Deed of Trust, the Note and the other
documents described in the Note as Loan Documents ("Loan Documents").


ARTICLE 1.  DEED OF TRUST

1.1     GRANT.  For the purposes of and upon the terms and conditions of this
Deed of Trust, Trustor irrevocably grants, conveys and assigns to Trust-
ee, in trust for the benefit of Beneficiary, with power of sale and right
of entry and possession, all estate, right, title and interest which
Trustor now has or may hereafter acquire in, to, under or derived from
any or all of the following:

a.      That real property ("Land") located in Fremont, county of Alameda,
state of California, and more particularly described on Exhibit A
attached hereto;

b.      All appurtenances, easements, rights of way, water and water
rights, pumps, pipes, flumes and ditches and ditch rights, water
stock, ditch and/or reservoir stock or interests, royalties,
development rights and credits, air rights, minerals, oil rights, and
gas rights, now or later used or useful in connection with,
appurtenant to or related to the Land;

c.      All buildings, structures, facilities, other improvements and
fixtures now or hereafter located on the Land;

d.      All apparatus, equipment, machinery and appliances and all
accessions thereto and renewals and replacements thereof and
substitutions therefor used in the operation or occupancy of the
Land, it being intended by the parties that all such items shall be
conclusively considered to be a part of the Land, whether or not
attached or affixed to the Land;

e.      All land lying in the right-of-way of any street, road, avenue,
alley or right-of-way opened, proposed or vacated, and all sidewalks,
strips and gores of land adjacent to or used in connection with the
Land;

f.      All additions and accretions to the property described above;

g.      All licenses, authorizations, certificates, variances, consents,
approvals and other permits now or hereafter pertaining to the Land
and all estate, right, title and interest of Trustor in, to, under or
derived from all tradenames or business names relating to the Land or
the present or future development, construction, operation or use of
the Land; and

h.      All proceeds of any of the foregoing.

All of the property described above is hereinafter collectively defined as
the "Property".  The listing of specific rights or property shall not be
interpreted as a limitation of general terms.


ARTICLE 2.  OBLIGATIONS SECURED

2.1     OBLIGATIONS SECURED.  Trustor makes the foregoing grant and assignment
for the purpose of securing the following obligations ("Secured Obliga-
tions"):

a.      Full and punctual payment to Beneficiary of all sums at any time
owing under the Note;

b.      Payment and performance of all covenants and obligations of Trustor
under this Deed of Trust including, without limitation,
indemnification obligations and advances made to protect the
Property;

c.      Payment and performance of all additional covenants and obligations
of Borrower and Trustor under the Loan Documents;

d.      Payment and performance of all covenants and obligations, if any,
which any rider attached as an exhibit to this Deed of Trust recites
are secured hereby;

e.      Payment and performance of all future advances and other
obligations that the then record owner of all or part of the Property
may agree to pay and/or perform (whether as principal, surety or
guarantor) for the benefit of Beneficiary, when the obligation is
evidenced by a writing which recites that it is secured by this Deed
of Trust;

f.      All interest and charges on all obligations secured hereby
including, without limitation, prepayment charges, late charges and
loan fees; and

g.      All modifications, extensions and renewals of any of the
obligations secured hereby, however evidenced, including, without
limitation: (i) modifications of the required principal payment dates
or interest payment dates or both, as the case may be, deferring or
accelerating payment dates wholly or partly; and (ii) modifications,
extensions or renewals at a different rate of interest whether or not
any such modification, extension or renewal is evidenced by a new or
additional promissory note or notes.

2.2     OBLIGATIONS.  The term "obligations" is used herein in its broadest and
most comprehensive sense and shall be deemed to include, without
limitation, all interest and charges, prepayment charges, late charges
and loan fees at any time accruing or assessed on any of the Secured
Obligations.

2.3 INCORPORATION.  All terms and conditions of the documents which evidence
any of the Secured Obligations are incorporated herein by this reference.
 All persons who may have or acquire an interest in the Property shall be
deemed to have notice of the terms of the Secured Obligations and to have
notice that the rate of interest on one or more Secured Obligation may
vary from time to time.


ARTICLE 3.  ABSOLUTE ASSIGNMENT OF RENTS AND LEASES

3.1 ASSIGNMENT.  Trustor irrevocably assigns to Beneficiary all of Trustor's
right, title and interest in, to and under: (a) all present and future
leases of the Property or any portion thereof, all licenses and
agreements relating to the management, leasing or operation of the
Property or any portion thereof, and all other agreements of any kind
relating to the use or occupancy of the Property or any portion thereof,
whether such leases, licenses and agreements are now existing or entered
into after the date hereof ("Leases"); and (b) the rents, issues,
deposits and profits of the Property, including, without limitation, all
amounts payable and all rights and benefits accruing to Trustor under the
Leases ("Payments").  The term "Leases" shall also include all guarantees
of and security for the tenants' performance thereunder, and all
amendments, extensions, renewals or modifications thereto which are
permitted hereunder.  This is a present and absolute assignment, not an
assignment for security purposes only, and Beneficiary's right to the
Leases and Payments is not contingent upon, and may be exercised without
possession of, the Property.

3.2     GRANT OF LICENSE.  Beneficiary confers upon Trustor a revocable license
("License") to collect and retain the Payments as they become due and
payable, until the occurrence of a Default (as hereinafter defined).  Upon
a Default, the License shall be automatically revoked and Beneficiary may
collect and apply the Payments pursuant to the terms hereof without notice
and without taking possession of the Property.  All Payments thereafter
collected by Trustor shall be held by Trustor as trustee under a
constructive trust for the benefit of Beneficiary.  Trustor hereby
irrevocably authorizes and directs the tenants under the Leases to rely
upon and comply with any notice or demand by Beneficiary for the payment
to Beneficiary of any rental or other sums which may at any time become
due under the Leases, or for the performance of any of the tenants'
undertakings under the Leases, and the tenants shall have no right or duty
to inquire as to whether any Default has actually occurred or is then
existing.  Trustor hereby relieves the tenants from any liability to
Trustor by reason of relying upon and complying with any such notice or
demand by Beneficiary. Beneficiary may apply, in its sole discretion, any
Payments so collected by Beneficiary against any Secured Obligation or any
other obligation of Borrower, Trustor or any other person or entity, under
any document or instrument related to or executed in connection with the
Loan Documents, whether existing on the date hereof or hereafter arising.
 Collection of any Payments by Beneficiary shall not cure or waive any
Default or notice of Default or invalidate any acts done pursuant to such
notice.

3.3     EFFECT OF ASSIGNMENT.  The foregoing irrevocable assignment shall not
cause Beneficiary to be: (a) a mortgagee in possession; (b) responsible or
liable for the control, care, management or repair of the Property or for
performing any of the terms, agreements, undertakings, obligations,
representations, warranties, covenants and conditions of the Leases; (c)
responsible or liable for any waste committed on the Property by the
tenants under any of the Leases or by any other parties; for any dangerous
or defective condition of the Property; or for any negligence in the
management, upkeep, repair or control of the Property resulting in loss or
injury or death to any tenant, licensee, employee, invitee or other
person; or (d) responsible for or impose upon Beneficiary any duty to
produce rents or profits.  Beneficiary shall not directly or indirectly be
liable to Trustor or any other person as a consequence of:  (e) the
exercise or failure to exercise any of the rights, remedies or powers
granted to Beneficiary hereunder; or (f) the failure or refusal of
Beneficiary to perform or discharge any obligation, duty or liability of
Trustor arising under the Leases.

3.4     COVENANTS.

a.      All Leases.  Trustor shall, at Trustor's sole cost and expense:

(i)     perform all obligations of the landlord under the Leases and
use reasonable efforts to enforce performance by the tenants of
all obligations of the tenants under the Leases;

(ii)    use reasonable efforts to keep the Property leased at all
times to tenants which Trustor reasonably and in good faith
believes are creditworthy at rents not less than the fair market
rental value (including, but not limited to, free or discounted
rents to the extent the market so requires);

(iii)   promptly upon Beneficiary's request, deliver to Beneficiary a
copy of each requested Lease and all amendments thereto and
waivers thereof; and

(iv)    promptly upon Beneficiary's request, execute and record any
additional assignments of landlord's interest under any Lease to
Beneficiary and specific subordinations of any Lease to this
Deed of Trust, in form and substance satisfactory to
Beneficiary.

Unless consented to in writing by Beneficiary or otherwise permitted
under any other provision of the Loan Documents, Trustor shall not:

(v)     grant any tenant under any Lease any option, right of first
refusal or other right to purchase all or any portion of the
Property under any circumstances;

(vi)    grant any tenant under any Lease any right to prepay rent
more than 1 month in advance;

(vii)   except upon Beneficiary's request, execute any assignment of
landlord's interest in any Lease; or

(viii)  collect rent or other sums due under any Lease in advance,
other than to collect rent 1 month in advance of the time when
it becomes due.

Any such attempted action in violation of the provisions of this
Section shall be null and void.

Beneficiary's failure to deny any written request by Trustor for
consent under the foregoing provisions of this Section within
5 Business Days after Beneficiary's receipt of such request (and all
documents and information reasonably related thereto) shall be deemed
to constitute Beneficiary's consent to such request.

Trustor shall deposit with Beneficiary any sums received by Trustor
in consideration of any termination, modification or amendment of any
Lease or any release or discharge of any tenant under any Lease from
any obligation thereunder and any such sums received by Trustor shall
be held in trust by Trustor for such purpose. Notwithstanding the
foregoing, so long as no Default exists, the portion of any such sum
received by Trustor with respect to any Lease which is less than
$50,000 shall be payable to Trustor. All such sums received by
Beneficiary with respect to any Lease shall be deemed "Impounds" (as
defined in Section 6.12b) and shall be deposited by Beneficiary into
a pledged account in accordance with Section 6.12b. If no Default
exists, Beneficiary shall release such Impounds to Trustor from time
to time as necessary to pay or reimburse Trustor for such tenant
improvements, brokerage commissions and other leasing costs as may be
required to re-tenant the affected space; provided, however,
Beneficiary shall have received and approved each of the following
for each tenant for which such costs were incurred; (1) Trustor's
written request for such release, including the name of the tenant,
the location and net rentable area of the space and a description and
cost breakdown of the tenant improvements or other leasing costs
covered by the request; (2) Trustor's certification that any tenant
improvements have been completed lien-free and in a workmanlike
manner; (3) a fully executed Lease, or extension or renewal of the
current Lease; (4) an estoppel certificate executed by the tenant
including its acknowledgement that all tenant improvements have been
satisfactorily completed; and (5) such other information with respect
to such costs as Beneficiary may require. Following the re-tenanting
of all affected space (including, without limitation, the completion
of all tenant improvements), and provided no Default exists,
Beneficiary shall release any remaining such Impounds relating to the
affected space to Trustor. Trustor shall construct all tenant
improvements in a workmanlike manner and in accordance with all
applicable laws, ordinances, rules and regulations.

b.      Major Leases.  Trustor shall, at Trustor's sole cost and expense,
give Beneficiary prompt written notice of any material default by
landlord or tenant under any Major Lease (as defined below). Unless
consented to in writing by Beneficiary or otherwise permitted under
any other provision of the Loan Documents, Trustor shall not:

(i)     enter into any Major Lease which (aa) is not on fair market
terms (which terms may include free or discounted rent to the
extent the market so requires); (bb) does not contain a
provision requiring the tenant to execute and deliver to the
landlord an estoppel certificate in form and substance
satisfactory to the landlord promptly upon the landlord's
request; or (cc) allows the tenant to assign or sublet the
premises without the landlord's consent;

(ii)    reduce any rent or other sums due from the tenant under any
Major Lease;

(iii)   terminate or materially modify or amend any Major Lease; or

(iv)    release or discharge the tenant or any guarantor under any
Major Lease from any material obligation thereunder.

Any such attempted action in violation of the provisions of this
Section shall be null and void.

"Major Lease", as used herein, shall mean any Lease, which is, at any
time: (1) a Lease of more than 20% of the total rentable area of the
Property, as reasonably determined by Beneficiary; or (2) a Lease
which generates a gross base monthly rent exceeding 20% of the total
gross base monthly rent generated by all Leases (excluding all Leases
under which the tenant is then in default), as reasonably determined
by Beneficiary. Trustor's obligations with respect to Major Leases
shall be governed by the provisions of Section 3.4a as well as by the
provisions of this Section. Beneficiary's failure to deny any written
request by Trustor for consent under this Section within 5 Business
Days after Beneficiary's receipt of such request (and all documents
and information reasonably related thereto) such be deemed to
constitute Beneficiary's consent to such request.

3.5     ESTOPPEL CERTIFICATES.  Within 30 days after request by Beneficiary,
Trustor shall deliver to Beneficiary and to any party designated by
Beneficiary, estoppel certificates relating to the Leases executed by
Trustor and by each of the tenants, in form and substance acceptable to
Beneficiary; provided, however, if any tenant shall fail or refuse to so
execute and deliver any such estoppel certificate upon request, Trustor
shall use reasonable efforts to cause such tenant to execute and deliver
such estoppel certificate but such tenant's continued failure or refusal
to do so, despite Trustor's reasonable efforts,  shall not constitute a
default by Trustor under this Section.

3.6     RIGHT OF SUBORDINATION.  Beneficiary may at any time and from time to
time by specific written instrument intended for the purpose unilaterally
subordinate the lien of this Deed of Trust to any Lease, without joinder
or consent of, or notice to, Trustor, any tenant or any other person.
Notice is hereby given to each tenant under a Lease of such right to
subordinate. No subordination referred to in this Section shall constitute
a subordination to any lien or other encumbrance, whenever arising, or
improve the right of any junior lienholder.  Nothing herein shall be
construed as subordinating this Deed of Trust to any Lease.


ARTICLE 4.  SECURITY AGREEMENT AND FIXTURE FILING

4.1 SECURITY INTEREST.  Trustor grants and assigns to Beneficiary a security
interest to secure payment and performance of all of the Secured
Obligations, in all of the following described personal property in which
Trustor now or at any time hereafter has any interest ("Collateral"):

All goods, building and other materials, supplies, work in process,
equipment, machinery, fixtures, furniture, furnishings, signs and
other personal property, wherever situated, which are or are to be
incorporated into, used in connection with or appropriated for use
on the Property; all rents, issues, deposits and profits of the
Property (to the extent, if any, they are not subject to the
Absolute Assignment of Rents and Leases); all inventory, accounts,
cash receipts, deposit accounts, impounds, accounts receivable,
contract rights, general intangibles, chattel paper, instruments,
documents, notes, drafts, letters of credit, insurance policies,
insurance and condemnation awards and proceeds, any other rights to
the payment of money, trade names, trademarks and service marks
arising from or related to the Property or any business now or
hereafter conducted thereon by Trustor; all permits, consents,
approvals, licenses, authorizations and other rights granted by,
given by or obtained from, any governmental entity with respect to
the Property; all deposits or other security now or hereafter made
with or given to utility companies by Trustor with respect to the
Property; all advance payments of insurance premiums made by Trustor
with respect to the Property; all plans, drawings and specifications
relating to the Property; all loan funds held by Beneficiary,
whether or not disbursed; all funds deposited with Beneficiary
pursuant to any Loan Document, including, without limitation, all
"Restoration Funds" as defined herein; all reserves, deferred
payments, deposits, accounts, refunds, cost savings and payments of
any kind related to the Property or any portion thereof, including,
without limitation, all "Impounds" as defined herein; together with
all replacements and proceeds of, and additions and accessions to,
any of the foregoing, and all books, records and files relating to
any of the foregoing.

As to all of the above described personal property which is or which
hereafter becomes a "fixture" under applicable law, this Deed of Trust
constitutes a fixture filing under the California Uniform Commercial Code,
as amended or recodified from time to time ("UCC").

4.2     RIGHTS OF BENEFICIARY.  In addition to Beneficiary's rights as a
"Secured Party" under the UCC, Beneficiary may, but shall not be
obligated to, at any time without notice and at the expense of Trustor:
(a) give notice to any person of Beneficiary's rights hereunder and
enforce such rights at law or in equity; (b) insure, protect, defend and
preserve the Collateral or any rights or interests of Beneficiary
therein; (c) inspect the Collateral; and  (d) endorse, collect and
receive any right to payment of money owing to Trustor under or from the
Collateral.  Notwithstanding the above, in no event shall Beneficiary be
deemed to have accepted any property other than cash in satisfaction of
any obligation of Trustor to Beneficiary unless Beneficiary shall make an
express written election of said remedy under the UCC or other applicable
law.

4.3 ADDITIONAL RIGHTS OF BENEFICIARY UPON DEFAULT.  Upon the occurrence of a
Default hereunder, then in addition to all of Beneficiary's rights as a
"Secured Party" under the UCC or otherwise at law:

a.      Sale of Collateral.  Beneficiary may: (i) upon written notice,
require Trustor to assemble any or all of the Collateral and make it
available to Beneficiary at a place designated by Beneficiary;
(ii) without prior notice, enter upon the Property or other place
where any of the Collateral may be located and take possession of,
collect, sell and dispose of any or all of the Collateral, and store
the same at locations acceptable to Beneficiary at Trustor's
expense; or (iii) sell, assign and deliver at any place or in any
lawful manner all or any part of the Collateral and bid and become
purchaser at any such sales; and

b.      Other Rights.  Beneficiary may, for the account of Trustor and at
Trustor's expense: (i) operate, use, consume, sell or dispose of the
Collateral as Beneficiary deems appropriate for the purpose of
performing any or all of the Secured Obligations; (ii) enter into any
agreement, compromise or settlement including insurance claims, which
Beneficiary may deem desirable or proper with respect to any of the
Collateral; and (iii) endorse and deliver evidences of title for, and
receive, enforce and collect by legal action or otherwise, all
indebtedness and obligations now or hereafter owing to Trustor in
connection with or on account of any or all of the Collateral.

Trustor acknowledges and agrees that a disposition of the Collateral in
accordance with Beneficiary's rights and remedies as heretofore provided
is a disposition thereof in a commercially reasonable manner and that
5 days prior notice of such disposition is commercially reasonable notice.
 Trustor further agrees that any sale or other disposition of all or any
portion of the Collateral may be applied by Beneficiary first to the
reasonable expenses in connection therewith, including reasonable
attorneys' fees and disbursements, and then to the payment of the Secured
Obligations.

4.4     POWER OF ATTORNEY.  Trustor hereby irrevocably appoints Beneficiary as
Trustor's attorney-in-fact (such agency being coupled with an interest),
and as such attorney-in-fact, Beneficiary may, without the obligation to
do so, in Beneficiary's name or in the name of Trustor, prepare, execute,
file and record financing statements, continuation statements,
applications for registration and like papers necessary to create,
perfect or preserve any of Beneficiary's security interests and rights in
or to any of the Collateral, and upon a Default hereunder, take any other
action required of Trustor; provided, however, that Beneficiary as such
attorney-in-fact shall be accountable only for such funds as are actually
received by Beneficiary.


ARTICLE 5.  REPRESENTATIONS AND WARRANTIES

5.1     REPRESENTATIONS AND WARRANTIES.  Trustor represents and warrants to
Beneficiary that, to Trustor's current actual knowledge after reasonable
investigation and inquiry, the following statements are true and correct
as of the Effective Date:

a.      Legal Status.  Trustor and Borrower are duly organized and
existing and in good standing under the laws of the state(s) in
which Trustor and Borrower are organized.  Trustor and Borrower are
qualified or licensed to do business in all jurisdictions in which
such qualification or licensing is required.

b.      Permits.  Trustor and Borrower possess all permits, franchises and
licenses and all rights to all trademarks, trade names, patents and
fictitious names, if any, necessary to enable Trustor and Borrower to
conduct the business(es) in which Trustor and Borrower are now
engaged in compliance with applicable law.

c.      Authorization and Validity.  The execution and delivery of the Loan
Documents have been duly authorized and the Loan Documents constitute
valid and binding obligations of Trustor, Borrower or the party which
executed the same, enforceable in accordance with their respective
terms, except as such enforcement may be limited by bankruptcy,
insolvency, moratorium or other laws affecting the enforcement of
creditors' rights, or by the application of rules of equity.

d.      Violations.  The execution, delivery and performance by Trustor and
Borrower of each of the Loan Documents do not violate any provision
of any law or regulation, or result in any breach or default under
any contract, obligation, indenture or other instrument to which
Trustor or Borrower is a party or by which Trustor or Borrower is
bound.

e.      Litigation.  There are no pending or threatened actions, claims,
investigations, suits or proceedings before any governmental
authority, court or administrative agency which may adversely affect
the financial condition or operations of Trustor or Borrower other
than those previously disclosed in writing by Trustor or Borrower to
Beneficiary.

f.      Financial Statements.  The financial statements of Trustor and
Borrower, of each general partner (if Trustor or Borrower is a
partnership), of each member (if Trustor or Borrower is a limited
liability company) and of each guarantor, if any, previously
delivered by Trustor or Borrower to Beneficiary: (i) are materially
complete and correct; (ii) present fairly the financial condition of
such party; and (iii) have been prepared in accordance with the same
accounting standard used by Trustor or Borrower to prepare the
financial statements delivered to and approved by Beneficiary in
connection with the making of the Loan, or other accounting standards
approved by Beneficiary.  Since the date of such financial
statements, there has been no material adverse change in such
financial condition, nor have any assets or properties reflected on
such financial statements been sold, transferred, assigned,
mortgaged, pledged or encumbered except as previously disclosed in
writing by Trustor or Borrower to Beneficiary and approved in writing
by Beneficiary.

g.      Reports.  All reports, documents, instruments and information
delivered to Beneficiary in connection with the Loan: (i) are correct
and sufficiently complete to give Beneficiary accurate knowledge of
their subject matter; and (ii) do not contain any misrepresentation
of a material fact or omission of a material fact which omission
makes the provided information misleading.

h.      Income Taxes.  There are no pending assessments or adjustments of
Trustor's or Borrower's income tax payable with respect to any year.

i.      Subordination.  There is no agreement or instrument to which
Borrower is a party or by which Borrower is bound that would require
the subordination in right of payment of any of Borrower's
obligations under the Note to an obligation owed to another party.

j.      Title.  Trustor lawfully holds and possesses fee simple title to
the Property, without limitation on the right to encumber same. This
Deed of Trust is a first lien on the Property prior and superior to
all other liens and encumbrances on the Property except:  (i) liens
for real estate taxes and assessments not yet due and payable; (ii)
senior exceptions previously approved by Beneficiary and shown in the
title insurance policy insuring the lien of this Deed of Trust; and
(iii) other matters, if any, previously disclosed to Beneficiary by
Trustor in a writing specifically referring to this representation
and warranty.

k.      Mechanics' Liens.  There are no mechanics' or similar liens or
claims which have been filed for work, labor or material (and no
rights are outstanding that under law could give rise to any such
liens) affecting the Property which are or may be prior to or equal
to the lien of this Deed of Trust.

l.      Encroachments.  Except as shown in the survey, if any, previously
delivered to Beneficiary, none of the buildings or other improvements
which were included for the purpose of determining the appraised
value of the Property lies outside of the boundaries or building
restriction lines of the Property and no buildings or other
improvements located on adjoining properties encroach upon the
Property.

m.      Leases.  All existing Leases are in full force and effect and are
enforceable in accordance with their respective terms. No material
breach or default by any party, or event which would constitute a
material breach or default by any party after notice or the passage
of time, or both, exists under any existing Lease. None of the
landlord's interests under any of the Leases, including, but not
limited to, rents, additional rents, charges, issues or profits, has
been transferred or assigned.  No rent or other payment under any
existing Lease has been paid by any tenant for more than 1 month in
advance.

n.      Collateral.  Trustor has good title to the existing Collateral,
free and clear of all liens and encumbrances except those, if any,
previously disclosed to Beneficiary by Trustor in writing
specifically referring to this representation and warranty. Trustor's
principal place of business is located at the address shown in this
Deed of Trust.

o.      Condition of Property.  Except as shown in the property condition
survey or other engineering reports, if any, previously delivered to
or obtained by Beneficiary, the Property is in good condition and
repair and is free from any damage that would materially and
adversely affect the value of the Property as security for the Loan
or the intended use of the Property.

p.      Hazardous Materials.  Except as shown in the environmental
assessment report(s), if any, previously delivered to or obtained by
Beneficiary, the Property is not and has not been a site for the use,
generation, manufacture, storage, treatment, release, threatened
release, discharge, disposal, transportation or presence of
Hazardous Materials  (as hereinafter defined) except as otherwise
previously disclosed in writing by Trustor to Beneficiary.

q.      Hazardous Materials Laws.  The Property complies with all Hazardous
Materials Laws  (as hereinafter defined).

r.      Hazardous Materials Claims.  There are no pending or threatened
Hazardous Materials Claims (as hereinafter defined).

s.      Wetlands.  No part of the Property consists of or is classified as
wetlands, tidelands or swamp and overflow lands.

t.      Compliance With Laws.  All federal, state and local laws, rules and
regulations applicable to the Property, including, without
limitation, all zoning and building requirements  and all
requirements of the Americans With Disabilities Act of 1990, as
amended from time to time (42 U. S. C. Section 12101 et seq.) have
been satisfied or complied with.  Trustor is in possession of all
certificates of occupancy and all other licenses, permits and other
authorizations required by applicable law for the existing use of the
Property.  All such certificates of occupancy and other  licenses,
permits and authorizations are valid and in full force and effect.

u.      Property Taxes and Other Liabilities.  All taxes, governmental
assessments, insurance premiums, water, sewer and municipal charges,
and ground rents, if any, which previously became due and owing in
respect of the Property have been paid.

v.      Condemnation.  There is no proceeding pending or threatened for the
total or partial condemnation of the Property.

w.      Homestead.  There is no homestead or other exemption available to
Trustor which would materially interfere with the right to sell the
Property at a trustee's sale or the right to foreclose this Deed of
Trust.

x.      Solvency.  None of the transactions contemplated by the Loan will
be or have been made with an actual intent to hinder, delay or
defraud any present or future creditors of Trustor, and Trustor, on
the Effective Date, will have received fair and reasonably
equivalent value in good faith for the grant of the liens or
security interests effected by the Loan Documents.  On the Effective
Date, Trustor will be solvent and will not be rendered insolvent by
the transactions contemplated by the Loan Documents. Trustor is able
to pay its debts as they become due.

y.      Separate Tax Parcel(s). The Property is assessed for the real
estate tax purposes as one or more wholly independent tax parcels,
separate from any other real property, and no other real property is
assessed and taxed together with the Property or any portion
thereof.

5.2     REPRESENTATIONS, WARRANTIES AND COVENANTS REGARDING STATUS. Trustor and
FREMONT MANAGEMENT, INC., a Delaware corporation hereby represent,
warrant and covenant to Beneficiary as follows:

a.      each such entity was organized solely for the purpose of (i)
owning the Property; (ii) acting as a general partner of a
partnership which owns the Property; or (iii) acting as a managing
member of a limited liability company which owns the Property;

b.      each such entity has not and will not engage in any business
unrelated to (i) the ownership of the Property; (ii) acting as
general partner of a partnership which owns the Property; or (iii)
acting as a managing member of a limited liability company which
owns the Property;

c.      each such entity has not and will not have any assets other than
the Property (and personal property incidental to the ownership and
operation of the Property) or its partnership or membership interest
in the partnership or limited liability company which owns the
Property;

d.      each such entity has not and will not engage in, seek or consent
to any dissolution, winding up, liquidation, consolidation, merger,
asset sale, transfer of partnership or membership interest, or
amendment of its articles of incorporation, articles of
organization, certificate of formation, partnership agreement or
operating agreement, as applicable;

e.      if such entity is a partnership, all of its general partners are
corporations that satisfy the requirements set forth in this
Section 5.2;

f.      if such entity is a limited liability company, it has at least one
managing member that is a corporation that satisfies the
requirements set forth in this Section 5.2;

g.      each such entity, without the unanimous consent of all of its
general partners, directors or members, as applicable, shall not
file a bankruptcy or insolvency petition or otherwise institute
insolvency proceedings with respect to itself or any other entity in
which it has a direct or indirect legal or beneficial ownership
interest;

h.      each such entity has no indebtedness (and will have no
indebtedness) other than (i) the Loan (to the extent it is liable
under the terms of the Loan Documents); and (ii) unsecured trade
debt which is not evidenced by a note and is incurred in the
ordinary course of its business in connection with owning, operating
and maintaining the Property (or its interest in Trustor, as
applicable) and is paid within 30 days from the date incurred;

i.      each such entity has not and will not fail to correct any known
misunderstanding regarding the separate identity of such entity;

j.      each such entity has maintained and will maintain its accounts,
books and records separate from any other person or entity;

k.      each such entity has maintained and will maintain its books,
records, resolutions and agreements as official records;

l.      each such entity (i) has not and will not commingle its funds or
assets with those of any other entity; and (ii) has held and will
hold its assets in its own name;

m.      each such entity has conducted and will conduct its business in
its own name;

n.      each such entity has maintained and will maintain its financial
statements, accounting records and other entity documents separate
from any other person or entity;

o.      each such entity has paid and will pay its own liabilities out of
its own funds and assets;

p.      each such entity has observed and will observe all partnership,
corporate or limited liability company formalities, as applicable;

q.      each such entity has not and will not assume or guarantee or
become obligated for the debts of any other entity or hold out its
credit as being available to satisfy the obligations of any other
entity except for liabilities permitted to be guaranteed by the Loan
Documents;

r.      each such entity has not and will not acquire obligations or
securities of its partners, members or shareholders;

s.      each such entity has allocated and will allocate fairly and
reasonably any overhead for shared office space and uses separate
stationery, invoices and checks;

t.      each such entity has not and will not pledge its assets for the
benefit of any other person or entity;

u.      each such entity has held and identified itself and will hold
itself out and identify itself as a separate and distinct entity
under its own name and not as a division or part of any other person
or entity;

v.      each such entity has not made and will not make loans to any
person or entity;

w.      each such entity has not and will not identify its partners,
members or shareholders, as applicable, or any affiliates of any of
the foregoing, as a division or part of it;

x.      each such entity has not entered into and will not enter into or
be a party to, any transaction with its partners, members,
shareholders, or any affiliates of any of the foregoing, except in
the ordinary course of its business and on terms which are
intrinsically fair and are no less favorable to it than would be
obtained in a comparable arm's-length transaction with an unrelated
third party;

y.      if such entity is a corporation, the directors of the corporation
shall consider the interests of the creditors of the corporation in
connection with all corporate action;

z.      each such entity has paid and will pay the salaries of its own
employees and has maintained and will maintain a sufficient number
of employees in light of its contemplated business operations;

aa.     each such entity has maintained and will maintain adequate capital
in light of its contemplated business operations;

bb.     if such entity is a limited liability company (i) its articles of
organization, certificate of formation and/or operating agreement,
as applicable, provide that the vote of a majority-in-interest of
the remaining members is sufficient to continue the life of the
limited liability company in the event of a termination event, such
as a bankruptcy of the managing member; and (ii) if the vote of a
majority-in-interest of the remaining members is not obtained to
continue the life of the limited liability company upon a
termination event, its articles of organization, certificate of
formation and/or operating agreement, as applicable, provide that
the limited liability company may not liquidate its assets without
the consent of the Beneficiary;

cc.     if such entity is a partnership with more than one general
partner, its partnership agreement requires the remaining partners
to continue the partnership as long as one solvent general partner
exists; and

dd.     if such entity is a limited liability company, its operating
agreement, if such entity is a partnership, its partnership
agreement, and if such entity is a corporation, to the full extent
permitted by applicable law, its articles of incorporation, contain
the provisions set forth in this Section 5.2 and such entity shall
conduct its business and operations in strict compliance with the
terms contained therein.


ARTICLE 6.  RIGHTS AND DUTIES OF THE PARTIES

6.1     MAINTENANCE AND PRESERVATION OF THE PROPERTY.  Trustor shall:  (a) keep
the Property in good condition and repair; (b) complete or restore
promptly and in workmanlike manner the Property or any part thereof which
may be damaged or destroyed (unless, if and to the extent permitted under
Section 6.11, Beneficiary elects to require that insurance proceeds be
used to reduce the Secured Obligations and after such repayment the ratio
of Secured Obligations to the value of the Property, as reasonably
determined by Beneficiary is the same as or lower than it was immediately
before the loss or taking occurred); (c) comply and cause the Property to
comply with (i) all laws, ordinances, regulations and standards, (ii) all
covenants, conditions, restrictions and equitable servitudes, whether
public or private, of every kind and character and (iii) all requirements
of insurance companies and any bureau or agency which establishes
standards of insurability, which laws, covenants or requirements affect
the Property and pertain to acts committed or conditions existing
thereon, including, without limitation, any work of alteration,
improvement or demolition as such laws, covenants or requirements
mandate; (d) operate and manage the Property at all times in a
professional manner and do all other acts which from the character or use
of the Property may be reasonably necessary to maintain and preserve its
value; (e) promptly after execution, deliver to Beneficiary a copy of any
management agreement concerning the Property and all amendments thereto
and waivers thereof; and (f) execute and acknowledge all further
documents, instruments and other papers as Beneficiary or Trustee deems
necessary or appropriate to preserve, continue, perfect and enjoy the
benefits of this Deed of Trust and perform Trustor's obligations,
including, without limitation, statements of the amount secured hereby
then owing and statements of no offset.  Trustor shall not: (g) remove or
demolish all or any material part of the Property; (h) alter either (i)
the exterior of the Property in a manner which materially and adversely
affects the value of the Property or (ii) the roof or other structural
elements of the Property in a manner which requires a building permit
except for tenant improvements required under the Leases; (i) initiate or
acquiesce in any change in any zoning or other land classification which
affects the Property; (j) materially alter the type of occupancy or use
of all or any part of the Property; or (k) commit or permit waste of the
Property.

6.2     HAZARDOUS MATERIALS.  Without limiting any other provision of this Deed
of Trust, Trustor agrees as follows:

a.      Prohibited Activities.  Trustor shall not cause or permit the
Property to be used as a site for the use, generation, manufacture,
storage, treatment, release, discharge, disposal, transportation or
presence of any oil or other petroleum products, flammable
explosives, asbestos, urea formaldehyde insulation, radioactive
materials, hazardous wastes, toxic or contaminated substances or
similar materials, including, without limitation, any substances
which are "hazardous substances," "hazardous wastes," "hazardous
materials" or "toxic substances" under the Hazardous Materials Laws
(defined below) and/or other applicable environmental laws,
ordinances or regulations ("Hazardous Materials").

The foregoing to the contrary notwithstanding, (i) Trustor may store,
maintain and use on the Property janitorial and maintenance supplies,
paint and other Hazardous Materials of a type and in a quantity
readily available for purchase by the general public and normally
stored, maintained and used by owners and managers of properties of a
type similar to the Property; and (ii) tenants of the Property may
store, maintain and use on the Property (and, if any tenant is a
retail business, hold in inventory and sell in the ordinary course of
such tenant's business) Hazardous Materials of a type and quantity
readily available for purchase by the general public and normally
stored, maintained and used (and, if tenant is a retail business,
sold) by tenants in similar lines of business on properties similar
to the Property; and (iii) tenants of the Property may store,
maintain and use on the Property Hazardous Materials of types and
quantities necessary or appropriate for carrying out their
biotechnology business operations so long as all such storage,
maintenance and use of Hazardous Material is carried on in compliance
with all applicable Hazards Materials Laws.

b.      Hazardous Materials Laws.  Trustor shall comply and cause the
Property to comply with all federal, state and local laws,
ordinances and regulations relating to Hazardous Materials
("Hazardous Materials Laws"), including, without limitation:  the
Clean Air Act, as amended, 42 U.S.C. Section 7401 et seq.; the
Federal Water Pollution Control Act, as amended, 33 U.S.C. Section
1251 et seq.; the Resource Conservation and Recovery Act of 1976, as
amended, 42 U.S.C. Section 6901 et seq.; the Comprehensive
Environmental Response, Compensation and Liability Act of 1980, as
amended (including the Superfund Amendments and Reauthorization Act
of 1986, "CERCLA"), 42 U.S.C. Section 9601 et seq.; the Toxic
Substances Control Act, as amended, 15 U.S.C. Section 2601 et seq.;
the Occupational Safety and Health Act, as amended, 29 U.S.C.
Section 651; the Emergency Planning and Community Right-to-Know Act
of 1986, 42 U.S.C. Section 11001 et seq.; the Mine Safety and Health
Act of 1977, as amended, 30 U.S.C. Section 801 et seq.; the Safe
Drinking Water Act, 42 U.S.C. Section 300f et seq.;  and all
comparable state and local laws, laws of other jurisdictions or
orders and regulations.

c.      Notices.  Trustor shall immediately notify Beneficiary in writing
of:  (i) the discovery of any Hazardous Materials on, under or about
the Property (other than Hazardous Materials permitted under
Section 6.2(a)); (ii) any knowledge by Trustor that the Property does
not comply with any Hazardous Materials Laws; (iii) any claims or
actions ("Hazardous Materials Claims") pending or threatened against
Trustor or the Property by any governmental entity or agency or any
other person or entity relating to Hazardous Materials or pursuant to
the Hazardous Materials Laws; and (iv) the discovery of any
occurrence or condition on any real property adjoining or in the
vicinity of the Property that could cause the Property or any part
thereof to become contaminated with Hazardous Materials.

d.      Remedial Action.  In response to the presence of any Hazardous
Materials on, under or about the Property, Trustor shall immediately
take, at Trustor's sole expense, all remedial action required by any
Hazardous Materials Laws or any judgment, consent decree, settlement
or compromise in respect to any Hazardous Materials Claims.

e.      Inspection By Beneficiary.  Upon reasonable prior notice to
Trustor, Beneficiary, its employees and agents, may from time to time
(whether before or after the commencement of a nonjudicial or
judicial foreclosure proceeding), enter and inspect the Property for
the purpose of determining the existence, location, nature and
magnitude of any past or present release or threatened release of any
Hazardous Materials into, onto, beneath or from the Property.

f.      Legal Effect of Section.  Trustor and Beneficiary agree that:  (i)
this Hazardous Materials Section is intended as Beneficiary's written
request for information (and Trustor's response) concerning the
environmental condition of the real property security as required by
California Code of Civil Procedure Section 726.5; and (ii) each
representation and warranty and covenant in this Section (together
with any indemnity applicable to a breach of any such representation
and warranty) with respect to the environmental condition of the
Property is intended by Beneficiary and Trustor to be an
"environmental provision" for purposes of California Code of Civil
Procedure Section 736.

6.3  COMPLIANCE WITH LAWS.  Trustor shall comply with all federal, state and
local laws, rules and regulations applicable to the Property, including,
without limitation, all zoning and building requirements and all
requirements of the Americans With Disabilities Act of 1990 (42 U.S.C.
Section 12101 et seq.), as amended from time to time. Trustor shall
possess and maintain or cause Borrower to possess and maintain in full
force and effect at all times (a) all certificates of occupancy and other
licenses, permits and authorizations required by applicable law for the
existing use of the Property and (b) all permits, franchises and licenses
and all rights to all trademarks, trade names, patents and fictitious
names, if any, required by applicable law for Trustor and Borrower to
conduct the business(es) in which Trustor and Borrower are now engaged.

6.4 LITIGATION.  Trustor shall promptly notify Beneficiary in writing of any
litigation pending or threatened against Trustor or Borrower claiming
damages in excess of $50,000 and of all pending or threatened litigation
against Trustor or Borrower if the aggregate damage claims against Trustor
or Borrower exceed $100,000.

6.5 MERGER, CONSOLIDATION, TRANSFER OF ASSETS.  Trustor shall not:(a) merge
or consolidate with any other entity or permit Borrower to merge or
consolidate with any other entity; (b) make any substantial change in the
nature of Trustor's business or structure or permit Borrower to make any
substantial change in the nature of Borrower's business or structure; (c)
acquire all or substantially all of the assets of any other entity or
permit Borrower to acquire all or substantially all of the assets of any
other entity; or (d) sell, lease, assign, transfer or otherwise dispose of
a material part of Trustor's assets except in the ordinary course of
Trustor's business or permit Borrower to sell, lease, assign, transfer or
otherwise dispose of a material part of Borrower's assets except in the
ordinary course of Borrower's business.

6.6     ACCOUNTING RECORDS.  Trustor shall maintain and cause Borrower to
maintain adequate books and records in accordance with the same accounting
standard used by Trustor or Borrower to prepare the financial statements
delivered to and approved by Beneficiary in connection with the making of
the Loan or other accounting standards approved by Beneficiary.  Trustor
shall permit and shall cause Borrower to permit any representative of
Beneficiary, at any reasonable time and from time to time, to inspect,
audit and examine such books and records and make copies of same.

6.7     COSTS, EXPENSES AND ATTORNEYS' FEES.  Trustor shall pay to Beneficiary
the full amount of all costs and expenses, including, without limitation,
reasonable attorneys' fees and expenses of Beneficiary's in-house or
outside counsel, incurred by Beneficiary in connection with: (a)
appraisals and inspections of the Property or Collateral required by
Beneficiary as a result of (i) a Transfer or proposed Transfer (as defined
below), or (ii) a Default; (b) appraisals and inspections of the Property
or Collateral required by applicable law, including, without limitation,
federal or state regulatory reporting requirements; and (c) any acts
performed by Beneficiary at Trustor's request or wholly or partially for
the benefit of Trustor (including, without limitation, the preparation or
review of amendments, assumptions, waivers, releases, reconveyances,
estoppel certificates or statements of amounts owing under any Secured
Obligation).  In connection with appraisals and inspections, Trustor
specifically (but not by way of limitation) acknowledges that:  (aa) a
formal written appraisal of the Property by a state certified or licensed
appraiser may be required by federal regulatory reporting requirements on
an annual or more frequent basis; and (bb) Beneficiary may require
inspection of the Property by an independent supervising architect, a cost
engineering specialist, or both.  Trustor shall pay all indebtedness
arising under this Section immediately upon demand by Beneficiary together
with interest thereon following notice of such indebtedness at the rate of
interest then applicable to the principal balance of the Note as specified
therein.

6.8 LIENS, ENCUMBRANCES AND CHARGES.  Trustor shall immediately discharge by
bonding or otherwise any lien, charge or other encumbrance which attaches
to the Property in violation of Section 6.15. Subject to Trustor's right
to contest such matters under this Deed of Trust or as expressly permitted
in the Loan Documents, Trustor shall pay when due all obligations secured
by or reducible to liens and encumbrances which shall now or hereafter
encumber or appear to encumber all or any part of the Property or any
interest therein, whether senior or subordinate hereto, including, without
limitation, all claims for work or labor performed, or materials or
supplies furnished, in connection with any work of demolition, alteration,
repair, improvement or construction of or upon the Property, except such
as Trustor may in good faith contest or as to which a bona fide dispute
may arise (provided provision is made to the satisfaction of Beneficiary
for eventual payment thereof in the event that Trustor is obligated to
make such payment and that any recorded claim of lien, charge or other
encumbrance against the Property is immediately discharged by bonding or
otherwise).

6.9     TAXES AND OTHER LIABILITIES.  Trustor shall pay and discharge when due
any and all indebtedness, obligations, assessments and taxes, both real
and personal and including federal and state income taxes and state and
local property taxes and assessments.  Trustor shall promptly provide to
Beneficiary copies of all tax and assessment notices pertaining to the
Property.  Trustor hereby authorizes Beneficiary to obtain, at Trustor's
expense, a tax service contract which shall provide tax information on the
Property to Beneficiary for the term of the Loan and any extensions or
renewals of the Loan.

6.10    INSURANCE COVERAGE.  Trustor shall insure the Property against loss or
damage by fire and such other hazards as Beneficiary shall from time to
time require; provided, however, (a) Beneficiary, at Beneficiary's
election, may only require flood insurance if all or any portion of the
improvements located on the Property is or becomes located in a special
flood hazard area, and (b) Beneficiary, at Beneficiary's election, may
only require earthquake insurance if all or any portion of the Property is
or becomes located in an earthquake fault zone.  Trustor shall also carry
public liability insurance and such other insurance as Beneficiary may
require, including, without limitation, business interruption insurance or
loss of rents insurance.  Such policies shall contain a standard mortgage
clause naming Beneficiary and its successors in interest as a loss payee
and requiring at least 30 days prior notice to the holder at termination
or cancellation. Trustor shall maintain all required insurance throughout
the term of the Loan and while any liabilities of Borrower or Trustor to
Beneficiary under any of the Loan Documents remain outstanding at
Trustor's expense, with companies, and in substance and form satisfactory
to Beneficiary.  Neither Beneficiary nor Trustee, by reason of accepting,
rejecting, approving or obtaining insurance shall incur any liability for:
(c) the existence, nonexistence, form or legal sufficiency of any
insurance; (d) the solvency of any insurer; or (e) the payment of claims.

6.11    INSURANCE AND CONDEMNATION PROCEEDS.

a.      Assignment of Claims.  Trustor absolutely and irrevocably assigns
to Beneficiary all of the following rights, claims and amounts
(collectively, "Claims"), all of which shall be paid to Beneficiary:
(i) all awards of damages and all other compensation payable
directly or indirectly by reason of a condemnation or proposed
condemnation for public or private use affecting all or any part of,
or any interest in, the Property; (ii) all other claims and awards
for damages to or decrease in value of all or any part of, or any
interest in, the Property; (iii) all proceeds of any insurance
policies payable by reason of loss sustained to all or any part of
the Property; and (iv) all interest which may accrue on any of the
foregoing.  Trustor shall give Beneficiary prompt written notice of
the occurrence of any casualty affecting, or the institution of any
proceedings for eminent domain or for the condemnation of, the
Property or any portion thereof.  So long as no Default has occurred
and is continuing at the time, Trustor shall have the right to
adjust, compromise and settle any Claim of $100,000 or less without
the consent of Beneficiary, provided, however, all awards, proceeds
and other sums described herein shall continue to be payable to
Beneficiary.  Beneficiary may commence, appear in, defend or
prosecute any Claim exceeding $100,000, and may adjust, compromise
and settle all Claims (except for Claims which Trustor may settle as
provided herein), but shall not be responsible for any failure to
commence, appear in, defend, prosecute or collect any such Claim
regardless of the cause of the failure.  All awards, proceeds and
other sums described herein shall be payable to Beneficiary.

b.      Application of Proceeds; No Default.  So long as no Default has
occurred and is continuing at the time of Beneficiary's receipt of
the proceeds of the Claims ("Proceeds") and no Default occurs
thereafter, Beneficiary shall apply the Proceeds in the following
order of priority: First, to Beneficiary's expenses in settling,
prosecuting or defending the Claims; Second, to the repair or
restoration of the Property; and Third, to Trustor if the repair or
restoration of the Property has been completed, but to the Secured
Obligations in any order without suspending, extending or reducing
any obligation of Trustor to make installment payments if the repair
or restoration of the Property has not been completed.
Notwithstanding the foregoing, Beneficiary shall have no obligation
to make any Proceeds available for the repair or restoration of the
Property unless and until all the following conditions have been
satisfied: (i) delivery to Beneficiary of the Proceeds plus any
additional amount which is needed to pay all costs of the repair or
restoration (including, without limitation, taxes, financing charges,
insurance and rent during the repair period); (ii) establishment of
an arrangement for lien releases and disbursement of funds acceptable
to Beneficiary; (iii) delivery to Beneficiary in form and content
acceptable to Beneficiary of all of the following: (aa) plans and
specifications for the work; (bb) a contract for the work, signed by
a contractor acceptable to Beneficiary; (cc) a cost breakdown for the
work; (dd) if required by Beneficiary, a payment and performance bond
for the work; (ee) evidence of the continuation of all Leases unless
consented to in writing by Beneficiary; (ff) evidence that, upon
completion of the work, the size, capacity, value, and income
coverage ratios for the Property will be at least as great as those
which existed immediately before the damage or condemnation occurred;
and (gg) evidence of the satisfaction of any additional conditions
that Beneficiary may reasonably establish to protect Beneficiary's
security.  Trustor acknowledges that the specific conditions
described above are reasonable.

c.      Application of Proceeds; Default.  If a Default has occurred and is
continuing at the time of Beneficiary's receipt of the Proceeds or if
a Default occurs at any time thereafter, Beneficiary may, at
Beneficiary's absolute discretion and regardless of any impairment of
security or lack of impairment of security, but subject to applicable
law governing use of the Proceeds, if any, apply all or any of the
Proceeds to Beneficiary's expenses in settling, prosecuting or
defending the Claims and then apply the balance to the Secured
Obligations in any order without suspending, extending or reducing
any obligation of Trustor to make installment payments, and may
release all or any part of the Proceeds to Trustor upon any
conditions Beneficiary chooses.

6.12    IMPOUNDS.

a.      Post-Default Impounds.  If required by Beneficiary at any time
after a Default occurs (and regardless of whether such Default is
thereafter cured), Trustor shall deposit with Beneficiary such
amounts ("Post-Default Impounds") on such dates (determined by
Beneficiary as provided below) as will be sufficient to pay any or
all "Costs" (as defined below) specified by Beneficiary.  Beneficiary
in its sole discretion shall estimate the amount of such Costs that
will be payable or required during any period selected by Beneficiary
not exceeding 1 year and shall determine the fractional portion
thereof that Trustor shall deposit with Beneficiary on each date
specified by Beneficiary during such period.  If the Post-Default
Impounds paid by Trustor are not sufficient to pay the related Costs,
Trustor shall deposit with Beneficiary upon demand an amount equal to
the deficiency.  All Post-Default Impounds shall be payable by
Trustor in addition to (but without duplication of) any other
Impounds (as defined below).

b.      All Impounds.  Post-Default Impounds and any other impounds that
may be payable by Borrower under the Note are collectively called
"Impounds".  All Impounds shall be deposited into one or more
segregated or commingled accounts maintained by Beneficiary or its
servicing agent. Except as otherwise provided in the Note, such
account(s) shall not bear interest.  Beneficiary shall not be a
trustee, special depository or other fiduciary for Trustor with
respect to such account, and the existence of such account shall not
limit Beneficiary's rights under this Deed of Trust, any other
agreement or any provision of law.  If no Default exists, Beneficiary
shall apply all Impounds to the payment of the related Costs, or in
Beneficiary's sole discretion may release any or all Impounds to
Trustor for application to and payment of such Costs.  If a Default
exists, Beneficiary may apply any or all Impounds to any Secured
Obligation and/or to cure such Default, whereupon Trustor shall
restore all Impounds so applied and cure all Defaults not cured by
such application.  The obligations of Trustor hereunder shall not be
diminished by deposits of Impounds made by Trustor, except to the
extent that such obligations have actually been met by application of
such Impounds.  Upon any assignment of this Deed of Trust,
Beneficiary may assign all Impounds in its possession to
Beneficiary's assignee, whereupon Beneficiary and Trustee shall be
released from all liability with respect to such Impounds.  Within
60 days following full repayment of the Secured Obligations (other
than as a consequence of foreclosure or conveyance in lieu of
foreclosure) or at such earlier time as Beneficiary may elect,
Beneficiary shall pay to Trustor all Impounds in its possession, and
no other party shall have any right or claim thereto.  "Costs" means
(i) all taxes and other liabilities payable by Trustor under Section
6.9, (ii) all insurance premiums payable by Trustor under Section
6.10, (iii) all other costs and expenses for which Impounds are
required under the Note, and/or (iv) all other amounts that will be
required to preserve the value of the Property. Trustor shall deliver
to Beneficiary, promptly upon receipt, all bills for Costs for which
Beneficiary has required Post-Default Impounds.

6.13 DEFENSE AND NOTICE OF LOSSES, CLAIMS AND ACTIONS.  Trustor shall protect,
preserve and defend the Property and title to and right of possession of
the Property, the security of this Deed of Trust and the rights and powers
of Beneficiary and Trustee hereunder at Trustor's sole expense against all
adverse claims, whether the claim: (a) is against a possessory or non-
possessory interest; (b) arose prior or subsequent to the Effective Date;
or (c) is senior or junior to Trustor's or Beneficiary's rights.  Trustor
shall give Beneficiary and Trustee prompt notice in writing of the
assertion of any claim, of the filing of any action or proceeding, of the
occurrence of any damage to the Property and of any condemnation offer or
action.

6.14 RIGHT OF INSPECTION.  Beneficiary and its independent contractors, agents
and employees may enter the Property from time to time at any reasonable
time for the purpose of inspecting the Property and ascertaining Trustor's
compliance with the terms of this Deed of Trust.  Beneficiary shall use
reasonable efforts to assure that Beneficiary's entry upon and inspection
of the Property shall not materially and unreasonably interfere with the
business or operations of Trustor or Trustor's tenants on the Property.

6.15    PROHIBITION OF TRANSFER OF PROPERTY OR INTERESTS IN TRUSTOR.  Trustor
acknowledges that Beneficiary has relied upon the principals of Trustor
and Borrower and their experience in owning and operating properties
similar to the Property in connection with the closing of the Loan.
Accordingly, except with the prior written consent of Beneficiary or as
otherwise expressly permitted in the Note, Trustor shall not cause or
permit any sale, exchange, mortgage, pledge, hypothecation, assignment,
encumbrance or other transfer, conveyance or disposition, whether
voluntarily, involuntarily or by operation of law ("Transfer") of all or
any part of, or all or any direct or indirect interest in, the Property or
the Collateral (except for equipment and inventory in the ordinary course
of its business), or cause or permit a Transfer of any direct or indirect
interest (whether general or limited partnership interest, stock, limited
liability company interest, trust, or otherwise) in Trustor or Borrower.
In the event of any Transfer that is not expressly permitted in the Note
and is without the prior written consent of Beneficiary, Beneficiary shall
have the absolute right at its option, without prior demand or notice, to
declare all of the Secured Obligations immediately due and payable, except
to the extent prohibited by law, and pursue its rights and remedies under
Section 7.3 herein.  Trustor agrees to pay any prepayment fee as set forth
in the Note in the event the Secured Obligations are accelerated pursuant
to the terms of this Section.  Consent to one such Transfer shall not be
deemed to be a waiver of the right to require the consent to future or
successive Transfers.

6.16 ACCEPTANCE OF TRUST; POWERS AND DUTIES OF TRUSTEE.  Trustee accepts this
trust when this Deed of Trust is recorded.  From time to time upon written
request of Beneficiary and presentation of this Deed of Trust, or a
certified copy thereof, for endorsement, and without affecting the
personal liability of any person for payment of any indebtedness or
performance of any Secured Obligation, Trustee may, without liability
therefor and without notice:  (a) reconvey all or any part of the
Property; (b) consent to the making of any map or plat of the Property;
(c) join in granting any easement on the Property; (d) join in any
declaration of covenants and restrictions; or (e) join in any extension
agreement or any agreement subordinating the lien or charge of this Deed
of Trust. Notwithstanding the foregoing, Beneficiary shall first obtain
from Trustor, subject to no Default, their consent to subparagraphs (b),
(c), and (d), and such consent shall not be unreasonably withheld.
Nothing contained in the preceding sentences shall be construed to limit,
impair or otherwise affect the rights of Trustor in any respect.  Except
as may otherwise be required by applicable law, Trustee or Beneficiary may
from time to time apply to any court of competent jurisdiction for aid and
direction in the execution of the trusts hereunder and the enforcement of
the rights and remedies available hereunder, and Trustee or Beneficiary
may obtain orders or decrees directing or confirming or approving acts in
the execution of said trusts and the enforcement of said remedies.
Trustee has no obligation to notify any party of any pending sale or any
action or proceeding (including, without limitation, actions in which
Trustor, Beneficiary or Trustee shall be a party) unless held or commenced
and maintained by Trustee under this Deed of Trust.  Trustee shall not be
obligated to perform any act required of it hereunder unless the
performance of the act is requested in writing and Trustee is reasonably
indemnified and held harmless against loss, cost, liability and expense.

6.17    COMPENSATION OF TRUSTEE.  Trustor shall pay to Trustee reasonable
compensation and reimbursement for services and expenses in the
administration of this trust, including, without limitation, reasonable
attorneys' fees. Trustor shall pay all indebtedness arising under this
Section immediately upon demand by Trustee or Beneficiary together with
interest thereon from the date the indebtedness arises at the rate of
interest then applicable to the principal balance of the Note as specified
therein.

6.18   EXCULPATION.  Beneficiary shall not directly or indirectly be liable to
Trustor or any other person as a consequence of: (a) the lawful exercise
of the rights, remedies or powers granted to Beneficiary in this Deed of
Trust; (b) the failure or refusal of Beneficiary to perform or discharge
any obligation or liability of Trustor under any agreement related to the
Property or under this Deed of Trust; or (c) any loss sustained by Trustor
or any third party resulting from Beneficiary's failure to lease the
Property after a Default (hereafter defined) or from any other act or
omission of Beneficiary in managing the Property after a Default unless
the loss is caused by the willful misconduct and bad faith of Beneficiary
and no such liability shall be asserted or enforced against Beneficiary,
all such liability being expressly waived and released by Trustor.

6.19 INDEMNITY.  Without in any way limiting any other indemnity contained in
this Deed of Trust, Trustor agrees to defend, indemnify and hold harmless
Trustee and the Beneficiary Group from and against any claim, loss,
damage, cost, expense or liability directly or indirectly arising out of:
(a) the making of the Loan, except for violations of banking laws or
regulations by the Beneficiary Group; (b) this Deed of Trust; (c) the exe-
cution of this trust or the performance of any act required or permitted
hereunder or by law; (d) any failure of Trustor to perform Trustor's
obligations under this Deed of Trust or the other Loan Documents; (e) any
alleged obligation or undertaking on the Beneficiary Group's part to
perform or discharge any of the representations, warranties, conditions,
covenants or other obligations contained in any other document related to
the Property; (f) any act or omission by Trustor or any contractor, agent,
employee or representative of Trustor with respect to the Property; or (g)
any claim, loss, damage, cost, expense or liability directly or indirectly
arising out of: (i) the use, generation, manufacture, storage, treatment,
release, threatened release, discharge, disposal, transportation or
presence of any Hazardous Materials which are found in, on, under or about
the Property (including, without limitation, underground contamination);
or (ii) the breach of any covenant, representation or warranty of Trustor
under Section 6.2 above.  The foregoing to the contrary notwithstanding,
this indemnity shall not include any claim, loss, damage, cost, expense or
liability directly or indirectly arising out of the gross negligence or
willful misconduct of any member of the Beneficiary Group or Trustee, or
any claim, loss, damage, cost, expense or liability incurred by the
Beneficiary Group or Trustee arising from any act or incident on the
Property occurring after the full reconveyance and release of the lien of
this Deed of Trust on the Property, or with respect to the matters set
forth in clause (g) above, any claim, loss, damage, cost, expense or
liability incurred by the Beneficiary Group resulting from the
introduction and initial release of Hazardous Materials on the Property
occurring after the transfer of title to the Property at a foreclosure
sale under this Deed of Trust, either pursuant to judicial decree or the
power of sale, or by deed in lieu of such foreclosure.  This indemnity
shall include, without limitation:  (aa) all consequential damages
(including, without limitation, any third party tort claims or
governmental claims, fines or penalties against Trustee or the Beneficiary
Group); (bb) all court costs and reasonable attorneys' fees (including,
without limitation, expert witness fees) paid or incurred by Trustee or
the Beneficiary Group; and (cc) the costs, whether foreseeable or
unforeseeable, of any investigation, repair, cleanup or detoxification of
the Property which is required by any governmental entity or is otherwise
necessary to render the Property in compliance with all laws and
regulations pertaining to Hazardous Materials. "Beneficiary Group", as
used herein, shall mean (1) Beneficiary (including, without limitation,
any participant in the Loan), (2) any entity controlling, controlled by or
under common control with Beneficiary, (3) the directors, officers,
employees and agents of Beneficiary and such other entities, and (4) the
successors, heirs and assigns of the entities and persons described in
foregoing clauses (1) through (3). Trustor shall pay immediately upon
Trustee's or Beneficiary's demand any amounts owing under this indemnity
together with interest from the date the indebtedness arises until paid at
the rate of interest applicable to the principal balance of the Note as
specified therein.  Trustor agrees to use legal counsel reasonably
acceptable to Trustee and the Beneficiary Group in any action or
proceeding arising under this indemnity.  THE PROVISIONS OF THIS SECTION
SHALL SURVIVE THE TERMINATION AND RECONVEYANCE OF THIS DEED OF TRUST, BUT
TRUSTOR'S LIABILITY UNDER THIS INDEMNITY SHALL BE SUBJECT TO THE
PROVISIONS OF THE SECTION IN THE NOTE ENTITLED "BORROWER'S LIABILITY."

6.20    SUBSTITUTION OF TRUSTEE.  From time to time, by a writing signed and
acknowledged by Beneficiary and recorded in the Office of the Recorder of
the County in which the Property is situated, Beneficiary may appoint
another trustee to act in the place and stead of Trustee or any successor.
 Such writing shall set forth any information required by law.  The
recordation of such instrument of substitution shall discharge Trustee
herein named and shall appoint the new trustee as the trustee hereunder
with the same effect as if originally named trustee herein.  A writing
recorded pursuant to the provisions of this Section shall be conclusive
proof of the proper substitution of such new trustee.

6.21    RELEASES, EXTENSIONS, MODIFICATIONS AND ADDITIONAL SECURITY.  Without
notice to or the consent, approval or agreement of any persons or entities
having any interest at any time in the Property or in any manner obligated
under the Secured Obligations ("Interested Parties"), Beneficiary may,
from time to time: (a) fully or partially release any person or entity
from liability for the payment or performance of any Secured Obligation;
(b) extend the maturity of any Secured Obligation; (c) make any agreement
with Borrower increasing the amount or otherwise altering the terms of any
Secured Obligation; (d) accept additional security for any Secured
Obligation; or (e) release all or any portion of the Property, Collateral
and other security for any Secured Obligation.  None of the foregoing
actions shall release or reduce the personal liability of any of said
Interested Parties, or release or impair the priority of the lien of this
Deed of Trust upon the Property.

6.22 SALE OR PARTICIPATION OF LOAN.  Trustor  agrees that Beneficiary  may  at
any time sell, assign, participate or securitize all or any portion of
Beneficiary's rights and obligations under the Loan Documents, and that
any such sale, assignment, participation or securitization may be to one
or more financial institutions or other entities, to private investors,
and/or into the public securities market, in Beneficiary's sole
discretion. Trustor further agrees that Beneficiary may disseminate to any
such actual or potential purchaser(s), assignee(s) or participant(s) all
documents and financial and other information heretofore or hereafter
provided to or known to Beneficiary with respect to:  (a) the Property and
its operation; and/or (b) any party connected with the Loan (including,
without limitation, Trustor, any partner or member of Trustor, any
constituent partner or member of Trustor, any guarantor and any
nonborrower trustor).  In the event of any such sale, assignment,
participation or securitization, Beneficiary and the other parties to the
same shall share in the rights and obligations of Beneficiary set forth in
the Loan Documents as and to the extent they shall agree among themselves.
 In connection with any such sale, assignment, participation or
securitization, Trustor further agrees that the Loan Documents shall be
sufficient evidence of the obligations of Trustor to each purchaser,
assignee or participant, and Trustor shall, within 15 days after request
by Beneficiary, deliver an estoppel certificate verifying for the benefit
of Beneficiary and any other party designated by Beneficiary the status
and the terms and provisions of the Loan in form and substance acceptable
to Beneficiary, and enter into such amendments or modifications to the
Loan Documents as may be reasonably required in order to facilitate any
such sale, assignment, participation or securitization without impairing
Trustor's rights or increasing Trustor's obligations.  The indemnity
obligations of Trustor under the Loan Documents shall also apply with
respect to any purchaser, assignee or participant.

6.23 RECONVEYANCE.  Upon Beneficiary's written request, and upon surrender of
this Deed of Trust or certified copy thereof and any note, instrument or
instruments setting forth all obligations secured hereby to Trustee for
cancellation, Trustee shall reconvey, without warranty, the Property or
that portion thereof then held hereunder.  The recitals of any matters or
facts in any reconveyance executed hereunder shall be conclusive proof of
the truthfulness thereof.  To the extent permitted by law, the
reconveyance may describe the grantee as "the person or persons legally
entitled thereto".  Neither Beneficiary nor Trustee shall have any duty to
determine the rights of persons claiming to be rightful grantees of any
reconveyance.  When the Property has been fully reconveyed, the last such
reconveyance shall operate as a reassignment of all future rents, issues
and profits of the Property to the person or persons legally entitled
thereto.

6.24    SUBROGATION.  Beneficiary shall be subrogated to the lien of all
encumbrances, whether released of record or not, paid in whole or in part
by Beneficiary pursuant to this Deed of Trust or by the proceeds of any
loan secured by this Deed of Trust.

6.25    YEAR 2000 COMPLIANCE.  Trustor shall timely ensure that all software,
hardware, equipment, goods and systems used in the operation of Trustor
or the Property will properly perform date-sensitive functions before,
during and after the year 2000.


ARTICLE 7.  DEFAULT

7.1     DEFAULT.  For all purposes hereof, "Default" shall mean either an
"Optional Default" (as defined below) or an "Automatic Default" (as
defined below).

a.      Optional Default.  An "Optional Default" shall occur, at
Beneficiary's option, upon the occurrence of any of the following
events:

(i)     Monetary.  Borrower or Trustor shall fail to (aa) pay when
due any sums which by their express terms require immediate
payment without any grace period or sums which are payable on
the Maturity Date, or (bb) pay within 5 days when due any other
sums payable under the Note, this Deed of Trust or any of the
other Loan Documents, including without limitation, any monthly
payment due under the Note.

(ii)    Failure to Perform.  Borrower or Trustor shall fail to
observe, perform or discharge any of Borrower's or Trustor's
obligations, covenants, conditions or agreements, other than
Borrower's or Trustor's payment obligations, under the Note,
this Deed of Trust or any of the other Loan Documents, and (aa)
such failure shall remain uncured for 30 days after written
notice thereof shall have been given to Borrower or Trustor, as
the case may be, by Beneficiary or (bb) if such failure is of
such a nature that it cannot be cured within such 30 day period,
Borrower or Trustor shall fail to commence to cure such failure
within such 30 day period or shall fail to diligently prosecute
such curative action thereafter.

(iii)   Representations and Warranties.  Any representation,
warranty, certificate or other statement (financial or
otherwise) made or furnished by or on behalf of Borrower,
Trustor, or a guarantor, if any, to Beneficiary or in connection
with any of the Loan Documents, or as an inducement to
Beneficiary to make the Loan, shall be false, incorrect,
incomplete or misleading in any material respect when made or
furnished.

(iv)    Condemnation; Attachment.  The condemnation, seizure or
appropriation of any material portion (as reasonably determined
by Beneficiary) of the Property; or the sequestration or
attachment of, or levy or execution upon any of the Property,
the Collateral or any other collateral provided by Borrower or
Trustor under any of the Loan Documents, or any material portion
of the other assets of Borrower or Trustor, which sequestration,
attachment, levy or execution is not released or dismissed
within 45 days after its occurrence; or the sale of any assets
affected by any of the foregoing.

(v)     Uninsured Casualty.  The occurrence of an uninsured casualty
 with respect to any material portion (as reasonably determined
by Beneficiary) of the Property unless:  (aa) no other Default
has occurred and is continuing at the time of such casualty or
occurs thereafter; (bb) Trustor promptly notifies Beneficiary of
the occurrence of such casualty; and (cc) not more than 45 days
after the occurrence of such casualty, Trustor delivers to
Beneficiary immediately available funds ("Restoration Funds") in
an amount sufficient, in Beneficiary's reasonable opinion, to
pay all costs of the repair or restoration (including, without
limitation, taxes, financing charges, insurance and rent during
the repair period).  So long as no Default has occurred and is
continuing at the time of Beneficiary's receipt of the
Restoration Funds and no Default occurs thereafter, Beneficiary
shall make the Restoration Funds  available for the repair or
restoration of the Property.  Notwithstanding the foregoing,
Beneficiary shall have no obligation to make any Restoration
Funds available for repair or restoration of the Property unless
and until all the conditions set forth in clauses (ii) and (iii)
of the second sentence of Section 6.11(b) of this Deed of Trust
have been satisfied.  Trustor acknowledges that the specific
conditions described above are reasonable.

(vi)    Adverse Financial Change.  Any material adverse change in
the financial condition of Borrower or any general partner of
Borrower, any guarantor, or any other person or entity from the
condition shown on the financial statement(s) submitted to
Beneficiary and relied upon by Beneficiary in making the Loan,
and which change Beneficiary reasonably determines will have a
material adverse effect on (aa) the business, operations or
condition of the Property; or (bb) the ability of Borrower or
Trustor to pay or perform Borrower's or Trustor's obligations in
accordance with the terms of the Note, this Deed of Trust, and
the other Loan Documents.

b.      Automatic Default.  An "Automatic Default" shall occur
automatically upon the occurrence of any of the following events:

(i)     Voluntary Bankruptcy, Insolvency, Dissolution.  (aa)
Borrower's filing a petition for relief under the Bankruptcy
Reform Act of 1978, as amended or recodified ("Bankruptcy
Code"), or under any other present or future state or federal
law regarding bankruptcy, reorganization or other relief to
debtors (collectively, "Debtor Relief Law"); or (bb) Borrower's
filing any pleading in any involuntary proceeding under the
Bankruptcy Code or other Debtor Relief Law which admits the
jurisdiction of a court to regulate Borrower or the Property or
the petition's material allegations regarding Borrower's
insolvency; or (cc) Borrower's making a general assignment for
the benefit of creditors; or (dd) Borrower's applying for, or
the appointment of, a receiver, trustee, custodian or
liquidator of Borrower or any of its property; or (ee) the
filing by or against Borrower of a petition seeking the
liquidation or dissolution of Borrower or the commencement of
any other procedure to liquidate or dissolve Borrower.

(ii)    Involuntary Bankruptcy.  Borrower's failure to effect a full
dismissal of any involuntary petition under the Bankruptcy Code
or other Debtor Relief Law that is filed against Borrower or in
any way restrains or limits Borrower or Beneficiary regarding
the Loan or the Property, prior to the earlier of the entry of
any order granting relief sought in the involuntary petition or
45 days after the date of filing of the petition.

(iii)   Partners, Guarantors.  The occurrence of an event specified
in Sections (i) or (ii) as to Trustor, any general partner of
Borrower or Trustor, or any guarantor or other person or entity
in any manner obligated to Beneficiary under the Loan
Documents.

7.2     ACCELERATION.  Upon the occurrence of an Optional Default, Beneficiary
may, at its option, declare all sums owing to Beneficiary under the Note
and the other Loan Documents immediately due and payable. Upon the
occurrence of an Automatic Default, all sums owing to Beneficiary under
the Note and the other Loan Documents shall automatically become
immediately due and payable.

7.3     RIGHTS AND REMEDIES.  In addition to the rights and remedies in Section
7.2 above, at any time after a Default, Beneficiary shall have all of the
following rights and remedies:

a.      Entry on Property.  With or without notice, and without releasing
Trustor from any Secured Obligation, and without becoming a
mortgagee in possession, to enter upon the Property from time to
time and to do such acts and things as Beneficiary or Trustee deem
necessary or desirable in order to inspect, investigate, assess and
protect the security hereof or to cure any Default, including,
without limitation: (i) to take and possess all documents, books,
records, papers and accounts of Trustor, Borrower or the then owner
of the Property which relate to the Property; (ii) to make,
terminate, enforce or modify leases of the Property upon such terms
and conditions as Beneficiary deems proper; (iii) to make repairs,
alterations and improvements to the Property necessary, in Trustee's
or Beneficiary's sole judgment, to protect or enhance the security
hereof; (iv) to appear in and defend any action or proceeding
purporting to affect the security hereof or the rights or powers of
Beneficiary or Trustee hereunder; (v) to pay, purchase, contest or
compromise any encumbrance, charge, lien or claim of lien which, in
the sole judgment of either Beneficiary or Trustee, is or may be
senior in priority hereto, the judgment of Beneficiary or Trustee
being conclusive as between the parties hereto; (vi) to obtain
insurance; (vii) to pay any premiums or charges with respect to
insurance required to be carried hereunder; (viii) to obtain a court
order to enforce Beneficiary's right to enter and inspect the
Property for Hazardous Materials, in which regard the decision of
Beneficiary as to whether there exists a release or threatened
release of Hazardous Materials onto the Property shall be deemed
reasonable and conclusive as between the parties hereto; (ix) to
have a receiver appointed pursuant to applicable law to enforce
Beneficiary's rights to enter and inspect the Property for Hazardous
Materials; and/or (x) to employ legal counsel, accountants,
engineers, consultants, contractors and other appropriate persons to
assist them;

b.      Appointment of Receiver.  With or without notice or hearing, to
apply to a court of competent jurisdiction for and obtain appointment
of a receiver, trustee, liquidator or conservator of the Property,
for any purpose, including, without limitation, to enforce
Beneficiary's right to collect Payments and to enter on and inspect
the Property for Hazardous Materials, as a matter of strict right and
without regard to: (i) the adequacy of the security for the repayment
of the Secured Obligations; (ii) the existence of a declaration that
the Secured Obligations are immediately due and payable; (iii) the
filing of a notice of default; or (iv) the solvency of Trustor,
Borrower or any guarantor or other person or entity in any manner
obligated to Beneficiary under the Loan Documents;

c.      Judicial Foreclosure; Injunction.  To commence and maintain an
action or actions in any court of competent jurisdiction to foreclose
this instrument as a mortgage or to obtain specific enforcement of
the covenants of Trustor hereunder, and Trustor agrees that such
covenants shall be specifically enforceable by injunction or any
other appropriate equitable remedy and that for the purposes of any
suit brought under this subparagraph, Trustor waives the defense of
laches and any applicable statute of limitations;

d.      Nonjudicial Foreclosure.  To execute a written notice of such
Default and of the election to cause the Property to be sold to
satisfy the Secured Obligations.  Trustee shall give and record such
notice as the law then requires as a condition precedent to a
trustee's sale.  When the minimum period of time required by law
after such notice has elapsed, Trustee, without notice to or demand
upon Trustor except as required by law, shall sell the Property at
the time and place of sale fixed by it in the notice of sale, at one
or several sales, either as a whole or in separate parcels and in
such manner and order, all as Beneficiary in its sole discretion may
determine, at public auction to the highest bidder for cash, in
lawful money of the United States, payable at time of sale.  Neither
Trustor nor any other person or entity other than Beneficiary shall
have the right to direct the order in which the Property is sold.
Subject to requirements and limits imposed by law, Trustee may, from
time to time postpone sale of all or any portion of the Property by
public announcement at such time and place of sale, and from time to
time may postpone the sale by public announcement at the time and
place fixed by the preceding postponement.  A sale of less than the
whole of the Property or any defective or irregular sale made
hereunder shall not exhaust the power of sale provided for herein.
Trustee shall deliver to the purchaser at such sale a deed conveying
the Property or portion thereof so sold, but without any covenant or
warranty, express or implied.  The recitals in the deed of any
matters or facts shall be conclusive proof of the truthfulness
thereof.  Any person, including Trustee, Trustor or Beneficiary may
purchase at the sale;

Upon sale of the Property at any judicial or nonjudicial foreclosure,
Beneficiary may credit bid (as determined by Beneficiary in its sole
and absolute discretion) all or any portion of the Secured
Obligations.  In determining such credit bid, Beneficiary may, but is
not obligated to, take into account all or any of the following: (i)
appraisals of the Property as such appraisals may be discounted or
adjusted by Beneficiary in its sole and absolute underwriting
discretion; (ii) expenses and costs incurred by Beneficiary with
respect to the Property prior to foreclosure; (iii) expenses and
costs which Beneficiary anticipates will be incurred with respect to
the Property after foreclosure, but prior to resale, including,
without limitation, costs of structural reports and other due
diligence, costs to carry the Property prior to resale, costs of
resale (e.g. commissions, attorneys' fees, and taxes), costs of any
Hazardous Materials clean-up and monitoring, costs of deferred
maintenance, repair, refurbishment and retrofit, costs of defending
or settling litigation affecting the Property, and lost opportunity
costs (if any), including the time value of money during any
anticipated holding period by Beneficiary; (iv) declining trends in
real property values generally and with respect to properties similar
to the Property; (v) anticipated discounts upon resale of the
Property as a distressed or foreclosed property; (vi) the fact of
additional collateral (if any), for the Secured Obligations; and
(vii) such other factors or matters that Beneficiary (in its sole and
absolute discretion) deems appropriate.  In regard to the above,
Trustor acknowledges and agrees that: (viii) Beneficiary is not
required to use any or all of the foregoing factors to determine the
amount of its credit bid; (ix) this paragraph does not impose upon
Beneficiary any additional obligations that are not imposed by law at
the time the credit bid is made; (x) the amount of Beneficiary's
credit bid need not have any relation to any loan-to-value ratios
specified in the Loan Documents or previously discussed between
Trustor and Beneficiary; and (xi) Beneficiary's credit bid may be (at
Beneficiary's sole and absolute discretion) higher or lower than any
appraised value of the Property;

e.      Multiple Foreclosures.  To resort to and realize upon the security
hereunder and any other security now or later held by Beneficiary
concurrently or successively and in one or several consolidated or
independent judicial actions or lawfully taken nonjudicial
proceedings, or both, and to apply the proceeds received upon the
Secured Obligations all in such order and manner as Trustee and
Beneficiary or either of them determine in their sole discretion;

f.      Rights to Collateral.  To exercise all rights Trustee or
Beneficiary may have with respect to the Collateral under this Deed
of Trust, the UCC or otherwise at law; and

g.      Other Rights.  To exercise such other rights as Trustee or
Beneficiary may have at law or in equity or pursuant to the terms and
conditions of this Deed of Trust or any of the other Loan Documents.

In connection with any sale or sales hereunder, Beneficiary may elect to
treat any of the Property which consists of a right in action or which is
property that can be severed from the Property (including, without
limitation, any improvements forming a part thereof) without causing
structural damage thereto as if the same were personal property or a
fixture, as the case may be, and dispose of the same in accordance with
applicable law, separate and apart from the sale of the Property.  Any
sale of Collateral hereunder shall be conducted in any manner permitted by
the UCC.

7.4     APPLICATION OF FORECLOSURE SALE PROCEEDS.  If any foreclosure sale is
effected, Trustee shall apply the proceeds of such sale in the following
order of priority:  First, to the costs, fees and expenses of exercising
the power of sale and of sale, including, without limitation, the payment
of the Trustee's fees and attorneys' fees permitted pursuant to
subdivision (b) of California Civil Code Section 2924d and subdivision
(b) of Section 2924k; Second, to the payment of the Secured Obligations
which are secured by this Deed of Trust, in such order as Beneficiary
shall determine in its sole discretion;  Third, to satisfy the
outstanding balance of obligations secured by any junior liens or
encumbrances in the order of their priority; and Fourth, to the Trustor
or the Trustor's successor in interest, or in the event the Property has
been sold or transferred to another, to the vested owner of record at the
time of the Trustee's sale.

7.5     WAIVER OF MARSHALING RIGHTS.  Trustor, for itself and for all parties
claiming through or under Trustor, and for all parties who may acquire a
lien on or interest in the Property, hereby waives all rights to have the
Property and/or any other property, including, without limitation, the
Collateral, which is now or later may be security for any Secured
Obligation, marshaled upon any foreclosure of this Deed of Trust or on a
foreclosure of any other security for any of the Secured Obligations.

7.6     NO CURE OR WAIVER.  Neither Beneficiary's nor Trustee's nor any
receiver's entry upon and taking possession of all or any part of the
Property, nor any collection of rents, issues, profits, insurance
proceeds, condemnation proceeds or damages, other security or proceeds of
other security, or other sums, nor the application of any collected sum to
any Secured Obligation, nor the exercise of any other right or remedy by
Beneficiary or Trustee or any receiver shall cure or waive any Default or
notice of default under this Deed of Trust, or nullify the effect of any
notice of default or sale (unless all Secured Obligations then due have
been paid or performed and Trustor has cured all other Defaults
hereunder), or impair the status of the security, or prejudice Beneficiary
or Trustee in the exercise of any right or remedy, or be construed as an
affirmation by Beneficiary of any tenancy, lease or option or a
subordination of the lien of this Deed of Trust.

7.7 PAYMENT OF COSTS, EXPENSES AND ATTORNEYS' FEES.  Trustor agrees to pay to
Beneficiary immediately and upon demand all costs and expenses incurred by
Trustee and Beneficiary in the enforcement of the terms and conditions of
this Deed of Trust (including, without limitation, statutory trustee's
fees, court costs and attorneys' fees, whether incurred in litigation or
not) with interest from the date of expenditure until said sums have been
paid at the rate of interest applicable to the principal balance of the
Note as specified therein.

7.8     POWER TO FILE NOTICES AND CURE DEFAULTS.  Trustor hereby irrevocably
appoints Beneficiary and its successors and assigns, as its attorney-in-
fact, which agency is coupled with an interest, to perform any obligation
of Trustor hereunder upon the occurrence of an event, act or omission
which, with notice or passage of time or both, would constitute a Default,
provided, however, that: (i) Beneficiary as such attorney-in-fact shall
only be accountable for such funds as are actually received by
Beneficiary; and (ii) Beneficiary shall not be liable to Trustor or any
other person or entity for any failure to act under this Section.

7.9  REMEDIES CUMULATIVE.  All rights and remedies of Beneficiary and Trustee
provided hereunder are cumulative and are in addition to all rights and
remedies provided by applicable law (including specifically that of
foreclosure of this instrument as though it were a mortgage) or in any
other agreements between Trustor and Beneficiary.  Beneficiary may enforce
any one or more remedies or rights hereunder successively or concurrently.


ARTICLE 8.  MISCELLANEOUS PROVISIONS

8.1     ADDITIONAL PROVISIONS.  The Loan Documents contain or incorporate by
reference the entire agreement of the parties with respect to matters
contemplated herein and supersede all prior negotiations. The Loan
Documents grant further rights to Beneficiary and contain further
agreements and affirmative and negative covenants by Trustor which apply
to this Deed of Trust and to the Property and such further rights and
agreements are incorporated herein by this reference.  THE OBLIGATIONS AND
LIABILITIES OF TRUSTOR UNDER THIS DEED OF TRUST AND THE OTHER LOAN
DOCUMENTS ARE SUBJECT TO THE PROVISIONS OF THE SECTION IN THE NOTE
ENTITLED "BORROWER'S LIABILITY."

8.2 NON-WAIVER.  By accepting payment of any amount secured hereby after its
due date or late performance of any other Secured Obligation, Beneficiary
shall not waive its right against any person obligated directly or
indirectly hereunder or on any Secured Obligation, either to require
prompt payment or performance when due of all other sums and obligations
so secured or to declare default for failure to make such prompt payment
or performance.  No exercise of any right or remedy by Beneficiary or
Trustee hereunder shall constitute a waiver of any other right or remedy
herein contained or provided by law.  No failure by Beneficiary or Trustee
to exercise any right or remedy hereunder arising upon any Default shall
be construed to prejudice Beneficiary's or Trustee's rights or remedies
upon the occurrence of any other or subsequent Default.  No delay by
Beneficiary or Trustee in exercising any such right or remedy shall be
construed to preclude Beneficiary or Trustee from the exercise thereof at
any time while that Default is continuing.  No notice to nor demand on
Trustor shall of itself entitle Trustor to any other or further notice or
demand in similar or other circumstances.

8.3     CONSENTS AND APPROVALS.  Wherever Beneficiary's consent, approval,
acceptance or satisfaction is required under any provision of this Deed of
Trust or any of the other Loan Documents,  such consent, approval,
acceptance or satisfaction shall not be unreasonably withheld, conditioned
or delayed by Beneficiary unless such provision expressly so provides.

8.4  PERMITTED CONTESTS.  After prior written notice to Beneficiary, Trustor
may contest, by appropriate legal or other proceedings conducted in good
faith and with due diligence, the amount, validity or application, in
whole or in part, of any lien, levy, tax or assessment, or any lien of any
laborer, mechanic, materialman, supplier or vendor, or the application to
Trustor or the Property of any law or the validity thereof, the assertion
or imposition of which, or the failure to pay when due, would constitute a
Default; provided that (a) Trustor pursues the contest diligently, in a
manner which Beneficiary determines is not prejudicial to Beneficiary, and
does not impair the lien of this Deed of Trust; (b) the Property, or any
part hereof or estate or interest therein, shall not be in any danger of
being sold, forfeited or lost by reason of such proceedings; (c) in the
case of the contest of any law or other legal requirement, Beneficiary
shall not be in any danger of any civil or criminal liability; and (d) if
required by Beneficiary, Trustor deposits with Beneficiary any funds or
other forms of assurance (including a bond or letter of credit)
satisfactory to Beneficiary to protect Beneficiary from the consequences
of the contest being unsuccessful.  Trustor's right to contest pursuant to
the terms of this provision shall in no way relieve Trustor or Borrower of
its obligations under the Loan or to make payments to Beneficiary as and
when due.

8.5     FURTHER ASSURANCES.  Trustor shall, upon demand by Beneficiary or
Trustee, execute, acknowledge (if appropriate) and deliver any and all
documents and instruments and do or cause to be done all further acts
reasonably necessary or appropriate to effectuate the provisions hereof.

8.6     ATTORNEYS' FEES.  If any legal action, suit or proceeding is commenced
between Trustor and Beneficiary regarding their respective rights and
obligations under this Deed of Trust or any of the other Loan Documents,
the prevailing party shall be entitled to recover, in addition to damages
or other relief, costs and expenses, reasonable attorneys' fees and court
costs (including, without limitation, expert witness fees).  As used
herein the term "prevailing party" shall mean the party which obtains the
principal relief it has sought, whether by compromise settlement or
judgment.  If the party which commenced or instituted the action, suit or
proceeding shall dismiss or discontinue it without the concurrence of the
other party, such other party shall be deemed the prevailing party.

8.7     TRUSTOR AND BENEFICIARY DEFINED.  The term "Trustor" includes both the
original Trustor and any subsequent owner or owners of any of the
Property, and the term "Beneficiary" includes the original Beneficiary and
any future owner or holder, including assignees, pledges and participants,
of the Note or any interest therein.

8.8     DISCLAIMERS.

a.      Relationship.  The relationship of Trustor and Beneficiary under
this Deed of Trust and the other Loan Documents is, and shall at all
times remain, solely that of borrower and lender; and Beneficiary
neither undertakes nor assumes any responsibility or duty to Trustor
or to any third party with respect to the Property.  Notwithstanding
any other provisions of this Deed of Trust and the other Loan
Documents:  (i) Beneficiary is not, and shall not be construed to
be, a partner, joint venturer, member, alter ego, manager,
controlling person or other business associate or participant of any
kind of Trustor, and Beneficiary does not intend to ever assume such
status; (ii) Beneficiary's activities in connection with this Deed
of Trust and the other Loan Documents shall not be "outside the
scope of activities of a lender of money" within the meaning of
California Civil Code Section 3434, as amended or recodified from
time to time, and Beneficiary does not intend to ever assume any
responsibility to any person for the quality, suitability, safety or
condition of the Property; and (iii) Beneficiary shall not be deemed
responsible for or a participant in any acts, omissions or decisions
of Trustor.

b.      No Liability.  Beneficiary shall not be directly or indirectly
liable or responsible for any loss, claim, cause of action,
liability, indebtedness, damage or injury of any kind or character
to any person or property arising from any construction on, or
occupancy or use of, the Property, whether caused by or arising
from: (i) any defect in any building, structure, grading, fill,
landscaping or other improvements thereon or in any on-site or off-
site improvement or other facility therein or thereon; (ii) any act
or omission of Trustor or any of Trustor's agents, employees,
independent contractors, licensees or invitees; (iii) any accident
in or on the Property or any fire, flood or other casualty or hazard
thereon; (iv) the failure of Trustor or any of Trustor's licensees,
employees, invitees, agents, independent contractors or other
representatives to maintain the Property in a safe condition; or (v)
any nuisance made or suffered on any part of the Property.

8.9     SEVERABILITY.  If any term of this Deed of Trust, or the application
thereof to any person or circumstances, shall, to any extent, be invalid
or unenforceable, the remainder of this Deed of Trust, or the application
of such term to persons or circumstances other than those as to which it
is invalid or unenforceable, shall not be affected thereby, and each term
of this Deed of Trust shall be valid and enforceable to the fullest extent
permitted by law.

8.10    RELATIONSHIP OF ARTICLES.  The rights, remedies and interests of
Beneficiary under the deed of trust established by Article I and the
security agreement established by Article IV are independent and
cumulative, and there shall be no merger of any lien created by the deed
of trust with any security interest created by the security agreement.
Beneficiary may elect to exercise or enforce any of its rights, remedies
or interests under either or both the deed of trust or the security
agreement as Beneficiary may from time to time deem appropriate.  The
absolute assignment of rents and leases established by Article III is
similarly independent of and separate from the deed of trust and the
security agreement.

8.11 MERGER.  No merger shall occur as a result of Beneficiary's acquiring any
other estate in, or any other lien on, the Property unless Beneficiary
consents to a merger in writing.

8.12    OBLIGATIONS OF TRUSTOR, JOINT AND SEVERAL.  If more than one person has
executed this Deed of Trust as "Trustor", the obligations of all such
persons hereunder shall be joint and several.

8.13    SEPARATE AND COMMUNITY PROPERTY.  Any married person who executes this
Deed of Trust as a Trustor agrees that any money judgment which Benefi-
ciary or Trustee obtains pursuant to the terms of this Deed of Trust or
any other obligation of that married person secured by this Deed of Trust
may be collected by execution upon any separate property or community
property of that person.

8.14    INTEGRATION; INTERPRETATION.  The Loan Documents contain or expressly
incorporate by reference the entire agreement of the parties with respect
to the matters contemplated therein and supersede all prior negotiations
or agreements, written or oral.  The Loan Documents shall not be modified
except by written instrument executed by all parties.  Any reference in
any of the Loan Documents to the Property or Collateral shall include all
or any part of the Property or Collateral.  Any reference to the Loan
Documents includes any amendments, renewals or extensions now or
hereafter approved by Beneficiary in writing. When the identity of the
parties or other circumstances make it appropriate, the masculine gender
includes the feminine and/or neuter, and the singular number includes the
plural.

8.15  CAPITALIZED TERMS.  Capitalized terms not otherwise defined herein shall
have the meanings set forth in the Note.

8.16    SUCCESSORS IN INTEREST.  The terms, covenants, and conditions herein
contained shall be binding upon and inure to the benefit of the heirs,
successors and assigns of the parties hereto.  The foregoing sentence
shall not be construed to permit Trustor to assign the Loan except as
otherwise permitted under the Note or the other Loan Documents.

8.17    GOVERNING LAW.  This Deed of Trust was accepted by Beneficiary in the
state of California and the proceeds of the Note secured hereby were
disbursed from the state of California, which state the parties agree has
a substantial relationship to the parties and to the underlying
transaction embodied hereby. Accordingly, in all respects, including,
without limiting the generality of the foregoing, matters of
construction, validity, enforceability and performance, this Deed of
Trust, the Note and the other Loan Documents and the obligations arising
hereunder and thereunder shall be governed by, and construed in
accordance with, the laws of the state of California applicable to
contracts made and performed in such state and any applicable law of the
United States of America, except that at all times the provisions for
enforcement of Beneficiary's STATUTORY POWER OF SALE granted hereunder
and the creation, perfection and enforcement of the security interests
created pursuant thereto and pursuant to the other Loan Documents shall
be governed by and construed according to the law of the state where the
Property is located. Except as provided in the immediately preceding
sentence, Trustor hereby unconditionally and irrevocably waives, to the
fullest extent permitted by law, any claim to assert that the law of any
jurisdiction other than California governs this Deed of Trust, the Note
and other Loan Documents.

8.18 CONSENT TO JURISDICTION.  Trustor irrevocably submits to the jurisdiction
of: (a) any state or federal court sitting in the state of California over
any suit, action, or proceeding, brought by Trustor against Beneficiary,
arising out of or relating to this Deed of Trust, the Note or the Loan;
(b) any state or federal court sitting in the state where the Property is
located or the state in which Trustor's principal place of business is
located over any suit, action or proceeding, brought by Beneficiary
against Trustor, arising out of or relating to this Deed of Trust, the
Note or the Loan; and (c) any state court sitting in the county of the
state where the Property is located over any suit, action, or proceeding,
brought by Beneficiary to exercise its STATUTORY POWER OF SALE under this
Deed of Trust or any action brought by Beneficiary to enforce its rights
with respect to the Collateral.  Trustor irrevocably waives, to the
fullest extent permitted by law, any objection that Trustor may now or
hereafter have to the laying of venue of any such suit, action, or
proceeding brought in any such court and any claim that any such suit,
action, or proceeding brought in any such court has been brought in an
inconvenient forum.

8.19    EXHIBITS.  Exhibit A is incorporated into this Deed of Trust by this
reference.

8.20 ADDRESSES; REQUEST FOR NOTICE.  All notices and other communications that
are required or permitted to be given to a party under this Deed of Trust
shall be in writing, refer to the Loan number, and shall be sent to such
party, either by personal delivery, by overnight delivery service, by
certified first class mail, return receipt requested, or by facsimile
transmission to the addressee or facsimile number below.  All such notices
and communications shall be effective upon receipt of such delivery or
facsimile transmission. The addresses of the parties are set forth on page
1 of this Deed of Trust and the facsimile numbers for the parties are as
follows:

Beneficiary:

WELLS FARGO BANK, N.A.
FAX No.: (925) 691-5947
Trustee:

AMERICAN SECURITIES COMPANY
FAX No.: (925) 691-5947

Trustor:

FREMONT HOLDING L.L.C.
FAX No.: (510) 574-1500


Trustor's principal place of business is at the address set forth on page
1 of this Deed of Trust.

Any Trustor whose address is set forth on page 1 of this Deed of Trust
hereby requests that a copy of notice of default and notice of sale be
delivered to it at that address.  Failure to insert an address shall
constitute a designation of Trustor's last known address as the address
for such notice.  Any party shall have the right to change its address for
notice hereunder to any other location within the continental United
States by giving 30 days notice to the other parties in the manner set
forth above.

8.21    COUNTERPARTS.  This Deed of Trust may be executed in any number of
counterparts, each of which, when executed and delivered, will be deemed
an original and all of which taken together, will be deemed to be one and
the same instrument.

8.22    WAIVER OF JURY TRIAL. BENEFICIARY AND TRUSTOR HEREBY KNOWINGLY,
VOLUNTARILY AND INTENTIONALLY WAIVE ANY RIGHTS THEY MAY HAVE TO A TRIAL BY
JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER,
OR IN CONNECTION WITH, THIS DEED OF TRUST OR ANY OTHER LOAN DOCUMENT, OR
ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR
WRITTEN) OR ACTIONS OF BENEFICIARY OR TRUSTOR.  THIS PROVISION IS A
MATERIAL INDUCEMENT FOR BENEFICIARY TO ENTER INTO THIS DEED OF TRUST.

IN WITNESS WHEREOF, Trustor has executed this Deed of Trust as of the day and
year set forth above.

FREMONT HOLDING L.L.C.,
a Delaware limited liability company

By:  Fremont Management, Inc.,
     a Delaware corporation,
     Manager

     By:  _______________________________

     Its: _______________________________




(ALL SIGNATURES MUST BE ACKNOWLEDGED)

        Loan No. 31-0900011A
EXHIBIT A
Description Of Land


Exhibit A to DEED OF TRUST AND ABSOLUTE ASSIGNMENT OF RENTS AND LEASES AND
SECURITY AGREEMENT (AND FIXTURE FILING) ("Deed of Trust") among FREMONT HOLDING
L.L.C., a Delaware limited liability company, as "Trustor", AMERICAN
SECURITIES COMPANY, as "Trustee", and WELLS FARGO BANK, NATIONAL ASSOCIATION,
as "Beneficiary".

Description of Land.  The Land referred to in this Deed of Trust is situated in
the county of Alameda, state of California and is described as follows:


PARCEL 16, PARCEL MAP 4483, FILED MARCH 28, 1985 IN BOOK 152, PAGES 78 THROUGH
82 OF MAPS, ALAMEDA COUNTY RECORDS.

APN:  543-0439-108
          543-0439-109


Recording Requested by
and when recorded return to:

WELLS FARGO BANK, N.A.
Commercial Mortgage Servicing
417 Montgomery Street, 5th Floor
San Francisco, California 94104

Attention:      Jean Hembree
Loan No. :      31-0900011A





D E E D  O F  T R U S T
and
A B S O L U T E  A S S I G N M E N T  O F  R E N T S
A N D  L E A S E S
and
S E C U R I T Y  A G R E E M E N T
(A N D  F I X T U R E  F I L I N G)


The parties to this DEED OF TRUST AND ABSOLUTE ASSIGNMENT OF RENTS AND LEASES
AND SECURITY AGREEMENT (AND FIXTURE FILING) ("Deed of Trust"), dated as of
September 9, 1999 are FREMONT HOLDING L.L.C., a Delaware limited liability
company ("Trustor"), with a mailing address at 34801 Campus Drive, Fremont, CA
94555, AMERICAN SECURITIES COMPANY, a California corporation ("Trustee"), with
a mailing address at 1320 Willow Pass Road, Suite 205, Concord, California
94520, and WELLS FARGO BANK, NATIONAL ASSOCIATION ("Beneficiary"), with a
mailing address at 1320 Willow Pass Road, Suite 205, Concord, California 94520.


R E C I T A L S

A. FREMONT HOLDING L.L.C., a Delaware limited liability company ("Borrower")
proposes to borrow from Beneficiary, and Beneficiary proposes to lend to
Borrower the principal sum of TEN MILLION ONE HUNDRED FIFTY THOUSAND AND
NO/100THS DOLLARS ($10,150,000.00) ("Loan").  The Loan is evidenced by a
promissory note ("Note") executed by Borrower, dated the date of this Deed
of Trust, payable to the order of Beneficiary in the principal amount of
the Loan.

B. The loan documents include this Deed of Trust, the Note and the other
documents described in the Note as Loan Documents ("Loan Documents").


ARTICLE 1.  DEED OF TRUST

1.1     GRANT.  For the purposes of and upon the terms and conditions of this
Deed of Trust, Trustor irrevocably grants, conveys and assigns to Trust-
ee, in trust for the benefit of Beneficiary, with power of sale and right
of entry and possession, all estate, right, title and interest which
Trustor now has or may hereafter acquire in, to, under or derived from
any or all of the following:

a.      That real property ("Land") located in Fremont, county of Alameda,
state of California, and more particularly described on Exhibit A
attached hereto;

b.      All appurtenances, easements, rights of way, water and water
rights, pumps, pipes, flumes and ditches and ditch rights, water
stock, ditch and/or reservoir stock or interests, royalties,
development rights and credits, air rights, minerals, oil rights, and
gas rights, now or later used or useful in connection with,
appurtenant to or related to the Land;

c.      All buildings, structures, facilities, other improvements and
fixtures now or hereafter located on the Land;

d.      All apparatus, equipment, machinery and appliances and all
accessions thereto and renewals and replacements thereof and
substitutions therefor used in the operation or occupancy of the
Land, it being intended by the parties that all such items shall be
conclusively considered to be a part of the Land, whether or not
attached or affixed to the Land;

e.      All land lying in the right-of-way of any street, road, avenue,
alley or right-of-way opened, proposed or vacated, and all sidewalks,
strips and gores of land adjacent to or used in connection with the
Land;

f.      All additions and accretions to the property described above;

g.      All licenses, authorizations, certificates, variances, consents,
approvals and other permits now or hereafter pertaining to the Land
and all estate, right, title and interest of Trustor in, to, under or
derived from all tradenames or business names relating to the Land or
the present or future development, construction, operation or use of
the Land; and

h.      All proceeds of any of the foregoing.

All of the property described above is hereinafter collectively defined as
the "Property".  The listing of specific rights or property shall not be
interpreted as a limitation of general terms.


ARTICLE 2.  OBLIGATIONS SECURED

2.1     OBLIGATIONS SECURED.  Trustor makes the foregoing grant and assignment
for the purpose of securing the following obligations ("Secured Obliga-
tions"):

a.      Full and punctual payment to Beneficiary of all sums at any time
owing under the Note;

b.      Payment and performance of all covenants and obligations of Trustor
under this Deed of Trust including, without limitation,
indemnification obligations and advances made to protect the
Property;

c.      Payment and performance of all additional covenants and obligations
of Borrower and Trustor under the Loan Documents;

d.      Payment and performance of all covenants and obligations, if any,
which any rider attached as an exhibit to this Deed of Trust recites
are secured hereby;

e.      Payment and performance of all future advances and other
obligations that the then record owner of all or part of the Property
may agree to pay and/or perform (whether as principal, surety or
guarantor) for the benefit of Beneficiary, when the obligation is
evidenced by a writing which recites that it is secured by this Deed
of Trust;

f.      All interest and charges on all obligations secured hereby
including, without limitation, prepayment charges, late charges and
loan fees; and

g.      All modifications, extensions and renewals of any of the
obligations secured hereby, however evidenced, including, without
limitation: (i) modifications of the required principal payment dates
or interest payment dates or both, as the case may be, deferring or
accelerating payment dates wholly or partly; and (ii) modifications,
extensions or renewals at a different rate of interest whether or not
any such modification, extension or renewal is evidenced by a new or
additional promissory note or notes.

2.2     OBLIGATIONS.  The term "obligations" is used herein in its broadest and
most comprehensive sense and shall be deemed to include, without
limitation, all interest and charges, prepayment charges, late charges
and loan fees at any time accruing or assessed on any of the Secured
Obligations.

2.3    INCORPORATION.  All terms and conditions of the documents which evidence
any of the Secured Obligations are incorporated herein by this reference.
 All persons who may have or acquire an interest in the Property shall be
deemed to have notice of the terms of the Secured Obligations and to have
notice that the rate of interest on one or more Secured Obligation may
vary from time to time.


ARTICLE 3.  ABSOLUTE ASSIGNMENT OF RENTS AND LEASES

3.1     ASSIGNMENT.  Trustor irrevocably assigns to Beneficiary all of Trustor's
right, title and interest in, to and under: (a) all present and future
leases of the Property or any portion thereof, all licenses and
agreements relating to the management, leasing or operation of the
Property or any portion thereof, and all other agreements of any kind
relating to the use or occupancy of the Property or any portion thereof,
whether such leases, licenses and agreements are now existing or entered
into after the date hereof ("Leases"); and (b) the rents, issues,
deposits and profits of the Property, including, without limitation, all
amounts payable and all rights and benefits accruing to Trustor under the
Leases ("Payments").  The term "Leases" shall also include all guarantees
of and security for the tenants' performance thereunder, and all
amendments, extensions, renewals or modifications thereto which are
permitted hereunder.  This is a present and absolute assignment, not an
assignment for security purposes only, and Beneficiary's right to the
Leases and Payments is not contingent upon, and may be exercised without
possession of, the Property.

3.2     GRANT OF LICENSE.  Beneficiary confers upon Trustor a revocable license
("License") to collect and retain the Payments as they become due and
payable, until the occurrence of a Default (as hereinafter defined).  Upon
a Default, the License shall be automatically revoked and Beneficiary may
collect and apply the Payments pursuant to the terms hereof without notice
and without taking possession of the Property.  All Payments thereafter
collected by Trustor shall be held by Trustor as trustee under a
constructive trust for the benefit of Beneficiary.  Trustor hereby
irrevocably authorizes and directs the tenants under the Leases to rely
upon and comply with any notice or demand by Beneficiary for the payment
to Beneficiary of any rental or other sums which may at any time become
due under the Leases, or for the performance of any of the tenants'
undertakings under the Leases, and the tenants shall have no right or duty
to inquire as to whether any Default has actually occurred or is then
existing.  Trustor hereby relieves the tenants from any liability to
Trustor by reason of relying upon and complying with any such notice or
demand by Beneficiary. Beneficiary may apply, in its sole discretion, any
Payments so collected by Beneficiary against any Secured Obligation or any
other obligation of Borrower, Trustor or any other person or entity, under
any document or instrument related to or executed in connection with the
Loan Documents, whether existing on the date hereof or hereafter arising.
 Collection of any Payments by Beneficiary shall not cure or waive any
Default or notice of Default or invalidate any acts done pursuant to such
notice.

3.3     EFFECT OF ASSIGNMENT.  The foregoing irrevocable assignment shall not
cause Beneficiary to be: (a) a mortgagee in possession; (b) responsible or
liable for the control, care, management or repair of the Property or for
performing any of the terms, agreements, undertakings, obligations,
representations, warranties, covenants and conditions of the Leases; (c)
responsible or liable for any waste committed on the Property by the
tenants under any of the Leases or by any other parties; for any dangerous
or defective condition of the Property; or for any negligence in the
management, upkeep, repair or control of the Property resulting in loss or
injury or death to any tenant, licensee, employee, invitee or other
person; or (d) responsible for or impose upon Beneficiary any duty to
produce rents or profits.  Beneficiary shall not directly or indirectly be
liable to Trustor or any other person as a consequence of:  (e) the
exercise or failure to exercise any of the rights, remedies or powers
granted to Beneficiary hereunder; or (f) the failure or refusal of
Beneficiary to perform or discharge any obligation, duty or liability of
Trustor arising under the Leases.

3.4     COVENANTS.

a.      All Leases.  Trustor shall, at Trustor's sole cost and expense:

(i)     perform all obligations of the landlord under the Leases and
use reasonable efforts to enforce performance by the tenants of
all obligations of the tenants under the Leases;

(ii)    use reasonable efforts to keep the Property leased at all
times to tenants which Trustor reasonably and in good faith
believes are creditworthy at rents not less than the fair market
rental value (including, but not limited to, free or discounted
rents to the extent the market so requires);

(iii)   promptly upon Beneficiary's request, deliver to Beneficiary a
copy of each requested Lease and all amendments thereto and
waivers thereof; and

(iv)    promptly upon Beneficiary's request, execute and record any
additional assignments of landlord's interest under any Lease to
Beneficiary and specific subordinations of any Lease to this
Deed of Trust, in form and substance satisfactory to
Beneficiary.

Unless consented to in writing by Beneficiary or otherwise permitted
under any other provision of the Loan Documents, Trustor shall not:

(v)     grant any tenant under any Lease any option, right of first
refusal or other right to purchase all or any portion of the
Property under any circumstances;

(vi)    grant any tenant under any Lease any right to prepay rent
more than 1 month in advance;

(vii)   except upon Beneficiary's request, execute any assignment of
landlord's interest in any Lease; or

(viii)  collect rent or other sums due under any Lease in advance,
other than to collect rent 1 month in advance of the time when
it becomes due.

Any such attempted action in violation of the provisions of this
Section shall be null and void.

Beneficiary's failure to deny any written request by Trustor for
consent under the foregoing provisions of this Section within
5 Business Days after Beneficiary's receipt of such request (and all
documents and information reasonably related thereto) shall be deemed
to constitute Beneficiary's consent to such request.

Trustor shall deposit with Beneficiary any sums received by Trustor
in consideration of any termination, modification or amendment of any
Lease or any release or discharge of any tenant under any Lease from
any obligation thereunder and any such sums received by Trustor shall
be held in trust by Trustor for such purpose. Notwithstanding the
foregoing, so long as no Default exists, the portion of any such sum
received by Trustor with respect to any Lease which is less than
$50,000 shall be payable to Trustor. All such sums received by
Beneficiary with respect to any Lease shall be deemed "Impounds" (as
defined in Section 6.12b) and shall be deposited by Beneficiary into
a pledged account in accordance with Section 6.12b. If no Default
exists, Beneficiary shall release such Impounds to Trustor from time
to time as necessary to pay or reimburse Trustor for such tenant
improvements, brokerage commissions and other leasing costs as may be
required to re-tenant the affected space; provided, however,
Beneficiary shall have received and approved each of the following
for each tenant for which such costs were incurred; (1) Trustor's
written request for such release, including the name of the tenant,
the location and net rentable area of the space and a description and
cost breakdown of the tenant improvements or other leasing costs
covered by the request; (2) Trustor's certification that any tenant
improvements have been completed lien-free and in a workmanlike
manner; (3) a fully executed Lease, or extension or renewal of the
current Lease; (4) an estoppel certificate executed by the tenant
including its acknowledgement that all tenant improvements have been
satisfactorily completed; and (5) such other information with respect
to such costs as Beneficiary may require. Following the re-tenanting
of all affected space (including, without limitation, the completion
of all tenant improvements), and provided no Default exists,
Beneficiary shall release any remaining such Impounds relating to the
affected space to Trustor. Trustor shall construct all tenant
improvements in a workmanlike manner and in accordance with all
applicable laws, ordinances, rules and regulations.

b.      Major Leases.  Trustor shall, at Trustor's sole cost and expense,
give Beneficiary prompt written notice of any material default by
landlord or tenant under any Major Lease (as defined below). Unless
consented to in writing by Beneficiary or otherwise permitted under
any other provision of the Loan Documents, Trustor shall not:

(i)     enter into any Major Lease which (aa) is not on fair market
terms (which terms may include free or discounted rent to the
extent the market so requires); (bb) does not contain a
provision requiring the tenant to execute and deliver to the
landlord an estoppel certificate in form and substance
satisfactory to the landlord promptly upon the landlord's
request; or (cc) allows the tenant to assign or sublet the
premises without the landlord's consent;

(ii)    reduce any rent or other sums due from the tenant under any
Major Lease;

(iii)   terminate or materially modify or amend any Major Lease; or

(iv)    release or discharge the tenant or any guarantor under any
Major Lease from any material obligation thereunder.

Any such attempted action in violation of the provisions of this
Section shall be null and void.

"Major Lease", as used herein, shall mean any Lease, which is, at any
time: (1) a Lease of more than 20% of the total rentable area of the
Property, as reasonably determined by Beneficiary; or (2) a Lease
which generates a gross base monthly rent exceeding 20% of the total
gross base monthly rent generated by all Leases (excluding all Leases
under which the tenant is then in default), as reasonably determined
by Beneficiary. Trustor's obligations with respect to Major Leases
shall be governed by the provisions of Section 3.4a as well as by the
provisions of this Section. Beneficiary's failure to deny any written
request by Trustor for consent under this Section within 5 Business
Days after Beneficiary's receipt of such request (and all documents
and information reasonably related thereto) such be deemed to
constitute Beneficiary's consent to such request.

3.5     ESTOPPEL CERTIFICATES.  Within 30 days after request by Beneficiary,
Trustor shall deliver to Beneficiary and to any party designated by
Beneficiary, estoppel certificates relating to the Leases executed by
Trustor and by each of the tenants, in form and substance acceptable to
Beneficiary; provided, however, if any tenant shall fail or refuse to so
execute and deliver any such estoppel certificate upon request, Trustor
shall use reasonable efforts to cause such tenant to execute and deliver
such estoppel certificate but such tenant's continued failure or refusal
to do so, despite Trustor's reasonable efforts,  shall not constitute a
default by Trustor under this Section.

3.6     RIGHT OF SUBORDINATION.  Beneficiary may at any time and from time to
time by specific written instrument intended for the purpose unilaterally
subordinate the lien of this Deed of Trust to any Lease, without joinder
or consent of, or notice to, Trustor, any tenant or any other person.
Notice is hereby given to each tenant under a Lease of such right to
subordinate. No subordination referred to in this Section shall constitute
a subordination to any lien or other encumbrance, whenever arising, or
improve the right of any junior lienholder.  Nothing herein shall be
construed as subordinating this Deed of Trust to any Lease.


ARTICLE 4.  SECURITY AGREEMENT AND FIXTURE FILING

4.1     SECURITY INTEREST.  Trustor grants and assigns to Beneficiary a security
interest to secure payment and performance of all of the Secured
Obligations, in all of the following described personal property in which
Trustor now or at any time hereafter has any interest ("Collateral"):

All goods, building and other materials, supplies, work in process,
equipment, machinery, fixtures, furniture, furnishings, signs and
other personal property, wherever situated, which are or are to be
incorporated into, used in connection with or appropriated for use
on the Property; all rents, issues, deposits and profits of the
Property (to the extent, if any, they are not subject to the
Absolute Assignment of Rents and Leases); all inventory, accounts,
cash receipts, deposit accounts, impounds, accounts receivable,
contract rights, general intangibles, chattel paper, instruments,
documents, notes, drafts, letters of credit, insurance policies,
insurance and condemnation awards and proceeds, any other rights to
the payment of money, trade names, trademarks and service marks
arising from or related to the Property or any business now or
hereafter conducted thereon by Trustor; all permits, consents,
approvals, licenses, authorizations and other rights granted by,
given by or obtained from, any governmental entity with respect to
the Property; all deposits or other security now or hereafter made
with or given to utility companies by Trustor with respect to the
Property; all advance payments of insurance premiums made by Trustor
with respect to the Property; all plans, drawings and specifications
relating to the Property; all loan funds held by Beneficiary,
whether or not disbursed; all funds deposited with Beneficiary
pursuant to any Loan Document, including, without limitation, all
"Restoration Funds" as defined herein; all reserves, deferred
payments, deposits, accounts, refunds, cost savings and payments of
any kind related to the Property or any portion thereof, including,
without limitation, all "Impounds" as defined herein; together with
all replacements and proceeds of, and additions and accessions to,
any of the foregoing, and all books, records and files relating to
any of the foregoing.

As to all of the above described personal property which is or which
hereafter becomes a "fixture" under applicable law, this Deed of Trust
constitutes a fixture filing under the California Uniform Commercial Code,
as amended or recodified from time to time ("UCC").

4.2     RIGHTS OF BENEFICIARY.  In addition to Beneficiary's rights as a
"Secured Party" under the UCC, Beneficiary may, but shall not be
obligated to, at any time without notice and at the expense of Trustor:
(a) give notice to any person of Beneficiary's rights hereunder and
enforce such rights at law or in equity; (b) insure, protect, defend and
preserve the Collateral or any rights or interests of Beneficiary
therein; (c) inspect the Collateral; and  (d) endorse, collect and
receive any right to payment of money owing to Trustor under or from the
Collateral.  Notwithstanding the above, in no event shall Beneficiary be
deemed to have accepted any property other than cash in satisfaction of
any obligation of Trustor to Beneficiary unless Beneficiary shall make an
express written election of said remedy under the UCC or other applicable
law.

4.3    ADDITIONAL RIGHTS OF BENEFICIARY UPON DEFAULT.  Upon the occurrence of a
Default hereunder, then in addition to all of Beneficiary's rights as a
"Secured Party" under the UCC or otherwise at law:

a.      Sale of Collateral.  Beneficiary may: (i) upon written notice,
require Trustor to assemble any or all of the Collateral and make it
available to Beneficiary at a place designated by Beneficiary;
(ii) without prior notice, enter upon the Property or other place
where any of the Collateral may be located and take possession of,
collect, sell and dispose of any or all of the Collateral, and store
the same at locations acceptable to Beneficiary at Trustor's
expense; or (iii) sell, assign and deliver at any place or in any
lawful manner all or any part of the Collateral and bid and become
purchaser at any such sales; and

b.      Other Rights.  Beneficiary may, for the account of Trustor and at
Trustor's expense: (i) operate, use, consume, sell or dispose of the
Collateral as Beneficiary deems appropriate for the purpose of
performing any or all of the Secured Obligations; (ii) enter into any
agreement, compromise or settlement including insurance claims, which
Beneficiary may deem desirable or proper with respect to any of the
Collateral; and (iii) endorse and deliver evidences of title for, and
receive, enforce and collect by legal action or otherwise, all
indebtedness and obligations now or hereafter owing to Trustor in
connection with or on account of any or all of the Collateral.

Trustor acknowledges and agrees that a disposition of the Collateral in
accordance with Beneficiary's rights and remedies as heretofore provided
is a disposition thereof in a commercially reasonable manner and that
5 days prior notice of such disposition is commercially reasonable notice.
 Trustor further agrees that any sale or other disposition of all or any
portion of the Collateral may be applied by Beneficiary first to the
reasonable expenses in connection therewith, including reasonable
attorneys' fees and disbursements, and then to the payment of the Secured
Obligations.

4.4     POWER OF ATTORNEY.  Trustor hereby irrevocably appoints Beneficiary as
Trustor's attorney-in-fact (such agency being coupled with an interest),
and as such attorney-in-fact, Beneficiary may, without the obligation to
do so, in Beneficiary's name or in the name of Trustor, prepare, execute,
file and record financing statements, continuation statements,
applications for registration and like papers necessary to create,
perfect or preserve any of Beneficiary's security interests and rights in
or to any of the Collateral, and upon a Default hereunder, take any other
action required of Trustor; provided, however, that Beneficiary as such
attorney-in-fact shall be accountable only for such funds as are actually
received by Beneficiary.


ARTICLE 5.  REPRESENTATIONS AND WARRANTIES

5.1     REPRESENTATIONS AND WARRANTIES.  Trustor represents and warrants to
Beneficiary that, to Trustor's current actual knowledge after reasonable
investigation and inquiry, the following statements are true and correct
as of the Effective Date:

a.      Legal Status.  Trustor and Borrower are duly organized and
existing and in good standing under the laws of the state(s) in
which Trustor and Borrower are organized.  Trustor and Borrower are
qualified or licensed to do business in all jurisdictions in which
such qualification or licensing is required.

b.      Permits.  Trustor and Borrower possess all permits, franchises and
licenses and all rights to all trademarks, trade names, patents and
fictitious names, if any, necessary to enable Trustor and Borrower to
conduct the business(es) in which Trustor and Borrower are now
engaged in compliance with applicable law.

c.      Authorization and Validity.  The execution and delivery of the Loan
Documents have been duly authorized and the Loan Documents constitute
valid and binding obligations of Trustor, Borrower or the party which
executed the same, enforceable in accordance with their respective
terms, except as such enforcement may be limited by bankruptcy,
insolvency, moratorium or other laws affecting the enforcement of
creditors' rights, or by the application of rules of equity.

d.      Violations.  The execution, delivery and performance by Trustor and
Borrower of each of the Loan Documents do not violate any provision
of any law or regulation, or result in any breach or default under
any contract, obligation, indenture or other instrument to which
Trustor or Borrower is a party or by which Trustor or Borrower is
bound.

e.      Litigation.  There are no pending or threatened actions, claims,
investigations, suits or proceedings before any governmental
authority, court or administrative agency which may adversely affect
the financial condition or operations of Trustor or Borrower other
than those previously disclosed in writing by Trustor or Borrower to
Beneficiary.

f.      Financial Statements.  The financial statements of Trustor and
Borrower, of each general partner (if Trustor or Borrower is a
partnership), of each member (if Trustor or Borrower is a limited
liability company) and of each guarantor, if any, previously
delivered by Trustor or Borrower to Beneficiary: (i) are materially
complete and correct; (ii) present fairly the financial condition of
such party; and (iii) have been prepared in accordance with the same
accounting standard used by Trustor or Borrower to prepare the
financial statements delivered to and approved by Beneficiary in
connection with the making of the Loan, or other accounting standards
approved by Beneficiary.  Since the date of such financial
statements, there has been no material adverse change in such
financial condition, nor have any assets or properties reflected on
such financial statements been sold, transferred, assigned,
mortgaged, pledged or encumbered except as previously disclosed in
writing by Trustor or Borrower to Beneficiary and approved in writing
by Beneficiary.

g.      Reports.  All reports, documents, instruments and information
delivered to Beneficiary in connection with the Loan: (i) are correct
and sufficiently complete to give Beneficiary accurate knowledge of
their subject matter; and (ii) do not contain any misrepresentation
of a material fact or omission of a material fact which omission
makes the provided information misleading.

h.      Income Taxes.  There are no pending assessments or adjustments of
Trustor's or Borrower's income tax payable with respect to any year.

i.      Subordination.  There is no agreement or instrument to which
Borrower is a party or by which Borrower is bound that would require
the subordination in right of payment of any of Borrower's
obligations under the Note to an obligation owed to another party.

j.      Title.  Trustor lawfully holds and possesses fee simple title to
the Property, without limitation on the right to encumber same. This
Deed of Trust is a first lien on the Property prior and superior to
all other liens and encumbrances on the Property except:  (i) liens
for real estate taxes and assessments not yet due and payable; (ii)
senior exceptions previously approved by Beneficiary and shown in the
title insurance policy insuring the lien of this Deed of Trust; and
(iii) other matters, if any, previously disclosed to Beneficiary by
Trustor in a writing specifically referring to this representation
and warranty.

k.      Mechanics' Liens.  There are no mechanics' or similar liens or
claims which have been filed for work, labor or material (and no
rights are outstanding that under law could give rise to any such
liens) affecting the Property which are or may be prior to or equal
to the lien of this Deed of Trust.

l.      Encroachments.  Except as shown in the survey, if any, previously
delivered to Beneficiary, none of the buildings or other improvements
which were included for the purpose of determining the appraised
value of the Property lies outside of the boundaries or building
restriction lines of the Property and no buildings or other
improvements located on adjoining properties encroach upon the
Property.

m.      Leases.  All existing Leases are in full force and effect and are
enforceable in accordance with their respective terms. No material
breach or default by any party, or event which would constitute a
material breach or default by any party after notice or the passage
of time, or both, exists under any existing Lease. None of the
landlord's interests under any of the Leases, including, but not
limited to, rents, additional rents, charges, issues or profits, has
been transferred or assigned.  No rent or other payment under any
existing Lease has been paid by any tenant for more than 1 month in
advance.

n.      Collateral.  Trustor has good title to the existing Collateral,
free and clear of all liens and encumbrances except those, if any,
previously disclosed to Beneficiary by Trustor in writing
specifically referring to this representation and warranty. Trustor's
principal place of business is located at the address shown in this
Deed of Trust.

o.      Condition of Property.  Except as shown in the property condition
survey or other engineering reports, if any, previously delivered to
or obtained by Beneficiary, the Property is in good condition and
repair and is free from any damage that would materially and
adversely affect the value of the Property as security for the Loan
or the intended use of the Property.

p.      Hazardous Materials.  Except as shown in the environmental
assessment report(s), if any, previously delivered to or obtained by
Beneficiary, the Property is not and has not been a site for the use,
generation, manufacture, storage, treatment, release, threatened
release, discharge, disposal, transportation or presence of
Hazardous Materials  (as hereinafter defined) except as otherwise
previously disclosed in writing by Trustor to Beneficiary.

q.      Hazardous Materials Laws.  The Property complies with all Hazardous
Materials Laws  (as hereinafter defined).

r.      Hazardous Materials Claims.  There are no pending or threatened
Hazardous Materials Claims (as hereinafter defined).

s.      Wetlands.  No part of the Property consists of or is classified as
wetlands, tidelands or swamp and overflow lands.

t.      Compliance With Laws.  All federal, state and local laws, rules and
regulations applicable to the Property, including, without
limitation, all zoning and building requirements  and all
requirements of the Americans With Disabilities Act of 1990, as
amended from time to time (42 U. S. C. Section 12101 et seq.) have
been satisfied or complied with.  Trustor is in possession of all
certificates of occupancy and all other licenses, permits and other
authorizations required by applicable law for the existing use of the
Property.  All such certificates of occupancy and other  licenses,
permits and authorizations are valid and in full force and effect.

u.      Property Taxes and Other Liabilities.  All taxes, governmental
assessments, insurance premiums, water, sewer and municipal charges,
and ground rents, if any, which previously became due and owing in
respect of the Property have been paid.

v.      Condemnation.  There is no proceeding pending or threatened for the
total or partial condemnation of the Property.

w.      Homestead.  There is no homestead or other exemption available to
Trustor which would materially interfere with the right to sell the
Property at a trustee's sale or the right to foreclose this Deed of
Trust.

x.      Solvency.  None of the transactions contemplated by the Loan will
be or have been made with an actual intent to hinder, delay or
defraud any present or future creditors of Trustor, and Trustor, on
the Effective Date, will have received fair and reasonably
equivalent value in good faith for the grant of the liens or
security interests effected by the Loan Documents.  On the Effective
Date, Trustor will be solvent and will not be rendered insolvent by
the transactions contemplated by the Loan Documents. Trustor is able
to pay its debts as they become due.

y.      Separate Tax Parcel(s). The Property is assessed for the real
estate tax purposes as one or more wholly independent tax parcels,
separate from any other real property, and no other real property is
assessed and taxed together with the Property or any portion
thereof.

5.2    REPRESENTATIONS, WARRANTIES AND COVENANTS REGARDING STATUS. Trustor and
FREMONT MANAGEMENT, INC., a Delaware corporation hereby represent,
warrant and covenant to Beneficiary as follows:

a.      each such entity was organized solely for the purpose of (i)
owning the Property; (ii) acting as a general partner of a
partnership which owns the Property; or (iii) acting as a managing
member of a limited liability company which owns the Property;

b.      each such entity has not and will not engage in any business
unrelated to (i) the ownership of the Property; (ii) acting as
general partner of a partnership which owns the Property; or (iii)
acting as a managing member of a limited liability company which
owns the Property;

c.      each such entity has not and will not have any assets other than
the Property (and personal property incidental to the ownership and
operation of the Property) or its partnership or membership interest
in the partnership or limited liability company which owns the
Property;

d.      each such entity has not and will not engage in, seek or consent
to any dissolution, winding up, liquidation, consolidation, merger,
asset sale, transfer of partnership or membership interest, or
amendment of its articles of incorporation, articles of
organization, certificate of formation, partnership agreement or
operating agreement, as applicable;

e.      if such entity is a partnership, all of its general partners are
corporations that satisfy the requirements set forth in this
Section 5.2;

f.      if such entity is a limited liability company, it has at least one
managing member that is a corporation that satisfies the
requirements set forth in this Section 5.2;

g.      each such entity, without the unanimous consent of all of its
general partners, directors or members, as applicable, shall not
file a bankruptcy or insolvency petition or otherwise institute
insolvency proceedings with respect to itself or any other entity in
which it has a direct or indirect legal or beneficial ownership
interest;

h.      each such entity has no indebtedness (and will have no
indebtedness) other than (i) the Loan (to the extent it is liable
under the terms of the Loan Documents); and (ii) unsecured trade
debt which is not evidenced by a note and is incurred in the
ordinary course of its business in connection with owning, operating
and maintaining the Property (or its interest in Trustor, as
applicable) and is paid within 30 days from the date incurred;

i.      each such entity has not and will not fail to correct any known
misunderstanding regarding the separate identity of such entity;

j.      each such entity has maintained and will maintain its accounts,
books and records separate from any other person or entity;

k.      each such entity has maintained and will maintain its books,
records, resolutions and agreements as official records;

l.      each such entity (i) has not and will not commingle its funds or
assets with those of any other entity; and (ii) has held and will
hold its assets in its own name;

m.      each such entity has conducted and will conduct its business in
its own name;

n.      each such entity has maintained and will maintain its financial
statements, accounting records and other entity documents separate
from any other person or entity;

o.      each such entity has paid and will pay its own liabilities out of
its own funds and assets;

p.      each such entity has observed and will observe all partnership,
corporate or limited liability company formalities, as applicable;

q.      each such entity has not and will not assume or guarantee or
become obligated for the debts of any other entity or hold out its
credit as being available to satisfy the obligations of any other
entity except for liabilities permitted to be guaranteed by the Loan
Documents;

r.      each such entity has not and will not acquire obligations or
securities of its partners, members or shareholders;

s.      each such entity has allocated and will allocate fairly and
reasonably any overhead for shared office space and uses separate
stationery, invoices and checks;

t.      each such entity has not and will not pledge its assets for the
benefit of any other person or entity;

u.      each such entity has held and identified itself and will hold
itself out and identify itself as a separate and distinct entity
under its own name and not as a division or part of any other person
or entity;

v.      each such entity has not made and will not make loans to any
person or entity;

w.      each such entity has not and will not identify its partners,
members or shareholders, as applicable, or any affiliates of any of
the foregoing, as a division or part of it;

x.      each such entity has not entered into and will not enter into or
be a party to, any transaction with its partners, members,
shareholders, or any affiliates of any of the foregoing, except in
the ordinary course of its business and on terms which are
intrinsically fair and are no less favorable to it than would be
obtained in a comparable arm's-length transaction with an unrelated
third party;

y.      if such entity is a corporation, the directors of the corporation
shall consider the interests of the creditors of the corporation in
connection with all corporate action;

z.      each such entity has paid and will pay the salaries of its own
employees and has maintained and will maintain a sufficient number
of employees in light of its contemplated business operations;

aa.     each such entity has maintained and will maintain adequate capital
in light of its contemplated business operations;

bb.     if such entity is a limited liability company (i) its articles of
organization, certificate of formation and/or operating agreement,
as applicable, provide that the vote of a majority-in-interest of
the remaining members is sufficient to continue the life of the
limited liability company in the event of a termination event, such
as a bankruptcy of the managing member; and (ii) if the vote of a
majority-in-interest of the remaining members is not obtained to
continue the life of the limited liability company upon a
termination event, its articles of organization, certificate of
formation and/or operating agreement, as applicable, provide that
the limited liability company may not liquidate its assets without
the consent of the Beneficiary;

cc.     if such entity is a partnership with more than one general
partner, its partnership agreement requires the remaining partners
to continue the partnership as long as one solvent general partner
exists; and

dd.     if such entity is a limited liability company, its operating
agreement, if such entity is a partnership, its partnership
agreement, and if such entity is a corporation, to the full extent
permitted by applicable law, its articles of incorporation, contain
the provisions set forth in this Section 5.2 and such entity shall
conduct its business and operations in strict compliance with the
terms contained therein.


ARTICLE 6.  RIGHTS AND DUTIES OF THE PARTIES

6.1     MAINTENANCE AND PRESERVATION OF THE PROPERTY.  Trustor shall:  (a) keep
the Property in good condition and repair; (b) complete or restore
promptly and in workmanlike manner the Property or any part thereof which
may be damaged or destroyed (unless, if and to the extent permitted under
Section 6.11, Beneficiary elects to require that insurance proceeds be
used to reduce the Secured Obligations and after such repayment the ratio
of Secured Obligations to the value of the Property, as reasonably
determined by Beneficiary is the same as or lower than it was immediately
before the loss or taking occurred); (c) comply and cause the Property to
comply with (i) all laws, ordinances, regulations and standards, (ii) all
covenants, conditions, restrictions and equitable servitudes, whether
public or private, of every kind and character and (iii) all requirements
of insurance companies and any bureau or agency which establishes
standards of insurability, which laws, covenants or requirements affect
the Property and pertain to acts committed or conditions existing
thereon, including, without limitation, any work of alteration,
improvement or demolition as such laws, covenants or requirements
mandate; (d) operate and manage the Property at all times in a
professional manner and do all other acts which from the character or use
of the Property may be reasonably necessary to maintain and preserve its
value; (e) promptly after execution, deliver to Beneficiary a copy of any
management agreement concerning the Property and all amendments thereto
and waivers thereof; and (f) execute and acknowledge all further
documents, instruments and other papers as Beneficiary or Trustee deems
necessary or appropriate to preserve, continue, perfect and enjoy the
benefits of this Deed of Trust and perform Trustor's obligations,
including, without limitation, statements of the amount secured hereby
then owing and statements of no offset.  Trustor shall not: (g) remove or
demolish all or any material part of the Property; (h) alter either (i)
the exterior of the Property in a manner which materially and adversely
affects the value of the Property or (ii) the roof or other structural
elements of the Property in a manner which requires a building permit
except for tenant improvements required under the Leases; (i) initiate or
acquiesce in any change in any zoning or other land classification which
affects the Property; (j) materially alter the type of occupancy or use
of all or any part of the Property; or (k) commit or permit waste of the
Property.

6.2     HAZARDOUS MATERIALS.  Without limiting any other provision of this Deed
of Trust, Trustor agrees as follows:

a.      Prohibited Activities.  Trustor shall not cause or permit the
Property to be used as a site for the use, generation, manufacture,
storage, treatment, release, discharge, disposal, transportation or
presence of any oil or other petroleum products, flammable
explosives, asbestos, urea formaldehyde insulation, radioactive
materials, hazardous wastes, toxic or contaminated substances or
similar materials, including, without limitation, any substances
which are "hazardous substances," "hazardous wastes," "hazardous
materials" or "toxic substances" under the Hazardous Materials Laws
(defined below) and/or other applicable environmental laws,
ordinances or regulations ("Hazardous Materials").

The foregoing to the contrary notwithstanding, (i) Trustor may store,
maintain and use on the Property janitorial and maintenance supplies,
paint and other Hazardous Materials of a type and in a quantity
readily available for purchase by the general public and normally
stored, maintained and used by owners and managers of properties of a
type similar to the Property; and (ii) tenants of the Property may
store, maintain and use on the Property (and, if any tenant is a
retail business, hold in inventory and sell in the ordinary course of
such tenant's business) Hazardous Materials of a type and quantity
readily available for purchase by the general public and normally
stored, maintained and used (and, if tenant is a retail business,
sold) by tenants in similar lines of business on properties similar
to the Property; and (iii) tenants of the Property may store,
maintain and use on the Property Hazardous Materials of types and
quantities necessary or appropriate for carrying out their
biotechnology business operations so long as all such storage,
maintenance and use of Hazardous Material is carried on in compliance
with all applicable Hazards Materials Laws.

b.      Hazardous Materials Laws.  Trustor shall comply and cause the
Property to comply with all federal, state and local laws,
ordinances and regulations relating to Hazardous Materials
("Hazardous Materials Laws"), including, without limitation:  the
Clean Air Act, as amended, 42 U.S.C. Section 7401 et seq.; the
Federal Water Pollution Control Act, as amended, 33 U.S.C. Section
1251 et seq.; the Resource Conservation and Recovery Act of 1976, as
amended, 42 U.S.C. Section 6901 et seq.; the Comprehensive
Environmental Response, Compensation and Liability Act of 1980, as
amended (including the Superfund Amendments and Reauthorization Act
of 1986, "CERCLA"), 42 U.S.C. Section 9601 et seq.; the Toxic
Substances Control Act, as amended, 15 U.S.C. Section 2601 et seq.;
the Occupational Safety and Health Act, as amended, 29 U.S.C.
Section 651; the Emergency Planning and Community Right-to-Know Act
of 1986, 42 U.S.C. Section 11001 et seq.; the Mine Safety and Health
Act of 1977, as amended, 30 U.S.C. Section 801 et seq.; the Safe
Drinking Water Act, 42 U.S.C. Section 300f et seq.;  and all
comparable state and local laws, laws of other jurisdictions or
orders and regulations.

c.      Notices.  Trustor shall immediately notify Beneficiary in writing
of:  (i) the discovery of any Hazardous Materials on, under or about
the Property (other than Hazardous Materials permitted under
Section 6.2(a)); (ii) any knowledge by Trustor that the Property does
not comply with any Hazardous Materials Laws; (iii) any claims or
actions ("Hazardous Materials Claims") pending or threatened against
Trustor or the Property by any governmental entity or agency or any
other person or entity relating to Hazardous Materials or pursuant to
the Hazardous Materials Laws; and (iv) the discovery of any
occurrence or condition on any real property adjoining or in the
vicinity of the Property that could cause the Property or any part
thereof to become contaminated with Hazardous Materials.

d.      Remedial Action.  In response to the presence of any Hazardous
Materials on, under or about the Property, Trustor shall immediately
take, at Trustor's sole expense, all remedial action required by any
Hazardous Materials Laws or any judgment, consent decree, settlement
or compromise in respect to any Hazardous Materials Claims.

e.      Inspection By Beneficiary.  Upon reasonable prior notice to
Trustor, Beneficiary, its employees and agents, may from time to time
(whether before or after the commencement of a nonjudicial or
judicial foreclosure proceeding), enter and inspect the Property for
the purpose of determining the existence, location, nature and
magnitude of any past or present release or threatened release of any
Hazardous Materials into, onto, beneath or from the Property.

f.      Legal Effect of Section.  Trustor and Beneficiary agree that:  (i)
this Hazardous Materials Section is intended as Beneficiary's written
request for information (and Trustor's response) concerning the
environmental condition of the real property security as required by
California Code of Civil Procedure Section 726.5; and (ii) each
representation and warranty and covenant in this Section (together
with any indemnity applicable to a breach of any such representation
and warranty) with respect to the environmental condition of the
Property is intended by Beneficiary and Trustor to be an
"environmental provision" for purposes of California Code of Civil
Procedure Section 736.

6.3     COMPLIANCE WITH LAWS.  Trustor shall comply with all federal, state and
local laws, rules and regulations applicable to the Property, including,
without limitation, all zoning and building requirements and all
requirements of the Americans With Disabilities Act of 1990 (42 U.S.C.
Section 12101 et seq.), as amended from time to time. Trustor shall
possess and maintain or cause Borrower to possess and maintain in full
force and effect at all times (a) all certificates of occupancy and other
licenses, permits and authorizations required by applicable law for the
existing use of the Property and (b) all permits, franchises and licenses
and all rights to all trademarks, trade names, patents and fictitious
names, if any, required by applicable law for Trustor and Borrower to
conduct the business(es) in which Trustor and Borrower are now engaged.

6.4    LITIGATION.  Trustor shall promptly notify Beneficiary in writing of any
litigation pending or threatened against Trustor or Borrower claiming
damages in excess of $50,000 and of all pending or threatened litigation
against Trustor or Borrower if the aggregate damage claims against Trustor
or Borrower exceed $100,000.

6.5   MERGER, CONSOLIDATION, TRANSFER OF ASSETS.  Trustor shall not:  (a) merge
or consolidate with any other entity or permit Borrower to merge or
consolidate with any other entity; (b) make any substantial change in the
nature of Trustor's business or structure or permit Borrower to make any
substantial change in the nature of Borrower's business or structure; (c)
acquire all or substantially all of the assets of any other entity or
permit Borrower to acquire all or substantially all of the assets of any
other entity; or (d) sell, lease, assign, transfer or otherwise dispose of
a material part of Trustor's assets except in the ordinary course of
Trustor's business or permit Borrower to sell, lease, assign, transfer or
otherwise dispose of a material part of Borrower's assets except in the
ordinary course of Borrower's business.

6.6     ACCOUNTING RECORDS.  Trustor shall maintain and cause Borrower to
maintain adequate books and records in accordance with the same accounting
standard used by Trustor or Borrower to prepare the financial statements
delivered to and approved by Beneficiary in connection with the making of
the Loan or other accounting standards approved by Beneficiary.  Trustor
shall permit and shall cause Borrower to permit any representative of
Beneficiary, at any reasonable time and from time to time, to inspect,
audit and examine such books and records and make copies of same.

6.7     COSTS, EXPENSES AND ATTORNEYS' FEES.  Trustor shall pay to Beneficiary
the full amount of all costs and expenses, including, without limitation,
reasonable attorneys' fees and expenses of Beneficiary's in-house or
outside counsel, incurred by Beneficiary in connection with: (a)
appraisals and inspections of the Property or Collateral required by
Beneficiary as a result of (i) a Transfer or proposed Transfer (as defined
below), or (ii) a Default; (b) appraisals and inspections of the Property
or Collateral required by applicable law, including, without limitation,
federal or state regulatory reporting requirements; and (c) any acts
performed by Beneficiary at Trustor's request or wholly or partially for
the benefit of Trustor (including, without limitation, the preparation or
review of amendments, assumptions, waivers, releases, reconveyances,
estoppel certificates or statements of amounts owing under any Secured
Obligation).  In connection with appraisals and inspections, Trustor
specifically (but not by way of limitation) acknowledges that:  (aa) a
formal written appraisal of the Property by a state certified or licensed
appraiser may be required by federal regulatory reporting requirements on
an annual or more frequent basis; and (bb) Beneficiary may require
inspection of the Property by an independent supervising architect, a cost
engineering specialist, or both.  Trustor shall pay all indebtedness
arising under this Section immediately upon demand by Beneficiary together
with interest thereon following notice of such indebtedness at the rate of
interest then applicable to the principal balance of the Note as specified
therein.

6.8     LIENS, ENCUMBRANCES AND CHARGES.  Trustor shall immediately discharge by
bonding or otherwise any lien, charge or other encumbrance which attaches
to the Property in violation of Section 6.15. Subject to Trustor's right
to contest such matters under this Deed of Trust or as expressly permitted
in the Loan Documents, Trustor shall pay when due all obligations secured
by or reducible to liens and encumbrances which shall now or hereafter
encumber or appear to encumber all or any part of the Property or any
interest therein, whether senior or subordinate hereto, including, without
limitation, all claims for work or labor performed, or materials or
supplies furnished, in connection with any work of demolition, alteration,
repair, improvement or construction of or upon the Property, except such
as Trustor may in good faith contest or as to which a bona fide dispute
may arise (provided provision is made to the satisfaction of Beneficiary
for eventual payment thereof in the event that Trustor is obligated to
make such payment and that any recorded claim of lien, charge or other
encumbrance against the Property is immediately discharged by bonding or
otherwise).

6.9     TAXES AND OTHER LIABILITIES.  Trustor shall pay and discharge when due
any and all indebtedness, obligations, assessments and taxes, both real
and personal and including federal and state income taxes and state and
local property taxes and assessments.  Trustor shall promptly provide to
Beneficiary copies of all tax and assessment notices pertaining to the
Property.  Trustor hereby authorizes Beneficiary to obtain, at Trustor's
expense, a tax service contract which shall provide tax information on the
Property to Beneficiary for the term of the Loan and any extensions or
renewals of the Loan.

6.10    INSURANCE COVERAGE.  Trustor shall insure the Property against loss or
damage by fire and such other hazards as Beneficiary shall from time to
time require; provided, however, (a) Beneficiary, at Beneficiary's
election, may only require flood insurance if all or any portion of the
improvements located on the Property is or becomes located in a special
flood hazard area, and (b) Beneficiary, at Beneficiary's election, may
only require earthquake insurance if all or any portion of the Property is
or becomes located in an earthquake fault zone.  Trustor shall also carry
public liability insurance and such other insurance as Beneficiary may
require, including, without limitation, business interruption insurance or
loss of rents insurance.  Such policies shall contain a standard mortgage
clause naming Beneficiary and its successors in interest as a loss payee
and requiring at least 30 days prior notice to the holder at termination
or cancellation. Trustor shall maintain all required insurance throughout
the term of the Loan and while any liabilities of Borrower or Trustor to
Beneficiary under any of the Loan Documents remain outstanding at
Trustor's expense, with companies, and in substance and form satisfactory
to Beneficiary.  Neither Beneficiary nor Trustee, by reason of accepting,
rejecting, approving or obtaining insurance shall incur any liability for:
(c) the existence, nonexistence, form or legal sufficiency of any
insurance; (d) the solvency of any insurer; or (e) the payment of claims.

6.11    INSURANCE AND CONDEMNATION PROCEEDS.

a.      Assignment of Claims.  Trustor absolutely and irrevocably assigns
to Beneficiary all of the following rights, claims and amounts
(collectively, "Claims"), all of which shall be paid to Beneficiary:
(i) all awards of damages and all other compensation payable
directly or indirectly by reason of a condemnation or proposed
condemnation for public or private use affecting all or any part of,
or any interest in, the Property; (ii) all other claims and awards
for damages to or decrease in value of all or any part of, or any
interest in, the Property; (iii) all proceeds of any insurance
policies payable by reason of loss sustained to all or any part of
the Property; and (iv) all interest which may accrue on any of the
foregoing.  Trustor shall give Beneficiary prompt written notice of
the occurrence of any casualty affecting, or the institution of any
proceedings for eminent domain or for the condemnation of, the
Property or any portion thereof.  So long as no Default has occurred
and is continuing at the time, Trustor shall have the right to
adjust, compromise and settle any Claim of $100,000 or less without
the consent of Beneficiary, provided, however, all awards, proceeds
and other sums described herein shall continue to be payable to
Beneficiary.  Beneficiary may commence, appear in, defend or
prosecute any Claim exceeding $100,000, and may adjust, compromise
and settle all Claims (except for Claims which Trustor may settle as
provided herein), but shall not be responsible for any failure to
commence, appear in, defend, prosecute or collect any such Claim
regardless of the cause of the failure.  All awards, proceeds and
other sums described herein shall be payable to Beneficiary.

b.      Application of Proceeds; No Default.  So long as no Default has
occurred and is continuing at the time of Beneficiary's receipt of
the proceeds of the Claims ("Proceeds") and no Default occurs
thereafter, Beneficiary shall apply the Proceeds in the following
order of priority: First, to Beneficiary's expenses in settling,
prosecuting or defending the Claims; Second, to the repair or
restoration of the Property; and Third, to Trustor if the repair or
restoration of the Property has been completed, but to the Secured
Obligations in any order without suspending, extending or reducing
any obligation of Trustor to make installment payments if the repair
or restoration of the Property has not been completed.
Notwithstanding the foregoing, Beneficiary shall have no obligation
to make any Proceeds available for the repair or restoration of the
Property unless and until all the following conditions have been
satisfied: (i) delivery to Beneficiary of the Proceeds plus any
additional amount which is needed to pay all costs of the repair or
restoration (including, without limitation, taxes, financing charges,
insurance and rent during the repair period); (ii) establishment of
an arrangement for lien releases and disbursement of funds acceptable
to Beneficiary; (iii) delivery to Beneficiary in form and content
acceptable to Beneficiary of all of the following: (aa) plans and
specifications for the work; (bb) a contract for the work, signed by
a contractor acceptable to Beneficiary; (cc) a cost breakdown for the
work; (dd) if required by Beneficiary, a payment and performance bond
for the work; (ee) evidence of the continuation of all Leases unless
consented to in writing by Beneficiary; (ff) evidence that, upon
completion of the work, the size, capacity, value, and income
coverage ratios for the Property will be at least as great as those
which existed immediately before the damage or condemnation occurred;
and (gg) evidence of the satisfaction of any additional conditions
that Beneficiary may reasonably establish to protect Beneficiary's
security.  Trustor acknowledges that the specific conditions
described above are reasonable.

c.      Application of Proceeds; Default.  If a Default has occurred and is
continuing at the time of Beneficiary's receipt of the Proceeds or if
a Default occurs at any time thereafter, Beneficiary may, at
Beneficiary's absolute discretion and regardless of any impairment of
security or lack of impairment of security, but subject to applicable
law governing use of the Proceeds, if any, apply all or any of the
Proceeds to Beneficiary's expenses in settling, prosecuting or
defending the Claims and then apply the balance to the Secured
Obligations in any order without suspending, extending or reducing
any obligation of Trustor to make installment payments, and may
release all or any part of the Proceeds to Trustor upon any
conditions Beneficiary chooses.

6.12    IMPOUNDS.

a.      Post-Default Impounds.  If required by Beneficiary at any time
after a Default occurs (and regardless of whether such Default is
thereafter cured), Trustor shall deposit with Beneficiary such
amounts ("Post-Default Impounds") on such dates (determined by
Beneficiary as provided below) as will be sufficient to pay any or
all "Costs" (as defined below) specified by Beneficiary.  Beneficiary
in its sole discretion shall estimate the amount of such Costs that
will be payable or required during any period selected by Beneficiary
not exceeding 1 year and shall determine the fractional portion
thereof that Trustor shall deposit with Beneficiary on each date
specified by Beneficiary during such period.  If the Post-Default
Impounds paid by Trustor are not sufficient to pay the related Costs,
Trustor shall deposit with Beneficiary upon demand an amount equal to
the deficiency.  All Post-Default Impounds shall be payable by
Trustor in addition to (but without duplication of) any other
Impounds (as defined below).

b.      All Impounds.  Post-Default Impounds and any other impounds that
may be payable by Borrower under the Note are collectively called
"Impounds".  All Impounds shall be deposited into one or more
segregated or commingled accounts maintained by Beneficiary or its
servicing agent. Except as otherwise provided in the Note, such
account(s) shall not bear interest.  Beneficiary shall not be a
trustee, special depository or other fiduciary for Trustor with
respect to such account, and the existence of such account shall not
limit Beneficiary's rights under this Deed of Trust, any other
agreement or any provision of law.  If no Default exists, Beneficiary
shall apply all Impounds to the payment of the related Costs, or in
Beneficiary's sole discretion may release any or all Impounds to
Trustor for application to and payment of such Costs.  If a Default
exists, Beneficiary may apply any or all Impounds to any Secured
Obligation and/or to cure such Default, whereupon Trustor shall
restore all Impounds so applied and cure all Defaults not cured by
such application.  The obligations of Trustor hereunder shall not be
diminished by deposits of Impounds made by Trustor, except to the
extent that such obligations have actually been met by application of
such Impounds.  Upon any assignment of this Deed of Trust,
Beneficiary may assign all Impounds in its possession to
Beneficiary's assignee, whereupon Beneficiary and Trustee shall be
released from all liability with respect to such Impounds.  Within
60 days following full repayment of the Secured Obligations (other
than as a consequence of foreclosure or conveyance in lieu of
foreclosure) or at such earlier time as Beneficiary may elect,
Beneficiary shall pay to Trustor all Impounds in its possession, and
no other party shall have any right or claim thereto.  "Costs" means
(i) all taxes and other liabilities payable by Trustor under Section
6.9, (ii) all insurance premiums payable by Trustor under Section
6.10, (iii) all other costs and expenses for which Impounds are
required under the Note, and/or (iv) all other amounts that will be
required to preserve the value of the Property. Trustor shall deliver
to Beneficiary, promptly upon receipt, all bills for Costs for which
Beneficiary has required Post-Default Impounds.

6.13  DEFENSE AND NOTICE OF LOSSES, CLAIMS AND ACTIONS.  Trustor shall protect,
preserve and defend the Property and title to and right of possession of
the Property, the security of this Deed of Trust and the rights and powers
of Beneficiary and Trustee hereunder at Trustor's sole expense against all
adverse claims, whether the claim: (a) is against a possessory or non-
possessory interest; (b) arose prior or subsequent to the Effective Date;
or (c) is senior or junior to Trustor's or Beneficiary's rights.  Trustor
shall give Beneficiary and Trustee prompt notice in writing of the
assertion of any claim, of the filing of any action or proceeding, of the
occurrence of any damage to the Property and of any condemnation offer or
action.

6.14  RIGHT OF INSPECTION.  Beneficiary and its independent contractors, agents
and employees may enter the Property from time to time at any reasonable
time for the purpose of inspecting the Property and ascertaining Trustor's
compliance with the terms of this Deed of Trust.  Beneficiary shall use
reasonable efforts to assure that Beneficiary's entry upon and inspection
of the Property shall not materially and unreasonably interfere with the
business or operations of Trustor or Trustor's tenants on the Property.

6.15    PROHIBITION OF TRANSFER OF PROPERTY OR INTERESTS IN TRUSTOR.  Trustor
acknowledges that Beneficiary has relied upon the principals of Trustor
and Borrower and their experience in owning and operating properties
similar to the Property in connection with the closing of the Loan.
Accordingly, except with the prior written consent of Beneficiary or as
otherwise expressly permitted in the Note, Trustor shall not cause or
permit any sale, exchange, mortgage, pledge, hypothecation, assignment,
encumbrance or other transfer, conveyance or disposition, whether
voluntarily, involuntarily or by operation of law ("Transfer") of all or
any part of, or all or any direct or indirect interest in, the Property or
the Collateral (except for equipment and inventory in the ordinary course
of its business), or cause or permit a Transfer of any direct or indirect
interest (whether general or limited partnership interest, stock, limited
liability company interest, trust, or otherwise) in Trustor or Borrower.
In the event of any Transfer that is not expressly permitted in the Note
and is without the prior written consent of Beneficiary, Beneficiary shall
have the absolute right at its option, without prior demand or notice, to
declare all of the Secured Obligations immediately due and payable, except
to the extent prohibited by law, and pursue its rights and remedies under
Section 7.3 herein.  Trustor agrees to pay any prepayment fee as set forth
in the Note in the event the Secured Obligations are accelerated pursuant
to the terms of this Section.  Consent to one such Transfer shall not be
deemed to be a waiver of the right to require the consent to future or
successive Transfers.

6.16   ACCEPTANCE OF TRUST; POWERS AND DUTIES OF TRUSTEE.  Trustee accepts this
trust when this Deed of Trust is recorded.  From time to time upon written
request of Beneficiary and presentation of this Deed of Trust, or a
certified copy thereof, for endorsement, and without affecting the
personal liability of any person for payment of any indebtedness or
performance of any Secured Obligation, Trustee may, without liability
therefor and without notice:  (a) reconvey all or any part of the
Property; (b) consent to the making of any map or plat of the Property;
(c) join in granting any easement on the Property; (d) join in any
declaration of covenants and restrictions; or (e) join in any extension
agreement or any agreement subordinating the lien or charge of this Deed
of Trust. Notwithstanding the foregoing, Beneficiary shall first obtain
from Trustor, subject to no Default, their consent to subparagraphs (b),
(c), and (d), and such consent shall not be unreasonably withheld.
Nothing contained in the preceding sentences shall be construed to limit,
impair or otherwise affect the rights of Trustor in any respect.  Except
as may otherwise be required by applicable law, Trustee or Beneficiary may
from time to time apply to any court of competent jurisdiction for aid and
direction in the execution of the trusts hereunder and the enforcement of
the rights and remedies available hereunder, and Trustee or Beneficiary
may obtain orders or decrees directing or confirming or approving acts in
the execution of said trusts and the enforcement of said remedies.
Trustee has no obligation to notify any party of any pending sale or any
action or proceeding (including, without limitation, actions in which
Trustor, Beneficiary or Trustee shall be a party) unless held or commenced
and maintained by Trustee under this Deed of Trust.  Trustee shall not be
obligated to perform any act required of it hereunder unless the
performance of the act is requested in writing and Trustee is reasonably
indemnified and held harmless against loss, cost, liability and expense.

6.17    COMPENSATION OF TRUSTEE.  Trustor shall pay to Trustee reasonable
compensation and reimbursement for services and expenses in the
administration of this trust, including, without limitation, reasonable
attorneys' fees. Trustor shall pay all indebtedness arising under this
Section immediately upon demand by Trustee or Beneficiary together with
interest thereon from the date the indebtedness arises at the rate of
interest then applicable to the principal balance of the Note as specified
therein.

6.18    EXCULPATION.  Beneficiary shall not directly or indirectly be liable to
Trustor or any other person as a consequence of: (a) the lawful exercise
of the rights, remedies or powers granted to Beneficiary in this Deed of
Trust; (b) the failure or refusal of Beneficiary to perform or discharge
any obligation or liability of Trustor under any agreement related to the
Property or under this Deed of Trust; or (c) any loss sustained by Trustor
or any third party resulting from Beneficiary's failure to lease the
Property after a Default (hereafter defined) or from any other act or
omission of Beneficiary in managing the Property after a Default unless
the loss is caused by the willful misconduct and bad faith of Beneficiary
and no such liability shall be asserted or enforced against Beneficiary,
all such liability being expressly waived and released by Trustor.

6.19   INDEMNITY.  Without in any way limiting any other indemnity contained in
this Deed of Trust, Trustor agrees to defend, indemnify and hold harmless
Trustee and the Beneficiary Group from and against any claim, loss,
damage, cost, expense or liability directly or indirectly arising out of:
(a) the making of the Loan, except for violations of banking laws or
regulations by the Beneficiary Group; (b) this Deed of Trust; (c) the exe-
cution of this trust or the performance of any act required or permitted
hereunder or by law; (d) any failure of Trustor to perform Trustor's
obligations under this Deed of Trust or the other Loan Documents; (e) any
alleged obligation or undertaking on the Beneficiary Group's part to
perform or discharge any of the representations, warranties, conditions,
covenants or other obligations contained in any other document related to
the Property; (f) any act or omission by Trustor or any contractor, agent,
employee or representative of Trustor with respect to the Property; or (g)
any claim, loss, damage, cost, expense or liability directly or indirectly
arising out of: (i) the use, generation, manufacture, storage, treatment,
release, threatened release, discharge, disposal, transportation or
presence of any Hazardous Materials which are found in, on, under or about
the Property (including, without limitation, underground contamination);
or (ii) the breach of any covenant, representation or warranty of Trustor
under Section 6.2 above.  The foregoing to the contrary notwithstanding,
this indemnity shall not include any claim, loss, damage, cost, expense or
liability directly or indirectly arising out of the gross negligence or
willful misconduct of any member of the Beneficiary Group or Trustee, or
any claim, loss, damage, cost, expense or liability incurred by the
Beneficiary Group or Trustee arising from any act or incident on the
Property occurring after the full reconveyance and release of the lien of
this Deed of Trust on the Property, or with respect to the matters set
forth in clause (g) above, any claim, loss, damage, cost, expense or
liability incurred by the Beneficiary Group resulting from the
introduction and initial release of Hazardous Materials on the Property
occurring after the transfer of title to the Property at a foreclosure
sale under this Deed of Trust, either pursuant to judicial decree or the
power of sale, or by deed in lieu of such foreclosure.  This indemnity
shall include, without limitation:  (aa) all consequential damages
(including, without limitation, any third party tort claims or
governmental claims, fines or penalties against Trustee or the Beneficiary
Group); (bb) all court costs and reasonable attorneys' fees (including,
without limitation, expert witness fees) paid or incurred by Trustee or
the Beneficiary Group; and (cc) the costs, whether foreseeable or
unforeseeable, of any investigation, repair, cleanup or detoxification of
the Property which is required by any governmental entity or is otherwise
necessary to render the Property in compliance with all laws and
regulations pertaining to Hazardous Materials. "Beneficiary Group", as
used herein, shall mean (1) Beneficiary (including, without limitation,
any participant in the Loan), (2) any entity controlling, controlled by or
under common control with Beneficiary, (3) the directors, officers,
employees and agents of Beneficiary and such other entities, and (4) the
successors, heirs and assigns of the entities and persons described in
foregoing clauses (1) through (3). Trustor shall pay immediately upon
Trustee's or Beneficiary's demand any amounts owing under this indemnity
together with interest from the date the indebtedness arises until paid at
the rate of interest applicable to the principal balance of the Note as
specified therein.  Trustor agrees to use legal counsel reasonably
acceptable to Trustee and the Beneficiary Group in any action or
proceeding arising under this indemnity.  THE PROVISIONS OF THIS SECTION
SHALL SURVIVE THE TERMINATION AND RECONVEYANCE OF THIS DEED OF TRUST, BUT
TRUSTOR'S LIABILITY UNDER THIS INDEMNITY SHALL BE SUBJECT TO THE
PROVISIONS OF THE SECTION IN THE NOTE ENTITLED "BORROWER'S LIABILITY."

6.20    SUBSTITUTION OF TRUSTEE.  From time to time, by a writing signed and
acknowledged by Beneficiary and recorded in the Office of the Recorder of
the County in which the Property is situated, Beneficiary may appoint
another trustee to act in the place and stead of Trustee or any successor.
 Such writing shall set forth any information required by law.  The
recordation of such instrument of substitution shall discharge Trustee
herein named and shall appoint the new trustee as the trustee hereunder
with the same effect as if originally named trustee herein.  A writing
recorded pursuant to the provisions of this Section shall be conclusive
proof of the proper substitution of such new trustee.

6.21    RELEASES, EXTENSIONS, MODIFICATIONS AND ADDITIONAL SECURITY.  Without
notice to or the consent, approval or agreement of any persons or entities
having any interest at any time in the Property or in any manner obligated
under the Secured Obligations ("Interested Parties"), Beneficiary may,
from time to time: (a) fully or partially release any person or entity
from liability for the payment or performance of any Secured Obligation;
(b) extend the maturity of any Secured Obligation; (c) make any agreement
with Borrower increasing the amount or otherwise altering the terms of any
Secured Obligation; (d) accept additional security for any Secured
Obligation; or (e) release all or any portion of the Property, Collateral
and other security for any Secured Obligation.  None of the foregoing
actions shall release or reduce the personal liability of any of said
Interested Parties, or release or impair the priority of the lien of this
Deed of Trust upon the Property.

6.22    SALE OR PARTICIPATION OF LOAN.  Trustor agrees that Beneficiary may at
any time sell, assign, participate or securitize all or any portion of
Beneficiary's rights and obligations under the Loan Documents, and that
any such sale, assignment, participation or securitization may be to one
or more financial institutions or other entities, to private investors,
and/or into the public securities market, in Beneficiary's sole
discretion. Trustor further agrees that Beneficiary may disseminate to any
such actual or potential purchaser(s), assignee(s) or participant(s) all
documents and financial and other information heretofore or hereafter
provided to or known to Beneficiary with respect to:  (a) the Property and
its operation; and/or (b) any party connected with the Loan (including,
without limitation, Trustor, any partner or member of Trustor, any
constituent partner or member of Trustor, any guarantor and any
nonborrower trustor).  In the event of any such sale, assignment,
participation or securitization, Beneficiary and the other parties to the
same shall share in the rights and obligations of Beneficiary set forth in
the Loan Documents as and to the extent they shall agree among themselves.
 In connection with any such sale, assignment, participation or
securitization, Trustor further agrees that the Loan Documents shall be
sufficient evidence of the obligations of Trustor to each purchaser,
assignee or participant, and Trustor shall, within 15 days after request
by Beneficiary, deliver an estoppel certificate verifying for the benefit
of Beneficiary and any other party designated by Beneficiary the status
and the terms and provisions of the Loan in form and substance acceptable
to Beneficiary, and enter into such amendments or modifications to the
Loan Documents as may be reasonably required in order to facilitate any
such sale, assignment, participation or securitization without impairing
Trustor's rights or increasing Trustor's obligations.  The indemnity
obligations of Trustor under the Loan Documents shall also apply with
respect to any purchaser, assignee or participant.

6.23   RECONVEYANCE. Upon Beneficiary's written request, and upon surrender of
this Deed of Trust or certified copy thereof and any note, instrument or
instruments setting forth all obligations secured hereby to Trustee for
cancellation, Trustee shall reconvey, without warranty, the Property or
that portion thereof then held hereunder.  The recitals of any matters or
facts in any reconveyance executed hereunder shall be conclusive proof of
the truthfulness thereof.  To the extent permitted by law, the
reconveyance may describe the grantee as "the person or persons legally
entitled thereto".  Neither Beneficiary nor Trustee shall have any duty to
determine the rights of persons claiming to be rightful grantees of any
reconveyance.  When the Property has been fully reconveyed, the last such
reconveyance shall operate as a reassignment of all future rents, issues
and profits of the Property to the person or persons legally entitled
thereto.

6.24    SUBROGATION.  Beneficiary shall be subrogated to the lien of all
encumbrances, whether released of record or not, paid in whole or in part
by Beneficiary pursuant to this Deed of Trust or by the proceeds of any
loan secured by this Deed of Trust.

6.25    YEAR 2000 COMPLIANCE.  Trustor shall timely ensure that all software,
hardware, equipment, goods and systems used in the operation of Trustor
or the Property will properly perform date-sensitive functions before,
during and after the year 2000.


ARTICLE 7.  DEFAULT

7.1     DEFAULT.  For all purposes hereof, "Default" shall mean either an
"Optional Default" (as defined below) or an "Automatic Default" (as
defined below).

a.      Optional Default.  An "Optional Default" shall occur, at
Beneficiary's option, upon the occurrence of any of the following
events:

(i)     Monetary.  Borrower or Trustor shall fail to (aa) pay when
due any sums which by their express terms require immediate
payment without any grace period or sums which are payable on
the Maturity Date, or (bb) pay within 5 days when due any other
sums payable under the Note, this Deed of Trust or any of the
other Loan Documents, including without limitation, any monthly
payment due under the Note.

(ii)    Failure to Perform.  Borrower or Trustor shall fail to
observe, perform or discharge any of Borrower's or Trustor's
obligations, covenants, conditions or agreements, other than
Borrower's or Trustor's payment obligations, under the Note,
this Deed of Trust or any of the other Loan Documents, and (aa)
such failure shall remain uncured for 30 days after written
notice thereof shall have been given to Borrower or Trustor, as
the case may be, by Beneficiary or (bb) if such failure is of
such a nature that it cannot be cured within such 30 day period,
Borrower or Trustor shall fail to commence to cure such failure
within such 30 day period or shall fail to diligently prosecute
such curative action thereafter.

(iii)   Representations and Warranties.  Any representation,
warranty, certificate or other statement (financial or
otherwise) made or furnished by or on behalf of Borrower,
Trustor, or a guarantor, if any, to Beneficiary or in connection
with any of the Loan Documents, or as an inducement to
Beneficiary to make the Loan, shall be false, incorrect,
incomplete or misleading in any material respect when made or
furnished.

(iv)    Condemnation; Attachment.  The condemnation, seizure or
appropriation of any material portion (as reasonably determined
by Beneficiary) of the Property; or the sequestration or
attachment of, or levy or execution upon any of the Property,
the Collateral or any other collateral provided by Borrower or
Trustor under any of the Loan Documents, or any material portion
of the other assets of Borrower or Trustor, which sequestration,
attachment, levy or execution is not released or dismissed
within 45 days after its occurrence; or the sale of any assets
affected by any of the foregoing.

(v)     Uninsured Casualty.  The occurrence of an uninsured casualty
 with respect to any material portion (as reasonably determined
by Beneficiary) of the Property unless:  (aa) no other Default
has occurred and is continuing at the time of such casualty or
occurs thereafter; (bb) Trustor promptly notifies Beneficiary of
the occurrence of such casualty; and (cc) not more than 45 days
after the occurrence of such casualty, Trustor delivers to
Beneficiary immediately available funds ("Restoration Funds") in
an amount sufficient, in Beneficiary's reasonable opinion, to
pay all costs of the repair or restoration (including, without
limitation, taxes, financing charges, insurance and rent during
the repair period).  So long as no Default has occurred and is
continuing at the time of Beneficiary's receipt of the
Restoration Funds and no Default occurs thereafter, Beneficiary
shall make the Restoration Funds  available for the repair or
restoration of the Property.  Notwithstanding the foregoing,
Beneficiary shall have no obligation to make any Restoration
Funds available for repair or restoration of the Property unless
and until all the conditions set forth in clauses (ii) and (iii)
of the second sentence of Section 6.11(b) of this Deed of Trust
have been satisfied.  Trustor acknowledges that the specific
conditions described above are reasonable.

(vi)    Adverse Financial Change.  Any material adverse change in
the financial condition of Borrower or any general partner of
Borrower, any guarantor, or any other person or entity from the
condition shown on the financial statement(s) submitted to
Beneficiary and relied upon by Beneficiary in making the Loan,
and which change Beneficiary reasonably determines will have a
material adverse effect on (aa) the business, operations or
condition of the Property; or (bb) the ability of Borrower or
Trustor to pay or perform Borrower's or Trustor's obligations in
accordance with the terms of the Note, this Deed of Trust, and
the other Loan Documents.

b.      Automatic Default.  An "Automatic Default" shall occur
automatically upon the occurrence of any of the following events:

(i)     Voluntary Bankruptcy, Insolvency, Dissolution.  (aa)
Borrower's filing a petition for relief under the Bankruptcy
Reform Act of 1978, as amended or recodified ("Bankruptcy
Code"), or under any other present or future state or federal
law regarding bankruptcy, reorganization or other relief to
debtors (collectively, "Debtor Relief Law"); or (bb) Borrower's
filing any pleading in any involuntary proceeding under the
Bankruptcy Code or other Debtor Relief Law which admits the
jurisdiction of a court to regulate Borrower or the Property or
the petition's material allegations regarding Borrower's
insolvency; or (cc) Borrower's making a general assignment for
the benefit of creditors; or (dd) Borrower's applying for, or
the appointment of, a receiver, trustee, custodian or
liquidator of Borrower or any of its property; or (ee) the
filing by or against Borrower of a petition seeking the
liquidation or dissolution of Borrower or the commencement of
any other procedure to liquidate or dissolve Borrower.

(ii)    Involuntary Bankruptcy.  Borrower's failure to effect a full
dismissal of any involuntary petition under the Bankruptcy Code
or other Debtor Relief Law that is filed against Borrower or in
any way restrains or limits Borrower or Beneficiary regarding
the Loan or the Property, prior to the earlier of the entry of
any order granting relief sought in the involuntary petition or
45 days after the date of filing of the petition.

(iii)   Partners, Guarantors.  The occurrence of an event specified
in Sections (i) or (ii) as to Trustor, any general partner of
Borrower or Trustor, or any guarantor or other person or entity
in any manner obligated to Beneficiary under the Loan
Documents.

7.2     ACCELERATION.  Upon the occurrence of an Optional Default, Beneficiary
may, at its option, declare all sums owing to Beneficiary under the Note
and the other Loan Documents immediately due and payable. Upon the
occurrence of an Automatic Default, all sums owing to Beneficiary under
the Note and the other Loan Documents shall automatically become
immediately due and payable.

7.3     RIGHTS AND REMEDIES.  In addition to the rights and remedies in Section
7.2 above, at any time after a Default, Beneficiary shall have all of the
following rights and remedies:

a.      Entry on Property.  With or without notice, and without releasing
Trustor from any Secured Obligation, and without becoming a
mortgagee in possession, to enter upon the Property from time to
time and to do such acts and things as Beneficiary or Trustee deem
necessary or desirable in order to inspect, investigate, assess and
protect the security hereof or to cure any Default, including,
without limitation: (i) to take and possess all documents, books,
records, papers and accounts of Trustor, Borrower or the then owner
of the Property which relate to the Property; (ii) to make,
terminate, enforce or modify leases of the Property upon such terms
and conditions as Beneficiary deems proper; (iii) to make repairs,
alterations and improvements to the Property necessary, in Trustee's
or Beneficiary's sole judgment, to protect or enhance the security
hereof; (iv) to appear in and defend any action or proceeding
purporting to affect the security hereof or the rights or powers of
Beneficiary or Trustee hereunder; (v) to pay, purchase, contest or
compromise any encumbrance, charge, lien or claim of lien which, in
the sole judgment of either Beneficiary or Trustee, is or may be
senior in priority hereto, the judgment of Beneficiary or Trustee
being conclusive as between the parties hereto; (vi) to obtain
insurance; (vii) to pay any premiums or charges with respect to
insurance required to be carried hereunder; (viii) to obtain a court
order to enforce Beneficiary's right to enter and inspect the
Property for Hazardous Materials, in which regard the decision of
Beneficiary as to whether there exists a release or threatened
release of Hazardous Materials onto the Property shall be deemed
reasonable and conclusive as between the parties hereto; (ix) to
have a receiver appointed pursuant to applicable law to enforce
Beneficiary's rights to enter and inspect the Property for Hazardous
Materials; and/or (x) to employ legal counsel, accountants,
engineers, consultants, contractors and other appropriate persons to
assist them;

b.      Appointment of Receiver.  With or without notice or hearing, to
apply to a court of competent jurisdiction for and obtain appointment
of a receiver, trustee, liquidator or conservator of the Property,
for any purpose, including, without limitation, to enforce
Beneficiary's right to collect Payments and to enter on and inspect
the Property for Hazardous Materials, as a matter of strict right and
without regard to: (i) the adequacy of the security for the repayment
of the Secured Obligations; (ii) the existence of a declaration that
the Secured Obligations are immediately due and payable; (iii) the
filing of a notice of default; or (iv) the solvency of Trustor,
Borrower or any guarantor or other person or entity in any manner
obligated to Beneficiary under the Loan Documents;

c.      Judicial Foreclosure; Injunction.  To commence and maintain an
action or actions in any court of competent jurisdiction to foreclose
this instrument as a mortgage or to obtain specific enforcement of
the covenants of Trustor hereunder, and Trustor agrees that such
covenants shall be specifically enforceable by injunction or any
other appropriate equitable remedy and that for the purposes of any
suit brought under this subparagraph, Trustor waives the defense of
laches and any applicable statute of limitations;

d.      Nonjudicial Foreclosure.  To execute a written notice of such
Default and of the election to cause the Property to be sold to
satisfy the Secured Obligations.  Trustee shall give and record such
notice as the law then requires as a condition precedent to a
trustee's sale.  When the minimum period of time required by law
after such notice has elapsed, Trustee, without notice to or demand
upon Trustor except as required by law, shall sell the Property at
the time and place of sale fixed by it in the notice of sale, at one
or several sales, either as a whole or in separate parcels and in
such manner and order, all as Beneficiary in its sole discretion may
determine, at public auction to the highest bidder for cash, in
lawful money of the United States, payable at time of sale.  Neither
Trustor nor any other person or entity other than Beneficiary shall
have the right to direct the order in which the Property is sold.
Subject to requirements and limits imposed by law, Trustee may, from
time to time postpone sale of all or any portion of the Property by
public announcement at such time and place of sale, and from time to
time may postpone the sale by public announcement at the time and
place fixed by the preceding postponement.  A sale of less than the
whole of the Property or any defective or irregular sale made
hereunder shall not exhaust the power of sale provided for herein.
Trustee shall deliver to the purchaser at such sale a deed conveying
the Property or portion thereof so sold, but without any covenant or
warranty, express or implied.  The recitals in the deed of any
matters or facts shall be conclusive proof of the truthfulness
thereof.  Any person, including Trustee, Trustor or Beneficiary may
purchase at the sale;

Upon sale of the Property at any judicial or nonjudicial foreclosure,
Beneficiary may credit bid (as determined by Beneficiary in its sole
and absolute discretion) all or any portion of the Secured
Obligations.  In determining such credit bid, Beneficiary may, but is
not obligated to, take into account all or any of the following: (i)
appraisals of the Property as such appraisals may be discounted or
adjusted by Beneficiary in its sole and absolute underwriting
discretion; (ii) expenses and costs incurred by Beneficiary with
respect to the Property prior to foreclosure; (iii) expenses and
costs which Beneficiary anticipates will be incurred with respect to
the Property after foreclosure, but prior to resale, including,
without limitation, costs of structural reports and other due
diligence, costs to carry the Property prior to resale, costs of
resale (e.g. commissions, attorneys' fees, and taxes), costs of any
Hazardous Materials clean-up and monitoring, costs of deferred
maintenance, repair, refurbishment and retrofit, costs of defending
or settling litigation affecting the Property, and lost opportunity
costs (if any), including the time value of money during any
anticipated holding period by Beneficiary; (iv) declining trends in
real property values generally and with respect to properties similar
to the Property; (v) anticipated discounts upon resale of the
Property as a distressed or foreclosed property; (vi) the fact of
additional collateral (if any), for the Secured Obligations; and
(vii) such other factors or matters that Beneficiary (in its sole and
absolute discretion) deems appropriate.  In regard to the above,
Trustor acknowledges and agrees that: (viii) Beneficiary is not
required to use any or all of the foregoing factors to determine the
amount of its credit bid; (ix) this paragraph does not impose upon
Beneficiary any additional obligations that are not imposed by law at
the time the credit bid is made; (x) the amount of Beneficiary's
credit bid need not have any relation to any loan-to-value ratios
specified in the Loan Documents or previously discussed between
Trustor and Beneficiary; and (xi) Beneficiary's credit bid may be (at
Beneficiary's sole and absolute discretion) higher or lower than any
appraised value of the Property;

e.      Multiple Foreclosures.  To resort to and realize upon the security
hereunder and any other security now or later held by Beneficiary
concurrently or successively and in one or several consolidated or
independent judicial actions or lawfully taken nonjudicial
proceedings, or both, and to apply the proceeds received upon the
Secured Obligations all in such order and manner as Trustee and
Beneficiary or either of them determine in their sole discretion;

f.      Rights to Collateral.  To exercise all rights Trustee or
Beneficiary may have with respect to the Collateral under this Deed
of Trust, the UCC or otherwise at law; and

g.      Other Rights.  To exercise such other rights as Trustee or
Beneficiary may have at law or in equity or pursuant to the terms and
conditions of this Deed of Trust or any of the other Loan Documents.

In connection with any sale or sales hereunder, Beneficiary may elect to
treat any of the Property which consists of a right in action or which is
property that can be severed from the Property (including, without
limitation, any improvements forming a part thereof) without causing
structural damage thereto as if the same were personal property or a
fixture, as the case may be, and dispose of the same in accordance with
applicable law, separate and apart from the sale of the Property.  Any
sale of Collateral hereunder shall be conducted in any manner permitted by
the UCC.

7.4     APPLICATION OF FORECLOSURE SALE PROCEEDS.  If any foreclosure sale is
effected, Trustee shall apply the proceeds of such sale in the following
order of priority:  First, to the costs, fees and expenses of exercising
the power of sale and of sale, including, without limitation, the payment
of the Trustee's fees and attorneys' fees permitted pursuant to
subdivision (b) of California Civil Code Section 2924d and subdivision
(b) of Section 2924k; Second, to the payment of the Secured Obligations
which are secured by this Deed of Trust, in such order as Beneficiary
shall determine in its sole discretion;  Third, to satisfy the
outstanding balance of obligations secured by any junior liens or
encumbrances in the order of their priority; and Fourth, to the Trustor
or the Trustor's successor in interest, or in the event the Property has
been sold or transferred to another, to the vested owner of record at the
time of the Trustee's sale.

7.5     WAIVER OF MARSHALING RIGHTS.  Trustor, for itself and for all parties
claiming through or under Trustor, and for all parties who may acquire a
lien on or interest in the Property, hereby waives all rights to have the
Property and/or any other property, including, without limitation, the
Collateral, which is now or later may be security for any Secured
Obligation, marshaled upon any foreclosure of this Deed of Trust or on a
foreclosure of any other security for any of the Secured Obligations.

7.6     NO CURE OR WAIVER.  Neither Beneficiary's nor Trustee's nor any
receiver's entry upon and taking possession of all or any part of the
Property, nor any collection of rents, issues, profits, insurance
proceeds, condemnation proceeds or damages, other security or proceeds of
other security, or other sums, nor the application of any collected sum to
any Secured Obligation, nor the exercise of any other right or remedy by
Beneficiary or Trustee or any receiver shall cure or waive any Default or
notice of default under this Deed of Trust, or nullify the effect of any
notice of default or sale (unless all Secured Obligations then due have
been paid or performed and Trustor has cured all other Defaults
hereunder), or impair the status of the security, or prejudice Beneficiary
or Trustee in the exercise of any right or remedy, or be construed as an
affirmation by Beneficiary of any tenancy, lease or option or a
subordination of the lien of this Deed of Trust.

7.7    PAYMENT OF COSTS, EXPENSES AND ATTORNEYS' FEES. Trustor agrees to pay to
Beneficiary immediately and upon demand all costs and expenses incurred by
Trustee and Beneficiary in the enforcement of the terms and conditions of
this Deed of Trust (including, without limitation, statutory trustee's
fees, court costs and attorneys' fees, whether incurred in litigation or
not) with interest from the date of expenditure until said sums have been
paid at the rate of interest applicable to the principal balance of the
Note as specified therein.

7.8     POWER TO FILE NOTICES AND CURE DEFAULTS.  Trustor hereby irrevocably
appoints Beneficiary and its successors and assigns, as its attorney-in-
fact, which agency is coupled with an interest, to perform any obligation
of Trustor hereunder upon the occurrence of an event, act or omission
which, with notice or passage of time or both, would constitute a Default,
provided, however, that: (i) Beneficiary as such attorney-in-fact shall
only be accountable for such funds as are actually received by
Beneficiary; and (ii) Beneficiary shall not be liable to Trustor or any
other person or entity for any failure to act under this Section.

7.9     REMEDIES CUMULATIVE.  All rights and remedies of Beneficiary and Trustee
provided hereunder are cumulative and are in addition to all rights and
remedies provided by applicable law (including specifically that of
foreclosure of this instrument as though it were a mortgage) or in any
other agreements between Trustor and Beneficiary.  Beneficiary may enforce
any one or more remedies or rights hereunder successively or concurrently.


ARTICLE 8.  MISCELLANEOUS PROVISIONS

8.1     ADDITIONAL PROVISIONS.  The Loan Documents contain or incorporate by
reference the entire agreement of the parties with respect to matters
contemplated herein and supersede all prior negotiations. The Loan
Documents grant further rights to Beneficiary and contain further
agreements and affirmative and negative covenants by Trustor which apply
to this Deed of Trust and to the Property and such further rights and
agreements are incorporated herein by this reference.  THE OBLIGATIONS AND
LIABILITIES OF TRUSTOR UNDER THIS DEED OF TRUST AND THE OTHER LOAN
DOCUMENTS ARE SUBJECT TO THE PROVISIONS OF THE SECTION IN THE NOTE
ENTITLED "BORROWER'S LIABILITY."

8.2     NON-WAIVER.  By accepting payment of any amount secured hereby after its
due date or late performance of any other Secured Obligation, Beneficiary
shall not waive its right against any person obligated directly or
indirectly hereunder or on any Secured Obligation, either to require
prompt payment or performance when due of all other sums and obligations
so secured or to declare default for failure to make such prompt payment
or performance.  No exercise of any right or remedy by Beneficiary or
Trustee hereunder shall constitute a waiver of any other right or remedy
herein contained or provided by law.  No failure by Beneficiary or Trustee
to exercise any right or remedy hereunder arising upon any Default shall
be construed to prejudice Beneficiary's or Trustee's rights or remedies
upon the occurrence of any other or subsequent Default.  No delay by
Beneficiary or Trustee in exercising any such right or remedy shall be
construed to preclude Beneficiary or Trustee from the exercise thereof at
any time while that Default is continuing.  No notice to nor demand on
Trustor shall of itself entitle Trustor to any other or further notice or
demand in similar or other circumstances.

8.3     CONSENTS AND APPROVALS.  Wherever Beneficiary's consent, approval,
acceptance or satisfaction is required under any provision of this Deed of
Trust or any of the other Loan Documents,  such consent, approval,
acceptance or satisfaction shall not be unreasonably withheld, conditioned
or delayed by Beneficiary unless such provision expressly so provides.

8.4     PERMITTED CONTESTS.  After prior written notice to Beneficiary, Trustor
may contest, by appropriate legal or other proceedings conducted in good
faith and with due diligence, the amount, validity or application, in
whole or in part, of any lien, levy, tax or assessment, or any lien of any
laborer, mechanic, materialman, supplier or vendor, or the application to
Trustor or the Property of any law or the validity thereof, the assertion
or imposition of which, or the failure to pay when due, would constitute a
Default; provided that (a) Trustor pursues the contest diligently, in a
manner which Beneficiary determines is not prejudicial to Beneficiary, and
does not impair the lien of this Deed of Trust; (b) the Property, or any
part hereof or estate or interest therein, shall not be in any danger of
being sold, forfeited or lost by reason of such proceedings; (c) in the
case of the contest of any law or other legal requirement, Beneficiary
shall not be in any danger of any civil or criminal liability; and (d) if
required by Beneficiary, Trustor deposits with Beneficiary any funds or
other forms of assurance (including a bond or letter of credit)
satisfactory to Beneficiary to protect Beneficiary from the consequences
of the contest being unsuccessful.  Trustor's right to contest pursuant to
the terms of this provision shall in no way relieve Trustor or Borrower of
its obligations under the Loan or to make payments to Beneficiary as and
when due.

8.5     FURTHER ASSURANCES.  Trustor shall, upon demand by Beneficiary or
Trustee, execute, acknowledge (if appropriate) and deliver any and all
documents and instruments and do or cause to be done all further acts
reasonably necessary or appropriate to effectuate the provisions hereof.

8.6     ATTORNEYS' FEES.  If any legal action, suit or proceeding is commenced
between Trustor and Beneficiary regarding their respective rights and
obligations under this Deed of Trust or any of the other Loan Documents,
the prevailing party shall be entitled to recover, in addition to damages
or other relief, costs and expenses, reasonable attorneys' fees and court
costs (including, without limitation, expert witness fees).  As used
herein the term "prevailing party" shall mean the party which obtains the
principal relief it has sought, whether by compromise settlement or
judgment.  If the party which commenced or instituted the action, suit or
proceeding shall dismiss or discontinue it without the concurrence of the
other party, such other party shall be deemed the prevailing party.

8.7     TRUSTOR AND BENEFICIARY DEFINED.  The term "Trustor" includes both the
original Trustor and any subsequent owner or owners of any of the
Property, and the term "Beneficiary" includes the original Beneficiary and
any future owner or holder, including assignees, pledges and participants,
of the Note or any interest therein.

8.8     DISCLAIMERS.

a.      Relationship.  The relationship of Trustor and Beneficiary under
this Deed of Trust and the other Loan Documents is, and shall at all
times remain, solely that of borrower and lender; and Beneficiary
neither undertakes nor assumes any responsibility or duty to Trustor
or to any third party with respect to the Property.  Notwithstanding
any other provisions of this Deed of Trust and the other Loan
Documents:  (i) Beneficiary is not, and shall not be construed to
be, a partner, joint venturer, member, alter ego, manager,
controlling person or other business associate or participant of any
kind of Trustor, and Beneficiary does not intend to ever assume such
status; (ii) Beneficiary's activities in connection with this Deed
of Trust and the other Loan Documents shall not be "outside the
scope of activities of a lender of money" within the meaning of
California Civil Code Section 3434, as amended or recodified from
time to time, and Beneficiary does not intend to ever assume any
responsibility to any person for the quality, suitability, safety or
condition of the Property; and (iii) Beneficiary shall not be deemed
responsible for or a participant in any acts, omissions or decisions
of Trustor.

b.      No Liability.  Beneficiary shall not be directly or indirectly
liable or responsible for any loss, claim, cause of action,
liability, indebtedness, damage or injury of any kind or character
to any person or property arising from any construction on, or
occupancy or use of, the Property, whether caused by or arising
from: (i) any defect in any building, structure, grading, fill,
landscaping or other improvements thereon or in any on-site or off-
site improvement or other facility therein or thereon; (ii) any act
or omission of Trustor or any of Trustor's agents, employees,
independent contractors, licensees or invitees; (iii) any accident
in or on the Property or any fire, flood or other casualty or hazard
thereon; (iv) the failure of Trustor or any of Trustor's licensees,
employees, invitees, agents, independent contractors or other
representatives to maintain the Property in a safe condition; or (v)
any nuisance made or suffered on any part of the Property.

8.9     SEVERABILITY.  If any term of this Deed of Trust, or the application
thereof to any person or circumstances, shall, to any extent, be invalid
or unenforceable, the remainder of this Deed of Trust, or the application
of such term to persons or circumstances other than those as to which it
is invalid or unenforceable, shall not be affected thereby, and each term
of this Deed of Trust shall be valid and enforceable to the fullest extent
permitted by law.

8.10    RELATIONSHIP OF ARTICLES.  The rights, remedies and interests of
Beneficiary under the deed of trust established by Article I and the
security agreement established by Article IV are independent and
cumulative, and there shall be no merger of any lien created by the deed
of trust with any security interest created by the security agreement.
Beneficiary may elect to exercise or enforce any of its rights, remedies
or interests under either or both the deed of trust or the security
agreement as Beneficiary may from time to time deem appropriate.  The
absolute assignment of rents and leases established by Article III is
similarly independent of and separate from the deed of trust and the
security agreement.

8.11   MERGER.  No merger shall occur as a result of Beneficiary's acquiring any
other estate in, or any other lien on, the Property unless Beneficiary
consents to a merger in writing.

8.12    OBLIGATIONS OF TRUSTOR, JOINT AND SEVERAL.  If more than one person has
executed this Deed of Trust as "Trustor", the obligations of all such
persons hereunder shall be joint and several.

8.13    SEPARATE AND COMMUNITY PROPERTY.  Any married person who executes this
Deed of Trust as a Trustor agrees that any money judgment which Benefi-
ciary or Trustee obtains pursuant to the terms of this Deed of Trust or
any other obligation of that married person secured by this Deed of Trust
may be collected by execution upon any separate property or community
property of that person.

8.14    INTEGRATION; INTERPRETATION.  The Loan Documents contain or expressly
incorporate by reference the entire agreement of the parties with respect
to the matters contemplated therein and supersede all prior negotiations
or agreements, written or oral.  The Loan Documents shall not be modified
except by written instrument executed by all parties.  Any reference in
any of the Loan Documents to the Property or Collateral shall include all
or any part of the Property or Collateral.  Any reference to the Loan
Documents includes any amendments, renewals or extensions now or
hereafter approved by Beneficiary in writing. When the identity of the
parties or other circumstances make it appropriate, the masculine gender
includes the feminine and/or neuter, and the singular number includes the
plural.

8.15    CAPITALIZED TERMS.  Capitalized terms not otherwise defined herein shall
have the meanings set forth in the Note.

8.16    SUCCESSORS IN INTEREST.  The terms, covenants, and conditions herein
contained shall be binding upon and inure to the benefit of the heirs,
successors and assigns of the parties hereto.  The foregoing sentence
shall not be construed to permit Trustor to assign the Loan except as
otherwise permitted under the Note or the other Loan Documents.

8.17    GOVERNING LAW.  This Deed of Trust was accepted by Beneficiary in the
state of California and the proceeds of the Note secured hereby were
disbursed from the state of California, which state the parties agree has
a substantial relationship to the parties and to the underlying
transaction embodied hereby. Accordingly, in all respects, including,
without limiting the generality of the foregoing, matters of
construction, validity, enforceability and performance, this Deed of
Trust, the Note and the other Loan Documents and the obligations arising
hereunder and thereunder shall be governed by, and construed in
accordance with, the laws of the state of California applicable to
contracts made and performed in such state and any applicable law of the
United States of America, except that at all times the provisions for
enforcement of Beneficiary's STATUTORY POWER OF SALE granted hereunder
and the creation, perfection and enforcement of the security interests
created pursuant thereto and pursuant to the other Loan Documents shall
be governed by and construed according to the law of the state where the
Property is located. Except as provided in the immediately preceding
sentence, Trustor hereby unconditionally and irrevocably waives, to the
fullest extent permitted by law, any claim to assert that the law of any
jurisdiction other than California governs this Deed of Trust, the Note
and other Loan Documents.

8.18  CONSENT TO JURISDICTION.  Trustor irrevocably submits to the jurisdiction
of: (a) any state or federal court sitting in the state of California over
any suit, action, or proceeding, brought by Trustor against Beneficiary,
arising out of or relating to this Deed of Trust, the Note or the Loan;
(b) any state or federal court sitting in the state where the Property is
located or the state in which Trustor's principal place of business is
located over any suit, action or proceeding, brought by Beneficiary
against Trustor, arising out of or relating to this Deed of Trust, the
Note or the Loan; and (c) any state court sitting in the county of the
state where the Property is located over any suit, action, or proceeding,
brought by Beneficiary to exercise its STATUTORY POWER OF SALE under this
Deed of Trust or any action brought by Beneficiary to enforce its rights
with respect to the Collateral.  Trustor irrevocably waives, to the
fullest extent permitted by law, any objection that Trustor may now or
hereafter have to the laying of venue of any such suit, action, or
proceeding brought in any such court and any claim that any such suit,
action, or proceeding brought in any such court has been brought in an
inconvenient forum.

8.19    EXHIBITS.  Exhibit A is incorporated into this Deed of Trust by this
reference.

8.20   ADDRESSES; REQUEST FOR NOTICE.  All notices and other communications
that are required or permitted to be given to a party under this Deed of Trust
shall be in writing, refer to the Loan number, and shall be sent to such
party, either by personal delivery, by overnight delivery service, by
certified first class mail, return receipt requested, or by facsimile
transmission to the addressee or facsimile number below.  All such notices
and communications shall be effective upon receipt of such delivery or
facsimile transmission. The addresses of the parties are set forth on page
1 of this Deed of Trust and the facsimile numbers for the parties are as
follows:

Beneficiary:

WELLS FARGO BANK, N.A.
FAX No.: (925) 691-5947
Trustee:

AMERICAN SECURITIES COMPANY
FAX No.: (925) 691-5947

Trustor:

FREMONT HOLDING L.L.C.
FAX No.: (510) 574-1500


Trustor's principal place of business is at the address set forth on page
1 of this Deed of Trust.

Any Trustor whose address is set forth on page 1 of this Deed of Trust
hereby requests that a copy of notice of default and notice of sale be
delivered to it at that address.  Failure to insert an address shall
constitute a designation of Trustor's last known address as the address
for such notice.  Any party shall have the right to change its address for
notice hereunder to any other location within the continental United
States by giving 30 days notice to the other parties in the manner set
forth above.

8.21    COUNTERPARTS.  This Deed of Trust may be executed in any number of
counterparts, each of which, when executed and delivered, will be deemed
an original and all of which taken together, will be deemed to be one and
the same instrument.

8.22    WAIVER OF JURY TRIAL. BENEFICIARY AND TRUSTOR HEREBY KNOWINGLY,
VOLUNTARILY AND INTENTIONALLY WAIVE ANY RIGHTS THEY MAY HAVE TO A TRIAL BY
JURY IN RESPECT OF ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER,
OR IN CONNECTION WITH, THIS DEED OF TRUST OR ANY OTHER LOAN DOCUMENT, OR
ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS (WHETHER ORAL OR
WRITTEN) OR ACTIONS OF BENEFICIARY OR TRUSTOR.  THIS PROVISION IS A
MATERIAL INDUCEMENT FOR BENEFICIARY TO ENTER INTO THIS DEED OF TRUST.

IN WITNESS WHEREOF, Trustor has executed this Deed of Trust as of the day and
year set forth above.

FREMONT HOLDING L.L.C.,
a Delaware limited liability company

By:  Fremont Management, Inc.,
     a Delaware corporation,
     Manager

     By:  _______________________________

     Its: _______________________________




(ALL SIGNATURES MUST BE ACKNOWLEDGED)

        Loan No. 31-0900011A
EXHIBIT A
Description Of Land


Exhibit A to DEED OF TRUST AND ABSOLUTE ASSIGNMENT OF RENTS AND LEASES AND
SECURITY AGREEMENT (AND FIXTURE FILING) ("Deed of Trust") among FREMONT HOLDING
L.L.C., a Delaware limited liability company, as "Trustor", AMERICAN
SECURITIES COMPANY, as "Trustee", and WELLS FARGO BANK, NATIONAL ASSOCIATION,
as "Beneficiary".

Description of Land.  The Land referred to in this Deed of Trust is situated in
the county of Alameda, state of California and is described as follows:


PARCEL 16, PARCEL MAP 4483, FILED MARCH 28, 1985 IN BOOK 152, PAGES 78 THROUGH
82 OF MAPS, ALAMEDA COUNTY RECORDS.

APN:  543-0439-108
          543-0439-109






(..continued)
















EXHIBIT A
cadot  (Rev. 6/99)      1       \\wregsfo\v2\share\cmo\docs\loan



PATENT RIGHTS AGREEMENT

        This PATENT RIGHTS AGREEMENT (the "Agreement") is entered into as of
September 28, 1999 (the "Effective Date") by and between PROTEIN DESIGN LABS,
INC., a Delaware corporation having its principal office at 34801 Campus
Drive, Fremont, California 94555 (hereinafter referred to as "PDL"), and
SMITHKLINE BEECHAM CORPORATION, a Commonwealth of Pennsylvania corporation
having its principal office at One Franklin Plaza, Philadelphia, PA 19101
(hereinafter referred to as "SB").

RECITALS

     A.  PDL owns or has rights to certain patents designated as the Queen et
al. patents and identified on Exhibit A hereto (the "Queen et al. Patents");

     B.  PDL and SB are contemporaneously entering into an IL-5 Patent License
Agreement for an antibody directed against the IL-5 antigen (the "IL-5 Patent
License Agreement") and a Development and License Agreement for an antibody
directed against the IL-4 antigen (the "Development and License Agreement");
and

     C.  SB desires to obtain certain nonexclusive license rights under the
Queen et al. Patents for the development, manufacture and commercialization of
antibody products directed against up to three (3) target antigens under the
terms and conditions set forth below.

        AGREEMENT

     NOW, THEREFORE, in consideration of the mutual covenants herein contained
and intending to be legally bound, the parties agree as follows:

1.      SB'S RIGHTS TO LICENSES

     1.01 Election.  Subject to the terms and conditions of this Agreement, PDL
hereby grants to SB and SB accepts, for a period of [CONFIDENTIAL TREATMENT
REQUESTED] years from the Effective Date, the right to obtain up to three (3)
non-exclusive, royalty-bearing, worldwide licenses under the Queen et al.
Patents pursuant to the form of PDL License Agreement attached hereto as
Exhibit B (a "PDL License Agreement").

     1.02 Excluded Antigens.  SB's rights to elect a license under Section 1.01
shall not extend to the following target antigens and their receptors (or in
the case of receptors, ligands):  [CONFIDENTIAL TREATMENT REQUESTED].  Each
license elected by SB hereunder shall be pursuant to a separate PDL License
Agreement and shall be effective as of the date of execution of the PDL
License Agreement by both parties.

     1.03 Procedure for Exercise of License Rights.  If SB desires to exercise
a license right under this Agreement, SB shall provide PDL with written notice
identifying the target antigen or receptor for which SB desires to enter into
a PDL License Agreement pursuant to the provisions of Section 1.01.  PDL shall
promptly review and respond in writing to the request by SB for a license
within ten (10) business days of receipt of the written request. [CONFIDENTIAL
TREATMENT REQUESTED].  In the event that PDL denies SB's request for a PDL
License Agreement, PDL shall provide SB with a written certificate signed by
an officer of PDL specifying the reason for such denial, and SB's right under
Section 1.01 shall not be considered exercised.  If PDL does not deny SB's
request or has not responded within ten (10) business days of receipt of SB's
request under this Section 1.03, then SB and PDL shall promptly, but in no
event more than ten (10) business days thereafter, enter into a PDL License
Agreement (with a then-current Exhibit A to such PDL License Agreement) with
respect to the target antigen.

2.      CONDITION TO EFFECTIVENESS

    This Agreement shall be effective upon the execution and delivery by both
parties of the IL-5 Patent License Agreement and the Development and License
Agreement of even date herewith.

3.      REPRESENTATIONS; DISCLAIMERS

     3.01    Valid Agreement.  Each party represents and warrants to the other
that it knows of no legal reason to prevent it from entering into this
Agreement and that the signatory hereto is duly authorized to execute and
deliver this Agreement.

    3.02  No Warranty of Validity, Non-Infringement.  Nothing in this Agreement
shall be construed as (a) a warranty or representation by PDL as to the
validity or scope of the Queen et al. Patents; or (b) a warranty or
representation that anything made, used, sold or otherwise disposed of under
any PDL License Agreement is or will be free from infringement of patents,
copyrights, trademarks, trade secrets or other rights of third parties.

        3.03    Disclaimer of Warranties.  EXCEPT AS SPECIFICALLY SET FORTH IN
SECTION 3.01 ABOVE, PDL MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND,
EITHER EXPRESS OR IMPLIED.  FURTHER, PDL MAKES NO EXPRESS OR IMPLIED
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR THAT
PRACTICE UNDER ITS LICENSED PATENTS UNDER A PDL LICENSE AGREEMENT WILL NOT
INFRINGE ANY THIRD PARTY RIGHTS.

4.      CONFIDENTIALITY

        4.01  Obligations.  During the term of this Agreement and for five (5)
years thereafter, PDL and SB shall not use or reveal or disclose to third
parties any confidential information received from the other in the
performance of activities in furtherance of this Agreement without first
obtaining the written consent of the disclosing party, except (i) as may be
otherwise provided herein, (ii) as may be required for purposes of licensing,
developing, manufacturing or marketing a product subject to license grant
under the rights of SB set forth this Agreement, (iii) as may be required for
securing essential or desirable authorizations, approvals, privileges or
rights from governmental agencies or as may be required by law, statute or
regulation to be disclosed to a governmental agency, provided that the party
disclosing such information will use reasonable efforts to ensure that the
confidentiality of such confidential information is maintained by such
government regulatory agencies, (iv) as may be required or as necessary to
file or prosecute patent applications concerning the Queen et al. Patents, (v)
or as may be required to carry out any litigation concerning the subject
matter of this Agreement provided that the party disclosing such information
will use reasonable efforts to ensure that the confidentiality of such
confidential information is maintained.  This confidentiality obligation shall
not apply to confidential  information which is or becomes a matter of public
knowledge through no fault of the receiving party, or is already in the
possession of the receiving party, or is disclosed to the receiving party by a
third party having the right to do so, or is subsequently and independently
developed by employees of the receiving party or affiliates thereof who had no
knowledge of the confidential information disclosed.  The parties shall take
reasonable measures to assure that no unauthorized use or disclosure is made
by others to whom access to confidential information is granted.
4.02  Exceptions.  Nothing in this Article 4 shall be construed as
preventing either party from disclosing any information received from the
other party to:
        (i)  an affiliate or prospective sublicensee of the receiving party,
provided such affiliate or sublicensee has undertaken a similar obligation of
confidentiality with respect to the confidential information;
        (ii)  the FDA in connection with the approval to conduct clinical
studies, manufacture, market or sell a product whose license rights are
obtained hereunder; or

        (iii) any securities exchange to which the receiving party may be
subject if necessary to meet the requirements, rules and regulations of such
securities exchange, but only to the extent such disclosure is reasonably
required and subject to obligations of confidentiality wherever possible.
4.03  Ownership.  All confidential information
disclosed by one party to the other shall remain the
intellectual property of the disclosing party.  In the event
that a court or other legal or administrative tribunal,
directly or through an appointed master, trustee or
receiver, assumes partial or complete control over the
assets of a party to this Agreement based on the insolvency
or bankruptcy of such party, the bankrupt or insolvent party
shall promptly notify the court or other tribunal (i) that
confidential information received from the other party under
this Agreement remains the property of the other party and
(ii) of the confidentiality obligations under this
Agreement.  In addition, the bankrupt or insolvent party
shall, to the extent permitted by law, take all steps
necessary or desirable to maintain the confidentiality of
the other party's confidential information and to ensure
that the court, other tribunal or appointee maintains such
information in confidence in accordance with the terms of
this Agreement.

5.      TERM AND TERMINATION

    5.01    Term.  Unless earlier terminated in accordance with this Article 5,
this Agreement shall remain in effect until [CONFIDENTIAL TREATMENT
REQUESTED].

    5.02    Default.  This Agreement shall terminate upon the earlier of (i)
thirty (30) days' written notice if SB defaults in the performance of, or
fails to be in compliance with, any material agreement, condition or covenant
of this Agreement and such default or non-compliance is not cured within such
thirty (30) day period, or [CONFIDENTIAL TREATMENT REQUESTED].

        5.03    Rights and Obligations Upon Termination or Expiration.  Upon
expiration or termination of this Agreement for any reason, nothing herein
shall be construed to release either party from any obligation that matured
prior to the effective date of such termination.  In any event, termination or
expiration of this Agreement shall not effect any valid PDL License Agreement
in effect as of the date of such termination or expiration, the IL-5 Patent
License Agreement or the Development and License Agreement.  In addition, the
obligations set forth in Articles 4 and 6 shall survive the expiration or
termination of this Agreement.  Upon termination of this Agreement, each party
shall return to the other party any confidential information disclosed by the
other party under this Agreement.

6.      MISCELLANEOUS

    6.01    Assignment.. This Agreement and the rights granted herein shall be
binding upon and inure to the benefit of the successors in interest of the
respective parties.  Neither this Agreement nor any interest hereunder shall
be assignable by either party without the prior written consent of the other;
provided, however, that either party may assign this Agreement or any part of
its rights and obligations hereunder to any affiliate of such party or to any
corporation with which that party may merge or consolidate, or to which it may
transfer all or substantially all of its assets, without obtaining the consent
of the other party, provided that the party effecting such assignment shall
notify the other promptly following such assignment.

    6.02    Entire Agreement; Amendment This Agreement, including the Exhibits
hereto, constitutes the entire agreement between the parties relating to the
subject matter hereof and supersedes all previous writings and understandings.
No terms or provisions of this Agreement shall be varied or modified by any
prior or subsequent statement, conduct or act of either of the parties, except
that the parties may amend this Agreement by written instruments specifically
referring to and executed in the same manner as this Agreement.

        6.03    Severability
(a)     In the event any portion of this Agreement shall be held illegal,
void or ineffective, the remaining portions hereof shall remain in full force
and effect.
(b)     If any of the terms or provisions of this Agreement are in
conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law.
(c)     In the event that the terms and conditions of this Agreement are
materially altered as as provided in Sections 6.03(a) and (b), the parties
will in good faith renegotiate the terms and conditions of this Agreement to
carry out the intent of the parties.

    6.04    Notices. Notices required or permitted under this Agreement shall be
in writing in the English language and sent by overnight  mail (e.g., FedEx),
or by facsimile confirmed by overnight  mail (e.g., FedEx), and shall be
deemed to have been properly served to the addressee upon receipt of such
written communication, to the following addresses of the parties or to such
address or addresses as may be specified from time to time in a written
notice:

If to PDL:      Protein Design Labs, Inc.
        34801 Campus Drive
        Fremont, California 94555 USA
        Attention: General Counsel
        Facsimile number: (510) 574-1473

If to SB:       SmithKline Beecham Corporation
                One Franklin Plaza (Mail Code FP 1930)
                P.O. Box 7929
                Philadelphia, PA  19101
                Attn:  Senior Vice President, Business Development

                Facsimile number:  (215) 751-4253

Copy to:        SmithKline Beecham Corporation
                One Franklin Plaza (Mail Code FP 2360)
                P.O. Box 7929
                Philadelphia, PA 19101
                Attn:  Corporate Law - US

                Fax: number:  (215)751-3935


   6.05    Choice of Law.. This Agreement shall be deemed to have been made in
New York and its form, execution, validity, construction and effect shall be
determined in accordance with the laws thereof.

   6.06    Dispute Resolution.   Any dispute, controversy or claim arising out
of or relating to this Agreement, including without limitation, a dispute
concerning a termination of this Agreement (hereinafter collectively referred
to as "Dispute") shall be attempted to be settled by the parties, in good
faith, by submitting each such Dispute to appropriate senior management
representatives of each party in an effort to effect a mutually acceptable
resolution thereof within thirty (30) days of submission to such
representatives.  Within fifteen (15) days after submission of the Dispute to
such senior representatives, each party shall submit a brief, written summary
of the Dispute and their respective position with respect to the Dispute to
such senior representatives.  In the event no mutually acceptable resolution
is achieved in such time frame, then each party shall be entitled to seek
relief for such Dispute by using any appropriate judicial mechanism which may
be available in the courts.

        6.07    Waiver.   None of the terms, covenants and conditions of this
Agreement can be waived except by the written consent of the party waiving
compliance.

        6.08  Force Majeure.   If the performance of any part of this Agreement
by either party, or of any obligation under this Agreement, is prevented,
restricted, interfered with or delayed by reason of any cause beyond the
reasonable control of the party liable to perform, unless conclusive evidence
to the contrary is provided, the party so affected shall, upon giving written
notice to the other party, be excused from such performance to the extent of
such prevention, restriction, interference or delay; provided that the
affected party shall use its reasonable best efforts to avoid or remove such
causes of non-performance and shall continue performance with the utmost
dispatch whenever such causes are removed.  When such circumstances arise, the
parties shall discuss what, if any, modification of the terms of this
Agreement may be required in order to arrive at an equitable solution.

   6.09  Publicity.   It is contemplated that one or both of the parties may
issue a press release announcing this Agreement, the Development and License
Agreement and the IL-5 Patent License Agreement, the form and content of which
shall be mutually agreed upon.  No other public announcement or other
disclosure to third parties concerning the terms, financial or otherwise, of
this Agreement, the Development and License Agreement or the IL-5 Patent
License Agreement shall be made, either directly or indirectly, by any party
to this Agreement, except as may be legally required or as may be required for
recording purposes, without first obtaining the approval of the other party,
which approval shall not be unreasonably withheld, and agreement upon the
nature and text of such announcement or disclosure.  The party desiring to
make any such public announcement or other disclosure shall inform the other
party of the proposed announcement or disclosure in reasonably sufficient time
prior to public release, and shall provide the other party with a written copy
thereof, in order to allow such other party to comment upon such announcement
or disclosure.  The party reviewing the release shall use good faith efforts
to promptly review and provide comments upon the proposed public release,
which comments shall be provided as soon as practicable but in any event
within seven (7) days of delivery of the initial draft of the proposed
release.  Each party agrees that it shall cooperate fully with the other with
respect to all disclosures regarding this Agreement to the Securities Exchange
Commission, the U.K. Stock Exchange and any other governmental or regulatory
agencies, including requests for confidential treatment of proprietary
information of either party included in any such disclosure.  Notwithstanding
the foregoing, it is understood and agreed that the parties may issue a press
release in connection with the entering into of each PDL License Agreement in
accordance with the terms and conditions set forth therein.

   6.10    Headings.  The captions used herein are inserted for convenience of
reference only and shall not be construed to create obligations, benefits, or
limitations.

   6.11    Counterparts.   This Agreement may be executed in counterparts, all
of which taken together shall be regarded as one and the same instrument.


        6.12  Independent Contractors. The parties are independent contractors
under this Agreement and no other relationship is intended, including, without
limitation, partnership, joint venture or agency relationship.  Neither party
shall act in a manner which expresses or implies a relationship other than of
independent contractor, nor bind the other party, except as otherwise
expressly provided in this Agreement.  Nothing in this Agreement shall be
deemed to infer any direct relationship between PDL and any affiliate of SB.

        IN WITNESS WHEREOF, the parties have executed this Agreement as of the
date first written above.

Protein Design Labs, Inc.                       SmithKline Beecham Corporation

By                      _______                         By

Title                                                           Title



Exhibits

Exhibit A - Queen et al. Patents

Exhibit B - Form of PDL License Agreement

Exhibit A
PDL Licensed Patents

The following are patents and patent applications (also known as the "Queen et
al. patents") issued and filed in certain countries in the world and licensed
as part of the PDL Patent Rights under the Agreement (As of August 25, 1999).

1.  The following issued U.S. patents and U.S. patent applications:

No. 5,585,089, "Humanized Immunoglobulins," issued December 17, 1996.

No. 5,693,761, "Polynucleotides Encoding Improved Humanized
Immunoglobulins," issued December 2, 1997.

No. 5,693,762, "Humanized Immunoglobulins," issued December 2, 1997.

[CONFIDENTIAL TREATMENT REQUESTED]


2.  The following patents and patent applications outside the U.S.:

Patent No.

Country
Title*
Issued
647383
Australia
"Novel Immunoglobulins, Their Production
and Use"
Issued
671949
Australia
"
Issued
AT E133452
Austria
"
Issued
0451216
Belgium
"
Issued
61095
Bulgaria
"
Issued
970016

Brazil
"
Issued
0451 216B1
European
"
Issued
0682040 B1
European

Issued
FR0451216
France
"
Issued
DE
68925536
Germany
"
Issued
DD 296 964
East Germany
"
Issued
GB 0451216
Great Britain
"
Issued
1001050

Greece
"
Issued
211174

Hungary
"
Issued
IT O451216
Italy
"
Issued
2828340
Japan
"
Issued
LU O451216
Luxembourg
"
Issued
92.2146
Monaco
"
Issued
NL 0451216
Netherlands
"
Issued
231984
New Zealand
"
Issued
132068
Pakistan
"
Issued
29729
Philippines
"
Issued
92758
Portugal
"
Issued
4895847.13
Russia
"
Issued
2126046
Russia
"
Issued
SG O451216
Singapore
"
Issued
89/9956
South Africa
"
Issued
178385
South Korea
"
Issued
2081974 T3
Spain
"
Issued
SE O451216
Sweden
"
Issued
CHO 451216
Switzerland
"
Issued
50034
Taiwan
"
Issued
13349
Uruguay
"
Issued
48700
Yugoslavia
"







Country
Title*
Pending
Argentina
"Novel Immunoglobulins, Their
Production and Use"
Pending
Canada
"
Pending
Chile
"
Pending
China
"
Pending
Croatia
"
Pending
Czech Republic
"
Pending
Ecuador
"
Pending
Europe
"
Pending
Hong Kong
"
Pending
Ireland
"
Pending
Israel
"
Pending
Japan
"
Pending
South Korea

Pending
Romania
"
Pending
Slovak Republic
"
Pending
Venezuela
"
Pending
Denmark
"
Pending
Finland
"
Pending
Norway
"









*Exact titles may differ in different countries.

                                    EXHIBIT B
FORM OF
PATENT LICENSE AGREEMENT
between
PROTEIN DESIGN LABS, INC.
and
SMITHKLINE BEECHAM CORPORATION
This Patent License Agreement ("Agreement"), effective as of  __, ____
("Effective Date"), is made by and between PROTEIN DESIGN LABS, INC., a
Delaware corporation having offices at 34801 Campus Drive, Fremont, CA 94555
(hereinafter "PDL") and SMITHKLINE BEECHAM CORPORATION, a Commonwealth of
Pennsylvania corporation having offices at One Franklin Plaza, Philadelphia,
PA 19101 (hereinafter "SB").
RECITALS
A.  PDL and SB have entered into a Patent Rights Agreement effective as
of September __, 1999, pursuant to which SB may enter into this Agreement for
a license under the certain patents designated as the Queen et al. Patents for
a humanized antibody directed against the ________________ antigen.
B.  PDL desires to grant and SB desires to accept a nonexclusive,
worldwide, royalty-bearing license under the Licensed PDL Patents under the
terms and conditions of this Agreement with respect to such  humanized
antibody.
AGREEMENT

NOW THEREFORE, in consideration of the mutual covenants herein contained
and intending to be legally bound, the parties agree as follows:
1.      DEFINITIONS
Except as otherwise expressly provided herein, all references to
Exhibits, Articles and Sections shall be references to Exhibits, Articles and
Sections of this Agreement, and the following terms in this Agreement shall
have the following meanings:
1.01  "Affiliate" shall mean any corporation, firm, partnership or other
entity, whether de jure or de facto, which directly or indirectly owns, is
owned by or is under common ownership with a party to this Agreement to the
extent of at least fifty percent (50%) of the equity (or such lesser
percentage which is the maximum allowed to be owned by a foreign corporation
in a particular jurisdiction) having the power to vote on or direct the
affairs of the entity and any person, firm, partnership, corporation or other
entity actually controlled by, controlling or under common control with a
party to this Agreement; provided however any such person, corporation, firm,
partnership or other entity shall be deemed an Affiliate only for so long as
it meets the requirements of this definition.
1.02  "Antibody" shall mean any antibody, including without limitation,
monospecific and bispecific antibodies; less than full-length antibody forms
such as Fv, Fab, and F(ab')2; single-chain antibodies; and antibody conjugates
bound to a toxin, label or other moiety.
1.03  "Combination Product(s)" shall mean any product containing both a
pharmaceutically active agent or ingredient which constitutes a Licensed
Product and one or more other pharmaceutically active agents or ingredients
which do not constitute Licensed Products.
1.04  "Licensed PDL Patents" shall mean all United States and foreign
patents and patent applications identified on Exhibit A (including any and all
continuations, continuations-in-part, divisions, patents of addition,
reissues, renewals or extensions thereof, all SPCs thereof and all patents
issuing therefrom).  Exhibit A will be updated by PDL on an annual basis.
1.05  "Licensed Product(s)" shall mean human prophylactic, therapeutic,
and/or palliative products that include an Antibody [CONFIDENTIAL TREATMENT
REQUESTED].
1.06 "Marketing Approval" shall mean the first approval or authorization
in a country which is required for the marketing, promotion and sale of
Licensed Product in such country.

1.07  "Net Sales" shall mean the gross invoice price or contract price
from sales of Licensed Products in a form for use by an end user and not
intended for further genetic manipulation or transformation in the Territory
by SB, its Affiliates and sublicensees ("the Selling Party") to Third Parties
less

[CONFIDENTIAL TREATMENT REQUESTED]

Sales between SB, its Affiliates and its or their sublicensees shall be
excluded from the computation of Net Sales and no payments will be payable on
such sales except where such Affiliates or sublicensees are end users, but Net
Sales shall include the subsequent final sales to Third Parties by SB or such
Affiliates or sublicensees. [CONFIDENTIAL TREATMENT REQUESTED]

If SB or any of its Affiliates or sublicensees receive non-cash consideration
for any Licensed Product sold or otherwise transferred to Third Party in a
form other than bulk or intermediate, the fair market value of such non-cash
consideration on the date of such transfer as known to SB, or as reasonably
estimated by SB if unknown, shall be included in the definition of Net Sales.

1.08 "SPC"  shall mean a right based upon a patent to exclude others
from making, using or selling Licensed Product, such as a Supplementary
Protection Certificate.

                1.09 "Target Antigen" shall mean        .
1.10  "Territory" shall mean worldwide [CONFIDENTIAL TREATMENT
REQUESTED]
1.11  "Third Party" shall mean any party other than SB, PDL and their
respective Affiliates.
1.12  "Valid Claim" shall mean [CONFIDENTIAL TREATMENT REQUESTED].
2.      LICENSE
2.01  License Grant.  Subject to the terms and conditions of this
Agreement and in consideration of SB's fulfillment of its obligations to PDL
under this Agreement, PDL hereby grants and SB hereby accepts a worldwide,
nonexclusive royalty-bearing license under the Licensed PDL Patents, including
the right to grant sublicenses with respect to Licensed Products in accordance
with Section 2.02, to make, have made, import, use and sell Licensed Products
in the Territory.
2.02  Limitation on Sublicenses; Notification. SB shall have the right
to grant sublicenses of its rights under Section 2.01 with respect to Licensed
Products, provided that (i) SB shall grant such sublicenses only in connection
with the assignment or license by SB to such sublicensee of the right to use,
make, have made, sell or otherwise transfer the Licensed Products in such
country and (ii) SB shall pay to PDL [CONFIDENTIAL TREATMENT REQUESTED].
Notwithstanding the assignment or grant of a sublicense by SB hereunder, SB
shall remain obligated to pay all royalties due to PDL with respect to the
sale of Licensed Products by its assignee or sublicensee.  In addition, the
grant of any sublicenses under Section 2.01 shall be on terms and conditions
which are subject to and subordinate to the terms of this Agreement and SB
shall remain fully responsible to PDL for the performance of any and all such
terms by its sublicensees.  Promptly following execution of any sublicense
hereunder, SB shall notify PDL of the identity of the sublicensee and the
scope of the sublicense and provide a copy of the sublicense agreement, which
copy may be redacted to protect confidential technical or financial
information.
2.03  Updates to List of Licensed PDL Patents.  Not later than December
31 of each year during the term of this Agreement or earlier upon written
request of SB (which request shall not be made more than twice per calendar
year), PDL agrees to provide a written update listing the Licensed PDL
Patents, and such update shall constitute an amendment to Exhibit A.

2.04  No Other License Rights.  SB expressly acknowledges and agrees
that, except for the license expressly granted under Section 2.01, no rights
to any other PDL patents or patent applications, or to any know-how, trade
secrets or licenses are included in this Agreement or granted by implication,
estoppel or otherwise.

3.      PAYMENTS, ROYALTIES, REPORTS

3.01  Payments. In consideration for the license granted by PDL under
Article 2 of this Agreement, SB shall pay to PDL, within ten (10) business
days of the Effective Date of this Agreement, a non-refundable, non-creditable
signing and licensing fee in the sum of [CONFIDENTIAL TREATMENT REQUESTED].
3.02  Royalties to PDL. [CONFIDENTIAL TREATMENT REQUESTED]
3.03 Combination Products.  Net Sales in a particular country, in the
case of Combination Products for which the pharmaceutically active agent or
ingredient constituting a Licensed Product and each of the other
pharmaceutically active agents or ingredients not constituting Licensed
Products have established market prices in that country when sold separately,
shall be determined by multiplying the Net Sales for each such Combination
Product by a fraction, the numerator of which shall be the established market
price for the Licensed Product(s) contained in the Combination Product and the
denominator of which shall be the sum of the established market prices for the
Licensed Product(s) plus the established market prices for the other
pharmaceutically active agents or ingredients contained in the Combination
Product.  When such separate market prices are not established in that
country, then the parties shall negotiate in good faith to determine a fair
and equitable method of calculating Net Sales in that country for the
Combination Product in question.
3.04 Annual Maintenance Fee. In further consideration of the license
granted under Article 2, within fifteen (15) business days after the second
anniversary of the Effective Date and for each anniversary thereafter, SB
shall pay a nonrefundable annual maintenance fee in the amount of
[CONFIDENTIAL TREATMENT REQUESTED]. Such annual maintenance fee shall be
[CONFIDENTIAL TREATMENT REQUESTED] against royalties payable by SB for the
year with respect to which such annual maintenance fee is paid; provided,
however, that any quarterly payments due to PDL shall not be reduced by more
than [CONFIDENTIAL TREATMENT REQUESTED] by such offset.
3.05  Currency Conversion.  All amounts payable to PDL under this
Agreement shall be payable in U.S. Dollars by wire transfer to a bank account
designated by PDL.  In the case of royalties on Net Sales, all amounts payable
shall first be calculated in the currency of sale and then converted into U.S.
Dollars using the actual average  exchange rates for such currency as used by
SB in producing its quarterly and annual accounts, as confirmed by SB's
auditors.
3.06  Reports.
(a)  Current Reports.  SB agrees to make written reports and royalty
payments to PDL within forty-five (45) days after the close of each calendar
quarter during the term of this Agreement, beginning with the calendar quarter
in which the date of first commercial sale or other transfer for value of a
Licensed Product by SB, its Affiliates or sublicensees in the Territory
occurs.  These reports shall be certified by a duly authorized employee in the
Finance Department of SB and shall state for the calendar quarter in question:
(1) identification on a country-by-country basis of each Licensed Product upon
which SB is paying royalties; (2) Net Sales by SB and its Affiliates of such
Licensed Products; (3) Net Sales reported by sublicensees of such Licensed
Products; (4) the place of manufacture of Licensed Products sold in such
quarter; (5) applicable offsets or deductions; and (6) the net royalty due to
PDL thereon pursuant to this Article 3.  No later than at the time of the
making of each such report, SB shall make any payment due to PDL of royalties
for the period covered by such report.
(b)  Termination Report.  For each Licensed Product, SB also agrees to
make a written report to PDL within ninety (90) days after the date on which
SB, its Affiliates or sublicensees last sell or otherwise transfer for value
the Licensed Product anywhere in the Territory stating in such report the same
information required by quarterly reports for all such Licensed Products made,
sold or otherwise disposed of which were not previously reported to PDL.

(c)  Notification of Marketing Approval.        SB agrees to notify PDL in
writing within ten (10) days after the end of each month of the countries in
the Territory in which SB, its Affiliates or sublicensees obtains Marketing
Approval of a Licensed Product in the preceding month.  Such notice shall
specify the country and date of Marketing Approval.  SB shall assist PDL and
provide reasonable cooperation (including the execution and timely delivery of
any documents, certifications and the like) in obtaining any extensions of the
Licensed PDL Patents with respect to any Licensed Product in any country in
which SB markets Licensed Products.
3.07  Inspection.  SB agrees to keep, and to require any of its
Affiliates or sublicensees to keep, clear, accurate and complete records for a
period of at least three (3) years for each reporting period in which Net
Sales occur showing the manufacture, sales, use and other dispositions for
value of Licensed Products in sufficient detail to enable the royalties
payable hereunder to be determined.  SB further agrees to permit its books and
records, and to require any of its Affiliates or sublicensees to permit their
books and records, to be examined by an independent accounting firm selected
by PDL and reasonably acceptable to SB from time-to-time during regular
business hours, but not more than once a year.  Such independent accounting
firm shall report to PDL only with respect to the accuracy of Net Sales and
deductions reported and payments made by SB to PDL under this Agreement.  All
information disclosed in any such inspection shall be deemed confidential
under the terms of this Agreement. [CONFIDENTIAL TREATMENT REQUESTED]  Any
such discrepancies will be promptly corrected by a payment or refund by the
appropriate party.
3.08  Withholding.  SB may withhold from royalties due to PDL amounts
for payment of any withholding tax that SB has paid to any taxing authority
with respect to the royalty amounts due to PDL hereunder for which SB does not
receive a refund or credit. SB agrees to reasonably cooperate with PDL in
obtaining a foreign tax credit in the U.S. with respect to royalties due to
PDL on the sale or manufacture of Licensed Products.

3.09  Interest on Overdue Royalties. SB shall be liable for interest on
any overdue royalties, at the rate of [CONFIDENTIAL TREATMENT REQUESTED] per
annum or the highest rate allowed by law, whichever is less, commencing on the
date such royalties are due until paid.

3.10  Royalties to Third Parties.  SB acknowledges and agrees that other
licenses may be required from third parties with respect to the development,
manufacture, importation, use, and sale of any Licensed Product under this
Agreement, and that SB shall be solely responsible for any royalties and other
payments with respect to those license rights.  In no event shall SB have a
right to credit against, reduce or otherwise offset any royalty or payment
obligations to such third parties against royalty amounts payable to PDL under
this Agreement.
4.      INFRINGEMENT OF LICENSED PDL PATENTS
4.01  Suits.  PDL shall not have any obligation hereunder to institute
any action, suit or other proceeding against third parties for infringement of
any Licensed PDL Patents or to defend any action, suit or proceeding brought
by a third party which challenges or concerns the validity or enforceability
of any Licensed PDL Patents. Any moneys recovered from alleged infringers
shall be retained by PDL.
5.      REPRESENTATIONS AND WARRANTIES; DISCLAIMERS; INDEMNIFICATION
5.01  Valid Agreement.
(a)     Each party represents and warrants to the other that it knows of
no legal reason to prevent it from entering into this Agreement and that the
signatory hereto is duly authorized to execute and deliver this Agreement.
(b)     PDL represents and warrants to SB that it has the right to grant
the licenses to SB provided under this Agreement.
5.02  [CONFIDENTIAL TREATMENT REQUESTED]
5.03  Disclaimers.  Nothing in this Agreement shall be construed as (a)
a warranty or representation by PDL as to the validity, enforceability or
scope of any Licensed PDL Patents; (b) a requirement that PDL file any patent
application, or secure any patent or patent rights, or maintain any patent in
force, or provide copies of patent applications to SB or its Affiliates or
sublicensees, or disclose any inventions described or claimed in such patent
applications; or (c) a warranty or representation by PDL that any Licensed
Product made, used, sold or otherwise disposed of under the license granted in
this Agreement is or will be free from infringement of patents, copyrights,
trademarks, trade secrets or other rights of third parties.  SB acknowledges
and agrees that any royalties or payments that may be due to third parties in
order for SB to make, have made, use, sell or otherwise dispose of Licensed
Products shall be the sole responsibility of SB.
5.04  No Other Warranties.  EXCEPT AS SPECIFICALLY SET FORTH IN ARTICLE
5, PDL MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED, WITH RESPECT TO THE LICENSED PDL PATENTS OR ANY CELL LINES,
ANTIBODIES OR LICENSED PRODUCTS DEVELOPED BY SB UNDER THE LICENSE SET FORTH IN
THIS AGREEMENT AND PDL FURTHER MAKES NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF
LICENSED PDL PATENTS OR ANY CELL LINES, ANTIBODIES, LICENSED PRODUCTS OR OTHER
MATERIALS DEVELOPED BY SB UNDER THE LICENSE SET FORTH IN THIS AGREEMENT WILL
NOT INFRINGE ANY THIRD PARTY RIGHTS.
5.05  Indemnification.  Except as otherwise set forth in Article 4, SB
shall at all times, during the term of this Agreement and thereafter,
indemnify, defend and hold harmless PDL and its Affiliates, sublicensees,
directors, officers, agents and employees from any claim, proceeding, loss,
expense, and liability of any kind whatsoever (including but not limited to
those resulting from death, personal injury, illness or property damage and
including legal expenses and reasonable attorneys' fees) ("PDL Losses")
arising out of or resulting from third party claims based upon the
development, manufacture, holding, use, testing, advertisement, sale or other
disposition by SB, its Affiliates or sublicensees, or any distributor,
customer or representative thereof or any one in privity therewith, of any
Licensed Product; provided, however, that such indemnity shall not apply to
the extent any such PDL Losses result from the negligence or willful
misconduct of PDL or breach by PDL of any representation, warranty or other
provision of this Agreement.
In the event PDL is seeking indemnification from SB under this Section
5.05, SB shall have no such obligation unless PDL:
(i)  gives SB prompt notice of any claim or lawsuit or other action for
which it seeks to be indemnified under this Agreement;
(ii)  cooperates fully with SB and its agents in defense of any such
claim, complaint, lawsuit or other cause of action; and
(iii)  SB is granted full authority and control over the defense,
including settlement or other disposition thereof, against such claim or
lawsuit or other action, provided that PDL shall have the right to retain
counsel of its choice to participate in the defense of any such claim or
lawsuit at PDL's own expense, provided that such counsel shall not interfere
with SB's full authority and control.
Notwithstanding the foregoing, this Section 5.05 shall not be deemed to
permit SB to have authority or control over, or otherwise enter into any
settlement arrangement concerning the validity or scope of, the Licensed PDL
Patents.
6.      CONFIDENTIALITY

        6.01  Obligations.  During the term of this Agreement and for five (5)
years thereafter, PDL and SB shall not use or reveal or disclose to Third
Parties any confidential information received from the other in the
performance of activities in furtherance of this Agreement without first
obtaining the written consent of the disclosing party, except (i) as may be
otherwise provided herein, (ii) as may be required for purposes of developing,
manufacturing or marketing Licensed Product, (iii) as may be required for
securing essential or desirable authorizations, approvals, privileges or
rights from governmental agencies or as may be required by law, statute or
regulation to be disclosed to a governmental agency, provided that the party
disclosing such information will use reasonable efforts to ensure that the
confidentiality of such confidential information is maintained by such
government regulatory agencies, (iv) as may be required or as necessary to
file or prosecute patent applications concerning Licensed Product, (v) or as
may be required to carry out any litigation concerning Licensed Products
provided that the party disclosing such information will use reasonable
efforts to ensure that the confidentiality of such confidential information is
maintained.  This confidentiality obligation shall not apply to confidential
information which is or becomes a matter of public knowledge through no fault
of the receiving party, or is already in the possession of the receiving
party, or is disclosed to the receiving party by a Third Party having the
right to do so, or is subsequently and independently developed by employees of
the receiving party or Affiliates thereof who had no knowledge of the
confidential information disclosed.  The parties shall take reasonable
measures to assure that no unauthorized use or disclosure is made by others to
whom access to confidential information is granted.
6.02  Exceptions.  Nothing in this Article 6 shall be construed as
preventing either party from disclosing any information received from the
other party to:
        (i)  an Affiliate, sublicensee or distributor of the receiving party,
provided such Affiliate, sublicensee or distributor has undertaken a similar
obligation of confidentiality with respect to the confidential information;
        (ii)  the FDA in connection with the approval to conduct clinical
studies, manufacture, market or sell Licensed Product; or

        (iii) any securities exchange to which the receiving party may be
subject if necessary to meet the requirements, rules and regulations of such
securities exchange, but only to the extent such disclosure is reasonably
required and subject to obligations of confidentiality wherever possible.
6.03  Ownership.  All confidential information disclosed by one party to
the other shall remain the intellectual property of the disclosing party.  In
the event that a court or other legal or administrative tribunal, directly or
through an appointed master, trustee or receiver, assumes partial or complete
control over the assets of a party to this Agreement based on the insolvency
or bankruptcy of such party, the bankrupt or insolvent party shall promptly
notify the court or other tribunal (i) that confidential information received
from the other party under this Agreement remains the property of the other
party and (ii) of the confidentiality obligations under this Agreement.  In
addition, the bankrupt or insolvent party shall, to the extent permitted by
law, take all steps necessary or desirable to maintain the confidentiality of
the other party's confidential information and to ensure that the court, other
tribunal or appointee maintains such information in confidence in accordance
with the terms of this Agreement.
7.              TERM AND TERMINATION
7.01  Term.  Unless earlier terminated as provided in this Article 7,
SB's obligations to pay royalties to PDL hereunder shall come into force on
the Effective Date and shall continue, on a country by country basis,
[CONFIDENTIAL TREATMENT REQUESTED].  Unless earlier terminated, this Agreement
shall expire upon the expiration of all SB's royalty obligations to PDL
hereunder.  Expiration of this Agreement or expiration of SB's obligation to
pay royalties to PDL in any country hereunder shall not preclude SB from
continuing to market or have marketed Licensed Product in such country without
further payment to PDL.
7.02  Termination.
(a)  If either party shall at any time default in the payment of any
royalty, or the making of any report hereunder, or shall commit any material
breach of any covenant or agreement herein contained or shall make any false
report, and shall fail to have initiated and actively pursued remedy of any
such default or breach within (i) fifteen (15) days after receipt of written
notice of failure to pay royalties hereunder, or (ii) forty-five (45) days
after receipt of written notice of any default or breach (other than failure
to pay royalties) by the other party, the non-breaching party may, at its
option, cancel this Agreement and revoke any rights and licenses herein
granted and directly affected by the default or breach by notice in writing to
such effect, but such act shall not prejudice the right of the party giving
notice to recover any royalty or other sums due at the time of such
cancellation, it being understood, however, that if within forty-five (45)
days after receipt of any such notice the receiving party shall have initiated
and actively pursued remedy of its default (other than failure to pay
royalties), then the rights and licenses herein granted shall remain in force
as if no breach or default had occurred on the part of the receiving party,
unless such breach or default is not in fact remedied within a reasonable
period of time.
(b) This Agreement may be terminated by either party upon the occurrence
of any of the following which is not stayed or vacated within ninety (90) days
of such occurrence:  (i) petition in bankruptcy filed by or against the other
party; (ii) adjudication of the other party as bankrupt or insolvent; (iii)
appointment of a liquidator, receiver or trustee for all or a substantial part
of the other party's property; or (iv) an assignment for the benefit of
creditors of the other party.  Notwithstanding the bankruptcy of PDL, or the
impairment of performance by PDL of its obligations under this Agreement as a
result of bankruptcy or insolvency of PDL, SB shall be entitled to retain the
licenses granted herein, subject to PDL's rights to terminate this Agreement
for reasons other than bankruptcy or insolvency as expressly provided in this
Agreement.  All rights granted under or pursuant to this Agreement by PDL to
SB are, and shall otherwise be deemed to be, for purposes of Section 365(n) of
the U.S. Bankruptcy Code, licenses of rights to "intellectual property" as
defined under Section 101(35A) of the U.S. Bankruptcy Code.  The parties agree
that SB, as a licensee of such rights under this Agreement, shall retain and
may fully exercise all of its rights and elections under the U.S. Bankruptcy
Code, subject to performance by SB of its preexisting obligations under this
Agreement.
(c)     [CONFIDENTIAL TREATMENT REQUESTED]
(d)     SB may terminate the license granted under this Agreement as to
the Licensed PDL Patents in any country of the Territory at any time upon
sixty (60) days prior written notice.
7.03  No Waiver.  The right of either party to terminate this Agreement
as provided herein shall not be affected in any way by its waiver of any
previous failure to perform hereunder or by its failure to take action with
respect thereto.
7.04  Survival.  Termination for any reason hereunder shall not affect
any accrued rights or obligations of the parties arising in any manner under
this Agreement as of the date of termination.  In any event, the
confidentiality and indemnity obligations and any accrued but unpaid payment
obligations under Articles 3, 5 and 6, respectively, shall survive any
termination of this Agreement.
8.      MISCELLANEOUS
8.01  Assignment.   This Agreement and the licenses herein granted shall
be binding upon and inure to the benefit of the successors in interest of the
respective parties.  Neither this Agreement nor any interest hereunder shall
be assignable by either party without the prior written consent of the other;
provided, however, that either party may assign this Agreement or any part of
its rights and obligations hereunder to any Affiliate of such party or to any
corporation with which that party may merge or consolidate, or to which it may
transfer all or substantially all of its assets, without obtaining the consent
of the other party, provided that the party effecting such assignment shall
notify the other promptly following such assignment.
8.02  Entire Agreement.   This Agreement, entered into as of the date
written above, constitutes the entire agreement between the parties relating
to the subject matter hereof and supersedes all previous writings and
understandings.  No terms or provisions of this Agreement shall be varied or
modified by any prior or subsequent statement, conduct or act of either of the
parties, except that the parties may amend this Agreement by written
instruments specifically referring to and executed in the same manner as this
Agreement.
8.03  Severability.
        (a)  In the event any portion of this Agreement shall be held illegal,
void or ineffective, the remaining portions hereof shall remain in full force
and effect.
        (b)     If any of the terms or provisions of this Agreement are in
conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law.
        (c)     In the event that the terms and conditions of this Agreement are
materially altered as as provided in Sections 8.03(a) and (b), the parties
will in good faith renegotiate the terms and conditions of this Agreement to
carry out the intent of the parties.
8.04  Notices.  Notices required or permitted under this Agreement shall
be in writing in the English language and sent by by overnight  mail (e.g.,
FedEx), or by facsimile confirmed by by overnight  mail (e.g., FedEx), and
shall be deemed to have been properly served to the addressee upon receipt of
such written communication, to the following addresses of the parties or to
such address or addresses as may be specified from time to time in a written
notice:
If to PDL:      Protein Design Labs, Inc.
        34801 Campus Drive
        Fremont, California 94555 USA
        Attention: General Counsel
        Facsimile number: (510) 574-1473
If to SB:       SmithKline Beecham Corporation
                One Franklin Plaza (Mail Code FP 1930)
                P.O. Box 7929
                Philadelphia, PA  19101
                Attn:  Senior Vice President, Business Development

                Facsimile number:  (215) 751-4253

Copy to:        SmithKline Beecham Corporation
                One Franklin Plaza (Mail Code FP 2360)
                P.O. Box 7929
                Philadelphia, PA 19101
                Attn:  Corporate Law - US

                Fax: number:  (215)751-3935
8.05  Choice of Law.   This Agreement shall be deemed to have been made
in New York and its form, execution, validity, construction and effect shall
be determined in accordance with the laws thereof.
8.06  Dispute Resolution.   Any dispute, controversy or claim arising
out of or relating to this Agreement, including without limitation, a dispute
concerning a termination of this Agreement (hereinafter collectively referred
to as "Dispute") shall be attempted to be settled by the parties, in good
faith, by submitting each such Dispute to appropriate senior management
representatives of each party in an effort to effect a mutually acceptable
resolution thereof within thirty (30) days of submission to such
representatives.  Within fifteen (15) days after submission of the Dispute to
such senior representatives, each party shall submit a brief, written summary
of the Dispute and their respective positions with respect to the Dispute to
such senior representatives.  In the event no mutually acceptable resolution
is achieved in such time frame, then each party shall be entitled to seek
relief for such Dispute by using any appropriate judicial mechanism which may
be available in the courts.
8.07  Waiver.  None of the terms, covenants and conditions of this
Agreement can be waived except by the written consent of the party waiving
compliance.
8.08  Force Majeure.   If the performance of any part of this Agreement
by either party, or of any obligation under this Agreement, is prevented,
restricted, interfered with or delayed by reason of any cause beyond the
reasonable control of the party liable to perform, unless conclusive evidence
to the contrary is provided, the party so affected shall, upon giving written
notice to the other party, be excused from such performance to the extent of
such prevention, restriction, interference or delay; provided that the
affected party shall use its reasonable best efforts to avoid or remove such
causes of non-performance and shall continue performance with the utmost
dispatch whenever such causes are removed.  When such circumstances arise, the
parties shall discuss what, if any, modification of the terms of this
Agreement may be required in order to arrive at an equitable solution.
8.09  Publicity.   It is contemplated that one or both of the parties
may issue a press release announcing this Agreement, the form and content of
which shall be mutually agreed upon.  No other public announcement or other
disclosure to Third Parties concerning the terms, financial or otherwise shall
be made, either directly or indirectly, by any party to this Agreement, except
as may be legally required or as may be required for recording purposes,
without first obtaining the approval of the other Party, which approval shall
not be unreasonably withheld, and agreement upon the nature and text of such
announcement or disclosure.  The party desiring to make any such public
announcement or other disclosure shall inform the other party of the proposed
announcement or disclosure in reasonably sufficient time prior to public
release, and shall provide the other party with a written copy thereof, in
order to allow such other party to comment upon such announcement or
disclosure.  The party reviewing the release shall use good faith efforts to
promptly review and provide comments upon the proposed public release, which
comments shall be provided as soon as practicable but in any event within
seven (7) days of delivery of the initial draft of the proposed release.  Each
party agrees that it shall cooperate fully with the other with respect to all
disclosures regarding this Agreement to the Securities Exchange Commission,
the U.K. Stock Exchange and any other governmental or regulatory agencies,
including requests for confidential treatment of proprietary information of
either party included in any such disclosure.
8.10  Headings.  The captions used herein are inserted for convenience
of reference only and shall not be construed to create obligations, benefits,
or limitations.
8.11  Export.  Each party acknowledges that the laws and regulations of
the United States restrict the export and re-export of commodities and
technical data of United States origin.  Each party agrees that it will not
export or re-export restricted commodities or the technical data of the other
party in any form without the appropriate United States and foreign government
licenses.
8.12  Counterparts.  This Agreement may be executed in counterparts, all
of which taken together shall be regarded as one and the same instrument.

8.13  Independent Contractors. The parties are independent contractors
under this Agreement and no other relationship is intended, including, without
limitation, partnership, joint venture or agency relationship.  Neither party
shall act in a manner which expresses or implies a relationship other than of
independent contractor, nor bind the other party, except as otherwise
expressly provided in this Agreement.  Nothing in this Agreement shall be
deemed to infer any direct relationship between PDL and any Affiliate of SB.
IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement
as of the date first above written.


PROTEIN DESIGN LABS, INC.       SMITHKLINE BEECHAM
                                        CORPORATION


By:  ______________________             By:
____________________________

Title:                                  Title:



EXHIBIT A


Licensed PDL Patents



The following are patents and patent applications (also known as the "Queen et
al. patents") issued and filed in certain countries in the world and licensed
as part of the Licensed PDL Patents under the Agreement (As of August 25,
1999).

1.  The following issued U.S. patents and U.S. patent applications:

No. 5,585,089, "Humanized Immunoglobulins," issued December 17, 1996.

No. 5,693,761, "Polynucleotides Encoding Improved Humanized
Immunoglobulins," issued December 2, 1997.

No. 5,693,762, "Humanized Immunoglobulins," issued December 2, 1997.

[CONFIDENTIAL TREATMENT REQUESTED]


2.  The following patents and patent applications outside the U.S.:

Patent No.

Country
Title*
Issued
647383
Australia
"Novel Immunoglobulins, Their Production
and Use"
Issued
671949
Australia
"
Issued
AT E133452
Austria
"
Issued
0451216
Belgium
"
Issued
61095
Bulgaria
"
Issued
970016

Brazil
"
Issued
0451 216B1
European
"
Issued
0682040 B1
European

Issued
FR0451216
France
"
Issued
DE
68925536
Germany
"
Issued
DD 296 964
East Germany
"
Issued
GB 0451216
Great Britain
"
Issued
1001050

Greece
"
Issued
211174

Hungary
"
Issued
IT O451216
Italy
"
Issued
2828340
Japan
"
Issued
LU O451216
Luxembourg
"
Issued
92.2146
Monaco
"
Issued
NL 0451216
Netherlands
"
Issued
231984
New Zealand
"
Issued
132068
Pakistan
"
Issued
29729
Philippines
"
Issued
92758
Portugal
"
Issued
4895847.13
Russia
"
Issued
2126046
Russia
"
Issued
SG O451216
Singapore
"
Issued
89/9956
South Africa
"
Issued
178385
South Korea
"
Issued
2081974 T3
Spain
"
Issued
SE O451216
Sweden
"
Issued
CHO 451216
Switzerland
"
Issued
50034
Taiwan
"
Issued
13349
Uruguay
"
Issued
48700
Yugoslavia
"







Country
Title*
Pending
Argentina
"Novel Immunoglobulins, Their
Production and Use"
Pending
Canada
"
Pending
Chile
"
Pending
China
"
Pending
Croatia
"
Pending
Czech Republic
"
Pending
Ecuador
"
Pending
Europe
"
Pending
Hong Kong
"
Pending
Ireland
"
Pending
Israel
"
Pending
Japan
"
Pending
South Korea

Pending
Romania
"
Pending
Slovak Republic
"
Pending
Venezuela
"
Pending
Denmark
"
Pending
Finland
"
Pending
Norway
"









*Exact titles may differ in different countries.





IL-5 PATENT LICENSE AGREEMENT
between
PROTEIN DESIGN LABS, INC.
and
SMITHKLINE BEECHAM CORPORATION
This IL-5 Patent License Agreement ("Agreement"), effective as of
September 28, 1999 ("Effective Date"), is made by and between PROTEIN DESIGN
LABS, INC., a Delaware corporation having offices at 34801 Campus Drive,
Fremont, CA 94555 (hereinafter "PDL") and SMITHKLINE BEECHAM CORPORATION, a
Commonwealth of Pennsylvania corporation having offices at One Franklin Plaza,
Philadelphia, PA 19101 (hereinafter "SB").
RECITALS
A.  SB desires to exclusively license certain patents owned or
controlled by PDL related to humanized antibodies directed against the IL-5
antigen; and
B. PDL and SB are contemporaneously entering into an Patent Rights
Agreement (the "Rights Agreement") that grants SB an option to obtain certain
nonexclusive license rights under patents and patent applications owned or
controlled by PDL and a Development and License Agreement for an antibody
directed against the IL-4 antigen (the "Development and License Agreement").
In consideration of SB's obligations under this Agreement, PDL is willing to
exclusively license to SB certain patents owned or controlled by PDL related
to humanized antibodies directed against the IL-5 antigen under the terms and
conditions of this Agreement.
AGREEMENT
NOW THEREFORE, in consideration of the mutual covenants herein contained
and intending to be legally bound, the parties agree as follows:
1.      DEFINITIONS
Except as otherwise expressly provided herein, all references to
Exhibits, Articles and Sections shall be references to Exhibits, Articles and
Sections of this Agreement, and the following terms in this Agreement shall
have the following meanings:
1.01  "Affiliate" shall mean any corporation, firm, partnership or other
entity, whether de jure or de facto, which directly or indirectly owns, is
owned by or is under common ownership with a party to this Agreement to the
extent of at least fifty percent (50%) of the equity (or such lesser
percentage which is the maximum allowed to be owned by a foreign corporation
in a particular jurisdiction) having the power to vote on or direct the
affairs of the entity and any person, firm, partnership, corporation or other
entity actually controlled by, controlling or under common control with a
party to this Agreement; provided however any such person, corporation, firm,
partnership or other entity shall be deemed an Affiliate only for so long as
it meets the requirements of this definition.
1.02  "Antibody" shall mean any antibody, including without limitation,
monospecific and bispecific antibodies; less than full-length antibody forms
such as Fv, Fab, and F(ab')2; single-chain antibodies; and antibody conjugates
bound to a toxin, label or other moiety.
1.03  "Combination Product(s)" shall mean any product containing both a
pharmaceutically active agent or ingredient which constitutes a Licensed
Product and one or more other pharmaceutically active agents or ingredients
which do not constitute Licensed Products.
1.04    "IL-5" shall mean the human cytokine Interleukin 5.

        1.05  "Licensed PDL Patents" shall mean all United States and foreign
patents and patent applications identified on Exhibit A (including any and all
continuations, continuations-in-part, divisions, patents of addition,
reissues, renewals or extensions thereof, all SPCs (as defined below) thereof
and all patents issuing thereof.  Exhibit A will be updated by PDL on a semi-
annual basis.
1.06  "Licensed Product(s)" shall mean human prophylactic, therapeutic,
and/or palliative products that include an Antibody [CONFIDENTIAL TREATMENT
REQUESTED].

1.07  "Major Countries" shall mean the United States, Japan, the United
Kingdom, France, Italy, Spain and Germany.

1.08  "Marketing Approval" shall mean the first approval or
authorization in a country which is required for the marketing, promotion and
sale of Licensed Product in such country.

        1.09  "Net Sales" shall mean the gross invoice price or contract price
from sales of Licensed Products in a form for use by an end user and not
intended for further genetic manipulation or transformation in the Territory
by SB, its Affiliates and sublicensees ("the Selling Party") to Third Parties
less
[CONFIDENTIAL TREATMENT REQUESTED]

Sales between SB, its Affiliates and its or their sublicensees shall be
excluded from the computation of Net Sales and no payments will be payable on
such sales except where such Affiliates or sublicensees are end users, but Net
Sales shall include the subsequent final sales to Third Parties by SB or such
Affiliates or sublicensees. [CONFIDENTIAL TREATMENT REQUESTED]

If SB or any of its Affiliates or sublicensees receive non-cash consideration
for any Licensed Product sold or otherwise transferred to Third Party, the
fair market value of such non-cash consideration on the date of such transfer
as known to SB, or as reasonably estimated by SB if unknown, shall be included
in the definition of Net Sales.

1.10 "SPC"  shall mean a right based upon a patent to exclude others
from making, using or selling Licensed Product, such as a Supplementary
Protection Certificate.

                1.11 [CONFIDENTIAL TREATMENT REQUESTED].

        1.12 "Territory" shall mean worldwide, except in countries where SB's
rights terminate hereunder pursuant to Section 7.02(b) and/or Section 7.02(e).
1.13  "Third Party" shall mean any party other than SB, PDL and their
respective Affiliates.
1.14  "Valid Claim" shall mean [CONFIDENTIAL TREATMENT REQUESTED].
2.      LICENSE
2.01  License Grant.  Subject to the terms and conditions of this
Agreement and in consideration of SB's fulfillment of its obligations to PDL
under this Agreement, PDL hereby grants and SB hereby accepts a worldwide,
exclusive (except as provided in Sections 2.05 and 5.03) license under the
Licensed PDL Patents, including the right to grant sublicenses with respect to
Licensed Products in accordance with Section 2.02, to make, have made, import,
use and sell Licensed Products in the Territory.
2.02  Limitation on Sublicenses; Notification.
(a)  Subject to Section 2.02(b), SB shall have the right to grant
sublicenses of its rights under Section 2.01 with respect to Licensed
Products, provided that (i) SB shall grant such sublicenses only in connection
with the assignment or license by SB to such sublicensee of the right to use,
make, have made, sell or otherwise transfer the Licensed Products in such
country and (ii) [CONFIDENTIAL TREATMENT REQUESTED].  Notwithstanding the
assignment or grant of a sublicense by SB hereunder, SB shall remain obligated
to pay all royalties due to PDL with respect to the sale of Licensed Products
by its assignee or sublicensee.  In addition, the grant of any sublicenses
under Section 2.01 shall be on terms and conditions which are subject to and
subordinate to the terms of this Agreement and SB shall remain fully
responsible to PDL for the performance of any and all such terms by its
sublicensees.  Promptly following execution of any sublicense hereunder, SB
shall notify PDL of the identity of the sublicensee and the scope of the
sublicense and provide a copy of the sublicense agreement, which copy may be
redacted to protect confidential technical or financial information.
(b) [CONFIDENTIAL TREATMENT REQUESTED]
2.03  Updates to List of Licensed PDL Patents.  Not later than December
31 of each year during the term of this Agreement or earlier upon written
request of SB (which request shall not be made more than twice per calendar
year), PDL agrees to provide a written update listing the Licensed PDL
Patents, and such update shall constitute an amendment to Exhibit A.
2.04  No Other License Rights.  SB expressly acknowledges and agrees
that, except for the license expressly granted under Section 2.01, no rights
to any other PDL patents or patent applications, or to any know-how, trade
secrets or licenses are included in this Agreement or granted by implication,
estoppel or otherwise.
2.05 [CONFIDENTIAL TREATMENT REQUESTED]

3.      PAYMENTS, ROYALTIES, REPORTS

             3.01  Signing and Licensing Fee.  In consideration for the license
granted by PDL under Article 2 of this Agreement, SB shall pay to PDL a
nonrefundable non-creditable signing and licensing fee within ten (10)
business days of the Effective Date in the sum of [CONFIDENTIAL TREATMENT
REQUESTED].

           3.02  Annual Maintenance Fee.  In consideration of the rights and
licenses granted under Article 2 of this Agreement, not later than September
15, 2001 and continuing annually thereafter, SB shall pay PDL a nonrefundable
annual maintenance fee in the amount of [CONFIDENTIAL TREATMENT REQUESTED]
within thirty (30) days of each such anniversary. Such annual maintenance fees
shall be [CONFIDENTIAL TREATMENT REQUESTED]against royalties due to PDL in the
calendar year paid.
3.03    Royalties to PDL.  In further consideration of the rights and
licenses granted under Article 2 of this Agreement, subject to Section 2.05,
SB shall pay to PDL the following royalties on Net Sales of Licensed Product
sold by SB, its Affiliates or sublicensees, as applicable:
[CONFIDENTIAL TREATMENT REQUESTED]
3.04  Combination Products.  Net Sales in a particular country, in the
case of Combination Products for which the pharmaceutically active agent or
ingredient constituting a Licensed Product and each of the other
pharmaceutically active agents or ingredients not constituting Licensed
Products have established market prices in that country when sold separately,
shall be determined by multiplying the Net Sales for each such Combination
Product by a fraction, the numerator of which shall be the established market
price for the Licensed Product(s) contained in the Combination Product and the
denominator of which shall be the sum of the established market prices for the
Licensed Product(s) plus the established market prices for the other
pharmaceutically active agents or ingredients contained in the Combination
Product.  When such separate market prices are not established in that
country, then the parties shall negotiate in good faith to determine a fair
and equitable method of calculating Net Sales in that country for the
Combination Product in question.
3.05  Currency Conversion.  All amounts payable to PDL under this
Agreement shall be payable in U.S. Dollars by wire transfer to a bank account
designated by PDL.  In the case of royalties on Net Sales, all amounts payable
shall first be calculated in the currency of sale and then converted into U.S.
Dollars using the actual average  exchange rates for such currency as used by
SB in producing its quarterly and annual accounts, as confirmed by SB's
auditors.
3.06  Reports.
(a)  Current Reports.  SB agrees to make written reports and royalty
payments to PDL within forty-five (45) days after the close of each calendar
quarter during the term of this Agreement, beginning with the calendar quarter
in which the date of first commercial sale or other transfer for value of a
Licensed Product by SB, its Affiliates or sublicensees in the Territory
occurs.  These reports shall be certified by a duly authorized employee in the
Finance Department of SB and shall state for the calendar quarter in question:
(1) identification on a country-by-country basis of each Licensed Product upon
which SB is paying royalties; (2) Net Sales by SB and its Affiliates of such
Licensed Products; (3) Net Sales reported by sublicensees of such Licensed
Products; (4) the place of manufacture of such Licensed Productssold in such
quarter; (5) applicable offsets or deductions and (6) the net royalty due to
PDL thereon pursuant to this Article 3.  No later than at the time of the
making of each such report, SB shall make any payment due to PDL of royalties
for the period covered by such report.
(b)  Termination Report.  For each Licensed Product, SB also agrees to
make a written report to PDL within ninety (90) days after the date on which
SB, its Affiliates or sublicensees last sell or otherwise transfer for value
the Licensed Product anywhere in the Territory stating in such report the same
information required by quarterly reports for all such Licensed Products made,
sold or otherwise disposed of which were not previously reported to PDL.

           (c)  Notification of Marketing Approval.  SB agrees to notify PDL in
writing within ten (10) days after the end of each month of the countries in
the Territory in which SB, its Affiliates or sublicensees obtains Marketing
Approval of a Licensed Product in the preceding month.  Such notice shall
specify the country and date of Marketing Approval.  SB shall assist PDL and
provide reasonable cooperation (including the execution and timely delivery of
any documents, certifications and the like) in obtaining any extensions of the
Licensed PDL Patents with respect to any Licensed Product in any country in
which SB markets Licensed Products.
3.07  Inspection.  SB agrees to keep, and to require any of its
Affiliates or sublicensees to keep, clear, accurate and complete records for a
period of at least three (3) years for each reporting period in which Net
Sales occur showing the manufacture, sales, use and other dispositions for
value of Licensed Products in sufficient detail to enable the royalties
payable hereunder to be determined.  SB further agrees to permit its books and
records, and to require any of its Affiliates or sublicensees to permit their
books and records, to be examined by an independent accounting firm selected
by PDL and reasonably acceptable to SB from time-to-time during regular
business hours, but not more than once a year.  Such independent accounting
firm shall report to PDL only with respect to the accuracy of Net Sales and
deductions reported and payments made by SB to PDL under this Agreement.  All
information disclosed in any such inspection shall be deemed confidential
under the terms of this Agreement. [CONFIDENTIAL TREATMENT REQUESTED]
3.08  Withholding.  SB may withhold from royalties due to PDL amounts
for payment of any withholding tax that SB has paid to any taxing authority
with respect to the royalty amounts due to PDL hereunder for which SB does not
receive a refund or credit. SB agrees to reasonably cooperate with PDL in
obtaining a foreign tax credit in the U.S. with respect to royalties due to
PDL on the sale or manufacture of Licensed Products.
3.09  Interest on Overdue Royalties.  SB shall be liable for interest on
any overdue royalties, at the rate of [CONFIDENTIAL TREATMENT REQUESTED]per
annum, commencing on the date such royalties are due until paid.
4.      LICENSED PDL PATENTS
        4.01  Prosecution and Maintenance.  PDL shall have the sole right to
prepare, file, prosecute, maintain and extend, at its expense, all Licensed
PDL Patents, provided that SB shall have the right to assume responsibility,
at SB's expense, for preparing, filing, prosecuting, maintaining and extending
any such patent or patent application, or any part thereof, which PDL intends
to abandon or otherwise cause or allow to be forfeited.
        4.02  Infringement of Licensed PDL Patents.
        (a)  Notice.  In the event that PDL or SB becomes aware of actual or
threatened infringement of a Licensed PDL Patent anywhere in the Territory,
which infringement relates to an antibody that binds to the IL-5 antigen, that
party shall promptly notify the other party in writing.  The notice shall
describe in reasonable detail the facts and circumstances forming the basis
for the determination that there is actual or threatened infringement.  In the
event the notice specifies threatened, but not actual infringement, the
parties agree to discuss in good faith the proper course of action; provided,
however, that PDL shall have the final decision making authority with respect
to such course of action.  [CONFIDENTIAL TREATMENT REQUESTED]
        (b)  PDL First Right to Litigate For Actual Infringement.  PDL shall
have the first right but not the obligation to bring an infringement action or
file any other appropriate judicial action or claim directly related to actual
infringement of the Licensed PDL Patents against any Third Party that relates
to an antibody that binds to the IL-5 antigen (an "Action") and, if necessary,
to use SB's name in connection therewith and to include SB as a party thereto.
In the event PDL brings an Action, SB shall reimburse PDL for [CONFIDENTIAL
TREATMENT REQUESTED] in enforcing and/or defending the Licensed PDL Patents in
such Action, including without limitation the expenses directly related to the
preparation of such litigation; provided however that SB shall not be required
to reimburse PDL for those expenses that arise from any claims or suits that
are not related to the Licensed PDL Patents or are not related to an antibody
that binds to the IL-5 antigen.  Subject to Section 4.04, PDL shall have sole
control over any Action, including without limitation the right to select
counsel for such action; provided, however that PDL shall solicit, and
seriously consider in good faith SB's input with respect to all material
aspects of such Action, including without limitation the development of the
litigation strategy and the execution thereof.  In furtherance but not in
limitation of the foregoing, PDL shall keep SB promptly and fully informed of
the status of any such Action, and SB shall have the right to review and
comment upon PDL's activities related thereto.  SB shall consult with PDL
concerning such action at no cost to PDL.  To the extent PDL elects its first
right to bring an Action in any country of the Territory, PDL shall use
commercially reasonable good faith efforts, in each such country, to
diligently pursue such Action and obtain results that are consistent with the
respective objectives of the parties under this Agreement.  In the event that
PDL initiates an Action hereunder but subsequently determines not to proceed,
PDL shall provide SB with prompt written notice of such determination and SB
shall have the right to continue such Action as provided in Section 4.04(c).
        (c)  SB's Right to Litigate for Actual Infringement.  [CONFIDENTIAL
TREATMENT REQUESTED] Subject to Section 4.04, SB shall have sole control over
any Action initiated pursuant to this Section 4.02(c), including without
limitation the right to select counsel for such action; provided, however that
SB shall solicit, and seriously consider in good faith PDL's input with
respect to all material aspects of such Action, including without limitation,
the development of the litigation strategy and the execution thereof.  In
furtherance but not in limitation of the foregoing, SB shall keep PDL promptly
and fully informed of the status of any such Action, and PDL shall have the
right to review and comment upon SB's activities related thereto.  PDL shall
consult with SB concerning such action at no cost to SB.  To the extent SB
elects its right to bring an Action, SB shall use commercially reasonable good
faith efforts to diligently pursue such Action and obtain results in each
country that are consistent with the respective objectives of the parties
under this Agreement.
        4.03  Litigation and Settlement Costs.  Allocation of costs and expenses
and recoveries shall be as follows: [CONFIDENTIAL TREATMENT REQUESTED]
        4.04  Cooperation and Settlement.  The parties shall keep one another
informed of the status of and of their respective activities regarding any
Action, including without limitation any discussion concerning the settlement
thereof.  No settlement or consent judgment or other voluntary final
disposition of any suit defended or action brought by one party pursuant to
this Article 4 may be entered into without the consent of the non-settling
party if, and only if, such settlement would require the non-settling party to
be subject to an injunction, to make a monetary payment or would adversely
affect the non-settling party's rights under this Agreement, including without
limitation any settlement concerning the validity or scope of the Licensed PDL
Patents or any settlement concerning SB's exclusive license to the Licensed
PDL Patents set forth in this Agreement.
        4.05  Infringement of Third Party Intellectual Property Rights.
(a)     Notice.  In the event of the institution of any suit by a Third
Party against SB or its respective sublicensees or Affiliates for patent
infringement involving the manufacture, use, importation, sale, distribution
or marketing of Licensed Product anywhere in the Territory, SB shall promptly
notify PDL in writing.
(b)     Rights to Defend.  SB shall have the right but not the obligation
to defend such suit at its own expense, and to use PDL's name in connection
therewith.  Notwithstanding the foregoing, the responsibility for any claim
relating to the invalidity or unenforceability of the Licensed PDL Patents
shall be determined in accordance with Section 4.02.
(c)     Cooperation and Settlement.  SB shall keep PDL fully informed of
the status of its activities regarding any such action, including without
limitation any discussion concerning the settlement thereof.  No settlement or
consent judgment or other voluntary final disposition of any suit defended or
action brought by SB pursuant to this Section 4.05 may be entered into without
the prior written consent of PDL if such settlement would require PDL to be
subject to an injunction, to make a monetary payment or would adversely affect
the Licensed PDL Patents.
4.06  [CONFIDENTIAL TREATMENT REQUESTED]
5.      REPRESENTATIONS AND WARRANTIES; DISCLAIMERS; INDEMNIFICATION
5.01  Valid Agreement.
(a)     Each party represents and warrants to the other that it knows of
no legal reason to prevent it from entering into this Agreement and that the
signatory hereto is duly authorized to execute and deliver this Agreement.
(b)     PDL represents and warrants to SB that it has the right to grant
the licenses to SB provided under this Agreement.
5.02  [CONFIDENTIAL TREATMENT REQUESTED]
5.03  Disclaimers.  Nothing in this Agreement shall be construed as (a)
a warranty or representation by PDL as to the validity, enforceability or
scope of any Licensed PDL Patents; (b) a requirement that PDL file any patent
application, or secure any patent or patent rights, or maintain any patent in
force, or provide copies of patent applications to SB or its Affiliates or
sublicensees, or disclose any inventions described or claimed in such patent
applications; or (c) a warranty or representation by PDL that any Licensed
Product made, used, sold or otherwise disposed of under the license granted in
this Agreement is or will be free from infringement of patents, copyrights,
trademarks, trade secrets or other rights of third parties.  SB acknowledges
and agrees that any royalties or payments that may be due to third parties in
order for SB to make, have made, use, sell or otherwise dispose of Licensed
Products shall be the sole responsibility of SB.
5.04  Existing License.  SB acknowledges that PDL has previously granted
a non-exclusive license, with no ability to sublicense, to a Third Party under
the Licensed PDL Patents, the relevant terms of which have been previously
provided to SB.
5.05  No Other Warranties.  EXCEPT AS SPECIFICALLY SET FORTH IN ARTICLE
5, PDL MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR
IMPLIED, WITH RESPECT TO THE LICENSED PDL PATENTS OR ANY CELL LINES,
ANTIBODIES OR LICENSED PRODUCTS DEVELOPED BY SB UNDER THE LICENSE SET FORTH IN
THIS AGREEMENT AND PDL FURTHER MAKES NO EXPRESS OR IMPLIED WARRANTIES OF
MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF
LICENSED PDL PATENTS OR ANY CELL LINES, ANTIBODIES, LICENSED PRODUCTS OR OTHER
MATERIALS DEVELOPED BY SB UNDER THE LICENSE SET FORTH IN THIS AGREEMENT WILL
NOT INFRINGE ANY THIRD PARTY RIGHTS.
5.06  Indemnification.  Except as otherwise set forth in Article 4
(which Article governs indemnification regarding Licensed PDL Patents), SB
shall at all times, during the term of this Agreement and thereafter,
indemnify and hold harmless PDL and its Affiliates, sublicensees, directors,
officers, agents and employees from any claim, proceeding, loss, expense, and
liability of any kind whatsoever (including but not limited to those resulting
from death, personal injury, illness or property damage and including legal
expenses and reasonable attorneys' fees) ("PDL Losses") arising out of or
resulting from third party claims based upon the development, manufacture,
holding, use, testing, advertisement, sale or other disposition by SB, its
Affiliates or sublicensees, or any distributor, customer or representative
thereof or any one in privity therewith, of any Licensed Product; provided,
however, that such indemnity shall not apply to the extent any such PDL Losses
result from the negligence or willful misconduct of PDL or breach by PDL of
any representation, warranty or other provision of this Agreement.
In the event PDL is seeking indemnification from SB under this Section
5.06, SB shall have no such obligation unless PDL:
(i)  gives SB prompt notice of any claim or lawsuit or other action for
which it seeks to be indemnified under this Agreement;
(ii)  cooperates fully with SB and its agents in defense of any such
claim, complaint, lawsuit or other cause of action; and
(iii)  SB is granted full authority and control over the defense,
including settlement or other disposition thereof, against such claim or
lawsuit or other action, provided that PDL shall have the right to retain
counsel of its choice to participate in the defense of any such claim or
lawsuit at PDL's own expense, provided that such counsel shall not interfere
with SB's full authority and control.
6.      CONFIDENTIALITY

        (a)     During the term of this Agreement and for five (5) years
thereafter, PDL and SB shall not use or reveal or disclose to Third Parties
any confidential information received from the other in the performance of
activities in furtherance of this Agreement without first obtaining the
written consent of the disclosing party, except (i) as may be otherwise
provided herein, (ii) as may be required for purposes of developing,
manufacturing or marketing Licensed Product, (iii) as may be required for
securing essential or desirable authorizations, approvals, privileges or
rights from governmental agencies or as may be required by law, statute or
regulation to be disclosed to a governmental agency, provided that the party
disclosing such information will use reasonable efforts to ensure that the
confidentiality of such confidential information is maintained by such
government regulatory agencies, (iv) as may be required or as necessary to
file or prosecute patent applications concerning Licensed Product, (v) or as
may be required to carry out any litigation concerning Licensed Product
provided that the party disclosing such information will use reasonable
efforts to ensure that the confidentiality of such confidential information is
maintained.  This confidentiality obligation shall not apply to confidential
information which is or becomes a matter of public knowledge through no fault
of the receiving party, or is already in the possession of the receiving
party, or is disclosed to the receiving party by a Third Party having the
right to do so, or is subsequently and independently developed by employees of
the receiving party or Affiliates thereof who had no knowledge of the
confidential information disclosed.  The parties shall take reasonable
measures to assure that no unauthorized use or disclosure is made by others to
whom access to confidential information is granted.
(b)     Nothing herein shall be construed as preventing either party from
disclosing any information received from the other party to:
        (i)  an Affiliate, sublicensee or distributor of the receiving party,
provided such Affiliate, sublicensee or distributor has undertaken a similar
obligation of confidentiality with respect to the confidential information;
        (ii)  the FDA in connection with the approval to conduct clinical
studies, manufacture, market or sell Licensed Product; or

        (iii) any securities exchange to which the receiving party may be
subject if necessary to meet the requirements, rules and regulations of such
securities exchange, but only to the extent such disclosure is reasonably
required and subject to obligations of confidentiality wherever possible.
(c)     All confidential information disclosed by one party to the other
shall remain the intellectual property of the disclosing party.  In the event
that a court or other legal or administrative tribunal, directly or through an
appointed master, trustee or receiver, assumes partial or complete control
over the assets of a party to this Agreement based on the insolvency or
bankruptcy of such party, the bankrupt or insolvent party shall promptly
notify the court or other tribunal (i) that confidential information received
from the other party under this Agreement remains the property of the other
party and (ii) of the confidentiality obligations under this Agreement.  In
addition, the bankrupt or insolvent party shall, to the extent permitted by
law, take all steps necessary or desirable to maintain the confidentiality of
the other party's confidential information and to ensure that the court, other
tribunal or appointee maintains such information in confidence in accordance
with the terms of this Agreement.
7.              TERM AND TERMINATION
7.01  Term.  Unless earlier terminated as provided in this Article 7,
SB's obligations to pay royalties to PDL hereunder shall come into force on
the Effective Date and shall continue, on a country by country basis,
[CONFIDENTIAL TREATMENT REQUESTED].  Unless earlier terminated, this Agreement
shall expire upon the expiration of all SB's royalty obligations to PDL
hereunder.  Expiration of this Agreement or expiration of SB's obligation to
pay royalties to PDL in any country hereunder shall not preclude SB from
continuing to market or have marketed Licensed Product in such country without
further payment to PDL.
7.02  Termination.
(a)     If either party shall at any time default in the payment of any
royalty, or the making of any report hereunder, or shall commit any material
breach of any covenant or agreement herein contained or shall make any false
report, and shall fail to have initiated and actively pursued remedy of any
such default or breach within (i) fifteen (15) days after receipt of written
notice of failure to pay royalties hereunder, or (ii) forty-five (45) days
after receipt of written notice of any default or breach (other than failure
to pay royalties) by the other party, the non-breaching party may, at its
option, cancel this Agreement and revoke any rights and licenses herein
granted and directly affected by the default or breach by notice in writing to
such effect, but such act shall not prejudice the right of the party giving
notice to recover any royalty or other sums due at the time of such
cancellation, it being understood, however, that if within forty-five (45)
days after receipt of any such notice the receiving party shall have initiated
and actively pursued remedy of its default (other than failure to pay
royalties), then the rights and licenses herein granted shall remain in force
as if no breach or default had occurred on the part of the receiving party,
unless such breach or default is not in fact remedied within a reasonable
period of time.
(b)     [CONFIDENTIAL TREATMENT REQUESTED]
(c)     This Agreement may be terminated by either party upon the
occurrence of any of the following which is not stayed or vacated within
ninety (90) days of such occurrence:  (i) petition in bankruptcy filed by or
against the other party; (ii) adjudication of the other party as bankrupt or
insolvent; (iii) appointment of a liquidator, receiver or trustee for all or a
substantial part of the other party's property; or (iv) an assignment for the
benefit of creditors of the other party.  Notwithstanding the bankruptcy of
PDL, or the impairment of performance by PDL of its obligations under this
Agreement as a result of bankruptcy or insolvency of PDL, SB shall be entitled
to retain the licenses granted herein, subject to PDL's rights to terminate
this Agreement for reasons other than bankruptcy or insolvency as expressly
provided in this Agreement.  All rights granted under or pursuant to this
Agreement by PDL to SB are, and shall otherwise be deemed to be, for purposes
of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to
"intellectual property" as defined under Section 101(35A) of the U.S.
Bankruptcy Code.  The parties agree that SB, as a licensee of such rights
under this Agreement, shall retain and may fully exercise all of its rights
and elections under the U.S. Bankruptcy Code, subject to performance by SB of
its preexisting obligations under this Agreement.
        (d)      [CONFIDENTIAL TREATMENT REQUESTED]
(e)     SB may terminate the license granted under this Agreement as to
the Licensed PDL Patents in any country of the Territory at any time upon
sixty (60) days prior written notice.
7.03  No Waiver.  The right of either party to terminate this Agreement as
provided herein shall not be affected in any way by its waiver of any previous
failure to perform hereunder or by its failure to take action with respect
thereto.
7.04  Survival.  Termination for any reason hereunder shall not affect any
accrued rights or obligations of the parties arising in any manner under this
Agreement as of the date of termination.  In any event, the confidentiality
and indemnity obligations and any accrued but unpaid payment obligations under
Articles 3, 5 and 6, respectively, shall survive any termination of this
Agreement.
8.      MISCELLANEOUS
8.01  Assignment.   This Agreement and the licenses herein granted shall
be binding upon and inure to the benefit of the successors in interest of the
respective parties.  Neither this Agreement nor any interest hereunder shall
be assignable by either party without the prior written consent of the other;
provided, however, that either party may assign this Agreement or any part of
its rights and obligations hereunder to any Affiliate of such party or to any
corporation with which that party may merge or consolidate, or to which it may
transfer all or substantially all of its assets, without obtaining the consent
of the other party, provided that the party effecting such assignment shall
notify the other promptly following such assignment.
8.02  Entire Agreement.   This Agreement, entered into as of the date
written above, constitutes the entire agreement between the parties relating
to the subject matter hereof and supersedes all previous writings and
understandings.  No terms or provisions of this Agreement shall be varied or
modified by any prior or subsequent statement, conduct or act of either of the
parties, except that the parties may amend this Agreement by written
instruments specifically referring to and executed in the same manner as this
Agreement.
8.03  Severability.
      (a)   In the event any portion of this Agreement shall be held illegal,
void or ineffective, the remaining portions hereof shall remain in full force
and effect.
      (b)     If any of the terms or provisions of this Agreement are in
conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law.
      (c)   In the event that the terms and conditions of this Agreement are
materially altered as as provided in Sections 8.03(a) and (b), the parties
will in good faith renegotiate the terms and conditions of this Agreement to
carry out the intent of the parties.
8.04  Notices.  Notices required or permitted under this Agreement shall
be in writing in the English language and sent by overnight  mail (e.g.,
FedEx), or by facsimile confirmed by overnight  mail (e.g., FedEx), and shall
be deemed to have been properly served to the addressee upon receipt of such
written communication, to the following addresses of the parties or to such
address or addresses as may be specified from time to time in a written
notice:
If to PDL:      Protein Design Labs, Inc.
        34801 Campus Drive
        Fremont, California 94555 USA
        Attention: General Counsel
        Facsimile number: (510) 574-1473
If to SB:       SmithKline Beecham Corporation
                One Franklin Plaza (Mail Code FP 1930)
                P.O. Box 7929
                Philadelphia, PA  19101
                Attn:  Senior Vice President, Business Development

                Facsimile number:  (215) 751-4253

Copy to:        SmithKline Beecham Corporation
                One Franklin Plaza (Mail Code FP 2360)
                P.O. Box 7929
                Philadelphia, PA 19101
                Attn:  Corporate Law - US

                Fax: number:  (215)751-3935
8.05  Choice of Law.   This Agreement shall be deemed to have been made
in New York and its form, execution, validity, construction and effect shall
be determined in accordance with the laws thereof.
8.06  Dispute Resolution.   Any dispute, controversy or claim arising
out of or relating to this Agreement, including without limitation, a dispute
concerning a termination of this Agreement (hereinafter collectively referred
to as "Dispute") shall be attempted to be settled by the parties, in good
faith, by submitting each such Dispute to appropriate senior management
representatives of each party in an effort to effect a mutually acceptable
resolution thereof within thirty (30) days of submission to such
representatives.  Within fifteen (15) days after submission of the Dispute to
such senior representatives, each party shall submit a brief, written summary
of the Dispute and their respective position with respect to the Dispute to
such senior representatives.  In the event no mutually acceptable resolution
is achieved in such time frame, then each party shall be entitled to seek
relief for such Dispute by using any appropriate judicial mechanism which may
be available in the courts.
8.07  Waiver.  None of the terms, covenants and conditions of this
Agreement can be waived except by the written consent of the party waiving
compliance.
8.08  Force Majeure.   If the performance of any part of this Agreement
by either party, or of any obligation under this Agreement, is prevented,
restricted, interfered with or delayed by reason of any cause beyond the
reasonable control of the party liable to perform, unless conclusive evidence
to the contrary is provided, the party so affected shall, upon giving written
notice to the other party, be excused from such performance to the extent of
such prevention, restriction, interference or delay; provided that the
affected party shall use its reasonable best efforts to avoid or remove such
causes of non-performance and shall continue performance with the utmost
dispatch whenever such causes are removed.  When such circumstances arise, the
parties shall discuss what, if any, modification of the terms of this
Agreement may be required in order to arrive at an equitable solution.
8.09  Publicity.   It is contemplated that one or both of the parties
may issue a press release announcing this Agreement, the Development and
License Agreement and the Option Agreement, the form and content of which
shall be mutually agreed upon.  No other public announcement or other
disclosure to Third Parties concerning the terms, financial or otherwise, of
this Agreement, the Development and License Agreement or the Option Agreement
shall be made, either directly or indirectly, by any party to this Agreement,
except as may be legally required or as may be required for recording
purposes, without first obtaining the approval of the other Party, which
approval shall not be unreasonably withheld, and agreement upon the nature and
text of such announcement or disclosure.  The party desiring to make any such
public announcement or other disclosure shall inform the other party of the
proposed announcement or disclosure in reasonably sufficient time prior to
public release, and shall provide the other party with a written copy thereof,
in order to allow such other party to comment upon such announcement or
disclosure.  The party reviewing the release shall use good faith efforts to
promptly review and provide comments upon the proposed public release, which
comments shall be provided as soon as practicable but in any event within
seven (7) days of delivery of the initial draft of the proposed release.  Each
party agrees that it shall cooperate fully with the other with respect to all
disclosures regarding this Agreement to the Securities Exchange Commission,
the U.K. Stock Exchange and any other governmental or regulatory agencies,
including requests for confidential treatment of proprietary information of
either party included in any such disclosure.
8.10  Headings.  The captions used herein are inserted for convenience
of reference only and shall not be construed to create obligations, benefits,
or limitations.
8.11  Export.  Each party acknowledges that the laws and regulations of
the United States restrict the export and re-export of commodities and
technical data of United States origin.  Each party agrees that it will not
export or re-export restricted commodities or the technical data of the other
party in any form without the appropriate United States and foreign government
licenses.
8.12  Counterparts.  This Agreement may be executed in counterparts, all
of which taken together shall be regarded as one and the same instrument.


8.13  Independent Contractors. The parties are independent contractors
under this Agreement and no other relationship is intended, including, without
limitation, partnership, joint venture or agency relationship.  Neither party
shall act in a manner which expresses or implies a relationship other than of
independent contractor, nor bind the other party, except as otherwise
expressly provided in this Agreement.  Nothing in this Agreement shall be
deemed to infer any direct relationship between PDL and any Affiliate of SB.
IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement
as of the date first above written.


PROTEIN DESIGN LABS, INC.       SMITHKLINE BEECHAM
                                        CORPORATION


By:  ______________________             By:
____________________________

Title:                                  Title:



EXHIBIT A


Licensed PDL Patents

The following are patents and patent applications (also known as the "Queen et
al. patents") issued and filed in certain countries in the world and licensed
as part of the Licensed PDL Patents under the Agreement (As of August 25,
1999)

1.  The following issued U.S. patents and U.S. patent applications:

No. 5,585,089, "Humanized Immunoglobulins," issued December 17, 1996.

No. 5,693,761, "Polynucleotides Encoding Improved Humanized
Immunoglobulins," issued December 2, 1997.

No. 5,693,762, "Humanized Immunoglobulins," issued December 2, 1997.

[CONFIDENTIAL TREATMENT REQUESTED]


2.  The following patents and patent applications outside the U.S.:

Patent No.

Country
Title*
Issued
647383
Australia
"Novel Immunoglobulins, Their Production
and Use"
Issued
671949
Australia
"
Issued
AT E133452
Austria
"
Issued
0451216
Belgium
"
Issued
61095
Bulgaria
"
Issued
970016

Brazil
"
Issued
0451 216B1
European
"
Issued
0682040 B1
European

Issued
FR0451216
France
"
Issued
DE
68925536
Germany
"
Issued
DD 296 964
East Germany
"
Issued
GB 0451216
Great Britain
"
Issued
1001050

Greece
"
Issued
211174

Hungary
"
Issued
IT O451216
Italy
"
Issued
2828340
Japan
"
Issued
LU O451216
Luxembourg
"
Issued
92.2146
Monaco
"
Issued
NL 0451216
Netherlands
"
Issued
231984
New Zealand
"
Issued
132068
Pakistan
"
Issued
29729
Philippines
"
Issued
92758
Portugal
"
Issued
4895847.13
Russia
"
Issued
2126046
Russia
"
Issued
SG O451216
Singapore
"
Issued
89/9956
South Africa
"
Issued
178385
South Korea
"
Issued
2081974 T3
Spain
"
Issued
SE O451216
Sweden
"
Issued
CHO 451216
Switzerland
"
Issued
50034
Taiwan
"
Issued
13349
Uruguay
"
Issued
48700
Yugoslavia
"







Country
Title*
Pending
Argentina
"Novel Immunoglobulins, Their
Production and Use"
Pending
Canada
"
Pending
Chile
"
Pending
China
"
Pending
Croatia
"
Pending
Czech Republic
"
Pending
Ecuador
"
Pending
Europe
"
Pending
Hong Kong
"
Pending
Ireland
"
Pending
Israel
"
Pending
Japan
"
Pending
South Korea

Pending
Romania
"
Pending
Slovak Republic
"
Pending
Venezuela
"
Pending
Denmark
"
Pending
Finland
"
Pending
Norway
"









*Exact titles may differ in different countries.


CONFIDENTIAL TREATMENT REQUESTED WITH RESPECT TO
DESIGNATED PORTIONS OF THIS DOCUMENT




1721
1721
IL-5 PATENT LICENSE AGREEMENT



DEVELOPMENT AND LICENSE AGREEMENT

between

SMITHKLINE BEECHAM CORPORATION

and

PROTEIN DESIGN LABS, INC.







DEVELOPMENT AND LICENSE AGREEMENT

        THIS DEVELOPMENT AND LICENSE AGREEMENT (hereinafter "AGREEMENT"), is
made as of the 28th day of September 1999, between Protein Design Labs, Inc.,
a company organized under the laws of the state of Delaware and having its
principal place of business at 34801 Campus Drive, Fremont, California 94555
U.S.A. (hereinafter "PDL") and SmithKline Beecham Corporation, a corporation
organized and existing under the laws of the Commonwealth of Pennsylvania, and
having its principal office at One Franklin Plaza, Philadelphia, Pennsylvania
19101 U.S.A. (hereinafter "SB").

WITNESSETH THAT:
        WHEREAS, SB is the owner of all right, title and interest in, or
otherwise controls, certain SB PATENTS, identified in Appendix A hereto, and
know-how relating to an antibody that binds to IL-4, known as SB 240683;
        WHEREAS, PDL desires to obtain certain worldwide licenses from SB under
the aforesaid PATENTS and know-how in order to undertake certain development
and marketing efforts related to SB 240683, and SB is willing to grant to PDL
such licenses; and
        WHEREAS, PDL and SB are contemporaneously entering into a Patent Rights
Agreement (the "Rights Agreement") that grants SB rights to obtain certain
nonexclusive license rights under patents and patent applications owned or
controlled by PDL and a Patent License Agreement for an antibody directed
against the IL-5 antigen (the "IL-5 License Agreement").
        NOW, THEREFORE, in consideration of the covenants and obligations
expressed herein, and intending to be legally bound, the parties agree as
follows:

1.      DEFINITIONS
                Except as expressly provided herein, capitalized terms in this
AGREEMENT (including appendices hereto) shall have the following meanings:
        1.01    "ADMINISTRATION COSTS" shall mean those non-direct costs
associated with supporting the commercialization of PRODUCT incurred after the
commercial launch of the PRODUCT.  "SB ADMINISTRATION COSTS" shall equal
[CONFIDENTIAL TREATMENT REQUESTED] of SB NET SALES on an annual basis.  If PDL
co-promotes or otherwise markets or sells PRODUCT as set forth in Article 6,
"PDL ADMINISTRATION COSTS" shall mean those non-direct costs incurred by PDL
after the commercial launch of PRODUCT associated with supporting the
commercialization of PRODUCT and shall be in an amount (expressed as a
percentage of NET SALES) as agreed upon by the parties pursuant to Article 6;
provided however, that in no event shall the amount exceed [CONFIDENTIAL
TREATMENT REQUESTED]of NET SALES.
        1.02    "AFFILIATE(S)" shall mean any corporation, firm, partnership or
other entity, whether de jure or de facto, which directly or indirectly owns,
is owned by or is under common ownership with a party to this AGREEMENT to the
extent of at least fifty percent (50%) of the equity (or such lesser
percentage which is the maximum allowed to be owned by a foreign corporation
in a particular jurisdiction) having the power to vote on or direct the
affairs of the entity and any person, firm, partnership, corporation or other
entity actually controlled by, controlling or under common control with a
party to this AGREEMENT; provided however any such person, corporation, firm,
partnership or other entity shall be deemed an AFFILIATE only for so long as
it meets the requirements of this definition.
        1.03    "AGGREGATE PROJECTED DETAILS" shall mean the aggregate number of
DETAILS projected to be performed by SB sales representatives and, if
applicable, PDL sales representatives in the U.S.A., as determined in
accordance with Paragraph 7.03((b).
        1.04    "COST OF GOODS" as applied to the cost of manufacturing PRODUCT
for DEVELOPMENT and commercial purposes shall mean one or more of the
following:
                [CONFIDENTIAL TREATMENT REQUESTED]
For purposes of calculating PRE-TAX PROFITS, COST OF GOODS shall mean the COST
OF GOODS for the PRODUCT sold and reported in NET SALES during the relevant
reporting period.
        1.05  "DETAIL(S)" shall mean a face-to-face meeting, in an individual or
group practice setting, between a health care professional with prescribing
authority and a professional representative of the applicable party during
which a Major Presentation of PRODUCT is made to such health care
professional.  When used as a verb, "DETAIL" shall mean to engage in a DETAIL.
The term "Major Presentation" as used in this Paragraph 1.05 shall mean a full
PRODUCT presentation during which key PRODUCT attributes are verbally
presented; provided that there shall be no more than [CONFIDENTIAL TREATMENT
REQUESTED]Major Presentations in any DETAIL.
        1.06    "DEVELOPMENT" shall mean:
                (a) all activities related to the development of PRODUCT through
to NDA APPROVAL, including all requisite preclinical and clinical trials
required to confirm the profile of PRODUCT, such as, but not limited to,
trials required to confirm the clinical efficacy, tolerability and dosing
regimen of PRODUCT; and all activities associated with seeking NDA APPROVALS
of PRODUCT; provided that all such activities are undertaken in accordance
with the then-existing DEVELOPMENT PLAN; and
                (b) all activities related to:
(i) PRODUCT manufacture and PRODUCT improvement activities,
such as formulation or reformulation, whether occurring before or after NDA
APPROVAL including, without limitation, the activities set forth on Appendix
E;
(ii) the development of manufacturing processes for PRODUCT,
including without limitation, process development and optimization,
manufacturing scale-up, validation, qualification, and certification;
(iii) the establishment, improvement or expansion of
manufacturing plants and other facilities or equipment used solely for the
manufacture of PRODUCT or, if used for other applications in addition to the
manufacture of PRODUCT, solely to the extent used for the manufacture of
PRODUCT and in any event amortized in accordance with the accounting for such
expenditures in accordance with the then standard practices of the party
incurring the expenditure for such activities; and
(iv) any capital investment solely for PRODUCT associated with
(i), (ii), and (iii) above, provided that all such activities are approved in
advance by the JDC and undertaken in accordance with the then existing
DEVELOPMENT PLAN and in any event amortized in accordance with the accounting
for capital expenditures in accordance with the then standard practices of the
party incurring the expenditure for such activities.
1.07    "DEVELOPMENT COSTS" shall mean the following costs to the extent
incurred by a party after the EFFECTIVE DATE: (i) all costs incurred in
accordance with the then-current DEVELOPMENT PLAN, and (ii) all costs incurred
in excess of the budget in the then-current DEVELOPMENT PLAN provided that any
such excess costs have been approved in advance by each of the co-chairpersons
of the JDC or by the JDC, as appropriate.  DEVELOPMENT COSTS shall consist of
the following:
[CONFIDENTIAL TREATMENT REQUESTED]
The term "FTE" shall mean a full-time equivalent employee (other than
clerical, administrative assistant or secretarial employees) of a party for
whom a reasonable reimbursement allowance shall be determined by the JDC.  The
initial reimbursement rates for each party's FTE are set forth in the
DEVELOPMENT PLAN.  Such reimbursement allowance shall be prorated according to
the amount of time spent by the employee on activities for which reimbursement
is to be paid under this AGREEMENT.  By way of example, (i) if an employee is
a full-time employee and spends one hundred percent (100%) of his or her time
on activities for which reimbursement is to be paid under this AGREEMENT, such
employee shall count as one (1) FTE, and (ii) if an employee is a full-time
employee and spends forty percent (40%) of his or her time on activities for
which reimbursement is to be paid under this AGREEMENT, such employee shall
count as four-tenths (0.4) of an FTE.
        1.08    "DEVELOPMENT PLAN" shall mean the detailed plan for the
DEVELOPMENT of PRODUCT, which DEVELOPMENT PLAN shall include, without
limitation, the activities described in Paragraph 1.06 and a reasonably
detailed budget for the projected expenses to be incurred for the items
described in Paragraph 1.07.  The DEVELOPMENT PLAN, as of the EFFECTIVE DATE,
is summarized and attached to this AGREEMENT as Appendix D and is fully
incorporated into this AGREEMENT.  Such initial DEVELOPMENT PLAN may be
amended from time to time as provided in Article 3.
    1.09    "EFFECTIVE DATE" shall mean the date as of which this AGREEMENT is
effective and shall be the date of this AGREEMENT first written above.
     1.10    "FDA" shall mean, depending on context, the United States Food and
Drug Administration, or the corresponding REGULATORY AUTHORITY in the relevant
country of the TERRITORY, or any successor entities thereto.
        1.11    "IL-4" shall mean the human cytokine known as Interleukin 4.
        1.12    "INTEREST CHARGE ON WORKING CAPITAL" shall mean the quarterly
interest, calculated at the PRIME RATE, on the average Working Capital in the
TERRITORY from the beginning to the end of the relevant calendar quarter. For
purposes of this Paragraph 1.12, "Working Capital" shall mean the sum of
PRODUCT inventories held for sale in the TERRITORY and outstanding THIRD PARTY
trade receivables due from the NET SALES of PRODUCT in the TERRITORY, minus
outstanding THIRD PARTY trade credits due from the acquisition of PRODUCT from
a THIRD PARTY or materials for manufacture of PRODUCT from THIRD PARTIES in
the TERRITORY.
     1.13    "JDC" shall mean the joint development committee consisting of PDL
and SB representatives and other appropriate personnel assembled in accordance
with Paragraph 3.03.
        1.14    "JMC" shall mean the joint marketing committee consisting of PDL
and SB representatives and other appropriate personnel assembled in accordance
with Paragraph 7.01.
     1.15    "NDA" shall mean, depending on context, a New Drug Application or
Biologics License Application filed by or on behalf of SB or PDL with the FDA
requesting approval for commercialization of PRODUCT in the U.S.A. for an
indication, or the corresponding equivalent application in a given country or
regulatory jurisdiction of the TERRITORY.
        1.16    "NDA APPROVAL" shall mean, depending on context, the FDA's
approval of an NDA filed by or on behalf of SB or PDL for marketing PRODUCT
for an indication in any country or regulatory jurisdiction in the TERRITORY
and the approval of all authorizations by governmental authorities which are
required for the marketing, promotion, pricing and sale of PRODUCT in a given
country or regulatory jurisdiction of the TERRITORY, including all
manufacturing, pricing and reimbursement approvals.
     1.17    "OUT OF POCKET COSTS" shall mean any out-of-pocket payment made by
a party to a THIRD PARTY in accordance with the terms and conditions of this
AGREEMENT, but only to the extent such payment relates to costs which are
incurred by a party after the EFFECTIVE DATE.
     1.18    "PATENT COSTS" shall mean the OUT OF POCKET COSTS incurred by a
party in connection with the filing, prosecution and maintenance of SB PATENTS
or PDL PATENTS, as well as the OUT OF POCKET COSTS of any patent interference,
reexamination, reissue, opposition and revocation proceedings in connection
with such SB PATENTS or PDL PATENTS, as the case may be. [CONFIDENTIAL
TREATMENT REQUESTED]
        1.19    "PDL" shall mean Protein Design Labs, Inc., a company organized
under Delaware law and as of the EFFECTIVE DATE having its principal place of
business at 34801 Campus Drive, Fremont, California, 94555 U.S.A.
        1.20    "PDL KNOW-HOW" shall mean all present and future technical
information and know-how which relates to PRODUCT and shall include, without
limitation, all biological, chemical, pharmacological, toxicological,
clinical, assay, and control data and any other information relating to
PRODUCT and useful for the DEVELOPMENT and commercialization of PRODUCT.
Notwithstanding the above, it is understood that the term PDL KNOW-HOW shall
not include any information or know-how related to the manufacture (e.g., cell
culture, fermentation) or purification of any monoclonal antibody including,
without limitation, PRODUCT, except to the extent such information or know-how
shall be reasonably required with respect to a claim of product liability
related to PRODUCT.
        1.21    "PDL NET SALES" shall mean the gross receipts from sales of
PRODUCT in each country in the TERRITORY by PDL, its AFFILIATES and
sublicensees ("the Selling Party") to THIRD PARTIES less

[CONFIDENTIAL TREATMENT REQUESTED]
Sales between PDL, its AFFILIATES and its or their sublicensees shall be
excluded from the computation of PDL NET SALES and no payments will be payable
on such sales except where such AFFILIATES or sublicensees are end users, but
PDL NET SALES shall include the subsequent final sales to THIRD PARTIES by
such AFFILIATES or sublicensees. [CONFIDENTIAL TREATMENT REQUESTED] If a
Selling Party receives non-cash consideration for any PRODUCT sold or
otherwise transferred to a THIRD PARTY, the fair market value of such non-cash
consideration on the date of such transfer as known to PDL, or as reasonably
estimated by PDL if unknown, shall be included in the definition of Net Sales.
        1.22    "PDL PATENTS" shall mean either:
                 (a) Unless and until PDL's rights are terminated pursuant to
Paragraph 3.06 or Article 12, all U.S.A. and other patents and patent
applications (including any and all continuations, continuations-in-part,
divisions, patents of addition, reissues, renewals or extensions thereof and
all SPCs (as defined below)) during the term of this AGREEMENT which are or
become owned by PDL, or to which PDL otherwise has, now or in the future, the
right to grant licenses, which generically or specifically claim PRODUCT, a
process for manufacturing PRODUCT, an intermediate used in such process or a
use of PRODUCT.  Also included within the definition of PDL PATENTS under this
Paragraph 1.22(a) are any patents or patent applications which generically or
specifically claim any improvements on PRODUCT or intermediates or
manufacturing processes required or useful for production of PRODUCT which are
developed by PDL, or which PDL otherwise has the right to grant licenses, now
or in the future, during the term of this AGREEMENT.  The current list of PDL
PATENTS is set forth in Appendix A attached hereto.
            (b)  If PDL's rights to PRODUCT are terminated under Paragraph 3.06
or Article 12, all U.S.A. and other patents and patent applications (including
any and all continuations, continuations-in-part, divisions, patents of
addition, reissues, renewals or extensions thereof and all SPCs) which are or,
at any time during the term of this AGREEMENT through the effective date of
termination of PDL's rights under Paragraph 3.06 or Article 12 become owned by
PDL, or to which PDL otherwise has, now or at any time during the term of this
AGREEMENT through the effective date of termination of PDL's rights under
Paragraph 3.06 or Article 12, the right to grant licenses, which generically
or specifically claim PRODUCT, a process for manufacturing PRODUCT, an
intermediate used in such process or a use of PRODUCT.  Also included within
the definition of PDL PATENTS under this Paragraph 1.22 are any patents or
patent applications which generically or specifically claim any improvements
on PRODUCT or intermediates or manufacturing processes required or useful for
production of PRODUCT which are developed by PDL during the term of this
AGREEMENT through the effective date of termination of PDL's rights under
Paragraph 3.06 or Article 12.
        1.23    "PHASE II REVIEW POINT" shall mean the date of notification from
PDL that it has delivered to SB all of the clinical safety and efficacy data
due [CONFIDENTIAL TREATMENT REQUESTED].
        1.24    "PHASE II REVIEW POINT PAYMENT" shall mean the payment indicated
in Paragraph 3.04(a).
        1.25    "PRE-LAUNCH COMMERCIAL EXPENSES" shall mean the sum of the
following expenses: [CONFIDENTIAL TREATMENT REQUESTED].
        1.26    " PRE-TAX PROFITS" shall mean the following calculation:
[CONFIDENTIAL TREATMENT REQUESTED].
      1.27    "PRIME RATE" shall mean the U.S.A. prime rate quoted by Citibank,
N.A. for the applicable period.
        1.28    "PRODUCT" shall mean a pharmaceutical product comprising
[CONFIDENTIAL TREATMENT REQUESTED].
        1.29    "PROMOTION EXPENSES" shall mean all direct and/or allocated
selling, promotional, marketing and medical expenses for PRODUCT in the
TERRITORY incurred by SB or PDL after the PHASE II REVIEW POINT PAYMENT which
are directly related to:
                [CONFIDENTIAL TREATMENT REQUESTED]
provided that the scope of the term PROMOTION EXPENSES as it applies to
expenses incurred by PDL shall be limited to those which are incurred for the
promotion of PRODUCT in the U.S.A. in accordance with the procedures set forth
in Article 7.
     1.30    "REGULATORY AUTHORITY(IES)" shall mean, depending on context, the
FDA in the U.S.A. and/or the corresponding authorities in a given country or
regulatory jurisdiction of the TERRITORY with responsibility for granting
regulatory approval and pricing/reimbursement approval where appropriate for
the manufacture, marketing, import, sale or use of PRODUCT in such country or
regulatory jurisdiction.
        1.31    [CONFIDENTIAL TREATMENT REQUESTED]
    1.32    "SB 240683" shall mean that humanized antibody which binds to the
human cytokine Interleukin 4 (IL-4) designated by SB as of the EFFECTIVE DATE
as SB 240683.
        1.33    "SB" shall mean SmithKline Beecham Corporation, a corporation
organized and existing under the laws of the Commonwealth of Pennsylvania, and
as of the EFFECTIVE DATE having its principal office at One Franklin Plaza,
Philadelphia, Pennsylvania 19101 U.S.A.
        1.34    "SB KNOW-HOW" shall mean all present and future technical
information and know-how which relates to PRODUCT and shall include, without
limitation, all biological, chemical, pharmacological, toxicological,
clinical, assay, and control data and any other information relating to
PRODUCT and useful for the DEVELOPMENT and commercialization of PRODUCT.
Notwithstanding the above, it is understood that the term SB KNOW-HOW shall
not include any information or know-how related to the manufacture (e.g., cell
culture, fermentation) or purification of any monoclonal antibody including,
without limitation, PRODUCT, except to the extent such information or know-how
shall be reasonably required with respect to a claim of product liability
related to PRODUCT.
     1.35    "SB NET SALES" shall mean the gross receipts from sales of PRODUCT
in the TERRITORY by SB, its AFFILIATES and sublicensees ("the Selling Party")
to THIRD PARTIES less [CONFIDENTIAL TREATMENT REQUESTED]Sales between SB, its
AFFILIATES and its or their sublicensees shall be excluded from the
computation of SB NET SALES and no payments will be payable on such sales
except where such AFFILIATES or sublicensees are end users, but SB NET SALES
shall include the subsequent final sales to THIRD PARTIES by such AFFILIATES
or sublicensees. [CONFIDENTIAL TREATMENT REQUESTED]  If a Selling Party
receives non-cash consideration for any PRODUCT sold or otherwise transferred
to a THIRD PARTY, the fair market value of such non-cash consideration on the
date of such transfer as known to SB, or as reasonably estimated by SB if
unknown, shall be included in the definition of Net Sales.
        1.36    "SB PATENTS" shall mean either:
        (a) Unless and until SB's rights are terminated pursuant to Paragraph
3.06 or Article 12, all U.S.A. and other patents and patent applications
(including any and all continuations, continuations-in-part, divisions,
patents of addition, reissues, renewals or extensions thereof and all SPCs)
during the term of this AGREEMENT which are or become owned by SB, or to which
SB otherwise has, now or in the future, the right to grant licenses, which
generically or specifically claim PRODUCT, a process for manufacturing
PRODUCT, an intermediate used in such process or a use of PRODUCT. Also
included within the definition of SB PATENTS under this Paragraph 1.36(a) are
any patents or patent applications which generically or specifically claim any
improvements on PRODUCT or intermediates or manufacturing processes required
or useful for production of PRODUCT which are developed by SB, or which SB
otherwise has the right to grant licenses, now or in the future, during the
term of this AGREEMENT.  The current list of SB PATENTS is set forth in
Appendix A attached hereto.
        (b)  If SB's rights to PRODUCT are terminated under Paragraph 3.06 or
Article 12, all U.S.A. and other patents and patent applications (including
any and all continuations, continuations-in-part, divisions, patents of
addition, reissues, renewals or extensions thereof and all SPCs ) which are
or, at any time during the term of this AGREEMENT through the effective date
of termination of SB's rights under Paragraph 3.06 or Article 12 become owned
by SB, or to which SB otherwise has, now or at any time during the term of
this AGREEMENT through the effective date of termination of SB's rights under
Paragraph 3.06 or Article 12, the right to grant licenses, which generically
or specifically claim PRODUCT, a process for manufacturing PRODUCT, an
intermediate used in such process or a use of PRODUCT.  Also included within
the definition of SB PATENTS under this Paragraph 1.36(b) are any patents or
patent applications which generically or specifically claim any improvements
on PRODUCT or intermediates or manufacturing processes required or useful for
production of PRODUCT which are developed by SB during the term of this
AGREEMENT through the effective date of termination of SB's rights under
Articles 3 or Article 12.
     1.37    "SPC(s)" shall mean a right based upon a patent to exclude others
from making, using or selling PRODUCT, such as a Supplementary Protection
Certificate.
        1.38    "TERRITORY" shall mean all of the countries of the world.
        1.39    "THIRD PARTY(IES)" shall mean any party other than SB, PDL and
their respective AFFILIATES.
        1.40    "THIRD PARTY ROYALTIES" shall mean one hundred percent (100%) of
those payments set forth in Paragraph 5.06.
      1.41    "TRADEMARK COSTS" shall mean the OUT OF POCKET COSTS incurred by
SB after the EFFECTIVE DATE, including without limitation, the fees and
expenses paid to outside legal counsel and experts, related to creation,
search, trademark marketing research, prosecution, registration and
maintenance of trademarks which may be employed by SB specifically in
conjunction with the commercialization of PRODUCT in the TERRITORY and which
are directly related to PRODUCT ("Trademark").  TRADEMARK COSTS shall also
include the OUT OF POCKET COSTS incurred by SB, including without limitation,
the fees and expenses paid to outside legal counsel and experts and other
THIRD PARTIES which were incurred in bringing, maintaining and prosecuting any
action related to any actual, alleged or threatened infringement of any
Trademark or of any unfair trade practices, trade dress imitation, passing off
of counterfeit goods, or like offenses, or defending any such claims brought
by a THIRD PARTY against a Trademark used on a PRODUCT.  TRADEMARK COSTS shall
in no event include costs or expenses related to a "house name" or trade name
which is not used exclusively in connection with PRODUCT.
        1.42    "U.S.A." shall mean the United States of America and all of its
territories, trusteeships and possessions including, without limitation, the
Commonwealth of Puerto Rico.
        1.43    "VALID CLAIM" shall mean [CONFIDENTIAL TREATMENT REQUESTED] 2.
        LICENSE GRANTS
        2.01    SB Grant.
                (a)     Subject to the terms and conditions of this
AGREEMENT, SB hereby grants to PDL, under SB PATENTS and SB KNOW-HOW, a co-
exclusive license to make, have made, use, sell, import, and offer for sale
PRODUCT in the TERRITORY in accordance with the terms and conditions of this
AGREEMENT, with the right to sublicense as set forth in Paragraph 2.03 below.
                (b)     Subject to the terms and conditions of this
AGREEMENT, SB shall not grant to any THIRD PARTY, under SB PATENTS and SB
KNOW-HOW, any license to make, have made, use, sell, import, and offer for
sale PRODUCT in the TERRITORY, except as set forth in  Paragraph 2.03 below.
                (c)     In the event SB's rights to PRODUCT are
terminated in accordance with Paragraph 3.06 or Article 12, the license
granted in Paragraph 2.01(a) shall terminate and the license from SB to PDL,
under SB PATENTS and SB KNOW-HOW, shall become as of the effective date of
such termination a royalty-bearing, exclusive license to make, have made, use,
sell, import, and offer for sale PRODUCT in the TERRITORY in accordance with
the terms and conditions of this AGREEMENT, with the right to sublicense as
set forth in Paragraph 2.03 below.
        2.02    PDL Grant.
                (a)     Subject to the terms and conditions of this
AGREEMENT, PDL hereby grants to SB, under PDL PATENTS and PDL KNOW-HOW, a co-
exclusive license to make, have made, use, sell, import and offer for sale
PRODUCT in the TERRITORY in accordance with the terms and conditions of this
AGREEMENT, with the right to sublicense as set forth in Paragraph 2.03 below.
                (b)     Subject to the terms and conditions of this
AGREEMENT, PDL shall not grant to any THIRD PARTY, under PDL PATENTS and PDL
KNOW-HOW, any license to make, have made, use, sell, import and offer for sale
PRODUCT in the TERRITORY, except as set forth in Paragraph 2.03 below.
                (c)     In the event PDL's rights to PRODUCT are
terminated in accordance with Paragraph 3.06 or Article 12, the license
granted in Paragraph 2.02(a) shall terminate and  the license from PDL to SB,
under PDL PATENTS and PDL KNOW-HOW, shall become as of the effective date of
such termination a royalty-bearing, exclusive license to make, have made, use,
sell, import, and offer for sale PRODUCT in the TERRITORY in accordance with
the terms and conditions of this AGREEMENT, with the right to sublicense as
set forth in Paragraph 2.03 below.
        2.03    Sublicensing.
             (a)  Prior to the PHASE II REVIEW POINT, neither party shall have
the right to license its rights to PRODUCT, including both its own rights and
those rights it receives from the other party under this AGREEMENT, to a THIRD
PARTY without the approval of the other party.
             (b)  Subject to Paragraph 7.03(f), in the event SB makes the PHASE
II REVIEW POINT PAYMENT and neither party's rights to PRODUCT have been
terminated hereunder, neither party shall have the right to license its rights
to PRODUCT, including both its own rights and those rights it receives from
the other party under this AGREEMENT, to a THIRD PARTY without the approval of
the other party, such approval not to be unreasonably withheld.
                (c)  In the event SB's rights to PRODUCT are terminated in
accordance with Paragraph 3.06 or Article 12, PDL shall have the right to
license its rights to PRODUCT, including both its own rights and those rights
it receives from SB under this AGREEMENT, to a THIRD PARTY; provided, however,
that PDL's right to grant sublicenses pursuant to this Paragraph 2.03(c) shall
be subject to [CONFIDENTIAL TREATMENT REQUESTED].
                (d)  In the event PDL's rights to PRODUCT are terminated in
accordance with Paragraph 3.06 or Article 12, SB shall have the right to
license its rights to PRODUCT, including both its own rights and those rights
it receives from PDL under this AGREEMENT, to a THIRD PARTY.
        2.04    Each license and right granted pursuant to this AGREEMENT is
subject to all of the terms and conditions of this AGREEMENT in addition to
such terms and conditions as may be explicitly referenced in the provision
granting such license or right.
      2.05    Subject to Paragraphs 2.03, 5.03, 5.04 and 5.05, each party shall
have the right to grant sublicenses of its rights under this Article 2 with
respect to PRODUCT, provided that  each party shall grant such sublicenses
only in connection with the assignment or license by that party to such
sublicensee of the right to use, make, have made, sell or otherwise transfer
the PRODUCT in such country.  Notwithstanding the assignment or grant of a
sublicense by a party hereunder, the sublicensing party shall remain obligated
to pay all royalties due to the other party with respect to the sale of
PRODUCT by its assignee or sublicensee.  In addition, the grant of any
sublicenses under this AGREEMENT shall be on terms and conditions which are
subject to and subordinate to the terms of this AGREEMENT and the sublicensing
party shall remain fully responsible to the other party for the performance of
any and all such terms by its sublicensees.  Promptly following execution of
any sublicense hereunder, the sublicensing party shall notify the other party
of the identity of the sublicensee and the scope of the sublicense and provide
a copy of the sublicense agreement, which copy may be redacted to protect
confidential technical or financial information.
3.      DEVELOPMENT
        3.01    DEVELOPMENT Responsibility.
         (a)  Through PHASE II REVIEW POINT Decision.  After the EFFECTIVE
DATE and up through the PHASE II REVIEW POINT, PDL shall be responsible for
undertaking the DEVELOPMENT of PRODUCT in accordance with the DEVELOPMENT
PLAN, except as set forth in Paragraph 4.01.  PDL and SB (to the extent
applicable) shall use commercially reasonable efforts and diligence to
complete the activities set forth in the DEVELOPMENT PLAN in accordance with
the time frames set forth therein.  The parties expressly acknowledge that PDL
shall be solely responsible for the DEVELOPMENT COSTS through the PHASE II
REVIEW POINT pursuant to Paragraph 3.04, except as expressly provided herein
and in Paragraph 4.01; provided that each party shall be responsible for their
own PATENT COSTS incurred prior to the PHASE II REVIEW POINT.  The DEVELOPMENT
PLAN will be revised or amended as determined by the JDC but in any event at
least annually to reflect new data or information, including without
limitation information or data from clinical trials with PRODUCT and
[CONFIDENTIAL TREATMENT REQUESTED].  If, during the term of the AGREEMENT up
through the PHASE II REVIEW POINT, SB requests that additional DEVELOPMENT
activities which are not included in the DEVELOPMENT PLAN be carried out by
PDL (or by SB, in the case of DEVELOPMENT activities related to Paragraph
1.06(b)), and the JDC determines that such work is:
                (i) not critical to the timely registration of PRODUCT, then
PDL (or by SB, in the case of DEVELOPMENT activities related to Paragraph
1.06(b)) shall undertake such work at SB's expense, subject to SB's approval
that such activities should be performed and that the associated expense is
acceptable, or
              (ii) critical to the timely registration of PRODUCT, then
the DEVELOPMENT PLAN shall be amended and PDL (or SB, in the case of
DEVELOPMENT activities related to Paragraph 1.06(b)) shall undertake such work
at PDL's expense.
                (b)  After PHASE II REVIEW POINT Payment.  If SB has made the
PHASE II REVIEW POINT PAYMENT, the JDC shall allocate the various activities
to be performed under the DEVELOPMENT PLAN between the parties in accordance
with the terms and conditions of this AGREEMENT.  The DEVELOPMENT COSTS
incurred by either party subsequent to the PHASE II REVIEW POINT shall be
allocated between the parties as provided in Paragraph 3.04(a)(iii).  If SB
does not make the PHASE II REVIEW POINT PAYMENT, then the provisions of
Paragraph 3.04(b) shall be applicable, and all DEVELOPMENT COSTS for the
continuation of the DEVELOPMENT shall be borne solely by PDL.
   3.02    Development Coordinators.  Promptly after the EFFECTIVE DATE, each
party shall designate a Development Coordinator who will be responsible for
scheduling meetings and identifying appropriate contact individuals at SB and
PDL involved in the DEVELOPMENT of PRODUCT, promoting the progress of the
DEVELOPMENT PLAN, facilitating the exchange of data and information, preparing
and distributing minutes of the meetings of the JDC and other meetings
substantially focused on the DEVELOPMENT of PRODUCT and coordinating the
respective DEVELOPMENT efforts of the parties from time to time during the
term of this AGREEMENT.  Each party shall bear its own expenses, including
travel, accommodations, and living expenses, incurred in connection with their
respective efforts described in this Paragraph 3.02.  The role of each party's
Development Coordinator shall be subject to the direction of the respective
party's representatives on the JDC. The role of the Development Coordinators
shall terminate in the event that either party loses their rights to PRODUCT
in accordance with this AGREEMENT.
        3.03    JDC.
                (a)  Appointment. Within thirty (30) days after the EFFECTIVE
DATE, the parties will establish a JDC composed of three (3) representatives
from each party with appropriate background, experience and qualifications to
oversee the progress of DEVELOPMENT.  The initial PDL representatives shall be
[CONFIDENTIAL TREATMENT REQUESTED].  Either party may change its
representatives on the JDC at any time by written notice to the other party.
                (b)  Responsibilities. The JDC shall be responsible for:
(i) overseeing the implementation of and monitoring of the
DEVELOPMENT PLAN, including a coordination of the timelines, goals and
implementation of manufacturing and clinical efforts for DEVELOPMENT;
 (ii) coordinating the timely commitment of identified
resources to implement the DEVELOPMENT PLAN, including the timely manufacture
and release of PRODUCT supplies for use in clinical trials contemplated under
the DEVELOPMENT PLAN and timely preparation and filing of associated
regulatory filings;
(iii) regularly reviewing and providing written updates on
the progress of the DEVELOPMENT efforts under the DEVELOPMENT PLAN to
appropriate management of PDL and SB;
(iv) subject to Paragraph 3.03(d), attempting to settle any
issues or disputes that may arise between the functional departments of the
parties related to the DEVELOPMENT of PRODUCT;
                 (v) overseeing the activities carried out by the Development
Coordinators (as defined in Paragraph 3.02);
                 (vi) carrying out any other responsibilities not outlined in
this Paragraph which are specified for the JDC in this AGREEMENT; and
(vii) following the date on which SB has made the PHASE II
REVIEW POINT PAYMENT, in addition to the responsibilities outlined above, the
JDC shall have the following additional responsibilities:
        (A) preparing a comprehensive budget and related
annual budgets to be mutually agreed upon in advance of the relevant period
for which they apply for all subsequent DEVELOPMENT efforts, such
comprehensive budget to then become part of the DEVELOPMENT PLAN, provided it
is understood that an updated DEVELOPMENT PLAN will be drafted and presented
to the JDC at such times as the JDC deems appropriate, but no less frequently
than annually, and the JDC will review each update thereto and will amend such
plan as required to achieve approval by the JDC no later than thirty (30) days
after submission of the drafts prepared by the parties pursuant this
Paragraph;
        (B) administration of the annual budget, provided that
the JDC's authority is limited to such DEVELOPMENT PLAN and budget except as
otherwise provided in Paragraph 3.03(b)(vii)(C) below; and
        (C) except as expressly contemplated in a mutually
agreed upon budget and/or the DEVELOPMENT PLAN, each party agrees that
decisions of the JDC regarding the commitment of expenditures of amounts in
excess of [CONFIDENTIAL TREATMENT REQUESTED] of an approved annual budget, or
additional internal resources of a party beyond those specified in the
DEVELOPMENT PLAN, shall be subject to prior approval pursuant to that party's
then-current internal review and approval processes.
              (c)  Meetings, Reporting and Decisions.  The JDC will meet at
least once per calendar quarter at mutually agreed upon times and locations
using mutually agreed upon meeting formats, including videoconferencing and
teleconferencing, unless otherwise mutually agreed by the parties.  After the
EFFECTIVE DATE, it is envisioned that meetings of the JDC will be held at
facilities alternately selected by PDL and by SB.  Each party shall promptly
report to the JDC on all material issues relating to DEVELOPMENT of PRODUCT
including, but not limited to the status of formulation efforts, the status of
patient enrollment in the ongoing clinical trials, the status of clinical
supplies, target dates for data analysis and report preparation, and target
dates for the PHASE II REVIEW POINT and IND and NDA filings.  Each party shall
cause its representatives to attend the meetings of the JDC provided, however,
that meetings of the JDC shall be effective for decision-making if at least
one representative of each party is present or participating.  If a
representative of a party is unable to attend a meeting, such party may
designate an alternate to attend such meeting in place of the missing
representative.  In addition, each party may, at its discretion, invite non-
voting employees, consultants or advisors whose presence is considered of
importance or value to the DEVELOPMENT to attend and participate in the
meetings of the JDC, provided that any such consultant or advisor shall have
undertaken confidentiality obligations to PDL or SB, as the case may be, at
least comparable to the confidentiality provisions undertaken by the parties
under this AGREEMENT, with respect to the subject matter of any such meeting.
Minutes shall be kept of all JDC meetings, shall be promptly reviewed by both
parties within twenty (20) business days of delivery, and shall be deemed
approved when mutually accepted by the parties as evidenced in writing or if
one party has not responded to the draft and/or comments delivered by the
other party by the later of  the 20-day period or five (5) business days after
receipt of comments from the other party, if any.  The parties shall use good
faith efforts to finalize the minutes within five (5) business days after
receipt of comments, if any.  Decisions of the JDC shall be by unanimous vote,
with each party having one (1) vote.
          (d)  Deadlock - In the event of a deadlock by the JDC, in lieu of
invoking the dispute resolution process set forth in Article 17, the deadlock
shall be resolved as follows:
[CONFIDENTIAL TREATMENT REQUESTED]
           (e)  Expenses - Each party shall bear its own expenses, including
travel, accommodations, and living expense, incurred in connection with their
respective efforts described in Paragraph 3.03, except as otherwise provided
in Paragraph 3.03(d)(ii).
        3.04    PHASE II REVIEW POINT Decision.  Promptly after the PHASE II
REVIEW POINT, but, in any event, no later than sixty (60) days thereafter,
based, in part, on a review of the final, quality-assured data tables (in a
form to be mutually agreed upon) for all pre-specified safety and efficacy
data on PRODUCT described in the approved protocols from the studies outlined
in the DEVELOPMENT PLAN, SB, at its sole discretion, shall have the option to
elect to participate in the further DEVELOPMENT and commercialization of
PRODUCT in all countries in the TERRITORY in accordance with the terms and
conditions of this AGREEMENT by providing written notice to PDL.
             (a)  SB Exercises Right.  In the event SB makes such election,
the following provisions shall apply:
                (i)  In consideration for the licenses under PDL PATENTS and
PDL KNOW-HOW granted to SB under this AGREEMENT, SB shall pay to PDL a non-
refundable, non-creditable payment of [CONFIDENTIAL TREATMENT REQUESTED]within
fifteen (15) days after SB notifies PDL of its election.
              (ii)  The JDC shall promptly meet to decide which party can
most effectively and expeditiously complete the remaining DEVELOPMENT of
PRODUCT, which party shall be named on each regulatory filing in the
TERRITORY, and how to appropriately amend the DEVELOPMENT PLAN to reflect such
decisions; and
                      (iii)  The DEVELOPMENT COSTS and PRE-LAUNCH COMMERCIAL
EXPENSES incurred by either party subsequent to the PHASE II REVIEW POINT
shall be shared by the parties, with SB bearing [CONFIDENTIAL TREATMENT
REQUESTED]and PDL bearing [CONFIDENTIAL TREATMENT REQUESTED].  Accounting and
sharing of these costs shall be as provided in Article 11.
              (b)  SB Does Not Exercise Right.  In the event that SB elects
not to or fails to make the PHASE II REVIEW POINT PAYMENT,  the JDC and
Development Coordinators shall be terminated and the provisions of Paragraph
5.03 shall apply effective as of the date of expiration or termination of SB's
rights.  Thereafter, subject to SB's rights and obligations pursuant to
Article 4, SB shall have no further rights or obligations with respect to the
DEVELOPMENT or commercialization of the PRODUCT.  PDL shall thereafter use
commercially reasonable efforts and diligence, consistent with the effort that
is used by PDL in the development, testing, manufacture, registration,
marketing and sale of pharmaceutical products at a similar stage of
development, having a comparable level of market potential, and being subject
to a comparable regulatory review, to develop and commercialize the PRODUCT in
the TERRITORY and shall provide bi-annual updates to SB on the progress of the
DEVELOPMENT of PRODUCT.  All such bi-annual updates shall be considered the
confidential information of PDL and subject to the provisions of Paragraph
8.03.
        3.05    Information Exchange.  In order to facilitate DEVELOPMENT and
PDL's accomplishment of the responsibilities outlined in Paragraphs 3.01,
3.02, and 3.03, SB shall supply PDL, promptly after the EFFECTIVE DATE, with
the information and access to information set forth in Appendix E as well as
all relevant clinical, preclinical and other relevant data related to PRODUCT
in its possession. [CONFIDENTIAL TREATMENT REQUESTED]
        3.06    Termination of DEVELOPMENT.
                (a)  Termination of PDL DEVELOPMENT.
                        (i)  PDL Funding Difficulties.  In the event that PDL
becomes aware that it will have significant problems providing the funding it
requires in order to carry out its DEVELOPMENT obligations under this
AGREEMENT (including by reason of a decision by PDL not to provide such
funding), it shall promptly notify SB, in writing.  In this event, SB shall
have the option, at its sole discretion, within thirty (30) days of receipt of
such notice from PDL, to solely assume DEVELOPMENT responsibility.  If SB
elects to assume this responsibility, it shall so notify PDL in writing, in
which case the JDC and the Development Coordinators shall terminate and SB
shall be solely responsible for the continued DEVELOPMENT and
commercialization of PRODUCT, all rights to PRODUCT granted to PDL shall
terminate and revert to SB, PDL's license under SB PATENTS and SB KNOW-HOW
shall terminate, and PDL shall transfer all clinical, preclinical and other
relevant information and data related to PRODUCT in its possession to SB
(including the assignment of any filings with REGULATORY AUTHORITIES held by
PDL) at no cost to SB, and SB shall immediately have an exclusive license to
make, have made, import, use, sell and offer to sell PRODUCT in the TERRITORY
under all relevant PDL PATENTS and PDL KNOW-HOW.  In such case,  SB shall use
commercially reasonable efforts and diligence, consistent with the effort that
is used by SB in the development, testing, manufacture, registration,
marketing and sale of pharmaceutical products at a similar stage of
development, having a comparable level of market potential, and being subject
to a comparable regulatory review, to develop and commercialize PRODUCT in the
TERRITORY and any subsequent SB NET SALES of PRODUCT shall be subject to the
royalty obligations as set forth in Paragraph 5.05.  If SB elects not to
assume this responsibility, [CONFIDENTIAL TREATMENT REQUESTED].
                (ii)  PDL Failure to meet Material DEVELOPMENT Obligations.
In the event that either (A) the PHASE II REVIEW POINT is delayed more than
[CONFIDENTIAL TREATMENT REQUESTED] beyond the date set forth in the
DEVELOPMENT PLAN, and such delay is not agreed upon by both parties or is not
due to circumstances which are beyond PDL's reasonable control, or (B) PDL
fails to meet a material DEVELOPMENT obligation set forth in the DEVELOPMENT
PLAN due to action or failure to act in circumstances within PDL's reasonable
control and such failure is not corrected within thirty (30) days after
receipt of written notification from SB of such failure or PDL has not
provided a written plan setting forth its corrective efforts within such time
period, which plan shall be subject to the reasonable approval of SB, then SB
shall have the option, at its sole discretion, to solely assume DEVELOPMENT
responsibility.  If SB elects to assume this responsibility, it shall so
notify PDL, in writing within thirty (30) days of either (1) the projected
date of the PHASE II REVIEW POINT in the case of failure pursuant to Paragraph
3.06(a)(ii)(A)or (2) PDL's failure to correct within the 30-day corrective
period or SB's rejection of a corrective plan submitted by PDL in the case of
failure pursuant to Paragraph 3.06(a)(ii)(B).  If SB does not provide written
notice to PDL within such time limit, then SB shall irrevocably lose its
option to assume DEVELOPMENT responsibility hereunder with respect to that
particular delay or that particular failure to perform a material DEVELOPMENT
obligation.  If SB provides timely written notice to PDL of its election to
assume this responsibility, the JDC and the Development Coordinators shall
terminate and SB shall be solely responsible for the continued DEVELOPMENT and
commercialization of PRODUCT, all rights to PRODUCT granted to PDL shall
terminate and revert to SB, PDL's license under SB PATENTS and SB KNOW-HOW
shall terminate, and PDL shall transfer all clinical, preclinical and other
relevant information and data related to PRODUCT in its possession to SB
(including the assignment of any filings with REGULATORY AUTHORITIES held by
PDL) at no cost to SB, and SB shall immediately have an exclusive license to
make, have made, import, use and sell PRODUCT in the TERRITORY under all
relevant PDL PATENTS and PDL KNOW-HOW.  In such case, SB shall use
commercially reasonable efforts and diligence, consistent with the effort that
is used by SB in the development, testing, manufacture, registration,
marketing and sale of pharmaceutical products at a similar stage of
development, having a comparable level of market potential, and being subject
to a comparable regulatory review, to develop and commercialize PRODUCT in the
TERRITORY and any subsequent SB NET SALES of PRODUCT shall be subject to the
royalty obligations set forth in Paragraph 5.05.  If SB elects not to assume
this responsibility, it shall so notify PDL in writing, in which case this
AGREEMENT shall, at SB's option, [CONFIDENTIAL TREATMENT REQUESTED].
                (b)  Termination of SB DEVELOPMENT.
               (i)  SB Funding Difficulties.  In the event that SB becomes
aware that it will have significant problems providing the funding it requires
in order to carry out its DEVELOPMENT obligations under this AGREEMENT
(including by reason of a decision by SB not to provide such funding), it
shall promptly notify PDL, in writing.  In this event, PDL shall have the
option, at its sole discretion, within thirty (30) days of receipt of such
notice from SB, to solely assume DEVELOPMENT responsibility.  If PDL elects to
assume this responsibility, it shall so notify SB, in writing, in which case
the JDC and the Development Coordinators shall terminate and PDL shall have
sole responsibility for the DEVELOPMENT and commercialization of PRODUCT, all
rights to PRODUCT granted to SB shall terminate and revert to PDL, SB's
license under PDL PATENTS and PDL KNOW-HOW shall terminate, and SB shall
transfer all clinical, preclinical and other relevant information and data
related to PRODUCT in its possession to PDL (including the assignment of any
filings with REGULATORY AUTHORITIES held by SB) at no cost to PDL, and PDL
shall immediately have an exclusive license to make, have made, import, use,
sell and offer to sell PRODUCT in the TERRITORY under all relevant SB PATENTS
and SB KNOW-HOW.  In such case, PDL shall use commercially reasonable efforts
and diligence, consistent with the effort that is used by PDL in the
development, testing, manufacture, registration, marketing and sale of
pharmaceutical products at a similar stage of development, having a comparable
level of market potential, and being subject to a comparable regulatory
review, to develop and commercialize PRODUCT in the TERRITORY and any
subsequent PDL NET SALES of PRODUCT shall be subject to the royalty obligation
set forth in Paragraph 5.04. If PDL elects not to assume this responsibility,
[CONFIDENTIAL TREATMENT REQUESTED].
                (ii)  SB Failure to meet Material DEVELOPMENT Obligations.
In the event that SB fails to meet any material DEVELOPMENT obligation set
forth in the DEVELOPMENT PLAN due to action or failure to act in circumstances
within SB's reasonable control and such failure is not corrected within thirty
(30) days after receipt of written notification from PDL of such failure or,
if not corrected within such 30-day period and SB has not provided a written
plan setting forth its corrective efforts, which plan shall be subject to the
reasonable approval of PDL, then PDL shall have the option, at its sole
discretion, to solely assume DEVELOPMENT responsibility.  If PDL elects to
assume this responsibility, it shall so notify SB in writing within thirty
(30) days after SB's failure to correct within the 30-day corrective period or
PDL's rejection of a corrective plan submitted by SB, as the case may be.  If
PDL does not provide written notice to SB within such time limit, then PDL
shall irrevocably lose its option to assume DEVELOPMENT responsibility
hereunder with respect to that particular failure to perform a material
DEVELOPMENT obligation.  If PDL provides timely written notice to SB of its
election to assume this responsibility, the JDC and the Development
Coordinators shall terminate and PDL shall be solely responsible for the
continued DEVELOPMENT and commercialization of PRODUCT, all rights to PRODUCT
granted to SB shall terminate and revert to PDL, SB's license under PDL
PATENTS and PDL KNOW-HOW shall terminate, and SB shall transfer all clinical,
preclinical and other relevant information and data related to PRODUCT in its
possession to PDL (including the assignment of any filings with REGULATORY
AUTHORITIES held by SB) at no cost to PDL, and PDL shall immediately have an
exclusive license to make, have made, use and sell PRODUCT in the TERRITORY
under all relevant SB PATENTS and SB KNOW-HOW.  In such case, PDL shall use
commercially reasonable efforts and diligence, consistent with the effort that
is used by PDL in the development, testing, manufacture, registration,
marketing and sale of pharmaceutical products at a similar stage of
development, having a comparable level of market potential, and being subject
to a comparable regulatory review, to develop and commercialize PRODUCT in the
TERRITORY and any subsequent PDL NET SALES of PRODUCT shall be subject to the
royalty obligation set forth in Paragraph 5.04.  If PDL elects not to assume
this responsibility, it shall so notify SB in writing, in which case this
AGREEMENT shall, at PDL's option, either [CONFIDENTIAL TREATMENT REQUESTED].


4.      MANUFACTURE AND SUPPLY
     4.01    Pre-PHASE II REVIEW POINT.  Prior to the PHASE II REVIEW POINT, SB
will use commercially reasonable efforts to manufacture all clinical and
preclinical supplies of PRODUCT required for DEVELOPMENT in accordance with
the DEVELOPMENT PLAN and conduct certain additional activities and provide
materials, data and information as set forth in Appendix E.  PDL shall have
certain audit, data and information rights with respect to the efforts of SB
hereunder as provided in Appendix E.  PDL will pay to SB one hundred percent
(100%) of the COST OF GOODS incurred by SB for such clinical supplies from the
EFFECTIVE DATE through to the PHASE II REVIEW POINT and the costs incurred by
SB in performing the activities conducted in accordance with Appendix E.  SB
will provide reasonable detail of the activities performed and services
provided together with an invoice on a quarterly basis and PDL shall pay SB
for all such costs within thirty (30) days after receiving each of SB's
invoices therefor.  In any event, PDL's responsibility for the total COST OF
GOODS through the PHASE II REVIEW POINT plus the costs incurred by SB under
Appendix E shall not exceed [CONFIDENTIAL TREATMENT REQUESTED]unless (a) the
DEVELOPMENT PLAN is amended to increase the amount of PRODUCT required or
increase the activities required under Appendix E in order to complete the
DEVELOPMENT PLAN through to the PHASE II REVIEW POINT or (b) as otherwise
agreed by the JDC.
4.02    Post-PHASE II REVIEW POINT.  If SB has made the PHASE II REVIEW
POINT PAYMENT all COST OF GOODS for further DEVELOPMENT and commercial
manufacture, if applicable, incurred by either party after the date of such
payment will be shared by the parties, with [CONFIDENTIAL TREATMENT
REQUESTED].  If SB elects not to make the PHASE II REVIEW POINT PAYMENT, all
COSTS OF GOODS incurred by PDL after the PHASE II REVIEW POINT, whether
manufactured by SB, PDL or a THIRD PARTY, shall be at PDL's sole
responsibility and expense.  Reconciliation of amounts incurred hereunder
shall be as provided in Paragraph 11.02.
        4.03    Commercial Manufacturing Rights.
     (a)     SB makes PHASE II REVIEW POINT PAYMENT.  In the event SB makes the
PHASE II REVIEW POINT PAYMENT, SB shall have the first right to be the primary
and secondary manufacturer of commercial supplies of PRODUCT (including, for
the avoidance of doubt, supplies of PRODUCT for Phase III clinical trials),
[CONFIDENTIAL TREATMENT REQUESTED].  The term "primary manufacture" shall mean
the preparation of bulk biological substance.  The term "secondary
manufacture" shall mean the preparation of lyophile vials, labeling, finishing
and packaging.  If SB is not selected by the parties as the primary and
secondary manufacturer of PRODUCT, PDL shall have the second right to become
the primary and secondary manufacturer, [CONFIDENTIAL TREATMENT REQUESTED].
        (b)     SB Does Not Make PHASE II REVIEW POINT PAYMENT.  In the event SB
does not make the PHASE II REVIEW POINT PAYMENT, SB shall have the first right
to be the primary and secondary manufacturer of commercial supplies of PRODUCT
(including, for the avoidance of doubt, supplies of PRODUCT for Phase III
clinical trials), [CONFIDENTIAL TREATMENT REQUESTED].  The terms "primary
manufacture" and "secondary manufacture" shall have the meanings set forth in
Paragraph 4.03(a) above.  If SB is not selected by the PDL as the primary and
secondary manufacturer of PRODUCT, PDL shall select the manufacturer of
PRODUCT, which may be PDL itself.
        (c)     Transitional Manufacturing Services. [CONFIDENTIAL TREATMENT
REQUESTED]
        (d)     SB Involvement in CMC and DMF Questions If SB Does Not
Manufacture. [CONFIDENTIAL TREATMENT REQUESTED]
5.      PAYMENTS AND ROYALTIES
    5.01    Payments.  In consideration for the licenses under PDL PATENTS and
PDL KNOW-HOW granted to SB under this AGREEMENT, SB will make the following
payments to PDL within thirty (30) days of the first occurrence of the
following milestones:

                                (a)   [CONFIDENTIAL TREATMENT REQUESTED]

                                (b)     [CONFIDENTIAL TREATMENT REQUESTED],

provided that:
            (i) each such payment shall be made only one time regardless of
how many times any PRODUCT achieves each of the indicated milestones, and no
payment shall be owed for a milestone which is not reached;
           (ii) each such payment by SB shall be non-refundable and non-
creditable;
          (iii) in the event that PDL's rights to PRODUCT are terminated
under Paragraph 3.06 or Article 12, no payments shall be due under this
Paragraph 5.01 for milestones achieved after the notice date of termination;
and
          (iv) in the event that PDL has an overdue negative balance with
respect to any undisputed amount invoiced by SB under Paragraph 4.01, SB shall
have the right to offset any payments due under this Paragraph 5.01 against
the total of such amounts outstanding as part of the quarterly reconciliation
for the period in which the milestone is payable.
As used in this Paragraph 5.01, the term [CONFIDENTIAL TREATMENT REQUESTED]
means [CONFIDENTIAL TREATMENT REQUESTED];
[CONFIDENTIAL TREATMENT REQUESTED].
        5.02    SB Makes PHASE II REVIEW POINT PAYMENT: Profit-Sharing
Scenario.  In the event SB makes the PHASE II REVIEW POINT PAYMENT, and
neither party's rights under this AGREEMENT have been terminated, the
following provisions shall apply:
                [CONFIDENTIAL TREATMENT REQUESTED]
        5.03    SB Does Not Make PHASE II REVIEW POINT PAYMENT: Royalties.  In
the event SB does not make the PHASE II REVIEW POINT PAYMENT, in consideration
of the licenses granted by SB to PDL hereunder, as the sole compensation to
SB, PDL shall pay SB a royalty of:
                        [CONFIDENTIAL TREATMENT REQUESTED]
        5.04    SB Rights Terminated.
                In the event SB's rights to PRODUCT are terminated in accordance
with Paragraph 3.06 or Article 12 of this AGREEMENT, in consideration for the
license rights granted by SB to PDL hereunder, as the sole compensation to SB,
PDL shall pay to SB royalties as follows:
               (i) in those countries in the TERRITORY in which PDL NET SALES
are covered by a VALID CLAIM of an SB PATENT:
                                [CONFIDENTIAL TREATMENT REQUESTED]
        5.05    PDL Rights Terminated.  In the event of termination of PDL's
rights to PRODUCT as provided under Paragraph 3.06 or Article 12, SB will
provide, as the sole compensation to PDL, the following royalties to PDL, such
royalties to be based upon the phase of development that PRODUCT reached at
time of termination of PDL's rights:

        5.06            THIRD PARTY Payments.
                (a)  Pre-PHASE II REVIEW POINT.  Subject to Paragraph 5.06(b),
during the term of this AGREEMENT through the PHASE II REVIEW POINT, if
neither party's rights to PRODUCT have terminated hereunder, the parties shall
mutually determine in good faith if it is necessary to (i) seek a license from
a THIRD PARTY and if so, whether one or both parties should approach such
THIRD PARTY with respect to obtaining such a license, or (ii) otherwise
exercise an existing THIRD PARTY license between SB or PDL, on the one hand,
and a THIRD PARTY, on the other hand, as of the EFFECTIVE DATE, and, in each
case, make royalty or other fee payments to any THIRD PARTY in order to avoid
infringement with respect to the making, use, import or sale of PRODUCT
anywhere in the TERRITORY; provided that if the parties cannot agree on the
need for any such license or the commercial provisions relating to such
license or the need to exercise an existing THIRD PARTY license, the parties
shall endeavor to find a mutually acceptable resolution of this matter.  If
the parties cannot determine such a mutually acceptable resolution, the
parties shall submit the matter to a mutually acceptable THIRD PARTY expert
for a final and binding resolution, the cost of such expert to be equally
shared by the parties.  Prior to the PHASE II REVIEW POINT, all payments made
to THIRD PARTIES [CONFIDENTIAL TREATMENT REQUESTED]in accordance with
Paragraphs 5.06(a) and 5.06(b) throughout the TERRITORY will be the
responsibility of PDL; provided, however, that SB shall reimburse or credit
[CONFIDENTIAL TREATMENT REQUESTED] of all such payments when and if SB makes
the PHASE II REVIEW POINT PAYMENT.
                (b) [CONFIDENTIAL TREATMENT REQUESTED]
        (c) Post-PHASE II REVIEW POINT.  If SB makes the PHASE II REVIEW POINT
PAYMENT, then all of the payments to THIRD PARTIES outlined in Paragraphs
5.06(a) and 5.06(b) throughout the TERRITORY subsequent to the PHASE II REVIEW
POINT will be considered a THIRD PARTY ROYALTY.  If SB does not make the PHASE
II REVIEW POINT PAYMENT, then all of the payments to THIRD PARTIES outlined in
Paragraphs 5.06(a) and 5.06(b) throughout the TERRITORY subsequent to the
PHASE II REVIEW POINT will be borne solely by PDL.

6.      PDL CO-PROMOTION OPTION
If, at the time of filing of an NDA in the U.S.A. by PDL or SB, SB has made
the PHASE II REVIEW POINT PAYMENT and PDL is current in its payment of its
share of DEVELOPMENT COSTS in accordance with this AGREEMENT, and the rights
of both parties with respect to PRODUCT remain in effect, PDL shall have the
option to co-promote PRODUCT with SB (using the same Trademark) in the U.S.A.
in accordance with the terms and conditions of this AGREEMENT.  SB shall
provide to PDL a copy of its sales and marketing plan for PRODUCT as soon as
practicable following the completion of the last pivotal Phase III clinical
study set forth in the DEVELOPMENT PLAN.  PDL shall have sixty (60) days from
the later of (a) the filing of the first NDA for PRODUCT in the U.S.A. or (b)
delivery to PDL of a written sales and marketing plan for PRODUCT in the
U.S.A. prepared by SB in accordance with SB's then current internal sales and
marketing plans for other similar products in the U.S.A., to notify SB in
writing of its exercise of the co-promotion option under this Article 6.
Following receipt of such written notification from PDL, SB shall grant to PDL
a license to co-promote PRODUCT in the U.S.A. in accordance with both the
terms and conditions contained in this AGREEMENT as well as the terms and
conditions set forth in a separate written co-promotion agreement to be
entered into in accordance with Article 7.  If PDL does not send any written
notification to SB within the specified time limit set forth in this Article
6, then PDL shall irrevocably lose its rights to co-promote PRODUCT with SB in
the U.S.A.

7.      MARKETING AND CO-PROMOTION
        7.01    Joint Marketing Committee.
            (a)  Appointment. Within thirty (30) days after the filing of the
NDA for a PRODUCT in the [CONFIDENTIAL TREATMENT REQUESTED], the parties will
establish a Joint Marketing Committee ("JMC") composed of three (3)
representatives from SB and two (2) representatives from PDL, each with
appropriate background, experience and qualifications to productively discuss
the commercialization of PRODUCT in the TERRITORY.  Each party shall appoint
its own representatives and may change its representatives on the JMC at any
time by written notice to the other party.
                (b)  Purpose and Responsibilities.
                   (i)  PDL Does Not Co-Promote. For any year in which PDL is
not co-promoting PRODUCT in accordance with this Article 7, the primary
purpose of the JMC shall be to provide a forum in which the parties can share
and discuss information concerning the commercialization of PRODUCT in the
TERRITORY, including the strategic direction of the commercialization.  During
these periods, the JMC shall meet on a semi-annual basis.  The parties shall
discuss the annual marketing plan and budget for the TERRITORY, as prepared by
SB in accordance with Paragraph 7.02, and SB's performance against such plan
and budget.  During this period, SB shall have final decision making
responsibility with respect to the commercialization of PRODUCT in the
TERRITORY; provided that SB shall seriously consider, in good faith, all
reasonable suggestions of PDL.
                      (ii)  PDL Co-Promotes.  For any year in which PDL is co-
promoting PRODUCT in the U.S.A. in accordance with this Article 7, in addition
to the purposes and responsibilities set forth in Paragraph 7.01(b)(i) above,
the JMC shall also oversee, monitor and coordinate the activities of the
parties in marketing, selling and distributing PRODUCT in the U.S.A.;
provided, however, it is understood and agreed that, except as set forth in
Paragraph 7.03 below, SB shall have final decision-making responsibility with
respect to the commercialization of PRODUCT in the U.S.A and the rest of the
TERRITORY.  During these periods, the JMC shall meet on a quarterly basis.
                (c)  Meetings, Reporting and Decisions.  The JMC will meet at
least as often as set forth in Paragraph 7.01(b)(i) and (b)(ii) above at
mutually agreed upon times and locations using mutually agreed upon meeting
formats, including videoconferencing and teleconferencing, unless otherwise
mutually agreed by the parties.  It is envisioned that meetings of the JMC
will be held at facilities alternately selected by PDL and by SB.  Each party
shall promptly report to the JMC on all material issues relating to
commercialization of PRODUCT in the TERRITORY.  Each party shall cause its
representatives to attend the meetings of the JMC; provided, however, that
meetings of the JMC shall be effective for decision-making if at least one (1)
representative of each party is present or participating.  If a representative
of a party is unable to attend a meeting, such party may designate an
alternate to attend such meeting in place of the missing representative.  In
addition, each party may, at its discretion, invite employees, consultants or
advisors whose presence is considered of importance or value to the
commercialization of PRODUCT in the TERRITORY to attend and participate in the
meetings of the JMC, provided that any such consultant or advisor shall have
undertaken confidentiality obligations to PDL or SB, as the case may be, at
least comparable to the confidentiality provisions undertaken by the parties
under this AGREEMENT, with respect to the subject matter of any such meeting.
Minutes shall be kept of all JMC meetings..  At the first JMC meeting,
additional administrative details, including the review periods for minutes
from meetings, shall be determined.
         (d)  Expenses - Each party shall bear its own expenses, including
travel, accommodations, and living expense, incurred in connection with their
respective efforts described in this Paragraph 7.01 and such costs and
expenses shall not be included in PROMOTION EXPENSES.
                7.02    Annual Sales and Marketing Plan and Budget.  SB shall
prepare and deliver to PDL an annual sales and marketing plan for PRODUCT for
the TERRITORY in accordance with SB's standard internal procedures.  Such plan
and budget shall be reviewed and approved by SB management.  In addition, SB
shall provide PDL with a draft of SB's annual sales and marketing plan for
PRODUCT for the TERRITORY at least thirty (30) days prior to its approval by
SB management in order to give PDL the opportunity to review and comment.  PDL
shall have twenty (20) calendar days after receipt of the draft plan to
provide comments and/or suggestions to SB.  SB shall consider in good faith
all comments and suggestions received from PDL, but SB shall have the final
decision making responsibility with respect to such plan. The plan will detail
the proposed sales and marketing efforts, including, without limitation, the
AGGREGATE PROJECTED DETAILS in the U.S.A., to be undertaken with respect to
PRODUCT in the year, as well as marketing/promotional budget, any local Phase
IV medical support studies, selling investment required for PRODUCT, in each
country in the TERRITORY during such year, and estimated total PROMOTION
EXPENSES related thereto.  For the avoidance of doubt, it is understood and
agreed that, for so long as SB retains its rights to market and sell PRODUCT
under this AGREEMENT, SB shall be responsible for the booking of sales
throughout the TERRITORY.
        7.03    PDL Co-promotes.  In the event PDL elects the co-promotion
option in accordance with Article 6 above, the parties shall use reasonable
good faith efforts to negotiate and enter into a separate co-promotion
agreement (the "Co-Promotion Agreement") within ninety (90) days of PDL's
election to co-promote in accordance with Article 6.  The parties agree that
the following principles, as well as the relevant provisions of Paragraphs
7.01 and 7.02, shall, unless otherwise mutually agreed by the parties, apply
to any co-promotion activities and shall be included in the Co-Promotion
Agreement:                          (a) Target Audiences.  SB shall
determine the target audiences for PRODUCT in the U.S.A.
                (b) Projection of AGGREGATE PROJECTED DETAILS.  As part of SB's
annual sales and marketing planning process described in Paragraph 7.02, SB
shall reasonably determine the aggregate number of DETAILS to be performed for
PRODUCT in the U.S.A. ("AGGREGATE PROJECTED DETAILS") to all target audiences.
PDL shall have the opportunity to validate the reasonableness of the AGGREGATE
PROJECTED DETAILS determined by SB against the practices engaged by other
large pharmaceutical companies based upon widely available sales/market
research data.
                (c)  PDL Proposal.  On an annual basis, within sixty (60) days
after receipt by PDL of SB's annual sales and marketing plan for PRODUCT for
the year, PDL shall submit to SB a proposal (the "PDL Proposal") specifying
(i) the sales and marketing activities proposed to be performed by PDL as part
of its co-promotion activities in the U.S.A., which activities may include
without limitation, DETAILING PRODUCT, or, in lieu thereof, engaging in other
marketing, sales and distribution efforts such as conducting symposia,
educational sessions and other activities to promote PRODUCT, and conducting
post-regulatory approval clinical trials for PRODUCT, provided however, that
any non-DETAIL sales and marketing activities proposed by PDL must be
supplemental to the activities set forth in the Annual Sales and Marketing
Plan provided by SB, (ii) PDL's estimated PROMOTION EXPENSES related to such
activities and (iii) PDL's proposed profit split adjustment for such
activities; provided, however, that in no event shall the profit split
adjustment for the U.S.A. be more than [CONFIDENTIAL TREATMENT REQUESTED] of
PRE-TAX PROFITS derived from the U.S.A.
                (d)     SB Determination.  SB shall review and consider PDL's
proposal in good faith and determine, within thirty (30) days of receipt of
the PDL Proposal, the co-promotion activities to be performed by PDL, the
allowable PROMOTION EXPENSES related thereto, and the profit split adjustment
to be paid to PDL for such activities (the "SB Determination").  In making
such a determination, the following shall apply:
         (i)  DETAILS.  SB shall accept any PDL Proposal that specifies
that PDL will perform [CONFIDENTIAL TREATMENT REQUESTED] of the AGGREGATE
PROJECTED DETAILS in the U.S.A.  The profit-split adjustment for PRE-TAX
PROFITS derived from the U.S.A. for the performance of DETAILS is set forth on
Exhibit B.
                        (ii) [CONFIDENTIAL TREATMENT REQUESTED]
         (e)  PDL Guaranteed DETAILS.  To the extent PDL agrees to provide
DETAILS during a given year, PDL shall be required to perform a guaranteed
number of DETAILS ("PDL'S Guaranteed DETAILS"); such number shall be
determined by SB in accordance with Paragraph 7.03(b) above. During any co-
promotion year, if PDL shall fail to perform at least [CONFIDENTIAL TREATMENT
REQUESTED] of PDL's Guaranteed DETAILS and SB has performed its share of the
AGGREGATE PROJECTED DETAILS, PDL's right to co-promote PRODUCT under this
AGREEMENT shall irrevocably be terminated.
          (f)  No Sublicense Rights. In no event, shall PDL be permitted to
sublicense its right to co-promote PRODUCT with SB in the U.S.A. to any THIRD
PARTY without SB's prior written consent.
         (g)  In any event, any co-promotion arrangement shall provide for
(a) the marketing of PRODUCT under one brand name selected by SB, and (b) the
booking of all sales by SB.

8.      EXCHANGE OF INFORMATION AND CONFIDENTIALITY
        8.01    Transfer of Information.  Promptly after the EFFECTIVE DATE and
during the term of the AGREEMENT, SB shall disclose and supply to PDL all SB
KNOW-HOW.  Promptly after receipt of the PHASE II REVIEW POINT PAYMENT and
thereafter through the term of the AGREEMENT, PDL shall disclose and supply to
SB all PDL KNOW-HOW.  Notwithstanding the foregoing, the obligation of a party
to provide any further SB KNOW-HOW or PDL KNOW-HOW which may become known to
them during the term of the AGREEMENT, as the case may be, shall continue so
long as the other party has a continuing right to PRODUCT beyond the right to
receive royalties under this AGREEMENT.
     8.02    Adverse Experience Reporting.  The responsibilities of the parties
for the reporting of adverse experiences related to PRODUCT to regulatory
authorities throughout the TERRITORY shall be performed in accordance with the
Pharmacovigilance Agreement attached to this AGREEMENT as Appendix C.
        8.03    Confidentiality.
                (a)     The Confidentiality Agreement between the
parties dated December 22, 1998, as amended ("Confidentiality Agreement"),
shall terminate as of the EFFECTIVE DATE.
                (b)     During the term of this AGREEMENT and for
five (5) years thereafter, irrespective of any termination earlier than the
expiration of the term of this AGREEMENT, PDL and SB shall not use or reveal
or disclose to THIRD PARTIES any confidential information either:
(i) disclosed under the Confidentiality Agreement, or
(ii) received from the other party or otherwise developed by either
party in the performance of activities in furtherance of this
AGREEMENT
without first obtaining the written consent of the disclosing party, except as
may be otherwise provided herein, or as may be required for purposes of
investigating, developing, manufacturing or marketing PRODUCT or for securing
essential or desirable authorizations, privileges or rights from governmental
agencies, or as required to be disclosed to a governmental agency or as
necessary to file or prosecute patent applications concerning PRODUCT or to
carry out any litigation concerning PRODUCT.  This confidentiality obligation
shall not apply to such information which is or becomes a matter of public
knowledge, or is already in the possession of the receiving party, or is
disclosed to the receiving party by a THIRD PARTY having the right to do so,
or is subsequently and independently developed by employees of the receiving
party or AFFILIATES thereof who had no knowledge of the confidential
information disclosed.  The parties shall take reasonable measures to assure
that no unauthorized use or disclosure is made by others to whom access to
such information is granted.
                (c)     Nothing herein shall be construed as
preventing either party from disclosing any information received from the
other party to:
             (i)  an AFFILIATE, sublicensee or distributor of the receiving
party, provided such AFFILIATE, sublicensee or distributor has undertaken a
similar obligation of confidentiality with respect to the confidential
information; or
                   (ii)  the FDA in connection with the approval to conduct
clinical studies, manufacture, market or sell PRODUCT.
                (d)     All confidential information disclosed by one
party to the other shall remain the intellectual property of the disclosing
party.  In the event that a court or other legal or administrative tribunal,
directly or through an appointed master, trustee or receiver, assumes partial
or complete control over the assets of a party to this AGREEMENT based on the
insolvency or bankruptcy of such party, the bankrupt or insolvent party shall
promptly notify the court or other tribunal (i) that confidential information
received from the other party under this AGREEMENT remains the property of the
other party and (ii) of the confidentiality obligations under this AGREEMENT.
In addition, the bankrupt or insolvent party shall, to the extent permitted by
law, take all steps necessary or desirable to maintain the confidentiality of
the other party's confidential information and to ensure that the court, other
tribunal or appointee maintains such information in confidence in accordance
with the terms of this AGREEMENT.
      8.04    Public Announcements.  It is contemplated that one or both of the
parties will issue a press release announcing this AGREEMENT, the Rights
Agreement and the IL-5 License Agreement, the form and content of which shall
be mutually agreed upon.  No other public announcement or other disclosure to
THIRD PARTIES concerning the terms, financial or otherwise, of this AGREEMENT
shall be made, either directly or indirectly, by any party to this AGREEMENT,
except as may be legally required or as may be required for recording
purposes, without first obtaining the approval of the other party, which
approval shall not be unreasonably withheld, and agreement upon the nature and
text of such announcement or disclosure.  The party desiring to make any such
public announcement or other disclosure (whether such disclosure is legally
required or otherwise) shall inform the other party of the proposed
announcement or disclosure in reasonably sufficient time prior to public
release, and shall provide the other party with a written copy thereof, in
order to allow such other party to comment upon such announcement or
disclosure.  The party reviewing the release shall use good faith efforts to
promptly review and provide comments upon the proposed public release, which
comments shall be provided as soon as practicable but in any event within
seven (7) days of delivery of the initial draft of the proposed release.  Each
party agrees that it shall cooperate fully with the other with respect to all
disclosures regarding this AGREEMENT to the Securities Exchange Commission,
the U.K. Stock Exchange and any other governmental or regulatory agencies,
including requests for confidential treatment of proprietary information of
either party included in any such disclosure.
     8.05    Publications.  Neither SB nor PDL shall submit for written or oral
publication any manuscript, abstract or the like which includes data or other
information generated under this AGREEMENT and/or provided by the other party
under this AGREEMENT without first obtaining the prior written consent of the
other party in accordance with the procedure set forth in this Paragraph 8.05,
which consent shall not be unreasonably withheld.  Any proposed publication
which includes data or other information generated under this AGREEMENT and/or
provided by the other party under this AGREEMENT shall be subject to the prior
review and approval of the other party.  The party proposing publication
("Publishing Party") shall provide a draft or summary of the proposed
publication for review by the other party ("Reviewing Party") not less than
thirty (30) calendar days prior to the proposed date of submission for
publication.  The Reviewing Party shall review and provide comments upon the
proposed publication, which comments shall be provided as soon as practicable
but in any event within twenty (20) calendar days of delivery of the initial
draft of the proposed publication.  The Reviewing Party shall have the right
to require that any confidential information of the Reviewing Party be removed
from the proposed publication or presentation, or that any information to be
used as the basis of a proposed patent application be removed from the
proposed publication or presentation until the proposed patent application is
prepared and filed by either the Reviewing or Publishing Party.  In any event,
the contribution of each party (as determined in accordance with then current
practices for scientific or clinical publications) shall be noted in all
publications or presentations by acknowledgment or co-authorship, whichever is
appropriate.
     8.06    Statutory and Regulatory Requirements.  Nothing in this AGREEMENT
shall be construed as preventing or in any way inhibiting either party from
complying with statutory and regulatory requirements governing the
development, manufacture, use, importation, marketing, sale or other
distribution of PRODUCT in any manner which it reasonably deems appropriate,
including, for example, by disclosing to regulatory authorities confidential
or other information received from the other party or THIRD PARTIES.

9.      PATENT PROSECUTION AND LITIGATION
        9.01    Ownership of Intellectual Property.  Each party shall have
and retain sole and exclusive title to all inventions, discoveries, and know-
how which are made (as determined in accordance with the patent laws of the
U.S.A.) solely by its employees or agents in the course of or as a result of
activities performed in furtherance of the AGREEMENT.  Each party shall own a
fifty percent (50%) undivided interest in all joint inventions, discoveries,
and know-how made (as determined in accordance with the patent laws of the
U.S.A.) by employees or agents of both parties as a result of activities
performed in furtherance of the AGREEMENT.  Subject to the terms of this
AGREEMENT, each party shall own, and may fully exploit, all of its rights and
interests in such joint inventions, discoveries, and know-how, without any
encumbrances to each other.  Subject to the terms of this AGREEMENT, each
party shall promptly notify the other upon the determination to file, and in
any event prior to filing, a patent application with respect to any invention
or discovery referred to in this Paragraph 9.01, except that, notwithstanding
the above, neither party shall have the obligation to disclose to the other
party any invention made by its employees and agents related to the
manufacture (e.g., cell culture, fermentation) or purification of monoclonal
antibodies.
        9.02    Prosecution and Maintenance.
        (a) SB PATENTS.  SB shall have the first right, using in-house or
outside legal counsel selected at SB's sole discretion, to prepare, file,
prosecute, maintain and extend, at its expense, all SB PATENTS, as well as any
other patent applications which arise under Paragraph 9.01 which are owned in
whole or in part by SB, provided that PDL shall have the right to assume
responsibility, at PDL's expense, for preparing, filing, prosecuting,
maintaining and extending any such SB PATENT, or any part thereof, to which SB
intends to abandon or otherwise cause or allow to be forfeited to the extent
such is related to PRODUCT.
        (b) PDL PATENTS.  PDL shall have the first right, using in-house or
outside legal counsel selected at PDL's sole discretion, to prepare, file,
prosecute, maintain and extend, at its expense, all PDL PATENTS, as well as
any other patent applications which are owned solely by PDL and arise under
Paragraph 9.01, provided that SB shall have the right to assume
responsibility, at SB's expense, for preparing, filing, prosecuting,
maintaining and extending any such patent or patent application, or any part
thereof, which PDL intends to abandon or otherwise cause or allow to be
forfeited to the extent such is related to PRODUCT.
        9.03    Reasonable Assistance.  Notwithstanding the provisions of
Paragraph 9.02, each party shall, at its own expense, provide reasonable
assistance to the other party to facilitate filing, prosecution and issuance
of all patent applications covering inventions related to PRODUCT which are
referred to in Paragraph 9.01, or which are necessary for fulfillment of the
obligations set out in this AGREEMENT, and shall execute all documents deemed
necessary or desirable therefor.
        9.04    Infringement of PDL PATENTs.
         (a)  Notice.  In the event that PDL or SB becomes aware of actual or
threatened infringement of a PDL PATENT anywhere in the TERRITORY, wherein
such infringement relates to an antibody that binds to the IL-4 antigen, that
party shall promptly notify the other party in writing.  The notice shall
describe in reasonable detail the facts and circumstances forming the basis
for the determination that there is actual or threatened infringement.  In the
event the notice specifies threatened, but not actual infringement, the
parties agree to discuss in good faith the proper course of action; provided,
that PDL shall have the final decision making authority with respect to such
course of action.  [CONFIDENTIAL TREATMENT REQUESTED]   (b)  PDL First
Right to Litigate For Actual Infringement.  PDL shall have the first right but
not the obligation to bring an infringement action or file any other
appropriate action or claim directly related to actual infringement of the PDL
PATENTS related to an antibody that binds to the IL-4 antigen against any
THIRD PARTY (an "Action") and to use SB's name in connection therewith and to
include SB's name as a party thereto.  If PDL elects to bring an Action in
accordance with this Paragraph 9.04(b), PDL shall have sole control over any
Action, including the right to select counsel for such Action; provided
however that PDL shall solicit, and seriously consider in good faith SB's
input with respect to all material aspects of such Action, including without
limitation, the development of the litigation strategy and the execution
thereof. In furtherance and not in limitation of the foregoing, PDL shall keep
SB promptly and fully informed of the status of any such Action, and SB shall
have the right to review and comment upon PDL's activities related thereto. SB
shall consult with PDL concerning such Action at no cost to PDL.  To the
extent PDL elects its first right to bring an Action in any country of the
TERRITORY, PDL shall use commercially reasonable efforts, in each such
country, to diligently pursue such Action and obtain results that are
consistent with the respective objectives of the parties under this Agreement.
All cost and expenses related to any such Action shall be paid by PDL;
provided however that, in the event SB makes the PHASE II REVIEW POINT
PAYMENT, all such OUT OF POCKET COSTS, whether incurred prior to or after the
PHASE II REVIEW POINT, shall be considered PATENT COSTS for the determination
of PRE-LAUNCH COMMERCIAL EXPENSES and PRE-TAX PROFITS.
        (c)  SB's Right to Litigate for Actual Infringement.  At any time prior
to the PHASE II REVIEW POINT or at any time after SB makes the PHASE II REVIEW
POINT PAYMENT, SB shall have the following rights to file an Action with
respect to actual infringement of PDL PATENTs related to an antibody that
binds to the IL-4 Antigen.  [CONFIDENTIAL TREATMENT REQUESTED] SB shall have
sole control over any Action, including the right to select counsel for such
Action; provided however that SB shall solicit, and seriously consider in good
faith PDL's input with respect to all material aspects of such Action,
including without limitation, the development of the litigation strategy and
the execution thereof.  In furtherance but not in limitation of the foregoing,
SB shall keep PDL promptly and fully informed of the status of any such
Action, and PDL shall have the right to review and comment upon SB's
activities related thereto.  All cost and expenses related to any such Action
shall be paid by SB; provided however that, in the event SB makes the PHASE II
REVIEW POINT PAYMENT, all such OUT OF POCKET COSTS, whether incurred prior to
or after the PHASE II REVIEW POINT PAYMENT, shall be considered PATENT COSTS
for the determination of PRE-LAUNCH COMMERCIAL EXPENSES and PRE-TAX PROFITS.
PDL and its counsel shall consult with SB concerning such Action at no cost to
SB.  To the extent SB elects to bring an Action in accordance with this
Paragraph 9.04(c), SB shall use commercially reasonable efforts to diligently
pursue such Action and to obtain results that are consistent with the
respective objectives of the parties under this Agreement.  In the event SB
commences an Action prior to the PHASE II REVIEW POINT and later elects not to
make the PHASE II REVIEW POINT PAYMENT, the parties shall meet and negotiate
in good faith to determine an equitable and fair way to proceed or discontinue
with any such Action.
                (d)     Litigation and Settlement Costs.   In the event SB does
not make the PHASE II REVIEW POINT PAYMENT and PDL has paid for all costs and
expenses related to an  Action, PDL shall retain the entire recovery made with
respect to any such Action.  In the event SB makes the PHASE II REVIEW POINT
PAYMENT, any recovery made by either party with respect to any such Action
shall be considered a positive PATENT COST for the calculation of PRE-LAUNCH
COMMERCIAL EXPENSES and PRE-TAX PROFITS.
                (e)     Cooperation and Settlement.  The parties shall keep one
another informed of the status of and of their respective activities regarding
any Action, including without limitation any discussion concerning the
settlement thereof.  No settlement or consent judgment or other voluntary
final disposition of any suit defended or action brought by one party pursuant
to this Paragraph 9.04 may be entered into without the consent of the non-
settling party if such settlement would require the non-settling party to be
subject to an injunction, to make a monetary payment or would adversely affect
the non-settling party's rights under this AGREEMENT, including the PDL's
rights in PDL PATENTS and the licenses granted to SB hereunder.
        9.05    Infringement of SB PATENTs.
            (a)  Notice.  In the event that PDL or SB becomes aware of actual
or threatened infringement of a SB PATENT anywhere in the TERRITORY, wherein
such infringement relates to an antibody that binds to the IL-4 antigen, that
party shall promptly notify the other party in writing.  The notice shall
describe in reasonable detail the facts and circumstances forming the basis
for the determination that there is actual or threatened infringement.  In the
event the notice specifies threatened, but not actual infringement, the
parties agree to discuss in good faith the proper course of action; provided
that, unless SB has elected not to make the PHASE II REVIEW POINT PAYMENT, SB
shall have the final decision making authority with respect to such course of
action.  [CONFIDENTIAL TREATMENT REQUESTED]             (b)
SB's First Right to Litigate For Actual Infringement. SB shall have the first
right but not the obligation to bring an infringement action or file any other
appropriate action or claim directly related to actual infringement of the SB
PATENTS related to an antibody that binds to the IL-4 antigen against any
THIRD PARTY (an "Action") and to use PDL's name in connection therewith and to
include PDL's name as a party thereto.  If SB elects to bring an Action in
accordance with this Paragraph 9.05(b), SB shall have sole control over the
Action, including without limitation, the right to select counsel for such
Action; provided however that SB shall solicit, and seriously consider in good
faith, PDL's input with respect to all material aspects of such Action,
including without limitation the development of the litigation strategy and
the execution thereof.  In furtherance and not in limitation of the foregoing,
SB shall keep PDL promptly and fully informed of the status of any such
Action, and PDL shall have the right to review and comment upon SB's
activities related thereto. PDL shall consult with SB concerning such Action
at no cost to SB.  To the extent SB elects its first right to bring an Action
in any country of the TERRITORY, SB shall use commercially reasonable efforts,
in each such country, to diligently pursue such Action and to obtain results
that are consistent with the respective objectives of the parties under this
AGREEMENT.  All costs and expenses related to any such Action shall be paid by
SB; provided however that, in the event SB makes the PHASE II REVIEW POINT
PAYMENT, all such OUT OF POCKET COSTS, whether incurred prior to or after the
PHASE II REVIEW POINT PAYMENT, shall be considered PATENT COSTS for the
calculation of PRE-LAUNCH COMMERCIAL EXPENSES and PRE-TAX PROFITS.
            (c)  PDL's Right to Litigate for Actual Infringement.  If SB does
not commence a particular Action [CONFIDENTIAL TREATMENT REQUESTED] PDL shall
have sole control over any Action, including the right to select counsel for
such Action; provided however that PDL shall solicit, and seriously consider
in good faith SB's input with respect to all material aspects of such Action,
including without limitation, the development of the litigation strategy and
the execution thereof.  In furtherance but not in limitation of the foregoing,
PDL shall keep SB promptly and fully informed of the status of any such
Action, and SB shall have the right to review and comment upon PDL's
activities related thereto.  All costs and expenses related to any such Action
shall be paid by PDL; provided however that, in the event SB makes the PHASE
II REVIEW POINT PAYMENT, all such OUT OF POCKET COSTS, whether incurred prior
to or after the PHASE II REVIEW POINT, shall be considered PATENT COSTS for
the calculation of PRE-LAUNCH COMMERCIAL EXPENSES and PRE-TAX PROFITS.  SB and
its counsel shall consult with PDL concerning such Action at no cost to PDL.
To the extent PDL elects to bring an Action in accordance with this Paragraph
9.05(c), PDL shall use commercially reasonable efforts to obtain results that
are consistent with the respective objectives of the parties under this
Agreement.
                (d) Litigation and Settlement Costs.   In the event SB does not
make the PHASE II REVIEW POINT PAYMENT and PDL has paid for all costs and
expenses related to an  Action, PDL shall retain the entire recovery made with
respect to any such Action.  In the event SB makes the PHASE II REVIEW POINT
PAYMENT, any recovery made by either party with respect to any such Action
shall be deemed a positive PATENT COST for the calculation of PRE-TAX PROFITS.
                (e)     Cooperation and Settlement.  The parties shall keep one
another informed of the status of and of their respective activities regarding
any Action, including without limitation any discussion concerning the
settlement thereof.  No settlement or consent judgment or other voluntary
final disposition of any suit defended or Action brought by one party pursuant
to this Paragraph 9.05 may be entered into without the consent of the non-
settling party if such settlement would require the non-settling party to be
subject to an injunction, to make a monetary payment or would adversely affect
the non-settling party's rights under this AGREEMENT, including the SB's
rights in SB PATENTS and the  licenses granted to PDL hereunder.
        9.06    Infringement of THIRD PARTY Intellectual Property Rights.
                (a)  Notice.  In the event of the institution of any suit by a
THIRD PARTY against PDL or SB or their respective sublicensees or AFFILIATES
for patent infringement involving the manufacture, use, sale, distribution or
marketing of PRODUCT anywhere in the TERRITORY, the party sued shall promptly
notify the other party in writing.
                (b) Rights to Defend.  In the event SB has made the PHASE II
REVIEW POINT PAYMENT, SB shall have the right but not the obligation to defend
such suit and to use PDL's  name in connection therewith; provided however
that if SB does not defend such suit in a timely manner, PDL shall have the
right but not the obligation to defend such suit and to use SB's name in
connection therewith.  If SB elects not to make the PHASE II REVIEW POINT
PAYMENT, PDL shall have the sole right but not the obligation to defend such
suit at its own expense.  If SB has made the PHASE II REVIEW POINT PAYMENT,
all costs and expenses incurred by either party with respect to such suit,
whether incurred before or after the date of the PHASE II REVIEW POINT, shall
be considered PATENT COSTS for the calculation of PRE-LAUNCH COMMERCIAL
EXPENSES and PRETAX PROFITS.
                (c)     Cooperation and Settlement.  The parties shall keep one
another informed of the status of and of their respective activities regarding
any Action, including without limitation any discussion concerning the
settlement thereof.  No settlement or consent judgment or other voluntary
final disposition of any suit defended or action brought by one party pursuant
to this Paragraph may be entered into without the consent of the non-settling
party if such settlement would require the non-settling party to be subject to
an injunction, to make a monetary payment or would adversely affect the non-
settling party's rights under this Agreement
        9.07    Extensions of PDL AND SB PATENTS.
                (a)  In the event that SB has made the PHASE II REVIEW POINT
PAYMENT and SB's and PDL's rights have not been otherwise terminated, each
party shall have the  obligation to seek extensions of the terms of their
respective PDL PATENTS and SB PATENTS and to seek and obtain SPCs directly
related to the PRODUCT.
                (b)  In the event SB does not make the PHASE II REVIEW POINT
PAYMENT or SB's rights to PRODUCT (other than to receive royalties) have
otherwise been terminated,  PDL shall have the right but not the obligation to
seek extensions of the terms of SB PATENTS and to seek and obtain SPCs
directly related to the PRODUCT. At PDL's request, SB shall provide reasonable
assistance therefor to PDL, at PDL's expense for all OUT OF POCKET COSTS
incurred by SB. At PDL's request, SB shall authorize PDL to act as SB's agent
for the purpose of making any application for any extensions of the term of SB
PATENTS or for obtaining SPCs in such countries.
                (c) In the event PDL's rights to PRODUCT (other than to receive
royalties) are terminated, SB shall have the right but not the obligation to
seek extensions of the terms of PDL PATENTS and to seek and obtain SPCs
directly related to the PRODUCT.  At SB's request, PDL shall provide
reasonable assistance therefor to SB, at SB's expense for all OUT OF POCKET
COSTS incurred by PDL.  At SB's request, PDL shall authorize SB to act as
PDL's agent for the purpose of making any application for any extensions of
the term of PDL PATENTS or for obtaining SPCs in such countries.

10.     TRADEMARKS AND NON-PROPRIETARY NAMES
  10.01   Pre-PHASE II REVIEW POINT.  Prior to the PHASE II REVIEW POINT, SB
shall be responsible, at its expense, for the trademark development process,
which may include  the selection, registration, and maintenance of all
Trademarks for proposed use  in connection with PRODUCT throughout the
TERRITORY.  SB shall also be responsible for the development of a non-
proprietary name for the PRODUCT, at its expense, which may include obtaining
a USAN and INN.  SB shall keep PDL reasonably informed with respect to any
such activites.
        10.02   SB Makes PHASE II REVIEW POINT PAYMENT.
                (a)  Trademarks. In the event SB makes the PHASE II REVIEW POINT
PAYMENT and SB's rights have not been otherwise terminated, SB shall be
responsible for the selection, registration and maintenance of all Trademarks
which it uses in connection with PRODUCT throughout the TERRITORY and SB shall
own and control such Trademarks.  In the event that SB makes the PHASE II
REVIEW POINT PAYMENT but SB's rights to PRODUCT are terminated prior to the
completion of the first Phase III clinical trial, SB shall exclusively assign
to PDL all right, title and interest to all Trademarks used by SB in
connection with PRODUCT throughout the TERRITORY (or the relevant countries
within the TERRITORY); provided that PDL shall pay for all TRADEMARK COSTS
associated with the Trademarks to be assigned and all OUT OF POCKET COSTS
associated with the assignment thereof.  To the extent such assignment is
prohibited by the law of a country where a Trademark has been selected,
registered or maintained by SB, the parties shall take all necessary steps to
ensure that all rights in such Trademark is promptly transferred to PDL, and
SB shall cooperate with and reasonably assist PDL in protecting such
Trademark. Subsequently, PDL, at its expense, shall be responsible for the
selection, registration and maintenance of all Trademarks employed in
connection with PRODUCT throughout the TERRITORY (or the relevant countries in
the TERRITORY) and PDL shall own and control such Trademarks.  Except as
expressly provided herein, nothing in this AGREEMENT shall be construed as a
grant of rights, by license or otherwise, by SB to PDL to use such Trademarks
for any purpose, except as may be agreed upon to enable PDL to co-promote
PRODUCT in accordance with Article 6.
                (b)  Non-proprietary Names. If SB has made the PHASE II REVIEW
POINT PAYMENT and SB's rights have not been otherwise terminated, SB shall be
responsible for the selection and registration of non-proprietary names for
PRODUCT in the TERRITORY, including obtaining a USAN and INN.  In the event
that SB makes the PHASE II REVIEW POINT PAYMENT but SB's rights to PRODUCT are
terminated prior to the completion of the first Phase III clinical trial, PDL,
at its expense, shall be responsible for the selection and registration of
non-proprietary names for PRODUCT in the TERRITORY (or the relevant countries
of the TERRITORY), and, if necessary and appropriate, SB will cooperate with
and reasonably assist PDL in obtaining these non-proprietary names.
        10.03    SB Does Not Make PHASE II REVIEW POINT Payment.  If SB has not
made the PHASE II REVIEW POINT PAYMENT, or in the event that SB otherwise
loses or terminates its rights to PRODUCT under this AGREEMENT after the
completion of the first Phase III clinical study of PRODUCT in the TERRITORY
or in a given country of the TERRITORY, the following will apply:
                (a) Trademarks. If SB and PDL have not used a trademark in
connection with PRODUCT, PDL shall have no right to request an assignment
hereunder.  If SB or PDL has used a trademark designated by SB with respect to
the PRODUCT, then at PDL's request, that Trademark shall be assigned to PDL in
the TERRITORY if SB terminates or otherwise loses its rights to the PRODUCT in
the whole TERRITORY, or, in the event that SB terminates or otherwise loses
its rights to the PRODUCT in only certain specified countries, then SB shall
assign that Trademark in such specified countries.  To the extent such
assignment is prohibited by the law of a country where a Trademark has been
selected, registered or maintained by SB, the parties shall take all necessary
steps to ensure that all rights in such Trademark is promptly transferred to
PDL, and SB shall cooperate with and reasonably assist PDL in protecting such
Trademark.  PDL shall reimburse SB for all TRADEMARK COSTS associated with the
assigned Trademark and all OUT OF POCKET COSTS related to the assignment
thereof  within thirty (30) days after receipt of SB's invoice therefor.
Subsequently, PDL, at its expense, shall be responsible for the selection,
registration and maintenance of all Trademarks employed in connection with
PRODUCT throughout the TERRITORY (or the relevant countries in the TERRITORY)
and PDL shall own and control such trademarks.
                (b) Non-proprietary Names. PDL, at its expense, shall be
responsible for the selection and registration of non-proprietary names for
PRODUCT in the TERRITORY (or the relevant countries of the TERRITORY), and, if
necessary and appropriate, SB will cooperate with and reasonably assist PDL in
obtaining these non-proprietary names.
        10.04   Infringement of Trademarks. In the event that PDL or SB becomes
aware of actual or threatened infringement of a Trademark selected for a
PRODUCT anywhere in the TERRITORY, that party shall promptly notify the other
party in writing.  The notice shall describe in reasonable detail the facts
and circumstances forming the basis for the determination that there is actual
or threatened infringement.  The party responsible for the prosecution and
maintenance of Trademarks in accordance with this Article 10 shall have sole
control over any infringement action related to the Trademarks, including
without limitation, the right to select counsel; provided however that the
party controlling such action shall solicit, and seriously consider in good
faith, the other party's input with respect to all material aspects of such
action, including without limitation the development of the litigation
strategy and the execution thereof.
        10.05   Defense of Trademarks. In the event of the institution of any
opposition or cancellation action or suit by a THIRD PARTY against PDL or SB
or their respective sublicensees or AFFILIATES for trademark infringement
involving publication of the Trademark for opposition or cancellation, or the
manufacture, use, sale, distribution or marketing of PRODUCT anywhere in the
TERRITORY, the party sued shall promptly notify the other party in writing.
The party responsible for the prosecution and maintenance of Trademarks in
accordance with this Article 10 shall have sole control over the defense of
any such action, including without limitation, the right to select counsel;
provided however that the party controlling such action shall solicit, and
seriously consider in good faith, the other party's input with respect to all
material aspects of such action, including without limitation the development
of the litigation strategy and the execution thereof.

11.     STATEMENTS AND REMITTANCES
        11.01   Records and Audits.
                (a)  Records and Audits at SB.  SB shall keep and require its
AFFILIATES and sublicensees to keep complete and accurate records, including
details of the calculation, of all DEVELOPMENT COSTS, COSTS OF GOODS (for both
DEVELOPMENT and  commercialization), SB NET SALES, THIRD PARTY ROYALTIES,
PATENT COSTS, TRADEMARKS COSTS, INTEREST CHARGE ON WORKING CAPITAL, PROMOTION
EXPENSES, PRE-TAX PROFITS and royalties and any other amounts due to PDL (if
applicable).  PDL shall have the right, at PDL's expense, through a certified
public accountant or like person reasonably acceptable to SB, to examine such
records during regular business hours during the life of this AGREEMENT and
[CONFIDENTIAL TREATMENT REQUESTED] after its termination; provided, however,
that such examination shall not take place more often than once a calendar
year and shall not cover such records for more [CONFIDENTIAL TREATMENT
REQUESTED] years and provided further that such accountant shall report to PDL
only as to the accuracy of the reports from SB and amounts owed by or to PDL
hereunder.
                (b)  Records and Audits at PDL. PDL shall keep and require its
AFFILIATES and sublicensees to keep complete and accurate records of all
DEVELOPMENT COSTS, COST OF GOODS (for commercial manufacture, if applicable),
PDL NET SALES, THIRD PARTY ROYALTIES, PATENT COSTS, INTEREST CHARGE ON WORKING
CAPITAL, PROMOTION EXPENSES and the royalty and any other amounts due to SB
hereunder (if applicable).  SB shall have the right, at SB's expense, through
a certified public accountant or like person reasonably acceptable to PDL, to
examine such records during regular business hours during the life of this
AGREEMENT and for [CONFIDENTIAL TREATMENT REQUESTED] after its termination;
provided, however, that such examination shall not take place more often than
once a calendar year and shall not cover such records for more than the
[CONFIDENTIAL TREATMENT REQUESTED] years and provided further that such
accountant shall report to SB only as to the accuracy of the reports provided
by PDL to SB and amounts owed by or to SB hereunder.
        11.02   Quarter-Year Accounting.
                (a)  Prior to First Commercial Launch.  If SB has made the PHASE
II REVIEW POINT PAYMENT and neither SB's nor PDL's rights under this AGREEMENT
have otherwise been terminated, then (i) within thirty (30) days after the end
of each calendar quarter until such time as Paragraph 11.02(b) applies, PDL
shall provide SB with a statement setting forth in reasonable detail the
DEVELOPMENT COSTS, COST OF GOODS for DEVELOPMENT (if applicable) and PRE-
LAUNCH COMMERCIAL EXPENSES incurred by PDL during the preceding calendar
quarter, and (ii) SB shall use commercially reasonable efforts to provide as
soon as practicable consistent with the timing of SB's internal financial
reporting practices, a statement setting forth in reasonable detail its
estimated DEVELOPMENT COSTS, COST OF GOODS for DEVELOPMENT (if applicable) and
PRE-LAUNCH COMMERCIAL EXPENSES incurred by SB during the preceding calendar
quarter.  In any event, within sixty (60) days after each such calendar
quarter, SB shall deliver to PDL a true accounting for the applicable quarter
of:  all DEVELOPMENT COSTS, COST OF GOODS for DEVELOPMENT and PRE-LAUNCH
COMMERCIAL EXPENSES incurred by PDL and SB, and a reconciliation of any
amounts owed by one party to the other.  Any amount payable by a party shall
be paid within ten (10) days following receipt of such reconciliation
delivered by SB hereunder.
                (b)  After Commercial Launch.
                (i) PDL Sells. Within sixty (60) days after the end of each
calendar quarter during which there are PDL NET SALES, PDL shall deliver to SB
a true accounting of all  PRODUCT sold by PDL and its AFFILIATES during such
quarter and reports delivered by its sublicensees during such quarter,
including a reasonably detailed calculation of PDL NET SALES.  PDL shall pay
all royalties due SB under Paragraph 5.05 with the report for the applicable
quarter.  Such accounting shall show PDL NET SALES on a country-by-country
basis.
               (ii)  SB Sells.  Within thirty (30) days after the end of each
calendar quarter during which there are SB NET SALES, (A) PDL shall deliver to
SB a true accounting of all DEVELOPMENT COSTS, COST OF GOODS (if applicable),
THIRD PARTY ROYALTIES, PATENT COSTS and PROMOTION EXPENSES incurred by PDL
during the applicable quarter, and (B) SB shall use commercially reasonable
efforts to provide as soon as practicable consistent with the timing of SB's
internal financial reporting practices, a statement setting forth in
reasonable detail its estimated DEVELOPMENT COSTS, COST OF GOODS for
DEVELOPMENT (if applicable) and PRE-LAUNCH COMMERCIAL EXPENSES incurred by SB
during the preceding calendar quarter.  In any event, w ithin sixty (60) days
after the end of each calendar quarter during which there are SB NET SALES, SB
shall deliver to PDL a true accounting of all DEVELOPMENT COSTS, PRE-TAX
PROFITS, whether positive or negative, and royalty calculations, where
applicable, showing on a country-by-country basis SB NET SALES, COST OF GOODS,
DEVELOPMENT COSTS, THIRD PARTY ROYALTIES, TRADEMARK COSTS, PATENT COSTS,
INTEREST CHARGE ON WORKING CAPITAL, and PROMOTION EXPENSES incurred by both
parties, and SB shall, at the same time, pay, as a single payment, the
relevant share of PRE-TAX PROFITS, if any, due to PDL in accordance with
Paragraph 5.02, or, if applicable, all royalties, if any, due under Article 5.
and any amounts due to PDL for DEVELOPMENT COSTS in accordance with Paragraph
3.04(a)(iii).  To the extent PRE-TAX PROFITS are negative for any given
quarter, such negative amount shall be carried forward and applied to reduce
PRE-TAX PROFITS in succeeding quarters.  To the extent PDL owes SB for
DEVELOPMENT COSTS in accordance with Paragraph 3.04(a)(iii), SB shall deduct
such amounts from any payments due to PDL hereunder or, if no such payment is
due, PDL shall pay such amounts to SB within thirty (30) days.   It is
understood and agreed that pre-commercial launch PROMOTION EXPENSES incurred
by either party are not included in PRE-LAUNCH COMMERCIAL EXPENSES and shall
be applied to the calculation of PRE-TAX PROFITS until fully reimbursed as
provided in Paragraph 5.02(e).
   11.03   Withholding. Any taxes, levies or other duties paid or required to
be withheld by one party on account of payments made to the other party under
this AGREEMENT shall be identified and deducted from the payments otherwise
due.  The paying party shall secure and send to the other party proof of any
such taxes, levies or other duties withheld and paid by the paying party or
its sublicensees for the benefit of the other party.
        11.04   Payments.  All royalties and other payments due under this
AGREEMENT shall be payable in U.S. dollars and shall be paid by bank wire
transfer or by automated clearinghouse (electronic funds transfer) in
immediately available funds to such bank account designated in writing by SB
and PDL from time to time.  Interest shall accrue on delinquent payments from
the date such payments are due at the [CONFIDENTIAL TREATMENT REQUESTED].  If
governmental regulations prevent remittances from a foreign country with
respect to sales made in that country, the obligation of the paying party to
pay royalties or other payments on sales in that country shall be suspended
until such remittances are possible.  The other party shall have the right,
upon giving written notice to the paying party, to receive payment in that
country in local currency.
        11.05   Currency Exchange.  Monetary conversions from the currency of a
foreign country in which PRODUCT is sold, into U.S. dollars shall be
calculated as follows:
             (a) if by SB, at the actual average rates of exchange for the year
to date as used by SB in producing its quarterly and annual accounts, as
confirmed by SB's auditors, or
             (b) if by PDL, at the average of the daily exchange rates for such
currency quoted by Citibank, N.A., for each of the last five (5) banking days
of each calendar quarter.
        11.06   No Double Counting of Costs.  For the purpose of determining any
cost or expense which is shared by the parties or otherwise invoiced by one
party to another under this AGREEMENT, any cost or expense allocated by either
party to a particular cost category shall be consistent with the terms of this
AGREEMENT and shall not also be allocated to another category.  In the event a
cost or expense might arguably fall into more than one category, the party
shall determine in good faith which category such cost or expense most
appropriately falls into.

12.     TERM AND TERMINATION
        12.01  Termination Rights.
                (a)  Termination by SB.  SB may terminate its rights to
DEVELOPMENT and commercialization of PRODUCT [CONFIDENTIAL TREATMENT
REQUESTED] SB, using the same standards SB would use in assessing whether or
not to continue development or commercialization of a product of its own
making, that the patent, medical/scientific, technical, regulatory or
commercial profile of PRODUCT does not justify continued SB involvement in the
development or commercialization of PRODUCT in such [CONFIDENTIAL TREATMENT
REQUESTED].  In such event, the provisions of Paragraph 12.01(c) and Paragraph
5.03 or 5.04, as the case may be, shall apply.
                (b) Termination by PDL.  PDL may terminate its rights to
DEVELOPMENT and commercialization of PRODUCT [CONFIDENTIAL TREATMENT
REQUESTED] PDL, using the same standards PDL would use in assessing whether or
not to continue development or commercialization of a product of its own
making, that the patent, medical/scientific, technical, regulatory or
commercial profile of PRODUCT does not justify continued PDL involvement in
the development or commercialization of PRODUCT in such [CONFIDENTIAL
TREATMENT REQUESTED].  In such event, the provisions of Paragraph 12.01(c) and
Paragraph 5.05 shall apply.
                (c) Effect of Termination.  In the event that a party
("Terminating Party") elects to terminate its DEVELOPMENT and/or
commercialization of PRODUCT in any [CONFIDENTIAL TREATMENT REQUESTED]  at any
time under this AGREEMENT in accordance with Paragraph 12.01, then all rights
to PRODUCT granted to the Terminating Party in the [CONFIDENTIAL TREATMENT
REQUESTED] shall terminate and revert to the other party ("Surviving Party"),
the JDC, the Development Coordinators and/or the JMC shall terminate with
respect to such [CONFIDENTIAL TREATMENT REQUESTED] and the Surviving Party
shall have sole responsibility for DEVELOPMENT and commercialization in the
[CONFIDENTIAL TREATMENT REQUESTED], the licenses to the Terminating Party
under SB PATENTS and SB KNOW-HOW or PDL PATENTS and PDL KNOW-HOW, as the case
may be, shall terminate in the [CONFIDENTIAL TREATMENT REQUESTED], and the
Terminating Party shall promptly transfer all clinical, preclinical and other
relevant data and information related to PRODUCT in the [CONFIDENTIAL
TREATMENT REQUESTED] in its possession (including the assignment of any
filings with REGULATORY AUTHORITIES held by the Terminating Party) to the
Surviving Party at no cost to the Surviving Party, and the Surviving Party
shall immediately have an exclusive license to make, have made, import, use
and sell PRODUCT in the [CONFIDENTIAL TREATMENT REQUESTED] under all relevant
SB PATENTS, SB KNOW-HOW or PDL PATENTS and PDL KNOW-HOW, as the case may be.
In either case, the Surviving Party shall be fully responsible for the costs
and expenses of further DEVELOPMENT and commercialization in the [CONFIDENTIAL
TREATMENT REQUESTED] and use commercially reasonable efforts and diligence,
consistent with the effort that is used by the Surviving Party in the
development, testing, manufacture, registration, marketing and sale of
pharmaceutical products at a similar stage of development, having a comparable
level of market potential, and being subject to a comparable regulatory
review, to develop and commercialize PRODUCT in the [CONFIDENTIAL TREATMENT
REQUESTED] and any subsequent sales of PRODUCT by the Surviving Party in the
[CONFIDENTIAL TREATMENT REQUESTED] shall be subject to the royalty obligation
set forth in Paragraphs 5.03 or 5.04 (if SB elects to terminate) or 5.05 (if
PDL elects to terminate), as the case may be.
        12.02   Royalty Obligations.
                (a) PDL Royalty Obligations.  PDL's royalty obligations under
Paragraph 5.03(a) or 5.04(i), as applicable, in each country of the TERRITORY
shall expire on a country-by-country basis upon the [CONFIDENTIAL TREATMENT
REQUESTED].  PDL's royalty obligations under Paragraph 5.03(b) or 5.04(ii), as
applicable, in each country of the TERRITORY shall expire upon [CONFIDENTIAL
TREATMENT REQUESTED]  of the date of first marketing of PRODUCT in such
country by or on behalf of PDL.
                (b) SB Royalty Obligations.  SB's royalty obligations under
Paragraph 5.05(a) in each country of the world shall expire on a country-by-
country basis upon the [CONFIDENTIAL TREATMENT REQUESTED].  SB's royalty
obligations under Paragraphs 5.04(b) in each country of the TERRITORY shall
expire upon the [CONFIDENTIAL TREATMENT REQUESTED] date of first marketing in
such country by or on behalf of SB.
             (c) Profit-Sharing Scenario.  SB's obligation to make the payments
to PDL under Paragraph 5.02 shall expire on a country-by-country basis upon
the date that [CONFIDENTIAL TREATMENT REQUESTED].
     12.03   Term of Agreement in its Entirety.  Unless otherwise terminated in
accordance with the terms of this AGREEMENT, this AGREEMENT shall expire, on a
country-by-country basis upon the later of the expiration of SB's obligation
to make payments to PDL under Paragraph 5.02 or the expiration of all royalty
obligations owed by one party to the other party in such country of the
TERRITORY as set forth in this AGREEMENT.  Expiration of this AGREEMENT in a
particular country under this provision shall not preclude either party from
continuing to market or have marketed PRODUCT and to use SB KNOW-HOW and PDL
KNOW-HOW, as the case may be, in such country without further payments to the
other party.
        12.04   Termination Due to Default.
                (a)  If either party fails or neglects to perform covenants or
provisions of this AGREEMENT (other than pursuant to Paragraph 3.06) and if
such default is (a) for failure to pay undisputed amounts due hereunder and
such default is not cured within ten (10) business days, or (b) for any
default other than non-payment and such default is not corrected within sixty
(60) days after receiving written notice from the other party with respect to
such default, such other party shall have the right to terminate rights to
PRODUCT of the defaulting party under this AGREEMENT by giving written notice
to the party in default provided the notice of termination is given within six
(6) months of the default and prior to correction of the default.
                (b) In the event that a party's ("Terminating Party") rights to
the DEVELOPMENT and/or commercialization of PRODUCT in the TERRITORY are
terminated at any time under this AGREEMENT in accordance with Paragraph
12.04, then all rights to PRODUCT granted to the Terminating Party in the
TERRITORY shall terminate and revert to the other party ("Surviving Party"),
the JDC, the Development Coordinators and/or the JMC shall terminate and the
Surviving Party shall have sole responsibility for DEVELOPMENT and
commercialization in the TERRITORY, the licenses to the Terminating Party
under SB PATENTS and SB KNOW-HOW or PDL PATENTS and PDL KNOW-HOW, as the case
may be, shall terminate in the TERRITORY, and the Terminating Party shall
promptly transfer all clinical, preclinical and other relevant data and
information related to PRODUCT in the TERRITORY in its possession (including
the assignment of any filings with  REGULATORY AUTHORITIES held by the
Terminating Party) to the Surviving Party at no cost to the Surviving Party,
and the Surviving Party shall immediately have an exclusive license to make,
have made, import, use and sell PRODUCT in the TERRITORY under all relevant SB
PATENTS, SB KNOW-HOW or PDL PATENTS and PDL KNOW-HOW, as the case may be.  In
either case, the Surviving Party shall use commercially reasonable efforts and
diligence, consistent with the effort that is used by the Surviving Party in
the development, testing, manufacture, registration, marketing and sale of
pharmaceutical products at a similar stage of development, having a comparable
level of market potential, and being subject to a comparable regulatory
review, to develop and commercialize PRODUCT in the TERRITORY and any
subsequent sales of PRODUCT by the Surviving Party in the [CONFIDENTIAL
TREATMENT REQUESTED] shall be subject to the royalty obligation set forth in
Paragraphs 5.03 or 5.04 (if SB elects to terminate) or 5.05 (if PDL elects to
terminate), as the case may be.
        12.05   Termination Due to Bankruptcy.
                (a)  Either party may terminate this AGREEMENT if, at any time,
the other party shall file in any court or agency pursuant to any statute or
regulation of any state or country, a petition in bankruptcy or insolvency or
for reorganization or for an arrangement or for the appointment of a receiver
or trustee of the party or of its assets, or if the other party proposes a
written agreement of composition or extension of its debts, or if the other
party shall be served with an involuntary petition against it, filed in any
insolvency proceeding, and such petition shall not be dismissed within sixty
(60) days after the filing thereof, or if the other party shall propose or be
a party to any dissolution or liquidation, or if the other party shall make an
assignment for the benefit of creditors.
             (b)  Notwithstanding the bankruptcy of either party hereunder, or
the impairment of performance by that party of its obligations under this
AGREEMENT as a result of bankruptcy or insolvency of a party, the non-bankrupt
party shall be entitled to retain the licenses granted herein, subject to the
bankrupt party's rights to terminate this AGREEMENT for reasons other than
bankruptcy or insolvency as expressly provided in this AGREEMENT.
             (c)  All rights and distribution rights granted under or pursuant
to this AGREEMENT by one party to the other under this Agreement are, and
shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S.
Bankruptcy Code, licenses of rights to "intellectual property" as defined
under Section 101(35A) of the U.S. Bankruptcy Code.  The parties agree that
the licensee of such rights under this AGREEMENT shall retain and may fully
exercise all of its rights and elections under the U.S. Bankruptcy Code,
subject to performance by the licensee of its preexisting obligations under
this AGREEMENT.  The parties further agree that, in the event of the
commencement of a bankruptcy proceeding by or against the licensor under the
U.S. Bankruptcy Code, the licensee shall be entitled to a complete duplicate
of (or complete access to, as appropriate) any such intellectual property and
all embodiments of such intellectual property, and same, if not already in its
possession, shall be promptly delivered to the licensee (i) upon any such
commencement of a bankruptcy proceeding upon written request therefor by the
licensee, unless the licensor elects to continue to perform all of its
obligations under this AGREEMENT, or (ii) if not delivered under (i) above,
upon the rejection of this AGREEMENT by or on behalf of the licensor upon
written request therefor by the licensee, provided, however, that upon the
licensor's (or its successor's) written notification to the licensee that it
is again willing and able to perform all of its obligations under this
AGREEMENT, the licensee shall promptly return all such tangible materials to
the licensor, but only to the extent that the licensee does not require
continued access to such materials to enable the licensee to perform its
obligations under this AGREEMENT.

13.     RIGHTS AND DUTIES UPON TERMINATION
     13.01   Payments.  Upon termination of this AGREEMENT, PDL shall have the
right to retain any sums already paid by SB hereunder, and SB shall pay all
sums accrued hereunder which are then due, and SB shall have the right to
retain any sums already paid by PDL hereunder, and PDL shall pay all sums
accrued hereunder which are then due.
        13.02   Product Inventory.  Upon termination of this AGREEMENT following
NDA APPROVAL of PRODUCT anywhere in the TERRITORY but earlier than its
expiration in accordance with Paragraph 12.03, either party holding inventory
of PRODUCT shall notify the other of the amount of PRODUCT such party, its
AFFILIATES, sublicensees and distributors then have on hand, the sale of which
would, but for the termination, be subject to payment in accordance with
Paragraph 5.02, 5.03, 5.04 or 5.05, as the case may be, and each party and its
AFFILIATES, sublicensees and distributors shall thereupon be permitted to sell
that amount of PRODUCT, provided that the selling party shall pay the payment
thereon at the time herein provided for and provided further that the other
party shall have the first option to purchase such PRODUCT at a reasonable
cost to be negotiated by the parties.  If the parties fail to enter into an
agreement for purchase of such PRODUCT, the party holding the inventory of
PRODUCT will be free to sell such PRODUCT to THIRD PARTIES for a period not to
exceed ninety (90) days from the termination of negotiations for the purchase
of such PRODUCT; provided, however, that the party selling the inventory of
PRODUCT may only offer such PRODUCT on terms no more favorable to the THIRD
PARTY than those offered to the other party.
        13.03   Survival.  Subject to Paragraph 13.01, termination of this
AGREEMENT shall terminate all outstanding obligations and liabilities between
the parties arising from this AGREEMENT except those described in Paragraphs
8.03, 8.04, 9.01, 11.01, 14.03, 14.04, and 14.05 and Articles 12, 13, 16, 17
and 20, as well as any other provision, such as Paragraph 8.03 which, by its
terms, is stated to survive the termination or expiration of this AGREEMENT.
In addition, any other provision required to interpret and enforce the
parties' respective rights and obligations under this AGREEMENT shall also
survive, but only to the extent that such survival is required for the full
observation and performance of this AGREEMENT by the parties hereto.
        13.04   Remedies.  Termination of the AGREEMENT in accordance with the
provisions hereof shall not limit remedies which may be otherwise available in
law or equity.

14.     WARRANTIES, REPRESENTATIONS, INDEMNIFICATIONS
        AND INSURANCE
      14.01   Warranty by SB.  SB represents and warrants that, to the best of
its belief and knowledge, it owns the entire right and title to the extent of
its ownership interest in SB PATENTS, and that it has given to PDL all
information requested by PDL prior to the EFFECTIVE DATE, relating to SB
PATENTS, SB KNOW-HOW or PRODUCT, in SB's possession to the extent directly
related to PRODUCT.  Nothing in this AGREEMENT shall be construed as a
warranty that SB PATENTS are valid or enforceable or that their exercise does
not infringe any patent rights of THIRD PARTIES.  A holding of invalidity or
unenforceability of any SB PATENT, from which no further appeal is or can be
taken, shall not affect any obligation already accrued hereunder, but shall
only eliminate royalties otherwise due under such patent from the date such
holding becomes final in accordance with this AGREEMENT.
     14.02   Warranty by PDL.  PDL represents and warrants that, to the best of
its belief and knowledge, it owns the entire right and title to the extent of
its ownership interest in PDL PATENTS, and that is has given to SB all
information requested by SB prior to the EFFECTIVE DATE, relating to PDL
PATENTS, PDL KNOW-HOW or PRODUCT, in PDL's possession to the extent directly
related to PRODUCT.  Nothing in this AGREEMENT shall be construed as a
warranty that PDL PATENTS are valid or enforceable or that their exercise does
not infringe any patent rights of THIRD PARTIES.  A holding of invalidity or
unenforceability of any PDL PATENT, from which no further appeal is or can be
taken, shall not affect any obligation already accrued hereunder, but shall
only eliminate royalties otherwise due under such patent from the date such
holding becomes final in accordance with this AGREEMENT.
     14.03   Indemnification by SB.  SB hereby agrees to save, defend and hold
PDL, its AFFILIATES and their respective officers, directors, stockholders,
representatives, agents, employees, successors and assigns harmless from and
against any and all suits, claims, actions, demands, liabilities, expenses
and/or losses, including reasonable legal expense and attorneys' fees, brought
by a THIRD PARTY or that arise in connection with any claim brought by a THIRD
PARTY with respect to PRODUCT related to (a) death or other physical injury to
any person to the extent caused by the use or administration of PRODUCT
provided or sold by SB and its AFFILIATES hereunder; or which injury is due to
the negligence or willful misconduct of SB, (b) property damage to the extent
such damage is due to the negligence or willful misconduct of SB or (c) breach
of any representation or warranty of SB under this AGREEMENT provided that SB
shall not be required to provide indemnification hereunder to the extent that
any losses, claims, damages or liability result from (i) the negligence or
willful misconduct of PDL or breach by PDL of any provision of this AGREEMENT,
or (ii) PDL's manufacture (including its manufacture through THIRD PARTY
suppliers) of PRODUCT, or (iii) PDL's failure to perform its obligations with
respect to the marketing of PRODUCT in accordance with Article 7.
        14.04   Indemnification by PDL.  PDL hereby agrees to save, defend and
hold SB, its AFFILIATES and their respective officers, directors,
shareholders, representatives, agents, employees, successors and assigns
harmless from and against any and all suits, claims, actions, demands,
liabilities, expenses and/or losses, including reasonable legal expense and
attorneys' fees, brought by a THIRD PARTY or that arise in connection with any
claim brought by a THIRD PARTY with respect to PRODUCT related to (a) death or
other physical injury to any person to the extent caused by the use or
administration of PRODUCT provided or sold by PDL and its AFFILIATES
hereunder; or which injury is due to the negligence or willful misconduct of
PDL, (b) property damage to the extent such damage is due to the negligence or
willful misconduct of PDL or (c) breach of any representation or warranty of
PDL under this AGREEMENT provided that PDL shall not be required to provide
indemnification hereunder to the extent that any losses, claims, damages or
liability result from (i) the negligence or willful misconduct of SB or breach
by SB of any provision of this AGREEMENT, or (ii) SB's manufacture (including
its manufacture through THIRD PARTY suppliers) of PRODUCT, or (iii) SB's
failure to perform its obligations with respect to the marketing of PRODUCT in
accordance with Article 7.
14.05   Indemnification Procedure.
(a)  PDL Seeks Indemnification from SB.  In the event PDL is
seeking indemnification from SB under Paragraph 14.03, SB shall have no such
obligation unless PDL:
(i)  gives SB prompt notice of any claim or lawsuit or other
action for which it seeks to be indemnified under this AGREEMENT;
(ii)  cooperates fully with SB and its agents in defense of
any such claim, complaint, lawsuit or other cause of action; and
(iii)  SB is granted full authority and control over the
defense, including settlement or other disposition thereof, against such claim
or lawsuit or other action, provided that PDL shall have the right to retain
counsel of its choice to participate in the defense of any such claim or
lawsuit at PDL's own expense, provided that such counsel shall not interfere
with SB's full authority and control.
(b)  SB Seeks Indemnification from PDL.  In the event SB is
seeking indemnification under Paragraph 14.04, PDL shall have no such
obligation unless SB:
(i)  gives PDL prompt notice of any claim or lawsuit or
other action for which it seeks to be indemnified under this AGREEMENT;
(ii)  cooperates fully with PDL and its agents in defense of
any such claim, complaint, lawsuit or other cause of action; and
(iii)  PDL is granted full authority and control over the
defense, including settlement or other disposition thereof, against such claim
or lawsuit or other action, provided that SB shall have the right to retain
counsel of its choice to participate in the defense of any such claim or
lawsuit at SB's own expense, provided that such counsel shall not interfere
with PDL's full authority and control.
14.06   Insurance.  During the term of the AGREEMENT, and for a period of
five (5) years after the expiration or termination of this AGREEMENT or the
earlier termination thereof, each party shall maintain, respectively, at its
sole cost and expense insurance coverage from insurance companies having a
rating of at least "A-VIII" as published in the most recent edition of A.M.
Best's Insurance Reports, product liability and general liability coverage, in
amounts, respectively, which are reasonable and customary in the U.S.
pharmaceutical industry for companies of comparable size and activities at the
respective place of business of each party, or, solely in the case of SB, self
insure with the substantially the same protections.  Such product liability
insurance shall insure against all liability, including personal injury,
physical injury, or property damage arising out of the manufacture, sale,
distribution, or marketing of PRODUCT in the countries of the world in which
the party is permitted to undertake such activities in accordance with this
AGREEMENT.  Each party shall provide written proof of the existence of such
insurance to the other party upon request.  Notwithstanding the foregoing, (a)
during the conduct of Phase I and II clinical trials, each party shall always
maintain product liability insurance (or, in the case of SB, self-insure) with
a minimum of [CONFIDENTIAL TREATMENT REQUESTED] per occurrence (or claim) and
annual aggregate limit of liability of [CONFIDENTIAL TREATMENT REQUESTED],
(b) during the conduct of Phase III clinical trials, each party shall maintain
product liability insurance (or, in the case of SB, self-insure) with a
minimum of [CONFIDENTIAL TREATMENT REQUESTED]per occurence (or claim) and
annual aggregate limit of liability of [CONFIDENTIAL TREATMENT REQUESTED]and
(c) and after first commercial sale each party shall always maintain product
liability insurance (or, in the case of SB, self-insure) with a minimum of
[CONFIDENTIAL TREATMENT REQUESTED] per occurrence (or claim) and annual
aggregate limit of liability.

15.     FORCE MAJEURE
        If the performance of any part of this AGREEMENT by either party, or of
any obligation under this AGREEMENT, is prevented, restricted, interfered with
or delayed by reason of any cause beyond the reasonable control of the party
liable to perform, unless conclusive evidence to the contrary is provided, the
party so affected shall, upon giving written notice to the other party, be
excused from such performance to the extent of such prevention, restriction,
interference or delay, provided that the affected party shall use its
reasonable best efforts to avoid or remove such causes of non-performance and
shall continue performance with the utmost dispatch whenever such causes are
removed.  When such circumstances arise, the parties shall discuss what, if
any, modification of the terms of this AGREEMENT may be required in order to
arrive at an equitable solution.

16.     GOVERNING LAW
        This AGREEMENT shall be deemed to have been made in New York and its
form, execution, validity, construction and effect shall be determined in
accordance with the laws thereof.

17.     DISPUTE RESOLUTION
Except as otherwise described in Paragraphs 3.03(d), 5.06(a) and 7.03(d)(iii),
any dispute, controversy or claim arising out of or relating to this AGREEMENT
(hereinafter collectively referred to as "Dispute") shall be attempted to be
settled by the parties, in good faith, by submitting each such Dispute to
appropriate senior management representatives of each party in an effort to
effect a mutually acceptable resolution thereof within thirty (30) days.
Within fifteen (15) days after submission of the Dispute to such senior
representatives, each party shall submit a brief, written summary of the
Dispute and their respective position with respect to the Dispute to such
senior representatives.  In the event no mutually acceptable resolution is
achieved, then each party shall be entitled to seek relief for such Dispute by
using any appropriate judicial mechanism which may be available in the courts.

18.     SEPARABILITY
       18.01   In the event any portion of this AGREEMENT shall be held illegal,
void or ineffective, the remaining portions hereof shall remain in full force
and effect.
        18.02   If any of the terms or provisions of this AGREEMENT are in
conflict with any applicable statute or rule of law, then such terms or
provisions shall be deemed inoperative to the extent that they may conflict
therewith and shall be deemed to be modified to conform with such statute or
rule of law.
        18.03   In the event that the terms and conditions of this AGREEMENT are
materially altered as a result of Paragraph 18.01 or 18.02, the parties will
in good faith renegotiate the terms and conditions of this AGREEMENT to carry
out the original intent of the parties.

19.     ENTIRE  AGREEMENT
        This AGREEMENT (including Appendices hereto), entered into as of the
date written above, constitutes the entire agreement between the parties
relating to the subject matter hereof and supersedes all previous writings and
understandings.  No terms or provisions of this AGREEMENT shall be varied or
modified by any prior or subsequent statement, conduct or act of either of the
parties, except that the parties may amend this AGREEMENT by written
instruments specifically referring to and executed in the same manner as this
AGREEMENT.

20.     NOTICES
        20.01   Notices required or permitted under this AGREEMENT shall be in
writing in the English Language and sent by overnight express mail (e.g.,
FedEx), or by facsimile confirmed by overnight express mail (e.g., FedEx), and
shall be deemed to have been properly served to the addressee upon receipt of
such written communication, to the following addresses of the parties or to
such address or addresses as may be specified from time to time in a written
notice:
                PDL
                Protein Design Labs, Inc.
                34801 Campus Drive
                Fremont, California  94555  U.S.A.
                                Attention:  General Counsel
Fax: (510) 574-1473

                SB
                SmithKline Beecham Corporation
                One Franklin Plaza (Mail Code FP1930)
                P.O. Box 7929
                Philadelphia, Pennsylvania 19101
                U.S.A.
                Attention: Senior Vice President, Business Development
Fax: (215) 751-4253

                        copy to:

                        SmithKline Beecham Corporation
                        One Franklin Plaza (Mail Code FP2360)
                        P.O. Box 7929
                        Philadelphia, Pennsylvania 19101, U.S.A.
                        Attention:  Corporate Law-U.S.
Fax: (215) 751-3935

        20.02   Any notice required or permitted to be given concerning this
AGREEMENT shall be effective upon receipt by the party to whom it is
addressed.

21.     ASSIGNMENT
      This AGREEMENT and the licenses herein granted shall be binding upon and
inure to the benefit of the successors in interest of the respective parties.
Neither this AGREEMENT nor any interest hereunder shall be assignable by
either party without the written consent of the other provided, however, that
either party may assign this AGREEMENT or any part of its rights and
obligations hereunder to any AFFILIATE of such party or to any corporation
with which that party may merge or consolidate, or to which it may transfer
all or substantially all of its assets to which this AGREEMENT relates,
without obtaining the consent of the other party, provided that the party
effecting such assignment shall notify the other promptly following such
assignment.

22.     RECORDING
        SB and PDL, as appropriate, shall have the right, at any time, to
record, register, or otherwise notify this AGREEMENT in appropriate
governmental or regulatory offices anywhere in the TERRITORY, and PDL and SB,
as appropriate, shall provide reasonable assistance to the other in effecting
such recording, registering or notifying.

23.     INDEPENDENT CONTRACTORS
        The parties are independent contractors under this AGREEMENT and no
other relationship is intended, including, without limitation, partnership,
joint venture or agency relationship.  Neither party shall act in a manner
which expresses or implies a relationship other than of independent
contractor, nor bind the other party, except as otherwise expressly provided
in this AGREEMENT.  Nothing in this AGREEMENT shall be deemed to infer any
direct relationship between PDL and any AFFILIATE of SB.


24.     EXECUTION IN COUNTERPARTS
        This AGREEMENT may be executed in any number of counterparts, each of
which shall be deemed an original but all of which together shall constitute
one and the same instrument.
      IN WITNESS WHEREOF, the parties, through their authorized officers, have
executed this AGREEMENT as of the date first written above.


SMITHKLINE BEECHAM CORPORATION

BY:

TITLE:


PROTEIN DESIGN LABS, INC.

BY:

TITLE:


DEVELOPMENT AND LICENSE AGREEMENT
SMITHKLINE BEECHAM CORPORATION-PROTEIN DESIGN LABS, INC.
APPENDIX A

The following are patents and patent applications (also known as the "Queen et
al. patents") issued and filed in certain countries in the world and licensed
as part of the PDL PATENTS under the Agreement (As of August 25, 1999)

1.  The following issued U.S. patents and U.S. patent applications:

No. 5,585,089, "Humanized Immunoglobulins," issued December 17, 1996.

No. 5,693,761, "Polynucleotides Encoding Improved Humanized
Immunoglobulins," issued December 2, 1997.

No. 5,693,762, "Humanized Immunoglobulins," issued December 2, 1997.

[CONFIDENTIAL TREATMENT REQUESTED]


2.  The following patents and patent applications outside the U.S.:

Patent No.

Country
Title*
Issued
647383
Australia
"Novel Immunoglobulins, Their Production
and Use"
Issued
671949
Australia
"
Issued
AT E133452
Austria
"
Issued
0451216
Belgium
"
Issued
61095
Bulgaria
"
Issued
970016

Brazil
"
Issued
0451 216B1
European
"
Issued
0682040 B1
European

Issued
FR0451216
France
"
Issued
DE
68925536
Germany
"
Issued
DD 296 964
East Germany
"
Issued
GB 0451216
Great Britain
"
Issued
1001050

Greece
"
Issued
211174

Hungary
"
Issued
IT O451216
Italy
"
Issued
2828340
Japan
"
Issued
LU O451216
Luxembourg
"
Issued
92.2146
Monaco
"
Issued
NL 0451216
Netherlands
"
Issued
231984
New Zealand
"
Issued
132068
Pakistan
"
Issued
29729
Philippines
"
Issued
92758
Portugal
"
Issued
4895847.13
Russia
"
Issued
2126046
Russia
"
Issued
SG O451216
Singapore
"
Issued
89/9956
South Africa
"
Issued
178385
South Korea
"
Issued
2081974 T3
Spain
"
Issued
SE O451216
Sweden
"
Issued
CHO 451216
Switzerland
"
Issued
50034
Taiwan
"
Issued
13349
Uruguay
"
Issued
48700
Yugoslavia
"







Country
Title*
Pending
Argentina
"Novel Immunoglobulins, Their
Production and Use"
Pending
Canada
"
Pending
Chile
"
Pending
China
"
Pending
Croatia
"
Pending
Czech Republic
"
Pending
Ecuador
"
Pending
Europe
"
Pending
Hong Kong
"
Pending
Ireland
"
Pending
Israel
"
Pending
Japan
"
Pending
South Korea

Pending
Romania
"
Pending
Slovak Republic
"
Pending
Venezuela
"
Pending
Denmark
"
Pending
Finland
"
Pending
Norway
"









*Exact titles may differ in different countries.

SB PATENTS

[CONFIDENTIAL TREATMENT REQUESTED]

DEVELOPMENT AND LICENSE AGREEMENT
SMITHKLINE BEECHAM CORPORATION-PROTEIN DESIGN LABS, INC.
APPENDIX B
CO-PROMOTION TERMS: PROFIT SPLIT FOR DETAILING
[CONFIDENTIAL TREATMENT REQUESTED]

DEVELOPMENTAND LICENSE AGREEMENT
SMITHKLINE BEECHAM CORPORATION-PROTEIN DESIGN LABS, INC.
APPENDIX C
PHARMACOVIGILANCE AGREEMENT
Procedure for Exchange of Adverse Event data between
SB Worldwide Clinical Safety and PDL for PRODUCT (e.g., SB 240683)
1.0  Background:
This Pharmacovigilance procedure shall be effective for the term of the
AGREEMENT.  In the event SB makes the PHASE II REVIEW POINT PAYMENT, the
parties will review this Appendix C to assess whether amendments are required.

2.0  Definitions:

A.  Serious Adverse Event.  A serious adverse event includes any
experience/event that results in any of the following outcomes:
  death
  life-threatening (at immediate risk of death from the event as it
occurs)
  requires inpatient hospitalization or prolongation of existing
hospitalization
  a persistent or significant disability/incapacity
  a congenital anomaly/birth defect
  is an important medical event that may not result in any of the above
outcomes, but based upon appropriate medical judgment, may jeopardize
the patient or subject and may require medical or surgical intervention
to prevent one of the outcomes listed in the definition.

B.  Unexpected adverse drug experience.  An unexpected adverse drug
experience is any adverse drug experience that is not listed in the current
labeling for the Product. "Unexpected" refers to an adverse drug experience
that has not been previously observed (i.e. is not included in the
investigator brochure) rather than an experience that is not anticipated
based on the pharmacological properties of the pharmaceutical product.

3.0  Policy Statements:

A. Each Party will follow its existing procedures for intake, review and
reporting of adverse events.
B. Each Party will maintain the original source documents in accordance
with current regulatory requirements.
C. PDL and SB will exchange safety information as appropriate.
D. SB and PDL Central Safety Departments(or equivalents) will review this
Appendix periodically and revise same as necessary.
E. PDL will maintain the central international adverse event database of
adverse event reports associated with PRODUCT.

4.0  Processing Adverse Events Associated With PRODUCT:

A. PDL Responsibilities:

1. PDL will acknowledge all reports submitted by SB under 4.B.1 below.

2. PDL will generate and submit all serious and unexpected adverse event
(SAE) reports associated with PRODUCT to the FDA within 7 or 15 calendar
days of the initial report of information by PDL in accordance with
local regulations.  PDL will cross reference SB's IND on all such
reports and will provide SB Worldwide Clinical Safety (SB WWCS)
Department with a copy of any report at the time of submission  to the
FDA as well as a copy of the final report.

3. Prior to initiating the first clinical trial with PRODUCT, PDL will
provide SB with a copy of PDL's standard operating procedure "SOP"
related to safety reporting, including a technical description of the
information to be captured in the safety database.  SB will review this
SOP to ensure that regulatory reporting requirements will be met and,
and to ensure that the data captured is of sufficient detail to allow
the data to be integrated after the PHASE II REVIEW POINT PAYMENT, if
the parties decide that safety reporting shall be managed by SB in
accordance with Paragraph 3.04(a)(ii) of the AGREEMENT.

PDL will generate and submit a line listing of all SAEs to SB WWCS.
Such line-listing will be produced on a quarterly basis and will
indicate the patient number, SAE(s) reported for each patient, and
causality assigned by the clinical investigator for each SAE.

4. PDL will generate and submit all necessary documents associated with the
IND Annual Report to the FDA in accordance with regulations and will
cross reference SB's IND in doing so.  PDL will simultaneously submit a
copy of each IND Annual Report to SB WWCS.

5. PDL will generate and submit any necessary Investigator Letters
regarding serious and unexpected adverse reactions to the FDA in
accordance with regulations and will cross reference SB's IND in doing
so.  PDL will simultaneously submit a copy of each Investigator Letter
to SB WWCS.

B. SB Responsibilities:

1. Within 30 days following execution of this AGREEMENT, SB WWCS will
submit via CIOMS I forms all SAEs associated with PRODUCT entered into
SB's Safety Database as of the EFFECTIVE DATE.

2. In the event that SB is inadvertently contacted by a clinical
investigator to report a PRODUCT-related SAE, SB will attempt to (i)
forward the clinical investigator to PDL for follow-up and (ii) if this
is not immediately possible, record the SAE and send to PDL by facsimile
within 24 hours of receipt by SB WWCS.

3. SB will no longer enter any SAE reports associated with PRODUCT on its
Safety Database, as these reports will be maintained in PDL's Safety
Database as described in 4.A.3 above.

5.0  Pharmacovigilance Contacts In Each Party:
A.  For SB:                                                     Contact
Address and Numbers
Primary:        [CONFIDENTIAL TREATMENT REQUESTED]


B.  For PDL:                                                            Contact
Address and Numbers
[CONFIDENTIAL TREATMENT REQUESTED]

copy to:
[CONFIDENTIAL TREATMENT REQUESTED]

DEVELOPMENT AND LICENSE AGREEMENT
SMITHKLINE BEECHAM CORPORATION-PROTEIN DESIGN LABS, INC.
APPENDIX D
DEVELOPMENT PLAN
[CONFIDENTIAL TREATMENT
REQUESTED]



DEVELOPMENT AND LICENSE AGREEMENT
SMITHKLINE BEECHAM CORPORATION-PROTEIN DESIGN LABS, INC.
APPENDIX E
THE MANUFACTURING PLAN
[CONFIDENTIAL TREATMENT REQUESTED]



CONFIDENTIAL TREATMENT REQUESTED WITH RESPECT TO
DESIGNATED PORTIONS OF THIS DOCUMENT

DEVELOPMENT AND LICENSE AGREEMENT

CONFIDENTIAL TREATMENT REQUESTED WITH RESPECT TO
DESIGNATED PORTIONS OF THIS DOCUMENT

DEVELOPMENT AND LICENSE AGREEMENT               Page 70



AMENDED AND RESTATED AGREEMENT

        This Amended and Restated Agreement is entered into as of October 20,
1999 ("Signing Date"), by and among, on the one hand, HOFFMANN-LA ROCHE INC.,
a New Jersey corporation having offices at 340 Kingsland Street, Nutley, New
Jersey  07110 ("Roche-Nutley") and F. HOFFMANN-LA ROCHE LTD of Basel,
Switzerland ("F. Roche") (Roche-Nutley and F.Roche are hereinafter
individually and collectively referred to as "Roche") and PROTEIN DESIGN LABS,
INC., a Delaware corporation having offices at 34801 Campus Drive, Fremont,
California  94555 ("PDL").

RECITALS
A. Roche and PDL are parties to Agreements dated January 31, 1989, as amended
(the "1989 Agreements") pertaining to humanized and chimeric antibodies
against the interleukin-2 receptor ("IL-2R").
B. Under the 1989 Agreements, PDL exclusively licensed to Roche rights to a
humanized antibody now known as Daclizumab (as defined below).
C. Roche is currently marketing Daclizumab under the trademark Zenapaxr for
the prevention of acute organ rejection in patients receiving kidney
transplants.
D. Roche and PDL now desire to replace the 1989 Agreements with new agreements
to provide PDL with rights to develop and, if successful, promote
Daclizumab in autoimmune indications for increased compensation from the
1989 Agreements.
E. Concurrently with the entering into of this Amended and Restated Agreement,
PDL and F. Roche are replacing the 1989 Agreements with respect to rights
outside of the U.S. and Canada with a new agreement ("F. Roche Agreement").
NOW, THEREFORE, in consideration of the premises and the mutual promises and
covenants set forth below, PDL and Roche mutually agree to replace the 1989
Agreements with respect to the U.S. and Canada as follows:
I.  DEFINITIONS
        For the purposes of this Amended and Restated Agreement, the following
terms, when written with an initial capital letter (except as set forth in
Sections 1.24 and 1.25), shall have the meaning ascribed to them below.  All
references to particular Appendices, Articles and Sections shall mean the
Appendices to, and Articles and Sections of, this Amended and Restated
Agreement, unless otherwise specified.
1.1     "Affiliates" means any corporation or other business entity
controlled by, controlling, or under common control with another entity, with
"control" meaning direct or indirect beneficial ownership of more than fifty
percent (50%) of the voting stock of, or more than a fifty percent (50%)
interest in the income of, such corporation or other business entity.
1.2     "Combination Product" means any product containing both an
ingredient which causes it to be considered a Licensed Product and one or more
other therapeutically active ingredients.
1.3     "FDA" shall mean the United States Food and Drug Administration.
1.4     "Field" means any humanized or chimeric antibody which binds to
the IL-2R, where "humanized" means a genetically engineered combination of a
substantially human framework region and constant region, and complementarity
determining regions from non-human antibodies, and where "chimeric" means a
genetically engineered combination of human constant region and non-human
variable region.  "Antibodies in the Field" means humanized and chimeric
antibodies which bind to the IL-2R.  It is believed that these Antibodies in
the Field may be useful for therapeutic, diagnostic, imaging and similar
purposes.  It is understood that the Field includes, but is not limited to,
that certain humanized murine monoclonal antibody prepared against the p55
component of the IL-2R ("humanized anti-Tac"). Furthermore, the Field
includes, but is not limited to, all improvements relating to humanized anti-
Tac, including without limitation modifications in structure introduced by
genetic engineering, or by chemical or enzymatic cleavage.  Also included
within the Field shall be alternate hosts for producing humanized anti-Tac,
methods for purification, formulations incorporating humanized anti-Tac, and
uses and methods of use for humanized anti-Tac in human medicine. Humanized
anti-Tac is also known as "Daclizumab".  "Daclizumab" as used in this Amended
and Restated Agreement means any product that contains Daclizumab.
1.5     "Initial Commercialization" means either of the following,
depending on context:
(a)  For the United States, the end of the calendar month containing the
date following FDA approval of the Biologics License Application filed for a
Licensed Product for human therapeutic use for prevention of kidney transplant
rejection or a major disease (within the meaning of Milestone #2 in
Section 3.2 of the 1989 Agreement) on which Roche, its Affiliates or
sublicensees first sell such a product to an independent third party not an
Affiliate of the seller in the Territory.  With respect to Daclizumab,
"Initial Commercialization" occurred in the United States on December 31,
1997.
(b)  For Canada, the end of the calendar month containing the date
following Regulatory Approval (as defined in the F.Roche Agreement) for a
Licensed Product for human therapeutic use for prevention of kidney transplant
rejection or a major disease (within the meaning of Milestone #2 in
Section 3.2 of the 1989 Agreement) on which Roche, its Affiliates or
sublicensees first sell such a product to an independent third party not an
Affiliate of the seller in a major market outside the Territory, where "major
market" means either Japan or two of the following three countries:  France,
Italy or the United Kingdom.  .
1.6     "Joint Inventions" means any inventions in the Field, whether
patented or not, which are jointly made during the period beginning on January
31, 1989 and ending upon expiration or termination of this Amended and
Restated Agreement by at least one PDL employee or person contractually
required to assign or license patent rights covering such inventions to PDL
and at least one Roche or F. Roche employee or person contractually required
to assign or license patent rights covering such inventions to Roche or F.
Roche.
1.7     "Licensed Product" means any product in the Field, including any
Combination Product, the making, use or sale of which utilizes PDL Know-How,
PDL Patents or Joint Inventions or would, in the absence of this Amended and
Restated Agreement, infringe a Valid Claim.  Daclizumab  shall be deemed to be
a Licensed Product.
1.8     "Adjusted Gross Sales" means the gross invoice price of all
Licensed Products sold or otherwise disposed of for consideration by Roche,
its Affiliates or sublicensees (other than PDL and its Affiliates hereunder)
to independent third parties not an Affiliate of the seller, after deducting,
if not already deducted, from the amount invoiced:
(a) the amounts actually allowed as volume or quantity
discounts, rebates, price reductions, returns (including
withdrawals and recalls); and
(b) sales, excise and turnover taxes imposed directly upon and
actually paid by Roche, its Affiliates or sublicencees.
When calculating the Adjusted Gross Sales, the amount of such sales in
foreign currencies shall be converted into U.S. dollars at the average rate of
exchange at the time for the applicable calendar quarter in accordance with
Roche's then current standard practices.
In the case of Combination Products for which the Licensed Product and
each of the other therapeutically active ingredients contained in the
Combination Product have established market prices when sold separately,
Adjusted Gross Sales shall be determined by multiplying the Adjusted Gross
Sales for each such Combination Product by a fraction, the numerator of which
shall be the established market price for the Licensed Product(s) contained in
the Combination Product, and the denominator of which shall be the sum of the
established market prices for the Licensed Product(s) plus the other active
ingredients contained in the Combination Product.  When such separate market
prices are not established, then the parties shall negotiate in good faith to
determine the method of calculating Adjusted Gross Sales for Combination
Products.
If Roche or its Affiliates or sublicensees receive non-cash
consideration for any Licensed Product sold or otherwise transferred to an
independent third party not an Affiliate of the seller or transferor, the fair
market value of such non-cash consideration on the date of the transfer as
known to Roche, or as reasonably estimated by Roche if unknown, shall be
included in the definition of Adjusted Gross Sales.
1.9     "PDL Know-How" means, except as otherwise set forth in this
Section 1.9,
(a) all inventions, discoveries, trade secrets, information, experience,
data, formulas, procedures and results in the Field, and improvements thereon,
(collectively, "Know-How in the Field") including any information regarding
the structure, sequence and characterization of Antibodies in the Field,
methods of making and the characterization of cell lines producing Antibodies
in the Field, and methods of achieving high levels of expression of Antibodies
in the Field, which was rightfully held by PDL as of January 31, 1989, or
which was developed or acquired by PDL during the period beginning on  January
31, 1989 and ending January 31, 1996 (such date being one year after
termination of the Research Program, as defined in the 1989 Agreements), and
which Know-How in the Field is reasonably required or useful for registration,
manufacturing, using or selling products in the Field, and
(b) all Know-How in the Field, including any information regarding the
physical, chemical, biological, toxicological, pharmacological, clinical, and
veterinary data, dosage regimens, control assays and specifications of
Daclizumab, which is rightfully held by PDL or its Affiliates as of the
Signing Date, or which is developed or acquired by PDL or its Affiliates with
the right to license or sublicense during the term of this Amended and
Restated Agreement, and which Know-How in the Field is reasonably required or
useful  for registration, using or selling Daclizumab;
provided, however, that PDL Know-How excludes any Know-How in the Field of any
kind concerning generic methods of manufacturing (except as set forth in the
following paragraph), designing, developing or preparing antibodies including,
but not limited to, methods of humanizing antibodies, methods of reducing the
immunogenicity of antibodies, and methods of increasing the affinity of
antibodies.
In the event Roche manufactures a form or formulation of Daclizumab for
Autoimmune Indications under this Amended and Restated Agreement that Roche is
not otherwise manufacturing for the Transplant Indications, PDL Know-How shall
also include all Know-How in the Field which is rightfully held by PDL or its
Affiliates as of the Signing Date, or which is developed or acquired by PDL or
its Affiliates with the right to license or sublicense during the term of this
Amended and Restated Agreement, and which Know-How in the Field is reasonably
required or useful for manufacturing such form or formulation of  Daclizumab
for Autoimmune Indications.
1.10    "PDL Patents" means all patent applications owned or controlled by
PDL ("Sole PDL Patents") and all patent applications resulting from Joint
Inventions ("Joint Roche-PDL Patents") containing claims in the Field, which
are filed prior to or during the term of this Amended and Restated Agreement
in the United States or any foreign jurisdiction, including any addition,
continuation, continuation-in-part or division thereof or any substitute
application therefor; any patent issued with respect to such patent
application, any reissue, extension or patent term extension of any such
patent, and any confirmation patent or registration patent or patent of
addition based on any such patent; and any other United States or foreign
patent or inventor's certificate covering claims in the Field.  "Queen et al.
Patents" mean those Sole PDL Patents in the Territory claiming priority under
35 USC 120 to U.S. Patent Application Serial No. 290,975, filed December 28,
1988.
1.11    "Roche Inventions" means any inventions in the Field which are
made prior to or during the term of this Amended and Restated Agreement by
employees of Roche or persons contractually required to assign or license
patent rights covering such inventions to Roche.
1.12    "Territory" means, collectively, (1) the United States of America
("U.S." or "U.S.A." or "United States") and its territories and possessions
where the patent laws of the United States are in force, and (2) Canada and
its territories and possessions.  It is understood that PDL and  F. Roche are
contemporaneously entering into the F. Roche Agreement for all other countries
of the world outside the Territory.
1.13    "Valid Claim" means a claim in any issued patent within the PDL
Patents which has not been disclaimed or held unenforceable or invalid by a
decision of a court or governmental agency of competent jurisdiction by a
decision beyond right of review.
1.14    "Roche Know-How" means all inventions, discoveries, trade secrets,
information, experience, data, formulas, procedures and results specifically
related to Daclizumab, and improvements thereon (collectively, "Daclizumab
Know-How"), including any information regarding the physical, chemical,
biological, toxicological, pharmacological, clinical, and veterinary data,
dosage regimens, control assays and specifications of Daclizumab, which is
rightfully held by Roche or its Affiliates as of the Signing Date, or which is
developed or acquired by Roche or its Affiliates with the right to license or
sublicense during the term of this Amended and Restated Agreement, and which
Daclizumab Know-How is reasonably required or useful for development of a
subcutaneous formulation for Daclizumab, or for using or promoting Daclizumab
for Autoimmune Indications.
In the event that pursuant to Section 3C.2, PDL obtains a right to
manufacture Daclizumab for Autoimmune Indications, Roche Know-How shall also
include all Daclizumab Know-How which is rightfully held by Roche or its
Affiliates as of the Signing Date, or which is developed or acquired by Roche
or its Affiliates with the right to license or sublicense during the term of
this Amended and Restated Agreement, and which Daclizumab Know-How is
reasonably required or useful  for manufacturing Daclizumab.
1.15    "Roche Patents" means all patent applications owned or controlled
by Roche or its Affiliates ("Sole Roche Patents") and all patent applications
resulting from Joint Inventions ("Joint Roche-PDL Patents") containing claims
in the Field, which are filed prior to or during the term of this Amended and
Restated Agreement in the United States or any foreign jurisdiction, including
any addition, continuation, continuation-in-part or division thereof or any
substitute application therefor; any patent issued with respect to such patent
application, any reissue, extension or patent term extension of any such
patent, and any confirmation patent or registration patent or patent of
addition based on any such patent; and any other United States or foreign
patent or inventor's certificate covering claims in the Field.
1.16    "Autoimmune Indications" means all indications that involve
pathogenic consequences, including tissue injury, produced by autoantibodies
or autoreactive T lymphocytes interacting with self epitopes, i.e.,
autoantigens.  Autoimmune Indications shall include without limitation,
psoriasis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma,
juvenile rheumatoid arthritis, polymytosis, Type I diabetes, sarcoidosis,
Sjogrens syndrome, chronic active non-pathogenic hepatitis, non-infectous
uveitis (Behcets), aplastic anemia, regional non-pathogenic enteritis
(including ulcerative colitis, Crohn's Disease and inflammatory bowel
disease), Kawasaki's disease, post-infectious encephalitis, multiple
sclerosis, and tropic spastic paraparesis..
1.17    "Transplant Indications" means all indications  that are not
Autoimmune Indications, including, without limitation, solid organ
transplantation (including  tolerance induction and xenotransplantation), bone
marrow transplantation, graft versus host disease and cell transplantation.
In any event, should a given indication have applicability in both Autoimmune
Indications and transplantation, such indication shall be deemed a Transplant
Indication and not an Autoimmune Indication, provided that an Autoimmune
Indication shall not be deemed a Transplant Indication merely because it may
cause the need for a transplant (e.g., Type I diabetes, even if it causes the
need for an organ transplant).
1.18    "Adjusted Gross Transplant Sales" means the sum of Adjusted Gross
Sales of (i) Daclizumab in all Transplant Indications and (ii) all Licensed
Products other than Daclizumab.  "Net Transplant Sales" means the amount
determined by deducting [CONFIDENTIAL TREATMENT REQUESTED] from Adjusted Gross
Transplant Sales to cover all other expenses or discounts, including but not
limited to cash discounts, custom duties, transportation and insurance charges
and other direct expenses, to the extent not already deducted from the amount
invoiced.
1.19    "Adjusted Gross Autoimmune Sales" means the amount determined by
subtracting Adjusted Gross Transplant Sales from Adjusted Gross Sales.  "Net
Autoimmune Sales" means the amount determined by deducting [CONFIDENTIAL
TREATMENT REQUESTED] from Adjusted Gross Autoimmune Sales to cover all other
expenses or discounts, including but not limited to cash discounts, custom
duties, transportation and insurance charges and other direct expenses, to the
extent not already deducted from the amount invoiced.
1.20    "Total Net Sales" means the sum of Net Transplant Sales and Net
Autoimmune Sales.
1.21    "Cost of Goods Sold" means the manufacturing cost of unformulated
bulk Daclizumab, calculated in accordance with reasonable cost accounting
methods consistently applied by a party for its other pharmaceutical products,
provided that such methods comply with generally accepted accounting
principles.  Cost of Goods Sold shall include direct labor (including fringe
benefits), direct materials (including taxes and duties), and a reasonable
allocation of indirect labor and materials, facilities expense (including
occupancy costs and depreciation of property, plant and equipment),
administration costs and other costs allocable to the manufacturing process.
1.22    "Reimbursable Promotion Cost" means, for a given Autoimmune
Indication, the costs actually incurred by Roche and specifically attributable
to the marketing, promoting and detailing of Daclizumab, in accordance with
annual promotional plans and operational budgets  pursuant to Section 3B.3,
for the given Autoimmune Indication.
1.23    "Contract Sales Organization" means an entity  having a primary
purpose to detail pharmaceutical products of unrelated third parties.
1.24    "documents" used as a verb, for example in Section 3A.4 and
similar uses, means provides factual or substantial support, which support may
include, among other things, expert opinion.
1.25    "cover" (including variations thereof such as "covering" or
"covered") as used for example in Article IV and Article IV-A, means that the
manufacture, use, sale or importation of a particular Licensed Product would
infringe a Valid Claim in the absence of rights under such patent.  The
determination of whether a particular Licensed Product is covered by
particular Valid Claims shall be made on a country-by-country basis.
1.26    "Application" means a new application, or a supplement or an
amendment to an existing application, for marketing approval for an Autoimmune
Indication in the Territory.

II.  LICENSE GRANTS
2.1     License Grant to Roche.  Subject to Section 2.3, Article III-A,
Article III-B,  Article III-C, Section 8.1 and Section 8.2, PDL grants to
Roche and to Roche's Affiliates, the exclusive rights to the PDL Know-How and
the PDL Patents, but only to the extent reasonably required or useful to make,
have made, use and sell Licensed Products in the Field within the Territory.
For so long as Roche is in compliance with its obligations under Section 7.1,
Roche may sublicense the right to make, have made, use and sell Licensed
Products in the Field within the Territory, but no other rights may be
sublicensed, provided that no such sublicense shall be granted as to any
Autoimmune Indication without first obtaining PDL's written consent, which
consent may be withheld in PDL's sole discretion.  Any such sublicense shall
be subject to Section 4.5 hereof, and shall terminate automatically if Roche
or F. Roche shall not have remedied or initiated steps to remedy a breach of
Section 7.1 hereof or Section 5.1 of the F. Roche Agreement, respectively, in
a manner reasonably satisfactory to PDL within sixty (60) days after receipt
by Roche of notice of such breach from PDL.
2.2     Identification of Patents.  Set forth on Appendix A is a list
identifying patents or patent applications which comprise Sole PDL Patents.
If there are any changes, PDL shall update this list by delivering a
supplement to Roche no less frequently than once per year during the term of
this Amended and Restated Agreement.
2.3     License Grant to PDL.  Roche grants to PDL and to PDL's Affiliates
the exclusive rights to the Roche Know-How, Roche Patents, PDL Know-How, and
PDL Patents, but only to the extent reasonably required or useful (a) to
import and use Daclizumab within the Territory for the sole purpose of
conducting development and seeking registration of Daclizumab in Autoimmune
Indications as contemplated by this Amended and Restated Agreement and (b),
subject to Section 3B.3, to market, promote and detail Daclizumab within the
Territory in Autoimmune Indications as contemplated by this Amended and
Restated Agreement and (c) in the event that pursuant to Section 3C.1(d) or
3C.2, PDL exercises or obtains its right to manufacture Daclizumab for
Autoimmune Indications, to make and have made Daclizumab in the Territory as
contemplated by this Amended and Restated Agreement.  PDL may not sublicense
its rights hereunder to import and use or to make or have made Daclizumab
within the Territory without first obtaining Roche's written consent, which
consent may be withheld in Roche's sole discretion.  PDL may not sublicense
its rights hereunder to market, promote and detail Daclizumab within the
Territory without first obtaining Roche's written consent, which consent may
be withheld in Roche's sole discretion, except that PDL may without first
obtaining Roche's written consent sublicense its rights hereunder to market,
promote and detail Daclizumab within the Territory to a Contract Sales
Organization, provided such Contract Sales Organization is not owned or
controlled by a pharmaceutical organization. PDL may sublicense its rights
hereunder to market, promote and detail Daclizumab within the Territory to a
Contract Sales Organization that is owned or controlled by a pharmaceutical
organization only after first obtaining Roche's written consent, which consent
may not be unreasonably withheld or delayed.  In the event that pursuant to
Section 3C.1(d) or 3C.2, PDL makes a different form or formulation of
Daclizumab or manufactures Daclizumab for Autoimmune Indications, as the case
may be, PDL may sublicense its rights hereunder to make and have made
Daclizumab in the Territory as contemplated by this Amended and Restated
Agreement without the prior consent of Roche.

III-A.  DEVELOPMENT OF DACLIZUMAB IN AUTOIMMUNE INDICATIONS
3A.1    Development Responsibility. On and after the Signing Date,  PDL
shall be solely responsible at its sole cost and expense to develop Daclizumab
for Autoimmune Indications ("AI Development"), including, without limitation,
any further preclinical studies or formulation development (such as the
development of a subcutaneous formulation) reasonably required or useful by
PDL for such AI Development.  All data and information generated by such
activities shall be PDL Know-How and PDL shall have the right to publish such
data and information in accordance with Section 12.3(b).
3A.2    Transfer of Know-How
(a)  Transfer of PDL Know-How.  During the term of this Amended and
Restated Agreement, PDL shall transfer within sixty (60) days of each June 30
and December 31, PDL Know-How which is reasonably required or useful  for
Roche to carry out its obligations under this Amended and Restated Agreement.
PDL will permit access by Roche during the AI Development at reasonable times
and with reasonable frequency to the relevant scientific personnel of PDL, but
in any event not more than once per calendar quarter.  PDL agrees to inform
Roche on a timely basis of all results in the Field obtained by PDL during the
AI Development to the extent such results are reasonably required or useful
for Roche to carry out its obligations under this Amended and Restated
Agreement.


(b)     Transfer of Roche Know-How.
(i)     PDL and Roche shall each immediately identify a person to
coordinate communications related to review of Roche Know-How by PDL
("Coordinators").  The  Coordinators shall agree upon a period of time,
including the starting date of such period and duration of such period, during
which Roche shall make Roche Know-How available for PDL's review. Such period
shall occur within ninety (90) days after the Signing Date.
PDL's review of Roche Know-How in accordance with this Section 3A.2(b)
shall occur during Roche's normal business hours and at an agreed upon site(s)
of Roche.  During such review, PDL shall have the right to (i) copy such
available Roche Know-How as it deems reasonably required or useful and (ii)
discuss the available Roche Know-How with the relevant Roche personnel.  Roche
shall use its best efforts to answer PDL's questions related to the available
Roche Know-How, but Roche shall have no liability to PDL if despite Roche's
best efforts, it is unable to answer any such questions to PDL's satisfaction;
provided that Roche will not intentionally withhold from PDL any material or
pertinent information.
It is understood that Roche Know-How may be embraced within documents
that contain  information not specifically related to Daclizumab, including
information related to products of Roche other than Daclizumab.  Accordingly,
to the extent any given document within the scope of Roche Know-How contains
information not specifically related to Daclizumab, Roche may redact such
document prior to PDL review thereof, provided that Roche will not
intentionally withhold from PDL any Roche Know-How.  To the extent any given
document within the scope of Roche Know-How contains unredacted information
not specifically related to Daclizumab, PDL shall maintain such information as
Confidential Information.
(ii)  After the transfer of Roche Know-How pursuant to Section
3A.2(b)(i), upon written request by PDL, Roche shall, within a reasonable
time, provide PDL with Roche Know-How as is required for AI Development by any
regulatory or governmental authority in the Territory if and when such Roche
Know-How is located, but Roche shall have no liability to PDL if despite
Roche's commercially reasonable efforts, it is unable to locate any such Roche
Know-How.
(iii)   Subject to Section 7.1, in no event shall there be any obligation
on the part of Roche to generate any new data or information related to
Licensed Products.
3A.3    Development Plan.  Within sixty (60) days after the Signing Date,
PDL shall prepare and deliver to Roche an AI Development plan, including
intended AI Development activities and budgets for each intended AI
Development activity.  Beginning December 31, 2000, PDL shall update this plan
by delivering a supplement to Roche within sixty (60) days of each December 31
during the term of this Amended and Restated Agreement.
3A.4    Joint Development Committee.

Within thirty (30) days after the Signing Date, PDL and Roche shall form
a Joint Development Committee ("JDC") consisting of two (2) representatives
from PDL and two (2) representatives from Roche.  The JDC shall meet at least
semi-annually and shall generally review and update PDL's AI Development plan,
as it may be supplemented, including intended AI Development activities and
budgets.  The JDC shall also review the activities of PDL to  coordinate both
the AI Development and sales of Daclizumab for Transplant Indications.  PDL
will make the final decision with respect to all AI Development activities,
except that Roche will have the right to veto any AI Development activity for
which Roche documents that such activity is reasonably likely to have a
material adverse impact on sales of Daclizumab for Transplant Indications
within the Territory.  Unless otherwise agreed or initiated by Roche, PDL will
not undertake any AI Development activity which (i) is outside the scope of
PDL's AI Development plan or (ii) Roche documents that such activity is
reasonably likely to have a material adverse impact on sales of Daclizumab for
Transplant Indications within the Territory.
3A.5    Reports.        PDL will provide Roche within forty-five (45) days of
each June 30 and December 31 during the term of this Amended and Restated
Agreement, a written report summarizing for the preceding semi-annual period
all PDL AI Development activities, including publications.
3A.6    Certain Regulatory Matters.
(a)     Clinical Trials.  PDL shall have the right to file in PDL's name
Investigational New Drug Applications, joint regulatory filings based on such
applications and foreign equivalents of the foregoing ("INDs") for AI
Development in the Territory.  Roche shall, at no cost to PDL, provide
assistance reasonably required or useful to allow PDL to cross-reference Roche
filings to allow PDL to carry out without delay any related clinical trial in
the Territory.  PDL shall advise and consult with Roche with respect to any
significant issues or questions raised by any regulatory authorities with
respect to any such IND or related clinical trial.  PDL shall provide copies
to Roche of any such IND and any other records of interactions with regulatory
authorities (e.g., correspondence, minutes or notes of telephone conferences
or meetings, etc.) with respect to any such IND or related clinical trials.
To the extent Roche is required under applicable law, rule or
regulation, at PDL's cost, Roche shall make all filings reasonably required or
useful to permit the use of the clinical materials supplied pursuant to
Section 3C.1.  PDL and Roche, including its Affiliates, shall each supply the
other copies of all regulatory filings related to the use of the clinical
materials for AI Development promptly after the time of such filings.
(b)     Adverse Event Reporting.  Each party shall notify the other of all
information coming into its possession concerning any and all side effects,
injury, toxicity, pregnancy or sensitivity  event associated with commercial
or clinical uses, studies, investigations or tests with Daclizumab, throughout
the world, whether or not determined to be attributable to Daclizumab
("Adverse  Event Reports").  The parties shall each identify a person to
coordinate the exchange of Adverse Event Reports ("Report Coordinators") so as
to enable timely reporting of such Reports to appropriate government and
regulatory authorities consistent with all laws, rules and regulations. The
Report Coordinators shall agree in writing upon formal procedures for such
exchange.


3A.7    Registration.
(a)     PDL shall notify Roche in writing ("Filing Notice") should PDL in
good faith determine, in its sole discretion, that clinical trial results for
Daclizumab justify filing an Application.  Such Filing Notice shall be
accompanied by a report of all clinical trial results for the particular
Autoimmune Indication, if not previously delivered.  Promptly following
receipt by Roche of a Filing Notice, the parties shall discuss in good faith
the relevant clinical trial results and underlying data in an attempt to reach
mutual agreement relating to whether to file such Application.  Should the
parties disagree as to whether to file such Application or not reach agreement
within thirty (30) days of delivery of the Filing Notice, then within twenty
(20) business days thereafter, Roche shall provide PDL with a written list of
specifically identified activities that in Roche's good faith opinion PDL
should conduct in order to achieve clinical trial results that would justify
filing such Application.  PDL shall seriously consider in good faith Roche's
opinion, but thereafter the final decision as to whether to file such
Application shall remain with PDL.  PDL shall notify Roche of its final
decision in writing ("Final Decision Notice").
(b)     For a given Autoimmune Indication, if (i) the parties agree that
clinical trial results for Daclizumab justify filing an Application , or (ii)
PDL provides a Final Decision Notice of PDL's final decision that clinical
trial results for Daclizumab justify filing an Application, then Roche shall
cooperate with and authorize PDL to compile and submit such Application.
Ownership of any such Application shall be as determined under
applicable law.  If Roche owns such Application, PDL shall compile and submit
any such Application on Roche's behalf at PDL's cost.If PDL owns any such
Applications, PDL shall be solely responsible to compile and submit any such
Application at its cost.
Roche shall provide cross reference letters reasonably required or
useful  to allow PDL to make any such filing and to allow PDL to carry out
without delay any related clinical trial in the Territory.  PDL shall be
responsible for preparing annual reports required by the FDA related to any
such Applications and Roche shall be responsible for timely filing such annual
reports with the FDA.
Prior to PDL submitting an Application, PDL shall send Roche by express
air mail a copy of the Application to be submitted and shall allow Roche a
reasonable time period (not to exceed thirty (30) days from the date of
mailing) to review the Application for the purpose of determining whether the
Application contains information which is reasonably likely to have a material
adverse impact on sales of Daclizumab for Transplant Indications in the
Territory.  Should, prior to the expiration of thirty (30) days from the date
of mailing of such application to Roche by PDL, Roche document that the
Application contains information which is reasonably likely to  have a
material adverse impact on sales of Daclizumab for Transplant Indications
within the Territory, then PDL shall withhold submission of the Application.
Otherwise, PDL shall be free to submit such Application to the FDA.
Each party shall promptly provide copies to the other of such
Application and any other records of interactions with regulatory authorities
(e.g., correspondence, minutes or notes of telephone conferences or meetings,
etc.) with respect to such Application.
Each party shall advise and consult with the other with respect to any
significant issues or questions raised by any regulatory authorities with
respect to Daclizumab.
The parties shall discuss in good faith the labeling to be requested for
marketing approval for any Autoimmune Indication. If the parties are unable to
agree upon the labeling to be requested for an Autoimmune Indication, PDL
shall have the final say, except with respect to safety matters, for which
Roche shall have final say.  Notwithstanding the above, the label shall not
include, without Roche's prior written consent, any information for which
Roche documents such information is reasonably likely to have a material
adverse impact on sales of Daclizumab for Transplant Indications within the
Territory.  Roche shall have sole responsibility for preparing and filing with
regulatory authorities in the Territory safety updates for Daclizumab and
shall, in its sole discretion, effect label changes based upon such safety
updates.

III-B.  COMMERCIALIZATION
3B.1    Transplant Indications.  Within the Territory, Roche shall be
solely responsible for all aspects of commercialization of (i) Licensed
Products other than Daclizumab and (ii) Daclizumab for Transplant Indications,
and shall pay royalties on Net Transplant Sales as provided in Articles IV and
IV-B.
3B.2    Booking of Sales.  Within the Territory, Roche shall be solely
responsible at its sole cost to book all sales of Licensed Products,
distribute all Licensed Products and, subject to Section 3C.2, manufacture all
Licensed Products.  If PDL promotes or co-promotes Daclizumab in the Territory
for any Autoimmune Indication, PDL shall submit all resulting orders for
Daclizumab in the Territory to Roche.  Roche shall accept and fill such orders
on a non-discriminatory basis relative to accepting and filling orders from
its own sales force.
3B.3    Joint Commercialization Committee.  Within ninety (90) days after
the Signing Date,  Roche and PDL shall form a joint commercialization
committee (the "JCC") consisting of two representatives from PDL and two
representatives from Roche with the appropriate background and experience in
marketing and commercialization of products in transplantation and Autoimmune
Indications. The JCC shall meet at least semi-annually and shall generally
review the promotional efforts relating to Daclizumab for Autoimmune
Indications, with  one of its goals being ensuring that Roche's intended
activities in transplantation are not materially adversely impacted.  In
particular, the JCC shall decide upon annual promotional plans and operational
budgets for Autoimmune Indications (collectively, "Promotional Plans").  A
Promotional Plan shall, for at least each upcoming year, set the percent of
the total promotional effort for each party, and address such issues as
training materials, training, sampling, promotional materials, product
presentations, incentive programs, professional educational efforts and
detailing with respect to each Autoimmune Indication.

PDL will make the final decision with respect to all JCC decisions not
otherwise agreed upon, except that Roche (1) will have the final say on all
decisions for which Roche documents that carrying out such decision is
reasonably likely to have a material adverse impact on sales of Daclizumab in
Transplant Indications within the Territory and (2) may veto any decision
which requires a financial commitment or allocation of personnel on behalf of
Roche.  PDL will not undertake any promotional activity (including providing
any medical professional written information) which (i) is outside the scope
of the Promotional Plan or (ii) Roche documents that such activity is
reasonably likely to have a material adverse impact on Daclizumab in
Transplant Indications within the Territory.

3B.4    Non-Assignment of Right to Promote and Detail.  PDL may not assign
its rights hereunder to market, promote and detail Daclizumab within the
Territory to a successor of PDL without first obtaining Roche's written
consent, which consent may be withheld in Roche's sole discretion.   However,
PDL may assign its rights hereunder to market, promote and detail Daclizumab
within the Territory to an assignee of all the good will and entire business
assets of PDL or an Affiliate of PDL,  only after first obtaining Roche's
written consent, which consent may not be unreasonably withheld or delayed.

III-C.  MANUFACTURING FOR AUTOIMMUNE INDICATIONS
3C.1    Clinical Supplies. References to Roche in Sections 3C.1 and 3C.2
shall include Roche, its Affiliates and any sublicensees manufacturing
Daclizumab for Roche and its Affiliates.
(a)     Supply.  Subject to Section 3C.1(b), Roche has agreed and shall
use commercially reasonable efforts to exclusively supply to PDL, all
Daclizumab and placebo requested by PDL for the AI Development in the form
(e.g., unformulated bulk, bulk, vialed, labeled) and formulation (e.g.,
intravenous, subcutaneous) specified by PDL.  Notwithstanding the above, Roche
shall not be obligated to supply (i) any amount of Daclizumab or placebo not
in accordance with the AI  Development plan, (ii) a number of units of placebo
in excess of the units of  Daclizumab supplied by Roche, or (ii) any form or
formulation of Daclizumab that Roche is not otherwise manufacturing for the
Transplant Indications.  In the event PDL requests Daclizumab in a form or
formulation that Roche is not otherwise manufacturing for the Transplant
Indications, Roche shall be obligated to supply to PDL only unformulated bulk
Daclizumab.  All Daclizumab for the AI Development in the Territory,
regardless of form or formulation, shall be manufactured in accordance with
cGMPs and any other applicable regulatory or legal requirements.  Promptly
after the Signing Date, the parties shall meet and discuss the availability
and timing of delivery of Daclizumab hereunder.
(b)     Limitations.  Roche shall  supply to PDL free of charge:
[CONFIDENTIAL TREATMENT REQUESTED]
(c)     Procedures. Promptly after the Signing Date, Roche and PDL shall
agree on (i) the  amount of Daclizumab and placebo to be supplied by Roche to
PDL for the first year after the Signing Date, which amounts shall be
delivered as soon as practicable but in any event not later than a mutually
agreed upon period after the Signing Date, and (ii) procedures for PDL
submitting its requirements and Roche supplying Daclizumab and placebo
thereafter.  Such procedures shall include PDL providing (a) annual non-
binding two (2) year forecasts of its requirements and (b) firm purchase
commitments no less than six (6) months prior to the time the order must be
delivered to PDL by Roche.
(d)     Formulations.  In the event PDL requests Daclizumab in a form or
formulation that Roche is not otherwise manufacturing for the Transplant
Indications, and Roche supplies such form or formulation (rather than only
unformulated bulk Daclizumab), PDL shall pay to Roche for such supplies an
amount equal to Roche's Cost of Goods Sold (which shall be zero (0) to the
extent provided without charge under Section 3C.1(a)) plus [CONFIDENTIAL
TREATMENT REQUESTED] of Roche's costs of such form or formulation.  If Roche
does not perform such form or formulation work for PDL, PDL shall have the
limited right to make or have made such form or formulation solely for
clinical use in Autoimmune Indications.  In any event, PDL shall not be
obligated to have Roche perform such form or formulation work.
3C.2    Commercial Manufacturing.

(a)     Supply.  Subject to Section 3C.2(b), Roche shall use commercially
reasonable efforts to ensure supply of requirements for Daclizumab in one of
the following forms for use or commercial sale in the Territory:  (a) finished
product form or formulated bulk form, if Roche then manufactures in the form
or formulation desired by PDL, or (b) unformulated bulk form.

(b)     PDL Right to Manufacture. [CONFIDENTIAL TREATMENT REQUESTED]

(c)     Transfer Pricing.  In the event that PDL has the exclusive right
to make and have made Daclizumab for Autoimmune Indications, PDL shall use
commercially reasonable efforts to supply Roche's requirements of Daclizumab
for Autoimmune Indications in the Territory.  In such event, PDL shall
transfer such Daclizumab to Roche at a price calculated as follows:

[CONFIDENTIAL TREATMENT REQUESTED]

In any event, if PDL provides Roche with its supply of Daclizumab for
any indications pursuant to this Section 3C.2(c), the parties shall negotiate
in good faith to enter into a separate supply agreement which shall provide
for procedures for Roche submitting its requirements for Autoimmune
Indications in the Territory and PDL supplying Daclizumab thereafter as well
as rights of PDL to dispose of Inventory (as defined below) then held by PDL
in the event of termination of this Amended and Restated Agreement.  Such
procedures shall include Roche providing (a) annual non-binding forecasts of
its requirements and (b) firm purchase commitments at least six (6) months
prior to the time the order must be delivered to Roche by PDL.

IV.  ROYALTIES ON NET TRANSPLANT SALES
4.1     Royalties on Transplant Sales. Roche agrees to pay PDL royalties
on Net Transplant Sales in the United States and Canada according to the
schedule and terms set forth below.
(a)     Years 1 through 3.  For the first three (3) years following
Initial Commercialization of a particular Licensed Product, Roche shall pay
PDL royalties on sales of that product at a rate determined [CONFIDENTIAL
TREATMENT REQUESTED] (such sum, the "Royalty Setting Sales"), with the
applicable royalty based on such Royalty Setting Sales determined as follows:

Royalty Setting Sales ($ in
millions)
Royalty Rate
Up to and including
[CONFIDENTIAL TREATMENT
REQUESTED]
[CONFIDENTIAL TREATMENT
REQUESTED]
Up to and including
[CONFIDENTIAL TREATMENT
REQUESTED]
[CONFIDENTIAL TREATMENT
REQUESTED]
Up to and including
[CONFIDENTIAL TREATMENT
REQUESTED]
[CONFIDENTIAL TREATMENT
REQUESTED]
Amount in excess of
[CONFIDENTIAL TREATMENT
REQUESTED]
[CONFIDENTIAL TREATMENT
REQUESTED]


Over [CONFIDENTIAL TREATMENT
REQUESTED]
[CONFIDENTIAL TREATMENT
REQUESTED]


For purposes of computing aggregate annual worldwide Royalty Setting
Sales, the relevant portion of  Roche's Net Sales in the Territory will be
combined with the relevant portion of the Net Sales of Roche's Affiliates and
sublicensees for all countries outside of the Territory..  This same
understanding is being incorporated into the F. Roche Agreement concerning the
sale of Licensed Products outside the Territory.


(b)  Years 4 and Succeeding.
(i)     For the United States, if a Valid Claim covering any
Licensed Product has been issued in the United States prior to or
during the three (3) year period following Initial Commercialization
in the United States, Roche shall pay PDL royalties in accordance
with the provisions of Section 4.1(a).  Subject to Section 4.2 below,
if no such Valid Claim has been issued in the United States then
Roche shall pay PDL a royalty rate of [CONFIDENTIAL TREATMENT
REQUESTED] of the Net Transplant Sales in the United States.  In such
case, Roche's obligation to pay PDL royalties with respect to Net
Transplant Sales of any particular Licensed Product in the United
States shall [CONFIDENTIAL TREATMENT REQUESTED], at which time Roche
shall resume paying PDL royalties at the rates specified in
Section 4.1(a) above.
(ii)    For Canada, for the fourth (4th) and each succeeding year
following Initial Commercialization in Canada, Roche shall pay PDL
royalties in accordance with the provisions of Section 4.1(a) for Net
Transplant Sales in the Canada, provided either (A) the use or sale
of Licensed Product in Transplant Indications or its method of
manufacture (wherever actually manufactured) is covered by a Valid
Claim in Canada, or (B) the Licensed Product is manufactured in a
country where the method of manufacture is covered by a Valid Claim
(together, (A) and (B) are referred to as the "Patentability
Criteria").
Subject to Section 4.2 below, if neither of the Patentability Criteria
have been satisfied, then Roche shall pay PDL a royalty rate of [CONFIDENTIAL
TREATMENT REQUESTED] of the Net Transplant Sales in Canada for the duration of
the royalty obligations in Canada in accordance with this Section 4.1 or until
such time as one of the Patentability Criteria is satisfied, at which time
Roche shall resume paying PDL royalties at the rates specified in Section 4.1
above.
(c)     [CONFIDENTIAL TREATMENT REQUESTED]
(d)     Antibodies in the Field Not Provided or Developed by PDL.
In consideration of the disclosure to Roche of PDL Know-How and cell
lines, Roche agrees that products incorporating or using Antibodies in the
Field which are not provided or developed by PDL shall nevertheless be
conclusively presumed to utilize PDL Know-How.  Accordingly, Roche shall pay
PDL royalties on sales of each such product in  a given country of the
Territory for a period of [CONFIDENTIAL TREATMENT REQUESTED] from Initial
Commercialization of such product in the given country in accordance with the
terms of this Section 4.1, and such sales shall constitute "Net Transplant
Sales" for purposes hereof.
4.2     De Facto Exclusivity.
(a)     For the United States, for purposes of this Article IV, the term
"de facto exclusivity" means that Roche, together with its Affiliates and
sublicensees, controls at least [CONFIDENTIAL TREATMENT REQUESTED] of the
market for a particular Licensed Product in the United States as measured by
unit sales.  If no Valid Claim covering Licensed Product in Transplant
Indications  has been issued in the United States  and Roche does not enjoy de
facto exclusivity in Transplant Indications for a Licensed Product at any time
after [CONFIDENTIAL TREATMENT REQUESTED] following Initial Commercialization,
then Roche shall pay PDL a royalty rate of [CONFIDENTIAL TREATMENT REQUESTED]
of the Net Transplant Sales in the  United States of that product
[CONFIDENTIAL TREATMENT REQUESTED] Initial Commercialization in the United
States, or until Roche shall acquire de facto exclusivity in Transplant
Indications for that product or until such time as a Valid Claim covering
Licensed Product in Transplant Indications issues in the  United States (at
which time Roche shall resume paying PDL royalties at the rates specified in
Sections 4.1(a) or (b) above, whichever is applicable).
(b)     For Canada, for purposes of this Article IV, the term "de facto
exclusivity" means that Roche, together with its Affiliates and sublicensees,
controls at least [CONFIDENTIAL TREATMENT REQUESTED] of the market for a
particular Licensed Product in Canada as measured by unit sales.  If neither
of the Patentability Criteria have been satisfied and Roche does not enjoy de
facto exclusivity for a particular Licensed Product in Canada at any time
after [CONFIDENTIAL TREATMENT REQUESTED] following Initial Commercialization
in Canada of such Licensed Product, then Roche shall pay PDL a royalty rate
of[CONFIDENTIAL TREATMENT REQUESTED] of the Net Transplant Sales of such
Licensed Product in Canada until [CONFIDENTIAL TREATMENT REQUESTED] Initial
Commercialization in Canada, or until Roche shall acquire de facto exclusivity
for that product or until such time as either of the Patentability Criteria is
satisfied (at which time Roche shall resume paying PDL royalties at the rates
specified in Sections 4.1(a) or 4.1(b) above, whichever is applicable).
4.3     Milestone Payments Credited Against Royalties.  Roche shall have
the right to credit [CONFIDENTIAL TREATMENT REQUESTED] of all Milestone
Payments (as defined in the 1989 Agreement with Roche-Nutley), exclusive of
bonus payments, actually made to PDL under the 1989 Agreement with Roche-
Nutley in excess of [CONFIDENTIAL TREATMENT REQUESTED], less credits already
taken under the 1989 Agreements, against future royalties due to PDL on Net
Transplant Sales in the United States pursuant to this Article IV provided
that such credits, when added to the offset provided for in Section 4B.1
below, may not reduce the royalties to be paid to PDL on account of Net
Transplant Sales in the United States to less than fifty percent (50%) of the
amount which would otherwise be due pursuant to Section 4.1 hereof.
IV-A. COMPENSATION TO PDL FOR NET AUTOIMMUNE SALES

        4A.1  Forecasted Baseline Transplant Sales.

Beginning with calendar year 2000 and for each calendar year thereafter
(a "Forecast Period"), Roche shall on a country-by-country basis for the
Territory provide to PDL a yearly forecast that Roche then uses for its own
internal marketing purposes of Adjusted Gross Transplant Sales  ("Forecasted
Baseline") which shall include a forecast for each reporting period of the
upcoming Forecast Period for each country of the Territory.  Forecasted
Baselines shall be provided not less than sixty (60) days prior to the
beginning of each upcoming Forecast Period.  Roche's obligation to provide
Forecasted Baselines shall expire, on a country-by-country basis, on the last
date that Roche enjoys de facto exclusivity for Daclizumab in the particular
country.

For a given reporting period, to the extent Adjusted Gross Sales in a
particular country of  the Territory are equal to or below the Forecasted
Baseline, for such country such Adjusted Gross Sales shall be deemed Adjusted
Gross Transplant Sales.

 For a given reporting period, to the extent Adjusted Gross Sales in a
particular country of the Territory are above the Forecasted Baseline, for
such country such Adjusted Gross Sales shall be deemed Adjusted Gross
Autoimmune Sales.

4A.2    Determination of Adjusted Gross Autoimmune Sales After Roche No
Longer Enjoys De Facto Exclusivity.

For a given country in the Territory, commencing with the reporting
period containing   the last date on which Roche enjoys de facto exclusivity
for Daclizumab in the particular country and until expiration, in accordance
with Section 4A.4, of Roche's obligation to pay PDL consideration in such
country in accordance with this Article IV-A, the percent of Adjusted Gross
Sales that shall be deemed Adjusted Gross Autoimmune Sales for such country
shall, on an ongoing basis, be the percent of Adjusted Gross Sales that was
Adjusted Gross Autoimmune Sales over[CONFIDENTIAL TREATMENT REQUESTED] before
such date.

[CONFIDENTIAL TREATMENT REQUESTED]

4A.3    Compensation to PDL for Net Autoimmune Sales.

(a)     For a given reporting period, Roche shall pay PDL consideration on
a country-by-country basis of sixty percent (60%) of Net Autoimmune Sales in
the United States and Canada, respectively, for the particular reporting
period.

(b)     Notwithstanding Section 4A.3(a), Roche shall be entitled to
reimbursement of its Reimbursable Promotion Costs by deducting such
Reimbursable Promotion Costs from the amount due to PDL under Section 4A.3(a)
up to fifty percent (50%) of the amount which would otherwise be due pursuant
to Section 4A.3(a) hereof.

(c)     In the event any Reimbursable Promotion Costs remain unreimbursed
after a given reporting period, such Reimbursable Promotion Costs shall be
deducted from the amount due under Section 4A.3(a) in subsequent reporting
periods up to fifty percent (50%) of the amount due to PDL in such reporting
period, and if no such subsequent reporting periods exist, then by PDL to
Roche within thirty (30) days after receipt by PDL of an invoice for such
amount.

4A.4    Expiration of Obligation.       Notwithstanding anything to the
contrary herein, in view of the parties' understanding of the unique nature of
the cross-licenses granted by each party to the other under this Amended and
Restated Agreement, Roche's obligation to pay PDL consideration in accordance
with this Article IV-A shall expire, on a country-by-country basis,
[CONFIDENTIAL TREATMENT REQUESTED] is a Valid Claim of a Queen et al. Patent
in the country covering Daclizumab.

4A.5    Annual Reconciliation and Adjustment.

(a)     Actual Baseline.        Within  ninety (90) days following the end of
each calendar year for which Roche provided a Forecasted Baseline,Roche shall
provide PDL with a written summary which details  Adjusted Gross Transplant
Sales in each country for which Roche provided a Forecasted Baseline, for the
calendar year ("Actual Baseline") as well as Roche's basis for such
determination. PDL shall have a period of sixty (60) days after receipt to
object in writing to the Actual Baseline provided by Roche, including detailed
reasons of a factual nature as to why PDL so objects to the Actual Baseline
provided by Roche.  If PDL timely objects in writing to the Actual Baseline
provided by Roche, then either party shall have the right to notify the other
in writing that it elects to have the matter submitted to determination by an
independent third party who is knowledgeable about marketing and sales of
pharmaceutical products in transplantation and Autoimmune Indications
("Arbiter").  The Arbiter shall be appointed by agreement between the parties
within thirty (30) days or, if the parties are unable to agree, the Arbiter
shall be designated by AAA.  The Arbiter shall (1) make a binding
determination of the Actual Baseline within thirty (30) business days of
receipt of the final submissions by the parties and (2) provide the margin of
error of the Arbiters' determination.  Roche shall provide and/or make
available to the Arbiter its relevant books and records regarding sales of
Daclizumab.  PDL shall bear the full cost of any such determination unless the
Actual Baseline determined by Arbiter differs from the Actual Baseline
provided by Roche by an amount exceeding the greater of (i) the margin of
error of the determination of the Arbiter  or (ii) [CONFIDENTIAL TREATMENT
REQUESTED], in which case Roche shall bear the full cost.  If PDL does not
timely object in writing to the Actual Baseline provided by Roche, then PDL
shall be deemed to have approved the Actual Baseline provided by Roche.

In the event the Actual Baseline for a given country exceeds the
Forecasted Baseline for the given country for the given calendar year
("Underestimate"), Roche shall be entitled to deduct the amount reflecting the
Underestimate from the next payment(s) due PDL under Article IV or Article IV-
A of this Amended and Restated Agreement, provided that such deductions shall
not exceed fifty percent (50%) of the amounts otherwise payable to PDL with
respect to such payment period.  If there is no next payment due PDL under
Article IV or Article IV-A of this Amended and Restated Agreement, PDL shall
promptly pay Roche the amount reflecting the Underestimate.  In the event the
Forecasted Baseline for a given country exceeds the Actual Baseline for the
given country for the given calendar year ("Overestimate"), Roche shall
promptly pay PDL the amount reflecting the Overestimate.

IV-B.   GENERAL CONSIDERATION TERMS

4B.1    Offset for Third Party Licenses.
(a)     Subject to Appendix B, if PDL and Roche agree in writing
that either party must obtain a license from an independent third party in
order for Roche or PDL to manufacture, use or sell a Licensed Product and if
PDL and Roche agree upon the terms of such license ("Third Party License"),
then the parties shall share the cost [CONFIDENTIAL TREATMENT REQUESTED].
Such cost includes license fees and any other fixed costs associated with the
Third Party License as well as any royalties.  The parties then shall, within
thirty (30) days, reimburse each other in the manner necessary to effect a
[CONFIDENTIAL TREATMENT REQUESTED] sharing of such license fees and other
fixed costs. [CONFIDENTIAL TREATMENT REQUESTED]
(b)     Notwithstanding anything to the contrary herein, PDL's share
of the royalties portion of the cost of any Third Party License, including
[CONFIDENTIAL TREATMENT REQUESTED], shall be (i) accrued against and deducted
from any amounts due to PDL from Roche pursuant to Article IV and Article IV-A
if Roche pays the royalties due under the Third Party License to such third
party, and (ii) accrued in favor of and added to any amounts due to PDL from
Roche pursuant to Article IV and Article IV-A if PDL pays the royalties due
under the Third Party License to such third party; provided, however, that
this addition or offset shall not cause the amount paid by Roche to PDL:

[CONFIDENTIAL TREATMENT REQUESTED]
4B.2    Sublicenses.  Any Net Transplant Sales or Net Autoimmune Sales by
a Roche sublicensee shall be treated as Net Transplant Sales or Net Autoimmune
Sales of Roche, as the case may be, for purposes of payments under Article IV
and IV-A.  If Roche shall grant any sublicenses under this Amended and
Restated Agreement, then Roche shall obtain the written commitment of such
sublicensees to abide by all applicable terms and conditions of this Amended
and Restated Agreement and Roche shall remain responsible to PDL for the
performance of any and all terms by such sublicensee.  All such sublicenses
shall terminate on termination of this Amended and Restated Agreement.
4B.3    Royalties upon Termination.  If this Amended and Restated
Agreement is terminated pursuant to Sections 11.2, 11.3, or 11.4 below, Roche
shall continue to pay PDL any royalties and compensation earned pursuant to
Article IV and Article IV-A prior to the date of termination and any royalties
and compensation earned thereafter as a result of sales under Section 11.5.
V.  ACCOUNTING AND PAYMENTS
5.1     Quarterly Royalty Payments and Reports.
(a)     Roche agrees to make payments and written reports to PDL within
forty-five (45) days after the end of each calendar quarter covering all sales
of Licensed Products in the Territory by Roche, its Affiliates or sublicensees
for which invoices were sent during such calendar quarter.  Each report shall
state for the period in question:
(i)     Forecasted Baselines (if applicable),
(ii)    for Licensed Products disposed of by sale, the quantity and
description of Licensed Products, Adjusted Gross Sales, Adjusted Gross
Transplant Sales, Net Transplant Sales, Adjusted Gross Autoimmune Sales, and
Net Autoimmune Sales,
(iii)   for Licensed Products disposed of other than by sale, the
quantity, description, and nature of the disposition, and
(iv)    the calculation of the amount due to PDL for such quarter
pursuant to Articles IV, IV-A and IV-B.
        (b)     Subject to Section 15.9, the information contained in each
report under this Section 5.1 shall be considered confidential and PDL agrees
not to disclose such information to any third party except as may be required
by law, rule or regulation.  Concurrent with the making of each quarterly
report, Roche shall include payment due PDL hereunder for the calendar quarter
covered by such report.
(c)     It is understood that pursuant to this provision, only one payment
hereunder shall be payable on a given unit of Licensed Product disposed of
under this Amended and Restated Agreement.  In the case of transfers or sales
of any Licensed Product between Roche or an Affiliate or sublicensee of Roche,
only one payment hereunder shall be due, and such royalty shall be payable
with respect to the sale of such Licensed Product to an independent third
party not an Affiliate of the seller.
5.2     Termination Report.  Roche also agrees to make a written report to
PDL within ninety (90) days after the date on which Roche, or  its Affiliates
or sublicensees last sell a Licensed Product, stating in such report the same
information called for in each quarterly report by Section 5.1 for all
Licensed Products made, sold or otherwise disposed of and upon which were not
previously reported to PDL.
5.3     Accounting.  Roche agrees to keep full, clear and accurate records
for a period of at least [CONFIDENTIAL TREATMENT REQUESTED], or such longer
period as may coincide with Roche's internal records retention policy, setting
forth the manufacturing, sales and other disposition of Licensed Products and
Combination Products sold or otherwise disposed of under the license herein
granted in sufficient detail to enable royalties and compensation payable to
PDL hereunder to be determined.  Roche further agrees to permit its books and
records to be examined by an independent accounting firm selected by PDL from
time to time to the extent necessary to verify reports provided for in
Sections 5.1 and 5.2 above.  Unless PDL obtains the prior written consent of
Roche, such accounting firms must be selected from among the five largest U.S.
accounting firms.  Such examination is to be made at the expense of PDL,
except in the event that the results of the audit reveal a discrepancy in
favor of Roche of [CONFIDENTIAL TREATMENT REQUESTED] or more over the period
being audited, in which case reasonable audit fees for such examination shall
be paid by Roche.
5.4     Methods of Payments.  All payments due to PDL under this Amended
and Restated Agreement shall be paid in United States dollars by wire transfer
to a bank in the United States designated in writing by PDL.
VI.  CELL LINES
6.1     Cell Lines
(a)     The parties acknowledge that PDL has delivered all cell
lines required under the 1989 Agreement.  Roche agrees to deliver back to PDL
viable samples of such cell lines as may be requested by PDL.
(b)     Ownership of any cell lines developed under Article VI of
the 1989 Agreement or delivered to Roche under Milestone #1 of Section 3.1 of
the 1989 Agreement, together with their progeny and derivatives, shall remain
vested at all times in PDL.
(c)     Roche may only use the cell lines delivered to it under the
1989 Agreement, or their progeny or derivatives or the plasmids contained
therein, to make, have made, use and sell Licensed Products in the Field
within the Territory.  Furthermore, the plasmids or parts thereof may only be
used with the genes encoding antibodies developed or provided by PDL.
(d)     PDL MAKES NO REPRESENTATIONS AND EXTENDS NO WARRANTIES OF
ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO ANY CELL LINES DELIVERED
HEREUNDER.  THERE ARE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE, OR THAT THE USE OF THE CELL LINES DELIVERED
TO ROCHE WILL NOT INFRINGE ANY PATENT OR OTHER RIGHTS.
VII.  DILIGENCE
7.1     Diligence.  Upon execution of this Amended and Restated Agreement,
Roche shall use reasonable diligence in proceeding with the manufacturing,
marketing and sale of Licensed Products in Transplant Indications within the
Territory.  Reasonable diligence as used in this Amended and Restated
Agreement shall mean the same standard of effort used by Roche in the
manufacturing, marketing and sale of its own protein-based products which must
be approved by the FDA before they can be sold in the Territory.  If Roche
fails to exercise such diligence, PDL may terminate this Amended and Restated
Agreement and Roche's rights hereunder pursuant to Section 11.4 below.
7.2     Reimbursement for Costs of Patent Application.

(a)     Roche agrees to reimburse PDL for all ex parte out-of-pocket
expenses incurred by PDL after January 31, 1989 in connection with the
prosecution and maintenance in Canada of patent applications and patents
included within the Sole PDL Patents or Joint Roche-PDL Patents for which PDL
makes filings pursuant to Article IX of this Amended and Restated Agreement
("Canada Transplant Foreign Filing Expenses").  Roche shall make such payment
to PDL no less frequently than semi-annually, within thirty (30) days after
submission by PDL of a reasonably itemized statement of such expenses incurred
by PDL during the relevant six-month period.  Notwithstanding the foregoing,
Roche shall not be obligated to reimburse PDL for such expenses to the extent
such expenses, when added to Transplant Foreign Filing Expenses (as defined in
the F.Roche Agreement), exceeds an aggregate of [CONFIDENTIAL TREATMENT
REQUESTED] in any calendar year.

(b)     Prior to the filing of a patent application in Canada for
Transplant Indications, PDL shall inform Roche concerning such proposed filing
and shall consult with Roche concerning the proposed filing procedures,
including specifically the determination of scope of any such patent.  PDL
shall regularly advise Roche of any substantial action or development in the
prosecution of its patent applications and patents in Canada related to the
Transplant Indications, in particular of the question of scope of, the
issuance of, the rejection of, or an opposition to any respective patent
application or patent.

(c)     Canada Transplant Foreign Filing Expenses shall be treated as part
of Transplant Foreign Filing Expenses under the F.Roche Agreement for purposes
of calculating F. Roche's credit against royalties payable in the ROW
Territory for Foreign Transplant Expenses as provided in the F.Roche
Agreement.

VIII.  OWNERSHIP OF TECHNOLOGY

8.1     PDL Technology.  Ownership of the PDL Know-How and PDL Patents
shall remain vested at all times in PDL. PDL expressly reserves under this
Amended and Restated Agreement (i) all rights to use the PDL Know-How, PDL's
rights under any Joint Roche-PDL Patents and PDL Patents to make, have made,
use and sell anywhere in the world all products not within the Field, and
(ii) the right to use the PDL Know-How, PDL's rights under any Joint Roche-PDL
Patents and PDL Patents for PDL's internal research and development purposes
in the Field.

8.2     Joint Inventions and Joint Roche-PDL Patents.  Subject to Article
IX, ownership of Joint Inventions and Joint Roche-PDL Patents shall be vested
jointly in PDL and Roche. Except as expressly provided herein, Roche shall
have the exclusive right within the Territory during the term of this Amended
and Restated Agreement to make, have made, use or sell any Joint Invention in
the Field under any Joint Roche-PDL Patent.  In any event, both parties shall
have the non-exclusive right within the Territory during the term of this
Amended and Restated Agreement to make, have made, use or sell any Joint
Invention outside the Field under any Joint Roche-PDL Patent, and neither
party shall be obligated to account to the other.  Upon the expiration or
termination of this Amended and Restated Agreement, both parties shall have
the non-exclusive right to make, have made, use or sell any Joint Invention
under any Joint Roche-PDL Patent without restriction and without any
obligation to account to the other party. PDL expressly reserves the right to
use any Joint Invention under any Joint Roche-PDL Patent for PDL's internal
research and development purposes in the Field.
8.3     Roche Inventions.  PDL hereby acknowledges that, except as
expressly provided herein, this Amended and Restated Agreement does not grant
PDL any ownership rights in the Roche Inventions, Roche Patents and Roche
Know-How.  Roche hereby confirms the rights of PDL to certain contingent
license grants to Roche Patents, Roche's rights under Joint Roche-PDL Patents
and Roche Know-How as provided in this Amended and Restated Agreement.
IX.  INVENTIONS
9.1     Sole Patents.  PDL agrees to prosecute and reasonably maintain all
of the patents and applications included within the Sole PDL Patents and Roche
agrees to prosecute and reasonably maintain all of the patents and
applications included within the Sole Roche Patents containing claims
specifically related to Daclizumab ("Sole Daclizumab Roche Patents").  The
party responsible for such patent ("responsible party") shall bear all costs
and expenses for such prosecution and maintenance except for the costs and
expenses of foreign filings for such patents which are to be borne by Roche in
accordance with Section 7.2 of this Amended and Restated Agreement and the
terms of the F. Roche Agreement. Upon the reasonable request of the
responsible party, the other party shall cooperate, in all reasonable ways, in
connection with the prosecution of all patent applications included within the
Sole PDL Patents or Sole Daclizumab Roche Patents, as the case may be.  Should
the responsible party decide that it is no longer interested in maintaining or
prosecuting a Sole PDL Patent or Sole Daclizumab Roche Patent, as the case may
be, it shall promptly advise the other party thereof and, at the request of
such other party, PDL and Roche shall negotiate in good faith to determine an
appropriate course of action in the interests of both parties.  If any Sole
PDL Patents are assigned to Roche, Roche will thereafter prosecute and
reasonably maintain such Sole PDL Patents at Roche's own cost to the extent
that Roche desires to do so, provided that to the extent such Sole PDL Patent
contains claims outside the Field, PDL and its Affiliates shall have a
worldwide immunity from suit thereunder.  If any Sole Daclizumab Roche Patents
are assigned to PDL, PDL will thereafter prosecute and reasonably maintain
such Sole Daclizumab Roche Patent at PDL's own cost to the extent that PDL
desires to do so, provided that to the extent such Sole Daclizumab Roche
Patent contains claims outside the Field, Roche and its Affiliates shall have
a worldwide immunity from suit thereunder.
9.2     Joint Inventions.
(a)     PDL will have the first right of election to file priority
patent applications for Joint Inventions in any country in the world.  If PDL
declines to file such applications then Roche may do so.  Regardless of which
party files a priority patent application, however, any claims covered by such
applications shall be considered as part of the PDL Patents for the purpose of
defining a Valid Claim under this Amended and Restated Agreement.
(b)     The party not performing the priority patent filings for
Joint Inventions pursuant to this Section 9.2 undertakes without cost to the
filing party to obtain all necessary assignment documents for the filing
party, to render all signatures which shall be necessary for such patent
filings and to assist the filing party in all other reasonable ways which are
necessary for the issuance of the patents involved as well as for the
maintenance and prosecution of such patents.  The party not performing the
patent filings shall upon request be authorized by the other party to have
access to the files concerning such patents in any patent offices in the
world.
(c)     The party performing the priority patent filings for Joint
Inventions pursuant to this Section 9.2 undertakes to perform the
corresponding convention filings from case to case, after having discussed the
countries for foreign filings with the other party at its cost and expense;
except for the costs and expenses of foreign filings for such patents which
are to be borne by Roche in accordance with Section 7.2 of this Amended and
Restated Agreement and the terms of the F. Roche Agreement.
        (d)     Should the responsible party decide that it is no longer
interested in maintaining or prosecuting a Joint Roche-PDL Patent, it shall
promptly advise the other party thereof.  Upon the written request of such
other party, such Joint Roche-PDL Patent shall be assigned to the other party
at no cost to the assignee.  If any such patents or patent applications are
assigned to Roche, they shall then be deemed to be a Sole Roche Patent and, to
the extent such Joint Roche-PDL Patent contains claims outside the Field, PDL
and its Affiliates shall have a worldwide immunity from suit thereunder.  If
any such patents or patent applications are assigned to PDL, they shall then
be deemed to be a Sole PDL Patent and, to the extent such Joint Roche-PDL
Patents contain claims outside the Field, Roche and its Affiliates shall have
a worldwide immunity from suit thereunder.
9.3     General Procedures.  The parties shall observe the following
procedures for patent applications for inventions arising from this Amended
and Restated Agreement:
(a)     As soon as one of the parties concludes that it wishes to
file a patent application covering an invention in the Field, it shall
immediately inform the other party thereof and consult about the filing
procedures concerning such patent application.  For this purpose, such party
will provide the other party with the determination of inventors and scope of
claims as early as possible.  Should a party be faced with possible loss of
rights, such communications may take place promptly after filing a convention
application.
(b)     Except as set forth in Sections 9.1 and 9.2 with respect to
the costs of foreign filings, the party performing any priority patent filings
as described above shall be obliged to prosecute and reasonably maintain such
applications and any patents resulting therefrom and will have to bear the
costs associated therewith.  On request of the party performing the filing,
the other party will cooperate, in all reasonable ways, in connection with the
prosecution of all such patent applications relating to inventions.  The party
performing the filing shall advise the other party of any substantial action
or development in the prosecution of its patent applications and patents, in
particular of the question of scope, the issuance of, or the rejection of, an
interference involving or an opposition to any respective patent application
or patent.
(c)     Inventions and other intellectual property made by either
party outside the Field shall be excluded from the provisions of this Amended
and Restated Agreement and shall belong solely to the party having made the
invention or other intellectual property.
X.  ENFORCEMENT OF PATENTS
10.1    Sole Patents.
(a)     In the event of any action against a third party for
infringement of any claim in any issued patent within the Sole PDL Patents or
Sole Daclizumab Roche Patents, as the case may be, or the institution by a
third party of any proceedings for the revocation of any such claim, each
party will notify the other promptly and, following such notification, the
parties shall confer.  PDL shall have the right, but shall not be obligated,
to prosecute such actions or to defend such proceedings involving the Sole PDL
Patents at its own expense, in its own name and entirely under its own
direction and control.  Roche shall have the right, but shall not be
obligated, to prosecute such actions or to defend such proceedings involving
the Sole Daclizumab Roche Patents, at its own expense, in its own name and
entirely under its own direction and control.
(b)     If a party with the first right hereunder elects not to
prosecute any action for infringement or to defend any proceeding for
revocation of any claims in any issued patent within the Sole PDL Patents or
Sole Daclizumab Roche Patents, as the case may be, within ninety (90) days of
being requested by the other party to do so, the other party may prosecute
such action or defend such proceeding at its own expense, in its own name and
entirely under its own direction and control.
(c)     In any event, the party bringing an action ("acting party")
pursuant to this Section 10.1 shall solicit, and seriously consider in good
faith the non-acting party's input with respect to all material aspects of
such action, including without limitation, the development of the litigation
strategy and the execution thereof.  In furtherance and not in limitation of
the foregoing, the acting party shall keep the other party promptly and fully
informed of the status of any such action, and the non-acting party shall have
the right to review and comment upon the acting party's activities related
thereto.
(d)     Each party will reasonably assist the acting party  in any such
action or proceeding being prosecuted or defended by the acting party, if so
requested by the acting party or required by law.  The acting party will pay
or reimburse the assisting party for all costs, expenses and liabilities which
the assisting party may incur or suffer in affording assistance to such
actions or proceedings.  No settlement of any such action or defense which
restricts the scope or affects the enforceability of PDL Know-How or Sole PDL
Patents may be entered into by either PDL or Roche without the prior consent
of the other party hereto, which consent, in the case of Roche shall not be
unreasonably withheld and in the case of PDL may be withheld in PDL's sole and
absolute discretion. No settlement of any such action or defense which
restricts the scope or affects the enforceability of Roche Know-How or Sole
Daclizumab Roche Patents may be entered into by either PDL or Roche without
the prior consent of the other party hereto, which consent, in the case of PDL
shall not be unreasonably withheld and in the case of Roche may be withheld in
Roche's sole and absolute discretion.
(e)     If either party elects to prosecute an action for
infringement or to defend any proceedings for revocation of any claims
pursuant to this Section 10.1 and subsequently ceases to continue or withdraws
from such action or defense, it shall forthwith so notify the other party in
writing and the other party may substitute itself for the withdrawing party
and the parties' respective rights and obligations under this Section 10.1
shall be reversed.
10.2    Joint Roche-PDL Patents.  In the event of any action against a
third party for infringement of any claim in any issued patent within the
Joint Roche-PDL Patents, or the institution by a third party of any
proceedings for the revocation of any such claim, each party will notify the
other promptly and, following such notification, the parties shall confer to
determine whether either or both parties shall control the prosecution or
defense of such action or proceeding and who shall bear the costs thereof.  If
the parties are unable to reach agreement within ninety (90) days of the
notification referred to above, then each party shall have the right to bring
such action or defend such proceeding at its own expense, in its own name and
entirely under its own direction and control; provided, however, that if both
parties elect to prosecute or defend, each party shall bear its own expenses
but both parties shall have equal control over such prosecution or defense.
No settlement of any action or defense which restricts the scope or affects
the enforceability of Joint Roche-PDL Patents may be entered into by either
PDL or Roche without the prior consent of the other party hereto, which
consent shall not be unreasonably withheld.  In any event, the party bringing
an action ("acting party") pursuant to this Section 10.2 shall solicit, and
seriously consider in good faith the other party's input with respect to all
material aspects of such action, including without limitation, the development
of the litigation strategy and the execution thereof.  In furtherance and not
in limitation of the foregoing, the acting party shall keep the other party
promptly and fully informed of the status of any such action, and the other
party shall have the right to review and comment upon the acting party's
activities related thereto.
10.3    Distribution of Proceeds.  In the event either party exercises the
rights conferred in Section 10.1 or 10.2 hereof, and recovers any damages or
other sums in such action, suit or proceeding or in settlement thereof, such
damages or other sums recovered, shall first be applied to all costs and
expenses connected therewith including reasonable attorneys' fees, necessarily
involved in the prosecution and/or defense of any suit or proceeding, and if
after such reimbursement any funds shall remain from such damages or other
sums recovered, said recovery shall belong to the party exercising its rights;
provided, however, that [CONFIDENTIAL TREATMENT REQUESTED].
10.4    Defense of Infringement Actions.
(a)     Roche shall defend at its own cost any infringement suit
that may be brought against PDL or Roche on account of the development,
manufacture, production, use or sale of any Licensed Product by Roche, and
shall indemnify and save PDL harmless against any such patent or other
infringement suits, and any claims, losses, damages, liabilities, expenses,
including reasonable attorneys' fees and cost, which may be incurred by PDL
therein or in settlement thereof.  Any and all settlements which restrict the
scope or enforceability of PDL Know-How or PDL Patents must be approved by PDL
in its sole and absolute discretion before execution by Roche.  Any and all
settlements which restrict the scope or enforceability of Joint Roche-PDL
Patents must be approved by PDL before execution by Roche, such approval not
to be unreasonably withheld.  PDL shall not be required to approve any
settlement which does not include as a condition thereof the granting to PDL
of a full and unconditional release of claims.
(b)     PDL shall defend at its own cost any infringement suit that
may be brought against Roche or PDL on account of the development,
manufacture, production, use or sale of Daclizumab by PDL, and shall indemnify
and save Roche harmless against any such patent or other infringement suits,
and any claims, losses, damages, liabilities, expenses, including reasonable
attorneys' fees and cost, which may be incurred by Roche therein or in
settlement thereof.  Any and all settlements which restrict the scope or
enforceability of Roche Know-How or Roche Patents must be approved by Roche in
its sole and absolute discretion before execution by PDL.  Any and all
settlements which restrict the scope or enforceability of Joint Roche-PDL
Patents must be approved by Roche before execution by PDL, such approval not
to be unreasonably withheld.  Roche shall not be required to approve any
settlement which does not include as a condition thereof the granting to Roche
of a full and unconditional release of claims.  Roche will use its best
efforts to avoid knowingly infringing any patents of third parties in Roche's
design of the cell lines that may be delivered to PDL hereunder, and Roche
will inform PDL of any such potential infringement promptly upon Roche's
becoming aware of such potential infringement.
10.5    Right to Counsel.  Each party to this Amended and Restated
Agreement shall always have the right to be represented by counsel of its own
selection and its own expense in any suit or other action instituted by the
other for infringement, under the terms of this Amended and Restated
Agreement.
10.6    Coordination.   Each party acknowledges and agrees that the
efforts of the parties under this Article X shall take into consideration the
efforts and responsibilities of PDL and Roche under the F.Roche Agreement.
XI.  TERM AND TERMINATION
11.1    Term.  Unless earlier terminated pursuant to the terms of this
Article XI, this Amended and Restated Agreement shall remain in effect until
the end of the date of expiration of all payment obligations, including
royalties and consideration, under Article IV and Article IV-A, at which time
all the rights and licences granted under this Amended and Restated Agreement
shall become irrevocable and fully-paid.
11.2    Termination by Mutual Agreement.  This Amended and Restated
Agreement may be terminated by the written agreement of the parties.
11.3    Termination by Roche.  On a country by country basis, Roche may
terminate its rights and obligations under this Amended and Restated Agreement
upon one hundred eighty (180) days written notice to PDL.
11.4    Termination by Default.  If either party defaults in the
performance of, or fails to be in compliance with, any material agreement,
condition or covenant of this Amended and Restated Agreement, the party not in
default may terminate this Amended and Restated Agreement at its option;
provided, however, that if such event of default or non-compliance is the
first occurrence of an event giving rise to the right of termination pursuant
to this Section 11.4, the non-defaulting party may, on a country-by-country
basis, terminate this Amended and Restated Agreement only if such default or
noncompliance shall not have been remedied, or steps initiated to remedy the
same to the other party's reasonable satisfaction within sixty (60) days after
receipt by the defaulting party of a written notice thereof from the other
party.  If either party terminates the F. Roche Agreement pursuant to
Section 11.4 thereof, the terminating party may, on a country-by-country
basis, elect to simultaneously terminate this Amended and Restated Agreement
upon written notice to the other party hereto.  Notwithstanding the foregoing,
a determination by PDL to terminate development of Daclizumab for Autoimmune
Indications hereunder shall not be deemed a default by PDL.
11.5    Inventory.  Subject to Section 11.7(b), upon termination of this
Amended and Restated Agreement for default by Roche, Roche shall notify PDL of
the amount of Daclizumab Roche, its Affiliates, sublicensees and distributors
then have on hand ("Inventory"), the sale of which would, but for the
termination, be subject to payment of royalties or other consideration under
this Amended and Restated Agreement.   Roche and its Affiliates, sublicensees
and distributors shall thereupon be permitted to sell the Inventory, provided
that  PDL shall have the first option for a period not to exceed sixty (60)
days to purchase all or part of the Inventory at [CONFIDENTIAL TREATMENT
REQUESTED].  If PDL fails to exercise its option to purchase all of the
Inventory or for that part of the Inventory with respect to which the option
is not exercised,  Roche will be free to sell such Inventory to third parties
for a period not to exceed one hundred eighty (180) days from the termination
of PDL's option.  In any event, Roche shall pay the royalties or other
consideration due on the sale of such Inventory in the amounts and manner
provided for in Articles IV and IVA.  Upon  termination of this Amended and
Restated Agreement for any reason other than default by Roche, Roche shall
have a right to sell Inventory for a period of one (1) year from the date of
such termination, subject to the obligation to pay the royalty or other
consideration due to PDL  with respect to the sale of such Inventory.  Any
sales of Inventory by Roche pursuant to this Section 11.5 for Autoimmune
Indications shall be done in compliance with the then applicable Promotional
Plan.
11.6    Return of Materials.  Subject to Section 11.8 hereof concerning
archival copies, upon termination of this Amended and Restated Agreement in
whole by Roche pursuant to Section 11.3 or by either or both parties pursuant
to Sections 11.2 or 11.4:  (a) Roche forthwith shall return to PDL all cell
lines and their progeny, antibodies and other biological materials provided by
PDL under the 1989 Agreement; and (b), subject to Section 11.5, at PDL's own
cost Roche shall deliver to PDL then available supplies of Daclizumab.
11.7    Rights and Obligations on Termination or Expiration.
(a)     Unless expressly provided to the contrary, the provisions of
Sections 3A.2, 3A.7, 3A.8(e), 4B.3, 5.2, 5.3 and 7.2 and Articles V, VIII, X,
XII, XIII and XV shall survive the termination of this Amended and Restated
Agreement.
(b)     In the event that termination by either party results in the
termination of rights to Daclizumab or Licensed Products and the reversion or
transfer of such rights to the other party, then upon written request of the
other party, the party whose rights are terminated shall act in good faith
using commercially reasonable efforts to (1) at no cost to the transferee
promptly transfer and assign to the other party all related regulatory
filings, regulatory approvals and clinical data and (2) at [CONFIDENTIAL
TREATMENT REQUESTED], provide sufficient supply of Daclizumab or Licensed
Products, as the case may be, for a period of time reasonably required to
prevent disruption of clinical development and market disruption.
(c)     In the event that in a given country of the Territory Roche
terminates this Agreement pursuant to Section 11.3 or PDL terminates this
Agreement due to default by Roche pursuant to Section 11.4, then effective as
of the date of termination, for the given country PDL shall have a fully-paid,
sole and exclusive license under the Roche Know-How and Roche Patents to make,
have made, use and sell Licensed Products in the Field in the Territory.
(d)     In the event that in a given country of the Territory Roche
terminates this Agreement pursuant to Section 11.4 due to default by PDL
pursuant to Section 11.4, then effective as of the date of termination, for
the given country Roche shall have a fully-paid, sole and exclusive license
under the PDL Know-How and PDL Patents to make, have made, use and sell
Licensed Products in the Field in the Territory.
           11.8 Archival Copies.  Section 11.6 notwithstanding, each
party shall be entitled to keep for archival purposes one copy of all written
materials returned to the other party pursuant to Section 11.6.
XII.  CONFIDENTIALITY, DISCLOSURE AND PUBLICATIONS
12.1    Confidentiality.  During the term of this Amended and Restated
Agreement and for a period of five (5) years following expiration or
termination of this Amended and Restated Agreement, each party shall maintain
in confidence all information and materials including, but not limited to,
cell lines, their progeny, and antibodies, disclosed by the other party hereto
which such party knows or has reason to know are or contain trade secrets or
other proprietary information of the other, including, without limitation,
information relating to the PDL Know-How, PDL Patents, Roche Know-How, Roche
Patents, Joint Roche-PDL Patents, Joint Inventions and inventions of the other
party, and the business plans of the other party, including, without
limitation, information provided by either party to the other party hereto
prior to the Signing Date, and shall not use such trade secrets or proprietary
information for any purpose, including, without limitation, for the purpose of
developing products in the Field except as permitted by this Amended and
Restated Agreement or disclose the same to anyone other than those of its
Affiliates, sublicensees, prospective sublicensees, employees, consultants,
agents or subcontractors as are necessary in connection with such party's
activities as contemplated in this Amended and Restated Agreement.  Each party
shall be responsible for ensuring compliance with these obligations by such
party's Affiliates, sublicensees, prospective sublicensees, employees,
consultants, agents and subcontractors.  Each party shall use a similar effort
to that which it uses to protect its own most valuable trade secrets or
proprietary information to ensure that its Affiliates, sublicensees,
employees, consultants, agents and subcontractors do not disclose or make any
unauthorized use of trade secrets or proprietary information of the other
party hereto.  Each party shall notify the other promptly upon discovery of
any unauthorized use or disclosure of the other's trade secrets or proprietary
information.
12.2    Exceptions.  The obligation of confidentiality contained in this
Amended and Restated Agreement shall not apply to the extent that (a) either
party (the "Recipient") is required to disclose information by order or
regulation of a governmental agency or a court of competent jurisdiction or
(b) the Recipient can demonstrate that (i) the disclosed information was at
the time of such disclosure by the Recipient already in the public domain
other than as a result of actions of the Recipient, its Affiliates, employees,
licensees, agents or subcontractors, in violation hereof; (ii) the disclosed
information was rightfully known by the Recipient or its Affiliates (as shown
by its written records) prior to the date of disclosure to the Recipient in
connection with the negotiation, execution or performance of this Amended and
Restated Agreement; or (iii) the disclosed information was received by the
Recipient or its Affiliates on an unrestricted basis from a source unrelated
to any party to this Amended and Restated Agreement and not under a duty of
confidentiality to the other party, or (c) the Recipient can demonstrate that
disclosure to a regulatory authority is required by its product license
approval process.
12.3    Publications.
(a)  Scientific Publications.  Prior to public disclosure or submission
for publication of a manuscript describing the results of any scientific
activity or collaboration between PDL and Roche in the Field, the party
disclosing or submitting such a manuscript ("Disclosing Party") shall send the
other party ("Responding Party") by expedited delivery a copy of the
manuscript to be submitted and shall allow the Responding Party a reasonable
time period (not to exceed forty-five (45) days from the date of confirmed
receipt) in which to determine whether the manuscript contains subject matter
of which patent protection should be sought (prior to publication of such
manuscript) for the purpose of protecting an invention conceived or developed
in connection with the PDL/Roche scientific collaboration, or whether the
manuscript contains confidential information belonging to the Responding
Party.  After the expiration of forty-five (45) days  from the date of
confirmed receipt of  such manuscript, the Disclosing Party shall be free to
submit such manuscript for publication and publish or otherwise disclose to
the public such research results.  Should the Responding Party believe the
subject matter of the manuscript contains confidential information or a
patentable invention of substantial commercial value to the Responding Party,
then prior to the expiration of forty-five (45) days  from the date of
confirmed receipt of such manuscript  by the  Responding Party, the Responding
Party shall notify the Disclosing Party in writing of its determination that
such manuscript contains such information or subject matter for which patent
protection should be sought.  Upon receipt of such written notice from the
Responding Party, the Disclosing Party shall delay public disclosure of such
information or submission of the manuscript for an additional period of sixty
(60) days to permit preparation and filing of a patent application on the
disclosed subject matter.  The Disclosing Party shall thereafter be free to
publish or disclose such information, except that the Disclosing Party may not
disclose any confidential information of the Responding Party in violation of
Sections 12.1 and 12.2 hereof. Each party agrees to give the other party
reasonable opportunity to review and comment on any proposed publication
arising from the research collaboration between the parties.  Determination of
authorship for any paper or patent shall be in accordance with accepted
scientific practice.  Should any questions on authorship arise, this will be
determined by good faith consultation between the respective heads of research
for each of the parties.
(b)  Clinical Studies.  Prior to public disclosure or submission for
publication of a manuscript by PDL describing the results of any scientific,
preclinical or clinical study conducted by or on behalf of PDL in Autoimmune
Indications, PDL shall send Roche by expedited delivery a copy of the
manuscript to be submitted and shall allow Roche a reasonable time period (not
to exceed forty-five (45) days  from the date of  confirmed receipt by Roche)
to review the manuscript, including for the purpose of determining whether the
manuscript contains information which  is reasonably likely to have a material
adverse impact on Daclizumab for Transplant Indications in the Territory or
confidential information belonging to Roche.  After the expiration of forty-
five (45) days  from the date of  confirmed receipt by Roche of such
manuscript, PDL shall be free to submit such manuscript for publication and
publish or otherwise disclose to the public such research results.  Should
Roche believe the manuscript contains information  which is reasonably likely
have a material adverse impact on Daclizumab for Transplant Indications in the
Territory or which is confidential information of Roche, then prior to the
expiration of forty-five (45) days  from the date of  confirmed receipt of
such manuscript  by Roche, Roche shall notify the PDL in writing of its
determination and the reasons therefor.  Upon receipt of such written notice
from Roche that the manuscript contains confidential information of Roche, PDL
shall delay public disclosure of such information or submission of the
manuscript for an additional period not to exceed sixty (60) days to permit
the parties to agree as to how to revise the manuscript so that PDL will not
disclose any confidential information of Roche in violation of Sections 12.1
and 12.2 hereof.
XIII.  DISPUTE RESOLUTION
13.1    Arbitration.  Except as expressly provided herein, any claim,
dispute or controversy arising out of or in connection with or relating to
this Amended and Restated Agreement or the breach or alleged breach thereof
shall be submitted by the parties to arbitration by the AAA in Santa Clara
County, California under the commercial rules then in effect for that AAA
except as provided herein.  All proceedings shall be held in English and a
transcribed record prepared in English.  The parties shall choose, by mutual
agreement, one arbitrator within thirty (30) days of receipt of notice of the
intent to arbitrate.  If no arbitrator is appointed within the times herein
provided or any extension of time which is mutually agreed upon, the AAA shall
make such appointment within thirty (30) days of such failure.  The award
rendered by the arbitrator shall include costs of arbitration, reasonable
attorneys' fees and reasonable costs for expert and other witnesses, and
judgment on such award may be entered in any court having jurisdiction
thereof.  The parties shall be entitled to discovery as provided in
Sections 1283.05 and 1283.1 of the Code of Civil Procedure of the State of
California, whether or not the California Arbitration Act is deemed to apply
to said arbitration.  Nothing in this Amended and Restated Agreement shall be
deemed as preventing either party from seeking injunctive relief (or any other
provisional remedy) from any court having jurisdiction over the parties and
the subject matter of the dispute as necessary to protect either party's name,
proprietary information, trade secrets, know-how or any other proprietary
right.  If the issues in dispute involve scientific or technical matters, any
arbitrator chosen hereunder shall have educational training and/or experience
sufficient to demonstrate a reasonable level of knowledge in the field of
biotechnology.  Judgment upon the award rendered by the arbitrator may be
entered in any court having jurisdiction thereof.
XIV.  FORCE MAJEURE
14.1    No Control.  If either party shall be delayed, interrupted in or
prevented from the performance of any obligation hereunder by reason of force
majeure including an act of God, fire, flood, earthquake, war (declared or
undeclared), public disaster, strike or labor differences, governmental
enactment, rule or regulation, or any other cause beyond such party's control,
such party shall not be liable to the other therefor; and the time for
performance of such obligation shall be extended for a period equal to the
duration of the contingency which occasioned the delay, interruption or
prevention.  The party invoking such force majeure rights of this subparagraph
must notify the other party by courier or overnight dispatch (e.g., Fedex)
within a period of fifteen (15) days, from the first and last day of the force
majeure unless the force majeure renders such notification impossible in which
case notification will be made as soon as possible.  If the delay resulting
from the force majeure exceeds six (6) months, both parties shall consult
together to find an appropriate solution.
XV.  MISCELLANEOUS
15.1    Representations.  Each party represents and warrants to the other
party hereto that, except as may otherwise be disclosed in writing to such
party:
(a) each party has the full right and authority to enter into this
Amended and Restated Agreement; and
(b) to the best knowledge of the party after reasonable
investigation, no third party has any right, title or interest in the PDL
Patents or PDL Know-How, Roche Know-How or Roche Patents, as the case may be,
as the result of such third party's former employment of any employee of that
party.
15.2    Assignment.  Subject to Section 3B.4, this Amended and Restated
Agreement and the licenses herein granted other than the aforementioned
agreements between PDL and F. Roche relating to the same Field but outside the
Territory shall be binding upon and shall inure to the benefit of, successors
of the parties hereto, or to an assignee of all of the good will and entire
business and assets of a party hereto relating to pharmaceutical and
veterinary products but shall not otherwise be assignable without the prior
written consent of the other party, which consent will not be unreasonably
withheld.
15.3    Entire Agreement.  This Amended and Restated Agreement and the
aforementioned agreements between PDL and F. Roche relating to the same Field
but outside the Territory constitute the entire agreement between the parties
hereto with respect to the within subject matter and supersede all previous
agreements (including the 1989 Agreement), whether written or oral.  This
Amended and Restated Agreement shall not be changed or modified orally, but
only by an instrument in writing signed by both parties.
15.4    Releases.
(a)  The parties agree that as of the Signing Date, PDL hereby releases
and forever discharges Roche and its Affiliates (including Genentech, Inc., a
Delaware corporation) from any and all claims, liabilities and demands
whatsoever on account of or arising from the 1989 Agreements that PDL may
have, otherwise continue to have or have had, past, present or future,
including with respect to milestone payments and diligence under each of the
1989 Agreements and including without limitation any and all claims
liabilities and demands on account of or arising from the respective sections
of 1989 Roche Agreements entitled "Antibodies in the Field Not Provided or
Developed by PDL", including any remedies which PDL may have on, prior to or
after the Signing Date thereunder both in equity and at law; provided that
nothing herein shall be deemed to release any claims, liabilities or demands
that PDL may have as a result of first arising after the Signing Date under
this Amended and Restated Agreement.
(b)  The parties agree that as of the Signing Date, F. Roche and its
Affiliates hereby release and forever discharge PDL from any and all claims,
liabilities and demands whatsoever on account of or arising from that certain
Joint Development, Marketing and License Agreement between PDL and Boehringer
Mannheim GmbH ("Boehringer") dated October 28, 1993, as amended, and all
related agreements entered into between PDL and Boehringer as of that same
date that F. Roche and its Affiliates may have or have had, past, present or
future, including any remedies which Roche may have on, prior to or after the
Signing Date thereunder both in equity and at law; provided that nothing
herein shall be deemed to release any claims, liabilities or demands that F.
Roche or its Affiliates may have after the Signing Date under this Amended and
Restated Agreement.
15.5    Severability.  If any provision of this Amended and Restated
Agreement is declared invalid by an arbitrator pursuant to Section 13.1 or by
a court of last resort or by any court or other governmental body from the
decision of which an appeal is not taken within the time provided by law, then
and in such event, this Amended and Restated Agreement will be deemed to have
been terminated only as to the portion thereof which relates to the provision
invalidated by that decision and only in the relevant jurisdiction, but this
Amended and Restated Agreement, in all other respects and all other
jurisdictions, will remain in force; provided, however, that if the provision
so invalidated is essential to the Amended and Restated Agreement as a whole,
then the parties shall negotiate in good faith to amend the terms hereof as
nearly as practical to carry out the original intent of the parties, and,
failing such amendment, either party may submit the matter to arbitration for
resolution pursuant to Section 13.1.
15.6    Indemnification.
(a)  Roche shall defend, indemnify and hold harmless PDL, its trustees,
officers, agents and employees harmless from any and all liability, demands,
damages, expenses, and losses of any kind, including those resulting from
death, personal injury, illness or property damage arising (i) out of the
manufacture, distribution, use, testing, sale or other disposition, by Roche,
an Affiliate of Roche, or any distributor, customer, sublicensee or
representative of Roche or anyone in privity therewith, of any Licensed
Product, or any cell lines, their progeny, or other biological materials,
method, process, device or apparatus licensed or provided by PDL pursuant to
the 1989 Agreement or this Amended and Restated Agreement, or (ii) as a result
of practicing a Joint Invention, or using PDL Know-How or PDL Patents licensed
to Roche under this Amended and Restated Agreement, except where such claim is
based on the negligent acts of commission or omission of PDL.
(b)  PDL shall defend, indemnify and hold harmless Roche, its trustees,
officers, agents and employees harmless from any and all liability, demands,
damages, expenses, and losses of any kind, including those resulting from
death, personal injury, illness or property damage arising (i) out of the
manufacture, distribution, use, testing, sale or other disposition, by PDL, an
Affiliate of PDL, or any distributor, customer, sublicensee or representative
of PDL or anyone in privity therewith, of Daclizumab, or any biological
materials, method, process, device or apparatus licensed or provided by Roche
pursuant to this Amended and Restated Agreement, or (ii) as a result of
practicing a Joint Invention, or using Roche Know-How or Roche Patents
licensed to PDL under this Amended and Restated Agreement, except where such
claim is based on the negligent acts of commission or omission of Roche.
15.7    Notices.  Any notice or report required or permitted to be given
under this Amended and Restated Agreement shall be in writing and shall be
mailed by certified or registered mail, or telexed or telecopied and confirmed
by mailing, as follows and shall be effective five (5) days after such
mailing:

If to PDL:      Protein Design Labs, Inc.
        34801 Campus Drive
Fremont, California U.S.A.  94555
Attention:  General Counsel

If to Roche:    Hoffmann-La Roche Inc.
        340 Kingsland Street
        Nutley, New Jersey  07110
        Attention:  Corporate Secretary

        and

        F. Hoffmann-La Roche Ltd
        Grenzacherstrasse 124
        CH-4002 Basel, Switzerland
        Attention:  Law Department


15.8    Choice of Law.  The validity, performance, construction, and
effect of this Amended and Restated Agreement shall be governed by the laws of
the State of California, U.S.A.

15.9    Publicity.  The parties agree to issue press releases in an
agreed-upon form and format concerning their entry into this Amended and
Restated Agreement, with the content of such releases to be approved in
advance by the parties.    In all other respects, no party to this Amended and
Restated Agreement shall use the name of the other parties in any publicity
release without the prior written permission of such other party, which shall
not be unreasonably withheld.  In any event, a party shall have a reasonable
opportunity to review and comment on any proposed publicity release.  Except
as required by law, no party hereto shall publicly disclose the terms of this
Amended and Restated Agreement, the 1989 Agreement, or their terms and
conditions unless expressly authorized to do so by the other parties which
authorization shall not be unreasonably withheld.  In the event that
disclosure shall be agreed upon then the parties will work together to develop
a mutually acceptable disclosure.  Notwithstanding anything to the contrary
herein, if not otherwise disclosed by Roche, PDL shall not disclose to any
third party the amount of sales of or royalties or consideration paid with
respect to Licensed Product without the prior written consent of Roche, which
consent shall not be unreasonably withheld.

15.10   Agency.    Neither party is, nor will be deemed to be an employee,
agent or representative of the other party for any purpose.  Each party is an
independent contractor, not an employee or partner of the other party.
Neither party shall have the authority to speak for, represent or obligate the
other party in any way without prior written authority from the other party.

15.11   Headings.  The captions used herein are inserted for convenience
of reference only and shall not be construed to create obligations, benefits,
or limitations.

[The remainder of this page intentionally left blank.]


15.12   Counterparts.  This Amended and Restated Agreement may be executed
in counterparts, all of which taken together shall be regarded as one and the
same instrument.

IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Agreement through their duly authorized representatives to be effective as of
the Signing Date.

PROTEIN DESIGN LABS, INC.                       HOFFMANN-LA ROCHE INC.

By:                                                     By:

Title:                                                  Title:


Date:                                                   Date:



                                                        F.HOFFMANN-LA ROCHE LTD

                                                        By:  ________________

                                                        Title:  ____________

                                                        Date:  ______________


Appendix A
PDL Patents

A.  The following are patents and patent applications (also known as the "Queen
et al. Patents") issued and filed in certain countries in the world.

        1.  The following issued U.S. patents and U.S. patent applications:

No. 5,585,089, "Humanized Immunoglobulins," issued December 17, 1996.

No. 5,693,761, "Polynucleotides Encoding Improved Humanized
Immunoglobulins," issued December 2, 1997.

No. 5,693,762, "Humanized Immunoglobulins," issued December 2, 1997.

[CONFIDENTIAL TREATMENT REQUESTED]


        2.  The following patents and patent applications outside the U.S.:

Patent No.

Country
Title*
Issued
647383
Australia
"Novel Immunoglobulins, Their Production
and Use"
Issued
671949
Australia
"
Issued
AT E133452
Austria
"
Issued
0451216
Belgium
"
Issued
61095
Bulgaria
"
Issued
970016

Brazil
"
Issued
0451 216B1
European
"
Issued
0682040 B1
European

Issued
FR0451216
France
"
Issued
DE
68925536
Germany
"
Issued
DD 296 964
East Germany
"
Issued
GB 0451216
Great Britain
"
Issued
1001050

Greece
"
Issued
211174

Hungary
"
Issued
IT O451216
Italy
"
Issued
2828340
Japan
"
Issued
LU O451216
Luxembourg
"
Issued
92.2146
Monaco
"
Issued
NL 0451216
Netherlands
"
Issued
231984
New Zealand
"
Issued
132068
Pakistan
"
Issued
29729
Philippines
"
Issued
92758
Portugal
"
Issued
4895847.13
Russia
"
Issued
2126046
Russia
"
Issued
SG O451216
Singapore
"
Issued
89/9956
South Africa
"
Issued
178385
South Korea
"
Issued
2081974 T3
Spain
"
Issued
SE O451216
Sweden
"
Issued
CHO 451216
Switzerland
"
Issued
50034
Taiwan
"
Issued
13349
Uruguay
"
Issued
48700
Yugoslavia
"




Country
Title*
Pending
Argentina
"Novel Immunoglobulins, Their
Production and Use"
Pending
Canada
"
Pending
Chile
"
Pending
China
"
Pending
Croatia
"
Pending
Czech Republic
"
Pending
Ecuador
"
Pending
Europe
"
Pending
Hong Kong
"
Pending
Ireland
"
Pending
Israel
"
Pending
Japan
"
Pending
South Korea

Pending
Romania
"
Pending
Slovak Republic
"
Pending
Venezuela
"
Pending
Denmark
"
Pending
Finland
"
Pending
Norway
"





*Exact titles may differ in different countries.


B.  The following patent applications relate to the use of anti-IL2 receptor
antibodies in treatment of acute transplant rejection.

Title:  Method of preventing acute rejection following solid organ
transplantation.

Inventors:  Susan Light and Cary Queen

PCT Publication No.:  WO 98/13067 claiming priority to U.S. provisional
patent application serial no. 60/026,643 filed September 24, 1996.


Appendix B
[CONFIDENTIAL TREATMENT REQUESTED]





(footnote continued from previous page)


(footnote continued on next page)

 common/contracts/roche/Roche99USAAmend v 11.0
        -33-

CONFIDENTIAL TREATMENT REQUESTED WITH RESPECT TO
DESIGNATED PORTIONS OF THIS DOCUMENT


common/contracts/roche/Roche99USAmend v 11.0




AMENDED AND RESTATED AGREEMENT

        This Amended and Restated Agreement ("Amended and Restated Agreement")
is entered into as of October 20, 1999 ("Signing Date"), by and between F.
HOFFMANN-LA ROCHE LTD of Basel, Switzerland ("F. Roche") as successor to F.
Hoffmann-La Roche & Co. Limited Company, and PROTEIN DESIGN LABS, INC., a
Delaware corporation having offices at 34801 Campus Drive, Fremont, California
94555, U.S.A. ("PDL").

RECITALS
A. F. Roche and PDL are parties to an Agreement dated January 31, 1989, as
amended (the "1989 F. Roche Agreement") pertaining to humanized and
chimeric antibodies against the interleukin-2 receptor ("IL-2R").
B. Under the 1989 F. Roche Agreement, PDL exclusively licensed to F. Roche
rights to a humanized antibody now known as Daclizumab (as defined below).
C. F. Roche is currently marketing Daclizumab under the trademark Zenapax*
for the prevention of acute organ rejection in patients receiving kidney
transplants.
D. F. Roche and PDL now desire to replace the 1989 F. Roche Agreement with a
new agreement to provide PDL with rights to develop and, if successful,
promote or market Daclizumab in Autoimmune Indications (as defined below)
for increased compensation from the 1989 F. Roche Agreement.
E. Concurrently with the entering into of this Agreement, PDL and Hoffmann-La
Roche Inc. ("Roche") are replacing an agreement addressing rights in the
United States of America similar to the 1989 F. Roche Agreement (the "1989
PDL/Roche Agreement") with a new agreement covering both the United States
of America and Canada (the "1999 PDL/Roche Agreement") with respect to
which F. Roche shall also be a party.
NOW, THEREFORE, in consideration of the premises and the mutual promises and
covenants set forth below, PDL and F. Roche mutually agree to replace the 1989
F. Roche Agreement as follows:
I.  DEFINITIONS
For the purposes of this Agreement, the following terms, when written
with an initial capital letter (except as set forth in Sections 1.29 and
1.30), shall have the meaning ascribed to them below.  All references to
particular Appendices, Articles and Sections shall mean the Appendices to, and
Articles and Sections of, this Agreement, unless otherwise specified.
1.1      "Affiliates" means any corporation or other business entity
controlled by, controlling, or under common control with another entity, with
"control" meaning direct or indirect beneficial ownership of more than fifty
percent (50%) of the voting stock of, or more than a fifty percent (50%)
interest in the income of, such corporation or other business entity.

1.2     "Combination Product" means any product containing both an
ingredient which causes it to be considered a Licensed Product and one or more
other therapeutically active ingredients.

1.3     "Field" means any humanized or chimeric antibody which binds to
the IL-2R, where "humanized" means a genetically engineered combination of a
substantially human framework region and constant region, and complementarity
determining regions from non-human antibodies, and where "chimeric" means a
genetically engineered combination of human constant region and non-human
variable region.  "Antibodies in the Field" means humanized and chimeric
antibodies which bind to the IL-2R.  It is believed that these Antibodies in
the Field may be useful for therapeutic, diagnostic, imaging and similar
purposes.  It is understood that the Field includes, but is not limited to,
that certain humanized murine monoclonal antibody prepared against the p55
component of the IL-2R ("humanized anti-Tac"). Furthermore, the Field
includes, but is not limited to, all improvements relating to humanized anti-
Tac, including without limitation modifications in structure introduced by
genetic engineering, or by chemical or enzymatic cleavage.  Also included
within the Field shall be alternate hosts for producing humanized anti-Tac,
methods for purification, formulations incorporating humanized anti-Tac, and
uses and methods of use for humanized anti-Tac in human medicine. Humanized
anti-Tac is also known as "Daclizumab".  "Daclizumab" as used in this Amended
and Restated Agreement means any product that contains Daclizumab.

1.4     "Initial Commercialization" means the end of the calendar month
containing the date following the granting of Regulatory Approval (as defined
in Section 1.10 hereof) for a Licensed Product for human therapeutic use for
prevention of kidney transplant rejection or a major disease (within the
meaning of Milestone #2 in Section 3.2 of the 1989 PDL/Roche Agreement) on
which F. Roche, its Affiliates or sublicensees first sell such a product to an
independent third party not an Affiliate of the seller in a major market
within the ROW Territory, where "major market" means either Japan or two of
the following three countries:  France, Italy or the United Kingdom.

1.5     "Joint Inventions" means any inventions in the Field, whether
patented or not, which are jointly made during the period beginning on January
31, 1989 and ending upon expiration or termination of this Amended and
Restated Agreement by at least one PDL employee or person contractually
required to assign or license patent rights covering such inventions to PDL
and at least one Roche or F. Roche employee or person contractually required
to assign or license patent rights covering such inventions to Roche or F.
Roche.

1.6     "Licensed Product" means any product in the Field, including any
Combination Product, the making, use or sale of which utilizes PDL Know-How,
PDL Patents or Joint Inventions or would, in the absence of this Amended and
Restated Agreement, infringe a Valid Claim.  Daclizumab  shall be deemed to be
a Licensed Product.

1.7     "Net Transplant Sales" means either Total Sales (until such time
as Section 3A.4 applies) or Total Transplant Sales (beginning at such time as
Section 3A.4 applies), after deducting, if not already deducted, from the
amount invoiced:

(a)     the amounts actually allowed as volume or quantity discounts,
sales rebates (including cash discounts), price reductions, returns (including
withdrawals and recalls); and

(b)     sales, excise and turnover taxes imposed directly upon and
actually paid by F. Roche, its Affiliates or sublicensees.

In addition, there shall be deducted, to the extent not already deducted
from the amount invoiced, an amount equal to [CONFIDENTIAL TREATMENT
REQUESTED] of the of the Total Sales or Total Transplant Sales, as
appropriate, to cover all other expenses or discounts, including but not
limited to customs duties, transportation and insurance charges and other
direct expenses.

1.8     "PDL Know-How" means, except as otherwise set forth in this
Section 1.8,

(a) all inventions, discoveries, trade secrets, information, experience,
data, formulas, procedures and results in the Field, and improvements thereon,
(collectively, "Know-How in the Field") including any information regarding
the structure, sequence and characterization of Antibodies in the Field,
methods of making and the characterization of cell lines producing Antibodies
in the Field, and methods of achieving high levels of expression of Antibodies
in the Field, which was rightfully held by PDL as of January 31, 1989, or
which was developed or acquired by PDL during the period beginning on January
31, 1989 and ending January 31, 1996 (such date representing the first (1st)
anniversary of the termination of the Research Program), and which Know-How in
the Field is required or useful for registration, manufacturing, using or
selling products in the Field, and

(b) all Know-How in the Field, including any information regarding the
physical, chemical, biological, toxicological, pharmacological, clinical, and
veterinary data, dosage regimens, control assays and specifications of
Daclizumab, which is rightfully held by PDL or its Affiliates as of the
Signing Date, or which is developed or acquired by PDL or its Affiliates with
the right to license or sublicense during the term of this Amended and
Restated Agreement, and which Know-How in the Field is required or useful for
registration, using or selling Daclizumab;
provided, however, that PDL Know-How excludes any Know-How in the Field of any
kind concerning generic methods of manufacturing (except as set forth in the
following paragraph) designing, developing or preparing antibodies including,
but not limited to, methods of humanizing antibodies, methods of reducing the
immunogenicity of antibodies, and methods of increasing the affinity of
antibodies.

In the event Roche or F. Roche manufactures a form or formulation of
Daclizumab for Autoimmune Indications under this Amended and Restated
Agreement that Roche or F. Roche is not otherwise manufacturing for the
Transplant Indications, PDL Know-How shall also include all Know-How in the
Field which is rightfully held by PDL or its Affiliates as of the Signing
Date, or which is developed or acquired by PDL or its Affiliates with the
right to license or sublicense during the term of this Amended and Restated
Agreement, and which Know-How in the Field is required or useful for
manufacturing such form or formulation of  Daclizumab for Autoimmune
Indications.

1.9     "PDL Patents" means all patent applications owned or controlled by
PDL ("Sole PDL Patents") and all patent applications resulting from Joint
Inventions ("Joint Roche-PDL Patents") containing claims in the Field, which
are filed prior to or during the term of this Amended and Restated Agreement
in the United States or any foreign jurisdiction, including any addition,
continuation, continuation-in-part or division thereof or any substitute
application therefor; any patent issued with respect to such patent
application, any reissue, extension or patent term extension of any such
patent, and any confirmation patent or registration patent or patent of
addition based on any such patent; and any other United States or foreign
patent or inventor's certificate covering claims in the Field.  "Queen et al.
Patents" mean those Sole PDL Patents in the ROW Territory claiming priority
under originally filed 12/28/89 as European application number 90903576.8 and
claiming priority under U.S. patent application serial nos. 290,975 filed
December 28, 1988 and 310,252 filed February 13, 1989.

1.10    "Regulatory Approval" means the granting of all governmental
regulatory approvals required, if any, for the sale of a Licensed Product in a
given country or jurisdiction within the ROW Territory.

1.11    "Research Program" means the collaborative scientific research
program between PDL and Roche which was completed in January 1995 and is
described more fully in the 1989 PDL/Roche Agreement.

1.12    "F. Roche Inventions" means any inventions in the Field which are
made during the term of this Amended and Restated Agreement by employees of
F. Roche or persons contractually required to assign or license patent rights
covering such inventions to F. Roche.

1.13    "Roche Territory" means the United States of America ("U.S." or
"U.S.A." or "United States") and its territories and possessions where the
patent laws of the United States are in force, and Canada and its territories
and possessions.  It is understood that the PDL/Roche Agreement comprises a
separate but complementary license agreement covering activities in the Roche
Territory.

1.14    "ROW Territory" means all countries of the world excluding the
Roche Territory.  The ROW Territory shall not include any countries with
respect to indications in which F. Roche grants an exclusive license to PDL
pursuant to Section 2.4.

1.15    "Valid Claim" means, as applicable, either (a) with respect to
royalties payable by F. Roche to PDL under this Agreement, a claim in any
issued patent within the PDL Patents which has not been disclaimed or held
unenforceable or invalid by a decision of a court or governmental agency of
competent jurisdiction by a decision beyond right of review, or (b) with
respect to royalties payable by PDL to F. Roche under this Agreement, a claim
in any issued patent within the Roche Patents which has not been disclaimed or
held unenforceable or invalid by a decision of a court or governmental agency
of competent jurisdiction by a decision beyond right of review.

1.16    "Roche Know-How" means all inventions, discoveries, trade secrets,
information, experience, data, formulas, procedures and results specifically
related to Daclizumab, and improvements thereon (collectively, "Daclizumab
Know-How") including any information regarding the physical, chemical,
biological, toxicological, pharmacological, clinical, and veterinary data,
dosage regimens, control assays and specifications of Daclizumab, which is
rightfully held by F. Roche or its Affiliates as of the Signing Date, or which
is developed or acquired by F. Roche or its Affiliates with the right to
license or sublicense during the term of this Amended and Restated Agreement,
and which Daclizumab Know-How is required or useful for development of a
subcutaneous formulation for Daclizumab, and for using or promoting Daclizumab
for Autoimmune Indications.

In the event that pursuant to Section 2C.2, PDL obtains a right to
manufacture Daclizumab for Autoimmune Indications, Roche Know-How shall also
include all Daclizumab Know-How which is rightfully held by F. Roche or its
Affiliates as of the Signing Date, or which is developed or acquired by F.
Roche or its Affiliates with the right to license or sublicense during the
term of this Amended and Restated Agreement, and which Daclizumab Know-How is
required or useful for manufacturing Daclizumab.

1.17    "Roche Patents" means all patent applications owned or controlled
by Roche, F. Roche or their Affiliates ("Sole Roche Patents") and all patent
applications resulting from Joint Inventions ("Joint Roche-PDL Patents")
containing claims in the Field, which are filed prior to or during the term of
this Amended and Restated Agreement in the United States or any foreign
jurisdiction, including any addition, continuation, continuation-in-part or
division thereof or any substitute application therefor; any patent issued
with respect to such patent application, any reissue, extension or patent term
extension of any such patent, and any confirmation patent or registration
patent or patent of addition based on any such patent; and any other United
States or foreign patent or inventor's certificate covering claims in the
Field.  "Sole Daclizumab Roche Patents" means those patents and applications
included within the Sole Roche Patents containing claims specifically related
to Daclizumab.

1.18     "Autoimmune Indications" means all indications that involve
pathogenic consequences, including tissue injury, produced by autoantibodies
or autoreactive T lymphocytes interacting with self epitopes, i.e.,
autoantigens.  Autoimmune Indications shall include, without limitation,
psoriasis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma,
juvenile rheumatoid arthritis, polymytosis, Type I diabetes, sarcoidosis,
Sjogrens syndrome, chronic active non-pathogenic hepatitis, non-infectous
uveitis (Behcets), aplastic anemia, regional non-pathogenic enteritis
(including ulcerative colitis, Crohn's Disease and inflammatory bowel
disease), Kawasaki's disease, post-infectious encephalitis, multiple
sclerosis, and tropic spastic paraparesis..

1.19    "Transplant Indications" means all indications that are not
Autoimmune Indications, including, without limitation, solid organ
transplantation (including  tolerance induction and xenotransplantation), bone
marrow transplantation, graft versus host disease and cell transplantation.
In any event, should a given indication have applicability in both Autoimmune
Indications and transplantation, such indication shall be deemed a Transplant
Indication and not an Autoimmune Indication; provided that an Autoimmune
Indication shall not be deemed a Transplant Indication merely because it may
cause the need for a transplant (e.g., Type I diabetes, even if it causes the
need for an organ transplant).

1.20    "Total Sales" means the gross invoice price ("GIP") of all
Licensed Products for all indications sold or otherwise disposed of for
consideration by F. Roche, its Affiliates or sublicensees (other than PDL and
its Affiliates) to independent third parties not an Affiliate of the seller,
as computed in the central F. Roche Swiss Francs Sales Statistics for the
countries concerned, whereby the amount of such sales in foreign currencies is
converted into Swiss Francs at the average rate of exchange at the time in
accordance with F. Roche's then current standard practices.

In the case of Combination Products for which the Licensed Product and
each of the other therapeutically active ingredients contained in the
Combination Product have established market prices when sold separately, Total
Sales shall be determined by multiplying the Total Sales for each such
Combination Product by a fraction, the numerator of which shall be the
established market price for the Licensed Product(s) contained in the
Combination Product, and the denominator of which shall be the sum of the
established market prices for the Licensed Product(s) plus the other active
ingredients contained in the Combination Product.  When such separate market
prices are not established, then the parties shall negotiate in good faith to
determine the method of calculating Total Sales for Combination Products.

If F. Roche or its Affiliates or sublicensees receive non-cash
consideration for any Licensed Product sold or otherwise transferred to an
independent third party not an Affiliate of the seller or transferor, the fair
market value of such non-cash consideration on the date of the transfer as
known to F. Roche, or as reasonably estimated by F. Roche if unknown, shall be
included in the definition of Total Sales.

1.21    "Total Autoimmune Sales" means the difference of Total Sales minus
Total Transplant Sales.

1.22    "Total Transplant Sales" means the portion of Total Sales derived
from Transplant Indications.

1.23    "Net Autoimmune Sales" means Total Autoimmune Sales, after
deducting, if not already deducted, from the amount invoiced:

(a)     the amounts actually allowed as volume or quantity discounts,
sales rebates (including cash discounts), price reductions, returns (including
withdrawals and recalls); and

(b)     sales, excise and turnover taxes imposed directly upon and
actually paid by F. Roche, its Affiliates or sublicensees.

In addition, there shall be deducted, to the extent not already deducted
from the amount invoiced, an amount equal to[CONFIDENTIAL TREATMENT REQUESTED]
of the Total Autoimmune Sales to cover all other expenses or discounts,
including but not limited to cash discounts, customs duties, transportation
and insurance charges and other direct expenses.

1.24    "Net Sales" means the aggregate of Net Transplant Sales and Net
Autoimmune Sales.

1.25    "PDL Development Costs" means, for a given Autoimmune Indication,
[CONFIDENTIAL TREATMENT REQUESTED] of the worldwide development costs accrued
by PDL for the development of Daclizumab.  All PDL Development Costs shall be
calculated in accordance with cost accounting methods consistently applied and
complying with generally accepted accounting principles, incurred by PDL
during a period commencing on the Signing Date and ending on the date of the
filing by F. Roche of the first (1st) application for marketing approval for
that Autoimmune Indication in a Major Country.  PDL Development Costs shall
not include any costs incurred by PDL for the purpose of manufacturing by PDL
of Daclizumab in bulk form, but shall include any costs incurred by PDL in
connection with formulation development and performance of formulation, fill
and finish, and related activities.  All PDL Development Costs that apply to
multiple Autoimmune Indications (e.g., a subcutaneous formulation of
Daclizumab) until the date of filing by F. Roche for marketing approval for an
Autoimmune Indication in a Major Country shall be allocated to the first
Autoimmune Indication to which such costs apply that F. Roche elects to market
and sell, co-market or co-promote.

1.26    "PDL Net Sales" means the GIP of Daclizumab sold or otherwise
disposed of for consideration by PDL, its Affiliates or sublicensees (other
than F. Roche and its Affiliates) to independent third parties not an
Affiliate of the seller after deducting, if not already deducted, from the
amount invoiced:

(a)     the amounts actually allowed as volume or quantity discounts,
rebates, price reductions, returns (including withdrawals and recalls); and

(b)     sales, excise and turnover taxes imposed directly upon and
actually paid by PDL, its Affiliates or sublicensees.

In addition, there shall be deducted, to the extent not already deducted
from the amount invoiced, an amount equal to [CONFIDENTIAL TREATMENT
REQUESTED] of the GIP to cover all other expenses or discounts, including but
not limited to cash discounts, custom duties, transportation and insurance
charges and other direct expenses.

In the case of Combination Products for which Daclizumab and each of the
other therapeutically active ingredients contained in the Combination Product
have established market prices when sold separately, PDL Net Sales shall be
determined by multiplying the PDL Net Sales for each such Combination Product
by a fraction, the numerator of which shall be the established market price
for Daclizumab, and the denominator of which shall be the sum of the
established market prices for Daclizumab plus the other active ingredients
contained in the Combination Product.  When such separate market prices are
not established, then the parties shall negotiate in good faith to determine
the method of calculating PDL Net Sales for Combination Products.

If PDL or its Affiliates or sublicensees receive non-cash consideration
for any units of Daclizumab sold or otherwise transferred to an independent
third party not an Affiliate of the seller or transferor, the fair market
value of such non-cash consideration on the date of the transfer as known to
PDL, or as reasonably estimated by PDL if unknown, shall be included in the
definition of PDL Net Sales.

1.27    "Major Countries" means the United Kingdom, France, Germany, Italy
and Spain.

1.28    "Cost of Goods Sold" means the manufacturing cost of unformulated
bulk Daclizumab, calculated in accordance with reasonable cost accounting
methods consistently applied by a party for its other pharmaceutical products,
provided that such methods comply with generally accepted accounting
principles.  Cost of Goods Sold shall include direct labor (including fringe
benefits), direct materials (including taxes and duties), and a reasonable
allocation of indirect labor and materials, facilities expense (including
occupancy costs and depreciation of property, plant and equipment),
administration costs and other costs allocable to the manufacturing process.

1.29    "documents" used as a verb, for example in Section 2A.5 and
similar uses, means provides factual or substantial support, which support may
include, among other things, expert opinion.

1.30    "cover" (including variations thereof such as "covering" or
"covered") as used for example in Article III and Article III-A, means that
the manufacture, use, sale or importation of a particular Licensed Product
would infringe a Valid Claim in the absence of rights under such patent(s).
The determination of whether a particular Licensed Product is covered by
particular Valid Claims shall be made on a country-by-country basis.

II.  LICENSE GRANTS
2.1     License Grant to F. Roche.  Subject to Sections 2.3, 2.4 and 5.2,
PDL grants to F. Roche and to F. Roche's Affiliates the sole and exclusive
right to the PDL Know-How and PDL Patents, but only to the extent necessary to
make, have made, use and sell Licensed Products in the Field within the ROW
Territory.  For so long as F. Roche is in compliance with its obligations
under Section 5.1, F. Roche may sublicense the right to make, have made, use
and sell Licensed Products in the Field within the ROW Territory with respect
to Transplant Indications, provided that no such sublicense shall be granted
with respect to Autoimmune Indications without first obtaining PDL's written
consent, which consent shall not be unreasonably withheld or delayed.  Any
such sublicense shall be subject to Section 3.5 hereof, and shall terminate
automatically if F. Roche shall not have remedied or initiated steps to remedy
a breach of Section 5.1 hereof, in a manner reasonably satisfactory to PDL
within sixty (60) days after receipt by F. Roche of notice of such breach from
PDL.

2.2     Identification of Patents.  Set forth on Appendix A is a list
identifying patents or patent applications which comprise PDL Patents as of
the Signing Date.  PDL shall update this list by delivering a supplement to
F. Roche no less frequently than once per year during the term of this Amended
and Restated Agreement.

2.3     License Grant to PDL.  F. Roche grants to PDL and to PDL's
Affiliates the exclusive right to Daclizumab, Roche Know-How and Roche
Patents, PDL Know-How, and PDL Patents but only to the extent necessary to
import, make, have made and use Daclizumab for the purpose of conducting
development and seeking registration of Daclizumab in Autoimmune Indications
in the ROW Territory as contemplated by this Amended and Restated Agreement.

2.4     Contingent License Grants to PDL.  Certain additional licenses are
granted by F. Roche to PDL as described in Sections 2B.8, 2B.9, 2C.2(b) and
5.2 subject to the occurrence of certain conditions.

2.5     Sublicensing by PDL.  Subject to the prior written consent of F.
Roche, which consent shall not be unreasonably withheld or delayed, PDL shall
have the right to sublicense [CONFIDENTIAL TREATMENT REQUESTED]  any exclusive
marketing rights of PDL under this Amended and Restated Agreement.

II-A.  DEVELOPMENT FOR AUTOIMMUNE INDICATIONS
2A.1    Development Responsibility.  On and after the Signing Date,  PDL
shall be solely responsible at its sole cost and expense to develop Daclizumab
for Autoimmune Indications ("AI Development"), including, without limitation,
any further preclinical studies or formulation development (such as the
development of a subcutaneous formulation) deemed required or useful by PDL
for such AI Development.  All data and information generated by such
activities shall be PDL Know-How and PDL shall have the right to publish such
data and information in accordance with Section 8.3(b).

2A.2    Transfer of Know-How.

(a)  Transfer of PDL Know-How.  During the term of this Amended and
Restated Agreement, PDL shall transfer within sixty (60) days of each June 30
and December 31, PDL Know-How which is required or useful for F. Roche to
carry out its obligations under this Amended and Restated Agreement.  PDL will
permit access by F. Roche during the AI Development at reasonable times and
with reasonable frequency to the relevant scientific personnel of PDL, but in
any event not more than once per calendar quarter.  PDL agrees to inform F.
Roche on a timely basis of all results in the Field obtained by PDL during the
AI Development to the extent such results are required or useful for F. Roche
to carry out its obligations under this Amended and Restated Agreement.

(b)     Transfer of Roche Know-How.

(i)     PDL and F. Roche shall each immediately identify a person to
coordinate communications related to review of Roche Know-How by PDL
("Coordinators").  The  Coordinators shall agree upon a period of time,
including the starting date of such period and duration of such period, during
which F. Roche shall make Roche Know-How available for PDL's review. Such
period shall occur within ninety (90) days after the Signing Date.

PDL's review of Roche Know-How in accordance with this Section 2A.2(b)
shall occur during Roche's normal business hours and at an agreed upon site(s)
of Roche.  During such review, PDL shall have the right to (i) copy such
available Roche Know-How as it deems required or useful and (ii) discuss the
available Roche Know-How with the relevant F. Roche personnel.  F. Roche shall
use its commercially reasonable efforts to answer PDL's questions related to
the available Roche Know-How, but F. Roche shall have no liability to PDL if
despite F. Roche's commercially reasonable efforts, it is unable to answer any
such questions to PDL's satisfaction; provided that F. Roche will not
intentionally withhold from PDL any material and pertinent Roche Know-How.

It is understood that Roche Know-How may be embraced within documents
that contain  information not specifically related to Daclizumab, including
information related to products of F. Roche other than Daclizumab.
Accordingly, to the extent any given document within the scope of Roche Know-
How contains information not specifically related to Daclizumab, F. Roche may
redact such information from the relevant document prior to PDL review
thereof.  To the extent any given document within the scope of Roche Know-How
contains unredacted information not specifically related to Daclizumab, PDL
shall maintain such information as Confidential Information.

(ii)    After the transfer of Roche Know-How pursuant to Section
2A.2(b)(i), upon written request by PDL, F. Roche shall, within a reasonable
time, provide PDL with Roche Know-How as is required for AI Development by any
regulatory or governmental authority in the ROW Territory if and when such
Roche Know-How is located, but F. Roche shall have no liability to PDL if
despite F. Roche's commercially reasonable efforts, it is unable to locate any
such Roche Know-How.

(iii)   Subject to Section 5.1, in no event shall there be any obligation
on the part of F. Roche to generate any new data or information related to
Licensed Products.

2A.3    Development Plan. Within sixty (60) days after the Signing Date,
PDL shall prepare and deliver to F. Roche an AI Development plan, including
intended AI Development activities and budgets for each intended AI
Development activity.  PDL shall update this plan by delivering a supplement
to F. Roche from time to time during the term of this Amended and Restated
Agrement, provided that PDL shall in any event provide a supplement within
sixty (60) days of each December 31 during the term of this Amended and
Restated Agreement.

2A.4    Reports.  PDL will provide F. Roche within forty-five (45) days of
each June 30 and December 31 during the term of this Amended and Restated
Agreement, a written report summarizing for the preceding semi-annual period
all PDL AI Development activities, including publications.  F. Roche shall
provide reports on the activities of F. Roche with respect to the development
and sales of Daclizumab in Transplant Indications and Autoimmune Indications,
if any, through the Joint Development Committee ("JDC") established pursuant
to the 1999 PDL/Roche Agreement.  PDL shall present the AI Development plans
for the ROW Territory to the JDC.

2A.5    Decisions.  PDL will make the final decision with respect to all
AI Development activities, except that F. Roche will have the right to veto
(through the JDC and subject to the decision-making process applicable to the
JDC) any AI Development activity for which F. Roche documents that such
activity is reasonably likely to have a material adverse impact on sales of
Daclizumab for Transplant Indications within the ROW Territory.  PDL will not
undertake any AI Development activity for which F. Roche documents that such
activity is reasonably likely to have a material adverse impact on sales of
Daclizumab for Transplant Indications within the ROW Territory.

2A.6    Certain Regulatory Matters.

(a)    Clinical Trials.  PDL shall have the right to file in PDL's name
Investigational New Drug Applications or corresponding filings in countries of
the ROW Territory ("INDs") for AI Development.  F. Roche shall, at no cost to
PDL, provide assistance required or useful to allow PDL to cross-reference F.
Roche filings to allow PDL to carry out without delay any related clinical
trial in the ROW Territory. PDL shall advise and consult with F. Roche with
respect to any significant issues or questions raised by any regulatory
authorities with respect to any such IND or related clinical trial.  PDL shall
provide copies to F. Roche of any such IND and any other records of
interactions with regulatory authorities (e.g., correspondence, minutes or
notes of telephone conferences or meetings, etc.) with respect to any such IND
or related clinical trials in a Major Country.  PDL and F. Roche, including
its Affiliates, shall each supply the other copies of all regulatory filings
in Major Countries related to the use of the clinical materials for AI
Development promptly after the time of such filings.

To the extent F. Roche is required under applicable law, rule or
regulation, F. Roche shall make all filings necessary to permit the use of the
clinical materials supplied by Roche or F. Roche pursuant to Section 3C.1.
PDL and F. Roche, including its Affiliates, shall each supply the other copies
of all regulatory filings related to the use of the clinical materials for AI
Development promptly after the time of such filings.

(b)     Adverse Event Reporting.  Each party shall notify the other of all
information coming into its possession concerning any and all side effects,
injury, toxicity, pregnancy or sensitivity reaction associated with commercial
or clinical uses, studies, investigations or tests with Daclizumab, throughout
the world, whether or not determined to be attributable to Daclizumab
("Adverse Event Reports").  The parties shall each identify a person to
coordinate the exchange of Adverse Event Reports ("Report Coordinators") so as
to enable timely reporting of such Adverse Event Reports to appropriate
government and regulatory authorities consistent with all laws, rules and
regulations. The Report Coordinators shall agree in writing upon formal
procedures for such exchange.
2A.7    Registration.

(a)     PDL shall notify in writing ("Filing Notice") F. Roche in the
event that PDL determines that any clinical trial results in an Autoimmune
Indication would justify filing by F. Roche in any country in the ROW
Territory of an application for Regulatory Approval for such indication.  The
Filing Notice shall be accompanied by (I) a list of countries in the ROW
Territory for which PDL is requesting such filing, (II) data and information
that PDL reasonably believes is sufficient to justify such filing, including
without limitation the clinical trial results in the specified Autoimmune
Indication, (III) the proposed labeling with respect to which PDL proposes
such filing, (IV) accrued PDL Development Costs through the most recent
calendar quarter for which PDL financial information is available prior to the
date of the Filing Notice and (V) an estimate of the PDL Development Costs to
be accrued through the expected date of first (1st) filing for Regulatory
Approval in a Major Country identified in the Filing Notice.  In any event, F.
Roche shall have the right to request, and PDL shall endeavor to timely supply
any existing additional data and information from PDL that F. Roche believes
to be reasonably required or useful to make its decision to file or not to
file hereunder.

Within sixty (60) days after receipt by F. Roche of the Filing Notice
(and accompanying information) ("Registration Review Period"), F. Roche shall
notify PDL in writing with respect to each country specified in the Filing
Notice of whether F. Roche  (i) elects to make such a filing in that country,
(ii) desires to file in that country but reasonably believes that the clinical
trial results would not justify a filing by F. Roche, including information in
reasonable detail setting forth the basis for such belief, or (iii) elects not
to make such a filing in that country (in which event F. Roche's rights to
make such filing and to market and sell Daclizumab in such country in the ROW
Territory for that Autoimmune Indication shall be deemed to revert to PDL as
provided in Section 2A.7(c)).  If F. Roche notifies PDL pursuant to (ii) of
the foregoing sentence, and if PDL disagrees with F. Roche, then F. Roche and
PDL shall submit the determination of whether the clinical trial results
support the labeling proposed by PDL in the countries identified in the Filing
Notice to an expert in regulatory matters ("Regulatory Arbiter"), including
expertise in the country(ies) in question.  The Regulatory Arbiter shall be an
individual with not less than five (5) years of regulatory approval experience
for products for use in Autoimmune Indications in the country in question and
shall not have any preexisting or prior relationship with either of the
parties within the past five (5) years.  If the parties are unable to agree
upon the Regulatory Arbiter within ten (10) business days, then each party
shall submit a list of up to three (3) individuals meeting the criteria
(including reasonable detail specifying the basis for why the individual is
appropriate to serve as the Regulatory Arbiter and a confirmation by the party
that such Arbiter is independent of the party submitting her/his name) to the
Administrator of the American Arbitration Association ("AAA Administrator") in
accordance with the AAA International Rules of Arbitration and the AAA shall
select an individual from the lists presented.  The Regulatory Arbiter shall
make a final, binding determination with respect to the submitted matter with
respect to the countries in question within thirty (30) days of submission to
the Regulatory Arbiter hereunder.  In the event that the Regulatory Arbiter
determines that the clinical trial results support the labeling proposed by
PDL in any of the countries identified in the Filing Notice, F. Roche shall
have fifteen (15) business days from such determination to elect either
Section 2A.7(i) or (iii) in each such country.  The parties shall each be
responsible for their respective costs for participation in the matter subject
to resolution by the Regulatory Arbiter and shall share equally the costs of
the Regulatory Arbiter.

For each country for which F. Roche has elected to make such a filing,
F. Roche or its Affiliates shall make such filing in all Major Countries and
Japan for which it has elected to proceed within the next ninety (90) day
period following the Registration Review Period, and in each other country for
which it has elected to proceed within the same time periods as would normally
be followed by F. Roche for additional indications of its other approved
products, but in no event more than one hundred eighty (180) days after the
Registration Review Period.  For each country in the ROW Territory for which
F. Roche has either elected not to make such a filing, has failed to make an
election within the Registration Review Period, or has made such election but
has failed to make such filing within the period specified above, F. Roche's
rights to make such filing and to market and sell Daclizumab in such country
in the ROW Territory for that Autoimmune Indication shall be deemed to revert
to PDL as provided in Section 2A.7(c).  In addition, if F. Roche has elected
pursuant to Section 2B.2 to allow PDL to (a) co-market in a country in the ROW
Territory for a specified Autoimmune Indication, PDL and F. Roche shall in the
first instance use commercially reasonable efforts to have F. Roche make such
filing and permit PDL to cross-reference the F. Roche filing in such country,
provided that if such procedure is not sufficient for PDL to market and sell
Daclizumab in such country in the ROW Territory for that Autoimmune
Indication, PDL shall have the right to make such filing in such country in
the ROW Territory for that Autoimmune Indication as provided in Section
2A.7(c) or (b) exclusively market and sell Daclizumab in a country in the ROW
Territory for a specified Autoimmune Indication, PDL shall have the right to
make such filing in such country in the ROW Territory for that Autoimmune
Indication as provided in Section 2A.7(c).

(b)     If F. Roche has elected pursuant to Section 2A.7(a) to file an
application for Regulatory Approval, PDL shall provide all assistance required
or useful to allow F. Roche to carry out such filing without delay, including
supplying relevant clinical data and promptly preparing and making any
necessary regulatory filings relating to manufacture of Daclizumab if it is
intended for PDL to conduct any manufacturing steps.  For each Major Country
and Japan in which F. Roche has filed an application for Regulatory Approval
pursuant to Section 2A.7(a), F. Roche shall diligently pursue the approval of
such application and shall advise and consult with PDL with respect to any
significant issues or questions raised by any regulatory authorities with
respect to such application.  F. Roche shall provide copies to PDL of all such
Major Country (and Japan) applications and any other records of interactions
with regulatory authorities relating to significant issues (e.g.,
correspondence, minutes or notes of telephone conferences or meetings, etc.)
with respect to such applications and Autoimmune Indications.  F. Roche shall
provide PDL with a quarterly summary and the status of all such applications,
including a summary of any significant issues and the strategy for dealing
with such issues.  The parties shall discuss in good faith the labeling for
Daclizumab to be requested for Regulatory Approval in a Major Country for a
period not to exceed thirty (30) days from the date of notification from F.
Roche that it elects to file for Regulatory Approval in a Major Country or
Japan pursuant to Section 2A.7(b).  If the parties are unable to agree upon
the labeling to be requested during such thirty (30)-day period, the parties
shall mutually agree upon a third party arbiter ("Labeling Arbiter") within
ten (10) business days following determination of the parties to have the
matter submitted to the Labeling Arbiter.  The Labeling Arbiter shall be an
individual with not less than five (5) years of marketing and/or regulatory
approval experience for products for use in Autoimmune Indications in the
country in question.   If the parties are unable to agree upon the Labeling
Arbiter within ten (10) business days, then each party shall submit a list of
up to three (3) individuals meeting the criteria (including reasonable detail
specifying the basis for why the individual is appropriate to serve as the
Labeling Arbiter and a confirmation by the party that such Arbiter is
independent of the party submitting her/his name) to the AAA Administrator in
accordance with the AAA International Rules of Arbitration and the AAA shall
select an individual from the lists presented.  The Labeling Arbiter shall
make a binding determination within thirty (30) days of the submission of the
matter to the Labeling Arbiter hereunder.  The parties shall each be
responsible for their respective costs for participation in the matter subject
to resolution by the Labeling Arbiter and shall share equally the costs of the
Labeling Arbiter.

(c)     For each Major Country and Japan for which the right to file an
application for Regulatory Approval has reverted to PDL pursuant to Section
2A.7(a) and with respect to which PDL elects to proceed with a filing for
Regulatory Approval, F. Roche shall provide all assistance required or useful
to allow PDL to assume responsibility for and to carry out such filing without
delay, including execution of any and all documents to transfer such authority
and promptly preparing and making any necessary regulatory filings relating to
manufacture of Daclizumab.  If PDL elects to proceed with such filing, PDL
shall diligently pursue the approval of such marketing applications and shall
advise and consult with F. Roche with respect to any significant issues or
questions raised by any regulatory authorities with respect to such
applications.  PDL shall provide copies to F. Roche of all such Major Country
(and Japan) applications and any other records of interactions with regulatory
authorities relating to significant issues (e.g., correspondence, minutes or
notes of telephone conferences or meetings, etc.) with respect to such
applications.

(d)     The costs of making any filing for Regulatory Approval for
Daclizumab in an Autoimmune Indication in a country in the ROW Territory shall
be allocated between the parties as follows:  (i) if the parties are co-
marketing, the costs of making any filing shall be shared equally; (ii) if the
parties are co-promoting, then the costs of making any filing shall be borne
in accordance with the profit allocation specified in the co-promotion
arrangement; or (iii) if either party is exclusively marketing and selling,
then that party will bear all of the costs of making any filing.




II-B.  COMMERCIALIZATION FOR AUTOIMMUNE INDICATIONS

2B.1    Transplant Indications. F. Roche shall continue to be responsible
for all aspects of commercialization of Licensed Products for Transplant
Indications in the ROW Territory and shall pay royalties on Net Transplant
Sales as provided in Article III.

2B.2    Autoimmune Indications.  For each country in the ROW Territory for
which F. Roche has elected to file an application for marketing approval of an
Autoimmune Indication pursuant to Section 2A.7(b), F. Roche shall notify PDL
within ninety (90) days after making such election to file whether, if such
application is approved, for that Autoimmune Indication in that country in the
ROW Territory, it elects:

(a)  to market and sell Daclizumab exclusively (in which case, Sections
2B.4(a) and 2B.6 will apply),

(b)  to co-promote Daclizumab exclusively with PDL (in which case,
Sections 2B.4(a) and 2B.7 will apply),

(c)  to co-market Daclizumab with PDL (in which case, Sections 2B.4(b)
and 2B.8 will apply), or

(d)  to license PDL exclusively to market and sell Daclizumab (in which
case, Sections 2B.4(b) and 2B.9 will apply).

For each country in the ROW Territory for which F. Roche fails to
provide notice of such election within the time specified above, PDL shall
have the sole right to market and sell Daclizumab for that Autoimmune
Indication in that country in the ROW Territory in accordance with the
provisions of Sections 2B.4(b) and 2B.9.

2B.3    One Time Elections.  It is understood and agreed that for each
Autoimmune Indication in a country in the ROW Territory, if F. Roche does not
elect to file for approval under Section 2A.7(a)(iii) or to market and sell,
co-promote or co-market under Section 2B.2(a), (b) or (c), as the case may be,
for a specified Autoimmune Indication, then F. Roche shall no longer have the
right to market and sell, co-promote or co-market Daclizumab in that country
in the ROW Territory for that Autoimmune Indication.

2B.4    Booking of Sales, Trademarks, Etc.

(a)     For each Autoimmune Indication, for all countries in the ROW
Territory in which F. Roche is exclusively promoting Daclizumab in that
country, or the parties are co-promoting Daclizumab in that country in the ROW
Territory, the parties intend (i) that F. Roche shall be responsible at its
sole cost for booking all sales of Daclizumab and for distribution of
Daclizumab and, subject to Article II-C, that Roche and its Affiliates shall
be responsible for manufacturing Daclizumab and (ii) that Daclizumab will be
marketed under the trademark "Zenapax" or such other trademark as is selected
by F. Roche.  In those countries in the ROW Territory in which PDL co-promotes
Daclizumab, PDL shall act as a sales agent for F. Roche and shall submit all
orders for Daclizumab to F. Roche and its Affiliates.

(b)     For each Autoimmune Indication, for all countries in the ROW
Territory in which PDL is exclusively promoting Daclizumab in that country in
the ROW Territory, or the parties are co-marketing Daclizumab in that country
in the ROW Territory, the parties intend (i) that each party shall be
responsible at its sole cost for booking its own sales of Daclizumab and for
its own distribution of Daclizumab, (ii) that manufacturing of Daclizumab will
be performed in accordance with Article II-C and (iii) that Daclizumab will be
marketed by each party under its own trademark.  PDL acknowledges that
"Zenapax" is a trademark of F. Roche and its Affiliates and agrees that any
PDL trademark for Daclizumab shall be selected using reasonable efforts to
avoid a trademark that is confusingly similar to "Zenapax".  If one party is
manufacturing and selling supplies of Daclizumab to the other party, it shall
accept and fill such orders on a non-discriminatory basis relative to
accepting and filling orders from its own sales force.

2B.5    Information.  In the event that F. Roche elects to exclusively
market and sell Daclizumab for Autoimmune Indications in a Major Country, F.
Roche shall provide to PDL regular, and in any event not less than semi-
annual, reports to PDL on F. Roche's efforts and plans to market and sell
Daclizumab in the Major Countries and on a summary basis for regions outside
of the Major Countries.

2B.6    Where F. Roche Promotes Alone.  For each country in the ROW
Territory for which F. Roche has elected pursuant to Section 2B.2 to
exclusively market and sell Daclizumab for a specified Autoimmune Indication
(or for which PDL has elected not to exercise co-promotion or co-marketing
rights if F. Roche has elected one of those options under Section 2B.2), F.
Roche shall use commercially reasonable efforts to diligently market and sell
Daclizumab for that Autoimmune Indication in that country in the ROW
Territory.  For each Major Country in the ROW Territory, F. Roche shall
propose by November 1 of each year a budget for that country in the ROW
Territory to be spent on marketing and sales of Daclizumab for each Autoimmune
Indication in the following calendar year, for approval by the JCC (as defined
in Section 2B.7(b)) or if no JCC exists, by each of the parties.  F. Roche
shall deliver a report to PDL by March 31 of each year detailing the level of
sales and marketing expenditure for Daclizumab for each Autoimmune Indication
during the preceding calendar year for each Major Country in the ROW
Territory. [CONFIDENTIAL TREATMENT REQUESTED]

2B.7    Where F. Roche and PDL Co-Promote.

(a)     For each country in the ROW Territory for which F. Roche has
elected pursuant to Section 2B.2 to co-promote Daclizumab with PDL for a
specified Autoimmune Indication, PDL shall notify F. Roche within thirty (30)
days after receiving the notice under Section 2B.2 from F. Roche of whether
PDL elects to co-promote Daclizumab for that Autoimmune Indication in that
country in the ROW Territory.  The terms of the co-promotion arrangement shall
be negotiated and agreed to promptly after notice from PDL hereunder, but in
any event not later than ninety (90) days following delivery of such notice.
In any event, such co-promotion arrangement shall assume a sharing of co-
promotion, marketing and selling expenses [CONFIDENTIAL TREATMENT REQUESTED],
except as may be adjusted pursuant to Section 2B.7(b).  If PDL elects not to
exercise such co-promotion rights for that Autoimmune Indication in that
country in the ROW Territory, then F. Roche shall have the sole right to
market and sell Daclizumab for that Autoimmune Indication in that country in
the ROW Territory in accordance with Section 2B.6.

(b)     Within thirty (30) days after the first election by F. Roche under
Section 2B.2(b) to co-promote Daclizumab with PDL for an Autoimmune Indication
in a country in the ROW Territory, F. Roche and PDL shall form a joint
commercialization committee (the "JCC") consisting of two representatives from
PDL and two representatives from F. Roche.  The JCC shall generally oversee
the co-promotion efforts relating to Daclizumab.  With respect to such co-
promotion efforts, the JCC shall develop a joint marketing plan, including,
but not limited to, an operational budget, addressing such issues as training
materials, training, sampling, promotional materials, product presentation,
professional educational efforts and detailing.  In the case in which the JCC
determines that it is deadlocked, each party shall thereafter within ten (10)
business days designate a representative at the Vice President level or higher
to discuss the dispute.  The designated representatives shall arrange promptly
to meet and discuss in good faith a resolution of the dispute.  If the
designated representatives are unable to resolve the matter in question within
thirty (30) days of the designation of the representatives, then to the extent
the matter affects any country in the ROW Territory in which F. Roche is co-
promoting Daclizumab for the Autoimmune Indication in question, F. Roche shall
have the final decision with respect to activities proposed to be conducted by
F. Roche.  Notwithstanding the foregoing, if the deadlock referenced above
relates to a budget for co-promotion, then although F. Roche may make the
final decision, PDL shall have the right to decrease its [CONFIDENTIAL
TREATMENT REQUESTED]

(c)     In each country in the ROW Territory for which PDL has elected to
co-promote Daclizumab for a specified Autoimmune Indication, PDL and F. Roche
shall use commercially reasonable efforts to diligently market and sell
Daclizumab for that Autoimmune Indication in that country in the ROW
Territory.  For each such country in the ROW Territory, the JCC, as provided
in Section 2B.7(b), shall mutually agree upon an annual marketing plan by
November 1 of each year which shall include a budget for that country in the
ROW Territory to be spent on marketing and sales of Daclizumab for that
Autoimmune Indication in the following calendar year.  Each party shall
deliver a report to the other party by March 31 of each year detailing the
level of sales and marketing efforts for Daclizumab for that Autoimmune
Indication during the preceding calendar year for each such country in the ROW
Territory.  If either party fails to expend [CONFIDENTIAL TREATMENT REQUESTED]
of the agreed upon expenditure by that party for any country in the ROW
Territory for two (2) consecutive calendar years, then the other party shall
have the option to solely promote Daclizumab in such country in the ROW
Territory for that Autoimmune Indication in accordance with Section 2B.6 or
2B.9, as the case may be, by notifying the party failing to meet its
expenditure obligations within ninety (90) days after receipt of the report
from the other party indicating such failure.

2B.8    Where F. Roche and PDL Co-Market. For each country in the ROW
Territory for which F. Roche has elected pursuant to Section 2B.2 to co-market
Daclizumab with PDL for a specified Autoimmune Indication, PDL shall notify F.
Roche within thirty (30) days after receiving the notice under Section 2B.2
from F. Roche of whether PDL elects to co-market Daclizumab for that
Autoimmune Indication in that country in the ROW Territory.  If PDL elects not
to exercise such co-marketing rights for that Autoimmune Indication in that
country in the ROW Territory, then F. Roche shall have the sole right to
market and sell Daclizumab for that Autoimmune Indication in that country in
the ROW Territory in accordance with Section 2B.6.

In each country in the ROW Territory for which PDL has elected to co-
market Daclizumab for a specified Autoimmune Indication, (a) PDL and F. Roche
shall act independently with respect to their own marketing and sales of
Daclizumab for that Autoimmune Indication in that country in the ROW
Territory, (b) the provisions of Section 2B.4(b) shall apply and (c) PDL shall
automatically be granted a nonexclusive license under all Roche Patents, Roche
Know-How, PDL Patents and PDL Know-How to the extent required or useful for
the purposes of carrying out such PDL marketing and selling activities.  F.
Roche or its Affiliates will supply commercial supplies of Daclizumab to PDL
in accordance with Article II-C.  Nothing in this Amended and Restated
Agreement shall be deemed to require the parties to share or provide any
information in contravention of any applicable law, rule or regulation.

2B.9    Where PDL Promotes Alone. For each country in the ROW Territory
for which F. Roche has elected pursuant to Section 2B.2 to allow PDL to
exclusively market and sell Daclizumab for a specified Autoimmune Indication,
or has not elected to file for marketing approval pursuant to Section
2A.7(a)(iii), or for which the option for PDL to exclusively market and sell
Daclizumab pursuant to Section 2B.2, 2B.6 or 2B.7 has been triggered, if PDL
then exercises its option to be the sole marketing and selling party in that
country in the ROW Territory for that Autoimmune Indication, then PDL shall
use commercially reasonable efforts to diligently market and sell Licensed
Products for that Autoimmune Indication in that country in the ROW Territory.
For each country in the ROW Territory for which PDL has exercised its option
to be the exclusive marketing and selling party of Daclizumab for a specified
Autoimmune Indication, upon such exercise, (a) the provisions of Section
2B.4(b) shall apply and (b) PDL shall automatically be granted a nonexclusive
license under all Roche Patents, Roche Know-How, PDL Patents and PDL Know-How
to the extent required or useful for the purposes of carrying out such PDL
marketing and selling activities.  In addition, F. Roche or its Affiliates
will supply commercial supplies of Daclizumab to PDL in accordance with
Article II-C.

II-C.  MANUFACTURING
2C.1    Clinical Supplies.

(a)     Supply.  Roche and its Affiliates have agreed and shall use
commercially reasonable efforts to provide clinical supplies of Daclizumab to
PDL for development for Autoimmune Indications in accordance with the 1999
PDL/Roche Agreement.  Nothing herein shall be deemed to limit or extend the
obligations of Roche and F. Roche and its Affiliates with respect to such
efforts.

(b)     Formulations.  In the event PDL requests Daclizumab in a
formulation that F. Roche is not otherwise manufacturing for the Transplant
Indications, and F. Roche supplies such form or formulation (rather than only
unformulated bulk Daclizumab), PDL shall pay to F. Roche for such supplies an
amount equal to F. Roche's Cost of Goods Sold (which shall be zero (0) to the
extent provided without charge under the 1999 PDL/Roche Agreement) plus
[CONFIDENTIAL TREATMENT REQUESTED] of F. Roche's costs of performing such
formulation work.  In any event, PDL shall not be obligated to have F. Roche
perform such form or formulation work.

2C.2    Commercial Manufacturing.

(a)     Supply.  Subject to Section 2C.2(b), F. Roche shall use
commercially reasonable efforts to ensure supply of requirements for
Daclizumab in one of the following forms if neither Roche nor F. Roche
manufactures in the formulation desired by PDL for use or sale in the ROW
Territory:  (a) finished product form or formulated bulk form, if Roche or F.
Roche then manufactures in the formulation desired by PDL, or (b) unformulated
bulk form.

(b)     PDL Right to Manufacture.

[CONFIDENTIAL TREATMENT REQUESTED]

(iii)  Other Manufacturing Rights.  Notwithstanding the foregoing, the
parties acknowledge and agree that if PDL exercises its right or obtains the
right to manufacture Daclizumab under Section 2.3(c) of the 1999 PDL/Roche
Agreement, F. Roche hereby grants and PDL accepts a nonexclusive worldwide
license to import, make and have made Daclizumab in the ROW Territory.

(c)     Transfer Pricing.

(i)  In the event that PDL has either (A) the exclusive right to make
and have made Daclizumab for Autoimmune Indications, or (B) the right to
perform formulation, fill and finish work for the final product version of
Daclizumab for any indications, PDL shall use commercially reasonable efforts
to supply worldwide requirements for Daclizumab for those indications.  In
such event, PDL shall transfer such Daclizumab to F. Roche at a price
calculated as follows:
[CONFIDENTIAL TREATMENT REQUESTED].

(ii)  If Roche or F. Roche continues to supply Daclizumab to PDL and PDL
is booking sales in any country under this Amended and Restated Agreement,
then the parties shall negotiate in good faith to enter into a separate supply
agreement which shall provide for a price to PDL calculated as follows:

[CONFIDENTIAL TREATMENT REQUESTED]

For purposes of the foregoing calculation, references to F. Roche shall mean
F. Roche and its Affiliates, as applicable.  The supply agreement shall also
include procedures for PDL submitting its requirements to Roche or F. Roche
for all indications with respect to which PDL has the right to develop, market
and sell under this Amended and Restated Agreement.  Such procedures shall
include PDL providing (a) annual non-binding forecasts of its requirements and
(b) firm purchase commitments a mutally acceptable period, but in any event
not less than six (6) months prior to the time the order must be delivered to
PDL by Roche or F. Roche.

III.  ROYALTIES ON TRANSPLANT SALES, ETC.
3.1     Royalties on Transplant Sales.  Subject to Article III-A, F. Roche
agrees to pay PDL royalties on Net Transplant Sales in the ROW Territory
according to the schedule and terms set forth below:

(a)     Years 1 through 3.  Prior to and for the first three (3) years
following Initial Commercialization of a particular Licensed Product, F. Roche
shall pay PDL royalties on sales of that product at a rate determined by the
sum of [CONFIDENTIAL TREATMENT REQUESTED]  (such sum, the "Royalty Setting
Sales"), with the applicable royalty based on such Royalty Setting Sales
determined as follows:

Royalty Setting Sales ($ in
millions)
Royalty Rate


Up to and including
[CONFIDENTIAL TREATMENT
REQUESTED]
[CONFIDENTIAL TREATMENT
REQUESTED]
Up to and including
[CONFIDENTIAL TREATMENT
REQUESTED]
[CONFIDENTIAL TREATMENT
REQUESTED]
Up to and including
[CONFIDENTIAL TREATMENT
REQUESTED]
[CONFIDENTIAL TREATMENT
REQUESTED]


Amount in excess of
[CONFIDENTIAL TREATMENT
REQUESTED]
[CONFIDENTIAL TREATMENT
REQUESTED]


Over [CONFIDENTIAL TREATMENT
REQUESTED]
[CONFIDENTIAL TREATMENT
REQUESTED]
For purposes of computing aggregate annual worldwide Royalty Setting
Sales, the relevant portion of F. Roche's Net Sales in the ROW Territory will
be combined with the relevant portion of the Net Sales of F. Roche's
Affiliates and sublicensees for all countries outside of the ROW Territory.
This same understanding is being incorporated into the 1999 PDL/Roche
Agreement.

(b)     Years 4 and Succeeding.  For the fourth and each succeeding year
following Initial Commercialization, F. Roche shall pay PDL royalties in
accordance with the provisions of Section 3.1(a) for Net Transplant Sales in a
particular country, provided either (i) the Licensed Product or its method of
manufacture (wherever actually manufactured) is covered by a Valid Claim in
the country of sale, or (ii) the Licensed Product is manufactured in a country
where the method of manufacture is covered by a Valid Claim (together, (i) and
(ii) are referred to as the "Patentability Criteria").

Subject to Section 3.2 below, if neither of the Patentability Criteria
have been satisfied, then F. Roche shall pay PDL a royalty rate of
[CONFIDENTIAL TREATMENT REQUESTED] of the Net Transplant Sales in the country
of sale for the duration of this Amended and Restated Agreement or until such
time as one of the Patentability Criteria is satisfied, at which time F. Roche
shall resume paying PDL royalties at the rates specified in Section 3.1(a)
above.

(c)     [CONFIDENTIAL TREATMENT REQUESTED]

(d)     Antibodies in the Field Not Provided or Developed by PDL.  In
consideration of the disclosure to F. Roche of PDL Know-How and cell lines as
provided for herein, F. Roche agrees that products incorporating or using
Antibodies in the Field which are not provided or developed by PDL shall
nevertheless be presumed to utilize PDL Know-How, with such presumption being
rebuttable by clear and convincing evidence with respect to sales of such
products made in those countries in the European Community, and such
presumption being conclusive as between the parties hereto with respect to
sales of such products made anywhere else within the ROW Territory.
Accordingly, F. Roche shall pay PDL royalties on sales of each such product in
the ROW Territory (except for sales with respect to which the above rebuttable
presumption has in fact been refuted by F. Roche) for a period of
[CONFIDENTIAL TREATMENT REQUESTED] from Initial Commercialization of such
product in accordance with the terms of this Section 3.1 or Article III-A, as
appropriate, and such sales shall constitute "Net Transplant Sales" if sold
for Transplant Indications or "Net Autoimmune Sales" if sold for Autoimmune
Indications.

3.2     De Facto Exclusivity.  For purposes of this Article III, the term
"de facto exclusivity" means that F. Roche, together with its Affiliates and
sublicensees, controls at least [CONFIDENTIAL TREATMENT REQUESTED] of the
market for a particular Licensed Product in a country as measured by unit
sales.  If neither of the Patentability Criteria have been satisfied and
F. Roche does not enjoy de facto exclusivity for a particular Licensed Product
in a particular country at any time after [CONFIDENTIAL TREATMENT REQUESTED]
following Initial Commercialization of such Licensed Product, then F. Roche
shall pay PDL [CONFIDENTIAL TREATMENT REQUESTED] of the Net Transplant Sales
of such Licensed Product in the country of sale until the tenth anniversary of
Initial Commercialization, or until F. Roche shall acquire de facto
exclusivity for that product or until such time as either of the Patentability
Criteria is satisfied (at which time F. Roche shall resume paying PDL
royalties at the rates specified in Sections 3.1(a) or (b) above, whichever is
applicable).  Valid Claims and de facto exclusivity are to be determined on a
country-by-country basis.

3.3     Foreign Filing Expenses Credited Against Royalties.  F. Roche
shall have the right to credit [CONFIDENTIAL TREATMENT REQUESTED] of all
Transplant Foreign Filing Expenses (as defined in Section 5.3 below) actually
paid to PDL, less credits already taken under the 1989 F. Roche Agreement,
against future royalties due to PDL pursuant to this Article III provided that
such credits, when added to the offset provided for in Section 3.4 below, may
not reduce the royalties to be paid to PDL to less [CONFIDENTIAL TREATMENT
REQUESTED] of the amount which would otherwise be due pursuant to Section 3.1
hereof.

3.4     Offset for Third Party Licenses.

(a)     If PDL and F. Roche agree in writing that either party must obtain
a license from an independent third party in order for F. Roche to
manufacture, use or sell a Licensed Product in the ROW Territory and if PDL
and F. Roche agree upon the terms of such license ("Third Party License"),
then the parties shall [CONFIDENTIAL TREATMENT REQUESTED].  Such cost includes
license fees and any other fixed costs associated with the Third Party License
as well as any royalties.  The parties then shall, within thirty (30) days,
reimburse each other in the manner necessary to effect a [CONFIDENTIAL
TREATMENT REQUESTED] sharing of such license fees and other fixed costs.

(b)     PDL's share of the royalties portion of the cost of any Third
Party License, shall be (i) accrued against and deducted from any royalties
due to PDL from F. Roche pursuant to Sections 3.1, 3.2 and 3A.4 if F. Roche
pays the royalties due under the Third Party License to such third party, and
(ii) accrued in favor of and added to any royalties due to PDL from F. Roche
pursuant to Sections 3.1, 3.2 and 3A.4 if PDL pays the royalties due under the
Third Party License to such third party; provided, however, that this addition
or offset shall not cause PDL's royalties to be reduced under the schedule set
forth in Section 3.1 to less [CONFIDENTIAL TREATMENT REQUESTED] of Net
Transplant Sales in any year, or under Sections 3.1(b) and 3.2 to less
[CONFIDENTIAL TREATMENT REQUESTED] if F. Roche has de facto exclusivity and
[CONFIDENTIAL TREATMENT REQUESTED] if F. Roche does not have de facto
exclusivity, and provided further, that F. Roche's total royalty obligations
to PDL under Sections 3.1 and 3.2 when added to those royalties payable to
third parties pursuant to Third Party Licenses [CONFIDENTIAL TREATMENT
REQUESTED] of Net Transplant Sales in any year.

3.5     Sublicenses.  Any Net Sales of an F. Roche sublicensee shall be
treated as Net Sales of F. Roche for purposes of royalty payments hereunder.
If F. Roche shall grant any sublicenses under this Amended and Restated
Agreement, then F. Roche shall obtain the written commitment of such
sublicensees to abide by all applicable terms and conditions of this Amended
and Restated Agreement and F. Roche shall remain responsible to PDL for the
performance of any and all terms by such sublicensee.  All such sublicenses
shall terminate on termination of this Amended and Restated Agreement.

3.6     Royalties upon Termination.  If this Amended and Restated
Agreement is terminated pursuant to Sections 7.2, 7.3 or 7.4 below, F. Roche
shall continue to pay PDL any royalties earned pursuant to this Article III or
Article III-A prior to the date of termination and any royalties earned
thereafter as a result of sales under Section 7.5.

III-A.  ROYALTIES AFTER AUTOIMMUNE APPROVAL

3A.1    Forecasts.  To the extent permissible under applicable law, F.
Roche shall provide forecast information regarding the estimated sales of
Daclizumab for an Autoimmune Indication in the ROW Territory as set forth in
this Section 3A.1; provided that if applicable laws prohibit the sharing of
such forecast information, the parties shall discuss in good faith an
alternative basis for calculating and verifying the Blended Rate (as defined
below) applicable for the Forecast Periods (as defined below) in question.

(a)  Initial Forecast Period.  Within sixty (60) days after the first
filing for Regulatory Approval of Daclizumab for an Autoimmune Indication in
the ROW Territory by F. Roche or its Affiliates, F. Roche shall provide PDL
[CONFIDENTIAL TREATMENT REQUESTED] (the "Initial Forecast Period") of the
following:

(i)  if F. Roche expects to elect to make the same election under
Section 2B.2(a), (b) or (c) for all countries of the ROW Territory
(including those countries not identified with the Filing Notice), then
F. Roche's best good faith estimate of its expected sales of Daclizumab
for the ROW Territory for that Autoimmune Indication for the Initial
Forecast Period (it being understood that such stated expectation shall
not be binding upon F. Roche), or

(ii)  if F. Roche expects not to elect to make the same election under
Section 2B.2(a), (b) or (c) for all countries of the ROW Territory
(including those countries not identified with the Filing Notice), then
for each country in the ROW Territory, F. Roche's best good faith
estimate of when it would make an election under Section 2B.2 for that
Autoimmune Indication, which election it expects to make, and its
expected sales of Daclizumab in that country for that Autoimmune
Indication for the Initial Forecast Period (it being understood that
such stated expectation shall not be binding upon F. Roche); and

(iii)  F. Roche's best good faith estimate of its expected total Net
Transplant Sales for the ROW Territory and worldwide for all Licensed
Products for the Initial Forecast Period (it being understood that such
stated expectation shall not be binding upon F. Roche).

(b)  Subsequent Forecast Periods.  The Initial Forecast Period shall end
upon the earliest of
(i) the end of the term specified in Section 3A.1(a),

(ii) the end of the calendar quarter during which Regulatory Approval
occurs for a second Autoimmune Indication for which F. Roche has elected
to market and sell exclusively, co-promote or co-market Daclizumab under
Section 2B.2(a), (b) or (c), or

(iii) the end of the calendar quarter during which Regulatory Approval
occurs in a Major Country for the initial Autoimmune Indication for
which F. Roche has elected to market and sell exclusively, co-promote or
co-market Daclizumab under Section 2B.2(a), (b) or (c) but had
previously not expected to make such election under Section 3A.1(a)(ii).

By way of clarification and without limitation, if F. Roche specifies
that it expects to elect in all countries of the ROW Territory pursuant to
Section 3A.1(a)(i), then Section 3A.1(b)(iii) above shall not apply.  By way
of illustration and without limitation, the following examples illustrate two
cases in which a new Blended Rate would apply due to the application of
Section 3(b)(iii):

(A)  Example 1.  If F. Roche specifies pursuant to a Filing Notice that
it expects to elect in Switzerland, France and Germany pursuant to
Section 3A.1(a)(ii) (i.e., for less than all of the Major Countries),
and F. Roche receives Regulatory Approval in the United Kingdom (i.e., a
Major Country in which F. Roche did not expect to elect to market
exclusively, co-market or co-promote), then Section 3A.1(b)(iii) above
would apply and the Initial Forecast Period would end as of the date of
such Regulatory Approval in the United Kingdom.

(B)  Example 2.  If F. Roche receives a Filing Notice only for
Switzerland and elects to file in Switzerland but specifies that it
expects not to make the same election in any or less than all of the
Major Countries pursuant to Section 3A.1(a)(ii), and F. Roche thereafter
receives Regulatory Approval in a Major Country in which F. Roche did
not expect to elect to market exclusively, co-market or co-promote, then
Section 3A.1(b)(iii) above would apply and the Initial Forecast Period
would end as of the date of such Regulatory Approval in the first Major
Country or in the first Major Country in which F. Roche specified that
it would not make the same election as it made in Switzerland, as the
case may be.

Each subsequent Forecast Period (as defined below) shall begin upon the
end of the immediately preceding Forecast Period and shall end upon the
earliest of

(I) the end of [CONFIDENTIAL TREATMENT REQUESTED] quarters after the end
of the prior Forecast Period,

(II) the end of the calendar quarter during which Regulatory Approval
occurs for the next Autoimmune Indication for which F. Roche has elected
to market and sell exclusively, co-promote or co-market Daclizumab under
Section 2B.2(a), (b) or (c) or

(III) the end of the calendar quarter during which F. Roche elects to
file for Regulatory Approval in a Major Country for an Autoimmune
Indication with respect to which F. Roche has previously elected to
market and sell exclusively, co-promote or co-market Daclizumab under
Section 2B.2(a), (b) or (c) in less than all Major Countries.

Each such period and the Initial Forecast Period are referred to as a
"Forecast Period".

Within sixty (60) days after the filing by F. Roche or its Affiliates
for Regulatory Approval of Daclizumab for an additional Autoimmune Indication
in the ROW Territory or for an additional Major Country by F. Roche or its
Affiliates (if such a filing is the triggering event of the end of a Forecast
Period) or within sixty (60) days prior to the end of the Forecast Period (if
it is to end [CONFIDENTIAL TREATMENT REQUESTED] after it began), F. Roche
shall provide PDL with its best good faith estimates for the next Forecast
Period of the following:

(i)  for each Autoimmune Indication for which F. Roche has made an
election under Section 2B.2 (a), (b) or (c), if F. Roche expects to
elect to make the same election for all countries of the ROW Territory
for that Autoimmune Indication, then F. Roche's best good faith estimate
of its expected sales of Daclizumab for the ROW Territory for that
Autoimmune Indication for the next Forecast Period (it being understood
that such stated expectation shall not be binding upon F. Roche), or

(ii) for each Autoimmune Indication for which F. Roche has made an
election under Section 2B.2 (a), (b) or (c), if F. Roche expects not to
elect to make the same election under Section 2B.2 (a), (b) or (c) for
all countries of the ROW Territory, then for each country in the ROW
Territory, F. Roche's best good faith estimate of when it would make an
election under Section 2B.2 for that Autoimmune Indication (if not
already made), which election it expects to make, and its expected sales
of Daclizumab in that country for that Autoimmune Indication for the
next Forecast Period (it being understood that such stated expectation
shall not be binding upon F. Roche), and

(iii) F. Roche's best good faith estimate of its expected total Net
Transplant Sales for the Territory and worldwide for all Licensed
Products for the next Forecast Period (it being understood that such
stated expectation shall not be binding upon F. Roche).

3A.2  Blended Rate.  Together with each forecast by F. Roche delivered
under Section 3A.1, F. Roche shall deliver a proposed royalty rate, as well as
the basis for its calculation, to be applied to all Net Sales of Licensed
Products in the ROW Territory during the corresponding Forecast Period by F.
Roche, its Affiliates and sublicensees.  Such rate shall take into account the
forecasted Net Transplant Sales and the applicable royalty rates under Section
3.1, forecasted Net Autoimmune Sales, Reimbursable Development Costs and
applicable royalty rates specified in Section 3A.3.  PDL shall notify F. Roche
within thirty (30) days after receipt of F. Roche's proposed royalty rate and
the basis for its calculation of whether it accepts such rate or not.  If PDL
disagrees with the proposed rate, the parties each shall submit their proposed
rate to an arbiter in accordance with the procedures described in Section
3A.6(c).  The royalty rate as accepted by PDL or determined by such arbiter
shall be the "Blended Rate" and shall be applied to Net Sales of Licensed
Products beginning with the first calendar quarter of the corresponding
Forecast Period.  For purposes of the calculations hereunder, once F. Roche's
obligations to pay royalties to PDL have expired under Section 3.1(c), that
component of the calculation of the royalties on Net Transplant Sales for
purposes of calculating the Blended Rate shall be deemed to equal zero (0).

3A.3  Royalty Rates.  For purposes of calculating the Blended Rate and
for performing the reconciliation under Section 3A.7, the following terms and
royalty rates shall apply:

(a)  Transplant Sales.  PDL shall be entitled to royalties on all Net
Transplant Sales at the rate calculated in accordance with Section 3.1.

(b)  Autoimmune Sales, Development Costs.  PDL shall be entitled to
reimbursement of and/or credit for the Reimbursable Development Costs by means
of a royalty on Net Autoimmune Sales at a higher "initial royalty rate" until
all Reimbursable Development Costs have been reimbursed to PDL and thereafter
at a "maintenance royalty rate" as described below. In the event that the
royalties for any Forecast Period are insufficient to fully reimburse PDL for
any and all Reimbursable Development Costs, PDL shall be entitled to a credit
in the subsequent Forecast Period for all such unreimbursed amounts.  The
applicable royalty rates on Net Autoimmune Sales shall depend for each country
in the ROW Territory and for each Autoimmune Indication on whether F. Roche
markets and sells exclusively or PDL co-promotes or co-markets with F. Roche
and shall be determined as follows:

(i)  Roche Markets Exclusively or Co-Markets.  For each country in the
ROW Territory and each Autoimmune Indication, if F. Roche markets and
sells exclusively or co-markets Daclizumab with PDL, Net Autoimmune
Sales by F. Roche, its Affiliates and sublicensees for that Autoimmune
Indication in that country in the ROW Territory shall bear royalties to
PDL at an initial royalty rate of fifty percent (50%) and a maintenance
royalty rate of thirty-two percent (32%).

(ii)  Roche and PDL Co-Promote.  For each country in the ROW Territory
and each Autoimmune Indication, if F. Roche and PDL co-promote
Daclizumab, Net Autoimmune Sales by F. Roche, its Affiliates and
sublicensees for that Autoimmune Indication in that country in the ROW
Territory shall bear royalties to PDL at an initial royalty rate of
fifty percent (50%) and a maintenance royalty rate of forty percent
(40%).  Such royalty rates assume a sharing of co-promotion expenses of
[CONFIDENTIAL TREATMENT REQUESTED] and shall be subject to adjustment in
the event of a different allocation between the parties as may be agreed
upon in accordance with Section 2B.7(b).

3A.4    Royalty Payments.  Beginning with the calendar quarter in which
the first Regulatory Approval occurs for Daclizumab for an Autoimmune
Indication in the ROW Territory for which F. Roche or its Affiliates has
elected to exclusively promote, co-promote or co-market Daclizumab, F. Roche
shall pay royalties to PDL on all Net Sales of Licensed Products in the ROW
Territory at the Blended Rate, rather than at the rates specified in Article
III, except as adjusted pursuant to Section 3.4.  F. Roche shall provide
quarterly reports in accordance with the procedures outlined in Article IV.

3A.5    Reimbursable Development Costs.  With respect to each Autoimmune
Indication, within thirty (30) days after the date of the first filing by F.
Roche of an application for Regulatory Approval for that Autoimmune Indication
in a Major Country, PDL shall provide F. Roche with the amount of PDL
Development Costs through the filing date for Regulatory Approval for that
Autoimmune Indication and for all other Autoimmune Indications to the extent
not previously reimbursed by F. Roche.  A portion of such costs ("Reimbursable
Development Costs") as calculated below shall be taken into account in setting
the Blended Rate pursuant to Section 3A.2, and shall be reimbursed to PDL
through the payments to be made to PDL pursuant to Section 3A.4.  The
Reimbursable Development Costs shall be calculated by the formula
[CONFIDENTIAL TREATMENT REQUESTED]

[CONFIDENTIAL TREATMENT REQUESTED]

[CONFIDENTIAL TREATMENT REQUESTED]

[CONFIDENTIAL TREATMENT REQUESTED]

3A.6    Records.  PDL agrees to keep and cause its Affiliates and third
parties acting on its behalf to keep full, clear and accurate records of the
Reimbursable Development Costs until reimbursed to PDL pursuant to Article
III-A, but in any event for a period of at least three (3) years or such
longer period as may coincide with PDL's internal record policy.  PDL further
agrees to permit such books and records to be examined by an independent
accounting firm selected by F. Roche from time to time to the extent necessary
to verify the PDL Development Costs.  Unless F. Roche obtains the prior
written consent of PDL, such accounting firms must be selected from among the
five (5) largest accounting firms in the Major Countries.  Such examination is
to be made at the expense of F. Roche, except in the event that the results of
the audit reveal a discrepancy in favor of PDL of [CONFIDENTIAL TREATMENT
REQUESTED] or more over the period being audited, in which case reasonable
audit fees for such examination shall be paid by PDL.

3A.7  Periodic Adjustment and Reconciliation.

(a)     Within forty-five (45) days following the end of each Forecast
Period (including the Initial Forecast Period), F. Roche shall provide PDL
with a written summary ("Proposed Allocation") covering for the ROW Territory
and for the entire immediately preceding Forecast Period the following:

(i)  Total Sales and Net Sales,

(ii)  the total Reimbursable Development Costs that has been
reimbursed to PDL through the Blended Rate royalty payments,

(iii)  Net Transplant Sales by year and the applicable royalties
that would have applied as calculated under Article III,

(iv)  Net Autoimmune Sales by country in the ROW Territory and by
Autoimmune Indication, and the applicable royalties that would
have applied in accordance with Section 3A.3,

(v)  royalties paid by F. Roche and PDL under Third Party Licenses
pursuant to Section 3.4,

(vi)  the total royalties (i.e., the sum of clauses (iii) and (iv)
above) that otherwise would have been due to PDL for the
Forecast Period for Net Sales of Licensed Products in the ROW
Territory, and the difference of such amount less the actual
royalties paid to PDL for the Forecast Period through use of
the Blended Rate pursuant to Section 3A.4 (the "Reconciliation
Amount"), and

(vii)  any additional information F. Roche has available and may
be reasonably required or useful to determine the proposed
allocation.

PDL shall have a period of sixty (60) days after receipt to review F.
Roche's Proposed Allocation.  During the review period, qualified
representatives of PDL and F. Roche shall consult with one another to address
any questions regarding the preparation and detail of the summaries provided
pursuant to this Section 3A.7(a).

(b)  PDL Agreement.  If PDL does not object to F. Roche's Proposed
Allocation within such sixty (60)-day period, then F. Roche shall, within ten
(10) business days following the earlier of (i) confirmation from PDL that it
does not object to the F. Roche Proposed Allocation or (ii) the expiration of
the sixty (60)-day period, prepare a final reconciliation of Total Sales for
the Forecast Period in question, including the information listed in Section
3A.6(a).  If the Reconciliation Amount is positive, such final reconciliation
shall be accompanied by payment of the Reconciliation Amount to PDL.  If the
Reconciliation Amount is negative, then F. Roche shall be entitled to a credit
equal to the Reconciliation Amount against future royalty payments to PDL,
provided that such credits, when added to any other offsets under this Amended
and Restated Agreement, may not reduce the royalties to be paid to PDL in any
period to less than [CONFIDENTIAL TREATMENT REQUESTED] of the royalties which
would otherwise be due to PDL for the Forecast Period.  All Reimbursable
Development Costs not reimbursed to PDL for the applicable Forecast Period
shall be carried over to the subsequent Forecast Period and shall be taken
into account in calculating the Blended Rate for the subsequent Forecast
Period.

(c)  PDL Disagreement.  If PDL objects to F. Roche's Proposed
Allocation, then PDL shall reply in writing specifying its objection and PDL's
estimate of the appropriate allocation.  Within ten (10) business days of the
written notice from PDL, each of the parties shall designate a representative
at the Vice President level or higher to discuss the disputed allocation.  The
designated representatives shall arrange promptly to meet and discuss in good
faith a resolution of the dispute.  If the designated representatives are
unable to resolve the matter in question within thirty (30) days of the
designation of the representatives, then PDL shall have thirty (30) days
thereafter to notify F. Roche that it elects to have the matter submitted to
determination and/or audit by an independent third party (i.e., such third
party has not had a financial or other relationship with either party during
the preceding five (5) years) who is knowledgeable about marketing and sales
of pharmaceutical products in the transplant and/or Autoimmune Indications and
may also be an auditing organization ("Allocation Arbiter") and selected by
the parties' designated representatives.  If the designated representatives
are unable to agree on an Allocation Arbiter within thirty (30) days of the
notification from PDL hereunder, the representatives shall each submit a list
of up to five (5) individuals whom the representative believes meets the
criteria set forth above to the Administrator of the American Arbitration
Association ("AAA Administrator") in accordance with the AAA International
Rules of Arbitration and the AAA shall select an individual from the lists
presented.  The AAA Administrator shall select an individual from one of the
lists to serve as the Allocation Arbiter and such selection shall be binding
upon the parties.

If PDL fails to so notify F. Roche, then PDL shall be deemed to have
agreed to F. Roche's Proposed Allocation and the parties shall proceed in
accordance with Section 3A.6(b).  If PDL elects to submit the matter to the
Allocation Arbiter, each of the parties shall submit to and/or provide access
to the Allocation Arbiter all books and records of a party (including any
relevant surveys that may be conducted by or for a party for submission
hereunder) that the Allocation Arbiter deems reasonably required in order to
make a determination regarding the allocation hereunder.  Such examination
and/or audit is to be made confidentially and at the expense of PDL, except in
the event that the Allocation Arbiter's determination reveals that F. Roche's
Proposed Allocation understated Net Sales or Net Autoimmune Sales by
[CONFIDENTIAL TREATMENT REQUESTED] or more, then the expense of the
examination and/or audit shall be paid by F. Roche.  The determination of the
Allocation Arbiter shall be final and binding on both parties for the Forecast
Period in question.

Within ten (10) business days following the resolution of any
disagreement regarding F. Roche's Proposed Allocation as provided under this
Section 3A.6(c), F. Roche shall prepare a final reconciliation of Total Sales
for the Forecast Period in question, including the information listed in
Section 3A.6(a).  If the Reconciliation Amount is positive, such final
reconciliation shall be accompanied by payment of the Reconciliation Amount to
PDL.  If the Reconciliation Amount is negative, then F. Roche shall be
entitled to a credit equal to the Reconciliation Amount against future royalty
payments to PDL, provided that such credits, when added to any other offsets
under this Amended and Restated Agreement, may not reduce the royalties to be
paid to PDL in any period to less than [CONFIDENTIAL TREATMENT REQUESTED] of
the total royalties which would otherwise be due to PDL.  All Reimbursable
Development Costs not reimbursed to PDL for the applicable Forecast Period
shall be carried over to the subsequent Forecast Period and shall be taken
into account in calculating the Blended Rate for the subsequent Forecast
Period.

3A.7    Royalties to F. Roche.

(a)     Royalty Rate.  In the event that PDL obtains rights under this
Amended and Restated Agreement to co-market with F. Roche or to exclusively
market and sell Daclizumab for specified Autoimmune Indications in any
countries in the ROW Territory, PDL shall pay F. Roche royalties on PDL Net
Sales of Daclizumab in those countries at a rate of eight percent (8%).

(b)     Other Royalty Terms. In the event that PDL becomes obligated to
pay royalties to F. Roche as provided in Section 3A.7(a), then the provisions
of Sections 3.4 (Offset for Third Party Licenses), 3.5 (Sublicenses), and 3.6
(Royalties upon Termination), and Article IV (Accounting and Payments) shall
be applied to such royalty payment obligation, with such changes as are
necessary to reflect that PDL would be the paying party and that PDL shall be
entitled to make calculations and payments in U.S. Dollars.  If such event
occurs, the parties shall attempt for convenience to restate such provisions
and attach them to this Amended and Restated Agreement.

3A.8    [CONFIDENTIAL TREATMENT REQUESTED]

IV.  ACCOUNTING AND PAYMENTS
4.1     Royalty Payments and Reports.  Until such time as the first
exercise of its rights pursuant to Section 2B.2, F. Roche shall make royalty
payments and written reports to PDL within forty-five (45) days after June 30
and December 31 of each year covering all sales of Licensed Products by F.
Roche, its Affiliates or sublicensees for which invoices were sent during such
semi-annual period.  Effective as of the first quarter following a semi-annual
period in which F. Roche first exercises its rights pursuant to Section 2B.2,
F. Roche agrees to make royalty payments and written reports to PDL within
forty-five (45) days after the end of each calendar quarter covering all sales
of Licensed Products by F. Roche, its Affiliates or sublicensees for which
invoices were sent during such calendar quarter (provided that the first
quarter for which this occurs, such report shall cover all sales since the
last semi-annual report).  Until such time as Section 3A.4 applies, each
report shall state:

(a)  for Licensed Products disposed of by sale, the quantity,
description, country(ies) of manufacture and sale, Net Sales, GIP
and the deductions pursuant to Section 1.7 by which such GIP is
reduced to Net Sales,

(b)  for Licensed Products disposed of other than by sale, the
quantity, description, country(ies) of manufacture and
disposition, and nature of the disposition, and

(c)     the calculation of royalties due to PDL for such period pursuant
to Section 1.7 and Article III hereof.

After such time as Section 3A.4 applies, each report shall state:
(a)  for Licensed Products disposed of by sale, the quantity and
description of Licensed Products, Total Sales, Net Sales, and
details of the calculation of such numbers by country in the ROW
Territory,

(b)  if known or if estimates exist within F. Roche, Net Transplant
Sales and Net Autoimmune Sales

(c)  for Licensed Products disposed of other than by sale, the
quantity, description, and nature of the disposition, and

(d)     the calculation of Reimbursable Development Costs and royalties
due to PDL for such quarter pursuant to Article III-A.

Subject to Section 11.9, the information contained in each such report
shall be considered confidential and PDL agrees not to disclose such
information to any third party except as may be required by law.  Concurrent
with the making of each quarterly report, F. Roche shall include payment due
PDL of royalties for the calendar quarter covered by such report.

It is understood that pursuant to this provision, only one royalty shall
be payable on a given unit of Licensed Product disposed of under this Amended
and Restated Agreement.  In the case of transfers or sales of any Licensed
Product between Roche, F. Roche or an Affiliate or sublicensee of Roche or F.
Roche, only one royalty payment shall be due, and such royalty shall be
payable with respect to the sale of such Licensed Product to an independent
third party not an Affiliate of the seller.

4.2     Termination Report. Roche also agrees to make a written report to
PDL within ninety (90) days after the date on which Roche, F. Roche or their
Affiliates or sublicensees last sell a Licensed Product, stating in such
report the same information called for in each quarterly report by Section 4.1
for all Licensed Products and Combination Products made, sold or otherwise
disposed of and upon which were not previously reported to PDL.



4.3     Accounting. F. Roche agrees to keep full, clear and accurate
records for a period of at least [CONFIDENTIAL TREATMENT REQUESTED] years, or
such longer period as may coincide with F. Roche's internal records retention
policy, setting forth the manufacturing, sales and other disposition of
Licensed Products and Combination Products sold or otherwise disposed of under
the license herein granted in sufficient detail to enable royalties payable to
PDL hereunder to be determined.  F. Roche further agrees to permit its books
and records to be examined by an independent accounting firm selected by PDL
from time to time to the extent necessary to verify reports provided for in
Sections 4.1 and 4.2 above.  Unless PDL obtains the prior written consent of
F. Roche, such accounting firms must be selected from among the five largest
U.S. accounting firms.  Such examination is to be made at the expense of PDL,
except in the event that the results of the audit reveal a discrepancy in
favor of F. Roche of [CONFIDENTIAL TREATMENT REQUESTED] or more over the
period being audited, in which case reasonable audit fees for such examination
shall be paid by F. Roche.

4.4     Methods of Payments.

(a)  All payments due to PDL under this Amended and Restated Agreement
shall be paid in U.S. dollars by wire transfer to a bank in the U.S.
designated in writing by PDL.  Whenever for the purpose of calculating
royalties conversion from any foreign currency shall be required, such
conversion shall be made as follows :

        (i) when calculating the Total Sales and Net Sales, the amount of such
sales in foreign currencies shall be converted into Swiss Francs at the
average rate of exchange at the time for the applicable calendar quarter for
the countries concerned in accordance with F. Roche's then current standard
practices (which practices shall be reasonably documented in the report with
respect to which such conversion applies),

        (ii) when converting the royalties on Net Sales calculated in Swiss
Francs, the conversion shall be at the average rate of the Swiss Franc to the
U. S. dollars at the time for the applicable calendar quarter in accordance
with F. Roche's then current standard practices (which practices shall be
reasonably documented in the report with respect to which such conversion
applies), and

        (iii)  in the case of sales by sublicensees, using the exchange rates
provided for in the written agreements between the sublicensee and F. Roche
(which rates shall be reasonably documented in the report with respect to
which such conversion applies).

        (b)  All payments due from PDL to F. Roche under this Amended and
Restated Agreement shall be paid in U.S. dollars by wire transfer to a bank
designated in writing by F. Roche. If any currency conversion shall be
required in connection with payments by PDL to F. Roche, such conversion shall
be made (i) by using the average of the daily exchange rates for such currency
quoted by Citibank, N.A. for each of the last five (5) business days of each
calendar quarter, or any other source otherwise agreed upon in writing by the
parties, and (ii) in the case of sales by sublicensees, using the exchange
rates provided for in the written agreements between the sublicensee and PDL
(which rates shall be reasonably documented in the report with respect to
which such conversion applies).

4.5     Withholding Taxes.  If law or regulation requires the withholding
of any taxes due by F. Roche's Affiliates or sublicensees on Net Sales by such
Affiliates or sublicensees in a given country in the ROW Territory, the
parties shall confer regarding possible alternative arrangements to lawfully
avoid such withholding.  If, between a country in the ROW Territory and any
other place as designated, a treaty for the avoidance of double taxation is in
force and such treaty reduces or eliminates the withholding of any taxes
otherwise due on royalties payable from such country, PDL may (but shall not
be obligated to) request a direct remittance of royalties to PDL at such place
that PDL may designate hereunder.  If the parties are unable to formulate or
agree upon action to lawfully avoid withholding, then the parties agree
[CONFIDENTIAL TREATMENT REQUESTED] of such taxes shall be applied to reduce
the Net Sales amount for sales of Licensed Products in such country.
Notwithstanding the foregoing, F. Roche shall be solely responsible for any
withholding of taxes due on royalties payable from Japan and the countries of
the European Community.

All amounts owed under this Amended and Restated Agreement shall be paid
net of all applicable taxes, fees, and other charges, excluding only taxes on
a party's income.    Any taxes on payments due hereunder which PDL or any of
its Affiliates or sublicensees shall be required by law to withhold or pay on
remittance of the royalty payments shall be deducted from the royalty payable
to F. Roche.  In such event, PDL shall furnish to the recipient copies of all
official receipts for such taxes and provide reasonable assistance in
obtaining a refund or credit for such taxes withheld.

4.6     Currency Transfer Restrictions.  If in any country in the ROW
Territory the payment or transfer of royalties on Net Sales in such country is
prohibited by law or regulation, the parties hereto shall confer regarding the
terms and conditions on which Licensed Products shall be sold in such
countries, including the possibility of payment of royalties to PDL in local
currency to a bank account in such country or the re-negotiation of royalty
rates and terms for such sales.  However, PDL shall be under no obligation to
accept terms and conditions other than those set forth herein, and if the
parties do not reach an alternative agreement then F. Roche shall either
(a) remain responsible for royalties payable to PDL with respect to Net Sales
in such countries, or (b) cease sales in such countries, which shall not be
deemed a breach by F. Roche of its due diligence obligations under Section 5.1
below.

V.  CERTAIN COVENANTS OF F. ROCHE

5.1     Diligence.  From and after the Signing Date, F. Roche shall use
reasonable diligence in proceeding with registering, marketing and selling
Licensed Products within the ROW Territory.  Reasonable diligence as used in
this Amended and Restated Agreement shall mean the same standard of effort
used by F. Roche in registering, marketing and selling its own protein-based
products which must receive Regulatory Approval.  The parties acknowledge that
F. Roche does not register, market and sell its own protein-based products in
every country within the ROW Territory, and it is understood that the exercise
by F. Roche of reasonable diligence is to be determined by judging its efforts
in the ROW Territory taken as a whole.  Notwithstanding the foregoing
sentence, if F. Roche elects to proceed with a registration in any country in
the ROW Territory pursuant to Section 2A.7, then F. Roche shall proceed with
reasonable diligence in filing for Regulatory Approval for the specified
Autoimmune Indication in that country in the ROW Territory.  Further, if F.
Roche elects to market Daclizumab for an Autoimmune Indication, either
exclusively or as a co-promotion or co-marketing arrangement with PDL, then F.
Roche shall not position Daclizumab vis a vis its other products to the
detriment of sales of Daclizumab.  If F. Roche fails to exercise such
diligence, PDL may terminate this Amended and Restated Agreement and
F. Roche's rights hereunder pursuant to Section 7.4 below.

5.2     Initial ROW Territory Review.

(a)  Initial Review.  Promptly following the Signing Date, F. Roche will
review its plans for obtaining marketing approvals and launching Daclizumab
for Transplant Indications in the countries of the ROW Territory.  For any
countries in which F. Roche does not have definite plans, supported by ongoing
activities to carry out those plans, both to obtain Regulatory Approval and to
launch Daclizumab for Transplant Indications, F. Roche will notify PDL within
sixty (60) days after the Signing Date of the identity of such countries and,
with respect to each such country, whether F. Roche elects (i) to return all
rights to Daclizumab to PDL for all indications, or (ii) to seek a sublicensee
of F. Roche's rights to Daclizumab.  For each country for which F. Roche
elects to seek a sublicensee, if F. Roche has not entered into a sublicense
agreement for Daclizumab for that country within[CONFIDENTIAL TREATMENT
REQUESTED] after the Signing Date, all rights to Daclizumab for all
indications in that country in the ROW Territory shall then immediately and
automatically revert to PDL.

(b)  Ongoing Review.  For any countries in the ROW Territory for which
F. Roche determines in its review pursuant to Section 5.2(a) that it has
specific plans, supported by ongoing activities to carry out those plans, to
obtain Regulatory Approval and to launch Daclizumab for Transplant
Indications, if F. Roche subsequently determines not to carry out such plans
or ceases to actively carry out the activities necessary to achieve such
plans, then F. Roche shall promptly notify PDL, with respect to such
country(ies) of whether it elects (i) to return all rights to Daclizumab to
PDL for all indications, or (ii) to seek a sublicensee of F. Roche's rights to
Daclizumab.  For each country in the ROW Territory for which F. Roche elects
to seek a sublicensee, if F. Roche has not entered into a sublicense agreement
for Daclizumab for that country within six (6) months after such notice to
PDL, all rights to Daclizumab for all indications in those countries in the
ROW Territory shall then immediately and automatically revert to PDL.

(c)  Reversion to PDL. For each country in the ROW Territory for which
all rights to Daclizumab have been returned or reverted to PDL pursuant to
this Section 5.2, PDL shall thereafter have the exclusive right to use, market
and sell Daclizumab for all indications in that country in the ROW Territory,
including the right to sublicense such rights to a sublicensee of PDL's choice
without any further compensation to F. Roche, subject to F. Roche's consent,
which shall not be unreasonably withheld or delayed.  Manufacturing and supply
of Daclizumab to PDL and regulatory matters shall be governed by Article II-C
and Section 2A.6 of this Amended and Restated Agreement in the same manner as
intended for countries in the ROW Territory in which PDL would obtain the
exclusive right to market and sell Daclizumab for Autoimmune Indications.

5.3     Reimbursement for Costs of Patent Applications for Transplant
Indications. For purposes of Sections 5.3 and 5.4, references to ROW Territory
shall also include Canada, including its territories and possessions.

(a)     Right to Reimbursement.  In any country in the ROW Territory
F. Roche agrees to reimburse PDL for all ex parte out-of-pocket expenses
incurred by PDL after January 31, 1989 in connection with the prosecution and
maintenance in the ROW Territory of patent applications and patents included
within the PDL Patents or Joint Roche-PDL Patents for which PDL has made or
makes filings with respect to Transplant Indications pursuant to Article IX of
the 1999 PDL/Roche Agreement ("Transplant Foreign Filing Expenses").  F. Roche
shall make such payments to PDL no less frequently than semi-annually, within
thirty (30) days after submission by PDL of a reasonably itemized statement of
such expenses incurred by PDL during the relevant six-month period.
Notwithstanding the foregoing, F. Roche shall not be obligated to reimburse
PDL for such Transplant Foreign Filing Expenses exceeding an aggregate of
[CONFIDENTIAL TREATMENT REQUESTED] in any calendar year.

(b)     Consultation.  Prior to the filing of a patent application for
Transplant Indications in the ROW Territory, PDL shall inform F. Roche
concerning such proposed filing and shall consult with F. Roche concerning the
proposed filing procedures, including specifically the determination of the
scope of any such patent and the countries in which such application is to be
filed.  PDL shall regularly advise F. Roche of any substantial action or
development in the prosecution of its patent applications and patents related
to Transplant Indications in the ROW Territory, in particular of the question
of scope of, the issuance of, the rejection of, or an opposition to any
respective patent application or patent.  In any event, all patent
applications filed prior to the Signing Date pursuant to Section 5.02 of the
1989 F. Roche Agreement shall be considered filings with respect to Transplant
Indications.

(c)     Credit.  F. Roche shall be entitled to a credit for Transplant
Foreign Filing Expenses against royalties payable hereunder as provided in
Section 3.3 hereof.

5.4     Reimbursement for Costs of Patent Applications for Autoimmune
Indications.

(a)     Accrual.  PDL shall be responsible for all ex parte out-of-pocket
expenses incurred by PDL after the Signing Date in connection with the
prosecution and maintenance in the ROW Territory of patent applications and
patents included within the PDL Patents or Joint Roche-PDL Patents for which
PDL makes filings with respect to Autoimmune Indications pursuant to
Article IX of the 1999 PDL/Roche Agreement ("Autoimmune Foreign Filing
Expenses"), which Autoimmune Foreign Filing Expenses shall be calculated as
the sum of the following amounts:

(i)  if such Autoimmune Foreign Filing Expenses are applicable to PDL
Patents or Joint Roche-PDL Patents with claims that cover an Autoimmune
Indication with respect to which F. Roche elects either 2B.2(a), (b) or
(c), then PDL shall be entitled to reimbursement of [CONFIDENTIAL
TREATMENT REQUESTED] of all ex parte out-of-pocket expenses incurred by
PDL with respect to those patents and patent applications (to the extent
not previously reimbursed); plus

(ii)  if such Autoimmune Foreign Filing Expenses are applicable to PDL
Patents or Joint Roche-PDL Patents with claims that cover an Autoimmune
Indication with respect to which F. Roche has not yet elected either
2B.2(a), (b) or (c), then PDL shall be entitled to reimbursement of
[CONFIDENTIAL TREATMENT REQUESTED] of all ex parte out-of-pocket
expenses incurred by PDL with respect to those patents and patent
applications (to the extent not previously reimbursed); plus

(iii)  if such Autoimmune Foreign Filing Expenses are applicable to PDL
Patents or Joint Roche-PDL Patents with claims that cover an Autoimmune
Indication with respect to which F. Roche has notified PDL in writing
that it will not elect either 2B.2(a), (b) or (c), then PDL shall be
entitled to no reimbursement of ex parte out-of-pocket expenses incurred
by PDL with respect to those patents and patent applications.

(b)     Reimbursement Following Election.  Following reimbursement to PDL
pursuant to Section 3A.5 for an Autoimmune Indication with respect to which F.
Roche elects either 2B.2(a), (b) or (c), PDL shall be reimbursed on an ongoing
basis one hundred percent (100%) of all ex parte out-of-pocket expenses
incurred by PDL with respect to prosecution and maintenance of the PDL Patents
or Joint Roche-PDL Patents containing claims that cover that Autoimmune
Indication.  PDL shall invoice F. Roche for such amounts on a quarterly basis
and payment from F. Roche shall be made to PDL within thirty (30) days of
receipt of invoice from PDL.

(c)     Limit on Reimbursement to PDL.  In any event, F. Roche shall not
be obligated to reimburse PDL pursuant to Sections 5.4 (a) or (b) for any
Autoimmune Foreign Filing Expenses exceeding an aggregate of [CONFIDENTIAL
TREATMENT REQUESTED] in any calendar year.

(d)     PDL Control.  PDL shall have full control over the strategy and
decisions with respect to the filing of any patent applications and patents
related to Autoimmune Indications in the ROW Territory.  F. Roche agrees to
cooperate with and reasonably assist PDL in the preparation of any patent
applications and the maintenance of any patents.  If F. Roche elects any of
its rights pursuant to Section 2B.2(a), (b) or (c), PDL shall regularly advise
F. Roche of any substantial action or development in the prosecution of its
patent applications and patents related to Transplant Indications in the
relevant countries in the ROW Territory, in particular advising F. Roche of
the scope of, the issuance of, the rejection of, or an opposition to any
respective patent application or patent related to Autoimmune Indications with
respect to which F. Roche has exercised its rights.

VI.  OWNERSHIP OF TECHNOLOGY

6.1     PDL Technology. Ownership of the PDL Know-How and PDL Patents
shall remain vested at all times in PDL.  Notwithstanding the provisions of
Section 2.1, PDL expressly reserves under this Amended and Restated Agreement
(i) all rights to use the PDL Know-How, PDL's rights under any Joint Roche-PDL
Patents and PDL Patents to make, have made, use and sell anywhere in the world
all products not within the Field, and (ii) the right to use the PDL Know-How,
PDL's rights under any Joint Roche-PDL Patents and PDL Patents for PDL's
internal research purposes in the Field, and as specified in Sections 2.3 and
2.4.

6.2     Joint Inventions and Joint Roche-PDL Patents.  Ownership of Joint
Inventions and Joint Roche-PDL Patents shall be vested jointly in PDL and F.
Roche. Except as expressly provided in this Amended and Restated Agreement, F.
Roche shall have the exclusive right within the Territory during the term of
this Amended and Restated Agreement to make, have made, use or sell any Joint
Invention in the Field under any Joint Roche-PDL Patent.  In any event, both
parties shall have the nonexclusive right within the Territory during the term
of this Amended and Restated Agreement to make, have made, use or sell any
Joint Invention outside the Field under any Joint Roche-PDL Patent, and
neither party shall be obligated to account to the other.  Upon the expiration
or termination of this Amended and Restated Agreement, both parties shall have
the nonexclusive right to make, have made, use or sell any Joint Invention
under any Joint Roche-PDL Patent without restriction and without any
obligation to account to the other party.  Notwithstanding the foregoing or
the provisions of Section 2.1, PDL expressly reserves the right to use any
Joint Invention under any Joint Roche-PDL Patent for PDL's internal research
purposes in the Field, and as specified in Sections 2.3 and 2.4.
6.3     F. Roche Inventions.  PDL hereby acknowledges that this Amended
and Restated Agreement does not grant PDL any ownership rights in the F. Roche
Inventions.  F. Roche hereby confirms the rights of PDL to certain contingent
license grants to Roche Patents, Roche's rights under Joint Roche-PDL Patents
and Roche Know-How as provided in this Amended and Restated Agreement.

VI-A.  ENFORCEMENT OF PATENTS

6A.1    Sole Patents.

(a)     In the event of any action against a third party for infringement
of any claim in any issued patent in the ROW Territory within the Sole PDL
Patents or Sole Daclizumab Roche Patents, as the case may be, or the
institution by a third party of any proceedings for the revocation of any such
claim, each party will notify the other promptly and, following such
notification, the parties shall confer.  PDL shall have the right, but shall
not be obligated, to prosecute such actions or to defend such proceedings
involving the Sole PDL Patents at its own expense, in its own name and
entirely under its own direction and control.  F. Roche shall have the right,
but shall not be obligated, to prosecute such actions or to defend such
proceedings involving the Sole Daclizumab Roche Patents, at its own expense,
in its own name and  entirely under its own direction and control.

(b)     If a party with the first right hereunder elects not to prosecute
any action for infringement or to defend any proceeding for revocation of any
claims in any issued patent in the ROW Territory within the Sole PDL Patents
or Sole Daclizumab Roche Patents, as the case may be, within ninety (90) days
of being requested by the other party to do so, the other party may prosecute
such action or defend such proceeding at its own expense, in its own name and
entirely under its own direction and control.

(c)     In any event, the party bringing an action ("acting party")
pursuant to this Section 6A.1 shall solicit, and seriously consider in good
faith the non-acting party's input with respect to all material aspects of
such action, including without limitation, the development of the litigation
strategy and the execution thereof.  In furtherance and not in limitation of
the foregoing, the acting party shall keep the other party promptly and fully
informed of the status of any such action, and the non-acting party shall have
the right to review and comment upon the acting party's activities related
thereto.

(d)     Each party will reasonably assist the acting party  in any such
action or proceeding being prosecuted or defended by the acting party, if so
requested by the acting party or required by law.  The acting party will pay
or reimburse the assisting party for all costs, expenses and liabilities which
the assisting party may incur or suffer in affording assistance to such
actions or proceedings.  No settlement of any such action or defense which
restricts the scope or affects the enforceability of PDL Know-How or Sole PDL
Patents may be entered into by either PDL or F. Roche without the prior
consent of the other party hereto, which consent, in the case of F. Roche
shall not be unreasonably withheld and in the case of PDL may be withheld in
PDL's sole and absolute discretion.  No settlement of any such action or
defense which restricts the scope or affects the enforceability of Roche Know-
How or Sole Daclizumab Roche Patents may be entered into by either PDL or F.
Roche without the prior consent of the other party hereto, which consent, in
the case of PDL shall not be unreasonably withheld and in the case of F. Roche
may be withheld in F. Roche's sole and absolute discretion.

(e)     If either party elects to prosecute an action for infringement or
to defend any proceedings for revocation of any claims pursuant to this
Section 6A.1 and subsequently ceases to continue or withdraws from such action
or defense, it shall forthwith so notify the other party in writing and the
other party may substitute itself for the withdrawing party and the parties'
respective rights and obligations under this Section 6A.1 shall be reversed.

6A.2    Joint Roche-PDL Patents.  In the event of any action against a
third party for infringement of any claim in any issued patent in the ROW
Territory within the Joint Roche-PDL Patents, or the institution by a third
party of any proceedings for the revocation of any such claim, each party will
notify the other promptly and, following such notification, the parties shall
confer to determine whether either or both parties shall control the
prosecution or defense of such action or proceeding and who shall bear the
costs thereof.  If the parties are unable to reach agreement within ninety
(90) days of the notification referred to above, then each party shall have
the right to bring such action or defend such proceeding at its own expense,
in its own name and entirely under its own direction and control; provided,
however, that if both parties elect to prosecute or defend, each party shall
bear its own expenses but both parties shall have equal control over such
prosecution or defense.  No settlement of any action or defense which
restricts the scope or affects the enforceability of Joint Roche-PDL Patents
may be entered into by either PDL or F. Roche without the prior consent of the
other party hereto, which consent shall not be unreasonably withheld.  In any
event, the party bringing an action ("acting party") pursuant to this Section
6A.2 shall solicit, and seriously consider in good faith the other party's
input with respect to all material aspects of such action, including without
limitation, the development of the litigation strategy and the execution
thereof.  In furtherance and not in limitation of the foregoing, the acting
party shall keep the other party promptly and fully informed of the status of
any such action, and the other party shall have the right to review and
comment upon the acting party's activities related thereto.

6A.3    Distribution of Proceeds.  In the event either party exercises the
rights conferred in Section 6A.1 or 6A.2 hereof, and recovers any damages or
other sums in such action, suit or proceeding or in settlement thereof, such
damages or other sums recovered, shall first be applied to all costs and
expenses connected therewith including reasonable attorneys' fees, necessarily
involved in the prosecution and/or defense of any suit or proceeding, and if
after such reimbursement any funds shall remain from such damages or other
sums recovered, said recovery shall belong to the party exercising its rights;
provided, however, that any remaining recovery by shall be shared
[CONFIDENTIAL TREATMENT REQUESTED].

6A.4    Defense of Infringement Actions.

(a)     F. Roche shall defend at its own cost any infringement suit that
may be brought against PDL or F. Roche on account of the development,
manufacture, production, use or sale of any Licensed Product by F. Roche in
the ROW Territory, and shall indemnify and save PDL harmless against any such
patent or other infringement suits, and any claims, losses, damages,
liabilities, expenses, including reasonable attorneys' fees and cost, which
may be incurred by PDL therein or in settlement thereof.  Any and all
settlements which restrict the scope or enforceability of PDL Know-How or PDL
Patents must be approved by PDL in its sole and absolute discretion before
execution by F. Roche.  Any and all settlements which restrict the scope or
enforceability of Joint Roche-PDL Patents must be approved by PDL before
execution by F. Roche, such approval not to be unreasonably withheld.  PDL
shall not be required to approve any settlement which does not include as a
condition thereof the granting to PDL of a full and unconditional release of
claims.

(b)     PDL shall defend at its own cost any infringement suit that may be
brought against F. Roche or PDL on account of the development, manufacture,
production, use or sale of Daclizumab in the ROW Territory by PDL, and shall
indemnify and save F. Roche harmless against any such patent or other
infringement suits, and any claims, losses, damages, liabilities, expenses,
including reasonable attorneys' fees and cost, which may be incurred by F.
Roche therein or in settlement thereof.  Any and all settlements which
restrict the scope or enforceability of Roche Know-How or Roche Patents must
be approved by F. Roche in its sole and absolute discretion before execution
by PDL.  Any and all settlements which restrict the scope or enforceability of
Joint Roche-PDL Patents must be approved by F. Roche before execution by PDL,
such approval not to be unreasonably withheld.  F. Roche shall not be required
to approve any settlement which does not include as a condition thereof the
granting to F. Roche of a full and unconditional release of claims.  F. Roche
will use commercially reasonable efforts to avoid knowingly infringing any
patents of third parties in F. Roche's design of the cell lines that may be
delivered to PDL hereunder, and F. Roche will inform PDL of any such potential
infringement promptly upon F. Roche's becoming aware of such potential
infringement.

6A.5    Right to Counsel.  Each party to this Amended and Restated
Agreement shall always have the right to be represented by counsel of its own
selection and its own expense in any suit or other action instituted by the
other for infringement, under the terms of this Amended and Restated
Agreement.

6A.6    Coordination.  Each party acknowledges and agrees that the efforts
of the parties under this Article VI-A shall take into consideration the
efforts and responsibilities of PDL and Roche under the 1999 PDL/Roche
Agreement.

VII.  TERM AND TERMINATION

7.1     Term.  Unless earlier terminated pursuant to the terms of this
Article VII, this Amended and Restated Agreement shall remain in effect until
the date of expiration of all payment obligations, including royalties and
reimbursement amounts, under Article III and Article III-A, at which time all
the rights and licenses granted under this Amended and Restated Agreement
shall become irrevocable and fully-paid.  Upon the expiration of this Amended
and Restated Agreement pursuant to this Section 7.1, if it is not otherwise
terminated pursuant to this Article VII, (a) in each country in which F. Roche
at the time of expiration has rights to Licensed Products hereunder, PDL shall
grant to F. Roche a nonexclusive, royalty-free license to use the PDL Know-
How, PDL's rights under any Joint Roche-PDL Patents and PDL Patents and cell
lines delivered by PDL pursuant to the 1989 and 1999 PDL/Roche Agreements, but
only to the extent necessary to make, have made, use and sell Licensed
Products for the indications with respect to which F. Roche has rights in
countries in the ROW Territory as of the expiration date; and (b) in each
country in which PDL at the time of expiration retains rights to Daclizumab or
other Licensed Products hereunder, F. Roche hereby grants to PDL a
nonexclusive, fully-paid license under the Roche Patents, Roche Know-How, and
F. Roche's rights under any Joint Roche-PDL Patents and Joint Inventions but
only to the extent necessary to make, have made, use and sell Daclizumab or
other such Licensed Products in with respect to which PDL has rights in
countries in the ROW Territory as of the expiration date.

7.2     Termination by Mutual Agreement.  This Amended and Restated
Agreement may be terminated by the written agreement of the parties.

7.3     Termination by F. Roche.  F. Roche may terminate its rights under
this Amended and Restated Agreement upon one hundred eighty (180) days written
notice to PDL.

7.4     Termination by Default.

(a)     If either party defaults in the performance of, or fails to be in
compliance with, any material agreement, condition or covenant of this Amended
and Restated Agreement, the party not in default may terminate the other
party's rights this Amended and Restated Agreement at its option; provided,
however, that if such event of default or non-compliance is the first (1st)
occurrence of an event giving rise to the right of termination pursuant to
this Section 7.4, the non-defaulting party may terminate the other party's
rights under this Amended and Restated Agreement only if such default or
noncompliance shall not have been remedied, or steps initiated to remedy the
same to the other party's reasonable satisfaction within sixty (60) days after
receipt by the defaulting party of a written notice thereof from the other
party.

(b)     If PDL terminates the 1999 PDL/Roche Agreement pursuant to
Section 11.4 thereof, PDL may elect to simultaneously terminate this Amended
and Restated Agreement upon written notice to F. Roche.  If Roche terminates
the 1999 PDL/Roche Agreement pursuant to Section 11.4 thereof, F. Roche may
elect to simultaneously terminate this Amended and Restated Agreement upon
written notice to PDL.

7.5     Inventory.  Upon termination of this Amended and Restated
Agreement for default by a party hereunder, the defaulting party holding
inventory of Daclizumab shall notify the other of the amount of Daclizumab
such defaulting party, its Affiliates, sublicensees and distributors then have
on hand ("Inventory"), the sale of which would, but for the termination, be
subject to payment of royalties or other consideration under this Amended and
Restated Agreement.  The defaulting party and its Affiliates, sublicensees and
distributors shall thereupon be permitted to sell the Inventory, provided that
the other party shall have the first option for a period not to exceed sixty
(60) days to purchase all or part of the Inventory [CONFIDENTIAL TREATMENT
REQUESTED].  If the non-defaulting party fails to exercise its option to
purchase all of the Inventory or for that part of the Inventory with respect
to which the option is not exercised, the party holding the Inventory will be
free to sell such Inventory to third parties for a period not to exceed one
hundred eighty (180) days from the termination of the non-defaulting party's
option.  In any event, the parties shall pay the royalties or other
consideration due on the sale of such Inventory in the amounts and manner
provided for in Articles III and III-A.  Upon expiration or termination of
this Amended and Restated Agreement for any reason other than default, each of
the parties shall have a right to sell Inventory for a period of one(1) year
from the date of such expiration or termination, subject to the obligation to
pay the royalty or other consideration due to the other party with respect to
the sale of such Inventory.  In any event, sales of Inventory by a party
pursuant to this Section 7.5 for Autoimmune Indications shall be in accordance
with the terms and conditions of this Amended and Restated Agreement.

7.6     Return of Materials.  Subject to Section 7.8 hereof concerning
archival copies, upon termination of this Amended and Restated Agreement by
F. Roche pursuant to Section 7.3 or by either or both parties pursuant to
Sections 7.2 or 7.4, F. Roche forthwith shall return to PDL all cell lines and
their progeny, antibodies and other biological materials provided by PDL under
the 1989 and 1999 PDL/Roche Agreements.

7.7     Rights and Obligations on Termination or Expiration.

(a)  Unless expressly provided to the contrary, the provisions of
Sections 3.6 and 5.3 and Articles III-A, IV, VI-A, VII, VIII, IX and XI shall
survive the termination of this Amended and Restated Agreement. In the event
that termination by either party results in the termination of rights to
Daclizumab or other Licensed Products and the reversion or transfer of such
rights to the other party, then the party whose rights are terminated shall
act in good faith using commercially reasonable efforts to transfer any and
all information, data and materials with the goal of providing minimal
disruption in the marketing and sale of Daclizumab or other Licensed Product,
as the case may be.

(b)  In the event of termination (i) by F. Roche pursuant to Section 7.3
or (ii) by PDL for default by F. Roche pursuant to Section 7.4, then effective
as of the date of termination, F. Roche hereby grants to PDL an exclusive,
fully-paid license under the Roche Patents, Roche Know-How, and F. Roche's
rights under any Joint Roche-PDL Patents and Joint Inventions to make, have
made, use and sell Daclizumab or other such Licensed Products in the ROW
Territory.

7.8     Archival Copies.  Section 7.6 notwithstanding, each party shall be
entitled to keep for archival purposes one copy of all written materials
returned to the other party pursuant to Section 7.6.

VIII.  CONFIDENTIALITY, DISCLOSURE AND PUBLICATIONS

8.1     Confidentiality.  During the term of this Amended and Restated
Agreement and for a period of five (5) years following expiration or
termination of this Amended and Restated Agreement, each party shall maintain
in confidence all information and materials including, but not limited to,
cell lines, their progeny, and antibodies, disclosed by the other party hereto
which such party knows or has reason to know are or contain trade secrets or
other proprietary information of the other, including, without limitation,
information relating to the PDL Know-How, PDL Patents, Roche Know-How, Roche
Patents, Joint Roche-PDL Patents, Joint Inventions and inventions of the other
party, and the business plans of the other party, including, without
limitation, information provided by either party to the other party hereto
prior to the Signing Date, and shall not use such trade secrets or proprietary
information for any purpose, including, without limitation, for the purpose of
developing products in the Field except as permitted by this Amended and
Restated Agreement or disclose the same to anyone other than those of its
Affiliates, sublicensees, prospective sublicensees, employees, consultants,
agents or subcontractors as are necessary in connection with such party's
activities as contemplated in this Amended and Restated Agreement.  Each party
shall be responsible for ensuring compliance with these obligations by such
party's Affiliates, sublicensees, prospective sublicensees, employees,
consultants, agents and subcontractors.  Each party shall use a similar effort
to that which it uses to protect its own most valuable trade secrets or
proprietary information to ensure that its Affiliates, sublicensees,
employees, consultants, agents and subcontractors do not disclose or make any
unauthorized use of trade secrets or proprietary information of the other
party hereto.  Each party shall notify the other promptly upon discovery of
any unauthorized use or disclosure of the other's trade secrets or proprietary
information.

8.2     Exceptions.  The obligation of confidentiality contained in this
Amended and Restated Agreement shall not apply to the extent that (a) either
party (the "Recipient") is required to disclose information by order or
regulation of a governmental agency or a court of competent jurisdiction or
(b) the Recipient can demonstrate that (i) the disclosed information was at
the time of such disclosure by the Recipient already in the public domain
other than as a result of actions of the Recipient, its Affiliates, employees,
licensees, agents or subcontractors, in violation hereof; (ii) the disclosed
information was rightfully known by the Recipient or its Affiliates (as shown
by its written records) prior to the date of disclosure to the Recipient in
connection with the negotiation, execution or performance of this Amended and
Restated Agreement; or (iii) the disclosed information was received by the
Recipient or its Affiliates on an unrestricted basis from a source unrelated
to any party to this Amended and Restated Agreement and not under a duty of
confidentiality to the other party, or (c) the Recipient can demonstrate that
disclosure to a regulatory authority is required by its product license
approval process.

8.3     Publications.

(a)  Scientific Publications.  Prior to public disclosure or submission
for publication of a manuscript describing the results of any scientific
activity or collaboration between PDL and F. Roche in the Field, the party
disclosing or submitting such a manuscript ("Disclosing Party") shall send the
other party ("Responding Party") by expedited delivery a copy of the
manuscript to be submitted and shall allow the Responding Party a reasonable
time period (not to exceed forty-five (45) days from the date of confirmed
receipt) in which to determine whether the manuscript contains subject matter
of which patent protection should be sought (prior to publication of such
manuscript) for the purpose of protecting an invention conceived or developed
in connection with the PDL/F. Roche scientific collaboration, or whether the
manuscript contains confidential information belonging to the Responding
Party.  After the expiration of forty-five (45) days  from the date of
confirmed receipt of  such manuscript, the Disclosing Party shall be free to
submit such manuscript for publication and publish or otherwise disclose to
the public such research results.  Should the Responding Party believe the
subject matter of the manuscript contains confidential information or a
patentable invention of substantial commercial value to the Responding Party,
then prior to the expiration of forty-five (45) days  from the date of
confirmed receipt of such manuscript by the Responding Party, the Responding
Party shall notify the Disclosing Party in writing of its determination that
such manuscript contains such information or subject matter for which patent
protection should be sought.  Upon receipt of such written notice from the
Responding Party, the Disclosing Party shall delay public disclosure of such
information or submission of the manuscript for an additional period of sixty
(60) days to permit preparation and filing of a patent application on the
disclosed subject matter.  The Disclosing Party shall thereafter be free to
publish or disclose such information, except that the Disclosing Party may not
disclose any confidential information of the Responding Party in violation of
Section 8.1hereof.  Determination of authorship for any paper or patent shall
be in accordance with accepted scientific practice.  Should any questions on
authorship arise, this will be determined by good faith consultation between
the respective heads of research for each of the parties.

(b)  Preclinical and Clinical Studies.  Prior to public disclosure or
submission for publication of a manuscript by PDL describing the results of
any preclinical or clinical study conducted by or on behalf of PDL in
Autoimmune Indications, PDL shall send F. Roche by expedited delivery a copy
of the manuscript to be submitted and shall allow F. Roche a reasonable time
period (not to exceed forty-five (45) days  from the date of  confirmed
receipt by F. Roche) to review the manuscript, including for the purpose of
determining whether the manuscript contains information which  is reasonably
likely to have a material adverse impact on Daclizumab for Transplant
Indications in the ROW Territory or confidential information belonging to F.
Roche.  After the expiration of forty-five (45) days  from the date of
confirmed receipt by F. Roche of such manuscript, PDL shall be free to submit
such manuscript for publication and publish or otherwise disclose to the
public such research results.  Should F. Roche believe the manuscript contains
information  which is reasonably likely  have a material adverse impact on
Daclizumab for Transplant Indications in the ROW Territory or which is
confidential information of F. Roche, then prior to the expiration of forty-
five (45) days  from the date of  confirmed receipt of such manuscript by F.
Roche, F. Roche shall notify the PDL in writing of its determination and the
reasons therefor.  Upon receipt of such written notice from F. Roche that the
manuscript contains confidential information of F. Roche, PDL shall delay
public disclosure of such information or submission of the manuscript for an
additional period not to exceed sixty (60) days to permit the parties to agree
as to how to revise the manuscript so that PDL will not disclose any
confidential information of F. Roche in violation of Section 8.1 hereof.

IX.  DISPUTE RESOLUTION

9.1     Arbitration.  Except as expressly provided herein, any claim,
dispute or controversy arising out of or in connection with or relating to
this agreement or the breach or alleged breach thereof shall be submitted by
the parties to arbitration by the AAA in Santa Clara County, California under
the International Arbitration Rules then in effect for that AAA except as
provided herein.  All proceedings shall be held in English and a transcribed
record prepared in English.  The parties shall choose, by mutual agreement,
one arbitrator within thirty (30) days of receipt of notice of the intent to
arbitrate.  If no arbitrator is appointed within the times herein provided or
any extension of time which is mutually agreed upon, the AAA Administrator in
accordance with the AAA International Rules of Arbitration and the AAA shall
select an individual within thirty (30) days of such failure.  The award
rendered by the arbitrator shall include costs of arbitration, reasonable
attorneys' fees and reasonable costs for expert and other witnesses, and
judgment on such award may be entered in any court having jurisdiction
thereof.  The parties shall be entitled to discovery as provided in
Sections 1283.05 and 1283.1 of the Code of Civil Procedure of the State of
California, whether or not the California Arbitration Act is deemed to apply
to said arbitration.  Nothing in this Amended and Restated Agreement shall be
deemed as preventing either party from seeking injunctive relief (or any other
provisional remedy) from any court having jurisdiction over the parties and
the subject matter of the dispute as necessary to protect either party's name,
proprietary information, trade secrets, know-how or any other proprietary
right.  If the issues in dispute involve scientific or technical matters, any
arbitrator chosen hereunder shall have educational training and/or experience
sufficient to demonstrate a reasonable level of knowledge in the field of
biotechnology.  Judgment upon the award rendered by the arbitrator may be
entered in any court having jurisdiction thereof.





X.  FORCE MAJEURE

10.1    If either party shall be delayed, interrupted in or prevented from
the performance of any obligation hereunder by reason of force majeure
including an act of God, fire, flood, earthquake, war (declared or
undeclared), public disaster, strike or labor differences, governmental
enactment, rule or regulation, or any other cause beyond such party's control,
such party shall not be liable to the other therefor; and the time for
performance of such obligation shall be extended for a period equal to the
duration of the contingency which occasioned the delay, interruption or
prevention.  The party invoking such force majeure rights of this subparagraph
must notify the other party by courier or overnight dispatch (e.g., Fedex)
within a period of fifteen (15) days, from the first and last day of the force
majeure unless the force majeure renders such notification impossible in which
case notification will be made as soon as possible.  If the delay resulting
from the force majeure exceeds six (6) months, both parties shall consult
together to find an appropriate solution.


XI.  MISCELLANEOUS


11.1    Representations of Each Party.  Each party represents and warrants
to the other party hereto that, except as may otherwise be disclosed in
writing to such party:

(a)     each party has the full right and authority to enter into this
Amended and Restated Agreement; and

(b)     to the best knowledge of the party after reasonable investigation,
no third party has any right, title or interest in the PDL
Patents, PDL Know-How, Joint Roche-PDL Patents, Roche Know-How or
Roche Patents, as the case may be, as the result of such third
party's former employment of any employee of that party.

11.2    Assignment.  This Amended and Restated Agreement and the licenses
herein granted other than the 1999 PDL/Roche Agreement relating to the same
Field but for the Roche Territory shall be binding upon and shall inure to the
benefit of, successors of the parties hereto, or to an assignee of all of the
good will and entire business and assets of a party hereto relating to
pharmaceutical and veterinary products but shall not otherwise be assignable
without the prior written consent of the other party, which consent will not
be unreasonably withheld.

11.3    Entire Agreement.  This Amended and Restated Agreement and the
1999 PDL/Roche Agreement constitute the entire agreement between the parties
hereto with respect to the within subject matter and supersede all previous
agreements, whether written or oral.  This Amended and Restated Agreement
shall not be changed or modified orally, but only by an instrument in writing
signed by both parties.



11.4    Releases.

(a)  The parties agree that as of the Signing Date, PDL hereby releases
and forever discharges F. Roche and its Affiliates (including Genentech, Inc.,
a Delaware corporation) from any and all claims, liabilities and demands
whatsoever on account of or arising from the 1989 F. Roche Agreement that PDL
may have, otherwise continue to have or have had, past, present or future,
including with respect to Article III and Article VII of the 1989 F. Roche
Agreement and including without limitation any and all claims liabilities and
demands on account of or arising from Section 3.1(d) of the 1989 F. Roche
Agreement, including any remedies which PDL may have on, prior to or after the
Signing Date thereunder both in equity and at law; provided that nothing
herein shall be deemed to release any claims, liabilities or demands that PDL
may have after the Signing Date under this Amended and Restated Agreement.

(b)  The parties agree that as of the Signing Date, F. Roche and its
Affiliates hereby release and forever discharge PDL from any and all claims,
liabilities and demands whatsoever on account of or arising from that certain
Joint Development, Marketing and License Agreement between PDL and Boehringer
Mannheim GmbH ("Boehringer") dated October 28, 1993, as amended, and all
related agreements entered into between PDL and Boehringer as of that same
date that F. Roche and its Affiliates may have, otherwise continue to have or
have had, past, present or future, including any remedies which Roche may have
on, prior to or after the Signing Date thereunder both in equity and at law;
provided that nothing herein shall be deemed to release any claims,
liabilities or demands that F. Roche or its Affiliates may have after the
Signing Date under this Amended and Restated Agreement.

11.5    Severability.  If any provision of this Amended and Restated
Agreement is declared invalid by an arbitrator pursuant to Section 9.1 or by a
court of last resort or by any court or other governmental body from the
decision of which an appeal is not taken within the time provided by law, then
and in such event, this Amended and Restated Agreement will be deemed to have
been terminated only as to the portion thereof which relates to the provision
invalidated by that decision and only in the relevant jurisdiction, but this
Amended and Restated Agreement, in all other respects and all other
jurisdictions, will remain in force; provided, however, that if the provision
so invalidated is essential to the Amended and Restated Agreement as a whole,
then the parties shall negotiate in good faith to amend the terms hereof as
nearly as practical to carry out the original intent of the parties, and,
failing such amendment, either party may submit the matter to arbitration for
resolution pursuant to Section 9.1.

11.6    Indemnification.

(a)     F. Roche shall defend, indemnify and hold harmless PDL, its
trustees, officers, agents and employees harmless from any and all liability,
demands, damages, expenses, and losses of any kind, including those resulting
from death, personal injury, illness or property damage arising (i) out of the
manufacture, distribution, use, testing, sale or other disposition, by
F. Roche, an Affiliate of F. Roche, or any distributor, customer, sublicensee
or representative of F. Roche or anyone in privity therewith, of any Licensed
Product, or any cell lines, their progeny, or other biological materials
provided by PDL pursuant to the 1999 PDL/Roche Agreement, method, process,
device or apparatus licensed or provided by PDL to F. Roche hereunder, or
(ii) as a result of practicing a Joint Invention, or using PDL Know-How or PDL
Patents licensed to F. Roche under this Amended and Restated Agreement, except
where such claim is based on the negligent acts of commission or omission of
PDL.

(b)     PDL shall defend, indemnify and hold harmless F. Roche, its
trustees, officers, agents and employees harmless from any and all liability,
demands, damages, expenses, and losses of any kind, including those resulting
from death, personal injury, illness or property damage arising (i) out of the
manufacture, distribution, use, testing, sale or other disposition, by PDL, an
Affiliate of PDL, or any distributor, customer, sublicensee or representative
of PDL or anyone in privity therewith, of Daclizumab or any other Licensed
Product in Autoimmune Indications, or (ii) as a result of practicing a Joint
Invention, using Roche Know-How or Roche Patents licensed to PDL under this
Amended and Restated Agreement, except where such claim is based on the
negligent acts of commission or omission of F. Roche.

11.7    Notices.  Any notice or report required or permitted to be given
under this Amended and Restated Agreement shall be in writing and shall be
mailed by certified or registered mail, or telexed or telecopied and confirmed
by mailing, as follows and shall be effective five (5) days after such
mailing:


If to PDL:      Protein Design Labs, Inc.
        34801 Campus Drive
Fremont, California U.S.A.  94555
Attention:  General Counsel

If to F. Roche: F. Hoffmann-La Roche Ltd
Grenzacherstrasse 124
CH-4002 Basle, Switzerland
Attention:  Law Department

11.8    Choice of Law.  The validity, performance, construction, and
effect of this Amended and Restated Agreement shall be governed by the laws of
the State of California, United States of America.

11.9    Publicity.  Both parties agree to issue a press release concerning
entry into this Amended and Restated Agreement, with the content of such
release to be approved in advance by both parties.  In all other respects,
neither party shall use the name of the other party in any publicity release
without the prior written permission of such other party, which shall not be
unreasonably withheld.  The other party shall have a reasonable opportunity to
review and comment on any such proposed publicity release.  Except as required
by law, neither party shall publicly disclose the terms of this Amended and
Restated Agreement or its terms and conditions unless expressly authorized to
do so by the other party which authorization shall not be unreasonably
withheld.  In the event that disclosure shall be agreed upon then the parties
will work together to develop a mutually acceptable disclosure.
Notwithstanding anything to the contrary herein, if not otherwise disclosed by
F. Roche, PDL shall not disclose to any third party the amount of sales of or
royalties or consideration paid with respect to Licensed Product without the
prior written consent of F. Roche, which consent shall not be unreasonably
withheld.

11.10   Headings.  The captions used herein are inserted for convenience
of reference only and shall not be construed to create obligations, benefits,
or limitations.

[The remainder of this page intentionally left blank.]


11.11   Counterparts.  This Amended and Restated Agreement may be executed
in counterparts, all of which taken together shall be regarded as one and the
same instrument.

IN WITNESS WHEREOF, the parties have executed this Amended and Restated
Agreement to be effective as of the Signing Date.

PROTEIN DESIGN LABS, INC.
By
Title:
Date:
F. HOFFMANN-LA ROCHE LTD

By
Title:
Date:

Solely with respect to the granting of rights in Joint Roche-PDL Patents to F.
Roche, Roche hereby joins in this Amended and Restated Agreement.

HOFFMANN-LA ROCHE INC.


By
Title:
Date:


Appendix A
PDL Patents

A.  The following are patents and patent applications (also known as the "Queen
et al. Patents") issued and filed in certain countries in the world.

        1.  The following issued U.S. patents and U.S. patent applications:

No. 5,585,089, "Humanized Immunoglobulins," issued December 17, 1996.

No. 5,693,761, "Polynucleotides Encoding Improved Humanized
Immunoglobulins," issued December 2, 1997.

No. 5,693,762, "Humanized Immunoglobulins," issued December 2, 1997.

[CONFIDENTIAL TREATMENT REQUESTED]


        2.  The following patents and patent applications outside the U.S.:

Patent No.

Country
Title*
Issued
647383
Australia
"Novel Immunoglobulins, Their Production
and Use"
Issued
671949
Australia
"
Issued
AT E133452
Austria
"
Issued
0451216
Belgium
"
Issued
61095
Bulgaria
"
Issued
970016

Brazil
"
Issued
0451 216B1
European
"
Issued
0682040 B1
European

Issued
FR0451216
France
"
Issued
DE
68925536
Germany
"
Issued
DD 296 964
East Germany
"
Issued
GB 0451216
Great Britain
"
Issued
1001050

Greece
"
Issued
211174

Hungary
"
Issued
IT O451216
Italy
"
Issued
2828340
Japan
"
Issued
LU O451216
Luxembourg
"
Issued
92.2146
Monaco
"
Issued
NL 0451216
Netherlands
"
Issued
231984
New Zealand
"
Issued
132068
Pakistan
"
Issued
29729
Philippines
"
Issued
92758
Portugal
"
Issued
4895847.13
Russia
"
Issued
2126046
Russia
"
Issued
SG O451216
Singapore
"
Issued
89/9956
South Africa
"
Issued
178385
South Korea
"
Issued
2081974 T3
Spain
"
Issued
SE O451216
Sweden
"
Issued
CHO 451216
Switzerland
"
Issued
50034
Taiwan
"
Issued
13349
Uruguay
"
Issued
48700
Yugoslavia
"




Country
Title*
Pending
Argentina
"Novel Immunoglobulins, Their
Production and Use"
Pending
Canada
"
Pending
Chile
"
Pending
China
"
Pending
Croatia
"
Pending
Czech Republic
"
Pending
Ecuador
"
Pending
Europe
"
Pending
Hong Kong
"
Pending
Ireland
"
Pending
Israel
"
Pending
Japan
"
Pending
South Korea

Pending
Romania
"
Pending
Slovak Republic
"
Pending
Venezuela
"
Pending
Denmark
"
Pending
Finland
"
Pending
Norway
"





*Exact titles may differ in different countries.


B.  The following patent applications relate to the use of anti-IL2 receptor
antibodies in treatment of acute transplant rejection.

Title:  Method of preventing acute rejection following solid organ
transplantation.

Inventors:  Susan Light and Cary Queen

PCT Publication No.:  WO 98/13067 claiming priority to U.S. provisional
patent application serial no. 60/026,643 filed September 24, 1996.








(footnote continued from previous page)


(footnote continued on next page)

 common/contracts/roche//Roche 99ROW Amend 8.0
        --

CONFIDENTIAL TREATMENT REQUESTED WITH RESPECT TO
DESIGNATED PORTIONS OF THIS DOCUMENT



common/contracts/roche//Roche 99 ROWAmend v8.0


  

5 THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE ACCOMPANYING FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS. 1,000 9-MOS DEC-31-1999 Jan-01-1999 Sep-30-1999 14,341 120,327 3,000 0 0 23,879 37,727 0 175,945 7,393 0 0 0 187 158,558 175,945 27,697 27,697 0 0 32,081 0 0 (4,384) 0 (4,384) 0 0 0 (4,384) ($0.24) ($0.24)